EFO URI,STUDY ACCESSION,PUBMEDID,ASSOCIATION COUNT,DISEASE/TRAIT
http://www.ebi.ac.uk/efo/efo_0007939,GCST008269,31295674,0,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0008459,GCST008269,31295674,0,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST008269,31295674,0,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0007939,GCST008268,31295674,0,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0008459,GCST008268,31295674,0,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST008268,31295674,0,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST008292,31299468,1,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
http://purl.obolibrary.org/obo/go_0031960,GCST008292,31299468,1,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005921,GCST008293,31299468,0,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST008293,31299468,0,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
http://purl.obolibrary.org/obo/go_0031960,GCST008293,31299468,0,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0007939,GCST008294,31299468,1,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST008294,31299468,1,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
http://purl.obolibrary.org/obo/go_0031960,GCST008294,31299468,1,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0003819,GCST008295,31235808,47,"Number of decayed, missing and filled tooth surfaces or use of dentures"
http://www.ebi.ac.uk/efo/efo_0000649,GCST008296,31235808,0,Periodontitis or loose teeth
http://www.ebi.ac.uk/efo/efo_0007780,GCST008296,31235808,0,Periodontitis or loose teeth
http://www.ebi.ac.uk/efo/efo_0007780,GCST008297,31235808,0,Loose teeth
http://purl.obolibrary.org/obo/hp_0000155,GCST008304,31235808,0,Mouth ulcers
http://www.ebi.ac.uk/efo/efo_0007780,GCST008303,31235808,0,Painful gums
http://purl.obolibrary.org/obo/hp_0000225,GCST008301,31235808,0,Bleeding gums
http://www.ebi.ac.uk/efo/efo_0000649,GCST008300,31235808,0,Periodontitis
http://www.ebi.ac.uk/efo/efo_0003819,GCST008299,31235808,0,Number of decayed and filled tooth surfaces per available tooth surface
http://www.ebi.ac.uk/efo/efo_0003819,GCST008302,31235808,2,"Number of decayed, missing and filled tooth surfaces"
http://www.ebi.ac.uk/efo/efo_0000681,GCST008225,31231134,3,Renal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0000681,GCST008226,31231134,8,Renal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0008343,GCST008224,31231134,1,Renal cell carcinoma x sex interaction
http://www.ebi.ac.uk/efo/efo_0000681,GCST008224,31231134,1,Renal cell carcinoma x sex interaction
http://www.ebi.ac.uk/efo/efo_0001663,GCST008231,31226226,3,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0004735,GCST008173,31219225,9,Alanine aminotransferase levels
http://www.ebi.ac.uk/efo/efo_0004736,GCST008174,31219225,6,Aspartate aminotransferase levels
http://www.ebi.ac.uk/efo/efo_0004532,GCST008175,31219225,8,Gamma glutamyl transferase levels
http://www.ebi.ac.uk/efo/efo_0004340,GCST008025,31217584,63,Body mass index
http://www.ebi.ac.uk/efo/efo_0004684,GCST008211,31217265,1,Tumor necrosis factor alpha levels
http://www.ebi.ac.uk/efo/efo_0008056,GCST008199,31217265,1,Interferon gamma-induced protein 10 levels
http://www.ebi.ac.uk/efo/efo_0008191,GCST008197,31217265,0,Interleukin-8 levels
http://www.ebi.ac.uk/efo/efo_0004810,GCST008200,31217265,0,Interleukin-6 levels
http://www.ebi.ac.uk/efo/efo_0008184,GCST008201,31217265,0,Interleukin-4 levels
http://www.ebi.ac.uk/efo/efo_0004754,GCST008203,31217265,0,Interleukin-1-receptor antagonist levels
http://www.ebi.ac.uk/efo/efo_0004812,GCST008209,31217265,2,Interleukin-1-beta levels
http://www.ebi.ac.uk/efo/efo_0004749,GCST008204,31217265,1,Monocyte chemoattractant protein-1 levels
http://www.ebi.ac.uk/efo/efo_0008174,GCST008205,31217265,0,Interleukin-17 levels
http://www.ebi.ac.uk/efo/efo_0004762,GCST008198,31217265,3,Vascular endothelial growth factor levels
http://www.ebi.ac.uk/efo/efo_0004792,GCST008206,31217265,0,Plasminogen activator inhibitor-1 (PAI-1) levels
http://www.ebi.ac.uk/efo/efo_0004790,GCST008208,31217265,0,Soluble CD40 ligand levels
http://www.ebi.ac.uk/efo/efo_0009412,GCST008207,31217265,0,Interleukin-1-alpha levels
http://www.ebi.ac.uk/efo/efo_0004520,GCST008210,31217265,3,Soluble ICAM-1
http://www.ebi.ac.uk/efo/efo_0004575,GCST008202,31217265,2,Soluble E-selectin levels
http://www.ebi.ac.uk/efo/efo_0004458,GCST008055,31217584,45,C-reactive protein levels
http://www.ebi.ac.uk/efo/efo_0005055,GCST008054,31217584,26,QRS duration
http://www.ebi.ac.uk/efo/efo_0004339,GCST008041,31217584,0,Height
http://www.ebi.ac.uk/efo/efo_0004339,GCST008040,31217584,0,Height
http://www.ebi.ac.uk/efo/efo_0004339,GCST008053,31217584,214,Height
http://www.ebi.ac.uk/efo/efo_0004343,GCST008052,31217584,11,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0004343,GCST008051,31217584,2,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0004343,GCST008050,31217584,12,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0004308,GCST008049,31217584,47,White blood cell count
http://www.ebi.ac.uk/efo/efo_0001360,GCST008048,31217584,2,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004530,GCST008046,31217584,137,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004574,GCST008045,31217584,170,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0006335,GCST008044,31217584,13,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004682,GCST008043,31217584,51,QT interval
http://www.ebi.ac.uk/efo/efo_0004462,GCST008042,31217584,31,PR interval
http://www.ebi.ac.uk/efo/efo_0004309,GCST008039,31217584,36,Platelet count
http://www.ebi.ac.uk/efo/efo_0004528,GCST008038,31217584,16,Mean corpuscular hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0004611,GCST008037,31217584,131,Low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0000537,GCST008036,31217584,2,Hypertension
http://www.ebi.ac.uk/efo/efo_0004612,GCST008035,31217584,153,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004541,GCST008034,31217584,20,Hemoglobin A1c levels
http://www.ebi.ac.uk/efo/efo_0004466,GCST008033,31217584,6,Fasting blood insulin
http://www.ebi.ac.uk/efo/efo_0004465,GCST008032,31217584,28,Fasting blood glucose
http://www.ebi.ac.uk/efo/efo_0003884,GCST008031,31217584,0,End-stage renal disease
http://www.ebi.ac.uk/efo/efo_0005208,GCST008030,31217584,9,Estimated glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0006336,GCST008029,31217584,13,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006782,GCST008028,31217584,16,Coffee consumption (cups per day)
http://www.ebi.ac.uk/efo/efo_0006525,GCST008027,31217584,5,Smoking behaviour (cigarettes smoked per day)
http://www.ebi.ac.uk/efo/efo_0003884,GCST008026,31217584,0,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0008336,GCST008274,31209788,1,Cerebral microbleed progression
http://www.ebi.ac.uk/efo/efo_0004999,GCST008108,31163085,7,N-glycan levels
http://www.ebi.ac.uk/efo/efo_0005112,GCST008176,31194736,9,Gestational age at birth (child effect)
http://www.ebi.ac.uk/efo/efo_0004309,GCST008168,31194788,1,Platelet count
http://www.ebi.ac.uk/efo/efo_0004526,GCST008166,31194788,3,Mean corpuscular volume
http://www.ebi.ac.uk/efo/efo_0004584,GCST008167,31194788,5,Mean platelet volume
http://www.ebi.ac.uk/efo/efo_0006917,GCST008181,31194736,22,Spontaneous preterm birth without premature rupture of membranes
http://purl.obolibrary.org/obo/mondo_0012511,GCST008180,31194736,18,Spontaneous preterm birth with premature rupture of membranes
http://www.ebi.ac.uk/efo/efo_0006917,GCST008180,31194736,18,Spontaneous preterm birth with premature rupture of membranes
http://www.ebi.ac.uk/efo/efo_0006917,GCST008179,31194736,24,Moderate-to-late spontaneous preterm birth
http://www.ebi.ac.uk/efo/efo_0006917,GCST008178,31194736,13,Early spontaneous preterm birth
http://www.ebi.ac.uk/efo/efo_0006917,GCST008177,31194736,19,Spontaneous preterm birth (preterm birth)
http://www.ebi.ac.uk/efo/efo_0004704,GCST008149,31188284,0,Age at menopause
http://www.ebi.ac.uk/efo/efo_0000195,GCST008140,31170924,1,Metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0000195,GCST008146,31170924,2,Metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0004342,GCST008145,31170924,3,Waist circumference
http://www.ebi.ac.uk/efo/efo_0004465,GCST008144,31170924,7,Fasting plasma glucose
http://www.ebi.ac.uk/efo/efo_0006336,GCST008143,31170924,2,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST008142,31170924,5,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004612,GCST008141,31170924,7,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004530,GCST008150,31170924,9,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0003761,GCST008118,31164008,20,Suicide attempts in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0004321,GCST008118,31164008,20,Suicide attempts in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0000692,GCST008122,31164008,18,Suicide attempts in bipolar disorder or schizophrenia
http://www.ebi.ac.uk/efo/efo_0000289,GCST008122,31164008,18,Suicide attempts in bipolar disorder or schizophrenia
http://www.ebi.ac.uk/efo/efo_0004321,GCST008122,31164008,18,Suicide attempts in bipolar disorder or schizophrenia
http://www.ebi.ac.uk/efo/efo_0003761,GCST008121,31164008,0,Suicide attempts in major depressive disorder or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST008121,31164008,0,Suicide attempts in major depressive disorder or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004321,GCST008121,31164008,0,Suicide attempts in major depressive disorder or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000692,GCST008120,31164008,20,Suicide attempts in schizophrenia
http://www.ebi.ac.uk/efo/efo_0004321,GCST008120,31164008,20,Suicide attempts in schizophrenia
http://www.ebi.ac.uk/efo/efo_0000289,GCST008119,31164008,14,Suicide attempts in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004321,GCST008119,31164008,14,Suicide attempts in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST008123,31164008,40,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST008123,31164008,40,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia
http://www.ebi.ac.uk/efo/efo_0000289,GCST008123,31164008,40,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia
http://www.ebi.ac.uk/efo/efo_0004321,GCST008123,31164008,40,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia
http://www.ebi.ac.uk/efo/efo_0005208,GCST008058,31152163,307,Estimated glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0005208,GCST008066,31152163,0,Estimated glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0003884,GCST008065,31152163,0,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST008064,31152163,47,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0004741,GCST008063,31152163,0,Blood urea nitrogen levels
http://www.ebi.ac.uk/efo/efo_0004741,GCST008062,31152163,132,Blood urea nitrogen levels
http://www.ebi.ac.uk/efo/efo_0005208,GCST008061,31152163,3,Estimated glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0005208,GCST008060,31152163,45,Estimated glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0005208,GCST008059,31152163,256,Estimated glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0003100,GCST008223,31127053,5,Diabetic peripheral neuropathy in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST008223,31127053,5,Diabetic peripheral neuropathy in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001365,GCST008356,31120506,3,Geographic atrophy lesion growth rate in age-related macular degeneration
http://purl.obolibrary.org/obo/hp_0012664,GCST007999,31113495,170,Heart rate in heart failure with reduced ejection fraction
http://www.ebi.ac.uk/efo/efo_0003144,GCST007999,31113495,170,Heart rate in heart failure with reduced ejection fraction
http://www.ebi.ac.uk/efo/efo_0004326,GCST007999,31113495,170,Heart rate in heart failure with reduced ejection fraction
http://www.orpha.net/ordo/orphanet_3389,GCST007897,31109976,2,Liver injury in anti-tuberculosis drug treatment
http://www.ebi.ac.uk/efo/efo_0007918,GCST007897,31109976,2,Liver injury in anti-tuberculosis drug treatment
http://www.ebi.ac.uk/efo/efo_0004228,GCST007897,31109976,2,Liver injury in anti-tuberculosis drug treatment
http://purl.obolibrary.org/obo/mondo_0044887,GCST007896,31102405,7,Primary central nervous system lymphoma
http://www.ebi.ac.uk/efo/efo_0004997,GCST007949,31092297,25,Type 2 diabetes and end-stage kidney disease
http://www.ebi.ac.uk/efo/efo_0009324,GCST007950,31092297,13,Type 2 diabetes and end-stage kidney disease in APOL1 risk genotype negative individuals
http://www.ebi.ac.uk/efo/efo_0004997,GCST007950,31092297,13,Type 2 diabetes and end-stage kidney disease in APOL1 risk genotype negative individuals
http://www.ebi.ac.uk/efo/efo_0005842,GCST007992,31089142,87,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0007835,GCST008291,31090166,0,Alcohol dependence (drinking despite problems)
http://www.ebi.ac.uk/efo/efo_0007835,GCST008290,31090166,1,Alcohol dependence (time spent drinking)
http://www.ebi.ac.uk/efo/efo_0007878,GCST008289,31090166,0,Alcohol dependence (giving up activities)
http://www.ebi.ac.uk/efo/efo_0007835,GCST008288,31090166,1,Alcohol dependence (desire to cut drinking)
http://www.ebi.ac.uk/efo/efo_0007835,GCST008287,31090166,1,Alcohol dependence (drinking more than intended)
http://www.ebi.ac.uk/efo/efo_0007835,GCST008286,31090166,0,Alcohol dependence (withdrawal)
http://www.ebi.ac.uk/efo/efo_0007835,GCST008285,31090166,1,Alcohol dependence (tolerance)
http://www.ebi.ac.uk/efo/efo_0007835,GCST008283,31090166,1,Alcohol dependence symptom count
http://purl.obolibrary.org/obo/hp_0002253,GCST007921,31089239,2,Right-sided colonic diverticulosis
http://www.ebi.ac.uk/efo/efo_0003829,GCST008284,31090166,1,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0007781,GCST007945,31081985,2,Psychological resilience (outcome-based) in high deployment stress exposure
http://www.ebi.ac.uk/efo/efo_0009945,GCST007945,31081985,2,Psychological resilience (outcome-based) in high deployment stress exposure
http://www.ebi.ac.uk/efo/efo_0009945,GCST007947,31081985,5,Psychological resilience (outcome-based)
http://www.ebi.ac.uk/efo/efo_0009945,GCST007946,31081985,2,Psychological resilience (self-assessed)
http://www.ebi.ac.uk/efo/efo_0003888,GCST007880,31085060,8,Emotional lability in attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0008475,GCST007880,31085060,8,Emotional lability in attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0009767,GCST007838,31070104,10,Glycine levels
http://www.ebi.ac.uk/efo/efo_0009767,GCST007836,31070104,12,Glycine levels
http://www.ebi.ac.uk/efo/efo_0009767,GCST007837,31070104,7,Glycine levels
http://www.ebi.ac.uk/efo/efo_0006792,GCST007881,31065058,2,Dementia with Lewy bodies
http://www.orpha.net/ordo/orphanet_683,GCST007845,31059154,1,Progressive supranuclear palsy
http://www.ebi.ac.uk/efo/efo_0004844,GCST008281,31053729,8,Hip bone size
http://www.ebi.ac.uk/efo/efo_0004508,GCST008282,31053729,9,Spine bone size
http://www.ebi.ac.uk/efo/efo_0001360,GCST008114,31049640,40,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004653,GCST008271,31043678,1,Anti-adalimumab antibody production in response to treatment in Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000384,GCST008271,31043678,1,Anti-adalimumab antibody production in response to treatment in Crohn's disease
http://www.ebi.ac.uk/efo/efo_0009963,GCST008115,31043756,61,Bipolar I disorder
http://www.ebi.ac.uk/efo/efo_0002690,GCST008307,31058715,0,Response to belimumab (SLE response index) in systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0001073,GCST007997,31118946,39,Obesity (extreme) (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0000289,GCST008103,31043756,184,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0009965,GCST008117,31043756,10,Schizoaffective disorder-bipolar type
http://www.ebi.ac.uk/efo/efo_0009964,GCST008116,31043756,5,Bipolar II disorder
http://www.ebi.ac.uk/efo/efo_0004587,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004584,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004308,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004526,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004348,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0005090,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004309,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0005192,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004833,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004509,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004305,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004528,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0005091,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004527,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004842,GCST008338,31080455,8,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0000341,GCST007996,31036433,1,Chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000270,GCST007994,31036433,31,Asthma (age of onset)
http://www.ebi.ac.uk/efo/efo_0004591,GCST007995,31036433,64,Asthma (childhood onset)
http://www.ebi.ac.uk/efo/efo_0004833,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004584,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004308,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004305,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004528,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004526,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0005091,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0005090,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004309,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0005192,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004842,GCST008337,31080455,3,Blood cell traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004584,GCST008336,31080455,2,Mean platelet volume
http://www.ebi.ac.uk/efo/efo_1002011,GCST007993,31036433,28,Asthma (adult onset)
http://www.ebi.ac.uk/efo/efo_0004591,GCST008273,31028280,6,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma
http://www.ebi.ac.uk/efo/efo_0004314,GCST008273,31028280,6,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma
http://www.ebi.ac.uk/efo/efo_0007908,GCST008273,31028280,6,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma
http://www.ebi.ac.uk/efo/efo_0004842,GCST008335,31080455,2,Eosinophil counts
http://www.ebi.ac.uk/efo/efo_0005090,GCST008328,31080455,0,Basophil count
http://www.ebi.ac.uk/efo/efo_0005091,GCST008327,31080455,0,Monocyte count
http://www.ebi.ac.uk/efo/efo_0004587,GCST008326,31080455,0,Lymphocyte counts
http://www.ebi.ac.uk/efo/efo_0004309,GCST008325,31080455,0,Platelet count
http://www.ebi.ac.uk/efo/efo_0004833,GCST008334,31080455,1,Neutrophil count
http://www.ebi.ac.uk/efo/efo_0004509,GCST008324,31080455,0,Hemoglobin
http://www.ebi.ac.uk/efo/efo_0004348,GCST008323,31080455,0,Hematocrit
http://www.ebi.ac.uk/efo/efo_0005192,GCST008333,31080455,1,Red cell distribution width
http://www.ebi.ac.uk/efo/efo_0004528,GCST008332,31080455,1,Mean corpuscular hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0004527,GCST008331,31080455,1,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0004526,GCST008330,31080455,1,Mean corpuscular volume
http://www.ebi.ac.uk/efo/efo_0004305,GCST008329,31080455,2,Red blood cell count
http://www.ebi.ac.uk/efo/efo_0004308,GCST008322,31080455,0,White blood cell count
http://www.ebi.ac.uk/efo/efo_0004591,GCST008272,31028280,6,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma
http://www.ebi.ac.uk/efo/efo_0004314,GCST008272,31028280,6,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma
http://www.ebi.ac.uk/efo/efo_0007908,GCST008272,31028280,6,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma
http://www.ebi.ac.uk/efo/efo_0005043,GCST008310,31014085,13,Cardiac Troponin-T levels
http://www.ebi.ac.uk/efo/efo_1001282,GCST008106,31241743,8,Candidemia
http://www.ebi.ac.uk/efo/efo_0009949,GCST007948,31020675,1,KANNO antigen negativity
http://www.ebi.ac.uk/efo/efo_0005208,GCST007876,31015462,147,Estimated glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0003884,GCST007879,31015462,3,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0009795,GCST007878,31015462,4,Urea levels
http://www.ebi.ac.uk/efo/efo_0004518,GCST007877,31015462,25,Creatinine levels
http://www.ebi.ac.uk/efo/efo_0009944,GCST007944,31015401,14,Medication use (antiglaucoma preparations and miotics)
http://www.ebi.ac.uk/efo/efo_0009943,GCST007943,31015401,8,Medication use (antihistamines for systemic use)
http://www.ebi.ac.uk/efo/efo_0009942,GCST007942,31015401,19,Medication use (glucocorticoids)
http://www.ebi.ac.uk/efo/efo_0009941,GCST007941,31015401,56,"Medication use (adrenergics, inhalants)"
http://www.ebi.ac.uk/efo/efo_0009940,GCST007940,31015401,1,Medication use (antidepressants)
http://www.ebi.ac.uk/efo/efo_0009939,GCST007939,31015401,13,Medication use (antimigraine preparations)
http://www.ebi.ac.uk/efo/efo_0009938,GCST007938,31015401,7,Medication use (anilides)
http://www.ebi.ac.uk/efo/efo_0007013,GCST007937,31015401,10,Medication use (salicylic acid and derivatives)
http://www.ebi.ac.uk/efo/efo_0009937,GCST007936,31015401,3,Medication use (opioids)
http://www.ebi.ac.uk/efo/efo_0009936,GCST007935,31015401,11,Medication use (drugs affecting bone structure and mineralization)
http://www.ebi.ac.uk/efo/efo_0009935,GCST007934,31015401,6,"Medication use (anti-inflammatory and antirheumatic products, non-steroids)"
http://www.ebi.ac.uk/efo/efo_0009934,GCST007933,31015401,2,Medication use (immunosuppressants)
http://www.ebi.ac.uk/efo/efo_0009933,GCST007932,31015401,132,Medication use (thyroid preparations)
http://www.ebi.ac.uk/efo/efo_0009932,GCST007931,31015401,97,Medication use (HMG CoA reductase inhibitors)
http://www.ebi.ac.uk/efo/efo_0009931,GCST007930,31015401,184,Medication use (agents acting on the renin-angiotensin system)
http://www.ebi.ac.uk/efo/efo_0009930,GCST007929,31015401,104,Medication use (calcium channel blockers)
http://www.ebi.ac.uk/efo/efo_0009929,GCST007927,31015401,59,Medication use (beta blocking agents)
http://www.ebi.ac.uk/efo/efo_0009928,GCST007928,31015401,102,Medication use (diuretics)
http://www.ebi.ac.uk/efo/efo_0009927,GCST007926,31015401,4,Medication use (antihypertensives)
http://www.ebi.ac.uk/efo/efo_0009926,GCST007925,31015401,3,Medication use (vasodilators used in cardiac diseases)
http://www.ebi.ac.uk/efo/efo_0009925,GCST007924,31015401,13,Medication use (antithrombotic agents)
http://www.ebi.ac.uk/efo/efo_0009924,GCST007923,31015401,57,Medication use (drugs used in diabetes)
http://www.ebi.ac.uk/efo/efo_0009923,GCST007922,31015401,5,Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease)
http://purl.obolibrary.org/obo/go_0050909,GCST008018,31005965,6,Sweet taste perception in obesity with metabolic syndrome
http://purl.obolibrary.org/obo/go_0050913,GCST008019,31005965,10,Bitter taste perception (phenylthiocarbamide) in obesity with metabolic syndrome
http://purl.obolibrary.org/obo/go_0050913,GCST008017,31005965,8,Bitter taste perception (6-n-propylthiouracil) in obesity with metabolic syndrome
http://purl.obolibrary.org/obo/go_0050909,GCST008021,31005965,2,Taste perception (total score including 6-n-propylthiouracil) in obesity with metabolic syndrome
http://purl.obolibrary.org/obo/go_0050909,GCST008020,31005965,5,Taste perception (total score including phenylthiocarbamide) in obesity with metabolic syndrome
http://purl.obolibrary.org/obo/go_0050909,GCST008022,31005965,4,Umami taste perception in obesity with metabolic syndrome
http://purl.obolibrary.org/obo/go_0050909,GCST008023,31005965,2,Sour taste perception in obesity with metabolic syndrome
http://purl.obolibrary.org/obo/go_0050909,GCST008024,31005965,3,Salty taste perception in obesity with metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0009960,GCST008097,31006051,37,Bisphosphonate-associated atypical femoral fracture
http://www.ebi.ac.uk/efo/efo_0009958,GCST008097,31006051,37,Bisphosphonate-associated atypical femoral fracture
http://www.ebi.ac.uk/efo/efo_0009960,GCST008098,31006051,14,Atypical femoral fracture in phosphonate treatment
http://www.ebi.ac.uk/efo/efo_0009958,GCST008098,31006051,14,Atypical femoral fracture in phosphonate treatment
http://purl.obolibrary.org/obo/hp_0002619,GCST008057,30998689,14,Varicose veins
http://www.ebi.ac.uk/efo/efo_0005301,GCST007862,30995994,0,Latent naming speed
http://www.ebi.ac.uk/efo/efo_0005301,GCST007863,30995994,3,Rapid alternating stimulus test for letters/numbers
http://www.ebi.ac.uk/efo/efo_0005301,GCST007864,30995994,3,Rapid automised naming of letters
http://www.ebi.ac.uk/efo/efo_0005301,GCST007865,30995994,0,Rapid automised naming of objects
http://www.ebi.ac.uk/efo/efo_0005301,GCST007860,30995994,7,Latent naming speed
http://www.ebi.ac.uk/efo/efo_0005301,GCST007859,30995994,4,Rapid automised naming and rapid alternating stimulus test performance
http://www.ebi.ac.uk/efo/efo_0005301,GCST007861,30995994,0,Latent naming speed
http://www.ebi.ac.uk/efo/efo_0007778,GCST007832,31040861,0,Urinary albumin-to-creatinine ratio
http://www.ebi.ac.uk/efo/efo_0000284,GCST008169,30988330,13,Benign prostatic hyperplasia
http://www.ebi.ac.uk/efo/efo_0009902,GCST007592,30980028,3,Handedness (Left-handed vs. non-left-handed)
http://www.ebi.ac.uk/efo/efo_0009902,GCST007593,30980028,0,Ambidextrousness
http://www.ebi.ac.uk/efo/efo_0009902,GCST007594,30980028,3,Handedness (Right-handed vs. non-right-handed)
http://www.ebi.ac.uk/efo/efo_0004246,GCST008314,30971808,1,Response to intravenous immunoglobulin treatment in Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0008259,GCST008260,31070471,14,group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP
http://www.ebi.ac.uk/efo/efo_0004458,GCST008260,31070471,14,group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP
http://www.ebi.ac.uk/efo/efo_0004517,GCST007846,31070453,6,Arterial stiffness
http://purl.obolibrary.org/obo/mondo_0024647,GCST007833,30975718,17,Urolithiasis
http://www.ebi.ac.uk/efo/efo_0008483,GCST008270,30999091,3,Post-traumatic stress disorder symptoms in trauma-exposed soldiers
http://www.ebi.ac.uk/efo/efo_0008535,GCST008270,30999091,3,Post-traumatic stress disorder symptoms in trauma-exposed soldiers
http://www.ebi.ac.uk/efo/efo_0004761,GCST007725,30993211,42,Serum uric acid levels
http://www.ebi.ac.uk/efo/efo_0007869,GCST008267,31003110,17,Psychological wellbeing index (total score)
http://www.ebi.ac.uk/efo/efo_0007869,GCST008266,31003110,24,Psychological wellbeing (health and vitality)
http://www.ebi.ac.uk/efo/efo_0007869,GCST008261,31003110,11,Psychological wellbeing (depressiveness)
http://www.ebi.ac.uk/efo/efo_0004761,GCST007733,30993211,71,Serum uric acid levels
http://www.ebi.ac.uk/efo/efo_0007869,GCST008265,31003110,9,Psychological wellbeing (social role performance and self-confidence)
http://www.ebi.ac.uk/efo/efo_0007869,GCST008264,31003110,6,Psychological wellbeing index 12 (lack of enjoying daily life)
http://www.ebi.ac.uk/efo/efo_0007869,GCST008263,31003110,27,Psychological wellbeing index 3 (fatigue and loss of appetite)
http://www.ebi.ac.uk/efo/efo_0007869,GCST008262,31003110,13,Psychological wellbeing index 1 (lack of subjective wellbeing and health)
http://www.ebi.ac.uk/efo/efo_0002508,GCST007780,30957308,4,Parkinson's disease (age of onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST007780,30957308,4,Parkinson's disease (age of onset)
http://www.ebi.ac.uk/efo/efo_0003884,GCST007734,30955190,2,Incident chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0005088,GCST007796,30952644,10,Tinnitus in cisplatin-treated testicular cancer
http://purl.obolibrary.org/obo/go_0072718,GCST007796,30952644,10,Tinnitus in cisplatin-treated testicular cancer
http://purl.obolibrary.org/obo/hp_0000360,GCST007796,30952644,10,Tinnitus in cisplatin-treated testicular cancer
http://www.ebi.ac.uk/efo/efo_0007828,GCST007808,30952852,0,Diurnal inactivity
http://www.ebi.ac.uk/efo/efo_0004870,GCST007807,30952852,0,Sleep (time to midpoint)
http://www.ebi.ac.uk/efo/efo_0004870,GCST007806,30952852,0,Time to most active 10 hours
http://www.ebi.ac.uk/efo/efo_0004870,GCST007805,30952852,0,Sleep (time to least active 5 hours)
http://www.ebi.ac.uk/efo/efo_0005272,GCST007804,30952852,1,Sleep (number of episodes)
http://www.ebi.ac.uk/efo/efo_0005272,GCST007803,30952852,0,Sleep efficiency
http://www.ebi.ac.uk/efo/efo_0004870,GCST007802,30952852,0,Sleep duration (variability)
http://www.ebi.ac.uk/efo/efo_0005271,GCST007801,30952852,0,Sleep duration
http://www.ebi.ac.uk/efo/efo_0000638,GCST007731,30945699,5,Postoperative survival time in hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0000182,GCST007731,30945699,5,Postoperative survival time in hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0009892,GCST007819,30946739,1,Facial attractiveness (male raters)
http://www.ebi.ac.uk/efo/efo_0009892,GCST007820,30946739,2,Facial attractiveness (female raters)
http://www.ebi.ac.uk/efo/efo_0009892,GCST007821,30946739,3,Facial attractiveness (female raters)
http://www.ebi.ac.uk/efo/efo_0009892,GCST007822,30946739,1,Facial attractiveness (male raters)
http://www.ebi.ac.uk/efo/efo_0009892,GCST007823,30946739,1,Facial attractiveness (male raters)
http://www.ebi.ac.uk/efo/efo_0009892,GCST007817,30946739,2,Facial attractiveness (male raters)
http://www.ebi.ac.uk/efo/efo_0004612,GCST007840,31006500,3,Low HDL-cholesterol levels
http://www.ebi.ac.uk/efo/efo_0003898,GCST007844,30946743,23,Ankylosing spondylitis
http://www.ebi.ac.uk/efo/efo_0009892,GCST007818,30946739,1,Facial attractiveness (female raters)
http://www.ebi.ac.uk/efo/efo_0004464,GCST007712,30941828,2,"Cortical brain region measurements (area, volume and thickness)"
http://www.ebi.ac.uk/efo/efo_0009890,GCST007816,30944420,5,Trunk fat mass adjusted for trunk lean mass
http://www.ebi.ac.uk/efo/efo_0009458,GCST008258,30940813,32,Alcohol use disorder (consumption score)
http://www.ebi.ac.uk/efo/efo_0007645,GCST008258,30940813,32,Alcohol use disorder (consumption score)
http://www.ebi.ac.uk/efo/efo_0004351,GCST007656,30940143,21,Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000341,GCST007656,30940143,21,Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0009458,GCST008259,30940813,25,Alcohol use disorder
http://www.ebi.ac.uk/efo/efo_0003829,GCST008259,30940813,25,Alcohol use disorder
http://www.ebi.ac.uk/efo/efo_0000712,GCST007613,30940143,0,Chronic obstructive pulmonary disease or stroke (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000341,GCST007613,30940143,0,Chronic obstructive pulmonary disease or stroke (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000341,GCST007612,30940143,3,Chronic obstructive pulmonary disease or coronary artery disease (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000378,GCST007612,30940143,3,Chronic obstructive pulmonary disease or coronary artery disease (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000537,GCST007611,30940143,22,Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000341,GCST007611,30940143,22,Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000537,GCST007610,30940143,0,Hypertension
http://www.ebi.ac.uk/efo/efo_0004351,GCST007609,30940143,0,Resting heart rate
http://www.ebi.ac.uk/efo/efo_0004609,GCST007686,30922102,2,Plasma norclozapine levels in treatment-resistant schizophrenia
http://purl.obolibrary.org/obo/go_0097338,GCST007686,30922102,2,Plasma norclozapine levels in treatment-resistant schizophrenia
http://www.ebi.ac.uk/efo/efo_0003779,GCST007851,30926877,10,Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis
http://www.ebi.ac.uk/efo/efo_0005666,GCST007851,30926877,10,Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis
http://www.ebi.ac.uk/efo/efo_0009896,GCST007851,30926877,10,Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis
http://www.ebi.ac.uk/efo/efo_0003779,GCST007831,30926877,9,Anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis
http://www.ebi.ac.uk/efo/efo_0009896,GCST007831,30926877,9,Anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis
http://www.ebi.ac.uk/efo/efo_0003779,GCST007830,30926877,11,Anti-thyroid peroxidase (TPOAb) levels in Hashimoto's thyroiditis
http://www.ebi.ac.uk/efo/efo_0005666,GCST007830,30926877,11,Anti-thyroid peroxidase (TPOAb) levels in Hashimoto's thyroiditis
http://www.ebi.ac.uk/efo/efo_0004609,GCST007685,30922102,1,Plasma clozapine levels in treatment-resistant schizophrenia
http://purl.obolibrary.org/obo/go_0097338,GCST007685,30922102,1,Plasma clozapine levels in treatment-resistant schizophrenia
http://www.ebi.ac.uk/efo/efo_0004609,GCST007684,30922102,3,Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia
http://purl.obolibrary.org/obo/go_0097338,GCST007684,30922102,3,Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia
http://www.ebi.ac.uk/efo/efo_0006337,GCST008148,30924126,1,Response to allopurinol in gout (change in serum uric acid levels)
http://www.ebi.ac.uk/efo/efo_0004274,GCST008148,30924126,1,Response to allopurinol in gout (change in serum uric acid levels)
http://www.ebi.ac.uk/efo/efo_0004761,GCST008148,30924126,1,Response to allopurinol in gout (change in serum uric acid levels)
http://www.ebi.ac.uk/efo/efo_0004847,GCST007797,30929738,55,Asthma onset (childhood vs adult)
http://www.ebi.ac.uk/efo/efo_0000270,GCST007797,30929738,55,Asthma onset (childhood vs adult)
http://www.ebi.ac.uk/efo/efo_0000270,GCST007798,30929738,160,Asthma
http://www.ebi.ac.uk/efo/efo_0006337,GCST008147,30924126,1,Response to allopurinol in gout (change in serum uric acid levels)
http://www.ebi.ac.uk/efo/efo_0004274,GCST008147,30924126,1,Response to allopurinol in gout (change in serum uric acid levels)
http://www.ebi.ac.uk/efo/efo_0004761,GCST008147,30924126,1,Response to allopurinol in gout (change in serum uric acid levels)
http://www.ebi.ac.uk/efo/efo_0004723,GCST007711,30921371,0,Severe coronary artery calcification
http://www.ebi.ac.uk/efo/efo_0000676,GCST008096,30921485,6,Psoriasis
http://www.ebi.ac.uk/efo/efo_1002011,GCST007799,30929738,46,Asthma (adult onset)
http://www.ebi.ac.uk/efo/efo_0004591,GCST007800,30929738,105,Asthma (childhood onset)
http://www.ebi.ac.uk/efo/efo_0004611,GCST007689,30911093,2,Low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004574,GCST007688,30911093,2,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST007702,30911093,10,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST007701,30911093,9,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004274,GCST008139,30899057,3,Gout
http://www.ebi.ac.uk/efo/efo_0009764,GCST007742,30895295,37,Iris heterochromicity
http://www.ebi.ac.uk/efo/efo_0009764,GCST007743,30895295,42,Iris color (L* coordinate)
http://www.ebi.ac.uk/efo/efo_0009764,GCST007741,30895295,45,Iris color (b* coordinate)
http://www.ebi.ac.uk/efo/efo_0009764,GCST007740,30895295,34,Iris color (a* coordinate)
http://www.ebi.ac.uk/efo/efo_0007009,GCST007739,30895295,63,Skin reflectance (Melanin index)
http://www.ebi.ac.uk/efo/efo_0007887,GCST007687,30899065,3,Photic sneeze reflex
http://www.ebi.ac.uk/efo/efo_0005213,GCST008317,30894546,11,Central corneal thickness
http://www.ebi.ac.uk/efo/efo_0004695,GCST008320,30894546,3,Intraocular pressure (Goldman correlated)
http://www.ebi.ac.uk/efo/efo_0004695,GCST008319,30894546,1,Intraocular pressure (corneal compensated)
http://www.ebi.ac.uk/efo/efo_0004511,GCST007639,30888730,2,Femoral neck length
http://www.ebi.ac.uk/efo/efo_0004511,GCST007642,30888730,0,Femoral neck-shaft angle
http://www.ebi.ac.uk/efo/efo_0004511,GCST007641,30888730,1,Femoral neck section modulus
http://www.ebi.ac.uk/efo/efo_0004511,GCST007640,30888730,2,Narrowest width of the femoral neck
http://www.ebi.ac.uk/efo/efo_0001075,GCST007728,30898391,126,Epithelial ovarian cancer
http://www.ebi.ac.uk/efo/efo_0009857,GCST007677,30886212,3,Rumination (response to stress)
http://www.ebi.ac.uk/efo/efo_0009859,GCST007679,30886212,4,Reflection (response to stress)
http://www.ebi.ac.uk/efo/efo_0009858,GCST007678,30886212,3,Brooding (response to stress)
http://purl.obolibrary.org/obo/mondo_0001475,GCST007643,30889042,6,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer
http://purl.obolibrary.org/obo/go_0036272,GCST007643,30889042,6,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0002618,GCST007643,30889042,6,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0009589,GCST007708,30867560,14,Worry/vulnerability (special factor of neuroticism)
http://www.ebi.ac.uk/efo/efo_0007660,GCST007709,30867560,308,General factor of neuroticism
http://www.ebi.ac.uk/efo/efo_0009863,GCST007710,30867560,20,Anxiety/tension (special factor of neuroticism)
http://www.ebi.ac.uk/efo/efo_0007778,GCST007718,30910378,12,Urinary albumin-to-creatinine ratio
http://www.ebi.ac.uk/efo/efo_0004285,GCST007719,30910378,8,Albuminuria
http://www.ebi.ac.uk/efo/efo_0009884,GCST007717,30910378,1,Urinary sodium to potassium ratio
http://www.ebi.ac.uk/efo/efo_0009883,GCST007778,30910378,2,Urinary sodium to creatinine ratio
http://www.ebi.ac.uk/efo/efo_0009882,GCST007721,30910378,4,Urinary potassium to creatinine ratio
http://www.ebi.ac.uk/efo/efo_1001486,GCST007737,30854688,2,Anti-sp100 seropositivity in primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0005949,GCST007737,30854688,2,Anti-sp100 seropositivity in primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_1001486,GCST007736,30854688,0,Anti-gp210 seropositivity in primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0005949,GCST007736,30854688,0,Anti-gp210 seropositivity in primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0009864,GCST007690,30852652,1,Metabolic coherence (transcriptomic)
http://www.ebi.ac.uk/efo/efo_0009865,GCST007690,30852652,1,Metabolic coherence (transcriptomic)
http://www.ebi.ac.uk/efo/efo_0009855,GCST007713,30850646,37,Frontal fibrosing alopecia
http://www.ebi.ac.uk/efo/efo_0006527,GCST008240,30845926,3,Airway obstruction (FEV1/FVC<70%) in never smokers
http://www.ebi.ac.uk/efo/efo_0003892,GCST008240,30845926,3,Airway obstruction (FEV1/FVC<70%) in never smokers
http://www.ebi.ac.uk/efo/efo_0006527,GCST008246,30845926,2,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
http://www.ebi.ac.uk/efo/efo_0003892,GCST008246,30845926,2,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
http://www.ebi.ac.uk/efo/efo_0006527,GCST008245,30845926,0,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers
http://www.ebi.ac.uk/efo/efo_0003892,GCST008245,30845926,0,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers
http://www.ebi.ac.uk/efo/efo_0006527,GCST008247,30845926,2,Airway obstruction (FEV1/FVC<70%) in never smokers
http://www.ebi.ac.uk/efo/efo_0003892,GCST008247,30845926,2,Airway obstruction (FEV1/FVC<70%) in never smokers
http://www.ebi.ac.uk/efo/efo_0005130,GCST007680,30843173,11,Triiodothyronine levels and thyroxine levels
http://www.ebi.ac.uk/efo/efo_0008392,GCST007680,30843173,11,Triiodothyronine levels and thyroxine levels
http://www.ebi.ac.uk/efo/efo_0004748,GCST007681,30843173,4,Thyroid stimulating hormone levels
http://www.ebi.ac.uk/efo/efo_0005130,GCST007682,30843173,4,Thyroxine levels
http://www.ebi.ac.uk/efo/efo_0005271,GCST007561,30846698,72,Sleep duration
http://www.ebi.ac.uk/efo/efo_0005271,GCST007560,30846698,8,Sleep duration (long sleep)
http://www.ebi.ac.uk/efo/efo_0006527,GCST008244,30845926,0,Airway obstruction (FEV1/FVC<70%) in ever smokers
http://www.ebi.ac.uk/efo/efo_0003892,GCST008244,30845926,0,Airway obstruction (FEV1/FVC<70%) in ever smokers
http://www.ebi.ac.uk/efo/efo_0008392,GCST007683,30843173,3,Triiodothyronine levels
http://www.ebi.ac.uk/efo/efo_0005271,GCST007559,30846698,27,Sleep duration (short sleep)
http://www.ebi.ac.uk/efo/efo_0004573,GCST007900,30866520,1,Chemerin levels
http://www.ebi.ac.uk/efo/efo_0006527,GCST008243,30845926,0,Airway obstruction (FEV1/FVC<70%) in ever smokers
http://www.ebi.ac.uk/efo/efo_0003892,GCST008243,30845926,0,Airway obstruction (FEV1/FVC<70%) in ever smokers
http://www.ebi.ac.uk/efo/efo_0006527,GCST008241,30845926,2,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
http://www.ebi.ac.uk/efo/efo_0003892,GCST008241,30845926,2,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
http://www.ebi.ac.uk/efo/efo_0006527,GCST008242,30845926,0,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers
http://www.ebi.ac.uk/efo/efo_0003892,GCST008242,30845926,0,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers
http://purl.obolibrary.org/obo/hp_0100543,GCST008234,31201950,0,Cognitive impairment and C-reactive protein levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004458,GCST008234,31201950,0,Cognitive impairment and C-reactive protein levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004574,GCST008239,31201950,5,Serum total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST008238,31201950,6,Low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST008237,31201950,4,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004458,GCST008236,31201950,7,C-reactive protein levels
http://purl.obolibrary.org/obo/hp_0100543,GCST008235,31201950,5,Cognitive impairment
http://purl.obolibrary.org/obo/hp_0100543,GCST008232,31201950,0,Cognitive impairment and total cholesterol levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004574,GCST008232,31201950,0,Cognitive impairment and total cholesterol levels (pleiotropy)
http://purl.obolibrary.org/obo/hp_0100543,GCST008233,31201950,0,Cognitive impairment and LDL levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004611,GCST008233,31201950,0,Cognitive impairment and LDL levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0009767,GCST007638,30837465,50,Glycine levels
http://purl.obolibrary.org/obo/hp_0000155,GCST007839,30837455,94,Mouth ulcers
http://www.ebi.ac.uk/efo/efo_0004143,GCST007581,30833571,16,Carpal tunnel syndrome
http://www.ebi.ac.uk/efo/efo_0003888,GCST007587,30818988,0,Attention deficit hyperactivity disorder or hippocampal volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0005035,GCST007587,30818988,0,Attention deficit hyperactivity disorder or hippocampal volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003888,GCST007584,30818988,0,Attention deficit hyperactivity disorder or thalamus volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006935,GCST007584,30818988,0,Attention deficit hyperactivity disorder or thalamus volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003888,GCST007585,30818988,0,Attention deficit hyperactivity disorder or pallidum volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006933,GCST007585,30818988,0,Attention deficit hyperactivity disorder or pallidum volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003888,GCST007588,30818988,1,Attention deficit hyperactivity disorder or amygdala volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006934,GCST007588,30818988,1,Attention deficit hyperactivity disorder or amygdala volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003888,GCST007582,30818988,2,Attention deficit hyperactivity disorder or putamen volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006932,GCST007582,30818988,2,Attention deficit hyperactivity disorder or putamen volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003888,GCST007586,30818988,3,Attention deficit hyperactivity disorder or intracranial volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004886,GCST007586,30818988,3,Attention deficit hyperactivity disorder or intracranial volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004886,GCST007589,30818988,7,Intracranial volume
http://www.ebi.ac.uk/efo/efo_0005035,GCST007590,30818988,6,Hippocampal volume
http://www.ebi.ac.uk/efo/efo_0003888,GCST007591,30818988,1,Attention deficit hyperactivity disorder or caudate nucleus volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004830,GCST007591,30818988,1,Attention deficit hyperactivity disorder or caudate nucleus volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003888,GCST007583,30818988,0,Attention deficit hyperactivity disorder or nucleus accumbens volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006931,GCST007583,30818988,0,Attention deficit hyperactivity disorder or nucleus accumbens volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000638,GCST007650,30945673,5,Postoperative survival time in hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0000182,GCST007650,30945673,5,Postoperative survival time in hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0009779,GCST007427,30824882,3,Triiodothyronine/thyroxine ratio
http://www.ebi.ac.uk/efo/efo_0008392,GCST007426,30824882,3,Triiodothyronine levels
http://www.ebi.ac.uk/efo/efo_0004895,GCST007277,30818990,24,Tourette syndrome
http://www.ebi.ac.uk/efo/efo_0005130,GCST007428,30824882,1,Thyroxine levels
http://www.ebi.ac.uk/efo/efo_1001870,GCST007511,30820047,24,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0005208,GCST007644,30920136,6,Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0005199,GCST007644,30920136,6,Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0007892,GCST007644,30920136,6,Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0005208,GCST007645,30920136,7,Estimated glomerular filtration rate after 1 year in renal transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0005199,GCST007645,30920136,7,Estimated glomerular filtration rate after 1 year in renal transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0005208,GCST007646,30920136,2,Estimated glomerular filtration rate change in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0005199,GCST007646,30920136,2,Estimated glomerular filtration rate change in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0007892,GCST007646,30920136,2,Estimated glomerular filtration rate change in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0005208,GCST007647,30920136,6,Estimated glomerular filtration rate change in renal transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0005199,GCST007647,30920136,6,Estimated glomerular filtration rate change in renal transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0005208,GCST007648,30920136,7,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0005199,GCST007648,30920136,7,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0007892,GCST007648,30920136,7,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0005208,GCST007649,30920136,10,Estimated glomerular filtration rate after 5 years in renal transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0005199,GCST007649,30920136,10,Estimated glomerular filtration rate after 5 years in renal transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0004608,GCST007367,30807572,7,Meconium ileus in cystic fibrosis
http://www.ebi.ac.uk/efo/efo_0005208,GCST007495,30809046,2,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function
http://www.ebi.ac.uk/efo/efo_0003884,GCST007495,30809046,2,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function
http://www.ebi.ac.uk/efo/efo_0000378,GCST007495,30809046,2,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function
http://www.ebi.ac.uk/efo/efo_0009795,GCST007536,30808845,6,Serum urea levels
http://purl.obolibrary.org/obo/hp_0030775,GCST007537,30808802,10,Modic changes
http://www.ebi.ac.uk/efo/efo_0000249,GCST007825,30805717,4,Alzheimer's disease or fasting glucose levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004465,GCST007825,30805717,4,Alzheimer's disease or fasting glucose levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000249,GCST007827,30805717,20,Alzheimer's disease or HDL levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004612,GCST007827,30805717,20,Alzheimer's disease or HDL levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000249,GCST007826,30805717,3,Alzheimer's disease or fasting insulin levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004466,GCST007826,30805717,3,Alzheimer's disease or fasting insulin levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0008341,GCST007985,30804565,42,Snoring
http://www.ebi.ac.uk/efo/efo_0007875,GCST007984,30804565,1,Daytime sleepiness
http://www.ebi.ac.uk/efo/efo_0008328,GCST007986,30804565,70,Ease of getting up in the morning
http://www.ebi.ac.uk/efo/efo_0005271,GCST007982,30804565,53,Sleep duration
http://www.ebi.ac.uk/efo/efo_0008328,GCST007983,30804565,274,Morningness
http://www.ebi.ac.uk/efo/efo_0003756,GCST007554,30804558,4,Autism and educational attainment (MTAG)
http://www.ebi.ac.uk/efo/efo_0004784,GCST007554,30804558,4,Autism and educational attainment (MTAG)
http://www.ebi.ac.uk/efo/efo_0000692,GCST007555,30804558,4,Autism and schizophrenia (MTAG)
http://www.ebi.ac.uk/efo/efo_0003756,GCST007555,30804558,4,Autism and schizophrenia (MTAG)
http://www.ebi.ac.uk/efo/efo_0003761,GCST007553,30804558,8,Autism and major depressive disorder (MTAG)
http://www.ebi.ac.uk/efo/efo_0003756,GCST007553,30804558,8,Autism and major depressive disorder (MTAG)
http://www.ebi.ac.uk/efo/efo_0007876,GCST007388,30804566,55,Insomnia symptoms (never/rarely vs. usually)
http://www.ebi.ac.uk/efo/efo_0007828,GCST007987,30804565,7,Daytime nap
http://www.ebi.ac.uk/efo/efo_0008336,GCST007499,30801121,15,Crohn's disease (indolent vs progressive)
http://www.ebi.ac.uk/efo/efo_0000384,GCST007499,30801121,15,Crohn's disease (indolent vs progressive)
http://www.ebi.ac.uk/efo/efo_0008336,GCST007498,30801121,7,Crohn's disease (time to first abdominal surgery)
http://www.ebi.ac.uk/efo/efo_0000384,GCST007498,30801121,7,Crohn's disease (time to first abdominal surgery)
http://www.ebi.ac.uk/efo/efo_0009718,GCST007430,30804560,133,Peak expiratory flow
http://www.ebi.ac.uk/efo/efo_0004713,GCST007431,30804560,162,Lung function (FEV1/FVC)
http://www.ebi.ac.uk/efo/efo_0004314,GCST007432,30804560,206,FEV1
http://www.ebi.ac.uk/efo/efo_0003870,GCST007354,30823506,29,Intracranial aneurysm
http://www.ebi.ac.uk/efo/efo_0007876,GCST007387,30804566,49,Insomnia symptoms (never/rarely vs. sometimes/usually)
http://www.ebi.ac.uk/efo/efo_0000341,GCST007692,30804561,124,Chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0003756,GCST007556,30804558,46,Autism spectrum disorder
http://www.ebi.ac.uk/efo/efo_0007876,GCST007988,30804565,364,Insomnia
http://www.ebi.ac.uk/efo/efo_0004312,GCST007429,30804560,161,Lung function (FVC)
http://www.ebi.ac.uk/efo/efo_0008336,GCST007497,30801121,12,Crohn's disease (time to progression)
http://www.ebi.ac.uk/efo/efo_0000384,GCST007497,30801121,12,Crohn's disease (time to progression)
http://purl.obolibrary.org/obo/hp_0002140,GCST007672,30796134,17,3-month functional outcome in ischaemic stroke (modified Rankin score)
http://www.ebi.ac.uk/efo/efo_0009603,GCST007672,30796134,17,3-month functional outcome in ischaemic stroke (modified Rankin score)
http://purl.obolibrary.org/obo/hp_0002140,GCST007676,30796134,18,3-month functional outcome in ischaemic stroke (modified Rankin score)
http://www.ebi.ac.uk/efo/efo_0009603,GCST007676,30796134,18,3-month functional outcome in ischaemic stroke (modified Rankin score)
http://purl.obolibrary.org/obo/hp_0002140,GCST007675,30796134,5,3-month functional outcome in non-lacunar ischaemic stroke (modified Rankin score)
http://www.ebi.ac.uk/efo/efo_0009603,GCST007675,30796134,5,3-month functional outcome in non-lacunar ischaemic stroke (modified Rankin score)
http://www.ebi.ac.uk/efo/efo_1001504,GCST007674,30796134,2,3-month functional outcome in lacunar ischaemic stroke (modified Rankin score)
http://www.ebi.ac.uk/efo/efo_0009603,GCST007674,30796134,2,3-month functional outcome in lacunar ischaemic stroke (modified Rankin score)
http://purl.obolibrary.org/obo/hp_0002140,GCST007673,30796134,19,3-month functional outcome in ischaemic stroke (modified Rankin score)
http://www.ebi.ac.uk/efo/efo_0009603,GCST007673,30796134,19,3-month functional outcome in ischaemic stroke (modified Rankin score)
http://www.ebi.ac.uk/efo/efo_0000305,GCST007477,30787463,47,Breast cancer specific mortality in breast cancer
http://www.ebi.ac.uk/efo/efo_0004352,GCST007477,30787463,47,Breast cancer specific mortality in breast cancer
http://www.ebi.ac.uk/efo/efo_1000649,GCST007475,30787463,22,Breast cancer specific mortality in estrogen receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_0004352,GCST007475,30787463,22,Breast cancer specific mortality in estrogen receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_1000650,GCST007476,30787463,28,Breast cancer specific mortality in estrogen receptor negative breast cancer
http://www.ebi.ac.uk/efo/efo_0004352,GCST007476,30787463,28,Breast cancer specific mortality in estrogen receptor negative breast cancer
http://www.ebi.ac.uk/efo/efo_0000270,GCST007266,30787307,11,Adult asthma
http://www.ebi.ac.uk/efo/efo_0007772,GCST007616,30779856,3,Calcaneus stiffness index
http://www.ebi.ac.uk/efo/efo_0007788,GCST007484,30778226,1,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007503,30778226,2,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007502,30778226,43,Waist-to-hip ratio adjusted for BMI (additive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007501,30778226,2,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007500,30778226,47,Waist-to-hip ratio adjusted for BMI (additive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007496,30778226,1,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007494,30778226,17,Waist-to-hip ratio adjusted for BMI (additive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007493,30778226,1,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007492,30778226,18,Waist-to-hip ratio adjusted for BMI (additive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007491,30778226,2,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007483,30778226,57,Waist-to-hip ratio adjusted for BMI (additive genetic model)
http://www.ebi.ac.uk/efo/efo_0007788,GCST007487,30778226,56,Waist-to-hip ratio adjusted for BMI (additive genetic model)
http://www.ebi.ac.uk/efo/efo_0009794,GCST007538,30767168,6,Cellular nuclear factor (erythroid-derived 2)-like 2 levels
http://www.ebi.ac.uk/efo/efo_0009439,GCST007280,30760885,2,Number of twin births
http://www.ebi.ac.uk/efo/efo_0005301,GCST007469,30741946,17,Rapid automised naming of digits
http://www.ebi.ac.uk/efo/efo_0005301,GCST007470,30741946,19,Rapid automised naming of letters
http://www.ebi.ac.uk/efo/efo_0005229,GCST007479,30741946,28,Reading ability (multivariate)
http://www.ebi.ac.uk/efo/efo_0005301,GCST007465,30741946,17,Phoneme awareness
http://www.ebi.ac.uk/efo/efo_0005300,GCST007466,30741946,17,Word reading
http://www.ebi.ac.uk/efo/efo_0005301,GCST007467,30741946,19,Word spelling
http://www.ebi.ac.uk/efo/efo_0005299,GCST007478,30741946,23,Non-word reading
http://www.ebi.ac.uk/efo/efo_0004335,GCST007471,30741946,12,Short-term memory (digit-span task)
http://www.ebi.ac.uk/efo/efo_0005301,GCST007473,30741946,15,Rapid automised naming of pictures
http://www.ebi.ac.uk/efo/efo_0007675,GCST007434,30738427,26,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event)
http://www.ebi.ac.uk/efo/efo_1001480,GCST007434,30738427,26,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event)
http://www.ebi.ac.uk/efo/efo_0008336,GCST007434,30738427,26,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event)
http://www.ebi.ac.uk/efo/efo_0000203,GCST007824,30737484,10,Monoclonal gammopathy of undetermined significance
http://www.ebi.ac.uk/efo/efo_0006882,GCST007391,30745170,1,Deliberate self-harm
http://www.ebi.ac.uk/efo/efo_0006882,GCST007389,30745170,3,Suicidality
http://www.ebi.ac.uk/efo/efo_0006882,GCST007390,30745170,1,Suicidality (suicidal ideation/attempts)
http://www.ebi.ac.uk/efo/efo_0005543,GCST007842,30714141,5,Glioma
http://www.ebi.ac.uk/efo/efo_0007006,GCST007413,30718454,8,Depressive symptoms x independent stressful life events interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0007781,GCST007413,30718454,8,Depressive symptoms x independent stressful life events interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0007006,GCST007412,30718454,9,Depressive symptoms x independent stressful life events interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0007781,GCST007412,30718454,9,Depressive symptoms x independent stressful life events interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0007006,GCST007411,30718454,11,Depressive symptoms x dependent stressful life events interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0007781,GCST007411,30718454,11,Depressive symptoms x dependent stressful life events interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0007006,GCST007410,30718454,12,Depressive symptoms x dependent stressful life events interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0007781,GCST007410,30718454,12,Depressive symptoms x dependent stressful life events interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0007006,GCST007409,30718454,0,Depressive symptoms x stressful life events interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0007781,GCST007409,30718454,0,Depressive symptoms x stressful life events interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0007006,GCST007408,30718454,0,Depressive symptoms x stressful life events interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0007781,GCST007408,30718454,0,Depressive symptoms x stressful life events interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0007010,GCST007630,30718321,5,Drug experimentation measurement
http://www.ebi.ac.uk/efo/efo_0006946,GCST007629,30718321,5,Impulsivity (non-planning)
http://www.ebi.ac.uk/efo/efo_0006946,GCST007628,30718321,5,Impulsivity (motor)
http://www.ebi.ac.uk/efo/efo_0006946,GCST007627,30718321,5,Impulsivity (attentional)
http://www.ebi.ac.uk/efo/efo_0006946,GCST007626,30718321,6,Lack of perseverance
http://www.ebi.ac.uk/efo/efo_0006946,GCST007625,30718321,5,Negative urgency
http://www.ebi.ac.uk/efo/efo_0006946,GCST007624,30718321,6,Positive urgency
http://www.ebi.ac.uk/efo/efo_0006946,GCST007623,30718321,5,Lack of premeditation
http://www.ebi.ac.uk/efo/efo_0006946,GCST007622,30718321,5,Impulsivity
http://www.ebi.ac.uk/efo/efo_0004735,GCST007440,30718733,5,Alanine aminotransferase levels
http://www.ebi.ac.uk/efo/efo_0004736,GCST007439,30718733,4,Aspartate aminotransferase levels
http://www.ebi.ac.uk/efo/efo_0004574,GCST007441,30718733,10,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST007438,30718733,17,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST007442,30718733,8,Low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST007437,30718733,11,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0001360,GCST007847,30718926,126,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0007006,GCST007407,30718454,0,Depressive symptoms
http://www.ebi.ac.uk/efo/efo_0003761,GCST007342,30718901,98,Depression
http://www.ebi.ac.uk/efo/efo_0006946,GCST007621,30718321,5,Sensation seeking
http://www.ebi.ac.uk/efo/efo_0009761,GCST007549,30794219,5,Osteolysis in total hip arthroplasty
http://www.ebi.ac.uk/efo/efo_0009806,GCST007549,30794219,5,Osteolysis in total hip arthroplasty
http://www.ebi.ac.uk/efo/efo_0009761,GCST007550,30794219,11,Osteolysis in total hip arthroplasty (time to prosthesis revision)
http://www.ebi.ac.uk/efo/efo_0009806,GCST007550,30794219,11,Osteolysis in total hip arthroplasty (time to prosthesis revision)
http://www.ebi.ac.uk/efo/efo_0008336,GCST007550,30794219,11,Osteolysis in total hip arthroplasty (time to prosthesis revision)
http://www.ebi.ac.uk/efo/efo_0006312,GCST007392,30704525,2,Mitochondrial DNA copy number (white blood cells)
http://purl.obolibrary.org/obo/go_0036276,GCST007356,30700811,4,Antidepressant treatment resistance (number of drugs prescribed)
http://purl.obolibrary.org/obo/go_0036276,GCST007355,30700811,4,Antidepressant treatment resistance (> 2 drugs prescribed)
http://www.ebi.ac.uk/efo/efo_0007006,GCST007297,30705256,23,Psychological distress
http://www.ebi.ac.uk/efo/efo_0006312,GCST007399,30704525,2,Mitochondrial DNA copy number
http://www.orpha.net/ordo/orphanet_101081,GCST007304,30706531,4,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A
http://www.ebi.ac.uk/efo/efo_0009699,GCST007304,30706531,4,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A
http://www.ebi.ac.uk/efo/efo_0006312,GCST007398,30704525,1,Mitochondrial DNA copy number (white blood cells)
http://www.ebi.ac.uk/efo/efo_0006312,GCST007397,30704525,1,Mitochondrial DNA copy number (white blood cells)
http://www.ebi.ac.uk/efo/efo_0006312,GCST007396,30704525,2,Mitochondrial DNA copy number (white blood cells)
http://www.ebi.ac.uk/efo/efo_0006312,GCST007395,30704525,3,Mitochondrial DNA copy number
http://www.ebi.ac.uk/efo/efo_0006312,GCST007394,30704525,2,Mitochondrial DNA copy number
http://www.ebi.ac.uk/efo/efo_0006312,GCST007393,30704525,11,Mitochondrial DNA copy number
http://purl.obolibrary.org/obo/mondo_0021107,GCST007779,30711515,0,Pandemrix-induced narcolepsy
http://www.ebi.ac.uk/efo/efo_0004645,GCST007779,30711515,0,Pandemrix-induced narcolepsy
http://www.ebi.ac.uk/efo/efo_0009762,GCST007406,30729179,2,Healthspan
http://www.ebi.ac.uk/efo/efo_0004612,GCST008070,30698716,141,HDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST008071,30698716,0,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0007878,GCST008071,30698716,0,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0007878,GCST008072,30698716,0,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0004612,GCST008072,30698716,0,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0004611,GCST008073,30698716,0,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0007878,GCST008073,30698716,0,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0004530,GCST008074,30698716,162,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0007878,GCST008074,30698716,162,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0007878,GCST008075,30698716,226,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004612,GCST008075,30698716,226,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004530,GCST008076,30698716,89,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST008077,30698716,88,LDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST008078,30698716,153,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0007878,GCST008078,30698716,153,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0009369,GCST007637,30694715,55,Diffusing capacity of carbon monoxide
http://www.ebi.ac.uk/efo/efo_0004611,GCST008079,30698716,162,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004329,GCST008079,30698716,162,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0007614,GCST007100,30697902,16,Asthma exacerbations in inhaled corticosteroid treatment
http://purl.obolibrary.org/obo/go_0031960,GCST007100,30697902,16,Asthma exacerbations in inhaled corticosteroid treatment
http://www.ebi.ac.uk/efo/efo_0008328,GCST007576,30696823,440,Chronotype
http://www.ebi.ac.uk/efo/efo_0008328,GCST007565,30696823,213,Morning person
http://www.ebi.ac.uk/efo/efo_0004530,GCST008080,30698716,0,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0004329,GCST008080,30698716,0,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0004329,GCST008081,30698716,0,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0004612,GCST008081,30698716,0,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0004611,GCST008082,30698716,0,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0004329,GCST008082,30698716,0,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
http://www.ebi.ac.uk/efo/efo_0004530,GCST008083,30698716,162,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004329,GCST008083,30698716,162,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004329,GCST008084,30698716,236,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004612,GCST008084,30698716,236,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004530,GCST008087,30698716,138,Triglyceride levels in current drinkers
http://www.ebi.ac.uk/efo/efo_0004329,GCST008087,30698716,138,Triglyceride levels in current drinkers
http://www.ebi.ac.uk/efo/efo_0004329,GCST008085,30698716,190,HDL cholesterol levels in current drinkers
http://www.ebi.ac.uk/efo/efo_0004612,GCST008085,30698716,190,HDL cholesterol levels in current drinkers
http://www.ebi.ac.uk/efo/efo_0004611,GCST008086,30698716,118,LDL cholesterol levels in current drinkers
http://www.ebi.ac.uk/efo/efo_0004329,GCST008086,30698716,118,LDL cholesterol levels in current drinkers
http://www.ebi.ac.uk/efo/efo_0004210,GCST007050,30692554,2,Gallstone disease
http://www.ebi.ac.uk/efo/efo_0004215,GCST007777,30692689,0,Psychiatric disorder
http://www.ebi.ac.uk/efo/efo_0003888,GCST007777,30692689,0,Psychiatric disorder
http://www.ebi.ac.uk/efo/efo_0000692,GCST007777,30692689,0,Psychiatric disorder
http://www.ebi.ac.uk/efo/efo_0003756,GCST007777,30692689,0,Psychiatric disorder
http://www.ebi.ac.uk/efo/efo_0000677,GCST007777,30692689,0,Psychiatric disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST007777,30692689,0,Psychiatric disorder
http://www.ebi.ac.uk/efo/efo_0004247,GCST007777,30692689,0,Psychiatric disorder
http://www.ebi.ac.uk/efo/efo_0009951,GCST007976,30678657,2,Postoperative myocardial infarction after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0009953,GCST007976,30678657,2,Postoperative myocardial infarction after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0009951,GCST007981,30678657,3,Postoperative complication after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0005323,GCST007981,30678657,3,Postoperative complication after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0009951,GCST007980,30678657,2,Postoperative delirium after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0009954,GCST007980,30678657,2,Postoperative delirium after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0009952,GCST007978,30678657,4,Postoperative atrial fibrillation after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0009951,GCST007978,30678657,4,Postoperative atrial fibrillation after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0009955,GCST007979,30678657,4,Postoperative acute renal failure after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0009951,GCST007979,30678657,4,Postoperative acute renal failure after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0009956,GCST007977,30678657,4,Postoperative stroke after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0009951,GCST007977,30678657,4,Postoperative stroke after cardiac surgery
http://www.ebi.ac.uk/efo/efo_0004831,GCST007217,30679814,8,RR interval (heart rate)
http://www.ebi.ac.uk/efo/efo_0004682,GCST007218,30679814,13,QT interval
http://www.ebi.ac.uk/efo/efo_0005055,GCST007227,30679814,12,QRS duration
http://www.ebi.ac.uk/efo/efo_0004462,GCST007226,30679814,15,PR interval
http://www.ebi.ac.uk/efo/efo_0004340,GCST007242,30677029,2,Normal body mass index vs. thin
http://www.ebi.ac.uk/efo/efo_0007041,GCST007241,30677029,13,Obesity (extreme)
http://www.ebi.ac.uk/efo/efo_0007041,GCST007240,30677029,14,Obese vs. thin
http://www.ebi.ac.uk/efo/efo_0004208,GCST007112,30674883,1,Vitiligo (late onset)
http://www.ebi.ac.uk/efo/efo_0009948,GCST007956,30674050,0,Maternal chorioamnionitis
http://www.ebi.ac.uk/efo/efo_0001359,GCST007605,30674623,1,Glycated hemoglobin levels in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004541,GCST007605,30674623,1,Glycated hemoglobin levels in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004208,GCST007111,30674883,2,Vitiligo (early onset)
http://www.ebi.ac.uk/efo/efo_0007805,GCST007282,30670697,42,HDL cholesterol x physical activity interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0003940,GCST007282,30670697,42,HDL cholesterol x physical activity interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0004530,GCST007285,30670697,0,Triglycerides x physical activity interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0003940,GCST007285,30670697,0,Triglycerides x physical activity interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0003940,GCST007281,30670697,3,HDL cholesterol x physical activity interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0004612,GCST007281,30670697,3,HDL cholesterol x physical activity interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0004611,GCST007283,30670697,1,LDL cholesterol x physical activity interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0003940,GCST007283,30670697,1,LDL cholesterol x physical activity interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0004530,GCST007286,30670697,24,Triglycerides x physical activity interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0003940,GCST007286,30670697,24,Triglycerides x physical activity interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0004611,GCST007284,30670697,39,LDL cholesterol x physical activity interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0003940,GCST007284,30670697,39,LDL cholesterol x physical activity interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0004341,GCST007293,30664634,144,Body fat distribution (arm fat ratio)
http://www.ebi.ac.uk/efo/efo_0007822,GCST007451,30664655,11,"Skin, hair and eye pigmentation (multivariate analysis)"
http://www.ebi.ac.uk/efo/efo_0009764,GCST007451,30664655,11,"Skin, hair and eye pigmentation (multivariate analysis)"
http://www.ebi.ac.uk/efo/efo_0007009,GCST007451,30664655,11,"Skin, hair and eye pigmentation (multivariate analysis)"
http://www.ebi.ac.uk/efo/efo_0009764,GCST007456,30664655,3,Eye color (hue)
http://www.ebi.ac.uk/efo/efo_0004341,GCST007294,30664634,186,Body fat distribution (trunk fat ratio)
http://www.ebi.ac.uk/efo/efo_0004341,GCST007295,30664634,176,Body fat distribution (leg fat ratio)
http://www.ebi.ac.uk/efo/efo_0009764,GCST007455,30664655,11,Eye color (brightness)
http://www.ebi.ac.uk/efo/efo_0007822,GCST007454,30664655,7,Hair color
http://www.ebi.ac.uk/efo/efo_0009764,GCST007453,30664655,9,Eye color
http://www.ebi.ac.uk/efo/efo_0009764,GCST007457,30664655,10,Eye color (saturation)
http://www.ebi.ac.uk/efo/efo_0002506,GCST007093,30664745,35,Osteoarthritis
http://www.ebi.ac.uk/efo/efo_1000786,GCST007092,30664745,30,Osteoarthritis of the hip or knee
http://www.ebi.ac.uk/efo/efo_0004616,GCST007092,30664745,30,Osteoarthritis of the hip or knee
http://www.ebi.ac.uk/efo/efo_1000786,GCST007091,30664745,30,Osteoarthritis (hip)
http://www.ebi.ac.uk/efo/efo_0004616,GCST007090,30664745,13,Knee osteoarthritis
http://www.ebi.ac.uk/efo/efo_0007009,GCST007452,30664655,14,Skin pigmentation
http://www.ebi.ac.uk/efo/efo_0004228,GCST007606,30661239,11,Drug-induced liver injury (flucloxacillin)
http://www.ebi.ac.uk/efo/efo_0004228,GCST007607,30661239,0,Drug-induced liver injury (amoxicillin)
http://www.ebi.ac.uk/efo/efo_0004228,GCST007608,30661239,0,Drug-induced liver injury (isoxazolyl penicillins)
http://www.ebi.ac.uk/efo/efo_0009959,GCST008105,30661054,3,Diverticular disease
http://www.ebi.ac.uk/efo/efo_0005134,GCST007382,30659259,38,Plasma free amino acid levels (adjusted for twenty other PFAAs)
http://www.orpha.net/ordo/orphanet_3389,GCST007232,30713548,18,Tuberculosis (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0005134,GCST007385,30659259,34,Plasma free amino acid levels
http://www.ebi.ac.uk/efo/efo_0009962,GCST008107,30654714,0,Radioiodine-refractory disease in thyroid cancer
http://www.ebi.ac.uk/efo/efo_0002892,GCST008107,30654714,0,Radioiodine-refractory disease in thyroid cancer
http://www.ebi.ac.uk/efo/efo_0009766,GCST007386,30659259,1,Plasma free asparagine levels
http://www.ebi.ac.uk/efo/efo_0009759,GCST007521,30657218,5,Asthma-chronic obstructive  pulmonary disease overlap syndrome
http://www.ebi.ac.uk/efo/efo_0007860,GCST007279,30659475,1,Attention deficit hyperactivity disorder symptom score
http://www.ebi.ac.uk/efo/efo_0005665,GCST007305,30659137,3,White matter hyperintensity volume
http://www.ebi.ac.uk/efo/efo_0000685,GCST007843,30891314,31,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0009773,GCST007384,30659259,1,Plasma free proline levels
http://www.ebi.ac.uk/efo/efo_0009759,GCST007520,30657218,0,Asthma-chronic obstructive pulmonary disease overlap syndrome in asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST007520,30657218,0,Asthma-chronic obstructive pulmonary disease overlap syndrome in asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST007519,30657218,2,Adult asthma
http://www.orpha.net/ordo/orphanet_3389,GCST007231,30713548,12,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0004228,GCST007774,30664875,0,Drug-induced liver injury
http://www.ebi.ac.uk/efo/efo_0005134,GCST007383,30659259,82,Plasma free amino acid levels (adjusted for one other PFAA)
http://www.ebi.ac.uk/efo/efo_0009282,GCST007814,30868120,1,Sodium levels in epilepsy
http://www.ebi.ac.uk/efo/efo_0000474,GCST007814,30868120,1,Sodium levels in epilepsy
http://www.ebi.ac.uk/efo/efo_0009891,GCST007813,30868120,3,"Carbamazepine metabolism (carbamazepine-10,11-diol to carbamazepine ratio) in epilepsy"
http://www.ebi.ac.uk/efo/efo_0000474,GCST007813,30868120,3,"Carbamazepine metabolism (carbamazepine-10,11-diol to carbamazepine ratio) in epilepsy"
http://www.ebi.ac.uk/efo/efo_0009893,GCST007812,30868120,1,Oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0009895,GCST007812,30868120,1,Oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0000474,GCST007812,30868120,1,Oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0009894,GCST007811,30868120,7,Carbamazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0000474,GCST007811,30868120,7,Carbamazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0008484,GCST007811,30868120,7,Carbamazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0009894,GCST007810,30868120,3,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0009893,GCST007810,30868120,3,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0009895,GCST007810,30868120,3,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0000474,GCST007810,30868120,3,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0008484,GCST007810,30868120,3,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0009894,GCST007809,30868120,3,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0009893,GCST007809,30868120,3,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0009895,GCST007809,30868120,3,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0000474,GCST007809,30868120,3,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0008484,GCST007809,30868120,3,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
http://www.ebi.ac.uk/efo/efo_0006882,GCST007019,30655502,2,Suicide attempt severity
http://www.ebi.ac.uk/efo/efo_0004715,GCST007729,30651383,0,Small subcortical brain infarct
http://purl.obolibrary.org/obo/go_0061477,GCST007664,30648747,47,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_1000649,GCST007664,30648747,47,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_0004346,GCST007357,30649180,4,Voxel-wise structural brain imaging measurements
http://www.ebi.ac.uk/efo/efo_0004715,GCST007730,30651383,0,Brain infarct
http://www.ebi.ac.uk/efo/efo_0004833,GCST006987,30647433,2,Neutrophil level response to clozapine in treatment-resistant schizophrenia
http://www.ebi.ac.uk/efo/efo_0004609,GCST006987,30647433,2,Neutrophil level response to clozapine in treatment-resistant schizophrenia
http://purl.obolibrary.org/obo/go_0097338,GCST006987,30647433,2,Neutrophil level response to clozapine in treatment-resistant schizophrenia
http://www.ebi.ac.uk/efo/efo_0008579,GCST007324,30643258,167,Adventurousness
http://www.ebi.ac.uk/efo/efo_0006335,GCST007288,30693016,0,Systolic blood pressure x alcohol consumption interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0004329,GCST007288,30693016,0,Systolic blood pressure x alcohol consumption interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0007878,GCST007472,30643251,155,Alcohol consumption (drinks per week) (MTAG)
http://www.ebi.ac.uk/efo/efo_0006527,GCST007468,30643251,685,Smoking initiation (ever regular vs never regular) (MTAG)
http://www.ebi.ac.uk/efo/efo_0004319,GCST007464,30643251,82,Smoking cessation (MTAG)
http://www.ebi.ac.uk/efo/efo_0006525,GCST007463,30643251,88,Cigarettes smoked per day (MTAG)
http://www.ebi.ac.uk/efo/efo_0005670,GCST007462,30643251,173,Age of smoking initiation (MTAG)
http://www.ebi.ac.uk/efo/efo_0007878,GCST007461,30643251,99,Alcohol consumption (drinks per week)
http://www.ebi.ac.uk/efo/efo_0006527,GCST007474,30643251,378,Smoking initiation (ever regular vs never regular)
http://www.ebi.ac.uk/efo/efo_0004319,GCST007460,30643251,24,Smoking cessation
http://www.ebi.ac.uk/efo/efo_0006525,GCST007459,30643251,55,Smoking behaviour (cigarettes smoked per day)
http://www.ebi.ac.uk/efo/efo_0005670,GCST007458,30643251,10,Age of smoking initiation
http://www.ebi.ac.uk/efo/efo_0004769,GCST007363,30649302,10,Anti-Mullerian hormone levels in pre-menopausal women of late reproductive age
http://www.ebi.ac.uk/efo/efo_1000391,GCST007443,30643255,18,Nasal polyps
http://www.ebi.ac.uk/efo/efo_1001486,GCST007036,30643196,5,Primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0004619,GCST007401,30642921,36,Factor VII activity
http://www.ebi.ac.uk/efo/efo_0000305,GCST006985,30642363,0,Breast cancer
http://www.ebi.ac.uk/efo/efo_0007869,GCST007341,30643256,231,Well-being spectrum (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0008579,GCST007322,30643258,0,General risk tolerance
http://www.ebi.ac.uk/efo/efo_0006336,GCST007287,30693016,1,Diastolic blood pressure x alcohol consumption interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0004329,GCST007287,30693016,1,Diastolic blood pressure x alcohol consumption interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0008579,GCST007323,30643258,106,Risk-taking tendency (4-domain principal component model)
http://www.ebi.ac.uk/efo/efo_0008579,GCST007325,30643258,312,General risk tolerance (MTAG)
http://www.ebi.ac.uk/efo/efo_0007006,GCST007340,30643256,239,Depressive symptoms
http://www.ebi.ac.uk/efo/efo_0007660,GCST007339,30643256,263,Neuroticism
http://www.ebi.ac.uk/efo/efo_0007869,GCST007338,30643256,191,Positive affect
http://www.ebi.ac.uk/efo/efo_0007869,GCST007337,30643256,148,Life satisfaction
http://www.ebi.ac.uk/efo/efo_0004619,GCST007402,30642921,6,Factor VII activity or levels
http://www.ebi.ac.uk/efo/efo_1000024,GCST007444,30643255,4,Chronic rhinosinusitis
http://www.ebi.ac.uk/efo/efo_0007877,GCST007326,30643258,118,Number of sexual partners
http://www.ebi.ac.uk/efo/efo_0004318,GCST007327,30643258,223,Smoking status (ever vs never smokers)
http://www.ebi.ac.uk/efo/efo_0007878,GCST007328,30643258,85,Alcohol consumption (drinks per week)
http://www.ebi.ac.uk/efo/efo_0008579,GCST007329,30643258,42,Automobile speeding propensity
http://www.ebi.ac.uk/efo/efo_0000249,GCST007600,30636644,91,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0003761,GCST007254,30626913,3,Broad depression or major depressive disorder (self-reported)
http://www.ebi.ac.uk/efo/efo_0003761,GCST007257,30626913,16,Broad depression or schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST007257,30626913,16,Broad depression or schizophrenia
http://www.ebi.ac.uk/efo/efo_0003761,GCST007255,30626913,3,Broad depression or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST007255,30626913,3,Broad depression or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST007256,30626913,1,Broad depression or major depressive disorder (recurrent)
http://www.ebi.ac.uk/efo/efo_0005670,GCST007603,30617275,40,Smoking initiation
http://www.ebi.ac.uk/efo/efo_0004319,GCST007604,30617275,2,Smoking cessation
http://www.ebi.ac.uk/efo/efo_0006526,GCST007601,30617275,0,Smoking behaviour (cigarette pack-years)
http://www.ebi.ac.uk/efo/efo_0006525,GCST007602,30617275,8,Smoking behaviour (cigarettes smoked per day)
http://www.ebi.ac.uk/efo/efo_0000249,GCST007320,30617256,108,Alzheimer's disease or family history of Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0009268,GCST007320,30617256,108,Alzheimer's disease or family history of Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0009268,GCST007321,30617256,33,Family history of Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000249,GCST007319,30617256,33,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0004570,GCST007018,30621171,23,Serum bilirubin levels in metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0000195,GCST007018,30621171,23,Serum bilirubin levels in metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0006882,GCST006977,30610202,2,Predicted suicide risk
http://www.ebi.ac.uk/efo/efo_0008111,GCST007017,30621171,26,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0004570,GCST007017,30621171,26,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0000195,GCST007017,30621171,26,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0008343,GCST007016,30621171,16,Serum bilirubin levels x sex interaction in metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0004570,GCST007016,30621171,16,Serum bilirubin levels x sex interaction in metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0000195,GCST007016,30621171,16,Serum bilirubin levels x sex interaction in metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0000692,GCST007782,30610197,0,Schizophrenia or intelligence (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004337,GCST007782,30610197,0,Schizophrenia or intelligence (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004337,GCST007781,30610197,0,Bipolar disorder or intelligence (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000289,GCST007781,30610197,0,Bipolar disorder or intelligence (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003888,GCST006983,30610198,16,Attention deficit hyperactivity disorder or cannabis use
http://www.ebi.ac.uk/efo/efo_0007585,GCST006983,30610198,16,Attention deficit hyperactivity disorder or cannabis use
http://www.ebi.ac.uk/efo/efo_0004321,GCST006978,30610202,0,Suicide attempts
http://www.ebi.ac.uk/efo/efo_0005208,GCST007344,30604766,136,Estimated glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0007047,GCST007726,30610941,4,Anti-Toxoplasma gondii IgG seropositivity
http://purl.obolibrary.org/obo/hp_0002140,GCST006935,30582445,1,3-month functional outcome in ischaemic stroke (modified Rankin score)
http://www.ebi.ac.uk/efo/efo_0009603,GCST006935,30582445,1,3-month functional outcome in ischaemic stroke (modified Rankin score)
http://www.ebi.ac.uk/efo/efo_0009270,GCST006979,30598549,1103,Heel bone mineral density
http://www.ebi.ac.uk/efo/efo_0003931,GCST006980,30598549,14,Fractures
http://www.ebi.ac.uk/efo/efo_0007800,GCST007064,30593698,162,Body fat percentage
http://www.ebi.ac.uk/efo/efo_0004995,GCST007063,30593698,407,Fat-free mass
http://www.ebi.ac.uk/efo/efo_0009946,GCST007955,30685440,0,Low density lipoprotein triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004784,GCST007037,30595370,322,Educational attainment (years of education)
http://www.ebi.ac.uk/efo/efo_0004736,GCST007378,30589442,39,Aspartate aminotransferase levels in low alcohol consumption
http://www.ebi.ac.uk/efo/efo_0007878,GCST007378,30589442,39,Aspartate aminotransferase levels in low alcohol consumption
http://www.ebi.ac.uk/efo/efo_0004735,GCST007379,30589442,16,Alanine aminotransferase levels in low alcohol consumption
http://www.ebi.ac.uk/efo/efo_0007878,GCST007379,30589442,16,Alanine aminotransferase levels in low alcohol consumption
http://www.ebi.ac.uk/efo/efo_0004532,GCST007380,30589442,25,Gamma glutamyl transferase levels in low alcohol consumption
http://www.ebi.ac.uk/efo/efo_0007878,GCST007380,30589442,25,Gamma glutamyl transferase levels in low alcohol consumption
http://www.ebi.ac.uk/efo/efo_0004736,GCST007377,30589442,19,Aspartate aminotransferase levels in excessive alcohol consumption
http://www.ebi.ac.uk/efo/efo_0007878,GCST007377,30589442,19,Aspartate aminotransferase levels in excessive alcohol consumption
http://www.ebi.ac.uk/efo/efo_0004735,GCST007381,30589442,28,Alanine aminotransferase levels in excessive alcohol consumption
http://www.ebi.ac.uk/efo/efo_0007878,GCST007381,30589442,28,Alanine aminotransferase levels in excessive alcohol consumption
http://www.ebi.ac.uk/efo/efo_0007747,GCST007252,30595539,4,Postburn scar pliability
http://www.ebi.ac.uk/efo/efo_0007747,GCST007251,30595539,2,Postburn scar height
http://www.ebi.ac.uk/efo/efo_0006335,GCST007087,30595370,720,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0003958,GCST007086,30595370,84,Sunburns
http://www.ebi.ac.uk/efo/efo_0006527,GCST007085,30595370,181,Smoking status
http://www.ebi.ac.uk/efo/efo_0007660,GCST007084,30595370,147,Neuroticism
http://www.ebi.ac.uk/efo/efo_0008328,GCST007083,30595370,168,Morning person
http://www.ebi.ac.uk/efo/efo_0007822,GCST007082,30595370,449,Hair color
http://www.ebi.ac.uk/efo/efo_0004312,GCST007081,30595370,570,Lung function (FVC)
http://www.ebi.ac.uk/efo/efo_0004713,GCST007080,30595370,719,Lung function (FEV1/FVC)
http://www.ebi.ac.uk/efo/efo_0004704,GCST007079,30595370,93,Age at menopause
http://www.ebi.ac.uk/efo/efo_0004703,GCST007078,30595370,340,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0001360,GCST007077,30595370,85,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000684,GCST007076,30595370,109,Respiratory diseases
http://www.ebi.ac.uk/efo/efo_0004705,GCST007073,30595370,153,Hypothyroidism
http://purl.obolibrary.org/obo/hp_0000964,GCST007075,30595370,198,Eczema
http://www.ebi.ac.uk/efo/efo_0000319,GCST007072,30595370,316,Cardiovascular disease
http://www.ebi.ac.uk/efo/efo_0005140,GCST007071,30595370,85,Autoimmune traits
http://www.ebi.ac.uk/efo/efo_0004308,GCST007070,30595370,757,White blood cell count
http://www.ebi.ac.uk/efo/efo_0005192,GCST007074,30595370,690,Red cell distribution width
http://www.ebi.ac.uk/efo/efo_0004305,GCST007069,30595370,891,Red blood cell count
http://www.ebi.ac.uk/efo/efo_0004527,GCST007068,30595370,799,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0004842,GCST007065,30595370,737,Eosinophil counts
http://www.ebi.ac.uk/efo/efo_0004343,GCST007067,30595370,509,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0004339,GCST007841,30595370,2451,Height
http://www.ebi.ac.uk/efo/efo_0009270,GCST007066,30595370,1176,Heel bone mineral density
http://www.ebi.ac.uk/efo/efo_0004340,GCST007039,30595370,964,Body mass index
http://www.ebi.ac.uk/efo/efo_0007825,GCST007038,30595370,348,Balding type 1
http://www.ebi.ac.uk/efo/efo_0004532,GCST007376,30589442,16,Gamma glutamyl transferase levels in excessive alcohol consumption
http://www.ebi.ac.uk/efo/efo_0007878,GCST007376,30589442,16,Gamma glutamyl transferase levels in excessive alcohol consumption
http://www.ebi.ac.uk/efo/efo_0009785,GCST007631,30593799,3,Hepatitis C (spontaneous viral clearance)
http://www.ebi.ac.uk/efo/efo_0003047,GCST007631,30593799,3,Hepatitis C (spontaneous viral clearance)
http://www.ebi.ac.uk/efo/efo_0009785,GCST007634,30593799,1,Hepatitis C (spontaneous viral clearance)
http://www.ebi.ac.uk/efo/efo_0003047,GCST007634,30593799,1,Hepatitis C (spontaneous viral clearance)
http://www.ebi.ac.uk/efo/efo_0009785,GCST007633,30593799,2,Hepatitis C (spontaneous viral clearance)
http://www.ebi.ac.uk/efo/efo_0003047,GCST007633,30593799,2,Hepatitis C (spontaneous viral clearance)
http://www.ebi.ac.uk/efo/efo_0009785,GCST007632,30593799,1,Hepatitis C (spontaneous viral clearance)
http://www.ebi.ac.uk/efo/efo_0003047,GCST007632,30593799,1,Hepatitis C (spontaneous viral clearance)
http://www.ebi.ac.uk/efo/efo_0004695,GCST007998,30591961,28,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0004621,GCST007260,30583557,3,B6 vitamer levels (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004621,GCST007265,30583557,1,Plasma pyridoxic acid to pyridoxal phosphate ratio
http://www.ebi.ac.uk/efo/efo_0004621,GCST007264,30583557,1,Plasma pyridoxal phosphate to pyridoxal ratio
http://www.ebi.ac.uk/efo/efo_0004621,GCST007263,30583557,1,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio
http://www.ebi.ac.uk/efo/efo_0004621,GCST007262,30583557,1,Plasma pyridoxal phosphate levels
http://www.ebi.ac.uk/efo/efo_0004621,GCST007261,30583557,1,Cerebrospinal fluid pyridoxal phosphate levels
http://www.ebi.ac.uk/efo/efo_0004234,GCST006956,30583798,23,Erectile dysfunction
http://www.ebi.ac.uk/efo/efo_0005763,GCST007272,30578418,45,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST007271,30578418,4,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST007270,30578418,14,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0005763,GCST007269,30578418,331,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST007268,30578418,80,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST007267,30578418,340,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0007825,GCST007020,30573740,622,Male-pattern baldness
http://www.ebi.ac.uk/efo/efo_0000717,GCST007278,30573655,26,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)
http://www.ebi.ac.uk/efo/efo_0000685,GCST007278,30573655,26,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)
http://www.ebi.ac.uk/efo/efo_0000783,GCST007278,30573655,26,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)
http://www.ebi.ac.uk/efo/efo_0002690,GCST007278,30573655,26,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)
http://www.ebi.ac.uk/efo/efo_0000270,GCST007596,30578877,3,Adult asthma
http://purl.obolibrary.org/obo/hp_0012594,GCST007022,30566433,6,Type 2 diabetes nephropathy including microalbuminuria
http://www.ebi.ac.uk/efo/efo_0004997,GCST007022,30566433,6,Type 2 diabetes nephropathy including microalbuminuria
http://www.ebi.ac.uk/efo/efo_0000270,GCST007597,30578877,0,Adult asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST007598,30578877,0,Adult asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST007599,30578877,0,Adult asthma
http://www.ebi.ac.uk/efo/efo_0000660,GCST007089,30566500,14,Polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0004997,GCST007021,30566433,6,Type 2 diabetes nephropathy
http://www.ebi.ac.uk/efo/efo_0009751,GCST007448,30631343,21,Normal facial asymmetry (angle of surface orientation score)
http://www.ebi.ac.uk/efo/efo_0009751,GCST007450,30631343,5,Normal facial asymmetry (deformation magnitude)
http://www.ebi.ac.uk/efo/efo_0003888,GCST006916,30563984,14,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0000182,GCST008104,30662464,0,Nucleoside diphosphate kinase A levels in hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0009947,GCST008104,30662464,0,Nucleoside diphosphate kinase A levels in hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0009751,GCST007449,30631343,4,Normal facial asymmetry (angle of deformation score)
http://www.ebi.ac.uk/efo/efo_0001075,GCST007239,30557369,28,Ovarian cancer
http://www.ebi.ac.uk/efo/efo_0005842,GCST007259,30557370,8,Severe skin toxicity response to cetuximab in colorectal cancer
http://www.ebi.ac.uk/efo/efo_0000701,GCST007259,30557370,8,Severe skin toxicity response to cetuximab in colorectal cancer
http://www.ebi.ac.uk/efo/efo_0007682,GCST007259,30557370,8,Severe skin toxicity response to cetuximab in colorectal cancer
http://www.ebi.ac.uk/efo/efo_0003890,GCST007700,30556296,1,Substance use disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST007316,30552317,7,Response to ketamine in bipolar disorder or major depression (antidepressant effects)
http://www.ebi.ac.uk/efo/efo_0007006,GCST007316,30552317,7,Response to ketamine in bipolar disorder or major depression (antidepressant effects)
http://www.ebi.ac.uk/efo/efo_0009748,GCST007316,30552317,7,Response to ketamine in bipolar disorder or major depression (antidepressant effects)
http://www.ebi.ac.uk/efo/efo_0000289,GCST007316,30552317,7,Response to ketamine in bipolar disorder or major depression (antidepressant effects)
http://www.ebi.ac.uk/efo/efo_0003778,GCST007043,30552173,38,Psoriatic arthritis
http://www.ebi.ac.uk/efo/efo_0001359,GCST007433,30552108,9,Fulminant type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0003761,GCST007317,30552317,12,Response to ketamine in bipolar disorder or major depression (dissociation effects)
http://www.ebi.ac.uk/efo/efo_0009748,GCST007317,30552317,12,Response to ketamine in bipolar disorder or major depression (dissociation effects)
http://www.ebi.ac.uk/efo/efo_0009750,GCST007317,30552317,12,Response to ketamine in bipolar disorder or major depression (dissociation effects)
http://www.ebi.ac.uk/efo/efo_0000289,GCST007317,30552317,12,Response to ketamine in bipolar disorder or major depression (dissociation effects)
http://www.ebi.ac.uk/efo/efo_0002618,GCST007235,30541042,9,Pancreatic ductal adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0003894,GCST007234,30542056,20,Acne (severe)
http://www.ebi.ac.uk/efo/efo_0000270,GCST006911,30552067,27,Asthma (moderate or severe)
http://www.ebi.ac.uk/efo/efo_0003924,GCST006986,30531825,40,Red vs. brown/black hair color
http://www.ebi.ac.uk/efo/efo_0008002,GCST006912,30531941,7,Physical activity (overall physical activity time)
http://www.ebi.ac.uk/efo/efo_0008002,GCST006915,30531941,2,Physical activity (moderate intensity activity duration)
http://www.ebi.ac.uk/efo/efo_0008002,GCST007110,30531941,1,Physical activity (walking duration)
http://www.ebi.ac.uk/efo/efo_0008002,GCST006913,30531941,6,Sedentary behaviour duration
http://www.ebi.ac.uk/efo/efo_0005271,GCST006914,30531941,27,Sleep duration
http://www.ebi.ac.uk/efo/efo_0005917,GCST007353,30531953,11,Generalized epilepsy
http://www.ebi.ac.uk/efo/efo_0004263,GCST007352,30531953,1,Focal epilepsy
http://www.ebi.ac.uk/efo/efo_0004263,GCST007351,30531953,0,Focal epilepsy (with lesion other than hippocampal sclerosis)
http://www.ebi.ac.uk/efo/efo_0004263,GCST007350,30531953,2,Focal epilepsy (with hippocampal sclerosis)
http://www.ebi.ac.uk/efo/efo_0004263,GCST007349,30531953,0,Focal epilepsy (lesion negative)
http://www.ebi.ac.uk/efo/efo_0007262,GCST007348,30531953,0,"Epilepsy (generalized, with tonic-clonic seizures alone)"
http://www.orpha.net/ordo/orphanet_307,GCST007347,30531953,1,Juvenile myoclonic epilepsy
http://www.orpha.net/ordo/orphanet_1941,GCST007346,30531953,0,Juvenile absence epilepsy
http://www.orpha.net/ordo/orphanet_64280,GCST007345,30531953,2,Childhood absence epilepsy
http://www.ebi.ac.uk/efo/efo_0003924,GCST006989,30531825,56,Brown vs. black hair color
http://www.ebi.ac.uk/efo/efo_0003924,GCST006988,30531825,213,Blond vs. brown/black hair color
http://www.ebi.ac.uk/efo/efo_0000474,GCST007343,30531953,3,Epilepsy
http://www.ebi.ac.uk/efo/efo_0008375,GCST006976,30535121,139,Macular thickness
http://www.orpha.net/ordo/orphanet_908,GCST007233,30531935,1,Fragile X syndrome
http://www.ebi.ac.uk/efo/efo_0005842,GCST007552,30529582,40,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0001361,GCST007228,30527956,3,Pulmonary arterial hypertension
http://www.ebi.ac.uk/efo/efo_0003761,GCST007230,30563176,5,Severe depressive disorders in coronary artery disease
http://www.ebi.ac.uk/efo/efo_0000378,GCST007230,30563176,5,Severe depressive disorders in coronary artery disease
http://www.ebi.ac.uk/efo/efo_0000249,GCST007330,30514930,2,Alzheimer's disease with memory domain impairment
http://www.ebi.ac.uk/efo/efo_0001072,GCST007330,30514930,2,Alzheimer's disease with memory domain impairment
http://www.ebi.ac.uk/efo/efo_0000249,GCST007331,30514930,0,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000249,GCST007333,30514930,7,Alzheimer's disease with no specific cognitive domain impairment
http://purl.obolibrary.org/obo/hp_0100543,GCST007332,30514930,9,Alzheimer's disease with multiple cognitive domain impairments
http://www.ebi.ac.uk/efo/efo_0000249,GCST007332,30514930,9,Alzheimer's disease with multiple cognitive domain impairments
http://www.ebi.ac.uk/efo/efo_0000249,GCST007318,30514930,9,Alzheimer's disease with visuospatial domain impairment
http://www.ebi.ac.uk/efo/efo_0009752,GCST007318,30514930,9,Alzheimer's disease with visuospatial domain impairment
http://www.ebi.ac.uk/efo/efo_0000249,GCST007334,30514930,6,Alzheimer's disease with language domain impairment
http://www.ebi.ac.uk/efo/efo_0005425,GCST007334,30514930,6,Alzheimer's disease with language domain impairment
http://www.ebi.ac.uk/efo/efo_0005842,GCST007856,30510241,121,Colorectal cancer or advanced adenoma
http://www.ebi.ac.uk/efo/efo_0005406,GCST007856,30510241,121,Colorectal cancer or advanced adenoma
http://www.ebi.ac.uk/efo/efo_0009783,GCST007435,30510157,7,Carotid plaque
http://www.ebi.ac.uk/efo/efo_0004860,GCST007436,30510157,13,Carotid intima media thickness
http://www.ebi.ac.uk/efo/efo_1000648,GCST007699,30511388,0,Developmental dysplasia of the hip
http://www.ebi.ac.uk/efo/efo_0000220,GCST007276,30510082,0,Acute lymphoblastic leukemia (B-cell precursor)
http://www.orpha.net/ordo/orphanet_232,GCST007210,30578281,1,Alloimmunization response to red blood cell transfusion in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0006804,GCST007210,30578281,1,Alloimmunization response to red blood cell transfusion in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0006802,GCST007210,30578281,1,Alloimmunization response to red blood cell transfusion in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0004574,GCST007544,30525989,1,Coronary artery disease and total cholesterol levels (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0000378,GCST007544,30525989,1,Coronary artery disease and total cholesterol levels (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004530,GCST007545,30525989,3,Coronary artery disease and triglyceride levels (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0000378,GCST007545,30525989,3,Coronary artery disease and triglyceride levels (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004611,GCST007546,30525989,2,Coronary artery disease and LDL cholesterol levels (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0000378,GCST007546,30525989,2,Coronary artery disease and LDL cholesterol levels (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004612,GCST007547,30525989,1,Coronary artery disease and HDL cholesterol levels (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0000378,GCST007547,30525989,1,Coronary artery disease and HDL cholesterol levels (multivariate analysis)
http://purl.obolibrary.org/obo/hp_0002619,GCST007225,30566020,30,Varicose veins
http://www.ebi.ac.uk/efo/efo_0004210,GCST007209,30504769,28,Gallstone disease
http://www.ebi.ac.uk/efo/efo_1001857,GCST006984,30498034,7,Takayasu arteritis
http://www.ebi.ac.uk/efo/efo_0000384,GCST007216,30500874,9,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0006335,GCST007703,30487518,146,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0000537,GCST007707,30487518,106,Hypertension
http://www.ebi.ac.uk/efo/efo_0006340,GCST007706,30487518,149,Mean arterial pressure
http://www.ebi.ac.uk/efo/efo_0005763,GCST007705,30487518,94,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST007704,30487518,122,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0003770,GCST007292,30487263,19,Diabetic retinopathy (all NPDR and PDR)
http://www.ebi.ac.uk/efo/efo_0009322,GCST007291,30487263,19,Proliferative diabetic retinopathy (vs no DR)
http://www.ebi.ac.uk/efo/efo_0003770,GCST007290,30487263,20,Diabetic retinopathy (moderate NPDR and PDR)
http://www.ebi.ac.uk/efo/efo_0009322,GCST007289,30487263,19,Proliferative diabetic retinopathy (vs NPDR and no DR)
http://www.ebi.ac.uk/efo/efo_0004776,GCST007657,30488612,0,Alcohol and nicotine co-dependence
http://www.ebi.ac.uk/efo/efo_0003888,GCST007543,30478444,15,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0009885,GCST007716,30475886,0,Frailty index
http://www.ebi.ac.uk/efo/efo_0009854,GCST007665,30468137,8,Treatment resistant depression
http://purl.obolibrary.org/obo/go_0036276,GCST007665,30468137,8,Treatment resistant depression
http://www.ebi.ac.uk/efo/efo_0000692,GCST007222,30470734,0,Schizophrenia vs schizophrenia and type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST007222,30470734,0,Schizophrenia vs schizophrenia and type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000692,GCST007220,30470734,2,Schizophrenia and type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST007220,30470734,2,Schizophrenia and type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0007006,GCST007666,30468137,16,Depressive symptom improvement
http://purl.obolibrary.org/obo/go_0036276,GCST007666,30468137,16,Depressive symptom improvement
http://www.ebi.ac.uk/efo/efo_0000692,GCST007224,30470734,0,Type 2 diabetes vs schizophrenia and type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST007224,30470734,0,Type 2 diabetes vs schizophrenia and type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0009854,GCST007667,30468137,7,Treatment resistant depression
http://purl.obolibrary.org/obo/go_0036276,GCST007667,30468137,7,Treatment resistant depression
http://www.ebi.ac.uk/efo/efo_0000692,GCST007223,30470734,1,Schizophrenia vs type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST007223,30470734,1,Schizophrenia vs type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST007221,30470734,2,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000692,GCST007219,30470734,1,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0001358,GCST007651,30467376,0,Post-traumatic stress disorder
http://www.ebi.ac.uk/efo/efo_0004242,GCST007208,30456828,20,Obsessive-compulsive disorder
http://www.ebi.ac.uk/efo/efo_0004630,GCST007447,30586737,2,vWF and FVIII levels
http://www.ebi.ac.uk/efo/efo_0004629,GCST007447,30586737,2,vWF and FVIII levels
http://www.ebi.ac.uk/efo/efo_0004629,GCST007446,30586737,87,vWF levels
http://www.ebi.ac.uk/efo/efo_0004242,GCST007207,30456828,2,Obsessive-compulsive disorder x sex interaction
http://www.ebi.ac.uk/efo/efo_0008343,GCST007207,30456828,2,Obsessive-compulsive disorder x sex interaction
http://www.ebi.ac.uk/efo/efo_0004630,GCST007445,30586737,66,Factor VIII levels
http://www.ebi.ac.uk/efo/efo_0003959,GCST007510,30452639,0,Cleft lip with or without cleft palate
http://www.ebi.ac.uk/efo/efo_0004985,GCST007652,30453346,0,Platelet count and reactivity phenotypes
http://www.ebi.ac.uk/efo/efo_0004309,GCST007652,30453346,0,Platelet count and reactivity phenotypes
http://purl.obolibrary.org/obo/hp_0000175,GCST007509,30452639,19,Cleft palate
http://www.ebi.ac.uk/efo/efo_0004881,GCST007540,30450575,11,PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0000220,GCST007540,30450575,11,PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0004881,GCST007541,30450575,0,PEG-asparaginase hypersensitivity in childhood acute lymphoblastic leukaemia (allergic reaction grade 2 or more)
http://www.ebi.ac.uk/efo/efo_0000220,GCST007541,30450575,0,PEG-asparaginase hypersensitivity in childhood acute lymphoblastic leukaemia (allergic reaction grade 2 or more)
http://www.ebi.ac.uk/efo/efo_0009790,GCST007539,30450575,0,Silent asparaginase inactivation in childhood acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0000220,GCST007539,30450575,0,Silent asparaginase inactivation in childhood acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0009791,GCST007635,30453627,6,Fatty acid desaturase activity (serum)
http://www.ebi.ac.uk/efo/efo_0009791,GCST007636,30453627,2,Fatty acid desaturase activity (adipose tissue)
http://www.ebi.ac.uk/efo/efo_0004574,GCST007203,30498476,15,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST007204,30498476,12,Low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST007202,30498476,20,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004632,GCST007505,30429480,30,Nevus count or cutaneous melanoma
http://www.ebi.ac.uk/efo/efo_0000389,GCST007505,30429480,30,Nevus count or cutaneous melanoma
http://www.ebi.ac.uk/efo/efo_0004632,GCST007504,30429480,12,Nevus count
http://www.ebi.ac.uk/efo/efo_0005279,GCST007619,30431558,1,Temporomandibular joint disorder
http://www.ebi.ac.uk/efo/efo_0001358,GCST007776,30699873,0,Post-traumatic stress disorder or brain volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006930,GCST007776,30699873,0,Post-traumatic stress disorder or brain volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006788,GCST007775,30699873,0,Anxiety disorder or brain volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006930,GCST007775,30699873,0,Anxiety disorder or brain volume (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000685,GCST006959,30423114,190,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0003144,GCST007715,30586722,0,Heart failure
http://www.ebi.ac.uk/efo/efo_0009881,GCST007714,30586722,0,Nonischemic cardiomyopathy
http://www.ebi.ac.uk/efo/efo_0001061,GCST007119,30412241,5,Cervical cancer
http://www.ebi.ac.uk/efo/efo_0000249,GCST007303,30413934,0,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004574,GCST007303,30413934,0,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004530,GCST007303,30413934,0,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004611,GCST007303,30413934,0,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004343,GCST007303,30413934,0,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001360,GCST007303,30413934,0,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004340,GCST007303,30413934,0,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004612,GCST007303,30413934,0,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000378,GCST007303,30413934,0,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0008008,GCST007507,30410027,23,Benign prostatic hyperplasia and lower urinary tract symptoms
http://www.ebi.ac.uk/efo/efo_0000284,GCST007507,30410027,23,Benign prostatic hyperplasia and lower urinary tract symptoms
http://www.ebi.ac.uk/efo/efo_0004624,GCST007513,30410027,8,Prostate-specific antigen levels
http://www.ebi.ac.uk/efo/efo_0001663,GCST007506,30410027,1,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0008008,GCST007512,30410027,22,Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded)
http://www.ebi.ac.uk/efo/efo_0000284,GCST007512,30410027,22,Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded)
http://www.ebi.ac.uk/efo/efo_0007149,GCST007595,30392061,1,Appendicitis
http://www.ebi.ac.uk/efo/efo_0009367,GCST007206,30596066,4,Brain glucose metabolism (fluorodeoxyglucose uptake)
http://www.ebi.ac.uk/efo/efo_0004458,GCST007615,30388399,80,C-reactive protein levels
http://www.ebi.ac.uk/efo/efo_0004458,GCST007614,30388399,56,C-reactive protein levels
http://www.ebi.ac.uk/efo/efo_0000195,GCST007738,30382898,24,Metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0000712,GCST007248,30383316,3,Stroke
http://purl.obolibrary.org/obo/hp_0002140,GCST007249,30383316,0,Ischemic stroke
http://www.ebi.ac.uk/efo/efo_0005423,GCST006902,30395268,10,Adolescent idiopathic scoliosis
http://www.ebi.ac.uk/efo/efo_0009363,GCST007296,30480742,2,Chronic central serous retinopathy
http://www.ebi.ac.uk/efo/efo_0009636,GCST007403,30378284,4,Verbal intelligence quotient (cesarean section interaction)
http://www.ebi.ac.uk/efo/efo_0004337,GCST007403,30378284,4,Verbal intelligence quotient (cesarean section interaction)
http://www.ebi.ac.uk/efo/efo_0009636,GCST007405,30378284,4,Full scale intelligence quotient (cesarean section interaction)
http://www.ebi.ac.uk/efo/efo_0004337,GCST007405,30378284,4,Full scale intelligence quotient (cesarean section interaction)
http://www.ebi.ac.uk/efo/efo_0009636,GCST007404,30378284,2,Performance intelligence quotient (cesarean section interaction)
http://www.ebi.ac.uk/efo/efo_0004337,GCST007404,30378284,2,Performance intelligence quotient (cesarean section interaction)
http://www.ebi.ac.uk/efo/efo_0005533,GCST007258,30377885,1,Non-steroidal anti-inflammatory drug-induced enteropathy
http://www.ebi.ac.uk/efo/efo_0009705,GCST007258,30377885,1,Non-steroidal anti-inflammatory drug-induced enteropathy
http://www.ebi.ac.uk/efo/efo_0004616,GCST006925,30374069,7,Knee osteoarthritis
http://www.ebi.ac.uk/efo/efo_1000786,GCST006926,30374069,32,Osteoarthritis (hip)
http://www.ebi.ac.uk/efo/efo_0004591,GCST007508,30373671,5,Self-reported childhood asthma in adult smokers
http://www.ebi.ac.uk/efo/efo_0006527,GCST007508,30373671,5,Self-reported childhood asthma in adult smokers
http://www.ebi.ac.uk/efo/efo_0005130,GCST006896,30367059,19,Free thyroxine concentration
http://www.ebi.ac.uk/efo/efo_0009189,GCST006897,30367059,9,Hyperthyroidism
http://www.ebi.ac.uk/efo/efo_0004705,GCST006898,30367059,8,Hypothyroidism
http://www.ebi.ac.uk/efo/efo_0004748,GCST006899,30367059,22,Thyroid stimulating hormone levels
http://www.ebi.ac.uk/efo/efo_0007707,GCST006904,30361487,41,Cerebral amyloid deposition (PET imaging)
http://purl.obolibrary.org/obo/go_0031960,GCST008230,30367910,1,Asthma control x inhaled corticosteroid treatment interaction (2df)
http://purl.obolibrary.org/obo/go_0031960,GCST008229,30367910,0,Asthma control x inhaled corticosteroid treatment interaction (1df)
http://www.ebi.ac.uk/efo/efo_0009796,GCST007558,30353303,14,Response to long-term oxygen therapy in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST007558,30353303,14,Response to long-term oxygen therapy in chronic obstructive pulmonary disease
http://purl.obolibrary.org/obo/go_0006306,GCST006660,30348214,436,DNA methylation variation (age effect)
http://www.ebi.ac.uk/efo/efo_0009458,GCST006716,30336701,15,Alcohol use disorder (total score)
http://www.ebi.ac.uk/efo/efo_0000660,GCST006659,30343302,3,Polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0007835,GCST006717,30336701,5,Alcohol use disorder (dependence and problematic use scores)
http://www.ebi.ac.uk/efo/efo_0007878,GCST006718,30336701,9,Alcohol use disorder (consumption score)
http://www.ebi.ac.uk/efo/efo_0004578,GCST007578,30339177,5,Plasma homocysteine levels
http://www.ebi.ac.uk/efo/efo_0005111,GCST007579,30339177,2,Serum folate levels
http://www.ebi.ac.uk/efo/efo_0009703,GCST007580,30339177,2,Red blood cell folate levels
http://www.ebi.ac.uk/efo/efo_0006312,GCST006936,30326835,1,Mitochondrial DNA levels
http://www.ebi.ac.uk/efo/efo_0005110,GCST007773,30327367,1,Hyperinsulinemia in less-fat diet
http://www.ebi.ac.uk/efo/efo_0004466,GCST007773,30327367,1,Hyperinsulinemia in less-fat diet
http://www.ebi.ac.uk/efo/efo_0005110,GCST007772,30327367,0,Hyperinsulinemia in more-fat diet
http://www.ebi.ac.uk/efo/efo_0004466,GCST007772,30327367,0,Hyperinsulinemia in more-fat diet
http://www.ebi.ac.uk/efo/efo_0008002,GCST007771,30327367,2,Hyperinsulinemia in lower physical activity
http://www.ebi.ac.uk/efo/efo_0004466,GCST007771,30327367,2,Hyperinsulinemia in lower physical activity
http://www.ebi.ac.uk/efo/efo_0008002,GCST007770,30327367,0,Hyperinsulinemia in higher physical activity
http://www.ebi.ac.uk/efo/efo_0004466,GCST007770,30327367,0,Hyperinsulinemia in higher physical activity
http://www.ebi.ac.uk/efo/efo_0004466,GCST007769,30327367,0,Hyperinsulinemia in non-obese individuals
http://www.ebi.ac.uk/efo/efo_0001073,GCST007768,30327367,1,Hyperinsulinemia in obesity
http://www.ebi.ac.uk/efo/efo_0004466,GCST007768,30327367,1,Hyperinsulinemia in obesity
http://www.ebi.ac.uk/efo/efo_0005110,GCST007767,30327367,1,Homeostasis model assessment of insulin resistance x saturated fatty acids interaction
http://www.ebi.ac.uk/efo/efo_0002614,GCST007767,30327367,1,Homeostasis model assessment of insulin resistance x saturated fatty acids interaction
http://www.ebi.ac.uk/efo/efo_0005110,GCST007766,30327367,1,Hyperinsulinemia x saturated fatty acids interaction
http://www.ebi.ac.uk/efo/efo_0004466,GCST007766,30327367,1,Hyperinsulinemia x saturated fatty acids interaction
http://www.ebi.ac.uk/efo/efo_0002614,GCST007765,30327367,0,Homeostasis model assessment of insulin resistance x physical activity interaction
http://www.ebi.ac.uk/efo/efo_0008002,GCST007765,30327367,0,Homeostasis model assessment of insulin resistance x physical activity interaction
http://www.ebi.ac.uk/efo/efo_0008002,GCST007764,30327367,1,Hyperinsulinemia x physical activity interaction
http://www.ebi.ac.uk/efo/efo_0004466,GCST007764,30327367,1,Hyperinsulinemia x physical activity interaction
http://www.ebi.ac.uk/efo/efo_0002614,GCST007763,30327367,0,Homeostasis model assessment of insulin resistance x BMI interaction
http://www.ebi.ac.uk/efo/efo_0004340,GCST007763,30327367,0,Homeostasis model assessment of insulin resistance x BMI interaction
http://www.ebi.ac.uk/efo/efo_0004340,GCST007762,30327367,1,Hyperinsulinemia x BMI interaction
http://www.ebi.ac.uk/efo/efo_0004466,GCST007762,30327367,1,Hyperinsulinemia x BMI interaction
http://www.ebi.ac.uk/efo/efo_0002614,GCST007761,30327367,2,Homeostasis model assessment of insulin resistance
http://www.ebi.ac.uk/efo/efo_0004466,GCST007760,30327367,0,Hyperinsulinemia
http://www.ebi.ac.uk/efo/efo_0005110,GCST007759,30327367,0,Hyperglycemia x saturated fatty acids interaction
http://www.ebi.ac.uk/efo/efo_0004465,GCST007759,30327367,0,Hyperglycemia x saturated fatty acids interaction
http://www.ebi.ac.uk/efo/efo_0008002,GCST007758,30327367,0,Hyperglycemia x physical activity interaction
http://www.ebi.ac.uk/efo/efo_0004465,GCST007758,30327367,0,Hyperglycemia x physical activity interaction
http://www.ebi.ac.uk/efo/efo_0004340,GCST007757,30327367,0,Hyperglycemia x BMI interaction
http://www.ebi.ac.uk/efo/efo_0004465,GCST007757,30327367,0,Hyperglycemia x BMI interaction
http://www.ebi.ac.uk/efo/efo_0005110,GCST007756,30327367,2,Homeostasis model assessment of insulin resistance in less-fat diet
http://www.ebi.ac.uk/efo/efo_0002614,GCST007756,30327367,2,Homeostasis model assessment of insulin resistance in less-fat diet
http://www.ebi.ac.uk/efo/efo_0005110,GCST007755,30327367,2,Homeostasis model assessment of insulin resistance in more-fat diet
http://www.ebi.ac.uk/efo/efo_0002614,GCST007755,30327367,2,Homeostasis model assessment of insulin resistance in more-fat diet
http://www.ebi.ac.uk/efo/efo_0002614,GCST007754,30327367,0,Homeostasis model assessment of insulin resistance in lower physical activity
http://www.ebi.ac.uk/efo/efo_0008002,GCST007754,30327367,0,Homeostasis model assessment of insulin resistance in lower physical activity
http://www.ebi.ac.uk/efo/efo_0002614,GCST007753,30327367,0,Homeostasis model assessment of insulin resistance in higher physical activity
http://www.ebi.ac.uk/efo/efo_0008002,GCST007753,30327367,0,Homeostasis model assessment of insulin resistance in higher physical activity
http://www.ebi.ac.uk/efo/efo_0002614,GCST007752,30327367,0,Homeostasis model assessment of insulin resistance in non-obese individuals
http://www.ebi.ac.uk/efo/efo_0002614,GCST007751,30327367,0,Homeostasis model assessment of insulin resistance in obesity
http://www.ebi.ac.uk/efo/efo_0001073,GCST007751,30327367,0,Homeostasis model assessment of insulin resistance in obesity
http://www.ebi.ac.uk/efo/efo_0005110,GCST007750,30327367,0,Hyperglycemia in less-fat diet
http://www.ebi.ac.uk/efo/efo_0004465,GCST007750,30327367,0,Hyperglycemia in less-fat diet
http://www.ebi.ac.uk/efo/efo_0005110,GCST007749,30327367,1,Hyperglycemia in more-fat diet
http://www.ebi.ac.uk/efo/efo_0004465,GCST007749,30327367,1,Hyperglycemia in more-fat diet
http://www.ebi.ac.uk/efo/efo_0008002,GCST007748,30327367,2,Hyperglycemia in higher physical activity
http://www.ebi.ac.uk/efo/efo_0004465,GCST007748,30327367,2,Hyperglycemia in higher physical activity
http://www.ebi.ac.uk/efo/efo_0008002,GCST007747,30327367,0,Hyperglycemia in lower physical activity
http://www.ebi.ac.uk/efo/efo_0004465,GCST007747,30327367,0,Hyperglycemia in lower physical activity
http://www.ebi.ac.uk/efo/efo_0004465,GCST007746,30327367,0,Hyperglycemia in non-obese individuals
http://www.ebi.ac.uk/efo/efo_0004465,GCST007745,30327367,0,Hyperglycemia in obesity
http://www.ebi.ac.uk/efo/efo_0001073,GCST007745,30327367,0,Hyperglycemia in obesity
http://www.ebi.ac.uk/efo/efo_0004465,GCST007744,30327367,1,Hyperglycemia
http://www.ebi.ac.uk/efo/efo_0004799,GCST007364,30325047,1,Gallstone disease
http://www.ebi.ac.uk/efo/efo_0004210,GCST007364,30325047,1,Gallstone disease
http://www.ebi.ac.uk/efo/efo_0004685,GCST006903,30320955,12,Hip shape (DXA scan)
http://www.ebi.ac.uk/efo/efo_0009443,GCST006719,30323354,19,BRCA1/2-negative high-risk breast cancer
http://www.ebi.ac.uk/efo/efo_0004190,GCST007199,30317457,1,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0000676,GCST007023,30315195,136,Psoriasis
http://www.ebi.ac.uk/efo/efo_1002040,GCST007157,30306274,10,Corneal astigmatism
http://purl.obolibrary.org/obo/hp_0000483,GCST007160,30306274,34,Refractive astigmatism
http://www.ebi.ac.uk/efo/efo_1002040,GCST007159,30306274,32,Corneal astigmatism
http://www.ebi.ac.uk/efo/efo_0009441,GCST006982,30305637,3,Waldenstrm macroglobulinemia / lymphoplasmacytic lymphoma
http://www.ebi.ac.uk/efo/efo_0004346,GCST006777,30305740,6,Brain imaging measurements
http://purl.obolibrary.org/obo/hp_0000483,GCST007158,30306274,10,Refractive astigmatism
http://www.ebi.ac.uk/efo/efo_0004234,GCST007118,30297428,1,Erectile dysfunction
http://purl.obolibrary.org/obo/go_0009314,GCST007200,30299488,2,Radiation-induced brain injury in nasopharyngeal carcinoma
http://www.ebi.ac.uk/efo/efo_0004252,GCST007200,30299488,2,Radiation-induced brain injury in nasopharyngeal carcinoma
http://www.ebi.ac.uk/efo/efo_0009704,GCST007200,30299488,2,Radiation-induced brain injury in nasopharyngeal carcinoma
http://www.ebi.ac.uk/efo/efo_0006510,GCST007139,30298529,11,Shingles
http://www.ebi.ac.uk/efo/efo_0002508,GCST007198,30338293,1,Parkinson's disease (age at diagnosis)
http://www.ebi.ac.uk/efo/efo_0004918,GCST007198,30338293,1,Parkinson's disease (age at diagnosis)
http://www.ebi.ac.uk/efo/efo_0003888,GCST006668,30289880,1,Psychiatric diseases (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0003761,GCST006668,30289880,1,Psychiatric diseases (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0000692,GCST006668,30289880,1,Psychiatric diseases (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0003756,GCST006668,30289880,1,Psychiatric diseases (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0000289,GCST006668,30289880,1,Psychiatric diseases (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0007660,GCST006665,30289880,14,Social science traits (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0007869,GCST006665,30289880,14,Social science traits (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0007006,GCST006665,30289880,14,Social science traits (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0004574,GCST006667,30289880,10,Lipid traits (pleiotropy) (HIPO component 2)
http://www.ebi.ac.uk/efo/efo_0004530,GCST006667,30289880,10,Lipid traits (pleiotropy) (HIPO component 2)
http://www.ebi.ac.uk/efo/efo_0004611,GCST006667,30289880,10,Lipid traits (pleiotropy) (HIPO component 2)
http://www.ebi.ac.uk/efo/efo_0004612,GCST006667,30289880,10,Lipid traits (pleiotropy) (HIPO component 2)
http://www.ebi.ac.uk/efo/efo_0004574,GCST006666,30289880,24,Lipid traits (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0004530,GCST006666,30289880,24,Lipid traits (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0004611,GCST006666,30289880,24,Lipid traits (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0004612,GCST006666,30289880,24,Lipid traits (pleiotropy) (HIPO component 1)
http://www.ebi.ac.uk/efo/efo_0009702,GCST007244,30287865,0,Intra-individual response time variability (response selection)
http://www.ebi.ac.uk/efo/efo_0009262,GCST006631,30287806,52,Nicotine dependence and major depression (severity of comorbidity)
http://www.ebi.ac.uk/efo/efo_0007006,GCST006631,30287806,52,Nicotine dependence and major depression (severity of comorbidity)
http://www.ebi.ac.uk/efo/efo_0009702,GCST007243,30287865,2,Intra-individual response time variability (selective attention)
http://www.ebi.ac.uk/efo/efo_0000649,GCST007197,30284742,1,Chronic periodontitis (localised)
http://www.orpha.net/ordo/orphanet_3389,GCST006619,30287856,2,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0000649,GCST007193,30284742,0,Chronic periodontitis (generalised)
http://www.ebi.ac.uk/efo/efo_0000649,GCST007194,30284742,0,Chronic periodontitis (severe)
http://www.ebi.ac.uk/efo/efo_0000649,GCST007195,30284742,0,Chronic periodontitis (slight)
http://www.ebi.ac.uk/efo/efo_0000649,GCST007196,30284742,0,Chronic periodontitis
http://www.ebi.ac.uk/efo/efo_0000178,GCST006707,30281874,6,Gastric cancer
http://www.ebi.ac.uk/efo/efo_0009861,GCST007724,30368896,0,Chromosomal aberration frequency (chromosome type)
http://www.ebi.ac.uk/efo/efo_0009862,GCST007723,30368896,0,Chromosomal aberration frequency (chromatid type)
http://www.ebi.ac.uk/efo/efo_0009860,GCST007722,30368896,0,Chromosomal aberration frequency (total)
http://www.ebi.ac.uk/efo/efo_0000692,GCST007201,30285260,472,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0003779,GCST007138,30284222,1,Hashimoto thyroiditis
http://www.ebi.ac.uk/efo/efo_0000692,GCST007205,30285260,13,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0007869,GCST006635,30279531,21,Eudaimonic well-being
http://www.ebi.ac.uk/efo/efo_0009405,GCST006895,30279459,0,Parasubiculum volume
http://www.ebi.ac.uk/efo/efo_0009401,GCST006894,30279459,1,HATA volume
http://www.ebi.ac.uk/efo/efo_0009402,GCST006893,30279459,0,Fimbria volume
http://www.ebi.ac.uk/efo/efo_0009398,GCST006870,30279459,7,Hippocampal tail volume
http://www.ebi.ac.uk/efo/efo_0009404,GCST006892,30279459,1,Hippocampal fissure volume
http://www.ebi.ac.uk/efo/efo_0009397,GCST006891,30279459,5,Dentate gyrus molecular layer volume
http://www.ebi.ac.uk/efo/efo_0009403,GCST006890,30279459,5,Dentate gyrus granule cell layer volume
http://www.ebi.ac.uk/efo/efo_0009396,GCST006889,30279459,5,Hippocampal subfield CA4 volume
http://www.ebi.ac.uk/efo/efo_0009395,GCST006888,30279459,3,Hippocampal subfield CA3 volume
http://www.ebi.ac.uk/efo/efo_0009394,GCST006887,30279459,3,Hippocampal subfield CA1 volume
http://www.ebi.ac.uk/efo/efo_0009399,GCST006886,30279459,4,Subiculum volume
http://www.ebi.ac.uk/efo/efo_0009400,GCST006885,30279459,1,Presubiculum volume
http://www.ebi.ac.uk/efo/efo_0009405,GCST006884,30279459,0,Parasubiculum volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009401,GCST006883,30279459,0,HATA volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009402,GCST006882,30279459,0,Fimbria volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009398,GCST006881,30279459,7,Hippocampal tail volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009404,GCST006880,30279459,0,Hippocampal fissure volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009397,GCST006878,30279459,1,Dentate gyrus molecular layer volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009403,GCST006877,30279459,1,Dentate gyrus granule cell layer volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009396,GCST006876,30279459,0,Hippocampal subfield CA4 volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009395,GCST006875,30279459,0,Hippocampal subfield CA3 volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009394,GCST006874,30279459,2,Hippocampal subfield CA1 volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009399,GCST006873,30279459,1,Subiculum volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0009400,GCST006872,30279459,1,Presubiculum volume (corrected for total hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0007869,GCST006634,30279531,6,Hedonic well-being
http://www.ebi.ac.uk/efo/efo_0005035,GCST006871,30279459,8,Total hippocampal volume
http://www.ebi.ac.uk/efo/efo_0004707,GCST006705,30281099,13,Infantile hypertrophic pyloric stenosis
http://www.ebi.ac.uk/efo/efo_0004761,GCST006905,30305239,3,Serum uric acid levels
http://purl.obolibrary.org/obo/go_0061476,GCST007137,30357299,1,Warfarin-associated bleeding
http://www.ebi.ac.uk/efo/efo_0004574,GCST006614,30275531,140,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST006613,30275531,151,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004611,GCST006612,30275531,125,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004612,GCST006611,30275531,158,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0005526,GCST006633,30276832,34,Initial alcohol sensitivity
http://www.ebi.ac.uk/efo/efo_0003821,GCST007154,30266756,2,Paediatric migraine
http://www.ebi.ac.uk/efo/efo_0004246,GCST007192,30267110,1,Coronary artery aneurysm in Kawasaki disease
http://www.ebi.ac.uk/efo/efo_1000881,GCST007192,30267110,1,Coronary artery aneurysm in Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0005246,GCST007191,30266950,1,Hypersomnia (HLA-DQB1*06:02 negative)
http://purl.obolibrary.org/obo/hp_0003418,GCST007152,30261039,4,Chronic back pain
http://www.ebi.ac.uk/efo/efo_0009701,GCST007189,30363675,1,visceral adipose tissue/total adipose tissue ratio
http://www.ebi.ac.uk/efo/efo_0004767,GCST007188,30363675,1,Visceral adipose tissue/subcutaneous adipose tissue ratio
http://www.ebi.ac.uk/efo/efo_0004765,GCST007187,30363675,1,Visceral adipose tissue
http://www.ebi.ac.uk/efo/efo_0004766,GCST007190,30363675,1,Subcutaneous adipose tissue
http://www.ebi.ac.uk/efo/efo_0008476,GCST007153,30265060,5,Delayed reward discounting
http://www.ebi.ac.uk/efo/efo_0008487,GCST007147,30258056,7,Lateral ventricular volume in normal aging
http://www.ebi.ac.uk/efo/efo_0004777,GCST008136,30252935,0,Alcohol withdrawal symptoms
http://www.ebi.ac.uk/efo/efo_0001359,GCST007247,30254083,1,Latent autoimmune diabetes vs. type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0009706,GCST007247,30254083,1,Latent autoimmune diabetes vs. type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0009706,GCST007246,30254083,4,Latent autoimmune diabetes vs. type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST007246,30254083,4,Latent autoimmune diabetes vs. type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004777,GCST008137,30252935,1,Alcohol withdrawal symptoms
http://www.ebi.ac.uk/efo/efo_0009706,GCST007245,30254083,3,Latent autoimmune diabetes
http://www.ebi.ac.uk/efo/efo_0004670,GCST006672,30319691,14,Cerebrospinal fluid AB1-42 levels
http://www.ebi.ac.uk/efo/efo_0000685,GCST007425,30251476,4,Carotid plaques in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0009783,GCST007425,30251476,4,Carotid plaques in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000685,GCST007088,30251476,3,Ischemic heart disease in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0001425,GCST007088,30251476,3,Ischemic heart disease in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000685,GCST007041,30251476,1,Cardiovascular event in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000319,GCST007041,30251476,1,Cardiovascular event in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000685,GCST007040,30251476,3,Carotid intima media thickness in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0007117,GCST007040,30251476,3,Carotid intima media thickness in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0007823,GCST006706,30248107,4,Eyebrow thickness
http://www.ebi.ac.uk/efo/efo_0007998,GCST006671,30319691,20,Cognitive impairment test score
http://www.ebi.ac.uk/efo/efo_0007709,GCST006674,30319691,14,Cerebrospinal fluid p-Tau181p:AB1-42 ratio
http://www.ebi.ac.uk/efo/efo_0007708,GCST006673,30319691,14,Cerebrospinal fluid t-tau:AB1-42 ratio
http://www.ebi.ac.uk/efo/efo_0000717,GCST006493,30247649,11,Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0009282,GCST007107,30242241,3,Diastolic blood pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006336,GCST007107,30242241,3,Diastolic blood pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0009282,GCST007108,30242241,1,Systolic blood pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006335,GCST007108,30242241,1,Systolic blood pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0009700,GCST007177,30242048,0,Perceptual rivalry (binocular rivalry task)
http://www.ebi.ac.uk/efo/efo_0009700,GCST007178,30242048,1,Perceptual rivalry (voluntary modulation strength)
http://www.ebi.ac.uk/efo/efo_0009700,GCST007176,30242048,0,Perceptual rivalry (Necker cube stimulus)
http://www.ebi.ac.uk/efo/efo_1002006,GCST007135,30237584,4,Resistant hypertension
http://www.ebi.ac.uk/efo/efo_1002006,GCST007136,30237584,3,Resistant hypertension
http://www.ebi.ac.uk/efo/efo_0008601,GCST008067,30230522,0,Pemphigus foliaceus
http://www.ebi.ac.uk/efo/efo_0004719,GCST008068,30230522,2,Pemphigus vulgaris
http://www.ebi.ac.uk/efo/efo_1000749,GCST008069,30230522,2,Pemphigus
http://www.ebi.ac.uk/efo/efo_0009698,GCST007179,30324795,1,Fasting glucose in pregnancy (gestational week 14-16)
http://www.ebi.ac.uk/efo/efo_0000731,GCST007548,30226466,0,Uterine fibroids
http://www.ebi.ac.uk/efo/efo_0007144,GCST007109,30228239,1,Diarrhoea-associated Entamoeba histolytica infection
http://www.ebi.ac.uk/efo/efo_0009698,GCST007186,30324795,0,Timing of glucose curve peak in pregnancy (gestational week 30-32)
http://www.ebi.ac.uk/efo/efo_0009698,GCST007185,30324795,0,Timing of glucose curve peak in pregnancy (gestational week 14-16)
http://www.ebi.ac.uk/efo/efo_0009698,GCST007184,30324795,1,General glucose level in pregnancy (gestational week 30-32)
http://www.ebi.ac.uk/efo/efo_0009698,GCST007183,30324795,0,General glucose level in pregnancy (gestational week 14-16)
http://www.ebi.ac.uk/efo/efo_0009698,GCST007182,30324795,2,Two-hour glucose in pregnancy (gestational week 30-32)
http://www.ebi.ac.uk/efo/efo_0009698,GCST007181,30324795,0,Two-hour glucose in pregnancy (gestational week 14-16)
http://www.ebi.ac.uk/efo/efo_0009698,GCST007180,30324795,0,Fasting glucose in pregnancy (gestational week 30-32)
http://purl.obolibrary.org/obo/go_0050913,GCST006703,30223776,11,Bitter taste perception (multivariate analysis)
http://purl.obolibrary.org/obo/go_0050913,GCST006704,30223776,6,Bitter taste perception
http://www.ebi.ac.uk/efo/efo_0004530,GCST006682,30275891,16,HDL cholesterol and triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST006682,30275891,16,HDL cholesterol and triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST006669,30263053,8,HDL cholesterol and triglyceride levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004612,GCST006669,30263053,8,HDL cholesterol and triglyceride levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004612,GCST006663,30263053,4,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004530,GCST006664,30263053,2,Triglyceride levels
http://purl.obolibrary.org/obo/go_1901557,GCST006683,30275891,0,Response to fenofibrate
http://www.ebi.ac.uk/efo/efo_0000292,GCST008217,31277774,0,Non-muscle-invasive bladder cancer age at diagnosis
http://www.ebi.ac.uk/efo/efo_0004918,GCST008217,31277774,0,Non-muscle-invasive bladder cancer age at diagnosis
http://www.ebi.ac.uk/efo/efo_0000292,GCST008222,31277774,0,Non-muscle-invasive bladder cancer EORTC risk category
http://www.ebi.ac.uk/efo/efo_0007936,GCST008222,31277774,0,Non-muscle-invasive bladder cancer EORTC risk category
http://www.ebi.ac.uk/efo/efo_0000292,GCST008221,31277774,0,Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1)
http://www.ebi.ac.uk/efo/efo_0008336,GCST008221,31277774,0,Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1)
http://www.ebi.ac.uk/efo/efo_0000292,GCST008220,31277774,0,Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta)
http://www.ebi.ac.uk/efo/efo_0008336,GCST008220,31277774,0,Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta)
http://www.ebi.ac.uk/efo/efo_0000292,GCST008219,31277774,0,Non-muscle-invasive bladder cancer tumour size (< 3 cm vs  3 cm)
http://www.ebi.ac.uk/efo/efo_0008336,GCST008219,31277774,0,Non-muscle-invasive bladder cancer tumour size (< 3 cm vs  3 cm)
http://www.ebi.ac.uk/efo/efo_0000292,GCST008216,31277774,1,Non-muscle-invasive bladder cancer tumour size
http://www.ebi.ac.uk/efo/efo_0008336,GCST008216,31277774,1,Non-muscle-invasive bladder cancer tumour size
http://www.ebi.ac.uk/efo/efo_0000292,GCST008218,31277774,0,Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs  70 years)
http://www.ebi.ac.uk/efo/efo_0004918,GCST008218,31277774,0,Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs  70 years)
http://www.ebi.ac.uk/efo/efo_0003761,GCST007101,30217971,0,Seasonality in depression
http://www.ebi.ac.uk/efo/efo_0006876,GCST007101,30217971,0,Seasonality in depression
http://www.ebi.ac.uk/efo/efo_0000289,GCST007101,30217971,0,Seasonality in depression
http://www.ebi.ac.uk/efo/efo_0000311,GCST007106,30277654,2,Response to opioid analgesics in cancer (pain decrease)
http://www.ebi.ac.uk/efo/efo_0008541,GCST007106,30277654,2,Response to opioid analgesics in cancer (pain decrease)
http://www.ebi.ac.uk/efo/efo_0000649,GCST006486,30218097,12,Periodontitis
http://www.ebi.ac.uk/efo/efo_0009381,GCST006491,30217807,19,Circulating fibroblast growth factor 23 levels
http://www.ebi.ac.uk/efo/efo_0003761,GCST007102,30217971,18,Seasonality and depression
http://www.ebi.ac.uk/efo/efo_0006876,GCST007102,30217971,18,Seasonality and depression
http://www.ebi.ac.uk/efo/efo_0000289,GCST007102,30217971,18,Seasonality and depression
http://www.ebi.ac.uk/efo/efo_0001378,GCST006432,30213928,9,Multiple myeloma
http://www.ebi.ac.uk/efo/efo_0006527,GCST007618,30219835,0,Blood pressure (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004325,GCST007618,30219835,0,Blood pressure (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004325,GCST007617,30219835,0,Blood pressure x alcohol consumption interaction
http://www.ebi.ac.uk/efo/efo_0007878,GCST007617,30219835,0,Blood pressure x alcohol consumption interaction
http://purl.obolibrary.org/obo/go_0097366,GCST007360,30206298,0,Bronchodilator response in asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST007360,30206298,0,Bronchodilator response in asthma
http://www.ebi.ac.uk/efo/efo_0004812,GCST007542,30206230,178,High IL-1beta levels in gingival crevicular fluid
http://purl.obolibrary.org/obo/hp_0000175,GCST006680,30277614,3,Nonsyndromic cleft lip with or without cleft palate x sex interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0008343,GCST006680,30277614,3,Nonsyndromic cleft lip with or without cleft palate x sex interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0003959,GCST006680,30277614,3,Nonsyndromic cleft lip with or without cleft palate x sex interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0009693,GCST007149,30201983,1,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0007853,GCST007149,30201983,1,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0000220,GCST007149,30201983,1,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0009693,GCST007148,30201983,1,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0007853,GCST007148,30201983,1,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0000220,GCST007148,30201983,1,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0004277,GCST007366,30202041,0,Homocysteine level response to multivitamin in cerebral infarction
http://www.ebi.ac.uk/efo/efo_0004578,GCST007366,30202041,0,Homocysteine level response to multivitamin in cerebral infarction
http://purl.obolibrary.org/obo/go_0033273,GCST007366,30202041,0,Homocysteine level response to multivitamin in cerebral infarction
http://www.ebi.ac.uk/efo/efo_0007761,GCST008102,30199657,0,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004314,GCST008102,30199657,0,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0007761,GCST008099,30199657,1,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004312,GCST008099,30199657,1,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0006809,GCST008100,30199657,0,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004312,GCST008100,30199657,0,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004314,GCST008101,30199657,0,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0006809,GCST008101,30199657,0,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
http://www.ebi.ac.uk/efo/efo_0004920,GCST007365,30202041,0,Progression-free survival response to gemcitabine in breast cancer
http://purl.obolibrary.org/obo/go_0036272,GCST007365,30202041,0,Progression-free survival response to gemcitabine in breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST007365,30202041,0,Progression-free survival response to gemcitabine in breast cancer
http://www.ebi.ac.uk/efo/efo_0009693,GCST007151,30201983,0,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0007853,GCST007151,30201983,0,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0000220,GCST007151,30201983,0,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0009693,GCST007150,30201983,1,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0007853,GCST007150,30201983,1,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0000220,GCST007150,30201983,1,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia
http://www.ebi.ac.uk/efo/efo_0001360,GCST007359,30270018,0,Type 2 diabetes or coronary artery disease (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000378,GCST007359,30270018,0,Type 2 diabetes or coronary artery disease (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0007786,GCST006958,30202859,5,Length of menstrual cycle
http://www.ebi.ac.uk/efo/efo_0004318,GCST006427,30219690,54,Depression in smokers
http://www.ebi.ac.uk/efo/efo_0003761,GCST006427,30219690,54,Depression in smokers
http://www.ebi.ac.uk/efo/efo_0000183,GCST007062,30194254,6,Hodgkin's lymphoma
http://www.ebi.ac.uk/efo/efo_0000731,GCST006462,30194396,53,Uterine fibroids
http://www.ebi.ac.uk/efo/efo_0009437,GCST006859,30188897,0,Infant death in continuous marriage (Proportion of children died <1 year)
http://www.ebi.ac.uk/efo/efo_0004285,GCST006586,30220432,46,Urinary albumin excretion
http://www.ebi.ac.uk/efo/efo_0009101,GCST006770,30188897,0,Age at first birth in continuous marriage
http://www.ebi.ac.uk/efo/efo_0009101,GCST006769,30188897,0,Age at first birth
http://www.ebi.ac.uk/efo/efo_0009440,GCST006776,30188897,0,Age at last pregnancy in continuous marriage
http://www.ebi.ac.uk/efo/efo_0009440,GCST006775,30188897,0,Age at last pregnancy
http://www.ebi.ac.uk/efo/efo_0009439,GCST006774,30188897,0,Number of twin births in continuous marriage
http://www.ebi.ac.uk/efo/efo_0009439,GCST006773,30188897,0,Number of twin births
http://www.ebi.ac.uk/efo/efo_0009438,GCST006772,30188897,0,Number of pregnancies in continuous marriage
http://www.ebi.ac.uk/efo/efo_0009438,GCST006771,30188897,1,Number of pregnancies
http://www.ebi.ac.uk/efo/efo_0006923,GCST006768,30188897,0,Proportion of live births in continuous marriage
http://www.ebi.ac.uk/efo/efo_0006923,GCST006767,30188897,0,Proportion of live births
http://www.ebi.ac.uk/efo/efo_0006923,GCST006766,30188897,0,Number of live births in continuous marriage
http://www.ebi.ac.uk/efo/efo_0006923,GCST006765,30188897,1,Number of live births
http://www.ebi.ac.uk/efo/efo_0009436,GCST006764,30188897,0,Juvenile survival in continuous marriage (Proportion of children surviving at 15 years)
http://www.ebi.ac.uk/efo/efo_0009436,GCST006763,30188897,0,Juvenile survival (Proportion of children surviving at 15 years)
http://www.ebi.ac.uk/efo/efo_0009436,GCST006762,30188897,0,Juvenile survival in continuous marriage (Number of children surviving at 15 years)
http://www.ebi.ac.uk/efo/efo_0009436,GCST006761,30188897,0,Juvenile survival (Number of children surviving at 15 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006760,30188897,0,Juvenile death in continuous marriage (Proportion of children surviving at 5 years but died <15 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006759,30188897,0,Juvenile death (Proportion of children surviving at 5 years but died <15 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006758,30188897,0,Juvenile death in continuous marriage (Number of children surviving at 5 years but died <15 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006757,30188897,0,Juvenile death (Number of children surviving at 5 years but died <15 years)
http://www.ebi.ac.uk/efo/efo_0009436,GCST006756,30188897,0,Child survival in continuous marriage (Proportion of children surviving at 5 years)
http://www.ebi.ac.uk/efo/efo_0009436,GCST006755,30188897,0,Child survival (Proportion of children surviving at 5 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006754,30188897,0,Child death in continuous marriage (Proportion of children surviving at 1 year but died <5 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006753,30188897,0,Child death (Proportion of children surviving at 1 year but died <5 years)
http://www.ebi.ac.uk/efo/efo_0009436,GCST006752,30188897,0,Child survival in continuous marriage (Number of children surviving at 5 years)
http://www.ebi.ac.uk/efo/efo_0009436,GCST006751,30188897,0,Child survival (Number of children surviving at 5 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006750,30188897,0,Child death in continuous marriage (Number of children surviving at 1 year but died <5 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006749,30188897,0,Child death (Number of children surviving at 1 year but died <5 years)
http://www.ebi.ac.uk/efo/efo_0004509,GCST006748,30188897,0,Deoxygenated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004509,GCST006747,30188897,1,Oxygenated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004351,GCST006746,30188897,0,Pulse rate
http://www.ebi.ac.uk/efo/efo_0005682,GCST006745,30188897,0,Oxygen saturation of hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0006923,GCST006744,30188897,0,Proportion of stillbirths in continuous marriage
http://www.ebi.ac.uk/efo/efo_0006923,GCST006743,30188897,0,Proportion of stillbirths
http://www.ebi.ac.uk/efo/efo_0006923,GCST006742,30188897,1,Number of stillbirths in continuous marriage
http://www.ebi.ac.uk/efo/efo_0006923,GCST006741,30188897,0,Number of stillbirths
http://www.ebi.ac.uk/efo/efo_0006923,GCST006740,30188897,0,Proportion of miscarriages in continuous marriage
http://www.ebi.ac.uk/efo/efo_0006923,GCST006739,30188897,0,Proportion of miscarriages
http://www.ebi.ac.uk/efo/efo_0006923,GCST006738,30188897,0,Number of miscarriages in continuous marriage
http://www.ebi.ac.uk/efo/efo_0006923,GCST006737,30188897,0,Number of miscarriages
http://www.ebi.ac.uk/efo/efo_0009436,GCST006736,30188897,0,Infant survival in continuous marriage (Proportion of children surviving at 1 year)
http://www.ebi.ac.uk/efo/efo_0009436,GCST006735,30188897,0,Infant survival (Proportion of children surviving at 1 year)
http://www.ebi.ac.uk/efo/efo_0009436,GCST006734,30188897,0,Infant survival in continuous marriage (Number of children surviving at 1 year)
http://www.ebi.ac.uk/efo/efo_0009436,GCST006733,30188897,0,Infant survival (Number of children surviving at 1 year)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006731,30188897,0,Infant death (Proportion of children died <1 year)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006729,30188897,0,Infant death in continuous marriage (Number of children died <1 year)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006728,30188897,0,Infant death (Number of children died <1 year)
http://www.ebi.ac.uk/efo/efo_0004285,GCST006463,30220432,23,Urinary albumin excretion (no hypertensive medication)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006730,30188897,1,"Infant, child and juvenile death in continuous marriage (proportion of children died <15 years)"
http://www.ebi.ac.uk/efo/efo_0009437,GCST006727,30188897,1,"Infant, child and juvenile death (proportion of children died <15 years)"
http://www.ebi.ac.uk/efo/efo_0009437,GCST006726,30188897,0,"Infant, child and juvenile death in continuous marriage (number of children died <15 years)"
http://www.ebi.ac.uk/efo/efo_0009437,GCST006725,30188897,0,"Infant, child and juvenile death (number of children died <15 years)"
http://www.ebi.ac.uk/efo/efo_0009437,GCST006724,30188897,0,Infant and Child death in continuous marriage (Proportion of children died <5 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006723,30188897,0,Infant and Child death (Proportion of children died <5 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006722,30188897,0,Infant and Child death in continuous marriage (Number of children died <5 years)
http://www.ebi.ac.uk/efo/efo_0009437,GCST006721,30188897,0,Infant and Child death (Number of children died <5 years)
http://www.ebi.ac.uk/efo/efo_0004509,GCST006720,30188897,1,Hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004505,GCST006485,30185882,15,Telomere length
http://www.ebi.ac.uk/efo/efo_0003770,GCST006424,30178632,2,Severe diabetic retinopathy in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST006424,30178632,2,Severe diabetic retinopathy in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004274,GCST006425,30181573,2,Gout in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST006425,30181573,2,Gout in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0008579,GCST006461,30181555,49,Self-reported risk-taking behaviour
http://www.ebi.ac.uk/efo/efo_0004531,GCST006426,30181573,7,Serum urate levels in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST006426,30181573,7,Serum urate levels in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0009959,GCST006479,30177863,153,Diverticular disease
http://www.ebi.ac.uk/efo/efo_0009410,GCST006616,30196971,8,Uterine fibroid number (single vs multiple)
http://www.ebi.ac.uk/efo/efo_0009410,GCST006617,30196971,6,Uterine fibroid size (maximum volume)
http://www.ebi.ac.uk/efo/efo_0009410,GCST006618,30196971,5,Uterine fibroid size (maximum dimension)
http://www.ebi.ac.uk/efo/efo_0000685,GCST006607,30166627,1,Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate)
http://www.ebi.ac.uk/efo/efo_0004653,GCST006607,30166627,1,Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate)
http://www.ebi.ac.uk/efo/efo_0004304,GCST006607,30166627,1,Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate)
http://www.ebi.ac.uk/efo/efo_0008601,GCST006520,30169916,2,Pemphigus foliaceus
http://www.ebi.ac.uk/efo/efo_0004719,GCST006521,30169916,4,Pemphigus vulgaris
http://www.ebi.ac.uk/efo/efo_0000685,GCST006610,30166627,1,Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score)
http://www.ebi.ac.uk/efo/efo_0004653,GCST006610,30166627,1,Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score)
http://www.ebi.ac.uk/efo/efo_0009435,GCST006610,30166627,1,Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score)
http://www.ebi.ac.uk/efo/efo_0000685,GCST006609,30166627,7,Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)
http://www.ebi.ac.uk/efo/efo_0004653,GCST006609,30166627,7,Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)
http://www.ebi.ac.uk/efo/efo_0005413,GCST006609,30166627,7,Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)
http://www.ebi.ac.uk/efo/efo_0000685,GCST006608,30166627,1,Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score)
http://www.ebi.ac.uk/efo/efo_0004778,GCST006608,30166627,1,Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score)
http://www.ebi.ac.uk/efo/efo_0004653,GCST006608,30166627,1,Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score)
http://www.ebi.ac.uk/efo/efo_0000685,GCST006606,30166627,13,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)
http://www.ebi.ac.uk/efo/efo_0004653,GCST006606,30166627,13,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)
http://www.ebi.ac.uk/efo/efo_0005413,GCST006606,30166627,13,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)
http://www.ebi.ac.uk/efo/efo_0001360,GCST006861,30172742,0,Femoral neck bone mineral density or type 2 diabetes (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0007785,GCST006861,30172742,0,Femoral neck bone mineral density or type 2 diabetes (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004326,GCST007481,30166351,1,Heart rate
http://www.ebi.ac.uk/efo/efo_0009902,GCST007482,30166351,1,Handedness
http://www.ebi.ac.uk/efo/efo_0007821,GCST007486,30166351,33,Hair morphology traits
http://www.ebi.ac.uk/efo/efo_0003784,GCST007488,30166351,43,Skin pigmentation traits
http://www.ebi.ac.uk/efo/efo_0003949,GCST007489,30166351,13,Eye color traits
http://purl.obolibrary.org/obo/hp_0003119,GCST007480,30166351,1,Disorders of lipid metabolism
http://www.ebi.ac.uk/efo/efo_0009391,GCST006615,30161160,2,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer
http://www.ebi.ac.uk/efo/efo_0005514,GCST006615,30161160,2,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer
http://www.ebi.ac.uk/efo/efo_1000649,GCST006615,30161160,2,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer
http://www.ebi.ac.uk/efo/efo_0007043,GCST006496,30160337,5,Glomerular filtration rate change in heart transplantation
http://www.ebi.ac.uk/efo/efo_0006829,GCST006496,30160337,5,Glomerular filtration rate change in heart transplantation
http://www.ebi.ac.uk/efo/efo_0007701,GCST006447,30172743,3,Bone mineral density (spine)
http://www.ebi.ac.uk/efo/efo_0007933,GCST006446,30172743,7,Ulna and radius bone mineral density
http://www.ebi.ac.uk/efo/efo_0007785,GCST006445,30172743,8,Femoral neck bone mineral density
http://www.ebi.ac.uk/efo/efo_0007702,GCST006444,30172743,24,Bone mineral density (hip)
http://www.ebi.ac.uk/efo/efo_0004324,GCST007485,30166351,15,Anthropometric traits
http://www.ebi.ac.uk/efo/efo_0004324,GCST007490,30166351,29,Anthropometric traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0003923,GCST006443,30172743,6,Total body bone mineral density
http://www.ebi.ac.uk/efo/efo_0003931,GCST006423,30158200,17,Fractures
http://www.ebi.ac.uk/efo/efo_0003931,GCST006422,30158200,5,Fractures
http://www.ebi.ac.uk/efo/efo_0007708,GCST007130,30153862,5,Cerebrospinal fluid t-tau:AB1-42 ratio
http://www.ebi.ac.uk/efo/efo_0007708,GCST007129,30153862,3,Cerebrospinal fluid t-tau:AB1-42 ratio
http://www.ebi.ac.uk/efo/efo_0004278,GCST006401,30169657,2,Sudden cardiac arrest
http://www.ebi.ac.uk/efo/efo_0007585,GCST006421,30150663,8,Cannabis use
http://www.ebi.ac.uk/efo/efo_0004847,GCST006480,30152087,20,Glioblastoma (age-stratified)
http://www.ebi.ac.uk/efo/efo_0000519,GCST006480,30152087,20,Glioblastoma (age-stratified)
http://www.ebi.ac.uk/efo/efo_0004300,GCST006658,30294719,20,Longevity
http://www.ebi.ac.uk/efo/efo_0004612,GCST006860,30132804,0,Low HDL-cholesterol levels
http://www.ebi.ac.uk/efo/efo_0007959,GCST006622,30134952,23,Neonatal cytokine/chemokine levels (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0004747,GCST006622,30134952,23,Neonatal cytokine/chemokine levels (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007964,GCST006623,30134952,1,Midgestational cytokine/chemokine levels (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007959,GCST006623,30134952,1,Midgestational cytokine/chemokine levels (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0004747,GCST006623,30134952,1,Midgestational cytokine/chemokine levels (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0004747,GCST006625,30134952,3,Neonatal cytokine/chemokine levels (maternal genetic effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST006625,30134952,3,Neonatal cytokine/chemokine levels (maternal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007964,GCST006621,30134952,3,Midgestational cytokine/chemokine levels (maternal genetic effect)
http://www.ebi.ac.uk/efo/efo_0004747,GCST006621,30134952,3,Midgestational cytokine/chemokine levels (maternal genetic effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST006621,30134952,3,Midgestational cytokine/chemokine levels (maternal genetic effect)
http://www.ebi.ac.uk/efo/efo_0001360,GCST006484,30130595,24,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0008237,GCST006440,30120420,5,Motor composite score
http://www.ebi.ac.uk/efo/efo_0007699,GCST006448,30120336,3,Eye movement in schizophrenia (horizontal position gain)
http://www.ebi.ac.uk/efo/efo_0000692,GCST006448,30120336,3,Eye movement in schizophrenia (horizontal position gain)
http://www.ebi.ac.uk/efo/efo_0009382,GCST006492,30120429,14,Obesity without metabolic disease
http://www.ebi.ac.uk/efo/efo_0008230,GCST006441,30120420,7,Mental composite score
http://www.ebi.ac.uk/efo/efo_0007699,GCST006449,30120336,0,Eye movement (integrated eye movement score)
http://www.ebi.ac.uk/efo/efo_0007699,GCST006450,30120336,0,Eye movement (integrated eye movement score)
http://www.ebi.ac.uk/efo/efo_0007699,GCST006451,30120336,0,Eye movement in schizophrenia (integrated eye movement score)
http://www.ebi.ac.uk/efo/efo_0000692,GCST006451,30120336,0,Eye movement in schizophrenia (integrated eye movement score)
http://www.ebi.ac.uk/efo/efo_0007699,GCST006452,30120336,0,Eye movement (duration of fixations)
http://www.ebi.ac.uk/efo/efo_0007699,GCST006453,30120336,0,Eye movement (duration of fixations)
http://www.ebi.ac.uk/efo/efo_0007699,GCST006454,30120336,0,Eye movement in schizophrenia (duration of fixations)
http://www.ebi.ac.uk/efo/efo_0000692,GCST006454,30120336,0,Eye movement in schizophrenia (duration of fixations)
http://www.ebi.ac.uk/efo/efo_0007699,GCST006455,30120336,0,Eye movement (scanpath length)
http://www.ebi.ac.uk/efo/efo_0007699,GCST006456,30120336,0,Eye movement (scanpath length)
http://www.ebi.ac.uk/efo/efo_0007699,GCST006457,30120336,1,Eye movement (horizontal position gain)
http://www.ebi.ac.uk/efo/efo_0007699,GCST006459,30120336,0,Eye movement in schizophrenia (scanpath length)
http://www.ebi.ac.uk/efo/efo_0000692,GCST006459,30120336,0,Eye movement in schizophrenia (scanpath length)
http://www.ebi.ac.uk/efo/efo_0007699,GCST006458,30120336,1,Eye movement (horizontal position gain)
http://www.ebi.ac.uk/efo/efo_0004340,GCST006900,30124842,0,Body mass index
http://www.ebi.ac.uk/efo/efo_0007955,GCST006518,30174134,0,Mouth morphology (partial least square model)
http://www.ebi.ac.uk/efo/efo_0007843,GCST006517,30174134,1,Nose morphology (partial least square model)
http://www.ebi.ac.uk/efo/efo_0007847,GCST006516,30174134,1,Cheek morphology (partial least square model)
http://www.ebi.ac.uk/efo/efo_0007841,GCST006515,30174134,1,Side of face morphology (partial least square model)
http://www.ebi.ac.uk/efo/efo_0007858,GCST006514,30174134,0,Eye morphology (partial least square model)
http://www.ebi.ac.uk/efo/efo_0007844,GCST006513,30174134,0,Brow ridge morphology (partial least square model)
http://www.ebi.ac.uk/efo/efo_0007955,GCST006512,30174134,1,Mouth morphology (principal component model)
http://www.ebi.ac.uk/efo/efo_0007843,GCST006511,30174134,0,Nose morphology (principal component model)
http://www.ebi.ac.uk/efo/efo_0007847,GCST006510,30174134,0,Cheek morphology (principal component model)
http://www.ebi.ac.uk/efo/efo_0007841,GCST006509,30174134,0,Side of face morphology (principal component model)
http://www.ebi.ac.uk/efo/efo_0007858,GCST006508,30174134,0,Eye morphology (principal component model)
http://www.ebi.ac.uk/efo/efo_0007844,GCST006498,30174134,0,Brow ridge morphology (principal component model)
http://www.ebi.ac.uk/efo/efo_0007841,GCST006507,30174134,0,Lower face length
http://www.ebi.ac.uk/efo/efo_0007845,GCST006506,30174134,0,Lip thickness
http://www.ebi.ac.uk/efo/efo_0007845,GCST006505,30174134,0,Labial fissure length
http://www.ebi.ac.uk/efo/efo_0007858,GCST006504,30174134,0,Interorbital distance
http://www.ebi.ac.uk/efo/efo_0007858,GCST006503,30174134,1,Eye length
http://www.ebi.ac.uk/efo/efo_0007843,GCST006502,30174134,0,Nasal root height
http://www.ebi.ac.uk/efo/efo_0007843,GCST006501,30174134,0,Nasal root breadth
http://www.ebi.ac.uk/efo/efo_0007843,GCST006500,30174134,0,Nosetip height
http://www.ebi.ac.uk/efo/efo_0007843,GCST006499,30174134,1,Nose length
http://www.ebi.ac.uk/efo/efo_0004339,GCST006901,30124842,0,Height
http://www.orpha.net/ordo/orphanet_70589,GCST006460,30113228,12,Bronchopulmonary dysplasia in preterm infants
http://www.ebi.ac.uk/efo/efo_0003917,GCST006460,30113228,12,Bronchopulmonary dysplasia in preterm infants
http://www.ebi.ac.uk/efo/efo_0004321,GCST006419,30116032,10,Suicide attempts
http://www.ebi.ac.uk/efo/efo_0004321,GCST006420,30116032,7,Affective disorder and suicide attempts
http://www.ebi.ac.uk/efo/efo_0004247,GCST006420,30116032,7,Affective disorder and suicide attempts
http://www.ebi.ac.uk/efo/efo_0007843,GCST006497,30174134,0,Nose wing breadth
http://www.ebi.ac.uk/efo/efo_0007937,GCST007128,30111768,8,Blood protein levels
http://www.ebi.ac.uk/efo/efo_0004326,GCST007051,30108283,0,Pulse rate
http://www.ebi.ac.uk/efo/efo_0004346,GCST006389,30108209,0,Brain imaging measurements
http://www.ebi.ac.uk/efo/efo_0004530,GCST006436,30108155,15,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004354,GCST006396,30120083,10,Disrupted circadian rhythm (low relative amplitude of rest-activity cycles)
http://www.ebi.ac.uk/efo/efo_0004340,GCST006368,30108127,289,Body mass index
http://www.ebi.ac.uk/efo/efo_0004354,GCST006397,30120083,13,Relative amplitude of rest-activity cycles
http://www.ebi.ac.uk/efo/efo_0005093,GCST007058,30108283,1,Hip circumference
http://www.ebi.ac.uk/efo/efo_0004339,GCST007057,30108283,0,Height
http://www.ebi.ac.uk/efo/efo_0004343,GCST007056,30108283,1,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0004342,GCST007055,30108283,1,Waist circumference
http://www.ebi.ac.uk/efo/efo_0004338,GCST007054,30108283,2,Weight
http://www.ebi.ac.uk/efo/efo_0004340,GCST007053,30108283,1,Body mass index
http://www.ebi.ac.uk/efo/efo_0006925,GCST007052,30108283,10,Lipoprotein (a) levels
http://www.ebi.ac.uk/efo/efo_0004574,GCST006439,30108155,0,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST006437,30108155,0,Low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST006438,30108155,2,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0006527,GCST006400,30104567,1,Lung cancer in ever smokers
http://www.ebi.ac.uk/efo/efo_0001071,GCST006400,30104567,1,Lung cancer in ever smokers
http://www.ebi.ac.uk/efo/efo_0003761,GCST006927,30104601,0,Anhedonia in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0009587,GCST006927,30104601,0,Anhedonia in major depressive disorder
http://www.orpha.net/ordo/orphanet_30391,GCST006390,30102696,3,Biliary atresia
http://www.ebi.ac.uk/efo/efo_0001071,GCST006399,30104567,1,Lung cancer
http://www.ebi.ac.uk/efo/efo_0003776,GCST006435,30103242,1,Thrombocytopenia in coronary artery bypass surgery
http://purl.obolibrary.org/obo/hp_0001873,GCST006435,30103242,1,Thrombocytopenia in coronary artery bypass surgery
http://www.ebi.ac.uk/efo/efo_0001071,GCST006398,30104567,25,Lung cancer (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0000483,GCST006857,30102679,2,Leisure-time exercise behaviour
http://www.ebi.ac.uk/efo/efo_0000483,GCST006858,30102679,3,Leisure-time exercise behaviour (age-stratified)
http://www.ebi.ac.uk/efo/efo_1001512,GCST006465,30093612,32,Endometrial cancer (endometrioid histology)
http://www.ebi.ac.uk/efo/efo_1001512,GCST006464,30093612,28,Endometrial cancer
http://www.ebi.ac.uk/efo/efo_0000174,GCST006467,30093639,4,Ewing sarcoma
http://www.ebi.ac.uk/efo/efo_0000249,GCST008056,30201328,2,Alzheimer's disease (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_1001512,GCST006466,30093612,7,Endometrial cancer (Non-endometrioid histology)
http://www.orpha.net/ordo/orphanet_683,GCST006418,30089514,13,Progressive supranuclear palsy
http://www.orpha.net/ordo/orphanet_558,GCST006957,30087447,4,Severe aortic features in Marfan syndrome
http://www.ebi.ac.uk/efo/efo_0004282,GCST006957,30087447,4,Severe aortic features in Marfan syndrome
http://www.ebi.ac.uk/efo/efo_0004215,GCST006576,30087453,3,Anorexia nervosa or obsessive-compulsive disorder
http://www.ebi.ac.uk/efo/efo_0004242,GCST006576,30087453,3,Anorexia nervosa or obsessive-compulsive disorder
http://www.ebi.ac.uk/efo/efo_1001436,GCST006387,30099483,2,Thyroid nodules
http://www.ebi.ac.uk/efo/efo_0007937,GCST006585,30072576,2961,Blood protein levels
http://www.ebi.ac.uk/efo/efo_0009374,GCST006402,30071075,4,Energy intake
http://www.ebi.ac.uk/efo/efo_0009363,GCST006416,30073298,7,Chronic central serous retinopathy
http://www.ebi.ac.uk/efo/efo_0009368,GCST006417,30070759,43,Plasma factor VII activating protease levels
http://www.ebi.ac.uk/efo/efo_0008005,GCST006403,30071075,11,Energy expenditure
http://www.ebi.ac.uk/efo/efo_0007292,GCST006836,30196823,0,Guillain-Barr syndrome
http://www.ebi.ac.uk/efo/efo_0004318,GCST006309,30068317,8,Post bronchodilator percent predicted FEV1 in smoking
http://www.ebi.ac.uk/efo/efo_0004314,GCST006309,30068317,8,Post bronchodilator percent predicted FEV1 in smoking
http://www.ebi.ac.uk/efo/efo_0009132,GCST007117,30369316,1,Cholesterol efflux capacity (BHK stimulated assay)
http://www.ebi.ac.uk/efo/efo_0009132,GCST007116,30369316,3,Cholesterol efflux capacity (ABCA-1 dependent assay)
http://www.ebi.ac.uk/efo/efo_0009132,GCST007115,30369316,2,Cholesterol efflux capacity (cAMP stimulated assay)
http://www.ebi.ac.uk/efo/efo_0009132,GCST007114,30369316,4,Cholesterol efflux capacity
http://www.ebi.ac.uk/efo/efo_0004318,GCST006310,30068317,8,Post bronchodilator FEV1/FVC ratio in smoking
http://www.ebi.ac.uk/efo/efo_0004713,GCST006310,30068317,8,Post bronchodilator FEV1/FVC ratio in smoking
http://purl.obolibrary.org/obo/hp_0000175,GCST006415,30067744,6,Nonsyndromic cleft lip with or without cleft palate
http://www.ebi.ac.uk/efo/efo_0003959,GCST006415,30067744,6,Nonsyndromic cleft lip with or without cleft palate
http://www.ebi.ac.uk/efo/efo_0004237,GCST006278,30067105,2,Adverse response to antithyroid drugs in Graves disease
http://www.ebi.ac.uk/efo/efo_0007838,GCST006278,30067105,2,Adverse response to antithyroid drugs in Graves disease
http://www.ebi.ac.uk/efo/efo_0007845,GCST006407,30067744,2,Philtrum width
http://www.orpha.net/ordo/orphanet_683,GCST006276,30066433,2,Non-Richardson's syndrome vs Richardson's syndrome in progressive supranuclear palsy
http://www.ebi.ac.uk/efo/efo_0004314,GCST006481,30061609,56,Lung function (FEV1)
http://www.ebi.ac.uk/efo/efo_0004312,GCST006483,30061609,69,Lung function (FVC)
http://www.ebi.ac.uk/efo/efo_0000275,GCST006414,30061737,142,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0004713,GCST006482,30061609,39,Lung function (FEV1/FVC)
http://www.ebi.ac.uk/efo/efo_0008348,GCST006277,30054556,4,Response to ranibizumab in age-related macular degeneration (exudative)
http://www.ebi.ac.uk/efo/efo_0004683,GCST006277,30054556,4,Response to ranibizumab in age-related macular degeneration (exudative)
http://www.ebi.ac.uk/efo/efo_0005611,GCST006856,30060048,2,Methadone dose in opioid dependence
http://www.ebi.ac.uk/efo/efo_0007907,GCST006856,30060048,2,Methadone dose in opioid dependence
http://www.ebi.ac.uk/efo/efo_0001360,GCST006868,30054458,11,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0009359,GCST006355,30053915,0,Anti-hepatitis B virus core antigen (HBc) IgG levels
http://www.ebi.ac.uk/efo/efo_0009358,GCST006354,30053915,0,Anti-hepatitis B virus surface antigen (HBs) IgG levels
http://www.ebi.ac.uk/efo/efo_0009357,GCST006353,30053915,2,Anti-rubella virus IgG levels
http://www.ebi.ac.uk/efo/efo_0009356,GCST006352,30053915,0,Anti-mumps virus IgG levels
http://www.ebi.ac.uk/efo/efo_0009355,GCST006351,30053915,0,Anti-measles virus IgG levels
http://www.ebi.ac.uk/efo/efo_0009354,GCST006350,30053915,0,Anti-influenza A virus IgG levels
http://www.ebi.ac.uk/efo/efo_0009353,GCST006349,30053915,0,Anti-Toxoplasma gondii IgG levels
http://www.ebi.ac.uk/efo/efo_0005247,GCST006363,30053915,0,Anti-Helicobacter pylori IgG levels
http://www.ebi.ac.uk/efo/efo_0009351,GCST006348,30053915,0,Anti-varicella zoster virus IgG levels
http://www.ebi.ac.uk/efo/efo_0009350,GCST006347,30053915,0,Anti-herpes simplex virus 2 IgG levels
http://www.ebi.ac.uk/efo/efo_0009349,GCST006346,30053915,0,Anti-herpes simplex virus 1 IgG levels
http://www.ebi.ac.uk/efo/efo_0009348,GCST006345,30053915,0,Anti-Epstein-Barr virus early antigen (EA) IgG levels
http://www.ebi.ac.uk/efo/efo_0009274,GCST006362,30053915,0,Anti-Epstein-Barr virus viral capsid antigen (VCA) IgG levels
http://www.ebi.ac.uk/efo/efo_0007790,GCST006361,30053915,2,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG levels
http://www.ebi.ac.uk/efo/efo_0009347,GCST006344,30053915,0,Anti-cytomegalovirus IgG levels
http://www.ebi.ac.uk/efo/efo_0004579,GCST006358,30053915,0,IgE levels
http://www.ebi.ac.uk/efo/efo_0004912,GCST006360,30053915,1,IgA levels
http://www.ebi.ac.uk/efo/efo_0004993,GCST006359,30053915,0,IgM levels
http://www.ebi.ac.uk/efo/efo_0004565,GCST006357,30053915,0,IgG levels
http://www.ebi.ac.uk/efo/efo_0009346,GCST006343,30053915,0,Anti-hepatitis B virus core antigen (HBc) IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009345,GCST006356,30053915,0,Anti-hepatitis B virus surface antigen (HBs) IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009344,GCST006342,30053915,0,Anti-rubella virus IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009343,GCST006341,30053915,0,Anti-mumps virus IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009342,GCST006340,30053915,0,Anti-measles virus IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0007038,GCST006339,30053915,0,Anti-influenza A virus IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0007047,GCST006338,30053915,0,Anti-Toxoplasma gondii IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009341,GCST006337,30053915,0,Anti-Helicobacter pylori IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009340,GCST006336,30053915,0,Anti-varicella zoster virus IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009339,GCST006335,30053915,0,Anti-herpes simplex virus 2 IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0007050,GCST006334,30053915,0,Anti-herpes simplex virus 1 IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009338,GCST006330,30053915,0,Anti-Epstein-Barr virus early antigen (EA) IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009272,GCST006333,30053915,0,Anti-Epstein-Barr virus viral capsid antigen (VCA) IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009271,GCST006332,30053915,0,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0000516,GCST006395,30054594,48,Glaucoma
http://www.ebi.ac.uk/efo/efo_0007037,GCST006331,30053915,0,Anti-cytomegalovirus IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0004695,GCST006394,30054594,106,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0001360,GCST006867,30054458,139,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0009270,GCST006433,30048462,1587,Heel bone mineral density
http://www.ebi.ac.uk/efo/efo_0009369,GCST006473,30049742,8,Diffusing capacity of the lung for carbon monoxide traits
http://www.ebi.ac.uk/efo/efo_0004462,GCST007045,30046033,44,PR interval
http://www.ebi.ac.uk/efo/efo_0004784,GCST006442,30038396,1640,Educational attainment (years of education)
http://www.ebi.ac.uk/efo/efo_0004875,GCST006568,30038396,1108,Highest math class taken (MTAG)
http://www.ebi.ac.uk/efo/efo_0004875,GCST006574,30038396,335,Highest math class taken
http://www.ebi.ac.uk/efo/efo_0004875,GCST006569,30038396,751,Self-reported math ability (MTAG)
http://www.ebi.ac.uk/efo/efo_0004875,GCST006573,30038396,544,Self-reported math ability
http://www.ebi.ac.uk/efo/efo_0008354,GCST006570,30038396,592,Cognitive performance (MTAG)
http://www.ebi.ac.uk/efo/efo_0008354,GCST006572,30038396,217,Cognitive performance
http://www.ebi.ac.uk/efo/efo_0004784,GCST006571,30038396,1343,Educational attainment (MTAG)
http://www.ebi.ac.uk/efo/efo_0007537,GCST006275,30079052,4,Vestibular neuritis
http://www.orpha.net/ordo/orphanet_388,GCST006272,30031151,0,Hirschsprung disease
http://www.orpha.net/ordo/orphanet_388,GCST006271,30031151,1,Hirschsprung disease
http://www.ebi.ac.uk/efo/efo_0005055,GCST007104,30012220,28,QRS duration
http://www.ebi.ac.uk/efo/efo_0005055,GCST007105,30012220,1,QRS duration
http://www.ebi.ac.uk/efo/efo_0005055,GCST007103,30012220,28,QRS duration
http://www.ebi.ac.uk/efo/efo_0004321,GCST006428,30145303,22,Suicide attempts
http://www.ebi.ac.uk/efo/efo_0004320,GCST006429,30145303,25,Suicidal ideation
http://www.ebi.ac.uk/efo/efo_0005423,GCST006287,30019117,1317,Adolescent idiopathic scoliosis
http://www.ebi.ac.uk/efo/efo_0003885,GCST006270,30013178,1,Drug-induced liver injury in interferon-beta-treated multiple sclerosis
http://purl.obolibrary.org/obo/go_0035456,GCST006270,30013178,1,Drug-induced liver injury in interferon-beta-treated multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0004228,GCST006270,30013178,1,Drug-induced liver injury in interferon-beta-treated multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0009364,GCST006474,30013184,0,Non-allergic rhinitis
http://www.ebi.ac.uk/efo/efo_0005298,GCST006408,30013184,19,Allergic sensitization
http://www.orpha.net/ordo/orphanet_98896,GCST006286,30014611,47,Age at loss of ambulation in Duchenne muscular dystrophy
http://www.ebi.ac.uk/efo/efo_0008336,GCST006286,30014611,47,Age at loss of ambulation in Duchenne muscular dystrophy
http://www.ebi.ac.uk/efo/efo_0004255,GCST006246,30012571,1,Childhood steroid-sensitive nephrotic syndrome
http://www.ebi.ac.uk/efo/efo_0009372,GCST006567,30009487,1,Response to ketogenic dietary therapies in epilepsy
http://www.ebi.ac.uk/efo/efo_0000474,GCST006567,30009487,1,Response to ketogenic dietary therapies in epilepsy
http://www.ebi.ac.uk/efo/efo_0005854,GCST006409,30013184,44,Allergic rhinitis
http://www.ebi.ac.uk/efo/efo_0007585,GCST006386,30003630,3,Cannabis use (age at onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST006386,30003630,3,Cannabis use (age at onset)
http://www.ebi.ac.uk/efo/efo_0000400,GCST006405,30003307,2,Coronary artery disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000378,GCST006405,30003307,2,Coronary artery disease in diabetes
http://www.ebi.ac.uk/efo/efo_0003939,GCST006388,29988085,5,Dietary macronutrient intake
http://www.ebi.ac.uk/efo/efo_0003761,GCST006267,30034349,3,Response to selective serotonin reuptake inhibitors in depression
http://www.ebi.ac.uk/efo/efo_0005658,GCST006267,30034349,3,Response to selective serotonin reuptake inhibitors in depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST006266,30034349,1,Remission after SSRI treatment in major depression
http://www.ebi.ac.uk/efo/efo_0005658,GCST006266,30034349,1,Remission after SSRI treatment in major depression
http://www.ebi.ac.uk/efo/efo_0008343,GCST008138,29981864,1,Allergic rhinitis x sex interaction
http://www.ebi.ac.uk/efo/efo_0005854,GCST008138,29981864,1,Allergic rhinitis x sex interaction
http://www.ebi.ac.uk/efo/efo_0009345,GCST006364,29975729,4,Hepatitis B surface antigen seroclearance in chronic hepatitis B infection
http://www.ebi.ac.uk/efo/efo_0004239,GCST006364,29975729,4,Hepatitis B surface antigen seroclearance in chronic hepatitis B infection
http://www.ebi.ac.uk/efo/efo_0000537,GCST006274,29973135,2,Systolic blood pressure night-to-day ratio in hypertension
http://www.ebi.ac.uk/efo/efo_0006944,GCST006274,29973135,2,Systolic blood pressure night-to-day ratio in hypertension
http://www.ebi.ac.uk/efo/efo_0006945,GCST006273,29973135,5,Diastolic blood pressure night-to-day ratio in hypertension
http://www.ebi.ac.uk/efo/efo_0000537,GCST006273,29973135,5,Diastolic blood pressure night-to-day ratio in hypertension
http://www.ebi.ac.uk/efo/efo_0007865,GCST006923,29970889,15,Loneliness
http://www.ebi.ac.uk/efo/efo_0006805,GCST006256,29970928,2,Long-term memory (delayed word recall task)
http://www.ebi.ac.uk/efo/efo_0007865,GCST006924,29970889,16,Loneliness (MTAG)
http://www.ebi.ac.uk/efo/efo_0001071,GCST006413,29971594,3,Lung cancer x radon exposure interaction (1df)
http://www.ebi.ac.uk/efo/efo_0009370,GCST006413,29971594,3,Lung cancer x radon exposure interaction (1df)
http://www.ebi.ac.uk/efo/efo_0004874,GCST006255,29970928,0,Short-term memory (shared component of digit-span and visuospatial tasks)
http://www.ebi.ac.uk/efo/efo_0004874,GCST006254,29970928,1,Short-term memory (visuospatial task)
http://www.ebi.ac.uk/efo/efo_0004874,GCST006253,29970928,0,Short-term memory (digit-span task)
http://www.ebi.ac.uk/efo/efo_0009592,GCST006922,29970889,19,Regular attendance at a religious group
http://www.ebi.ac.uk/efo/efo_0009592,GCST006921,29970889,13,Regular attendance at a pub or social club
http://www.ebi.ac.uk/efo/efo_0009592,GCST006920,29970889,8,Regular attendance at a gym or sports club
http://www.ebi.ac.uk/efo/efo_0009592,GCST006919,29970889,4,Ability to confide in someone
http://www.ebi.ac.uk/efo/efo_0009592,GCST006918,29970889,0,Social isolation
http://www.ebi.ac.uk/efo/efo_0004847,GCST006260,29967481,2,Childhood onset systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0002690,GCST006260,29967481,2,Childhood onset systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004465,GCST006257,30004843,5,Elevated fasting plasma glucose
http://www.ebi.ac.uk/efo/efo_0009332,GCST006406,30134085,5,Cognitive flexibility
http://www.ebi.ac.uk/efo/efo_0004340,GCST006369,30045251,10,Body mass index
http://www.ebi.ac.uk/efo/efo_0004246,GCST006809,30304924,0,Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0006794,GCST006279,29959729,6,Cerebrospinal fluid -synuclein levels
http://www.ebi.ac.uk/efo/efo_0009323,GCST006279,29959729,6,Cerebrospinal fluid -synuclein levels
http://www.ebi.ac.uk/efo/efo_0009586,GCST006939,30065583,0,Skin hydration
http://www.ebi.ac.uk/efo/efo_0004357,GCST006684,29947131,8,Electroencephalogram traits
http://www.ebi.ac.uk/efo/efo_0003761,GCST006477,29942085,82,Depression
http://www.ebi.ac.uk/efo/efo_0005111,GCST006137,29953918,17,Serum folate levels
http://www.ebi.ac.uk/efo/efo_0004337,GCST006250,29942086,524,Intelligence
http://www.ebi.ac.uk/efo/efo_0007660,GCST006476,29942085,371,Neuroticism
http://www.ebi.ac.uk/efo/efo_0009589,GCST006478,29942085,147,Worry
http://www.ebi.ac.uk/efo/efo_0003761,GCST006475,29942085,157,Depressed affect
http://www.ebi.ac.uk/efo/efo_0004247,GCST006475,29942085,157,Depressed affect
http://www.ebi.ac.uk/efo/efo_0009583,GCST007422,29936532,0,Socioeconomic status of place of residence
http://www.ebi.ac.uk/efo/efo_0009583,GCST007421,29936532,0,Population density of place of residence
http://www.ebi.ac.uk/efo/efo_0006816,GCST006144,29934777,3,Heparin-induced thrombocytopenia
http://purl.obolibrary.org/obo/hp_0001873,GCST006144,29934777,3,Heparin-induced thrombocytopenia
http://www.ebi.ac.uk/efo/efo_0003819,GCST006312,29931343,2,Childhood dental caries in primary teeth
http://www.ebi.ac.uk/efo/efo_0003819,GCST006311,29931343,1,Childhood dental caries in permanent teeth
http://www.ebi.ac.uk/efo/efo_0004233,GCST006200,29923122,0,Thiopurine-induced severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0006317,GCST006200,29923122,0,Thiopurine-induced severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0003767,GCST006200,29923122,0,Thiopurine-induced severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)
http://www.orpha.net/ordo/orphanet_79364,GCST006199,29923122,0,Thiopurine-induced severe alopecia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0006317,GCST006199,29923122,0,Thiopurine-induced severe alopecia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0003767,GCST006199,29923122,0,Thiopurine-induced severe alopecia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0004233,GCST006215,29923122,1,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0006317,GCST006215,29923122,1,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0003767,GCST006215,29923122,1,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)
http://www.orpha.net/ordo/orphanet_79364,GCST006214,29923122,0,Thiopurine-induced alopecia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0006317,GCST006214,29923122,0,Thiopurine-induced alopecia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0003767,GCST006214,29923122,0,Thiopurine-induced alopecia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0000701,GCST006213,29923122,0,Thiopurine-induced skin symptoms in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006213,29923122,0,Thiopurine-induced skin symptoms in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006213,29923122,0,Thiopurine-induced skin symptoms in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006212,29923122,0,Thiopurine-induced liver dysfunction in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006212,29923122,0,Thiopurine-induced liver dysfunction in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0001421,GCST006212,29923122,0,Thiopurine-induced liver dysfunction in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006211,29923122,0,Thiopurine-induced infection in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006211,29923122,0,Thiopurine-induced infection in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0008422,GCST006211,29923122,0,Thiopurine-induced infection in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0000405,GCST006210,29923122,1,Thiopurine-induced digestive symptoms in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006210,29923122,1,Thiopurine-induced digestive symptoms in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006210,29923122,1,Thiopurine-induced digestive symptoms in inflammatory bowel disease
http://purl.obolibrary.org/obo/hp_0001945,GCST006209,29923122,0,Thiopurine-induced fever in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006209,29923122,0,Thiopurine-induced fever in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006209,29923122,0,Thiopurine-induced fever in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0000278,GCST006208,29923122,2,Thiopurine-induced pancreatitis in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006208,29923122,2,Thiopurine-induced pancreatitis in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006208,29923122,2,Thiopurine-induced pancreatitis in inflammatory bowel disease
http://www.orpha.net/ordo/orphanet_79364,GCST006207,29923122,1,Thiopurine-induced severe alopecia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006207,29923122,1,Thiopurine-induced severe alopecia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006207,29923122,1,Thiopurine-induced severe alopecia in inflammatory bowel disease
http://www.orpha.net/ordo/orphanet_79364,GCST006206,29923122,5,Thiopurine-induced alopecia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006206,29923122,5,Thiopurine-induced alopecia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006206,29923122,5,Thiopurine-induced alopecia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0004233,GCST006205,29923122,1,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006205,29923122,1,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006205,29923122,1,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0004233,GCST006204,29923122,1,Thiopurine-induced severe leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006204,29923122,1,Thiopurine-induced severe leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006204,29923122,1,Thiopurine-induced severe leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0007858,GCST006107,29921221,16,Upper eyelid morphology
http://www.ebi.ac.uk/efo/efo_0007845,GCST006109,29921221,1,Lip morphology
http://www.ebi.ac.uk/efo/efo_0007843,GCST006110,29921221,38,Nose morphology
http://www.ebi.ac.uk/efo/efo_0007858,GCST006105,29921221,12,Eye morphology
http://www.ebi.ac.uk/efo/efo_0007844,GCST006106,29921221,6,Forehead morphology
http://www.ebi.ac.uk/efo/efo_0000708,GCST006088,29924316,68,Familial squamous cell lung carcinoma
http://www.ebi.ac.uk/efo/efo_0006953,GCST006088,29924316,68,Familial squamous cell lung carcinoma
http://www.ebi.ac.uk/efo/efo_0000571,GCST006087,29924316,36,Familial lung adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0006953,GCST006087,29924316,36,Familial lung adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0004233,GCST006202,29923122,1,Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0006317,GCST006202,29923122,1,Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0003767,GCST006202,29923122,1,Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232)
http://www.ebi.ac.uk/efo/efo_0001071,GCST006086,29924316,20,Familial lung cancer
http://www.ebi.ac.uk/efo/efo_0006953,GCST006086,29924316,20,Familial lung cancer
http://www.ebi.ac.uk/efo/efo_0004743,GCST006108,29921221,8,Facial morphology
http://www.ebi.ac.uk/efo/efo_0004233,GCST006201,29923122,2,Thiopurine-induced leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST006201,29923122,2,Thiopurine-induced leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST006201,29923122,2,Thiopurine-induced leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0005669,GCST006139,29915124,1,Hematoma volume in lobar spontaneous intracerebral hemorrhage
http://www.ebi.ac.uk/efo/efo_0005763,GCST006171,29912962,17,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0007878,GCST006171,29912962,17,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006336,GCST006166,29912962,114,Diastolic blood pressure x alcohol consumption interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0004329,GCST006166,29912962,114,Diastolic blood pressure x alcohol consumption interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006340,GCST006172,29912962,41,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0007878,GCST006172,29912962,41,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006340,GCST006167,29912962,85,Mean arterial pressure x alcohol consumption interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0004329,GCST006167,29912962,85,Mean arterial pressure x alcohol consumption interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0005763,GCST006168,29912962,59,Pulse pressure x alcohol consumption interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0004329,GCST006168,29912962,59,Pulse pressure x alcohol consumption interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006335,GCST006170,29912962,43,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0007878,GCST006170,29912962,43,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006335,GCST006434,29912962,114,Systolic blood pressure x alcohol consumption interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0004329,GCST006434,29912962,114,Systolic blood pressure x alcohol consumption interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0005669,GCST006140,29915124,1,Hematoma volume in non-lobar spontaneous intracerebral hemorrhage
http://www.ebi.ac.uk/efo/efo_0006336,GCST006169,29912962,41,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0007878,GCST006169,29912962,41,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0005842,GCST006131,29917119,28,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0004255,GCST006252,29903748,5,Childhood steroid-sensitive nephrotic syndrome
http://www.ebi.ac.uk/efo/efo_0009331,GCST006218,29898447,136,Erosive tooth wear (severe vs non-severe)
http://www.ebi.ac.uk/efo/efo_0009331,GCST006226,29898447,23,Erosive tooth wear (severe vs none or mild)
http://www.ebi.ac.uk/efo/efo_0005842,GCST006411,29942513,17,Mucinous adenocarcinoma in colorectal cancer
http://www.ebi.ac.uk/efo/efo_0009361,GCST006411,29942513,17,Mucinous adenocarcinoma in colorectal cancer
http://www.ebi.ac.uk/efo/efo_0008002,GCST006099,29899525,5,Accelerometer-based physical activity measurement (average acceleration)
http://www.ebi.ac.uk/efo/efo_0008002,GCST006100,29899525,8,Strenuous sports or other exercises
http://www.ebi.ac.uk/efo/efo_0008002,GCST006098,29899525,9,Vigorous physical activity
http://www.ebi.ac.uk/efo/efo_0008002,GCST006097,29899525,13,Moderate to vigorous physical activity levels
http://www.ebi.ac.uk/efo/efo_0008002,GCST006079,29899525,2,Accelerometer-based physical activity measurement (fraction of time with accelerations >425 milli-gravities)
http://www.ebi.ac.uk/efo/efo_0007636,GCST006929,29907492,1,Attention function
http://www.ebi.ac.uk/efo/efo_0007850,GCST006096,29895819,3,Age spots
http://www.ebi.ac.uk/efo/efo_0004363,GCST006934,29907492,1,Information processing speed
http://purl.obolibrary.org/obo/hp_0000975,GCST006090,29895819,3,Excessive sweating
http://purl.obolibrary.org/obo/hp_0001007,GCST006095,29895819,6,Excessive hairiness
http://www.ebi.ac.uk/efo/efo_0007821,GCST006094,29895819,1,Straight vs curly hair
http://www.ebi.ac.uk/efo/efo_0007823,GCST006093,29895819,1,Thick vs thin eyebrows
http://www.ebi.ac.uk/efo/efo_0007858,GCST006092,29895819,2,Double-edged eyelids
http://www.ebi.ac.uk/efo/efo_0003963,GCST006091,29895819,7,Freckles
http://www.ebi.ac.uk/efo/efo_0008354,GCST006933,29907492,3,Cognitive function
http://www.ebi.ac.uk/efo/efo_0004350,GCST006932,29907492,3,Reasoning
http://www.ebi.ac.uk/efo/efo_0009590,GCST006928,29907492,2,Visual memory
http://www.ebi.ac.uk/efo/efo_0009591,GCST006931,29907492,3,Verbal memory
http://www.ebi.ac.uk/efo/efo_0004335,GCST006930,29907492,3,Working memory
http://www.ebi.ac.uk/efo/efo_0000275,GCST006061,29892015,228,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0004190,GCST006065,29891935,47,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0001663,GCST006085,29892016,140,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0000203,GCST006917,30134812,15,Monoclonal gammopathy of undetermined significance
http://www.ebi.ac.uk/efo/efo_0004190,GCST006067,29891935,9,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0004190,GCST006066,29891935,9,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0001663,GCST006084,29892016,0,Prostate cancer (Gleason score)
http://www.ebi.ac.uk/efo/efo_0001663,GCST006089,29892016,11,Prostate cancer (early onset)
http://www.ebi.ac.uk/efo/efo_0001663,GCST006083,29892016,18,Prostate cancer (advanced)
http://www.ebi.ac.uk/efo/efo_0001663,GCST006081,29892016,0,Prostate cancer (advanced vs non-advanced)
http://www.ebi.ac.uk/efo/efo_0001663,GCST006082,29892016,0,Prostate cancer aggressiveness (high vs low/intermediate)
http://www.ebi.ac.uk/efo/efo_0001663,GCST006080,29892016,0,Prostate cancer aggressiveness (high vs low)
http://www.ebi.ac.uk/efo/efo_0006859,GCST005934,29884837,4,Neuropathic pain in head and neck cancer
http://www.ebi.ac.uk/efo/efo_0005762,GCST005934,29884837,4,Neuropathic pain in head and neck cancer
http://www.ebi.ac.uk/efo/efo_0007937,GCST005806,29875488,2784,Blood protein levels
http://www.ebi.ac.uk/efo/efo_0003884,GCST006814,29885931,7,End-stage renal disease
http://www.ebi.ac.uk/efo/efo_0007585,GCST006175,29875475,0,Cannabis-related aggression
http://www.ebi.ac.uk/efo/efo_0003015,GCST006175,29875475,0,Cannabis-related aggression
http://www.ebi.ac.uk/efo/efo_0003884,GCST006816,29885931,0,End stage renal disease in APOL1 risk genotype-positive individuals
http://www.ebi.ac.uk/efo/efo_0009324,GCST006816,29885931,0,End stage renal disease in APOL1 risk genotype-positive individuals
http://www.ebi.ac.uk/efo/efo_0003884,GCST006815,29885931,2,End stage renal disease in APOL1 risk genotype-negative individuals
http://www.ebi.ac.uk/efo/efo_0009324,GCST006815,29885931,2,End stage renal disease in APOL1 risk genotype-negative individuals
http://www.ebi.ac.uk/efo/efo_0003884,GCST006813,29885931,3,End stage renal disease x APOL1 genotype interaction
http://www.ebi.ac.uk/efo/efo_0009324,GCST006813,29885931,3,End stage renal disease x APOL1 genotype interaction
http://www.ebi.ac.uk/efo/efo_0007702,GCST006143,29883787,18,Bone mineral density (total hip)
http://www.ebi.ac.uk/efo/efo_0007701,GCST006142,29883787,0,Lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_0003923,GCST006141,29883787,0,High bone mineral density
http://www.ebi.ac.uk/efo/efo_0009330,GCST006225,29967566,5,Chlamydia trachomatis seropositivity
http://www.ebi.ac.uk/efo/efo_0000409,GCST007046,29768301,0,Disease-free survival in breast cancer treated with chemotherapy with or without bevacizumab
http://www.ebi.ac.uk/efo/efo_0000305,GCST007046,29768301,0,Disease-free survival in breast cancer treated with chemotherapy with or without bevacizumab
http://purl.obolibrary.org/obo/go_0097327,GCST007046,29768301,0,Disease-free survival in breast cancer treated with chemotherapy with or without bevacizumab
http://www.ebi.ac.uk/efo/efo_0007771,GCST007047,29768301,0,Pathological complete response in breast cancer treated with or without bevacizumab
http://www.ebi.ac.uk/efo/efo_0000305,GCST007047,29768301,0,Pathological complete response in breast cancer treated with or without bevacizumab
http://purl.obolibrary.org/obo/go_0097327,GCST007047,29768301,0,Pathological complete response in breast cancer treated with or without bevacizumab
http://www.ebi.ac.uk/efo/efo_0005943,GCST007048,29768301,0,Pathological complete response in breast cancer treated with chemotherapy with bevacizumab
http://www.ebi.ac.uk/efo/efo_0007771,GCST007048,29768301,0,Pathological complete response in breast cancer treated with chemotherapy with bevacizumab
http://www.ebi.ac.uk/efo/efo_0000305,GCST007048,29768301,0,Pathological complete response in breast cancer treated with chemotherapy with bevacizumab
http://purl.obolibrary.org/obo/go_0097327,GCST007048,29768301,0,Pathological complete response in breast cancer treated with chemotherapy with bevacizumab
http://www.ebi.ac.uk/efo/efo_0000638,GCST007049,29768301,0,Overall survival in breast cancer treated with chemotherapy with or without bevacizumab
http://www.ebi.ac.uk/efo/efo_0000305,GCST007049,29768301,0,Overall survival in breast cancer treated with chemotherapy with or without bevacizumab
http://purl.obolibrary.org/obo/go_0097327,GCST007049,29768301,0,Overall survival in breast cancer treated with chemotherapy with or without bevacizumab
http://www.ebi.ac.uk/efo/efo_0007889,GCST006656,29855537,5,Dysmenorrheic pain severity
http://www.ebi.ac.uk/efo/efo_0009336,GCST006280,29855589,89,Velopharyngeal dysfunction
http://www.ebi.ac.uk/efo/efo_0008385,GCST006808,29852030,0,Response to anti-VEGF treatment in neovascular age-related macular degeneration (visual acuity)
http://www.ebi.ac.uk/efo/efo_0009467,GCST006808,29852030,0,Response to anti-VEGF treatment in neovascular age-related macular degeneration (visual acuity)
http://www.ebi.ac.uk/efo/efo_0004683,GCST006808,29852030,0,Response to anti-VEGF treatment in neovascular age-related macular degeneration (visual acuity)
http://www.ebi.ac.uk/efo/efo_0004884,GCST006655,29855537,11,Breast size
http://www.ebi.ac.uk/efo/efo_1000648,GCST006566,30273415,3,Developmental dysplasia of the hip
http://www.ebi.ac.uk/efo/efo_0009408,GCST006654,29855537,5,Vaginal discharge (smell)
http://purl.obolibrary.org/obo/hp_0100608,GCST006657,29855537,2,Vaginal discharge (metrorrhagia)
http://www.ebi.ac.uk/efo/efo_0009365,GCST006657,29855537,2,Vaginal discharge (metrorrhagia)
http://www.ebi.ac.uk/efo/efo_0009409,GCST006653,29855537,5,Vaginal discharge (itching)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006652,29855537,4,Menstruation quality of life impact (stiff neck)
http://purl.obolibrary.org/obo/hp_0025258,GCST006652,29855537,4,Menstruation quality of life impact (stiff neck)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006651,29855537,3,Menstruation quality of life impact (sleepiness)
http://purl.obolibrary.org/obo/ncit_c95746,GCST006651,29855537,3,Menstruation quality of life impact (sleepiness)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006650,29855537,4,Menstruation quality of life impact (pressure in breast)
http://www.ebi.ac.uk/efo/efo_0009393,GCST006650,29855537,4,Menstruation quality of life impact (pressure in breast)
http://purl.obolibrary.org/obo/ncit_c74532,GCST006649,29855537,2,Menstruation quality of life impact (nervousness)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006649,29855537,2,Menstruation quality of life impact (nervousness)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006648,29855537,8,Menstruation quality of life impact (loss of concentration)
http://purl.obolibrary.org/obo/ncit_c117245,GCST006648,29855537,8,Menstruation quality of life impact (loss of concentration)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006647,29855537,4,Menstruation quality of life impact (joint pain)
http://purl.obolibrary.org/obo/hp_0002829,GCST006647,29855537,4,Menstruation quality of life impact (joint pain)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006646,29855537,4,Menstruation quality of life impact (headache)
http://purl.obolibrary.org/obo/hp_0002315,GCST006646,29855537,4,Menstruation quality of life impact (headache)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006645,29855537,3,Menstruation quality of life impact (edema)
http://www.ebi.ac.uk/efo/efo_0009373,GCST006645,29855537,3,Menstruation quality of life impact (edema)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006644,29855537,1,Menstruation quality of life impact (depression)
http://www.ebi.ac.uk/efo/efo_0003761,GCST006644,29855537,1,Menstruation quality of life impact (depression)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006643,29855537,5,Menstruation quality of life impact (bowel movement)
http://purl.obolibrary.org/obo/hp_0030914,GCST006643,29855537,5,Menstruation quality of life impact (bowel movement)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006642,29855537,3,Menstruation quality of life impact (increased appetite)
http://www.ebi.ac.uk/efo/efo_0007829,GCST006642,29855537,3,Menstruation quality of life impact (increased appetite)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006641,29855537,5,Menstruation quality of life impact (aggressiveness)
http://www.ebi.ac.uk/efo/efo_0003015,GCST006641,29855537,5,Menstruation quality of life impact (aggressiveness)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006640,29855537,8,Menstruation quality of life impact (acne)
http://www.ebi.ac.uk/efo/efo_0003894,GCST006640,29855537,8,Menstruation quality of life impact (acne)
http://www.ebi.ac.uk/efo/efo_0009366,GCST006639,29855537,3,Heavy vaginal discharge
http://www.ebi.ac.uk/efo/efo_0009365,GCST006639,29855537,3,Heavy vaginal discharge
http://www.ebi.ac.uk/efo/efo_0009366,GCST006638,29855537,2,Menstruation quality of life impact (fever)
http://purl.obolibrary.org/obo/hp_0001945,GCST006638,29855537,2,Menstruation quality of life impact (fever)
http://www.ebi.ac.uk/efo/efo_0007010,GCST006637,29855537,7,Pain medicine use during menstruation
http://www.ebi.ac.uk/efo/efo_0009366,GCST006637,29855537,7,Pain medicine use during menstruation
http://www.ebi.ac.uk/efo/efo_0009366,GCST006636,29855537,8,Menstruation quality of life impact (dysmenorrhea)
http://www.ebi.ac.uk/efo/efo_0007889,GCST006636,29855537,8,Menstruation quality of life impact (dysmenorrhea)
http://www.ebi.ac.uk/efo/efo_0005035,GCST006134,29860282,13,Hippocampal volume
http://www.ebi.ac.uk/efo/efo_0002690,GCST005831,29848360,5,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0006514,GCST006136,29860282,13,Alzheimer's disease progression score
http://www.ebi.ac.uk/efo/efo_0007707,GCST006135,29860282,15,Cortical amyloid beta load
http://www.ebi.ac.uk/efo/efo_0003931,GCST007250,30680360,44,Nonunion in individuals with fractures
http://www.ebi.ac.uk/efo/efo_0009707,GCST007250,30680360,44,Nonunion in individuals with fractures
http://www.ebi.ac.uk/efo/efo_0009303,GCST006056,29844224,2,Fructosamine levels
http://www.ebi.ac.uk/efo/efo_0004719,GCST006584,29857070,5,Pemphigus vulgaris
http://www.ebi.ac.uk/efo/efo_0009281,GCST006068,29844195,2,Sub-foveal choroidal thickness
http://www.ebi.ac.uk/efo/efo_0004337,GCST006269,29844566,1248,General cognitive ability
http://www.ebi.ac.uk/efo/efo_0007629,GCST006060,29844224,3,Hemoglobin A1c levels
http://www.ebi.ac.uk/efo/efo_0004465,GCST006059,29844224,1,Fasting blood glucose
http://www.ebi.ac.uk/efo/efo_0009305,GCST006058,29844224,3,Total glycated albumin levels
http://www.ebi.ac.uk/efo/efo_0009304,GCST006057,29844224,2,Percent glycated albumin
http://www.ebi.ac.uk/efo/efo_0008393,GCST006268,29844566,532,Reaction time
http://www.ebi.ac.uk/efo/efo_0007814,GCST006289,29808027,49,Spherical equivalent
http://www.ebi.ac.uk/efo/efo_0004847,GCST006291,29808027,140,Spherical equivalent or myopia (age of diagnosis)
http://purl.obolibrary.org/obo/hp_0000545,GCST006291,29808027,140,Spherical equivalent or myopia (age of diagnosis)
http://www.ebi.ac.uk/efo/efo_0007814,GCST006291,29808027,140,Spherical equivalent or myopia (age of diagnosis)
http://www.ebi.ac.uk/efo/efo_0004847,GCST006290,29808027,112,Myopia (age of diagnosis)
http://purl.obolibrary.org/obo/hp_0000545,GCST006290,29808027,112,Myopia (age of diagnosis)
http://www.ebi.ac.uk/efo/efo_0009785,GCST007423,29786918,0,Clinical remission in asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST007423,29786918,0,Clinical remission in asthma
http://www.ebi.ac.uk/efo/efo_0009785,GCST007424,29786918,1,Complete remission in asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST007424,29786918,1,Complete remission in asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST007562,29785011,6,Asthma
http://www.ebi.ac.uk/efo/efo_0005318,GCST006864,29781551,5,Axial length or spherical error (univariate decomposition analysis)
http://www.ebi.ac.uk/efo/efo_0007814,GCST006864,29781551,5,Axial length or spherical error (univariate decomposition analysis)
http://www.ebi.ac.uk/efo/efo_0007814,GCST006539,29781551,0,Spherical error
http://www.ebi.ac.uk/efo/efo_0009266,GCST005928,29787419,2,Refractory celiac disease type II
http://www.ebi.ac.uk/efo/efo_0004339,GCST005908,29782485,41,Height
http://www.ebi.ac.uk/efo/efo_0003785,GCST007564,29785011,38,Asthma or allergic disease (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000270,GCST007564,29785011,38,Asthma or allergic disease (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000182,GCST005746,29784950,7,Hepatocellular carcinoma in hepatitis B infection
http://www.ebi.ac.uk/efo/efo_0004197,GCST005746,29784950,7,Hepatocellular carcinoma in hepatitis B infection
http://www.ebi.ac.uk/efo/efo_0005318,GCST006541,29781551,1,Axial length
http://www.ebi.ac.uk/efo/efo_0004695,GCST006412,29785010,133,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0003785,GCST007563,29785011,33,"Allergic disease (asthma, hay fever or eczema)"
http://www.ebi.ac.uk/efo/efo_0000270,GCST007563,29785011,33,"Allergic disease (asthma, hay fever or eczema)"
http://www.ebi.ac.uk/efo/efo_0009268,GCST005920,29777097,2,Paternal history of Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004518,GCST006393,29779033,4,Serum creatinine levels
http://www.ebi.ac.uk/efo/efo_0005208,GCST006392,29779033,4,Estimated glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0009268,GCST005923,29777097,6,Maternal history of Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST006391,29779033,0,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0000249,GCST005922,29777097,221,Alzheimer's disease or family history of Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0009268,GCST005922,29777097,221,Alzheimer's disease or family history of Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0009268,GCST005921,29777097,61,Family history of Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004704,GCST005863,29773799,36,Menopause (age at onset)
http://www.ebi.ac.uk/efo/efo_0008391,GCST006536,30271932,1,Serum erythropoietin levels
http://www.ebi.ac.uk/efo/efo_0004703,GCST005864,29773799,0,Late age at menarche
http://www.ebi.ac.uk/efo/efo_0004703,GCST005865,29773799,1,Early age at menarche
http://www.ebi.ac.uk/efo/efo_0004703,GCST005867,29773799,31,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0009184,GCST005787,29769521,32,Heart rate response to exercise
http://www.ebi.ac.uk/efo/efo_0004343,GCST006430,29868124,8,Body mass index and waist-hip ratio (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004340,GCST006430,29868124,8,Body mass index and waist-hip ratio (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0009585,GCST006938,29769526,0,Neuromyelitis optica (AQP4-IgG-negative)
http://www.ebi.ac.uk/efo/efo_0009584,GCST006937,29769526,7,Neuromyelitis optica (AQP4-IgG-positive)
http://www.ebi.ac.uk/efo/efo_0004256,GCST005964,29769526,7,Neuromyelitis optica
http://www.ebi.ac.uk/efo/efo_0003888,GCST006219,29769613,1,Executive function in ADHD
http://www.ebi.ac.uk/efo/efo_0009332,GCST006219,29769613,1,Executive function in ADHD
http://www.ebi.ac.uk/efo/efo_0009180,GCST005790,29771307,98,Rosacea symptom severity
http://www.ebi.ac.uk/efo/efo_0004351,GCST005789,29769521,30,Resting heart rate
http://www.ebi.ac.uk/efo/efo_0009185,GCST005788,29769521,29,Heart rate response to recovery post exercise
http://www.ebi.ac.uk/efo/efo_0000341,GCST006042,29767774,2,Current cigarettes per day in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005671,GCST006042,29767774,2,Current cigarettes per day in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0004318,GCST005747,29766673,0,Non-small cell lung cancer in heavy smokers
http://www.ebi.ac.uk/efo/efo_0003060,GCST005747,29766673,0,Non-small cell lung cancer in heavy smokers
http://www.ebi.ac.uk/efo/efo_0005213,GCST005667,29760442,46,Central corneal thickness
http://www.ebi.ac.uk/efo/efo_0005213,GCST006367,29760442,1,Central corneal thickness
http://www.ebi.ac.uk/efo/efo_0005213,GCST006366,29760442,14,Central corneal thickness
http://www.orpha.net/ordo/orphanet_2495,GCST005870,29762745,1,Meningioma
http://www.orpha.net/ordo/orphanet_399,GCST007113,29750799,2,Huntington's disease (age at onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST007113,29750799,2,Huntington's disease (age at onset)
http://www.ebi.ac.uk/efo/efo_0005665,GCST006062,29752348,4,White matter hyperintensity volume
http://www.ebi.ac.uk/efo/efo_0004641,GCST006064,29752348,2,White matter integrity (mean diffusivity)
http://www.ebi.ac.uk/efo/efo_0004641,GCST006063,29752348,2,White matter integrity (fractional anisotropy)
http://www.ebi.ac.uk/efo/efo_0009179,GCST005714,29751835,8,Cerebrospinal fluid beta-site APP cleaving enzyme levels
http://www.ebi.ac.uk/efo/efo_0009178,GCST005713,29747637,2,Plasma neurofilament light levels
http://www.ebi.ac.uk/efo/efo_0005543,GCST005931,29743610,17,Glioma
http://www.ebi.ac.uk/efo/efo_0005543,GCST005933,29743610,11,Non-glioblastoma glioma
http://www.ebi.ac.uk/efo/efo_0005543,GCST005932,29743610,14,Glioblastoma
http://www.ebi.ac.uk/efo/efo_0009321,GCST006282,29739359,2,Diabetic macular edema in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST006282,29739359,2,Diabetic macular edema in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0009322,GCST006283,29739359,2,Proliferative diabetic retinopathy in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST006283,29739359,2,Proliferative diabetic retinopathy in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0005110,GCST005861,29738550,15,Circulating odd-numbered chain saturated fatty acid levels (C23:0)
http://www.ebi.ac.uk/efo/efo_0005110,GCST005862,29738550,15,Circulating odd-numbered chain saturated fatty acid levels (C19:0)
http://www.ebi.ac.uk/efo/efo_0005110,GCST005866,29738550,15,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0)
http://www.ebi.ac.uk/efo/efo_0005110,GCST005868,29738550,15,Circulating odd-numbered chain saturated fatty acid levels (C17:0)
http://www.ebi.ac.uk/efo/efo_0009260,GCST005896,29739929,82,Non-melanoma skin cancer
http://www.ebi.ac.uk/efo/efo_0004279,GCST005897,29739929,79,Low tan response
http://www.ebi.ac.uk/efo/efo_0005110,GCST005869,29738550,15,Circulating odd-numbered chain saturated fatty acid levels (C15:0)
http://www.ebi.ac.uk/efo/efo_0003761,GCST006818,29998114,0,Remission after antidepressant treatment in major depression
http://purl.obolibrary.org/obo/go_0036276,GCST006818,29998114,0,Remission after antidepressant treatment in major depression
http://www.ebi.ac.uk/efo/efo_0009177,GCST005715,29725004,1,Myopic maculopathy
http://www.ebi.ac.uk/efo/efo_0006527,GCST006812,30271922,7,Smoking status (ever vs never smokers)
http://www.ebi.ac.uk/efo/efo_0004340,GCST006811,30271922,4,Body mass index
http://www.ebi.ac.uk/efo/efo_0008579,GCST006810,30271922,26,Self-reported risk-taking behaviour
http://www.ebi.ac.uk/efo/efo_0003761,GCST006817,29998114,5,Response to antidepressants in depression
http://purl.obolibrary.org/obo/go_0036276,GCST006817,29998114,5,Response to antidepressants in depression
http://www.ebi.ac.uk/efo/efo_0000692,GCST006248,29730043,13,Response to lurasidone in schizophrenia
http://purl.obolibrary.org/obo/go_0097332,GCST006248,29730043,13,Response to lurasidone in schizophrenia
http://www.ebi.ac.uk/efo/efo_0006899,GCST006284,29748315,19,Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease
http://www.ebi.ac.uk/efo/efo_0005213,GCST006049,29847655,2,Central corneal thickness
http://www.ebi.ac.uk/efo/efo_0009133,GCST005672,29728394,3,Cholesteryl ester transfer protein levels
http://www.ebi.ac.uk/efo/efo_0005213,GCST006050,29847655,1,Central corneal thickness
http://www.orpha.net/ordo/orphanet_282,GCST006146,29724592,3,Behavioural changes in frontotemporal lobe dementia
http://purl.obolibrary.org/obo/go_0007610,GCST006146,29724592,3,Behavioural changes in frontotemporal lobe dementia
http://www.orpha.net/ordo/orphanet_282,GCST006154,29724592,6,Frontotemporal dementia
http://www.ebi.ac.uk/efo/efo_0002508,GCST006153,29724592,3,Parkinsonism in frontotemporal lobe dementia
http://www.orpha.net/ordo/orphanet_282,GCST006153,29724592,3,Parkinsonism in frontotemporal lobe dementia
http://www.ebi.ac.uk/efo/efo_0005425,GCST006152,29724592,2,Language impairment in frontotemporal lobe dementia
http://www.orpha.net/ordo/orphanet_282,GCST006152,29724592,2,Language impairment in frontotemporal lobe dementia
http://www.ebi.ac.uk/efo/efo_0001072,GCST006151,29724592,6,Memory dysfunction in frontotemporal lobe dementia
http://www.orpha.net/ordo/orphanet_282,GCST006151,29724592,6,Memory dysfunction in frontotemporal lobe dementia
http://www.orpha.net/ordo/orphanet_282,GCST006150,29724592,0,Frontotemporal dementia
http://www.ebi.ac.uk/efo/efo_0004847,GCST006149,29724592,6,Frontotemporal dementia with GRN mutation (age at onset)
http://www.orpha.net/ordo/orphanet_282,GCST006149,29724592,6,Frontotemporal dementia with GRN mutation (age at onset)
http://www.orpha.net/ordo/orphanet_282,GCST006148,29724592,12,Frontotemporal dementia with GRN mutation
http://www.ebi.ac.uk/efo/efo_0004847,GCST006147,29724592,5,Frontotemporal dementia (age at onset)
http://www.orpha.net/ordo/orphanet_282,GCST006147,29724592,5,Frontotemporal dementia (age at onset)
http://www.ebi.ac.uk/efo/efo_0000400,GCST005881,29703844,0,Diabetic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000401,GCST005881,29703844,0,Diabetic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000401,GCST005895,29703844,9,Diabetic kidney disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005895,29703844,9,Diabetic kidney disease in type 2 diabetes
http://purl.obolibrary.org/obo/go_0036273,GCST006217,29703846,0,Coronary heart disease events during statin therapy
http://www.ebi.ac.uk/efo/efo_0006919,GCST006217,29703846,0,Coronary heart disease events during statin therapy
http://www.ebi.ac.uk/efo/efo_0004357,GCST006138,29703947,45,Resting-state electroencephalogram vigilance
http://www.ebi.ac.uk/efo/efo_0003761,GCST005907,29728651,13,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0000400,GCST005894,29703844,1,Diabetic kidney disease in diabetes (ESRD vs. no ESRD)
http://www.ebi.ac.uk/efo/efo_0000401,GCST005894,29703844,1,Diabetic kidney disease in diabetes (ESRD vs. no ESRD)
http://www.ebi.ac.uk/efo/efo_0003884,GCST005893,29703844,14,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
http://www.ebi.ac.uk/efo/efo_0000401,GCST005893,29703844,14,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
http://www.ebi.ac.uk/efo/efo_0005208,GCST005891,29703844,7,Glomerular filtration rate in diabetes
http://www.ebi.ac.uk/efo/efo_0000400,GCST005891,29703844,7,Glomerular filtration rate in diabetes
http://www.ebi.ac.uk/efo/efo_0005208,GCST005892,29703844,7,Glomerular filtration rate in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005892,29703844,7,Glomerular filtration rate in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000400,GCST005890,29703844,5,Early diabetic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000401,GCST005890,29703844,5,Early diabetic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000401,GCST005889,29703844,1,Early diabetic kidney disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005889,29703844,1,Early diabetic kidney disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000400,GCST005888,29703844,0,Late diabetic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000401,GCST005888,29703844,0,Late diabetic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000401,GCST005887,29703844,4,Late diabetic kidney disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005887,29703844,4,Late diabetic kidney disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST005886,29703844,0,End-stage renal disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000400,GCST005886,29703844,0,End-stage renal disease in diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST005885,29703844,2,End-stage renal disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005885,29703844,2,End-stage renal disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST005884,29703844,1,Chronic kidney disease and diabetic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000400,GCST005884,29703844,1,Chronic kidney disease and diabetic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000401,GCST005884,29703844,1,Chronic kidney disease and diabetic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST005883,29703844,4,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000401,GCST005883,29703844,4,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005883,29703844,4,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST005880,29703844,1,Chronic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0000400,GCST005880,29703844,1,Chronic kidney disease in diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST005882,29703844,3,Chronic kidney disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005882,29703844,3,Chronic kidney disease in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0009278,GCST005938,29698431,22,Maximum cranial length
http://www.ebi.ac.uk/efo/efo_0003761,GCST005839,29700475,44,Depression
http://www.ebi.ac.uk/efo/efo_0005842,GCST006035,29698419,18,Breast cancer and/or colorectal cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST006035,29698419,18,Breast cancer and/or colorectal cancer
http://www.ebi.ac.uk/efo/efo_0009278,GCST005940,29698431,20,Maximum cranial width
http://www.ebi.ac.uk/efo/efo_0009278,GCST005939,29698431,14,Cephalic index
http://www.ebi.ac.uk/efo/efo_0001359,GCST006281,29695241,21,Coronary artery disease in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0000378,GCST006281,29695241,21,Coronary artery disease in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0006941,GCST005830,29691431,139,Hand grip strength
http://www.ebi.ac.uk/efo/efo_0001360,GCST006494,29691896,7,"Type 2 diabetes (SNP x SNP interaction, 1df)"
http://www.ebi.ac.uk/efo/efo_0001360,GCST006495,29691896,22,"Type 2 diabetes (SNP x SNP interaction, 2df)"
http://www.ebi.ac.uk/efo/efo_0006941,GCST005829,29691431,27,Hand grip strength
http://www.ebi.ac.uk/efo/efo_0009325,GCST006220,29682794,2,Basal ganglia growth
http://www.ebi.ac.uk/efo/efo_0009334,GCST006224,29682794,8,Right lateral prefrontal cortical growth
http://www.ebi.ac.uk/efo/efo_0009328,GCST006223,29682794,5,Cerebral cortical growth
http://www.ebi.ac.uk/efo/efo_0009327,GCST006222,29682794,4,Cerebellum growth
http://www.ebi.ac.uk/efo/efo_0009335,GCST006221,29682794,5,White matter growth
http://www.ebi.ac.uk/efo/efo_0000555,GCST006535,29673008,7,Irritable bowel syndrome
http://www.ebi.ac.uk/efo/efo_0003785,GCST007732,29679657,25,"Allergic disease (asthma, hay fever or eczema)"
http://www.ebi.ac.uk/efo/efo_0009480,GCST006819,29665250,0,Emotional support seeking
http://www.ebi.ac.uk/efo/efo_0009480,GCST006826,29665250,0,Emotional expression
http://www.ebi.ac.uk/efo/efo_0006783,GCST006825,29665250,0,Perceived stress
http://www.ebi.ac.uk/efo/efo_0009480,GCST006824,29665250,0,Approach coping (positive reappraisal/problem solving)
http://www.ebi.ac.uk/efo/efo_0009480,GCST006823,29665250,0,Emotional coping (emotional expression/emotional support seeking)
http://www.ebi.ac.uk/efo/efo_0009480,GCST006822,29665250,0,Disengagement
http://www.ebi.ac.uk/efo/efo_0009480,GCST006821,29665250,0,Problem solving
http://www.ebi.ac.uk/efo/efo_0009480,GCST006820,29665250,0,Positive reappraisal
http://www.ebi.ac.uk/efo/efo_0003761,GCST005904,29662059,9,Major depressive disorder (probable)
http://www.ebi.ac.uk/efo/efo_1001754,GCST005844,29884306,9,Placental abruption
http://www.ebi.ac.uk/efo/efo_0003761,GCST005902,29662059,111,Depression (broad)
http://www.ebi.ac.uk/efo/efo_0007822,GCST006075,29662168,24,Hair color
http://www.ebi.ac.uk/efo/efo_0003761,GCST005903,29662059,4,Major depressive disorder (ICD-10 coded)
http://www.ebi.ac.uk/efo/efo_0009360,GCST006365,29654602,4,Upper eyelid sagging severity
http://www.ebi.ac.uk/efo/efo_0004841,GCST005748,29659830,11,Digit length ratio (right hand)
http://www.ebi.ac.uk/efo/efo_0009132,GCST005671,29674289,3,Cholesterol efflux capacity
http://www.ebi.ac.uk/efo/efo_0004541,GCST005753,29650774,1,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005753,29650774,1,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
http://purl.obolibrary.org/obo/go_1901558,GCST005753,29650774,1,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004841,GCST005749,29659830,24,Digit length ratio (left hand)
http://www.ebi.ac.uk/efo/efo_0004841,GCST005750,29659830,12,Digit length ratio
http://www.ebi.ac.uk/efo/efo_0004752,GCST006431,30134803,30,Plasma parathyroid hormone levels
http://www.ebi.ac.uk/efo/efo_0006527,GCST005916,29631575,2,Cotinine levels in smokers with chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0007813,GCST005916,29631575,2,Cotinine levels in smokers with chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST005916,29631575,2,Cotinine levels in smokers with chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006527,GCST005919,29631575,3,Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST005919,29631575,3,Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006520,GCST005919,29631575,3,Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST005918,29631575,2,Smoking cessation in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0004319,GCST005918,29631575,2,Smoking cessation in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST005917,29631575,2,Current cigarettes per day in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006525,GCST005917,29631575,2,Current cigarettes per day in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0001360,GCST007515,29632382,37,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST007518,29632382,35,Type 2 diabetes (adjusted for BMI)
http://www.ebi.ac.uk/efo/efo_0001360,GCST007516,29632382,35,Type 2 diabetes (adjusted for BMI)
http://www.ebi.ac.uk/efo/efo_0001360,GCST007517,29632382,32,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000094,GCST005832,29632299,11,Acute lymphoblastic leukemia in childhood (B cell precursor)
http://www.ebi.ac.uk/efo/efo_0000195,GCST005878,29632305,10,Metabolic syndrome (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004327,GCST005905,29622589,15,Global electrical heterogeneity phenotypes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005912,29621232,3,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004541,GCST005914,29621232,1,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004466,GCST005915,29621232,1,Fasting blood insulin
http://www.ebi.ac.uk/efo/efo_0004465,GCST005913,29621232,5,Fasting blood glucose
http://www.ebi.ac.uk/efo/efo_1000830,GCST006805,29670602,0,Infective endocarditis in Staphylococcus aureus infection
http://www.ebi.ac.uk/efo/efo_0005681,GCST006805,29670602,0,Infective endocarditis in Staphylococcus aureus infection
http://www.ebi.ac.uk/efo/efo_0009277,GCST005936,29618737,6,Supraventricular ectopy
http://www.ebi.ac.uk/efo/efo_0009276,GCST005937,29618737,4,Ventricular ectopy
http://www.ebi.ac.uk/efo/efo_0000555,GCST006304,29626450,15,Irritable bowel syndrome
http://www.ebi.ac.uk/efo/efo_0009275,GCST005935,29618737,2,Ventricular ectopy or supraventricular ectopy (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0009277,GCST005935,29618737,2,Ventricular ectopy or supraventricular ectopy (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0009276,GCST005935,29618737,2,Ventricular ectopy or supraventricular ectopy (pleiotropy)
http://www.ebi.ac.uk/efo/efo_1001512,GCST005906,29608257,8,Endometriosis or endometrial cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001065,GCST005906,29608257,8,Endometriosis or endometrial cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006828,GCST006043,29650764,3,Plasma renin activity levels
http://www.ebi.ac.uk/efo/efo_0009182,GCST005718,29603866,0,Anhedonia
http://www.ebi.ac.uk/efo/efo_0009182,GCST005717,29603866,0,Paranoia and hallucinations
http://www.ebi.ac.uk/efo/efo_0009182,GCST005720,29603866,0,Parent-rated negative symptoms
http://www.ebi.ac.uk/efo/efo_0009182,GCST005719,29603866,0,Cognitive disorganisation
http://www.ebi.ac.uk/efo/efo_0003767,GCST005783,29603369,4,Bone mineral density (lumbar spine) in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0007701,GCST005783,29603369,4,Bone mineral density (lumbar spine) in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST005784,29603369,7,Bone mineral density (femoral neck) in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0007785,GCST005784,29603369,7,Bone mineral density (femoral neck) in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_1001132,GCST005688,29608535,15,Idiopathic intracranial hypertension
http://www.ebi.ac.uk/efo/efo_0004308,GCST005579,29596498,1,Low white blood cell count
http://www.ebi.ac.uk/efo/efo_0004308,GCST005578,29596498,16,Low white blood cell count (conditioned on rs2814778)
http://www.ebi.ac.uk/efo/efo_0004695,GCST005580,29617998,320,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0009130,GCST005686,29594489,59,Clostridium difficile infection in multiple myeloma
http://www.ebi.ac.uk/efo/efo_0001378,GCST005686,29594489,59,Clostridium difficile infection in multiple myeloma
http://www.ebi.ac.uk/efo/efo_0005202,GCST005646,29580174,0,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension
http://www.ebi.ac.uk/efo/efo_0000537,GCST005646,29580174,0,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension
http://www.ebi.ac.uk/efo/efo_0004761,GCST005646,29580174,0,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension
http://www.ebi.ac.uk/efo/efo_1001267,GCST005687,29590334,1,Aortic coarctation
http://www.ebi.ac.uk/efo/efo_0004640,GCST005807,29572449,1,Urinary haptoglobin levels in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005807,29572449,1,Urinary haptoglobin levels in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004640,GCST005808,29572449,1,Plasma haptoglobin levels in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005808,29572449,1,Plasma haptoglobin levels in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0009181,GCST005711,29628937,1,Growth differentiation factor-15 levels
http://www.ebi.ac.uk/efo/efo_0009181,GCST005712,29628937,2,Growth differentiation factor-15 levels (conditioned on rs888663)
http://www.ebi.ac.uk/efo/efo_0009134,GCST005670,29563342,6,Plasma trimethyllysine levels
http://www.ebi.ac.uk/efo/efo_0009265,GCST005929,29563502,7,Severity of nausea and vomiting of pregnancy
http://www.ebi.ac.uk/efo/efo_0000253,GCST005647,29566793,10,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_1000971,GCST005930,29563502,2,Hyperemesis gravidarum
http://www.ebi.ac.uk/efo/efo_0004518,GCST005791,29558500,0,Creatinine levels
http://www.ebi.ac.uk/efo/efo_0007887,GCST005809,29559738,3,Photic sneeze reflex
http://www.ebi.ac.uk/efo/efo_0004741,GCST005794,29558500,1,Blood urea nitrogen levels
http://www.ebi.ac.uk/efo/efo_0002506,GCST005811,29559693,29,Osteoarthritis (self-reported)
http://www.ebi.ac.uk/efo/efo_1000786,GCST005812,29559693,8,Osteoarthritis of the hip or knee (hospital diagnosed)
http://www.ebi.ac.uk/efo/efo_0004616,GCST005812,29559693,8,Osteoarthritis of the hip or knee (hospital diagnosed)
http://www.ebi.ac.uk/efo/efo_0004616,GCST005813,29559693,7,Osteoarthritis of the knee (hospital diagnosed)
http://www.ebi.ac.uk/efo/efo_0002506,GCST005814,29559693,6,Osteoarthritis (hospital diagnosed)
http://www.ebi.ac.uk/efo/efo_1000786,GCST005810,29559693,5,Osteoarthritis of the hip (hospital diagnosed)
http://www.ebi.ac.uk/efo/efo_0004761,GCST005793,29558500,6,Uric acid levels
http://www.ebi.ac.uk/efo/efo_0005208,GCST005792,29558500,0,Glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0004465,GCST006404,29743933,5,Glycemic traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0004307,GCST006404,29743933,5,Glycemic traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0004466,GCST006404,29743933,5,Glycemic traits (multi-trait analysis)
http://purl.obolibrary.org/obo/hp_0009762,GCST006981,29555444,19,Facial wrinkles
http://www.ebi.ac.uk/efo/efo_0003884,GCST005648,29545352,40,Serum metabolite concentrations in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0005653,GCST005648,29545352,40,Serum metabolite concentrations in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0009176,GCST005927,29551627,1,Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L)
http://purl.obolibrary.org/obo/go_0031960,GCST005927,29551627,1,Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L)
http://www.ebi.ac.uk/efo/efo_0004591,GCST005926,29551627,6,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma
http://www.ebi.ac.uk/efo/efo_0005843,GCST005926,29551627,6,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma
http://purl.obolibrary.org/obo/go_0031960,GCST005926,29551627,6,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma
http://www.ebi.ac.uk/efo/efo_0009175,GCST005926,29551627,6,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma
http://www.ebi.ac.uk/efo/efo_0004591,GCST005925,29551627,4,Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma
http://www.ebi.ac.uk/efo/efo_0005843,GCST005925,29551627,4,Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma
http://purl.obolibrary.org/obo/go_0031960,GCST005925,29551627,4,Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma
http://www.ebi.ac.uk/efo/efo_0009175,GCST005925,29551627,4,Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma
http://www.ebi.ac.uk/efo/efo_0009176,GCST005924,29551627,1,Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L)
http://purl.obolibrary.org/obo/go_0031960,GCST005924,29551627,1,Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L)
http://www.ebi.ac.uk/efo/efo_0003884,GCST005666,29545352,4,Fractional excretion of metabolites in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0005116,GCST005666,29545352,4,Fractional excretion of metabolites in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST005651,29545352,9,Urinary metabolite concentrations in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0005116,GCST005651,29545352,9,Urinary metabolite concentrations in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0000280,GCST006526,29551738,0,Barrett's esophagus x gastroesophageal reflux disease interaction
http://www.ebi.ac.uk/efo/efo_0003948,GCST006526,29551738,0,Barrett's esophagus x gastroesophageal reflux disease interaction
http://www.ebi.ac.uk/efo/efo_0006527,GCST006527,29551738,0,Barrett's esophagus x smoking interaction
http://www.ebi.ac.uk/efo/efo_0000280,GCST006527,29551738,0,Barrett's esophagus x smoking interaction
http://www.ebi.ac.uk/efo/efo_0006526,GCST006528,29551738,4,Barrett's esophagus x pack-years of smoking exposure interaction
http://www.ebi.ac.uk/efo/efo_0000280,GCST006528,29551738,4,Barrett's esophagus x pack-years of smoking exposure interaction
http://www.ebi.ac.uk/efo/efo_0000280,GCST006529,29551738,1,Barrett's esophagus x BMI interaction
http://www.ebi.ac.uk/efo/efo_0004340,GCST006529,29551738,1,Barrett's esophagus x BMI interaction
http://www.ebi.ac.uk/efo/efo_0000478,GCST006531,29551738,3,Esophageal adenocarcinoma x gastroesophageal reflux disease interaction
http://www.ebi.ac.uk/efo/efo_0003948,GCST006531,29551738,3,Esophageal adenocarcinoma x gastroesophageal reflux disease interaction
http://www.ebi.ac.uk/efo/efo_0000478,GCST006532,29551738,1,Esophageal adenocarcinoma x pack-years of smoking exposure interaction
http://www.ebi.ac.uk/efo/efo_0006526,GCST006532,29551738,1,Esophageal adenocarcinoma x pack-years of smoking exposure interaction
http://www.ebi.ac.uk/efo/efo_0000478,GCST006530,29551738,2,Esophageal adenocarcinoma x smoking interaction
http://www.ebi.ac.uk/efo/efo_0006527,GCST006530,29551738,2,Esophageal adenocarcinoma x smoking interaction
http://www.ebi.ac.uk/efo/efo_0003884,GCST005650,29545352,259,Serum metabolite ratios in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0005653,GCST005650,29545352,259,Serum metabolite ratios in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST005649,29545352,14,Urinary metabolite ratios in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0005116,GCST005649,29545352,14,Urinary metabolite ratios in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0000478,GCST006525,29551738,0,Esophageal adenocarcinoma x BMI interaction
http://www.ebi.ac.uk/efo/efo_0004340,GCST006525,29551738,0,Esophageal adenocarcinoma x BMI interaction
http://www.ebi.ac.uk/efo/efo_0003928,GCST005800,29538362,29,Surgical necrotising enterocolitis in extremely premature birth
http://www.ebi.ac.uk/efo/efo_0003917,GCST005800,29538362,29,Surgical necrotising enterocolitis in extremely premature birth
http://www.ebi.ac.uk/efo/efo_0004993,GCST005761,29547969,1,Immunoglobulin M against phosphorylcholine (IgM anti-PC) levels
http://www.ebi.ac.uk/efo/efo_0006525,GCST006299,29532581,0,Smoking behaviour (cigarettes smoked per day)
http://www.ebi.ac.uk/efo/efo_1001909,GCST005558,29534260,2,Plantar fascial disorders
http://www.ebi.ac.uk/efo/efo_1000481,GCST005558,29534260,2,Plantar fascial disorders
http://www.ebi.ac.uk/efo/efo_0009362,GCST006869,29532581,18,Nicotine withdrawal
http://www.ebi.ac.uk/efo/efo_0009263,GCST006303,29532581,25,Nicotine withdrawal symptom count
http://www.ebi.ac.uk/efo/efo_0003768,GCST006302,29532581,16,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0009262,GCST006301,29532581,35,Nicotine dependence symptom count
http://www.ebi.ac.uk/efo/efo_0009264,GCST006300,29532581,12,Smoking behaviour (maximum cigarettes in a 24 hour period)
http://www.ebi.ac.uk/efo/efo_0004645,GCST005606,29534301,20,Response to hepatitis B vaccine
http://www.ebi.ac.uk/efo/efo_0009183,GCST005751,29527006,11,Empathy quotient
http://www.ebi.ac.uk/efo/efo_1001976,GCST006910,29531354,5,Ischemic stroke (cardioembolic)
http://www.ebi.ac.uk/efo/efo_1001504,GCST006909,29531354,2,Ischemic stroke (small-vessel)
http://purl.obolibrary.org/obo/hp_0002140,GCST005843,29531354,28,Ischemic stroke
http://www.ebi.ac.uk/efo/efo_1001976,GCST005842,29531354,10,Ischemic stroke (cardioembolic)
http://www.ebi.ac.uk/efo/efo_1001504,GCST005841,29531354,9,Ischemic stroke (small-vessel)
http://www.ebi.ac.uk/efo/efo_0005524,GCST005840,29531354,8,Ischemic stroke (large artery atherosclerosis)
http://purl.obolibrary.org/obo/hp_0002140,GCST006908,29531354,19,Ischemic stroke
http://www.ebi.ac.uk/efo/efo_0005524,GCST006907,29531354,6,Ischemic stroke (large artery atherosclerosis)
http://www.ebi.ac.uk/efo/efo_0000712,GCST005838,29531354,32,Stroke
http://www.ebi.ac.uk/efo/efo_0003870,GCST005576,29531279,31,Intracranial aneurysm
http://www.ebi.ac.uk/efo/efo_0000712,GCST006906,29531354,22,Stroke
http://www.ebi.ac.uk/efo/efo_0009267,GCST005851,29631748,27,Delirium
http://www.ebi.ac.uk/efo/efo_0007981,GCST005577,29523524,6,Change in glucose in response to thiazide diuretic treatment in hypertension
http://www.ebi.ac.uk/efo/efo_0000537,GCST005577,29523524,6,Change in glucose in response to thiazide diuretic treatment in hypertension
http://www.ebi.ac.uk/efo/efo_0004468,GCST005577,29523524,6,Change in glucose in response to thiazide diuretic treatment in hypertension
http://www.ebi.ac.uk/efo/efo_0009087,GCST005590,29523850,2,Nontyphoidal Salmonella bacteraemia
http://www.ebi.ac.uk/efo/efo_0004318,GCST006133,29518117,3,Bone mineral density x blood lead interaction in current smokers (2df test)
http://www.ebi.ac.uk/efo/efo_0007040,GCST006133,29518117,3,Bone mineral density x blood lead interaction in current smokers (2df test)
http://www.ebi.ac.uk/efo/efo_0003923,GCST006133,29518117,3,Bone mineral density x blood lead interaction in current smokers (2df test)
http://www.ebi.ac.uk/efo/efo_0004318,GCST006132,29518117,1,Bone mineral density x blood lead interaction in current smokers (1df test)
http://www.ebi.ac.uk/efo/efo_0007040,GCST006132,29518117,1,Bone mineral density x blood lead interaction in current smokers (1df test)
http://www.ebi.ac.uk/efo/efo_0003923,GCST006132,29518117,1,Bone mineral density x blood lead interaction in current smokers (1df test)
http://www.ebi.ac.uk/efo/efo_0004337,GCST007044,29520040,25,Extremely high intelligence
http://www.ebi.ac.uk/efo/efo_0004698,GCST005566,29520036,28,Insomnia
http://www.ebi.ac.uk/efo/efo_0000266,GCST005785,29511167,1,Calcific aortic valve stenosis
http://www.ebi.ac.uk/efo/efo_0005239,GCST005785,29511167,1,Calcific aortic valve stenosis
http://www.ebi.ac.uk/efo/efo_0005110,GCST005587,29514873,8,Breast milk fatty acid composition (infant genotype effect)
http://www.ebi.ac.uk/efo/efo_0007959,GCST005587,29514873,8,Breast milk fatty acid composition (infant genotype effect)
http://www.ebi.ac.uk/efo/efo_0009092,GCST005587,29514873,8,Breast milk fatty acid composition (infant genotype effect)
http://www.ebi.ac.uk/efo/efo_1001231,GCST006126,29513936,0,Uveitis in juvenile idiopathic arthritis
http://www.ebi.ac.uk/efo/efo_0002609,GCST006126,29513936,0,Uveitis in juvenile idiopathic arthritis
http://www.ebi.ac.uk/efo/efo_1001231,GCST006127,29513936,2,Uveitis (juvenile idiopathic arthritis-associated)
http://www.ebi.ac.uk/efo/efo_0002609,GCST006127,29513936,2,Uveitis (juvenile idiopathic arthritis-associated)
http://www.ebi.ac.uk/efo/efo_0002609,GCST006128,29513936,0,Arthritis (juvenile idiopathic)
http://www.ebi.ac.uk/efo/efo_0005110,GCST005586,29514873,10,Breast milk fatty acid composition (maternal genotype effect)
http://www.ebi.ac.uk/efo/efo_0009092,GCST005586,29514873,10,Breast milk fatty acid composition (maternal genotype effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST005586,29514873,10,Breast milk fatty acid composition (maternal genotype effect)
http://www.ebi.ac.uk/efo/efo_0000266,GCST005561,29511194,5,Aortic valve stenosis
http://www.ebi.ac.uk/efo/efo_0007912,GCST005836,29559929,1,Response to SSRI in MDD or conscientiouness
http://www.ebi.ac.uk/efo/efo_0003761,GCST005836,29559929,1,Response to SSRI in MDD or conscientiouness
http://www.ebi.ac.uk/efo/efo_0005658,GCST005836,29559929,1,Response to SSRI in MDD or conscientiouness
http://www.ebi.ac.uk/efo/efo_0003761,GCST005834,29559929,6,Response to SSRI in MDD or openness
http://www.ebi.ac.uk/efo/efo_0005658,GCST005834,29559929,6,Response to SSRI in MDD or openness
http://www.ebi.ac.uk/efo/efo_0007914,GCST005834,29559929,6,Response to SSRI in MDD or openness
http://www.ebi.ac.uk/efo/efo_0004761,GCST005557,29559957,7,Serum uric acid levels
http://www.ebi.ac.uk/efo/efo_0003761,GCST005833,29559929,6,Remission after SSRI treatment in MDD or openness
http://www.ebi.ac.uk/efo/efo_0005658,GCST005833,29559929,6,Remission after SSRI treatment in MDD or openness
http://www.ebi.ac.uk/efo/efo_0007914,GCST005833,29559929,6,Remission after SSRI treatment in MDD or openness
http://www.ebi.ac.uk/efo/efo_0003761,GCST005835,29559929,7,Remission after SSRI treatment in MDD or neuroticism
http://www.ebi.ac.uk/efo/efo_0007660,GCST005835,29559929,7,Remission after SSRI treatment in MDD or neuroticism
http://www.ebi.ac.uk/efo/efo_0005658,GCST005835,29559929,7,Remission after SSRI treatment in MDD or neuroticism
http://www.ebi.ac.uk/efo/efo_0004611,GCST007131,29507422,23,Low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004574,GCST007143,29507422,805,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST007142,29507422,696,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004574,GCST007134,29507422,24,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST007133,29507422,22,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004612,GCST007132,29507422,23,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST007141,29507422,699,Low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST007140,29507422,797,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0003761,GCST005691,29495898,3,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST005689,29495898,4,Major depressive disorder (unexposed to adversity)
http://www.ebi.ac.uk/efo/efo_0003761,GCST005690,29495898,0,Major depressive disorder (exposed to adversity)
http://www.ebi.ac.uk/efo/efo_0009596,GCST006952,29500382,33,Feeling tense
http://www.ebi.ac.uk/efo/efo_0009599,GCST006951,29500382,46,Feeling hurt
http://www.ebi.ac.uk/efo/efo_0009589,GCST006950,29500382,71,Feeling worry
http://purl.obolibrary.org/obo/ncit_c74532,GCST006949,29500382,12,Suffering from nerves
http://www.ebi.ac.uk/efo/efo_0009597,GCST006948,29500382,67,Feeling nervous
http://www.ebi.ac.uk/efo/efo_0009588,GCST006947,29500382,60,Feeling fed-up
http://www.ebi.ac.uk/efo/efo_0009589,GCST006946,29500382,34,Worry too long after an embarrassing experience
http://www.ebi.ac.uk/efo/efo_0009595,GCST006945,29500382,29,Feeling guilty
http://www.ebi.ac.uk/efo/efo_0008475,GCST006944,29500382,69,Experiencing mood swings
http://www.ebi.ac.uk/efo/efo_0009598,GCST006943,29500382,64,Feeling miserable
http://www.ebi.ac.uk/efo/efo_0007865,GCST006942,29500382,10,Feeling lonely
http://www.ebi.ac.uk/efo/efo_0009594,GCST006941,29500382,67,Irritable mood
http://www.ebi.ac.uk/efo/efo_0007660,GCST006940,29500382,181,Neurociticism
http://www.ebi.ac.uk/efo/efo_0009184,GCST005845,29497042,11,Heart rate increase in response to exercise
http://www.ebi.ac.uk/efo/efo_0000729,GCST005815,29562276,4,Childhood onset ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0000692,GCST006293,29503163,2,Response to olanzapine in schizophrenia
http://purl.obolibrary.org/obo/go_0097333,GCST006293,29503163,2,Response to olanzapine in schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST006294,29503163,1,Response to risperidone in schizophrenia
http://purl.obolibrary.org/obo/go_0097336,GCST006294,29503163,1,Response to risperidone in schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST006285,29503163,2,Response to aripiprazole in schizophrenia
http://www.ebi.ac.uk/efo/efo_0009261,GCST006285,29503163,2,Response to aripiprazole in schizophrenia
http://purl.obolibrary.org/obo/go_0097332,GCST006285,29503163,2,Response to aripiprazole in schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST006295,29503163,15,Response to quetiapine in schizophrenia
http://purl.obolibrary.org/obo/go_0097335,GCST006295,29503163,15,Response to quetiapine in schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST006296,29503163,9,Response to ziprazidone in schizophrenia
http://purl.obolibrary.org/obo/go_0097337,GCST006296,29503163,9,Response to ziprazidone in schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST006297,29503163,5,Response to perphenazine in schizophrenia
http://purl.obolibrary.org/obo/go_0097334,GCST006297,29503163,5,Response to perphenazine in schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST006298,29503163,6,Response to haloperidol in schizophrenia
http://purl.obolibrary.org/obo/go_1905119,GCST006298,29503163,6,Response to haloperidol in schizophrenia
http://www.ebi.ac.uk/efo/efo_0004468,GCST005763,29615537,2,Blood glucose levels
http://purl.obolibrary.org/obo/go_0009314,GCST005589,29625478,0,Vision loss in proton beam irradiation treatment of choroidal melanoma
http://www.ebi.ac.uk/efo/efo_0009093,GCST005589,29625478,0,Vision loss in proton beam irradiation treatment of choroidal melanoma
http://www.ebi.ac.uk/efo/efo_0008385,GCST005589,29625478,0,Vision loss in proton beam irradiation treatment of choroidal melanoma
http://www.ebi.ac.uk/efo/efo_0004647,GCST007358,30207284,0,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression)
http://www.ebi.ac.uk/efo/efo_0008336,GCST007358,30207284,0,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression)
http://www.ebi.ac.uk/efo/efo_0003060,GCST007358,30207284,0,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression)
http://www.ebi.ac.uk/efo/efo_0003885,GCST005709,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
http://purl.obolibrary.org/obo/go_0035456,GCST005709,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
http://www.ebi.ac.uk/efo/efo_0004556,GCST005709,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
http://www.ebi.ac.uk/efo/efo_0003885,GCST005708,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
http://purl.obolibrary.org/obo/go_0035456,GCST005708,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
http://www.ebi.ac.uk/efo/efo_0004556,GCST005708,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
http://www.ebi.ac.uk/efo/efo_0003885,GCST005707,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
http://purl.obolibrary.org/obo/go_0035456,GCST005707,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
http://www.ebi.ac.uk/efo/efo_0004556,GCST005707,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
http://www.ebi.ac.uk/efo/efo_0003885,GCST005706,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
http://purl.obolibrary.org/obo/go_0035456,GCST005706,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
http://www.ebi.ac.uk/efo/efo_0004556,GCST005706,29521573,1,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
http://www.ebi.ac.uk/efo/efo_0000712,GCST005764,29615537,0,Stroke
http://www.ebi.ac.uk/efo/efo_0003144,GCST005765,29615537,0,Heart failure
http://www.ebi.ac.uk/efo/efo_0000400,GCST005766,29615537,1,Diabetes mellitus
http://www.ebi.ac.uk/efo/efo_0001645,GCST005767,29615537,2,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0000311,GCST005768,29615537,0,Cancer
http://www.ebi.ac.uk/efo/efo_0000275,GCST005778,29615537,0,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0000249,GCST005779,29615537,0,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004530,GCST005780,29615537,10,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004574,GCST005781,29615537,6,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0006335,GCST005777,29615537,2,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004612,GCST005776,29615537,8,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004348,GCST005775,29615537,1,Hematocrit
http://www.ebi.ac.uk/efo/efo_0004326,GCST005774,29615537,1,Heart rate
http://www.ebi.ac.uk/efo/efo_0004312,GCST005773,29615537,0,Lung function (forced vital capacity)
http://www.ebi.ac.uk/efo/efo_0006336,GCST005772,29615537,3,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004518,GCST005771,29615537,0,Creatinine levels
http://www.ebi.ac.uk/efo/efo_0004458,GCST005770,29615537,0,C-reactive protein levels
http://www.ebi.ac.uk/efo/efo_0004340,GCST005769,29615537,3,Body mass index
http://purl.obolibrary.org/obo/pato_0001422,GCST005762,29615537,0,Death
http://www.ebi.ac.uk/efo/efo_0009185,GCST005846,29497042,15,Heart rate response to recovery post exercise (10 sec)
http://www.ebi.ac.uk/efo/efo_0009185,GCST005847,29497042,16,Heart rate response to recovery post exercise (20 sec)
http://www.ebi.ac.uk/efo/efo_0007019,GCST005722,29489655,2,Milk allergy (maternal genetic effects)
http://www.ebi.ac.uk/efo/efo_0005939,GCST005722,29489655,2,Milk allergy (maternal genetic effects)
http://www.ebi.ac.uk/efo/efo_0007017,GCST005723,29489655,4,Peanut allergy (maternal genetic effects)
http://www.ebi.ac.uk/efo/efo_0005939,GCST005723,29489655,4,Peanut allergy (maternal genetic effects)
http://www.ebi.ac.uk/efo/efo_0007016,GCST005724,29489655,5,Food allergy (maternal genetic effects)
http://www.ebi.ac.uk/efo/efo_0005939,GCST005724,29489655,5,Food allergy (maternal genetic effects)
http://www.ebi.ac.uk/efo/efo_0007018,GCST005725,29489655,3,Egg allergy (parent-of-origin effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST005725,29489655,3,Egg allergy (parent-of-origin effect)
http://www.ebi.ac.uk/efo/efo_0007019,GCST005726,29489655,2,Milk allergy (parent-of-origin effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST005726,29489655,2,Milk allergy (parent-of-origin effect)
http://www.ebi.ac.uk/efo/efo_0007017,GCST005727,29489655,5,Peanut allergy (parent-of-origin effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST005727,29489655,5,Peanut allergy (parent-of-origin effect)
http://www.ebi.ac.uk/efo/efo_0004631,GCST005729,29545823,2,Serum 25-Hydroxyvitamin D levels
http://www.ebi.ac.uk/efo/efo_0000692,GCST006292,29503163,10,Response to antipsychotic treatment in schizophrenia
http://purl.obolibrary.org/obo/go_0097332,GCST006292,29503163,10,Response to antipsychotic treatment in schizophrenia
http://www.ebi.ac.uk/efo/efo_0002690,GCST005754,29494758,3,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0007018,GCST005728,29489655,5,Egg allergy (maternal genetic effects)
http://www.ebi.ac.uk/efo/efo_0005939,GCST005728,29489655,5,Egg allergy (maternal genetic effects)
http://www.ebi.ac.uk/efo/efo_0003885,GCST005710,29521573,0,Neutralising antibody response to interferon beta therapy in multiple sclerosis (time to production)
http://purl.obolibrary.org/obo/go_0035456,GCST005710,29521573,0,Neutralising antibody response to interferon beta therapy in multiple sclerosis (time to production)
http://www.ebi.ac.uk/efo/efo_0004556,GCST005710,29521573,0,Neutralising antibody response to interferon beta therapy in multiple sclerosis (time to production)
http://www.ebi.ac.uk/efo/efo_0009185,GCST005848,29497042,18,Heart rate response to recovery post exercise (50 sec)
http://www.ebi.ac.uk/efo/efo_0009185,GCST005849,29497042,14,Heart rate response to recovery post exercise (40 sec)
http://www.ebi.ac.uk/efo/efo_0009185,GCST005850,29497042,14,Heart rate response to recovery post exercise (30 sec)
http://www.ebi.ac.uk/efo/efo_0007016,GCST005721,29489655,6,Food allergy (parent-of-origin effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST005721,29489655,6,Food allergy (parent-of-origin effect)
http://www.ebi.ac.uk/efo/efo_0009010,GCST005559,29535370,12,Virologic severity in Herpes simplex virus type 2 infection
http://www.ebi.ac.uk/efo/efo_0007785,GCST005795,29499414,36,Femoral neck bone mineral density
http://www.ebi.ac.uk/efo/efo_0007701,GCST005796,29499414,34,Lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_0009094,GCST005588,29495422,42,Idiopathic dilated cardiomyopathy
http://www.ebi.ac.uk/efo/efo_0000692,GCST006803,29483656,108,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0003959,GCST005653,29535761,2,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction)
http://www.ebi.ac.uk/efo/efo_0009113,GCST005653,29535761,2,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction)
http://www.ebi.ac.uk/efo/efo_0009115,GCST005654,29535761,1,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction)
http://www.ebi.ac.uk/efo/efo_0003959,GCST005654,29535761,1,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction)
http://www.ebi.ac.uk/efo/efo_0005193,GCST005656,29535710,310,IgG glycosylation patterns
http://www.ebi.ac.uk/efo/efo_0009116,GCST005652,29535761,8,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)
http://www.ebi.ac.uk/efo/efo_0003959,GCST005652,29535761,8,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)
http://www.ebi.ac.uk/efo/efo_0007766,GCST005521,29478026,29,Heart rate response to beta blockers (atenolol monotherapy)
http://www.ebi.ac.uk/efo/efo_0004326,GCST005521,29478026,29,Heart rate response to beta blockers (atenolol monotherapy)
http://www.ebi.ac.uk/efo/efo_0007766,GCST005519,29478026,2,Heart rate response to beta blockers
http://www.ebi.ac.uk/efo/efo_0004326,GCST005519,29478026,2,Heart rate response to beta blockers
http://www.ebi.ac.uk/efo/efo_0007766,GCST005520,29478026,33,Heart rate response to beta blockers (atenolol add-on therapy)
http://www.ebi.ac.uk/efo/efo_0004326,GCST005520,29478026,33,Heart rate response to beta blockers (atenolol add-on therapy)
http://www.ebi.ac.uk/efo/efo_0000378,GCST005582,29472232,4,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_0009103,GCST005797,29472613,2,Theory of mind score in adolescence (Emotional Triangles Task)
http://www.ebi.ac.uk/efo/efo_0007835,GCST005440,29460428,17,Alcohol dependence symptom count
http://www.ebi.ac.uk/efo/efo_0006790,GCST005517,29458411,2,Neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006797,GCST005517,29458411,2,Neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006798,GCST005515,29458411,3,Neuritic plaques or cerebral amyloid angiopathy (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006790,GCST005515,29458411,3,Neuritic plaques or cerebral amyloid angiopathy (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006798,GCST005516,29458411,4,Neuritic plaques or neurofibrillary tangles (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006797,GCST005516,29458411,4,Neuritic plaques or neurofibrillary tangles (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0009098,GCST005760,29496196,10,Dimensional psychopathology (Cognitive)
http://www.ebi.ac.uk/efo/efo_0009100,GCST005759,29496196,10,Dimensional psychopathology (Social)
http://www.ebi.ac.uk/efo/efo_0009099,GCST005758,29496196,10,Dimensional psychopathology (Arousal)
http://www.ebi.ac.uk/efo/efo_0009097,GCST005757,29496196,10,Dimensional psychopathology (Positive)
http://www.ebi.ac.uk/efo/efo_0005526,GCST005439,29460428,7,Response to alcohol consumption (flushing response)
http://www.ebi.ac.uk/efo/efo_0007878,GCST005441,29460428,11,Alcohol consumption (max-drinks)
http://www.ebi.ac.uk/efo/efo_0009096,GCST005756,29496196,10,Dimensional psychopathology (Negative)
http://www.ebi.ac.uk/efo/efo_0006798,GCST005514,29458411,3,Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006790,GCST005514,29458411,3,Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006797,GCST005514,29458411,3,Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0007841,GCST007989,29459680,10,Facial morphology traits (63 three-dimensional facial segments)
http://www.ebi.ac.uk/efo/efo_0005842,GCST005591,29471430,30,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0008578,GCST005798,29453196,1,Sperm motility
http://www.ebi.ac.uk/efo/efo_0009104,GCST005802,29453348,1,Hyperuricemia
http://www.ebi.ac.uk/efo/efo_0004274,GCST005801,29453348,1,Gout vs. Hyperuricemia
http://www.ebi.ac.uk/efo/efo_0009104,GCST005801,29453348,1,Gout vs. Hyperuricemia
http://www.ebi.ac.uk/efo/efo_0004274,GCST005799,29453348,2,Gout
http://www.ebi.ac.uk/efo/efo_0006527,GCST006186,29455858,9,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006335,GCST006186,29455858,9,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006187,29455858,45,Diastolic blood pressure (cigarette smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006336,GCST006187,29455858,45,Diastolic blood pressure (cigarette smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006188,29455858,46,Systolic blood pressure (cigarette smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006335,GCST006188,29455858,46,Systolic blood pressure (cigarette smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006189,29455858,0,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006335,GCST006189,29455858,0,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006190,29455858,91,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006336,GCST006190,29455858,91,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006191,29455858,2,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006336,GCST006191,29455858,2,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006192,29455858,88,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006335,GCST006192,29455858,88,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006193,29455858,97,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006336,GCST006193,29455858,97,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006194,29455858,9,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006336,GCST006194,29455858,9,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006195,29455858,95,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006335,GCST006195,29455858,95,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0004190,GCST005407,29449654,4,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0004190,GCST005408,29449654,0,Open-angle glaucoma and intra-ocular pressure
http://www.ebi.ac.uk/efo/efo_0004695,GCST005408,29449654,0,Open-angle glaucoma and intra-ocular pressure
http://www.ebi.ac.uk/efo/efo_0006939,GCST005409,29449654,2,Open-angle glaucoma and vertical cup-disc ratio
http://www.ebi.ac.uk/efo/efo_0004190,GCST005409,29449654,2,Open-angle glaucoma and vertical cup-disc ratio
http://www.ebi.ac.uk/efo/efo_0004190,GCST005410,29449654,0,Open-angle glaucoma and optic disc area
http://www.ebi.ac.uk/efo/efo_0006937,GCST005410,29449654,0,Open-angle glaucoma and optic disc area
http://www.ebi.ac.uk/efo/efo_0000182,GCST005570,29246937,2,Hepatitis B virus-related hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0004197,GCST005570,29246937,2,Hepatitis B virus-related hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0006940,GCST005406,29449654,2,Open-angle glaucoma and optic cup area
http://www.ebi.ac.uk/efo/efo_0004190,GCST005406,29449654,2,Open-angle glaucoma and optic cup area
http://www.ebi.ac.uk/efo/efo_0004190,GCST005388,29452408,4,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_1000637,GCST005805,29425463,0,Acute respiratory distress syndrome
http://www.ebi.ac.uk/efo/efo_0004266,GCST005518,29432556,8,Premature menopause in childhood cancer survivors
http://www.ebi.ac.uk/efo/efo_0002618,GCST005434,29422604,32,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_1000786,GCST005571,29436472,1,Osteoarthritis of the hip or knee (with total joint replacement)
http://www.ebi.ac.uk/efo/efo_0004616,GCST005571,29436472,1,Osteoarthritis of the hip or knee (with total joint replacement)
http://www.ebi.ac.uk/efo/efo_0004616,GCST005574,29436472,5,Osteoarthritis of the knee (with total joint replacement)
http://www.ebi.ac.uk/efo/efo_1000786,GCST005572,29436472,6,Osteoarthritis of the hip (with total joint replacement)
http://www.ebi.ac.uk/efo/efo_1000786,GCST005573,29436472,2,Osteoarthritis of the hip or knee
http://www.ebi.ac.uk/efo/efo_0004616,GCST005573,29436472,2,Osteoarthritis of the hip or knee
http://www.ebi.ac.uk/efo/efo_0005187,GCST005435,29404672,2,Stimulated C-peptide levels in type I diabetes
http://www.ebi.ac.uk/efo/efo_0001359,GCST005435,29404672,2,Stimulated C-peptide levels in type I diabetes
http://www.ebi.ac.uk/efo/efo_0005187,GCST005436,29404672,4,C-peptide levels in type I diabetes
http://www.ebi.ac.uk/efo/efo_0001359,GCST005436,29404672,4,C-peptide levels in type I diabetes
http://www.ebi.ac.uk/efo/efo_0005187,GCST005437,29404672,1,Random C-peptide levels in type I diabetes
http://www.ebi.ac.uk/efo/efo_0001359,GCST005437,29404672,1,Random C-peptide levels in type I diabetes
http://www.ebi.ac.uk/efo/efo_0005187,GCST005438,29404672,0,Fasting C-peptide levels in type I diabetes
http://www.ebi.ac.uk/efo/efo_0001359,GCST005438,29404672,0,Fasting C-peptide levels in type I diabetes
http://www.ebi.ac.uk/efo/efo_1002040,GCST005803,29422769,16,Corneal astigmatism
http://www.ebi.ac.uk/efo/efo_0004761,GCST005369,29408531,2,Serum uric acid levels
http://www.ebi.ac.uk/efo/efo_0000341,GCST005417,29394082,2,Chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0003892,GCST005416,29394082,1,Airflow obstruction
http://www.ebi.ac.uk/efo/efo_0004713,GCST005419,29394082,3,Lung function (FEV1/FVC)
http://www.ebi.ac.uk/efo/efo_0004314,GCST005418,29394082,0,FEV1
http://www.ebi.ac.uk/efo/efo_0005924,GCST005386,29391396,5,Binge eating behaviour and bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST005386,29391396,5,Binge eating behaviour and bipolar disorder
http://www.ebi.ac.uk/efo/efo_0005924,GCST005387,29391396,5,Binge eating behaviour in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST005387,29391396,5,Binge eating behaviour in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0008579,GCST005415,29391395,1,Self-reported risk-taking behaviour
http://www.ebi.ac.uk/efo/efo_0008069,GCST005412,29378355,7,Thrombin-activatable fibrinolysis inhibitor levels
http://www.ebi.ac.uk/efo/efo_0003956,GCST005556,29581620,0,Pollinosis
http://www.ebi.ac.uk/efo/efo_0005199,GCST005433,29392897,0,Acute graft rejection in renal transplantation (donor-recipient interaction)
http://www.ebi.ac.uk/efo/efo_0007892,GCST005433,29392897,0,Acute graft rejection in renal transplantation (donor-recipient interaction)
http://www.ebi.ac.uk/efo/efo_0005199,GCST005432,29392897,0,Acute graft rejection in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0007892,GCST005432,29392897,0,Acute graft rejection in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0005199,GCST005431,29392897,0,Acute graft rejection in renal transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0005199,GCST005430,29392897,0,Graft survival time in renal transplantation (donor-recipient interaction)
http://www.ebi.ac.uk/efo/efo_0007892,GCST005430,29392897,0,Graft survival time in renal transplantation (donor-recipient interaction)
http://www.ebi.ac.uk/efo/efo_0005199,GCST005429,29392897,0,Graft survival time in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0007892,GCST005429,29392897,0,Graft survival time in renal transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0005199,GCST005428,29392897,0,Graft survival time in renal transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0005199,GCST005427,29392897,0,End stage renal failure in renal transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0003884,GCST005427,29392897,0,End stage renal failure in renal transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0005669,GCST005426,29392897,0,Intracranial haemorrhage in renal transplantation (donors)
http://www.ebi.ac.uk/efo/efo_0008543,GCST005365,29398083,2,Serum C3d:C3 ratio (systemic complement activation)
http://www.ebi.ac.uk/efo/efo_0008582,GCST005411,29378355,11,Thrombin-activatable fibrinolysis inhibitor activation peptide
http://www.ebi.ac.uk/efo/efo_0003100,GCST005804,29278617,3,Taxane-induced peripheral neuropathy in breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST005804,29278617,3,Taxane-induced peripheral neuropathy in breast cancer
http://www.ebi.ac.uk/efo/efo_0008580,GCST005804,29278617,3,Taxane-induced peripheral neuropathy in breast cancer
http://www.ebi.ac.uk/efo/efo_0000182,GCST005309,29385134,3,Nonalcoholic steatohepatitis-derived hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_1001249,GCST005309,29385134,3,Nonalcoholic steatohepatitis-derived hepatocellular carcinoma
http://purl.obolibrary.org/obo/hp_0002315,GCST005337,29397368,28,Headache
http://www.ebi.ac.uk/efo/efo_0003095,GCST005308,29385134,7,Nonalcoholic fatty liver disease
http://www.ebi.ac.uk/efo/efo_0008421,GCST005311,29385134,0,Hepatocyte fat droplet content in nonalcoholic fatty liver disease
http://www.ebi.ac.uk/efo/efo_0008421,GCST005310,29385134,0,Brunt grade in nonalcoholic fatty liver disease
http://www.ebi.ac.uk/efo/efo_0008421,GCST005307,29385134,0,Brunt stage in nonalcoholic fatty liver disease
http://www.ebi.ac.uk/efo/efo_0001068,GCST005357,29381699,14,Severe malaria (adjusted for sickle cell variant rs334)
http://www.ebi.ac.uk/efo/efo_0001068,GCST005356,29381699,15,Severe malaria
http://www.ebi.ac.uk/efo/efo_0003888,GCST005318,29382897,0,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder
http://purl.obolibrary.org/obo/go_0036271,GCST005318,29382897,0,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0004574,GCST006305,29404214,0,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004530,GCST006472,29404214,1,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST006471,29404214,0,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004612,GCST006470,29404214,1,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004574,GCST006469,29404214,1,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004530,GCST006308,29404214,4,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004611,GCST006307,29404214,0,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004612,GCST006306,29404214,4,HDL cholesterol
http://www.orpha.net/ordo/orphanet_388,GCST005289,29379196,7,Hirschsprung disease
http://purl.obolibrary.org/obo/go_0007568,GCST005288,29374233,3,Extrinsic epigenetic age acceleration
http://purl.obolibrary.org/obo/go_0007568,GCST005287,29374233,6,Intrinsic epigenetic age acceleration
http://www.orpha.net/ordo/orphanet_398934,GCST005352,29367611,31,Paclitaxel disposition in epithelial ovarian cancer
http://purl.obolibrary.org/obo/go_1901555,GCST005352,29367611,31,Paclitaxel disposition in epithelial ovarian cancer
http://www.ebi.ac.uk/efo/efo_0006782,GCST005330,29367735,4,Coffee consumption
http://www.ebi.ac.uk/efo/efo_0006782,GCST005329,29367735,1,Coffee consumption
http://www.orpha.net/ordo/orphanet_398934,GCST005351,29367611,18,Carboplatin disposition in epthelial ovarian cancer
http://purl.obolibrary.org/obo/go_0097328,GCST005351,29367611,18,Carboplatin disposition in epthelial ovarian cancer
http://www.ebi.ac.uk/efo/efo_0008534,GCST005331,29395996,10,CSF tryptophan concentration in tuberculous meningitis
http://www.ebi.ac.uk/efo/efo_1000039,GCST005331,29395996,10,CSF tryptophan concentration in tuberculous meningitis
http://www.ebi.ac.uk/efo/efo_0001360,GCST005414,29358691,24,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005898,29358691,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005899,29358691,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005413,29358691,20,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001663,GCST005786,29356057,25,Prostate cancer
http://www.ebi.ac.uk/efo/efo_1001870,GCST006806,29360470,1,Late-onset Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000220,GCST005315,29348612,9,Acute lymphoblastic leukemia (childhood)
http://www.ebi.ac.uk/efo/efo_0004631,GCST005366,29343764,5,Vitamin D levels (dietary vitamin D intake interaction)
http://www.ebi.ac.uk/efo/efo_0008539,GCST005366,29343764,5,Vitamin D levels (dietary vitamin D intake interaction)
http://www.ebi.ac.uk/efo/efo_0004631,GCST005367,29343764,6,Vitamin D levels
http://www.ebi.ac.uk/efo/efo_0001365,GCST005359,29346644,62,Disease progression in age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0008336,GCST005359,29346644,62,Disease progression in age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0008336,GCST005358,29346644,4,Disease progression to choroidal neovascularization form in age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0004683,GCST005358,29346644,4,Disease progression to choroidal neovascularization form in age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_1001492,GCST005360,29346644,2,Disease progression to geographic atrophy form in age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0008336,GCST005360,29346644,2,Disease progression to geographic atrophy form in age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0000783,GCST005341,29331962,0,Idiopathic inflammatory myopathy
http://www.ebi.ac.uk/efo/efo_0008532,GCST005338,29331962,1,Clinically amyopathic dermatomyositis
http://www.ebi.ac.uk/efo/efo_0000398,GCST005339,29331962,0,Dermatomyositis
http://www.ebi.ac.uk/efo/efo_0003063,GCST005340,29331962,0,Polymyositis
http://www.ebi.ac.uk/efo/efo_0001071,GCST005267,29330379,0,Schizophrenia or lung cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000692,GCST005267,29330379,0,Schizophrenia or lung cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000692,GCST005266,29330379,0,Schizophrenia or cigarettes per day (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006525,GCST005266,29330379,0,Schizophrenia or cigarettes per day (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0005611,GCST005368,29478698,11,Opioid dependence
http://www.ebi.ac.uk/efo/efo_0004337,GCST005316,29326435,645,Intelligence (MTAG)
http://www.ebi.ac.uk/efo/efo_0004529,GCST005317,29327327,0,Femoral neck bone mineral density or plasma lipids (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0007785,GCST005317,29327327,0,Femoral neck bone mineral density or plasma lipids (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0008538,GCST005355,29324852,7,Helping behaviour (self reported)
http://www.ebi.ac.uk/efo/efo_0003761,GCST005231,29317602,60,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST005230,29317602,23,Recurrent major depressive disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST005343,29317604,3,Plasma kynurenine to tryptophan ratio in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0008530,GCST005343,29317604,3,Plasma kynurenine to tryptophan ratio in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST005342,29317604,7,Plasma kynurenine levels in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0008529,GCST005342,29317604,7,Plasma kynurenine levels in major depressive disorder
http://www.orpha.net/ordo/orphanet_98974,GCST004217,28358029,6,Fuchs's corneal dystrophy
http://www.ebi.ac.uk/efo/efo_0007938,GCST004224,28355232,15,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)
http://www.ebi.ac.uk/efo/efo_0007908,GCST004224,28355232,15,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)
http://www.orpha.net/ordo/orphanet_3389,GCST004226,28355295,1,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0000326,GCST004347,28346443,18,Glioma
http://www.ebi.ac.uk/efo/efo_0005543,GCST004347,28346443,18,Glioma
http://www.ebi.ac.uk/efo/efo_0001360,GCST007620,28346466,0,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0005325,GCST004029,28030426,45,Angiotensin-converting enzyme inhibitor intolerance
http://www.ebi.ac.uk/efo/efo_0001075,GCST004415,28346442,19,Invasive epithelial ovarian cancer
http://www.ebi.ac.uk/efo/efo_0007658,GCST004414,28346442,4,Ovarian cancer in BRCA1 mutation carriers
http://www.ebi.ac.uk/efo/efo_0001075,GCST004414,28346442,4,Ovarian cancer in BRCA1 mutation carriers
http://www.ebi.ac.uk/efo/efo_1001516,GCST004461,28346442,1,Low-grade serous ovarian cancer
http://www.ebi.ac.uk/efo/efo_1001516,GCST004480,28346442,21,High-grade serous ovarian cancer
http://www.ebi.ac.uk/efo/efo_1001516,GCST004479,28346442,10,Serous borderline ovarian cancer
http://www.ebi.ac.uk/efo/efo_1001516,GCST004478,28346442,21,Serous invasive ovarian cancer
http://www.ebi.ac.uk/efo/efo_0006462,GCST004419,28346442,7,Mucinous ovarian carcinoma
http://www.ebi.ac.uk/efo/efo_1001515,GCST004418,28346442,1,Endometrioid ovarian cancer
http://www.ebi.ac.uk/efo/efo_1000042,GCST004417,28346442,2,Ovarian clear cell cancer
http://www.ebi.ac.uk/efo/efo_0001075,GCST004462,28346442,23,Epithelial ovarian cancer
http://www.ebi.ac.uk/efo/efo_0000326,GCST004349,28346443,13,Glioblastoma
http://www.ebi.ac.uk/efo/efo_0000519,GCST004349,28346443,13,Glioblastoma
http://www.ebi.ac.uk/efo/efo_0007658,GCST004416,28346442,2,Ovarian cancer in BRCA2 mutation carriers
http://www.ebi.ac.uk/efo/efo_0001075,GCST004416,28346442,2,Ovarian cancer in BRCA2 mutation carriers
http://www.ebi.ac.uk/efo/efo_0000326,GCST004348,28346443,19,Non-glioblastoma glioma
http://www.ebi.ac.uk/efo/efo_0005543,GCST004348,28346443,19,Non-glioblastoma glioma
http://www.ebi.ac.uk/efo/efo_1001516,GCST004481,28346442,12,Low-grade serous and serous borderline ovarian cancer
http://www.ebi.ac.uk/efo/efo_0007963,GCST004251,28352666,9,Paneth cell defects in Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000384,GCST004251,28352666,9,Paneth cell defects in Crohn's disease
http://www.ebi.ac.uk/efo/efo_0005130,GCST004277,28333968,0,Free thyroxine concentration
http://www.ebi.ac.uk/efo/efo_0004242,GCST004223,28386217,0,Attention deficit hyperactivity disorder and obsessive compulsive disorder
http://www.ebi.ac.uk/efo/efo_0003888,GCST004223,28386217,0,Attention deficit hyperactivity disorder and obsessive compulsive disorder
http://www.ebi.ac.uk/efo/efo_0004748,GCST004276,28333968,7,Plasma thyroid-stimulating hormone levels
http://www.ebi.ac.uk/efo/efo_0004995,GCST004218,28322352,0,Lean body mass
http://www.ebi.ac.uk/efo/efo_0000692,GCST004252,28322246,0,Amyotrophic lateral sclerosis or schizophrenia (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000253,GCST004252,28322246,0,Amyotrophic lateral sclerosis or schizophrenia (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0007942,GCST004199,28319091,2,Osteoarthritis (with total hip replacement)
http://www.ebi.ac.uk/efo/efo_0002506,GCST004199,28319091,2,Osteoarthritis (with total hip replacement)
http://www.ebi.ac.uk/efo/efo_0004502,GCST004289,28317342,3,Adiponectin levels in pregnancy
http://www.ebi.ac.uk/efo/efo_1002002,GCST004200,28415562,0,High-altitude pulmonary edema
http://www.ebi.ac.uk/efo/efo_0000717,GCST004202,28314753,7,Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0003784,GCST004219,28300201,42,Skin pigmentation
http://www.ebi.ac.uk/efo/efo_0007973,GCST004339,28298293,4,Palmitoleic acid (16:1n-7) levels
http://www.ebi.ac.uk/efo/efo_0007977,GCST004341,28298293,0,Nervonic acid (24:1n-9) levels
http://www.ebi.ac.uk/efo/efo_0007976,GCST004340,28298293,0,Erucic acid (22:1n-9) levels
http://www.ebi.ac.uk/efo/efo_0007975,GCST004337,28298293,4,Gondoic acid (20:1n-9) levels
http://www.ebi.ac.uk/efo/efo_0006810,GCST004338,28298293,4,Oleic acid (18:1n-9) levels
http://www.ebi.ac.uk/efo/efo_0007974,GCST004342,28298293,4,Vaccenic acid (18:1n-7) levels
http://www.ebi.ac.uk/efo/efo_0006527,GCST004254,28292921,4,"Urinary 1,3-butadiene metabolite levels in smokers"
http://www.ebi.ac.uk/efo/efo_0007957,GCST004254,28292921,4,"Urinary 1,3-butadiene metabolite levels in smokers"
http://www.ebi.ac.uk/efo/efo_0000638,GCST004228,28179588,0,Survival in TP53 positive breast cancer
http://www.ebi.ac.uk/efo/efo_1002010,GCST004228,28179588,0,Survival in TP53 positive breast cancer
http://www.ebi.ac.uk/efo/efo_0000638,GCST004229,28179588,0,Survival in breast cancer (TP53 expression interaction)
http://www.ebi.ac.uk/efo/efo_0000305,GCST004229,28179588,0,Survival in breast cancer (TP53 expression interaction)
http://www.ebi.ac.uk/efo/efo_0008382,GCST004229,28179588,0,Survival in breast cancer (TP53 expression interaction)
http://www.ebi.ac.uk/efo/efo_0005842,GCST004168,28295283,2,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0004288,GCST004167,28295283,2,Colon cancer
http://www.ebi.ac.uk/efo/efo_1000657,GCST004169,28295283,0,Rectal cancer
http://www.ebi.ac.uk/efo/efo_0004340,GCST004255,28296344,1,Body mass index
http://purl.obolibrary.org/obo/hp_0040187,GCST004230,28283553,6,Sepsis in extremely premature infants
http://www.ebi.ac.uk/efo/efo_1000616,GCST004661,28781888,2,Uveal melanoma
http://www.ebi.ac.uk/efo/efo_0005691,GCST004484,28439531,12,Plasma trimethylamine N-oxide levels
http://www.ebi.ac.uk/efo/efo_0007825,GCST007815,28272467,63,Male-pattern baldness
http://www.ebi.ac.uk/efo/efo_0006336,GCST004203,28270201,4,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0007788,GCST004216,28270201,4,Waist-to-hip ratio adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0004741,GCST004215,28270201,5,Urea levels
http://www.ebi.ac.uk/efo/efo_0004518,GCST004214,28270201,4,Creatinine levels
http://www.ebi.ac.uk/efo/efo_0004351,GCST004213,28270201,6,Resting heart rate
http://www.ebi.ac.uk/efo/efo_0004339,GCST004212,28270201,32,Height
http://www.ebi.ac.uk/efo/efo_0004531,GCST004211,28270201,4,Urate levels
http://www.ebi.ac.uk/efo/efo_0007800,GCST004210,28270201,6,Body fat percentage
http://www.ebi.ac.uk/efo/efo_0004574,GCST004209,28270201,17,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004340,GCST004208,28270201,5,Body mass index
http://www.ebi.ac.uk/efo/efo_0004612,GCST004207,28270201,26,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004465,GCST004206,28270201,16,Fasting plasma glucose
http://www.ebi.ac.uk/efo/efo_0005763,GCST004205,28270201,0,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST004204,28270201,0,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0007781,GCST004225,28265120,1,Alcohol misuse (trauma interaction)
http://www.ebi.ac.uk/efo/efo_0007835,GCST004225,28265120,1,Alcohol misuse (trauma interaction)
http://www.ebi.ac.uk/efo/efo_0008483,GCST005550,28262088,1,Post traumatic stress disorder symptom count in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0008535,GCST005550,28262088,1,Post traumatic stress disorder symptom count in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0005524,GCST007991,28265093,8,Large artery stroke
http://www.ebi.ac.uk/efo/efo_0000537,GCST004143,28273873,3,Hypertension
http://www.ebi.ac.uk/efo/efo_0004606,GCST004201,28274756,2,Gallbladder cancer
http://www.ebi.ac.uk/efo/efo_0004318,GCST004220,28253294,0,Adult onset asthma (smoking interaction)
http://www.ebi.ac.uk/efo/efo_1002011,GCST004220,28253294,0,Adult onset asthma (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004318,GCST004222,28253294,0,Adult onset asthma in ever-smokers
http://www.ebi.ac.uk/efo/efo_1002011,GCST004222,28253294,0,Adult onset asthma in ever-smokers
http://www.ebi.ac.uk/efo/efo_1002011,GCST004221,28253294,0,Adult onset asthma in non-smokers
http://www.ebi.ac.uk/efo/efo_0001360,GCST004758,28254843,8,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004670,GCST004069,28247064,16,Cerebrospinal fluid AB1-42 levels
http://www.ebi.ac.uk/efo/efo_0004760,GCST004071,28247064,19,Cerebrospinal T-tau levels
http://www.ebi.ac.uk/efo/efo_0004763,GCST004070,28247064,22,Cerebrospinal P-tau181p levels
http://www.ebi.ac.uk/efo/efo_0005423,GCST004288,28334814,8,Adolescent idiopathic scoliosis
http://www.ebi.ac.uk/efo/efo_1002009,GCST004171,28250457,5,Macular telangiectasia type 2
http://www.ebi.ac.uk/efo/efo_0007937,GCST004365,28240269,590,Blood protein levels
http://www.ebi.ac.uk/efo/efo_0004620,GCST004161,28334792,4,Vitamin B12 levels
http://purl.obolibrary.org/obo/hp_0000175,GCST004166,28232668,56,Nonsyndromic cleft lip with cleft palate
http://www.ebi.ac.uk/efo/efo_0003959,GCST004166,28232668,56,Nonsyndromic cleft lip with cleft palate
http://www.ebi.ac.uk/efo/efo_0006501,GCST004162,28282560,39,Carotid plaque burden
http://www.ebi.ac.uk/efo/efo_0005514,GCST004528,28649644,1,HER2 status in breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST004528,28649644,1,HER2 status in breast cancer
http://www.ebi.ac.uk/efo/efo_1002005,GCST004098,28223688,1,Sciatica caused by lumbar disc herniation (treated with microdiscectomy)
http://purl.obolibrary.org/obo/hp_0011868,GCST004098,28223688,1,Sciatica caused by lumbar disc herniation (treated with microdiscectomy)
http://www.ebi.ac.uk/efo/efo_0007941,GCST004098,28223688,1,Sciatica caused by lumbar disc herniation (treated with microdiscectomy)
http://www.ebi.ac.uk/efo/efo_0004193,GCST004113,28177523,2,Basal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0005409,GCST004141,28224759,3,Body fat mass
http://www.ebi.ac.uk/efo/efo_0004574,GCST004231,28334899,16,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST004232,28334899,90,HDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST004238,28334899,11,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST004237,28334899,49,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST004236,28334899,13,LDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004574,GCST004235,28334899,81,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST004234,28334899,18,HDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST004233,28334899,66,LDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004286,GCST004068,28203683,86,Venous thromboembolism adjusted for sickle cell variant rs77121243-T
http://www.ebi.ac.uk/efo/efo_0007956,GCST004170,28193307,3,Monocyte-lymphocyte ratio
http://www.orpha.net/ordo/orphanet_79364,GCST006661,28196072,335,Male-pattern baldness
http://www.ebi.ac.uk/efo/efo_0005091,GCST004164,28193307,5,Monocyte count
http://www.ebi.ac.uk/efo/efo_0007946,GCST004158,28194004,3,Self-reported tiredness
http://www.ebi.ac.uk/efo/efo_0002892,GCST004144,28195142,12,Thyroid cancer
http://www.ebi.ac.uk/efo/efo_0007947,GCST004159,28187132,4,Serum galactose-deficient IgA1 levels
http://www.ebi.ac.uk/efo/efo_0000756,GCST004142,28212542,28,Melanoma
http://www.ebi.ac.uk/efo/efo_0007621,GCST004180,28181694,15,Pediatric bone mineral content (hip)
http://www.ebi.ac.uk/efo/efo_0007621,GCST004182,28181694,12,Pediatric bone mineral content (spine)
http://www.ebi.ac.uk/efo/efo_0007621,GCST004175,28181694,21,Pediatric bone mineral content (radius)
http://www.ebi.ac.uk/efo/efo_0007702,GCST004178,28181694,15,Pediatric bone mineral density (hip)
http://www.ebi.ac.uk/efo/efo_0007785,GCST004177,28181694,17,Pediatric bone mineral density (femoral neck)
http://www.ebi.ac.uk/efo/efo_0007621,GCST004179,28181694,13,Pediatric bone mineral content (femoral neck)
http://www.ebi.ac.uk/efo/efo_0007701,GCST004181,28181694,15,Pediatric bone mineral density (spine)
http://www.ebi.ac.uk/efo/efo_0007933,GCST004176,28181694,14,Pediatric areal bone mineral density (radius)
http://www.ebi.ac.uk/efo/efo_0007945,GCST004109,28167838,0,Agoraphobic traits
http://www.ebi.ac.uk/efo/efo_0000095,GCST004146,28165464,37,Chronic lymphocytic leukemia
http://www.ebi.ac.uk/efo/efo_0000249,GCST004249,28183528,3,Alzheimer's disease in APOE e4- carriers
http://www.ebi.ac.uk/efo/efo_0000249,GCST004248,28183528,0,Alzheimer's disease in APOE e4+ carriers
http://www.ebi.ac.uk/efo/efo_0004713,GCST004185,28166213,56,Lung function (FEV1/FVC)
http://www.ebi.ac.uk/efo/efo_0000249,GCST004247,28183528,1,Alzheimer's disease (APOE e4 interaction)
http://www.ebi.ac.uk/efo/efo_0004312,GCST004184,28166213,20,Lung function (FVC)
http://www.ebi.ac.uk/efo/efo_0000249,GCST004246,28183528,11,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST004147,28166215,31,Chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0004314,GCST004183,28166213,33,Lung function (FEV1)
http://www.ebi.ac.uk/efo/efo_0007944,GCST004108,28167095,2,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)
http://www.ebi.ac.uk/efo/efo_0000270,GCST004108,28167095,2,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)
http://www.ebi.ac.uk/efo/efo_0004713,GCST004108,28167095,2,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)
http://www.ebi.ac.uk/efo/efo_0004314,GCST004107,28167095,5,Lung function (FEV1) in asthma (dust mite allergen exposure interaction)
http://www.ebi.ac.uk/efo/efo_0007944,GCST004107,28167095,5,Lung function (FEV1) in asthma (dust mite allergen exposure interaction)
http://www.ebi.ac.uk/efo/efo_0000270,GCST004107,28167095,5,Lung function (FEV1) in asthma (dust mite allergen exposure interaction)
http://www.ebi.ac.uk/efo/efo_0004875,GCST004123,28155865,4,Mathematical ability
http://www.orpha.net/ordo/orphanet_2828,GCST004138,28256260,13,Early-onset Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0007859,GCST004160,28163062,1,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy
http://www.ebi.ac.uk/efo/efo_0000182,GCST004160,28163062,1,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy
http://www.ebi.ac.uk/efo/efo_0006906,GCST004160,28163062,1,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy
http://www.ebi.ac.uk/efo/efo_0004308,GCST004126,28158719,5,White blood cell count
http://www.ebi.ac.uk/efo/efo_0004694,GCST004124,28053049,2,Factor XI
http://www.ebi.ac.uk/efo/efo_0004833,GCST004128,28158719,4,White blood cell count (neutrophil)
http://www.ebi.ac.uk/efo/efo_0005091,GCST004129,28158719,9,White blood cell count (monocyte)
http://www.ebi.ac.uk/efo/efo_0004587,GCST004130,28158719,2,White blood cell count (lymphocyte)
http://www.ebi.ac.uk/efo/efo_0004842,GCST004135,28158719,5,White blood cell count (eosinophil)
http://www.ebi.ac.uk/efo/efo_0005090,GCST004127,28158719,5,White blood cell count (basophil)
http://www.ebi.ac.uk/efo/efo_0004624,GCST004093,28139693,40,Prostate-specific antigen levels
http://purl.obolibrary.org/obo/hp_0011950,GCST004140,28139761,0,Bronchiolitis
http://www.ebi.ac.uk/efo/efo_0004624,GCST004094,28139693,21,Prostate-specific antigen levels (conditioned on lead SNPs)
http://www.ebi.ac.uk/efo/efo_0006336,GCST004280,28135244,94,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST004279,28135244,42,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0005763,GCST004278,28135244,94,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0007949,GCST004165,28130311,1,Acute-on-chronic liver failure in hepatitis B
http://www.ebi.ac.uk/efo/efo_0004197,GCST004165,28130311,1,Acute-on-chronic liver failure in hepatitis B
http://www.ebi.ac.uk/efo/efo_0001061,GCST004097,28120872,3,Response to platinum-based neoadjuvant chemotherapy in cervical cancer
http://www.ebi.ac.uk/efo/efo_0007943,GCST004097,28120872,3,Response to platinum-based neoadjuvant chemotherapy in cervical cancer
http://www.ebi.ac.uk/efo/efo_0000685,GCST004172,28118524,4,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000685,GCST004173,28118524,0,Rheumatoid arthritis (rheumatoid factor and anti-cyclic citrullinated peptide seronegative)
http://www.ebi.ac.uk/efo/efo_0000685,GCST004174,28118524,4,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)
http://www.ebi.ac.uk/efo/efo_0007837,GCST004174,28118524,4,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)
http://www.ebi.ac.uk/efo/efo_0007791,GCST004174,28118524,4,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)
http://www.ebi.ac.uk/efo/efo_0000289,GCST004139,28115744,23,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0005611,GCST004136,28115739,37,Methadone dose in opioid dependence
http://www.ebi.ac.uk/efo/efo_0007907,GCST004136,28115739,37,Methadone dose in opioid dependence
http://www.ebi.ac.uk/efo/efo_0004847,GCST004096,28128768,1,Frontotemporal dementia (age at onset)
http://www.orpha.net/ordo/orphanet_282,GCST004096,28128768,1,Frontotemporal dementia (age at onset)
http://www.ebi.ac.uk/efo/efo_0000183,GCST004099,28112199,20,"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0001378,GCST004099,28112199,20,"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0000095,GCST004099,28112199,20,"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0004623,GCST004122,28107422,36,Fibrinogen levels
http://www.ebi.ac.uk/efo/efo_0004623,GCST004121,28107422,36,Fibrinogen levels
http://www.ebi.ac.uk/efo/efo_0004276,GCST004072,28100913,3,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications
http://www.ebi.ac.uk/efo/efo_0004775,GCST004072,28100913,3,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications
http://www.ebi.ac.uk/efo/efo_0006997,GCST004072,28100913,3,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications
http://www.ebi.ac.uk/efo/efo_0005536,GCST004060,28109725,5,Exhaled nitric oxide output
http://www.ebi.ac.uk/efo/efo_0005536,GCST004059,28109725,2,Exhaled nitric oxide levels
http://www.ebi.ac.uk/efo/efo_0004760,GCST004092,28100725,4,Plasma t-tau levels
http://www.ebi.ac.uk/efo/efo_0005035,GCST003961,28098162,2,Hippocampal volume
http://www.ebi.ac.uk/efo/efo_0004761,GCST004054,28095793,1,Glomerular load of uric acid
http://www.ebi.ac.uk/efo/efo_0004337,GCST004077,28093568,13,Cognitive function
http://www.ebi.ac.uk/efo/efo_0007935,GCST004056,28095793,2,Urinary uric acid to urinary creatinine ratio
http://www.ebi.ac.uk/efo/efo_0007934,GCST004057,28095793,1,Creatinine clearance
http://www.ebi.ac.uk/efo/efo_0004761,GCST004055,28095793,1,Fractional excretion of uric acid
http://www.ebi.ac.uk/efo/efo_0004761,GCST004058,28095793,3,Uric acid clearance
http://www.ebi.ac.uk/efo/efo_0001360,GCST004125,28060188,26,Type 2 diabetes (age of onset)
http://www.ebi.ac.uk/efo/efo_0004735,GCST004250,28090653,54,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
http://www.ebi.ac.uk/efo/efo_0007965,GCST004250,28090653,54,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
http://www.ebi.ac.uk/efo/efo_0000220,GCST004250,28090653,54,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
http://www.ebi.ac.uk/efo/efo_1002000,GCST004095,28108127,5,Takotsubo syndrome
http://purl.obolibrary.org/obo/hp_0000175,GCST004088,28087736,13,Nonsyndromic cleft lip with or without cleft palate
http://www.ebi.ac.uk/efo/efo_0003959,GCST004088,28087736,13,Nonsyndromic cleft lip with or without cleft palate
http://www.ebi.ac.uk/efo/efo_0005325,GCST004049,28084903,32,Cough in response to angiotensin-converting enzyme inhibitor drugs
http://purl.obolibrary.org/obo/hp_0012735,GCST004049,28084903,32,Cough in response to angiotensin-converting enzyme inhibitor drugs
http://purl.obolibrary.org/obo/hp_0000175,GCST004089,28087736,0,Cleft palate
http://www.ebi.ac.uk/efo/efo_0004633,GCST006119,28082259,11,Protein C levels
http://www.ebi.ac.uk/efo/efo_0000707,GCST004134,28081215,17,Multiple keratinocyte cancers
http://www.ebi.ac.uk/efo/efo_0007932,GCST004134,28081215,17,Multiple keratinocyte cancers
http://www.ebi.ac.uk/efo/efo_0004193,GCST004134,28081215,17,Multiple keratinocyte cancers
http://www.ebi.ac.uk/efo/efo_0005279,GCST004034,28081371,5,Temporomandibular joint disorder
http://www.ebi.ac.uk/efo/efo_0007017,GCST003881,27883235,0,Peanut allergy
http://www.ebi.ac.uk/efo/efo_0000699,GCST004062,28076899,2,Sjgren's syndrome
http://www.ebi.ac.uk/efo/efo_0000699,GCST004061,28076899,20,Sjgren's syndrome
http://www.ebi.ac.uk/efo/efo_0006940,GCST004137,28073927,47,Optic cup area
http://www.ebi.ac.uk/efo/efo_0007680,GCST004110,28077804,19,Gait speed in old age
http://www.ebi.ac.uk/efo/efo_0004695,GCST004074,28073927,17,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0007939,GCST004073,28073367,0,Cough
http://www.ebi.ac.uk/efo/efo_0004357,GCST004048,28070124,1,Fast beta electroencephalogram
http://www.ebi.ac.uk/efo/efo_0000289,GCST003962,28072414,8,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0007939,GCST004112,28073367,0,Dyspnea
http://www.ebi.ac.uk/efo/efo_0007939,GCST004111,28073367,0,Phlegm
http://www.ebi.ac.uk/efo/efo_0006937,GCST004076,28073927,32,Optic disc area
http://www.ebi.ac.uk/efo/efo_0006939,GCST004075,28073927,46,Vertical cup-disc ratio
http://www.ebi.ac.uk/efo/efo_0000384,GCST004132,28067908,119,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000384,GCST004053,28067912,4,Poor prognosis in Crohn's disease
http://www.ebi.ac.uk/efo/efo_0007936,GCST004053,28067912,4,Poor prognosis in Crohn's disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST004131,28067908,135,Inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0000729,GCST004133,28067908,80,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_1001486,GCST004120,28056976,0,Primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0006511,GCST004091,28059113,0,Palmar length-width ratio in Kashin-Beck disease
http://www.ebi.ac.uk/efo/efo_0004268,GCST004119,28056976,0,Primary sclerosing cholangitis
http://purl.obolibrary.org/obo/go_0061479,GCST004114,28062682,1,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)
http://www.ebi.ac.uk/efo/efo_0000764,GCST004114,28062682,1,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)
http://www.ebi.ac.uk/efo/efo_0004228,GCST004114,28062682,1,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)
http://www.ebi.ac.uk/efo/efo_1001486,GCST004145,28062665,9,Primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_1000726,GCST004090,28065765,0,Lichen planus in hepatitis C
http://www.ebi.ac.uk/efo/efo_0003047,GCST004090,28065765,0,Lichen planus in hepatitis C
http://purl.obolibrary.org/obo/go_0061479,GCST004118,28062682,1,Nevirapine-induced hypersensitivity in HIV
http://www.ebi.ac.uk/efo/efo_1002003,GCST004118,28062682,1,Nevirapine-induced hypersensitivity in HIV
http://www.ebi.ac.uk/efo/efo_0000764,GCST004118,28062682,1,Nevirapine-induced hypersensitivity in HIV
http://purl.obolibrary.org/obo/go_0061479,GCST004117,28062682,0,Nevirapine-induced hypersensitivity in HIV (rash)
http://www.ebi.ac.uk/efo/efo_1001253,GCST004117,28062682,0,Nevirapine-induced hypersensitivity in HIV (rash)
http://www.ebi.ac.uk/efo/efo_0000764,GCST004117,28062682,0,Nevirapine-induced hypersensitivity in HIV (rash)
http://purl.obolibrary.org/obo/go_0061479,GCST004116,28062682,0,Nevirapine-induced hypersensitivity in HIV (hypersensitivity syndrome)
http://www.ebi.ac.uk/efo/efo_1002004,GCST004116,28062682,0,Nevirapine-induced hypersensitivity in HIV (hypersensitivity syndrome)
http://www.ebi.ac.uk/efo/efo_0000764,GCST004116,28062682,0,Nevirapine-induced hypersensitivity in HIV (hypersensitivity syndrome)
http://purl.obolibrary.org/obo/go_0061479,GCST004115,28062682,1,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
http://www.ebi.ac.uk/efo/efo_0004276,GCST004115,28062682,1,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
http://www.ebi.ac.uk/efo/efo_0004775,GCST004115,28062682,1,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
http://www.ebi.ac.uk/efo/efo_0000764,GCST004115,28062682,1,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
http://purl.obolibrary.org/obo/hp_0000175,GCST004050,28054174,32,Cleft lip with or without cleft palate
http://www.ebi.ac.uk/efo/efo_0003959,GCST004050,28054174,32,Cleft lip with or without cleft palate
http://www.ebi.ac.uk/efo/efo_0005762,GCST003963,28051079,4,Possible neuropathic pain in post total joint replacement surgery for osteoarthritis
http://www.ebi.ac.uk/efo/efo_0002506,GCST003963,28051079,4,Possible neuropathic pain in post total joint replacement surgery for osteoarthritis
http://purl.obolibrary.org/obo/hp_0000202,GCST004051,28054174,24,Orofacial clefts
http://purl.obolibrary.org/obo/hp_0000175,GCST004052,28054174,7,Cleft palate
http://www.ebi.ac.uk/efo/efo_0007931,GCST004035,28046027,1,NHDL cholesterol to HDL cholesterol ratio
http://www.ebi.ac.uk/efo/efo_0003780,GCST004019,28045058,0,Behcet's disease
http://www.ebi.ac.uk/efo/efo_0007929,GCST004037,28046027,2,Triglyceride to HDL cholesterol ratio
http://www.ebi.ac.uk/efo/efo_0007930,GCST004036,28046027,2,LDL cholesterol to HDL cholesterol ratio
http://www.ebi.ac.uk/efo/efo_0005937,GCST004100,28044437,4,Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_1000218,GCST004100,28044437,4,Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST004100,28044437,4,Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000311,GCST004106,28044437,1,Body mass index (change over time) in cancer
http://www.ebi.ac.uk/efo/efo_0005937,GCST004106,28044437,1,Body mass index (change over time) in cancer
http://www.ebi.ac.uk/efo/efo_0001071,GCST004102,28044437,5,Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005937,GCST004102,28044437,5,Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST004102,28044437,5,Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005937,GCST004105,28044437,6,Body mass index (change over time) in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST004105,28044437,6,Body mass index (change over time) in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005937,GCST004101,28044437,3,Body mass index (change over time) in gastrointestinal cancer
http://www.ebi.ac.uk/efo/efo_1000218,GCST004101,28044437,3,Body mass index (change over time) in gastrointestinal cancer
http://www.ebi.ac.uk/efo/efo_0001071,GCST004104,28044437,3,Body mass index (change over time) in lung cancer
http://www.ebi.ac.uk/efo/efo_0005937,GCST004104,28044437,3,Body mass index (change over time) in lung cancer
http://www.ebi.ac.uk/efo/efo_0000311,GCST004103,28044437,3,Body mass index (change over time) in cancer or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005937,GCST004103,28044437,3,Body mass index (change over time) in cancer or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST004103,28044437,3,Body mass index (change over time) in cancer or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_1002006,GCST004163,28222112,6,Resistance to antihypertensive treatment in hypertension
http://www.ebi.ac.uk/efo/efo_0006939,GCST004047,28061514,4,Optic nerve measurement (cup-to-disc ratio)
http://www.ebi.ac.uk/efo/efo_0005296,GCST004900,28952330,2,Migraine without aura
http://www.ebi.ac.uk/efo/efo_0003100,GCST003964,28317148,4,Bortezomib-induced peripheral neuropathy in multiple myeloma
http://www.ebi.ac.uk/efo/efo_0001378,GCST003964,28317148,4,Bortezomib-induced peripheral neuropathy in multiple myeloma
http://www.ebi.ac.uk/efo/efo_0007808,GCST003964,28317148,4,Bortezomib-induced peripheral neuropathy in multiple myeloma
http://www.ebi.ac.uk/efo/efo_0004228,GCST004078,28043905,1,Drug-induced liver injury (terbinafine)
http://www.ebi.ac.uk/efo/efo_0007923,GCST004078,28043905,1,Drug-induced liver injury (terbinafine)
http://www.ebi.ac.uk/efo/efo_0004831,GCST004011,28039329,3,RR interval (tricyclic/tetracyclic antidepressant use interaction)
http://www.ebi.ac.uk/efo/efo_0007917,GCST004011,28039329,3,RR interval (tricyclic/tetracyclic antidepressant use interaction)
http://www.ebi.ac.uk/efo/efo_0007916,GCST004011,28039329,3,RR interval (tricyclic/tetracyclic antidepressant use interaction)
http://www.ebi.ac.uk/efo/efo_0004228,GCST004086,28043905,4,Drug-induced liver injury
http://www.ebi.ac.uk/efo/efo_0006951,GCST003898,28039263,20,Cisplatin-induced ototoxicity
http://purl.obolibrary.org/obo/go_0072718,GCST003898,28039263,20,Cisplatin-induced ototoxicity
http://www.ebi.ac.uk/efo/efo_0007917,GCST004010,28039329,1,QT interval (tricyclic/tetracyclic antidepressant use interaction)
http://www.ebi.ac.uk/efo/efo_0004682,GCST004010,28039329,1,QT interval (tricyclic/tetracyclic antidepressant use interaction)
http://www.ebi.ac.uk/efo/efo_0007916,GCST004010,28039329,1,QT interval (tricyclic/tetracyclic antidepressant use interaction)
http://www.ebi.ac.uk/efo/efo_0005533,GCST004087,28043905,4,Drug-induced liver injury (nonsteroidal anti-inflammatory drugs)
http://www.ebi.ac.uk/efo/efo_0004228,GCST004087,28043905,4,Drug-induced liver injury (nonsteroidal anti-inflammatory drugs)
http://www.ebi.ac.uk/efo/efo_0007920,GCST004085,28043905,4,Drug-induced liver injury (fluoroquinolones)
http://www.ebi.ac.uk/efo/efo_0004228,GCST004085,28043905,4,Drug-induced liver injury (fluoroquinolones)
http://www.ebi.ac.uk/efo/efo_0007918,GCST004084,28043905,3,Drug-induced liver injury (anti-tuberculosis drugs)
http://www.ebi.ac.uk/efo/efo_0004228,GCST004084,28043905,3,Drug-induced liver injury (anti-tuberculosis drugs)
http://www.ebi.ac.uk/efo/efo_0007919,GCST004083,28043905,4,Drug-induced liver injury (diclofenac)
http://www.ebi.ac.uk/efo/efo_0004228,GCST004083,28043905,4,Drug-induced liver injury (diclofenac)
http://www.ebi.ac.uk/efo/efo_0007921,GCST004082,28043905,4,Drug-induced liver injury (nitrofurantoin)
http://www.ebi.ac.uk/efo/efo_0004228,GCST004082,28043905,4,Drug-induced liver injury (nitrofurantoin)
http://www.ebi.ac.uk/efo/efo_0004228,GCST004081,28043905,3,Drug-induced cholestatic/mixed liver injury
http://purl.obolibrary.org/obo/go_0036273,GCST004080,28043905,1,Drug-induced liver injury (statins)
http://www.ebi.ac.uk/efo/efo_0004228,GCST004080,28043905,1,Drug-induced liver injury (statins)
http://www.ebi.ac.uk/efo/efo_0004228,GCST004079,28043905,1,Drug-induced hepatocellular liver injury
http://www.ebi.ac.uk/efo/efo_1001209,GCST003928,28041642,5,Giant cell arteritis
http://www.ebi.ac.uk/efo/efo_0004826,GCST003977,28029757,1,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase
http://www.ebi.ac.uk/efo/efo_0007835,GCST003902,28040410,5,Fast beta electroencephalogram
http://www.ebi.ac.uk/efo/efo_0004357,GCST003902,28040410,5,Fast beta electroencephalogram
http://www.ebi.ac.uk/efo/efo_0004826,GCST003976,28029757,6,Antineutrophil cytoplasmic antibody-associated vasculitis
http://www.ebi.ac.uk/efo/efo_0004826,GCST003978,28029757,0,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to proteinase-3
http://www.orpha.net/ordo/orphanet_85443,GCST004028,28025584,10,Immunoglobulin light chain (AL) amyloidosis
http://www.ebi.ac.uk/efo/efo_0000384,GCST003959,28008999,9,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0007878,GCST003919,28012008,1,Spine bone mineral density and alcohol drinking
http://www.ebi.ac.uk/efo/efo_0007701,GCST003919,28012008,1,Spine bone mineral density and alcohol drinking
http://www.ebi.ac.uk/efo/efo_0003767,GCST003958,28008999,18,Inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0004286,GCST004012,28011674,2,Venous thromboembolism
http://www.ebi.ac.uk/efo/efo_0007702,GCST003920,28012008,0,Hip bone mineral density and alcohol drinking
http://www.ebi.ac.uk/efo/efo_0007878,GCST003920,28012008,0,Hip bone mineral density and alcohol drinking
http://www.ebi.ac.uk/efo/efo_0007878,GCST003921,28012008,0,Whole body bone mineral density and alcohol drinking
http://www.ebi.ac.uk/efo/efo_0003923,GCST003921,28012008,0,Whole body bone mineral density and alcohol drinking
http://www.ebi.ac.uk/efo/efo_0000729,GCST003960,28008999,9,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0004526,GCST004004,28017375,58,Mean corpuscular volume
http://www.ebi.ac.uk/efo/efo_0007900,GCST003937,28002826,0,Retinol levels
http://www.ebi.ac.uk/efo/efo_0007899,GCST003936,28002826,0,Vitamin E levels (gamma-tocopherol)
http://www.ebi.ac.uk/efo/efo_0007896,GCST003933,28002826,0,Carotenoid levels (zeaxanthin)
http://www.ebi.ac.uk/efo/efo_0007895,GCST003932,28002826,0,Carotenoid levels (lutein)
http://www.ebi.ac.uk/efo/efo_0007894,GCST003931,28002826,0,Carotenoid levels (beta-carotene)
http://www.ebi.ac.uk/efo/efo_0007898,GCST003935,28002826,0,Vitamin E levels (alpha-tocopherol)
http://www.ebi.ac.uk/efo/efo_0004348,GCST004003,28017375,15,Hematocrit
http://www.ebi.ac.uk/efo/efo_0002508,GCST003922,28011712,4,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0007910,GCST004038,28011710,5,Circulating chromogranin peptide levels
http://www.ebi.ac.uk/efo/efo_0007909,GCST004038,28011710,5,Circulating chromogranin peptide levels
http://www.ebi.ac.uk/efo/efo_0007893,GCST003938,28002826,3,Carotenoid levels (alpha-carotene)
http://www.ebi.ac.uk/efo/efo_0007897,GCST003934,28002826,0,Carotenoid levels (cryptoxanthin)
http://www.ebi.ac.uk/efo/efo_0004527,GCST004006,28017375,39,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0004305,GCST004008,28017375,20,Red blood cell count
http://www.ebi.ac.uk/efo/efo_0004528,GCST004007,28017375,20,Mean corpuscular hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0004509,GCST004005,28017375,14,Hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0007891,GCST003940,28011148,1,Trans-epidermal water loss
http://purl.obolibrary.org/obo/hp_0001268,GCST003901,28078323,20,Cognitive decline (age-related)
http://purl.obolibrary.org/obo/hp_0002140,GCST004023,27997041,7,Ischemic stroke
http://www.ebi.ac.uk/efo/efo_0005524,GCST004022,27997041,5,Large artery stroke
http://www.ebi.ac.uk/efo/efo_1001504,GCST004020,27997041,1,Small vessel stroke
http://www.ebi.ac.uk/efo/efo_1001976,GCST004021,27997041,0,Ischemic stroke (cardioembolic)
http://www.ebi.ac.uk/efo/efo_0007875,GCST003979,27992416,13,Excessive daytime sleepiness
http://www.ebi.ac.uk/efo/efo_0005943,GCST003939,27993963,0,Adverse response to chemotherapy (congestive heart failure) in breast cancer
http://www.ebi.ac.uk/efo/efo_0000373,GCST003939,27993963,0,Adverse response to chemotherapy (congestive heart failure) in breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST003939,27993963,0,Adverse response to chemotherapy (congestive heart failure) in breast cancer
http://www.ebi.ac.uk/efo/efo_0005257,GCST003939,27993963,0,Adverse response to chemotherapy (congestive heart failure) in breast cancer
http://www.ebi.ac.uk/efo/efo_0007876,GCST003981,27992416,8,Insomnia
http://www.ebi.ac.uk/efo/efo_0004268,GCST004030,27992413,30,Primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0005271,GCST003982,27992416,6,Sleep traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0004354,GCST003982,27992416,6,Sleep traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0007875,GCST003982,27992416,6,Sleep traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0007876,GCST003982,27992416,6,Sleep traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0005271,GCST003980,27992416,8,Sleep duration
http://www.ebi.ac.uk/efo/efo_0004985,GCST003899,27981573,0,Response to clopidogrel therapy in coronary heart disease
http://purl.obolibrary.org/obo/go_1903493,GCST003899,27981573,0,Response to clopidogrel therapy in coronary heart disease
http://www.ebi.ac.uk/efo/efo_0001645,GCST003899,27981573,0,Response to clopidogrel therapy in coronary heart disease
http://www.ebi.ac.uk/efo/efo_0001054,GCST004009,27976721,13,Leprosy
http://www.ebi.ac.uk/efo/efo_1001930,GCST003918,28000841,8,Idiopathic osteonecrosis of the femoral head
http://www.ebi.ac.uk/efo/efo_0006527,GCST003900,27957625,2,Cluster headache
http://purl.obolibrary.org/obo/hp_0012199,GCST003900,27957625,2,Cluster headache
http://www.ebi.ac.uk/efo/efo_0005055,GCST004033,27958378,18,QRS interval (sulfonylurea treatment interaction)
http://www.ebi.ac.uk/efo/efo_0007922,GCST004033,27958378,18,QRS interval (sulfonylurea treatment interaction)
http://www.ebi.ac.uk/efo/efo_0008300,GCST004424,27989323,58,TRAIL levels
http://www.ebi.ac.uk/efo/efo_0008308,GCST004425,27989323,11,Tumor necrosis factor beta levels
http://www.ebi.ac.uk/efo/efo_0004684,GCST004426,27989323,19,Tumor necrosis factor alpha levels
http://www.ebi.ac.uk/efo/efo_0008293,GCST004427,27989323,26,Stromal-cell-derived factor 1 alpha levels
http://www.ebi.ac.uk/efo/efo_0008292,GCST004428,27989323,53,Stem cell growth factor beta levels
http://www.ebi.ac.uk/efo/efo_0008291,GCST004429,27989323,29,Stem cell factor levels
http://www.ebi.ac.uk/efo/efo_0005117,GCST004431,27989323,33,RANTES levels
http://www.ebi.ac.uk/efo/efo_0008264,GCST004432,27989323,38,Platelet-derived growth factor BB levels
http://www.ebi.ac.uk/efo/efo_0008219,GCST004433,27989323,104,Macrophage inflammatory protein 1b levels
http://www.ebi.ac.uk/efo/efo_0008218,GCST004434,27989323,22,Macrophage inflammatory protein 1a levels
http://www.ebi.ac.uk/efo/efo_0008236,GCST004435,27989323,35,Monokine induced by gamma interferon levels
http://www.ebi.ac.uk/efo/efo_0008217,GCST004436,27989323,23,Macrophage colony stimulating factor levels
http://www.ebi.ac.uk/efo/efo_0008054,GCST004437,27989323,14,Monocyte chemoattractant protein-3 levels
http://www.ebi.ac.uk/efo/efo_0004749,GCST004438,27989323,53,Monocyte chemoattractant protein-1 levels
http://www.ebi.ac.uk/efo/efo_0008173,GCST004430,27989323,22,Interleukin-16 levels
http://www.ebi.ac.uk/efo/efo_0004753,GCST004439,27989323,36,Interleukin-12p70 levels
http://www.ebi.ac.uk/efo/efo_0008056,GCST004440,27989323,36,Interferon gamma-induced protein 10 levels
http://www.ebi.ac.uk/efo/efo_0008221,GCST004423,27989323,26,Macrophage Migration Inhibitory Factor levels
http://www.ebi.ac.uk/efo/efo_0004581,GCST004441,27989323,44,Interleukin-18 levels
http://www.ebi.ac.uk/efo/efo_0008174,GCST004442,27989323,34,Interleukin-17 levels
http://www.ebi.ac.uk/efo/efo_0008171,GCST004443,27989323,33,Interleukin-13 levels
http://www.ebi.ac.uk/efo/efo_0004750,GCST004444,27989323,34,Interleukin-10 levels
http://www.ebi.ac.uk/efo/efo_0008192,GCST004450,27989323,25,Interleukin-9 levels
http://www.ebi.ac.uk/efo/efo_0004811,GCST004445,27989323,18,Interleukin-8 levels
http://www.ebi.ac.uk/efo/efo_0008189,GCST004451,27989323,23,Interleukin-7 levels
http://www.ebi.ac.uk/efo/efo_0004810,GCST004446,27989323,29,Interleukin-6 levels
http://www.ebi.ac.uk/efo/efo_0008185,GCST004452,27989323,17,Interleukin-5 levels
http://www.ebi.ac.uk/efo/efo_0008184,GCST004453,27989323,24,Interleukin-4 levels
http://www.ebi.ac.uk/efo/efo_0008332,GCST004454,27989323,27,Interleukin-2 receptor antagonist levels
http://www.ebi.ac.uk/efo/efo_0008331,GCST004455,27989323,26,Interleukin-2 levels
http://www.ebi.ac.uk/efo/efo_0004754,GCST004447,27989323,22,Interleukin-1-receptor antagonist levels
http://www.ebi.ac.uk/efo/efo_0004812,GCST004448,27989323,23,Interleukin-1-beta levels
http://www.ebi.ac.uk/efo/efo_0008165,GCST004456,27989323,29,Interferon gamma levels
http://www.ebi.ac.uk/efo/efo_0006903,GCST004449,27989323,25,Hepatocyte growth factor levels
http://www.ebi.ac.uk/efo/efo_0008146,GCST004457,27989323,26,Growth-regulated protein alpha levels
http://www.ebi.ac.uk/efo/efo_0008142,GCST004458,27989323,20,Granulocyte-colony stimulating factor levels
http://www.ebi.ac.uk/efo/efo_0008130,GCST004459,27989323,28,Fibroblast growth factor basic levels
http://www.ebi.ac.uk/efo/efo_0008122,GCST004460,27989323,46,Eotaxin levels
http://www.ebi.ac.uk/efo/efo_0008082,GCST004420,27989323,46,CTACK levels
http://www.ebi.ac.uk/efo/efo_0004762,GCST004422,27989323,40,Vascular endothelial growth factor levels
http://www.ebi.ac.uk/efo/efo_0007922,GCST004031,27958378,12,QT interval (sulfonylurea treatment interaction)
http://www.ebi.ac.uk/efo/efo_0004682,GCST004031,27958378,12,QT interval (sulfonylurea treatment interaction)
http://www.ebi.ac.uk/efo/efo_0008035,GCST004421,27989323,26,beta-nerve growth factor levels
http://www.ebi.ac.uk/efo/efo_0007885,GCST004032,27958378,14,JT interval (sulfonylurea treatment interaction)
http://www.ebi.ac.uk/efo/efo_0007922,GCST004032,27958378,14,JT interval (sulfonylurea treatment interaction)
http://www.ebi.ac.uk/efo/efo_0007924,GCST003974,27941131,1,Tonsillectomy
http://www.ebi.ac.uk/efo/efo_0004240,GCST003878,27936112,8,Heroin dependence
http://www.ebi.ac.uk/efo/efo_0003761,GCST004024,28049566,2,Depressive symptom measurement or major depressive disorder
http://www.ebi.ac.uk/efo/efo_0007006,GCST004024,28049566,2,Depressive symptom measurement or major depressive disorder
http://www.ebi.ac.uk/efo/efo_1001999,GCST004025,27927641,25,Systemic juvenile idiopathic arthritis
http://www.ebi.ac.uk/efo/efo_0004752,GCST003879,27927781,6,Serum parathyroid hormone levels
http://www.ebi.ac.uk/efo/efo_0000692,GCST003880,27922604,9,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004766,GCST003965,27918534,1,Subcutaneous adipose tissue
http://www.ebi.ac.uk/efo/efo_0004340,GCST006554,27918534,0,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004767,GCST006554,27918534,0,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004340,GCST006553,27918534,0,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004767,GCST006553,27918534,0,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004767,GCST006551,27918534,0,Visceral adipose tissue/subcutaneous adipose tissue ratio
http://www.ebi.ac.uk/efo/efo_0004767,GCST006552,27918534,0,Visceral adipose tissue/subcutaneous adipose tissue ratio
http://www.ebi.ac.uk/efo/efo_0004765,GCST006548,27918534,0,Visceral adipose tissue attenuation (Hounslow unit scale)
http://www.ebi.ac.uk/efo/efo_0004765,GCST006547,27918534,1,Visceral adipose tissue attenuation (Hounslow unit scale)
http://www.ebi.ac.uk/efo/efo_0007890,GCST006546,27918534,0,Pericardial fat
http://www.ebi.ac.uk/efo/efo_0007890,GCST006545,27918534,0,Pericardial fat
http://www.ebi.ac.uk/efo/efo_0004766,GCST006549,27918534,2,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
http://www.ebi.ac.uk/efo/efo_0004766,GCST006550,27918534,0,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
http://www.ebi.ac.uk/efo/efo_0007890,GCST006544,27918534,3,Pericardial adipose tissue adjusted for height and weight
http://www.ebi.ac.uk/efo/efo_0004338,GCST006544,27918534,3,Pericardial adipose tissue adjusted for height and weight
http://www.ebi.ac.uk/efo/efo_0004339,GCST006544,27918534,3,Pericardial adipose tissue adjusted for height and weight
http://www.ebi.ac.uk/efo/efo_0007890,GCST006543,27918534,1,Pericardial adipose tissue adjusted for height and weight
http://www.ebi.ac.uk/efo/efo_0004338,GCST006543,27918534,1,Pericardial adipose tissue adjusted for height and weight
http://www.ebi.ac.uk/efo/efo_0004339,GCST006543,27918534,1,Pericardial adipose tissue adjusted for height and weight
http://www.ebi.ac.uk/efo/efo_0004765,GCST006542,27918534,1,Visceral adipose tissue
http://www.ebi.ac.uk/efo/efo_0004765,GCST006540,27918534,0,Visceral adipose tissue
http://www.ebi.ac.uk/efo/efo_0004766,GCST006538,27918534,0,Subcutaneous adipose tissue
http://www.ebi.ac.uk/efo/efo_0004766,GCST006537,27918534,1,Subcutaneous adipose tissue
http://www.ebi.ac.uk/efo/efo_0004765,GCST006533,27918534,2,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004340,GCST006533,27918534,2,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004765,GCST006534,27918534,1,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004340,GCST006534,27918534,1,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004340,GCST003973,27918534,4,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004767,GCST003973,27918534,4,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004767,GCST003972,27918534,4,Visceral adipose tissue/subcutaneous adipose tissue ratio
http://www.ebi.ac.uk/efo/efo_0004765,GCST003969,27918534,0,Visceral adipose tissue attenuation (Hounslow unit scale)
http://www.ebi.ac.uk/efo/efo_0004766,GCST003970,27918534,0,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
http://www.ebi.ac.uk/efo/efo_0007890,GCST003971,27918534,2,Pericardial fat
http://www.ebi.ac.uk/efo/efo_0007914,GCST004016,27918536,0,Openness
http://www.ebi.ac.uk/efo/efo_0007660,GCST004017,27918536,2,Neuroticism
http://www.ebi.ac.uk/efo/efo_0004317,GCST004015,27918536,5,Extraversion
http://www.ebi.ac.uk/efo/efo_0007912,GCST004014,27918536,1,Conscientiousness
http://www.ebi.ac.uk/efo/efo_0004765,GCST003967,27918534,2,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004340,GCST003967,27918534,2,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0007890,GCST003968,27918534,5,Pericardial adipose tissue adjusted for height and weight
http://www.ebi.ac.uk/efo/efo_0004338,GCST003968,27918534,5,Pericardial adipose tissue adjusted for height and weight
http://www.ebi.ac.uk/efo/efo_0004339,GCST003968,27918534,5,Pericardial adipose tissue adjusted for height and weight
http://www.ebi.ac.uk/efo/efo_0004765,GCST003966,27918534,0,Visceral adipose tissue
http://www.ebi.ac.uk/efo/efo_0007915,GCST004013,27918536,0,Agreeableness
http://www.ebi.ac.uk/efo/efo_0007903,GCST003929,27915449,3,Urinary electrolytes (magnesium/calcium ratio)
http://www.ebi.ac.uk/efo/efo_0004591,GCST003975,27901618,0,Childhood onset asthma (traffic air pollution exposure interaction)
http://www.ebi.ac.uk/efo/efo_0007908,GCST003975,27901618,0,Childhood onset asthma (traffic air pollution exposure interaction)
http://www.ebi.ac.uk/efo/efo_0004214,GCST003877,27899403,12,Abdominal aortic aneurysm
http://www.ebi.ac.uk/efo/efo_0004274,GCST003924,27899376,5,Renal overload gout
http://www.ebi.ac.uk/efo/efo_0004274,GCST003925,27899376,11,Gout
http://www.ebi.ac.uk/efo/efo_0005134,GCST006078,27898682,3,Branched-chain amino acid levels (Valine)
http://www.ebi.ac.uk/efo/efo_0005134,GCST006076,27898682,2,Branched-chain amino acid levels (Leucine)
http://www.ebi.ac.uk/efo/efo_0005134,GCST006077,27898682,5,Branched-chain amino acid levels (Isoleucine)
http://www.ebi.ac.uk/efo/efo_0004274,GCST003926,27899376,8,Renal underexcretion gout
http://www.ebi.ac.uk/efo/efo_0007878,GCST004026,27911795,3,Alcohol consumption
http://www.ebi.ac.uk/efo/efo_0007878,GCST004027,27911795,2,Alcohol consumption (heavy vs. light/non-drinkers)
http://www.ebi.ac.uk/efo/efo_0006794,GCST004000,28031287,65,Cerebrospinal fluid biomarker levels
http://www.ebi.ac.uk/efo/efo_0007991,GCST004600,27863252,198,Eosinophil percentage of white cells
http://www.ebi.ac.uk/efo/efo_0004305,GCST004601,27863252,212,Red blood cell count
http://www.ebi.ac.uk/efo/efo_0004584,GCST004599,27863252,294,Mean platelet volume
http://www.ebi.ac.uk/efo/efo_0007995,GCST004634,27863252,62,Basophil percentage of granulocytes
http://www.ebi.ac.uk/efo/efo_0007990,GCST004633,27863252,135,Neutrophil percentage of white cells
http://www.ebi.ac.uk/efo/efo_0007993,GCST004632,27863252,147,Lymphocyte percentage of white cells
http://www.ebi.ac.uk/efo/efo_0007992,GCST004631,27863252,65,Basophil percentage of white cells
http://www.ebi.ac.uk/efo/efo_0004527,GCST004630,27863252,275,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0004833,GCST004629,27863252,152,Neutrophil count
http://www.ebi.ac.uk/efo/efo_0007986,GCST004628,27863252,152,Immature fraction of reticulocytes
http://www.ebi.ac.uk/efo/efo_0004587,GCST004627,27863252,188,Lymphocyte counts
http://www.ebi.ac.uk/efo/efo_0007988,GCST004626,27863252,164,Myeloid white cell count
http://www.ebi.ac.uk/efo/efo_0005091,GCST004625,27863252,248,Monocyte count
http://www.ebi.ac.uk/efo/efo_0009389,GCST004624,27863252,206,Sum eosinophil basophil counts
http://www.ebi.ac.uk/efo/efo_0007994,GCST004623,27863252,171,Neutrophil percentage of granulocytes
http://www.ebi.ac.uk/efo/efo_0007986,GCST004622,27863252,210,Reticulocyte count
http://www.ebi.ac.uk/efo/efo_0005192,GCST004621,27863252,212,Red cell distribution width
http://www.ebi.ac.uk/efo/efo_0009388,GCST004620,27863252,153,Sum basophil neutrophil counts
http://www.ebi.ac.uk/efo/efo_0007986,GCST004619,27863252,218,Reticulocyte fraction of red cells
http://www.ebi.ac.uk/efo/efo_0005090,GCST004618,27863252,80,White blood cell count (basophil)
http://www.ebi.ac.uk/efo/efo_0007996,GCST004617,27863252,184,Eosinophil percentage of granulocytes
http://www.ebi.ac.uk/efo/efo_0007984,GCST004616,27863252,206,Platelet distribution width
http://www.ebi.ac.uk/efo/efo_0004509,GCST004615,27863252,140,Hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0007986,GCST004612,27863252,209,High light scatter reticulocyte percentage of red cells
http://www.ebi.ac.uk/efo/efo_0007987,GCST004614,27863252,155,Granulocyte count
http://www.ebi.ac.uk/efo/efo_0009390,GCST004613,27863252,154,Sum neutrophil eosinophil counts
http://www.ebi.ac.uk/efo/efo_0007986,GCST004611,27863252,219,High light scatter reticulocyte count
http://www.ebi.ac.uk/efo/efo_0004308,GCST004610,27863252,180,White blood cell count
http://www.ebi.ac.uk/efo/efo_0007989,GCST004609,27863252,236,Monocyte percentage of white cells
http://www.ebi.ac.uk/efo/efo_0007997,GCST004608,27863252,220,Granulocyte percentage of myeloid white cells
http://www.ebi.ac.uk/efo/efo_0007985,GCST004607,27863252,272,Plateletcrit
http://www.ebi.ac.uk/efo/efo_0004842,GCST004606,27863252,209,Eosinophil counts
http://www.ebi.ac.uk/efo/efo_0004528,GCST004605,27863252,84,Mean corpuscular hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0004348,GCST004604,27863252,133,Hematocrit
http://www.ebi.ac.uk/efo/efo_0004309,GCST004603,27863252,287,Platelet count
http://www.ebi.ac.uk/efo/efo_0004526,GCST004602,27863252,306,Mean corpuscular volume
http://www.ebi.ac.uk/efo/efo_0005213,GCST003856,28171582,6,Central corneal thickness
http://www.ebi.ac.uk/efo/efo_0004504,GCST003943,27846281,7,Hepcidin levels
http://www.ebi.ac.uk/efo/efo_0007901,GCST003944,27846281,43,Hepcidin/ferritin ratio
http://www.ebi.ac.uk/efo/efo_0007902,GCST003945,27846281,13,Hepcidin/transferrin saturation ratio
http://www.ebi.ac.uk/efo/efo_0006336,GCST007094,27841878,237,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST007095,27841878,144,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0005763,GCST007097,27841878,169,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST007098,27841878,127,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST007099,27841878,260,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0005763,GCST007096,27841878,257,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0000692,GCST004040,27846195,63,Response to paliperidone in schizophrenia (positive Marder score)
http://www.ebi.ac.uk/efo/efo_0007925,GCST004040,27846195,63,Response to paliperidone in schizophrenia (positive Marder score)
http://www.ebi.ac.uk/efo/efo_0007927,GCST004040,27846195,63,Response to paliperidone in schizophrenia (positive Marder score)
http://www.ebi.ac.uk/efo/efo_0007886,GCST003923,27839851,2,"DDT metabolite (p,p'-DDE levels)"
http://www.ebi.ac.uk/efo/efo_0000692,GCST004039,27846195,30,Response to paliperidone in schizophrenia (CGI-S score)
http://www.ebi.ac.uk/efo/efo_0007925,GCST004039,27846195,30,Response to paliperidone in schizophrenia (CGI-S score)
http://www.ebi.ac.uk/efo/efo_0007927,GCST004039,27846195,30,Response to paliperidone in schizophrenia (CGI-S score)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004043,27846195,26,Response to paliperidone in schizophrenia (Multivariate)
http://www.ebi.ac.uk/efo/efo_0007925,GCST004043,27846195,26,Response to paliperidone in schizophrenia (Multivariate)
http://www.ebi.ac.uk/efo/efo_0007927,GCST004043,27846195,26,Response to paliperidone in schizophrenia (Multivariate)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004042,27846195,64,Response to paliperidone in schizophrenia (PANSS score)
http://www.ebi.ac.uk/efo/efo_0007925,GCST004042,27846195,64,Response to paliperidone in schizophrenia (PANSS score)
http://www.ebi.ac.uk/efo/efo_0007927,GCST004042,27846195,64,Response to paliperidone in schizophrenia (PANSS score)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004041,27846195,66,Response to paliperidone in schizophrenia (negative Marder score)
http://www.ebi.ac.uk/efo/efo_0007925,GCST004041,27846195,66,Response to paliperidone in schizophrenia (negative Marder score)
http://www.ebi.ac.uk/efo/efo_0007927,GCST004041,27846195,66,Response to paliperidone in schizophrenia (negative Marder score)
http://www.ebi.ac.uk/efo/efo_0000275,GCST004018,27824142,0,Atrial fibrillation (SNPxSNP interaction)
http://www.ebi.ac.uk/efo/efo_0007796,GCST003882,27816938,1,Parental longevity (at least one long-lived parent)
http://www.ebi.ac.uk/efo/efo_0000311,GCST004044,27790247,14,Age-related diseases and mortality
http://www.ebi.ac.uk/efo/efo_0003144,GCST004044,27790247,14,Age-related diseases and mortality
http://www.ebi.ac.uk/efo/efo_0000400,GCST004044,27790247,14,Age-related diseases and mortality
http://www.ebi.ac.uk/efo/efo_0000712,GCST004044,27790247,14,Age-related diseases and mortality
http://www.ebi.ac.uk/efo/efo_0001645,GCST004044,27790247,14,Age-related diseases and mortality
http://www.ebi.ac.uk/efo/efo_0000275,GCST004044,27790247,14,Age-related diseases and mortality
http://www.ebi.ac.uk/efo/efo_0004352,GCST004044,27790247,14,Age-related diseases and mortality
http://www.ebi.ac.uk/efo/efo_0009696,GCST007156,27818178,0,Social deprivation
http://www.ebi.ac.uk/efo/efo_0009695,GCST007155,27818178,2,Household income
http://www.ebi.ac.uk/efo/efo_0004574,GCST004046,27790247,31,Age-related disease endophenotypes
http://www.ebi.ac.uk/efo/efo_0006336,GCST004046,27790247,31,Age-related disease endophenotypes
http://www.ebi.ac.uk/efo/efo_0004530,GCST004046,27790247,31,Age-related disease endophenotypes
http://www.ebi.ac.uk/efo/efo_0006335,GCST004046,27790247,31,Age-related disease endophenotypes
http://www.ebi.ac.uk/efo/efo_0004348,GCST004046,27790247,31,Age-related disease endophenotypes
http://www.ebi.ac.uk/efo/efo_0007928,GCST004046,27790247,31,Age-related disease endophenotypes
http://www.ebi.ac.uk/efo/efo_0004468,GCST004046,27790247,31,Age-related disease endophenotypes
http://www.ebi.ac.uk/efo/efo_0004340,GCST004046,27790247,31,Age-related disease endophenotypes
http://www.ebi.ac.uk/efo/efo_0004612,GCST004046,27790247,31,Age-related disease endophenotypes
http://www.ebi.ac.uk/efo/efo_0004574,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0004348,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0000712,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0007928,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0001645,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0004340,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0000275,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0004612,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0000311,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0006336,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0004530,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0006335,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0003144,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0000400,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0004468,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0004352,GCST004045,27790247,44,"Age-related diseases, mortality and associated endophenotypes"
http://www.ebi.ac.uk/efo/efo_0004208,GCST004785,27723757,57,Vitiligo
http://www.ebi.ac.uk/efo/efo_0005038,GCST006468,27487801,2,Straight vs curly hair
http://www.ebi.ac.uk/efo/efo_0007889,GCST003927,27454463,6,Dysmenorrheic pain
http://www.ebi.ac.uk/efo/efo_0004503,GCST006101,27668658,17,Cardiometabolic and hematological traits
http://www.ebi.ac.uk/efo/efo_0005202,GCST003805,27802415,8,Diastolic blood pressure response to hydrochlorothiazide in hypertension
http://www.ebi.ac.uk/efo/efo_0006945,GCST003805,27802415,8,Diastolic blood pressure response to hydrochlorothiazide in hypertension
http://www.ebi.ac.uk/efo/efo_0000537,GCST003805,27802415,8,Diastolic blood pressure response to hydrochlorothiazide in hypertension
http://www.ebi.ac.uk/efo/efo_0009101,GCST006045,27798627,10,Age at first birth
http://www.ebi.ac.uk/efo/efo_0009101,GCST006044,27798627,2,Age at first birth
http://www.ebi.ac.uk/efo/efo_0009101,GCST003795,27798627,10,Age at first birth
http://www.ebi.ac.uk/efo/efo_0004351,GCST003818,27798624,86,Resting heart rate
http://www.ebi.ac.uk/efo/efo_0005202,GCST003807,27802415,10,Systolic blood pressure response to hydrochlorothiazide in hypertension
http://www.ebi.ac.uk/efo/efo_0000537,GCST003807,27802415,10,Systolic blood pressure response to hydrochlorothiazide in hypertension
http://www.ebi.ac.uk/efo/efo_0006944,GCST003807,27802415,10,Systolic blood pressure response to hydrochlorothiazide in hypertension
http://www.ebi.ac.uk/efo/efo_0005921,GCST003830,26503814,57,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)
http://purl.obolibrary.org/obo/go_0097366,GCST003830,26503814,57,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)
http://www.ebi.ac.uk/efo/efo_0000341,GCST003830,26503814,57,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)
http://www.ebi.ac.uk/efo/efo_0003761,GCST005547,27777418,17,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0007852,GCST003841,27770449,4,Thiopurine S-methyltransferase activity
http://www.ebi.ac.uk/efo/efo_0003108,GCST003762,27797806,12,Essential tremor
http://www.ebi.ac.uk/efo/efo_1001870,GCST003815,27770636,123,Late-onset Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0005782,GCST003763,27764096,3,Age-related hearing impairment
http://purl.obolibrary.org/obo/hp_0011868,GCST003869,27764105,0,Sciatica
http://www.ebi.ac.uk/efo/efo_0003888,GCST004002,27890468,6,Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST004002,27890468,6,Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0006944,GCST003825,27980656,10,Systolic blood pressure change trajectories
http://www.ebi.ac.uk/efo/efo_0003888,GCST004001,27890468,15,Bipolar disorder or attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST004001,27890468,15,Bipolar disorder or attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0005577,GCST003857,27749845,5,Oral cavity and pharyngeal cancer
http://www.ebi.ac.uk/efo/efo_0005570,GCST003857,27749845,5,Oral cavity and pharyngeal cancer
http://www.ebi.ac.uk/efo/efo_0005570,GCST003858,27749845,9,Oral cavity cancer
http://www.ebi.ac.uk/efo/efo_1001931,GCST003859,27749845,17,Oropharynx cancer
http://www.ebi.ac.uk/efo/efo_0005512,GCST003821,27764800,1,Estrogen receptor status in breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST003821,27764800,1,Estrogen receptor status in breast cancer
http://www.ebi.ac.uk/efo/efo_0007879,GCST003843,27964859,0,Petaloid toenail
http://www.ebi.ac.uk/efo/efo_0005514,GCST003823,27764800,1,Estrogen receptor status in HER2 negative breast cancer
http://www.ebi.ac.uk/efo/efo_0005512,GCST003823,27764800,1,Estrogen receptor status in HER2 negative breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST003823,27764800,1,Estrogen receptor status in HER2 negative breast cancer
http://www.ebi.ac.uk/efo/efo_0005514,GCST003822,27764800,0,Estrogen receptor status in HER2 positive breast cancer
http://www.ebi.ac.uk/efo/efo_0005512,GCST003822,27764800,0,Estrogen receptor status in HER2 positive breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST003822,27764800,0,Estrogen receptor status in HER2 positive breast cancer
http://www.ebi.ac.uk/efo/efo_0004344,GCST005146,27680694,59,Birth weight
http://www.ebi.ac.uk/efo/efo_0006335,GCST007237,27736895,3,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004344,GCST007557,27680694,2,Birth weight
http://www.ebi.ac.uk/efo/efo_0006336,GCST007238,27736895,5,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0007874,GCST003876,27723756,15,Gut microbiota (beta diversity)
http://www.ebi.ac.uk/efo/efo_0007874,GCST003875,27723756,51,Gut microbiota (bacterial taxa)
http://www.ebi.ac.uk/efo/efo_0007883,GCST003875,27723756,51,Gut microbiota (bacterial taxa)
http://www.ebi.ac.uk/efo/efo_0006527,GCST003874,27723779,0,Colorectal cancer (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0005842,GCST003874,27723779,0,Colorectal cancer (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0005842,GCST003873,27723779,2,Colorectal cancer (alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0007878,GCST003873,27723779,2,Colorectal cancer (alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0004220,GCST003824,27723809,4,Depression in response to interferon-based therapy in chronic hepatitis C
http://www.ebi.ac.uk/efo/efo_0007859,GCST003824,27723809,4,Depression in response to interferon-based therapy in chronic hepatitis C
http://www.ebi.ac.uk/efo/efo_0007006,GCST003824,27723809,4,Depression in response to interferon-based therapy in chronic hepatitis C
http://www.ebi.ac.uk/efo/efo_1001929,GCST003814,27723758,33,Selective IgA deficiency
http://www.ebi.ac.uk/efo/efo_0004952,GCST003816,27758888,1,Breast cancer-free interval (treatment with aromatase inhibitor)
http://purl.obolibrary.org/obo/go_0061477,GCST003816,27758888,1,Breast cancer-free interval (treatment with aromatase inhibitor)
http://www.ebi.ac.uk/efo/efo_0000305,GCST003816,27758888,1,Breast cancer-free interval (treatment with aromatase inhibitor)
http://www.ebi.ac.uk/efo/efo_0007881,GCST003868,28364478,1,Job-related exhaustion in shift workers
http://www.ebi.ac.uk/efo/efo_0007880,GCST003852,27704462,0,Response to dendritic cell-based immunotherapy in HIV infection
http://www.ebi.ac.uk/efo/efo_0000764,GCST003852,27704462,0,Response to dendritic cell-based immunotherapy in HIV infection
http://www.ebi.ac.uk/efo/efo_0007873,GCST003853,27701424,9,Hip minimal joint space width
http://www.ebi.ac.uk/efo/efo_0007872,GCST003850,27702941,0,"Caffeine metabolism (plasma 1,3,7-trimethyluric acid level)"
http://www.ebi.ac.uk/efo/efo_0007872,GCST003851,27702941,31,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)"
http://www.ebi.ac.uk/efo/efo_0007872,GCST003848,27702941,4,"Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)"
http://www.orpha.net/ordo/orphanet_388,GCST003764,27702942,7,Hirschsprung disease
http://www.ebi.ac.uk/efo/efo_0000094,GCST003798,27694927,2,Acute lymphoblastic leukemia in childhood (B cell precursor)
http://www.ebi.ac.uk/efo/efo_0007874,GCST003855,27694959,21,Gut microbiota (bacterial taxa)
http://www.ebi.ac.uk/efo/efo_0004886,GCST003834,27694991,0,Intracranial volume
http://www.ebi.ac.uk/efo/efo_0007872,GCST003846,27702941,11,"Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)"
http://www.ebi.ac.uk/efo/efo_0007874,GCST003854,27694959,56,Gut microbiota (functional units)
http://www.ebi.ac.uk/efo/efo_0007872,GCST003849,27702941,1,"Caffeine metabolism (plasma 3,7-dimethylxanthine (theobromine) level)"
http://www.ebi.ac.uk/efo/efo_0007872,GCST003847,27702941,2,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)"
http://www.ebi.ac.uk/efo/efo_0006335,GCST006228,27618448,17,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0000537,GCST006229,27618448,5,Hypertension
http://www.ebi.ac.uk/efo/efo_0005763,GCST006230,27618448,11,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST006227,27618448,17,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0000537,GCST006023,27618447,12,Hypertension
http://www.ebi.ac.uk/efo/efo_0005763,GCST006022,27618447,17,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST006021,27618447,45,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST006020,27618447,44,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004616,GCST003820,27696742,6,Knee osteoarthritis
http://www.ebi.ac.uk/efo/efo_0006340,GCST006231,27618448,66,Mean arterial pressure
http://www.ebi.ac.uk/efo/efo_0000289,GCST003742,27769005,1,Bipolar disorder (early onset)
http://www.ebi.ac.uk/efo/efo_0003843,GCST003760,27670397,9,Pre-treatment pain in head and neck squamous cell carcinoma
http://www.ebi.ac.uk/efo/efo_0000181,GCST003760,27670397,9,Pre-treatment pain in head and neck squamous cell carcinoma
http://www.ebi.ac.uk/efo/efo_0007742,GCST003870,27659466,9,QRS complex (Sokolow-Lyon)
http://www.ebi.ac.uk/efo/efo_0005054,GCST003870,27659466,9,QRS complex (Sokolow-Lyon)
http://www.ebi.ac.uk/efo/efo_0007742,GCST003871,27659466,17,QRS complex (Cornell)
http://www.ebi.ac.uk/efo/efo_0005054,GCST003871,27659466,17,QRS complex (Cornell)
http://www.ebi.ac.uk/efo/efo_0007742,GCST003872,27659466,21,QRS complex (12-leadsum)
http://www.ebi.ac.uk/efo/efo_0005054,GCST003872,27659466,21,QRS complex (12-leadsum)
http://www.ebi.ac.uk/efo/efo_0005054,GCST003844,27659466,47,QRS duration
http://www.ebi.ac.uk/efo/efo_0005055,GCST003844,27659466,47,QRS duration
http://www.ebi.ac.uk/efo/efo_0005405,GCST003797,27670767,3,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
http://www.ebi.ac.uk/efo/efo_0000400,GCST003797,27670767,3,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
http://www.ebi.ac.uk/efo/efo_0000537,GCST003797,27670767,3,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
http://www.ebi.ac.uk/efo/efo_0007766,GCST003797,27670767,3,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
http://www.ebi.ac.uk/efo/efo_0007767,GCST003797,27670767,3,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
http://www.ebi.ac.uk/efo/efo_0004920,GCST003794,27669169,0,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib
http://www.ebi.ac.uk/efo/efo_0007867,GCST003794,27669169,0,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib
http://www.ebi.ac.uk/efo/efo_0007868,GCST003794,27669169,0,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib
http://www.ebi.ac.uk/efo/efo_0000571,GCST003794,27669169,0,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib
http://www.ebi.ac.uk/efo/efo_0007851,GCST003718,27665939,0,Hepatitis B (viral clearance)
http://www.ebi.ac.uk/efo/efo_0004197,GCST003718,27665939,0,Hepatitis B (viral clearance)
http://www.ebi.ac.uk/efo/efo_0004318,GCST003761,27669027,9,Emphysema distribution in smoking
http://www.ebi.ac.uk/efo/efo_0005850,GCST003761,27669027,9,Emphysema distribution in smoking
http://www.ebi.ac.uk/efo/efo_0007866,GCST003792,27671213,2,Liver injury in anti-tuberculosis drug treatment
http://www.orpha.net/ordo/orphanet_3389,GCST003792,27671213,2,Liver injury in anti-tuberculosis drug treatment
http://www.ebi.ac.uk/efo/efo_0004228,GCST003792,27671213,2,Liver injury in anti-tuberculosis drug treatment
http://www.ebi.ac.uk/efo/efo_0004874,GCST003698,27671502,0,Brain activation in response to working memory task
http://www.ebi.ac.uk/efo/efo_0007849,GCST003698,27671502,0,Brain activation in response to working memory task
http://www.ebi.ac.uk/efo/efo_0004335,GCST003698,27671502,0,Brain activation in response to working memory task
http://www.ebi.ac.uk/efo/efo_0004819,GCST003759,27664181,2,Resistin levels
http://www.ebi.ac.uk/efo/efo_0007636,GCST003719,27656889,0,Attention function
http://www.ebi.ac.uk/efo/efo_0006524,GCST003793,27656708,2,L-arginine levels
http://www.ebi.ac.uk/efo/efo_0007778,GCST003774,27650483,3,Urinary albumin-to-creatinine ratio
http://www.ebi.ac.uk/efo/efo_0004996,GCST003862,27647854,2,Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST003862,27647854,2,Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004996,GCST003867,27647854,1,Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST003867,27647854,1,Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004996,GCST003866,27647854,1,Kidney disease (late stage) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST003866,27647854,1,Kidney disease (late stage) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004996,GCST003865,27647854,3,Kidney disease (early stage) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST003865,27647854,3,Kidney disease (early stage) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004996,GCST003864,27647854,1,Kidney disease (early and late stages) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST003864,27647854,1,Kidney disease (early and late stages) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004996,GCST003863,27647854,2,Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST003863,27647854,2,Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004996,GCST003861,27647854,1,Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST003861,27647854,1,Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004992,GCST003827,27632927,4,Otitis media
http://www.ebi.ac.uk/efo/efo_0004992,GCST003829,27632927,4,Otitis media (recurrent)
http://www.ebi.ac.uk/efo/efo_0004992,GCST003828,27632927,2,Otitis media (chronic)
http://www.ebi.ac.uk/efo/efo_0007865,GCST003773,27629369,19,Loneliness (multivariate analysis)
http://purl.obolibrary.org/obo/hp_0100806,GCST003817,27639821,15,Mortality in sepsis
http://www.ebi.ac.uk/efo/efo_0004352,GCST003817,27639821,15,Mortality in sepsis
http://www.ebi.ac.uk/efo/efo_0007865,GCST003772,27629369,18,Loneliness (linear analysis)
http://www.ebi.ac.uk/efo/efo_0007865,GCST003771,27629369,22,Loneliness
http://www.ebi.ac.uk/efo/efo_0004340,GCST003789,27623749,0,Body mass index
http://www.ebi.ac.uk/efo/efo_1001050,GCST003784,27629089,22,Multiple system atrophy
http://www.ebi.ac.uk/efo/efo_1001050,GCST003783,27629089,16,Multiple system atrophy (pathologically confirmed)
http://www.ebi.ac.uk/efo/efo_0003761,GCST003800,27622933,5,Response to bupropion in depression
http://www.ebi.ac.uk/efo/efo_0006326,GCST003800,27622933,5,Response to bupropion in depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003800,27622933,5,Response to bupropion in depression
http://www.ebi.ac.uk/efo/efo_0004190,GCST003745,27623284,2,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0003761,GCST003813,27622933,5,Response to antidepressants and depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003813,27622933,5,Response to antidepressants and depression
http://purl.obolibrary.org/obo/go_0036276,GCST003813,27622933,5,Response to antidepressants and depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST003808,27622933,5,Non-response to selective serotonin reuptake inhibitors and depression
http://www.ebi.ac.uk/efo/efo_0005658,GCST003808,27622933,5,Non-response to selective serotonin reuptake inhibitors and depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003808,27622933,5,Non-response to selective serotonin reuptake inhibitors and depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST003812,27622933,5,Non-response to antidepressants and depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003812,27622933,5,Non-response to antidepressants and depression
http://purl.obolibrary.org/obo/go_0036276,GCST003812,27622933,5,Non-response to antidepressants and depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST003811,27622933,5,Response to citalopram or escitalopram and depression
http://www.ebi.ac.uk/efo/efo_0007871,GCST003811,27622933,5,Response to citalopram or escitalopram and depression
http://www.ebi.ac.uk/efo/efo_0006329,GCST003811,27622933,5,Response to citalopram or escitalopram and depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003811,27622933,5,Response to citalopram or escitalopram and depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST003810,27622933,5,Non-response to citalopram or escitalopram and depression
http://www.ebi.ac.uk/efo/efo_0007871,GCST003810,27622933,5,Non-response to citalopram or escitalopram and depression
http://www.ebi.ac.uk/efo/efo_0006329,GCST003810,27622933,5,Non-response to citalopram or escitalopram and depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003810,27622933,5,Non-response to citalopram or escitalopram and depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST003809,27622933,5,Response to selective serotonin reuptake inhibitors and depression
http://www.ebi.ac.uk/efo/efo_0005658,GCST003809,27622933,5,Response to selective serotonin reuptake inhibitors and depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003809,27622933,5,Response to selective serotonin reuptake inhibitors and depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST003806,27622933,5,Response to bupropion and depression
http://www.ebi.ac.uk/efo/efo_0006326,GCST003806,27622933,5,Response to bupropion and depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003806,27622933,5,Response to bupropion and depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST003804,27622933,6,Non-response to bupropion and depression
http://www.ebi.ac.uk/efo/efo_0006326,GCST003804,27622933,6,Non-response to bupropion and depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003804,27622933,6,Non-response to bupropion and depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST003803,27622933,5,Response to antidepressants in depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003803,27622933,5,Response to antidepressants in depression
http://purl.obolibrary.org/obo/go_0036276,GCST003803,27622933,5,Response to antidepressants in depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST003802,27622933,7,Response to citalopram or escitalopram in depression
http://www.ebi.ac.uk/efo/efo_0007871,GCST003802,27622933,7,Response to citalopram or escitalopram in depression
http://www.ebi.ac.uk/efo/efo_0006329,GCST003802,27622933,7,Response to citalopram or escitalopram in depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003802,27622933,7,Response to citalopram or escitalopram in depression
http://www.ebi.ac.uk/efo/efo_0003761,GCST003801,27622933,5,Response to selective serotonin reuptake inhibitors in depression
http://www.ebi.ac.uk/efo/efo_0005658,GCST003801,27622933,5,Response to selective serotonin reuptake inhibitors in depression
http://www.ebi.ac.uk/efo/efo_0004247,GCST003801,27622933,5,Response to selective serotonin reuptake inhibitors in depression
http://www.ebi.ac.uk/efo/efo_0006336,GCST006258,27618452,57,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST006259,27618452,62,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006952,GCST003791,28173075,12,Response to metformin (IC50)
http://purl.obolibrary.org/obo/go_1901558,GCST003791,28173075,12,Response to metformin (IC50)
http://www.ebi.ac.uk/efo/efo_0007803,GCST003765,27643478,1,Emotional dysregulation
http://www.ebi.ac.uk/efo/efo_0000270,GCST003832,27611488,27,Asthma (childhood onset)
http://www.ebi.ac.uk/efo/efo_0000270,GCST003831,27611488,49,Asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST003833,27611488,24,Adult asthma
http://www.ebi.ac.uk/efo/efo_0004211,GCST003743,27599772,10,Hypertriglyceridemia
http://www.ebi.ac.uk/efo/efo_0007780,GCST003744,27601451,5,Chronic periodontitis (mean interproximal clinical attachment level)
http://www.ebi.ac.uk/efo/efo_0007620,GCST007015,27476799,20,Lumbar spine bone mineral density (integral)
http://www.ebi.ac.uk/efo/efo_0007620,GCST007014,27476799,12,Lumbar spine bone mineral density (trabecular)
http://www.ebi.ac.uk/efo/efo_0006527,GCST003826,27612410,3,Pre bronchodilator FEV1/FVC ratio in never-smokers
http://www.ebi.ac.uk/efo/efo_0004713,GCST003826,27612410,3,Pre bronchodilator FEV1/FVC ratio in never-smokers
http://www.ebi.ac.uk/efo/efo_0004599,GCST003941,27595289,19,Acute graft versus host disease in bone marrow transplantation (recipient effect)
http://www.ebi.ac.uk/efo/efo_0004599,GCST003942,27595289,3,Acute graft versus host disease in bone marrow transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0007892,GCST003942,27595289,3,Acute graft versus host disease in bone marrow transplantation (donor effect)
http://www.ebi.ac.uk/efo/efo_0000305,GCST003782,28171663,2,Breast cancer
http://www.ebi.ac.uk/efo/efo_1000650,GCST003780,28171663,2,Breast cancer (estrogen-receptor negative)
http://www.ebi.ac.uk/efo/efo_1000649,GCST003781,28171663,1,Breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_0007805,GCST003617,27587472,2,Response to statins (HDL cholesterol change)
http://purl.obolibrary.org/obo/go_0036273,GCST003617,27587472,2,Response to statins (HDL cholesterol change)
http://www.ebi.ac.uk/efo/efo_0004541,GCST004522,27500523,1,Response to metformin in type 2 diabetes (HbA1c reduction)
http://www.ebi.ac.uk/efo/efo_0001360,GCST004522,27500523,1,Response to metformin in type 2 diabetes (HbA1c reduction)
http://purl.obolibrary.org/obo/go_1901558,GCST004522,27500523,1,Response to metformin in type 2 diabetes (HbA1c reduction)
http://www.ebi.ac.uk/efo/efo_0005208,GCST003790,27588450,42,Glomerular filtration rate
http://purl.obolibrary.org/obo/hp_0001919,GCST003656,27576016,3,Acute kidney injury in critical illness
http://www.ebi.ac.uk/efo/efo_0007863,GCST003656,27576016,3,Acute kidney injury in critical illness
http://www.ebi.ac.uk/efo/efo_0005055,GCST003598,27577874,54,QRS duration
http://www.ebi.ac.uk/efo/efo_0003931,GCST004403,28580392,9,Bone fracture in osteoporosis
http://www.ebi.ac.uk/efo/efo_0003882,GCST004403,28580392,9,Bone fracture in osteoporosis
http://www.ebi.ac.uk/efo/efo_0007852,GCST003609,27564568,1,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
http://www.ebi.ac.uk/efo/efo_0007853,GCST003609,27564568,1,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
http://www.ebi.ac.uk/efo/efo_0000220,GCST003609,27564568,1,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
http://www.ebi.ac.uk/efo/efo_0007855,GCST003641,27560520,4,Cranial base width
http://www.ebi.ac.uk/efo/efo_0007857,GCST003646,27560520,7,Facial depth
http://www.ebi.ac.uk/efo/efo_0007856,GCST003645,27560520,2,Lower facial height
http://www.ebi.ac.uk/efo/efo_0007845,GCST003644,27560520,5,Lip morphology
http://www.ebi.ac.uk/efo/efo_0007843,GCST003643,27560520,8,Nose morphology
http://www.ebi.ac.uk/efo/efo_0007858,GCST003642,27560520,5,Eye morphology
http://www.ebi.ac.uk/efo/efo_0003767,GCST003602,27569725,15,Inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0004330,GCST003621,27561104,5,Coffee consumption
http://www.ebi.ac.uk/efo/efo_0006782,GCST003621,27561104,5,Coffee consumption
http://www.ebi.ac.uk/efo/efo_0004233,GCST003603,27558924,2,Thiopurine-induced leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST003603,27558924,2,Thiopurine-induced leukopenia in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST003603,27558924,2,Thiopurine-induced leukopenia in inflammatory bowel disease
http://purl.obolibrary.org/obo/hp_0002014,GCST003626,27559109,1,diarrhoeal disease at age 1
http://purl.obolibrary.org/obo/hp_0002014,GCST003624,27559109,1,diarrhoeal disease at age 2 with doctor diagnosis
http://purl.obolibrary.org/obo/hp_0002014,GCST003623,27559109,1,diarrhoeal disease at age 2
http://purl.obolibrary.org/obo/hp_0002014,GCST003625,27559109,1,diarrhoeal disease at age 1 with doctor diagnosis
http://www.ebi.ac.uk/efo/efo_0006511,GCST003727,27545300,0,Joint destruction and growth retardation
http://www.ebi.ac.uk/efo/efo_0005413,GCST003727,27545300,0,Joint destruction and growth retardation
http://www.ebi.ac.uk/efo/efo_0005201,GCST003727,27545300,0,Joint destruction and growth retardation
http://www.ebi.ac.uk/efo/efo_0003780,GCST007551,27548383,3,Behcet's disease
http://www.ebi.ac.uk/efo/efo_0005271,GCST003741,27568811,0,Sleep duration
http://www.ebi.ac.uk/efo/efo_0004193,GCST003726,27539887,33,Basal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0006946,GCST003860,27531626,1,Risky sexual behaviors (alcohol dependence interaction)
http://www.ebi.ac.uk/efo/efo_0003829,GCST003860,27531626,1,Risky sexual behaviors (alcohol dependence interaction)
http://www.ebi.ac.uk/efo/efo_0007877,GCST003860,27531626,1,Risky sexual behaviors (alcohol dependence interaction)
http://www.ebi.ac.uk/efo/efo_0007006,GCST003836,27529621,1,Depressive symptoms
http://www.ebi.ac.uk/efo/efo_0007006,GCST003835,27529621,4,Depressive symptoms (stressful life events interaction)
http://www.ebi.ac.uk/efo/efo_0007781,GCST003835,27529621,4,Depressive symptoms (stressful life events interaction)
http://www.ebi.ac.uk/efo/efo_0000280,GCST003738,27527254,5,Barrett's esophagus
http://www.ebi.ac.uk/efo/efo_0000478,GCST003740,27527254,14,Barrett's esophagus  or Esophageal adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0000280,GCST003740,27527254,14,Barrett's esophagus  or Esophageal adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0000478,GCST003739,27527254,5,Esophageal adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0000571,GCST003605,27501781,6,EGFR mutation-positive lung adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0001065,GCST003819,27506219,4,Endometriosis
http://www.ebi.ac.uk/efo/efo_0000699,GCST003604,27503288,1,Sjgren's syndrome
http://www.ebi.ac.uk/efo/efo_0004354,GCST003837,27494321,14,Chronotype
http://www.ebi.ac.uk/efo/efo_0005271,GCST006686,27494321,0,Sleep duration (undersleepers)
http://www.ebi.ac.uk/efo/efo_0005271,GCST006685,27494321,0,Sleep duration (oversleepers)
http://www.ebi.ac.uk/efo/efo_0005271,GCST003840,27494321,2,Sleep duration (oversleepers vs undersleepers)
http://www.ebi.ac.uk/efo/efo_0004354,GCST003838,27494321,15,Morning vs. evening chronotype
http://www.ebi.ac.uk/efo/efo_0005271,GCST003839,27494321,3,Sleep duration
http://www.ebi.ac.uk/efo/efo_0007860,GCST003657,27663945,9,Attention deficit hyperactivity disorder symptom score
http://www.ebi.ac.uk/efo/efo_0005112,GCST003688,27490719,2,Gestational age at birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0006921,GCST003688,27490719,2,Gestational age at birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005112,GCST003686,27490719,13,Gestational age at birth (child effect)
http://www.ebi.ac.uk/efo/efo_0006921,GCST003686,27490719,13,Gestational age at birth (child effect)
http://www.ebi.ac.uk/efo/efo_0005112,GCST003685,27490719,8,Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect)
http://www.ebi.ac.uk/efo/efo_0006921,GCST003685,27490719,8,Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005112,GCST003684,27490719,2,Gestational age at birth in labor-initiated deliveries (maternal effect)
http://www.ebi.ac.uk/efo/efo_0006921,GCST003684,27490719,2,Gestational age at birth in labor-initiated deliveries (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005112,GCST003689,27490719,8,Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)
http://www.ebi.ac.uk/efo/efo_0006921,GCST003689,27490719,8,Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)
http://www.ebi.ac.uk/efo/efo_0005112,GCST003687,27490719,12,Gestational age at birth in labor-initiated deliveries (child effect)
http://www.ebi.ac.uk/efo/efo_0006921,GCST003687,27490719,12,Gestational age at birth in labor-initiated deliveries (child effect)
http://www.ebi.ac.uk/efo/efo_0003948,GCST003631,27485664,7,Gastroesophageal reflux disease
http://www.ebi.ac.uk/efo/efo_0002508,GCST003600,27545685,1,Parkinson's disease (pesticide exposure interaction)
http://www.ebi.ac.uk/efo/efo_0007840,GCST003600,27545685,1,Parkinson's disease (pesticide exposure interaction)
http://www.ebi.ac.uk/efo/efo_0004318,GCST003629,27488534,14,nicotine metabolite ratio in current smokers
http://www.ebi.ac.uk/efo/efo_0007794,GCST003629,27488534,14,nicotine metabolite ratio in current smokers
http://www.ebi.ac.uk/efo/efo_0000537,GCST003613,27480026,1,Hypertension
http://www.ebi.ac.uk/efo/efo_1001901,GCST003785,27492634,0,Neuroendocrine tumor
http://www.ebi.ac.uk/efo/efo_0005763,GCST006118,27271309,0,Pulse pressure x sodium interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0009282,GCST006118,27271309,0,Pulse pressure x sodium interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0005763,GCST006117,27271309,0,Pulse pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0009282,GCST006117,27271309,0,Pulse pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0003761,GCST006041,27479909,47,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0009282,GCST006116,27271309,0,Mean arterial pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006340,GCST006116,27271309,0,Mean arterial pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0009282,GCST006115,27271309,0,Systolic blood pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006335,GCST006115,27271309,0,Systolic blood pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0009282,GCST006114,27271309,1,Mean arterial pressure x sodium interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006340,GCST006114,27271309,1,Mean arterial pressure x sodium interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0009282,GCST006111,27271309,2,Diastolic blood pressure x sodium interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006336,GCST006111,27271309,2,Diastolic blood pressure x sodium interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0009282,GCST006113,27271309,2,Systolic blood pressure x sodium interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0006335,GCST006113,27271309,2,Systolic blood pressure x sodium interaction (2df test)
http://www.ebi.ac.uk/efo/efo_0002618,GCST003758,27579533,3,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0005220,GCST003787,27492634,1,Bronchial neuroendocrine tumor
http://www.ebi.ac.uk/efo/efo_1000045,GCST003788,27492634,0,Pancreatic neuroendocrine tumor
http://www.ebi.ac.uk/efo/efo_1001928,GCST003786,27492634,1,Small intestine neuroendocrine tumor
http://www.ebi.ac.uk/efo/efo_0009282,GCST006112,27271309,1,Diastolic blood pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0006336,GCST006112,27271309,1,Diastolic blood pressure x sodium interaction (1df test)
http://www.ebi.ac.uk/efo/efo_0000180,GCST003606,27339598,7,Liver fibrosis severity in HIV/hepatitis C co-infection
http://purl.obolibrary.org/obo/hp_0001395,GCST003606,27339598,7,Liver fibrosis severity in HIV/hepatitis C co-infection
http://www.ebi.ac.uk/efo/efo_0003047,GCST003606,27339598,7,Liver fibrosis severity in HIV/hepatitis C co-infection
http://www.ebi.ac.uk/efo/efo_0004340,GCST005181,27455349,1,Body mass index
http://www.ebi.ac.uk/efo/efo_0000253,GCST004692,27455348,7,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0003890,GCST003601,26202629,1,Drug abuse
http://www.ebi.ac.uk/efo/efo_0000270,GCST003589,27439200,1,Bronchial hyperresponsiveness in asthma
http://purl.obolibrary.org/obo/go_0009314,GCST003584,27515689,6,"Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)"
http://www.ebi.ac.uk/efo/efo_0001663,GCST003584,27515689,6,"Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)"
http://purl.obolibrary.org/obo/go_0009314,GCST003583,27515689,16,Response to radiotherapy in prostate cancer (overall toxicity)
http://www.ebi.ac.uk/efo/efo_0001663,GCST003583,27515689,16,Response to radiotherapy in prostate cancer (overall toxicity)
http://purl.obolibrary.org/obo/go_0009314,GCST003581,27515689,8,"Response to radiotherapy in prostate cancer (toxicity, decreased urine stream)"
http://www.ebi.ac.uk/efo/efo_0001663,GCST003581,27515689,8,"Response to radiotherapy in prostate cancer (toxicity, decreased urine stream)"
http://purl.obolibrary.org/obo/go_0009314,GCST003582,27515689,11,"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)"
http://www.ebi.ac.uk/efo/efo_0001663,GCST003582,27515689,11,"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)"
http://www.ebi.ac.uk/efo/efo_0004252,GCST003578,27436580,6,Nasopharyngeal carcinoma
http://www.ebi.ac.uk/efo/efo_1001927,GCST003655,27424798,13,Cutaneous squamous cell carcinoma
http://www.ebi.ac.uk/efo/efo_0007785,GCST003612,27424934,4,Bone mineral density (femoral neck)
http://www.ebi.ac.uk/efo/efo_0007701,GCST003610,27424934,2,Bone mineral density (spine)
http://www.ebi.ac.uk/efo/efo_0007702,GCST003611,27424934,4,Bone mineral density (total hip)
http://www.ebi.ac.uk/efo/efo_0004282,GCST003683,27418160,4,"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0004214,GCST003683,27418160,4,"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0003870,GCST003683,27418160,4,"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0004471,GCST003658,27416945,4,Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI)
http://www.ebi.ac.uk/efo/efo_0004340,GCST003658,27416945,4,Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI)
http://www.ebi.ac.uk/efo/efo_0004471,GCST005178,27416945,1,Modified Stumvoll Insulin Sensitivity Index
http://www.ebi.ac.uk/efo/efo_0004471,GCST003659,27416945,12,Modified Stumvoll Insulin Sensitivity Index (BMI interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST003659,27416945,12,Modified Stumvoll Insulin Sensitivity Index (BMI interaction)
http://www.ebi.ac.uk/efo/efo_0007864,GCST003723,27412988,6,Serum sulfate level
http://purl.obolibrary.org/obo/hp_0012235,GCST003628,27400856,10,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
http://www.ebi.ac.uk/efo/efo_0004609,GCST003628,27400856,10,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
http://purl.obolibrary.org/obo/go_0097338,GCST003628,27400856,10,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
http://www.ebi.ac.uk/efo/efo_0007848,GCST003590,27412012,4,Apolipoprotein A-IV levels
http://www.ebi.ac.uk/efo/efo_0002508,GCST003651,27402877,0,"Parkinson's disease (non-familial, age at onset)"
http://www.ebi.ac.uk/efo/efo_0004847,GCST003651,27402877,0,"Parkinson's disease (non-familial, age at onset)"
http://www.ebi.ac.uk/efo/efo_0002690,GCST003622,27399966,74,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0002508,GCST003652,27402877,4,"Parkinson's disease (familial, age at onset)"
http://www.ebi.ac.uk/efo/efo_0004847,GCST003652,27402877,4,"Parkinson's disease (familial, age at onset)"
http://www.ebi.ac.uk/efo/efo_0002508,GCST003653,27402877,0,Parkinson's disease (age of onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST003653,27402877,0,Parkinson's disease (age of onset)
http://www.ebi.ac.uk/efo/efo_0000270,GCST003682,27387956,0,Asthma (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0007785,GCST003654,27397699,18,Bone mineral density (Ward's triangle area)
http://www.ebi.ac.uk/efo/efo_0005921,GCST003567,27523435,0,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
http://purl.obolibrary.org/obo/go_0031960,GCST003567,27523435,0,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
http://www.ebi.ac.uk/efo/efo_0000270,GCST003567,27523435,0,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
http://www.ebi.ac.uk/efo/efo_0007805,GCST003485,27002377,15,Response to fenofibrate (HDL cholesterol levels)
http://purl.obolibrary.org/obo/go_1901557,GCST003485,27002377,15,Response to fenofibrate (HDL cholesterol levels)
http://www.ebi.ac.uk/efo/efo_0001378,GCST004483,27363682,23,Multiple myeloma
http://www.ebi.ac.uk/efo/efo_0007681,GCST003488,27002377,17,Response to fenofibrate (triglyceride levels)
http://purl.obolibrary.org/obo/go_1901557,GCST003488,27002377,17,Response to fenofibrate (triglyceride levels)
http://www.ebi.ac.uk/efo/efo_0007806,GCST003487,27002377,18,Response to fenofibrate (total cholesterol levels)
http://purl.obolibrary.org/obo/go_1901557,GCST003487,27002377,18,Response to fenofibrate (total cholesterol levels)
http://www.ebi.ac.uk/efo/efo_0007804,GCST003486,27002377,12,Response to fenofibrate (LDL cholesterol levels)
http://purl.obolibrary.org/obo/go_1901557,GCST003486,27002377,12,Response to fenofibrate (LDL cholesterol levels)
http://www.ebi.ac.uk/efo/efo_0001360,GCST005716,27362418,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000389,GCST003639,27347659,0,Breslow thickness in cutaneous melanoma
http://www.ebi.ac.uk/efo/efo_0004955,GCST003639,27347659,0,Breslow thickness in cutaneous melanoma
http://www.ebi.ac.uk/efo/efo_0000305,GCST003520,27354352,8,Breast cancer
http://www.ebi.ac.uk/efo/efo_0000289,GCST003724,27329760,6,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0007999,GCST004493,27325353,11,Lower body strength
http://www.ebi.ac.uk/efo/efo_0006941,GCST004494,27325353,4,Hand grip strength
http://www.ebi.ac.uk/efo/efo_0007009,GCST003591,27327535,2,Severity of facial solar lentigines
http://www.ebi.ac.uk/efo/efo_0003821,GCST003720,27322543,44,Migraine
http://www.ebi.ac.uk/efo/efo_0005295,GCST003722,27322543,0,Migraine with aura
http://www.ebi.ac.uk/efo/efo_0005296,GCST003721,27322543,7,Migraine without aura
http://www.ebi.ac.uk/efo/efo_0003885,GCST003566,27386562,16,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0007702,GCST003559,27311723,4,Bone mineral density (hip)
http://www.ebi.ac.uk/efo/efo_1001926,GCST003648,27315593,3,Pathological gambling
http://www.ebi.ac.uk/efo/efo_0004340,GCST003647,27296613,4,Body mass index
http://www.ebi.ac.uk/efo/efo_0004530,GCST003681,27286809,21,C-reactive protein levels or triglyceride levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004458,GCST003681,27286809,21,C-reactive protein levels or triglyceride levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004574,GCST003678,27286809,20,C-reactive protein levels or total cholesterol levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004458,GCST003678,27286809,20,C-reactive protein levels or total cholesterol levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_1001998,GCST003930,28025368,0,Complex regional pain syndrome
http://www.ebi.ac.uk/efo/efo_0004611,GCST003679,27286809,21,C-reactive protein levels or LDL-cholesterol levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004458,GCST003679,27286809,21,C-reactive protein levels or LDL-cholesterol levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004458,GCST003680,27286809,20,C-reactive protein levels or HDL-cholesterol levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004612,GCST003680,27286809,20,C-reactive protein levels or HDL-cholesterol levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001061,GCST003565,27285765,1,Cervical cancer
http://www.ebi.ac.uk/efo/efo_0001663,GCST003586,27262462,9,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0006999,GCST003585,27262462,0,Aggressive prostate cancer
http://www.ebi.ac.uk/efo/efo_0001663,GCST003585,27262462,0,Aggressive prostate cancer
http://www.ebi.ac.uk/efo/efo_1001925,GCST003649,27236921,9,Pneumococcal bacteremia
http://www.ebi.ac.uk/efo/efo_0003033,GCST003650,27236921,12,Bacteremia
http://www.ebi.ac.uk/efo/efo_0004237,GCST003640,27304844,1,Thyroid-associated orbitopathy in graves' disease
http://www.ebi.ac.uk/efo/efo_1001466,GCST003640,27304844,1,Thyroid-associated orbitopathy in graves' disease
http://www.ebi.ac.uk/efo/efo_0004197,GCST003615,27244555,4,Susceptibility to persistent hepatitis B virus infection
http://www.orpha.net/ordo/orphanet_391311,GCST003615,27244555,4,Susceptibility to persistent hepatitis B virus infection
http://www.ebi.ac.uk/efo/efo_0001357,GCST003632,27244217,6,Survival in sporadic amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0000714,GCST003632,27244217,6,Survival in sporadic amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0004784,GCST003676,27225129,162,Educational attainment (years of education)
http://www.orpha.net/ordo/orphanet_52,GCST003616,28090565,2,Liver disease severity in Alagille syndrome
http://www.ebi.ac.uk/efo/efo_0001421,GCST003616,28090565,2,Liver disease severity in Alagille syndrome
http://www.ebi.ac.uk/efo/efo_0004784,GCST003677,27225129,34,Educational attainment (college completion)
http://www.ebi.ac.uk/efo/efo_0003761,GCST003558,27519822,1,Major depressive disorder
http://purl.obolibrary.org/obo/hp_0002108,GCST003618,27203581,0,Primary spontaneous pneumothorax
http://www.ebi.ac.uk/efo/efo_0007843,GCST003633,27193062,0,middle facial morphology traits (ordinal measurement)
http://www.ebi.ac.uk/efo/efo_0007847,GCST003633,27193062,0,middle facial morphology traits (ordinal measurement)
http://www.ebi.ac.uk/efo/efo_0007844,GCST003638,27193062,0,upper facial morphology traits (ordinal measurement)
http://www.ebi.ac.uk/efo/efo_0007742,GCST003630,27195777,2,Left ventricular QRS voltage
http://www.ebi.ac.uk/efo/efo_0007740,GCST003630,27195777,2,Left ventricular QRS voltage
http://www.ebi.ac.uk/efo/efo_0007741,GCST003630,27195777,2,Left ventricular QRS voltage
http://www.ebi.ac.uk/efo/efo_0007788,GCST003564,27195708,7,Waist-to-hip ratio adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0007841,GCST003637,27193062,4,facial morphology traits (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0007845,GCST003636,27193062,1,lower facial morphology traits (quantitative measurement)
http://www.ebi.ac.uk/efo/efo_0007842,GCST003636,27193062,1,lower facial morphology traits (quantitative measurement)
http://www.ebi.ac.uk/efo/efo_0007843,GCST003635,27193062,7,middle facial morphology traits (quantitative measurement)
http://www.ebi.ac.uk/efo/efo_0007845,GCST003634,27193062,0,lower facial morphology traits (ordinal measurement)
http://www.ebi.ac.uk/efo/efo_0007842,GCST003634,27193062,0,lower facial morphology traits (ordinal measurement)
http://www.ebi.ac.uk/efo/efo_0001360,GCST003619,27189021,10,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000685,GCST003620,27193031,9,Systemic lupus erythematosus or rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0002690,GCST003620,27193031,9,Systemic lupus erythematosus or rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0002508,GCST003984,27182965,25,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0004705,GCST003988,27182965,26,Hypothyroidism
http://www.ebi.ac.uk/efo/efo_0004191,GCST003983,27182965,44,Male-pattern baldness
http://www.ebi.ac.uk/efo/efo_0007843,GCST003999,27182965,25,Nose size
http://www.ebi.ac.uk/efo/efo_0007905,GCST003998,27182965,25,Joint mobility (Beighton score)
http://purl.obolibrary.org/obo/hp_0000545,GCST003997,27182965,51,Myopia
http://www.ebi.ac.uk/efo/efo_0007906,GCST003996,27182965,50,Monobrow
http://www.ebi.ac.uk/efo/efo_0007924,GCST003995,27182965,36,Tonsillectomy
http://www.ebi.ac.uk/efo/efo_0007888,GCST003994,27182965,14,Age at voice drop
http://www.ebi.ac.uk/efo/efo_0004703,GCST003993,27182965,44,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0007887,GCST003992,27182965,50,Photic sneeze reflex
http://www.ebi.ac.uk/efo/efo_0007904,GCST003991,27182965,24,Childhood ear infection
http://www.ebi.ac.uk/efo/efo_0003785,GCST003990,27182965,26,Allergy
http://www.ebi.ac.uk/efo/efo_0007842,GCST003989,27182965,46,Chin dimples
http://www.ebi.ac.uk/efo/efo_0000270,GCST003987,27182965,27,Asthma
http://www.ebi.ac.uk/efo/efo_0003821,GCST003986,27182965,27,Migraine
http://www.ebi.ac.uk/efo/efo_0004884,GCST003985,27182965,23,Breast size
http://www.ebi.ac.uk/efo/efo_0001071,GCST003775,27393504,6,Lung cancer
http://www.ebi.ac.uk/efo/efo_0000708,GCST003777,27393504,0,Squamous cell lung carcinoma
http://www.ebi.ac.uk/efo/efo_0000571,GCST003776,27393504,1,Lung adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0000378,GCST003561,27191271,0,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_0006525,GCST003779,27393504,1,Smoking behaviour (cigarettes smoked per day)
http://www.ebi.ac.uk/efo/efo_0006527,GCST003778,27393504,1,Smoking status (current vs former)
http://www.ebi.ac.uk/efo/efo_0004246,GCST003560,27171184,20,Coronary artery aneurysm in Kawasaki disease
http://www.ebi.ac.uk/efo/efo_1000881,GCST003560,27171184,20,Coronary artery aneurysm in Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0001358,GCST003495,27167565,1,Post-traumatic stress disorder
http://www.ebi.ac.uk/efo/efo_0006859,GCST003541,27173062,1,Survival in head and neck cancer
http://www.ebi.ac.uk/efo/efo_0000714,GCST003541,27173062,1,Survival in head and neck cancer
http://www.ebi.ac.uk/efo/efo_0007795,GCST003562,27159506,0,Anxiety
http://www.ebi.ac.uk/efo/efo_0000398,GCST003522,27153935,4,Dermatomyositis
http://purl.obolibrary.org/obo/go_0060279,GCST004413,27132594,3,Spontaneous dizygotic twinning
http://www.ebi.ac.uk/efo/efo_0007835,GCST003538,27151647,6,Alcohol dependence symptom count
http://www.ebi.ac.uk/efo/efo_0005842,GCST003494,27145994,4,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0003144,GCST003539,27149122,2,Mortality in heart failure
http://www.ebi.ac.uk/efo/efo_0004352,GCST003539,27149122,2,Mortality in heart failure
http://www.ebi.ac.uk/efo/efo_0007836,GCST003523,27149984,25,Coenzyme Q10 levels
http://www.ebi.ac.uk/efo/efo_0000270,GCST003521,27445529,0,Asthma
http://www.ebi.ac.uk/efo/efo_0005280,GCST003481,27142678,1,Sleep latency
http://purl.obolibrary.org/obo/hp_0012235,GCST003527,27157822,6,Anti-thyroid drug induced agranulocytosis
http://www.ebi.ac.uk/efo/efo_0007838,GCST003527,27157822,6,Anti-thyroid drug induced agranulocytosis
http://purl.obolibrary.org/obo/hp_0012235,GCST003526,27157822,5,Non-chemotherapy drug induced agranulocytosis
http://purl.obolibrary.org/obo/go_0042493,GCST003526,27157822,5,Non-chemotherapy drug induced agranulocytosis
http://www.ebi.ac.uk/efo/efo_0004591,GCST003482,27142222,3,Asthma (childhood onset)
http://www.ebi.ac.uk/efo/efo_0003100,GCST003672,27143689,12,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer
http://purl.obolibrary.org/obo/go_1902519,GCST003672,27143689,12,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer
http://www.ebi.ac.uk/efo/efo_0000196,GCST003672,27143689,12,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer
http://www.ebi.ac.uk/efo/efo_1001514,GCST003525,27135401,7,Endometrial endometrioid carcinoma
http://www.ebi.ac.uk/efo/efo_1001512,GCST003524,27135401,8,Endometrial cancer
http://www.ebi.ac.uk/efo/efo_0002690,GCST003599,26663301,18,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0009466,GCST005540,26651848,1,Sarcoidosis (Lofgren's syndrome)
http://www.orpha.net/ordo/orphanet_797,GCST005541,26651848,25,Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)
http://www.orpha.net/ordo/orphanet_797,GCST005542,26651848,5,Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations)
http://www.orpha.net/ordo/orphanet_797,GCST005543,26651848,1,Sarcoidosis (non-Lofgren's syndrome)
http://www.ebi.ac.uk/efo/efo_0007828,GCST003518,27126917,101,Daytime sleep phenotypes
http://www.ebi.ac.uk/efo/efo_0005271,GCST003542,27126917,210,Night sleep phenotypes
http://www.ebi.ac.uk/efo/efo_0007827,GCST003542,27126917,210,Night sleep phenotypes
http://www.ebi.ac.uk/efo/efo_0005272,GCST003542,27126917,210,Night sleep phenotypes
http://www.ebi.ac.uk/efo/efo_0005280,GCST003542,27126917,210,Night sleep phenotypes
http://www.ebi.ac.uk/efo/efo_0000305,GCST003845,27117709,31,Breast cancer
http://www.ebi.ac.uk/efo/efo_1000650,GCST003842,27117709,25,Breast cancer (estrogen-receptor negative)
http://www.ebi.ac.uk/efo/efo_1001507,GCST003500,27114598,0,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_0000220,GCST003500,27114598,0,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_1001507,GCST003501,27114598,11,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
http://www.ebi.ac.uk/efo/efo_0000220,GCST003501,27114598,11,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
http://www.ebi.ac.uk/efo/efo_0007829,GCST003489,27106561,11,Food addiction
http://www.ebi.ac.uk/efo/efo_0007830,GCST003489,27106561,11,Food addiction
http://www.ebi.ac.uk/efo/efo_0005200,GCST003563,27098658,12,Presence of antiphospholipid antibodies
http://www.ebi.ac.uk/efo/efo_0000311,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001071,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_1000650,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0005842,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_1001515,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001663,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_1001516,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000305,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001075,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000571,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000708,GCST003588,27197191,26,Cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000311,GCST003587,27197191,17,Cancer
http://www.ebi.ac.uk/efo/efo_0001071,GCST003587,27197191,17,Cancer
http://www.ebi.ac.uk/efo/efo_1000650,GCST003587,27197191,17,Cancer
http://www.ebi.ac.uk/efo/efo_0005842,GCST003587,27197191,17,Cancer
http://www.ebi.ac.uk/efo/efo_1001515,GCST003587,27197191,17,Cancer
http://www.ebi.ac.uk/efo/efo_0001663,GCST003587,27197191,17,Cancer
http://www.ebi.ac.uk/efo/efo_1001516,GCST003587,27197191,17,Cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST003587,27197191,17,Cancer
http://www.ebi.ac.uk/efo/efo_0001075,GCST003587,27197191,17,Cancer
http://www.ebi.ac.uk/efo/efo_0000571,GCST003587,27197191,17,Cancer
http://www.ebi.ac.uk/efo/efo_0000708,GCST003587,27197191,17,Cancer
http://purl.obolibrary.org/obo/hp_0000225,GCST004198,28459102,5,Severe gingival inflammation
http://www.ebi.ac.uk/efo/efo_0007869,GCST003766,27089181,113,Subjective well-being
http://www.ebi.ac.uk/efo/efo_0009749,GCST007335,27089180,36,Age at first sexual intercourse
http://www.ebi.ac.uk/efo/efo_0009101,GCST007336,27089180,4,Age at first birth
http://www.ebi.ac.uk/efo/efo_0007660,GCST003770,27089181,114,Neuroticism
http://www.ebi.ac.uk/efo/efo_0003761,GCST003769,27089181,15,Depression
http://www.ebi.ac.uk/efo/efo_0007006,GCST003769,27089181,15,Depression
http://www.ebi.ac.uk/efo/efo_0005842,GCST003420,27207650,7,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0007869,GCST003768,27089181,30,Positive affect
http://www.ebi.ac.uk/efo/efo_0007869,GCST003767,27089181,28,Life satisfaction
http://www.ebi.ac.uk/efo/efo_0004210,GCST003725,27094239,6,Gallstone disease
http://www.ebi.ac.uk/efo/efo_0004265,GCST004482,27082954,159,Peripheral arterial disease (traffic-related air pollution interaction)
http://www.ebi.ac.uk/efo/efo_0007908,GCST004482,27082954,159,Peripheral arterial disease (traffic-related air pollution interaction)
http://www.ebi.ac.uk/efo/efo_0007660,GCST003447,27067015,13,Neuroticism
http://www.ebi.ac.uk/efo/efo_0005766,GCST003418,27207532,1,Skin fluorescence in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0001359,GCST003418,27207532,1,Skin fluorescence in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0007783,GCST003421,27064253,1,Mosaic loss of chromosome Y
http://www.ebi.ac.uk/efo/efo_0003100,GCST003438,27060151,0,Bortezomib-induced peripheral neuropathy in multiple myeloma
http://www.ebi.ac.uk/efo/efo_0001378,GCST003438,27060151,0,Bortezomib-induced peripheral neuropathy in multiple myeloma
http://www.ebi.ac.uk/efo/efo_0007808,GCST003438,27060151,0,Bortezomib-induced peripheral neuropathy in multiple myeloma
http://purl.obolibrary.org/obo/hp_0002140,GCST003492,27068588,0,Ischemic stroke
http://purl.obolibrary.org/obo/hp_0000175,GCST005947,27018472,13,Cleft palate
http://purl.obolibrary.org/obo/hp_0000175,GCST005948,27018472,4,Cleft palate
http://purl.obolibrary.org/obo/hp_0000175,GCST005946,27018472,22,Cleft palate
http://www.ebi.ac.uk/efo/efo_0000712,GCST003491,27068588,1,Stroke
http://purl.obolibrary.org/obo/hp_0002140,GCST003493,27068588,0,Ischemic stroke (non-cardioembolic)
http://purl.obolibrary.org/obo/hp_0002140,GCST003490,27068588,1,Ischemic stroke (cardioembolic)
http://www.ebi.ac.uk/efo/efo_1001493,GCST003490,27068588,1,Ischemic stroke (cardioembolic)
http://www.ebi.ac.uk/efo/efo_0004874,GCST003497,27046643,0,Memory performance
http://www.ebi.ac.uk/efo/efo_0008393,GCST003499,27046643,2,Reaction time
http://www.ebi.ac.uk/efo/efo_0007803,GCST003437,27043157,6,Discordance in emotional problems in monozygotic twins
http://www.ebi.ac.uk/efo/efo_0004784,GCST003496,27046643,15,Educational attainment
http://www.ebi.ac.uk/efo/efo_0004350,GCST003498,27046643,3,Verbal-numerical reasoning
http://www.ebi.ac.uk/efo/efo_1001506,GCST003467,27064256,17,Glaucoma (primary angle closure)
http://www.ebi.ac.uk/efo/efo_0004530,GCST003661,27036123,29,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004612,GCST003660,27036123,37,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004574,GCST003663,27036123,45,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004611,GCST003662,27036123,31,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004352,GCST005078,27029810,2,Mortality
http://www.ebi.ac.uk/efo/efo_0008457,GCST003465,27028160,30,Cannabis dependence symptom count
http://www.ebi.ac.uk/efo/efo_0004784,GCST003455,27020472,48,Spherical equivalent (joint analysis main effects and education interaction)
http://www.ebi.ac.uk/efo/efo_0007814,GCST003455,27020472,48,Spherical equivalent (joint analysis main effects and education interaction)
http://www.ebi.ac.uk/efo/efo_0000292,GCST003384,27206850,1,Bladder cancer
http://www.ebi.ac.uk/efo/efo_0007816,GCST003456,27023328,0,Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia)
http://purl.obolibrary.org/obo/hp_0001945,GCST003456,27023328,0,Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia)
http://www.ebi.ac.uk/efo/efo_0000756,GCST003456,27023328,0,Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia)
http://www.ebi.ac.uk/efo/efo_0007815,GCST003456,27023328,0,Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia)
http://www.ebi.ac.uk/efo/efo_0003888,GCST003472,27021288,24,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0007679,GCST003472,27021288,24,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0007585,GCST003382,27023175,6,Cannabis use
http://purl.obolibrary.org/obo/hp_0100543,GCST003399,27021820,0,Cognitive impairment (brain beta-amyloid deposition interaction)
http://www.ebi.ac.uk/efo/efo_0007707,GCST003399,27021820,0,Cognitive impairment (brain beta-amyloid deposition interaction)
http://www.ebi.ac.uk/efo/efo_0003888,GCST003473,27021288,32,Aggressiveness in attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0007826,GCST003473,27021288,32,Aggressiveness in attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0007663,GCST003473,27021288,32,Aggressiveness in attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0004576,GCST006251,27022141,1,High fetal hemoglobin in sickle cell disease
http://www.orpha.net/ordo/orphanet_275752,GCST006251,27022141,1,High fetal hemoglobin in sickle cell disease
http://www.ebi.ac.uk/efo/efo_1001510,GCST003396,27016271,4,Developmental language disorder
http://www.ebi.ac.uk/efo/efo_0007799,GCST003398,27016271,3,Developmental language disorder (syntactic complexity)
http://www.ebi.ac.uk/efo/efo_1001510,GCST003398,27016271,3,Developmental language disorder (syntactic complexity)
http://www.ebi.ac.uk/efo/efo_0007798,GCST003397,27016271,9,Developmental language disorder (linguistic errors)
http://www.ebi.ac.uk/efo/efo_1001510,GCST003397,27016271,9,Developmental language disorder (linguistic errors)
http://www.ebi.ac.uk/efo/efo_0007796,GCST003392,27015805,0,Parental longevity (father's age at death)
http://www.ebi.ac.uk/efo/efo_0007796,GCST003395,27015805,73,Parental extreme longevity (95 years and older)
http://www.ebi.ac.uk/efo/efo_0007796,GCST003394,27015805,51,Parental longevity (combined parental age at death)
http://www.ebi.ac.uk/efo/efo_0007796,GCST003393,27015805,51,Parental longevity (mother's age at death)
http://www.ebi.ac.uk/efo/efo_1001512,GCST003436,27008869,4,Endometrial cancer
http://www.ebi.ac.uk/efo/efo_0004732,GCST003665,27005778,35,Metabolite levels (lipoprotein measures)
http://www.ebi.ac.uk/efo/efo_0005664,GCST003665,27005778,35,Metabolite levels (lipoprotein measures)
http://www.ebi.ac.uk/efo/efo_0005664,GCST003666,27005778,33,Metabolite levels (small molecules and protein measures)
http://www.ebi.ac.uk/efo/efo_0004747,GCST003666,27005778,33,Metabolite levels (small molecules and protein measures)
http://www.ebi.ac.uk/efo/efo_0005134,GCST003666,27005778,33,Metabolite levels (small molecules and protein measures)
http://www.ebi.ac.uk/efo/efo_0004529,GCST003664,27005778,6,Metabolite levels (lipid measures)
http://www.ebi.ac.uk/efo/efo_0005664,GCST003664,27005778,6,Metabolite levels (lipid measures)
http://www.ebi.ac.uk/efo/efo_0004647,GCST003440,27047539,2,Response to carboplatin in ovarian cancer (MTT IC50)
http://www.ebi.ac.uk/efo/efo_0001075,GCST003440,27047539,2,Response to carboplatin in ovarian cancer (MTT IC50)
http://www.ebi.ac.uk/efo/efo_0006952,GCST003440,27047539,2,Response to carboplatin in ovarian cancer (MTT IC50)
http://www.ebi.ac.uk/efo/efo_0007807,GCST003448,27005419,7,Erythrocyte cadmium concentration in never smokers
http://www.ebi.ac.uk/efo/efo_0004647,GCST003444,27047539,2,Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)
http://www.ebi.ac.uk/efo/efo_0001075,GCST003444,27047539,2,Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)
http://www.ebi.ac.uk/efo/efo_0006952,GCST003444,27047539,2,Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)
http://purl.obolibrary.org/obo/go_1901555,GCST003444,27047539,2,Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)
http://www.ebi.ac.uk/efo/efo_0001075,GCST003441,27047539,1,Response to paclitaxel in ovarian cancer (MTT IC50)
http://www.ebi.ac.uk/efo/efo_0006952,GCST003441,27047539,1,Response to paclitaxel in ovarian cancer (MTT IC50)
http://purl.obolibrary.org/obo/go_1901555,GCST003441,27047539,1,Response to paclitaxel in ovarian cancer (MTT IC50)
http://www.ebi.ac.uk/efo/efo_0004647,GCST003442,27047539,0,Response to carboplatin in ovarian cancer (Caspase 3/7 EC50)
http://www.ebi.ac.uk/efo/efo_0001075,GCST003442,27047539,0,Response to carboplatin in ovarian cancer (Caspase 3/7 EC50)
http://www.ebi.ac.uk/efo/efo_0006952,GCST003442,27047539,0,Response to carboplatin in ovarian cancer (Caspase 3/7 EC50)
http://www.ebi.ac.uk/efo/efo_0004647,GCST003439,27047539,2,Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50)
http://www.ebi.ac.uk/efo/efo_0001075,GCST003439,27047539,2,Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50)
http://www.ebi.ac.uk/efo/efo_0006952,GCST003439,27047539,2,Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50)
http://www.ebi.ac.uk/efo/efo_0004647,GCST003443,27047539,3,Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)
http://www.ebi.ac.uk/efo/efo_0001075,GCST003443,27047539,3,Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)
http://www.ebi.ac.uk/efo/efo_0006952,GCST003443,27047539,3,Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)
http://purl.obolibrary.org/obo/go_1901555,GCST003443,27047539,3,Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)
http://www.ebi.ac.uk/efo/efo_0002609,GCST003424,27005825,1,Arthritis (juvenile idiopathic)
http://www.ebi.ac.uk/efo/efo_0007807,GCST003449,27005419,5,Erythrocyte cadmium concentration
http://www.ebi.ac.uk/efo/efo_0004190,GCST003446,27001270,5,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0007006,GCST003667,26997408,1,Depressive symptoms measurement (somatic complaints domain)
http://www.ebi.ac.uk/efo/efo_0007006,GCST003668,26997408,0,Depressive symptoms measurement (lack of positive affect domain)
http://www.ebi.ac.uk/efo/efo_0007006,GCST003669,26997408,0,Depressive symptoms measurement (lack of negative affect domain)
http://www.ebi.ac.uk/efo/efo_0007854,GCST003607,27001664,0,knee peak torque response
http://www.ebi.ac.uk/efo/efo_0004887,GCST003608,27001664,0,Maximal oxygen uptake response
http://www.ebi.ac.uk/efo/efo_0006788,GCST003469,26989097,12,Response to cognitive-behavioural therapy in anxiety disorder
http://www.ebi.ac.uk/efo/efo_0007820,GCST003469,26989097,12,Response to cognitive-behavioural therapy in anxiety disorder
http://www.ebi.ac.uk/efo/efo_0007817,GCST003674,26977737,12,Obstructive sleep apnea trait (apnea hypopnea index)
http://www.ebi.ac.uk/efo/efo_0003918,GCST003674,26977737,12,Obstructive sleep apnea trait (apnea hypopnea index)
http://www.ebi.ac.uk/efo/efo_0007817,GCST003675,26977737,14,Obstructive sleep apnea trait (average respiratory event duration)
http://www.ebi.ac.uk/efo/efo_0003918,GCST003675,26977737,14,Obstructive sleep apnea trait (average respiratory event duration)
http://www.ebi.ac.uk/efo/efo_0007817,GCST003673,26977737,5,Obstructive sleep apnea (average oxygen saturation during sleep)
http://www.ebi.ac.uk/efo/efo_0003918,GCST003673,26977737,5,Obstructive sleep apnea (average oxygen saturation during sleep)
http://www.ebi.ac.uk/efo/efo_0000249,GCST003452,26993346,18,Posterior cortical atrophy and Alzheimer's disease
http://www.orpha.net/ordo/orphanet_54247,GCST003452,26993346,18,Posterior cortical atrophy and Alzheimer's disease
http://purl.obolibrary.org/obo/go_1902518,GCST003445,26980576,14,Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis
http://www.ebi.ac.uk/efo/efo_0002690,GCST003445,26980576,14,Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis
http://www.ebi.ac.uk/efo/efo_0005761,GCST003445,26980576,14,Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis
http://www.ebi.ac.uk/efo/efo_0003898,GCST005537,26974007,244,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0000676,GCST005537,26974007,244,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0000729,GCST005537,26974007,244,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0000384,GCST005537,26974007,244,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0004268,GCST005537,26974007,244,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0006336,GCST003671,26969751,12,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST003670,26969751,16,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004340,GCST006802,26961502,36,Body mass index
http://www.ebi.ac.uk/efo/efo_0001360,GCST006801,26961502,13,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0007809,GCST003426,26959717,1,Drug-induced liver injury
http://www.ebi.ac.uk/efo/efo_0004228,GCST003426,26959717,1,Drug-induced liver injury
http://www.ebi.ac.uk/efo/efo_0004354,GCST003454,26955885,10,Morning vs. evening chronotype
http://www.ebi.ac.uk/efo/efo_0004318,GCST003483,26959369,3,S-phenylmercapturic acid levels in smokers
http://www.ebi.ac.uk/efo/efo_0007651,GCST003483,26959369,3,S-phenylmercapturic acid levels in smokers
http://www.ebi.ac.uk/efo/efo_0000095,GCST003468,26956414,31,Chronic lymphocytic leukemia
http://www.ebi.ac.uk/efo/efo_0004354,GCST003453,26955885,14,Chronotype
http://www.ebi.ac.uk/efo/efo_0005938,GCST003419,26965164,2,Congenital left-sided heart lesions
http://www.ebi.ac.uk/efo/efo_0000649,GCST003484,26962152,12,Periodontal disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0007780,GCST003484,26962152,12,Periodontal disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0005842,GCST003799,26965516,30,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0000612,GCST003430,26950853,4,Incident myocardial infarction
http://www.ebi.ac.uk/efo/efo_0001645,GCST003431,26950853,2,Incident coronary heart disease
http://www.ebi.ac.uk/efo/efo_0007824,GCST003474,26926045,9,Scalp hair shape
http://www.ebi.ac.uk/efo/efo_0007825,GCST003480,26926045,2,Balding
http://www.ebi.ac.uk/efo/efo_0007822,GCST003479,26926045,11,Hair color
http://www.ebi.ac.uk/efo/efo_0007822,GCST003478,26926045,8,Hair greying
http://www.ebi.ac.uk/efo/efo_0007823,GCST003477,26926045,7,Monobrow thickness
http://www.ebi.ac.uk/efo/efo_0007823,GCST003476,26926045,10,Eyebrow thickness
http://www.ebi.ac.uk/efo/efo_0007823,GCST003475,26926045,8,Beard thickness
http://www.ebi.ac.uk/efo/efo_0007794,GCST003376,26921259,1,Nicotine metabolite ratio
http://www.ebi.ac.uk/efo/efo_0003885,GCST007125,26920376,3,Multiple sclerosis and systolic blood pressure (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006335,GCST007125,26920376,3,Multiple sclerosis and systolic blood pressure (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003885,GCST007124,26920376,7,Multiple sclerosis and HDL levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004612,GCST007124,26920376,7,Multiple sclerosis and HDL levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003885,GCST007123,26920376,4,Multiple sclerosis and LDL levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004611,GCST007123,26920376,4,Multiple sclerosis and LDL levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003885,GCST007122,26920376,6,Multiple sclerosis and triglyceride levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004530,GCST007122,26920376,6,Multiple sclerosis and triglyceride levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003885,GCST007121,26920376,3,Multiple sclerosis and C-reactive protein levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004458,GCST007121,26920376,3,Multiple sclerosis and C-reactive protein levels (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003885,GCST007120,26920376,2,Multiple sclerosis and type 2 diabetes (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001360,GCST007120,26920376,2,Multiple sclerosis and type 2 diabetes (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003885,GCST007127,26920376,1,Multiple sclerosis and waist-to-hip-ratio (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004343,GCST007127,26920376,1,Multiple sclerosis and waist-to-hip-ratio (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003885,GCST007126,26920376,1,Multiple sclerosis and body mass index (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004340,GCST007126,26920376,1,Multiple sclerosis and body mass index (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004300,GCST003425,26912274,9,Longevity
http://www.ebi.ac.uk/efo/efo_0007785,GCST003381,26911590,6,Bone mineral density (femoral neck)
http://www.ebi.ac.uk/efo/efo_0007702,GCST003379,26911590,3,Bone mineral density (hip)
http://www.ebi.ac.uk/efo/efo_0007701,GCST003380,26911590,6,Bone mineral density (spine)
http://www.ebi.ac.uk/efo/efo_0004762,GCST003403,26910538,10,Vascular endothelial growth factor levels
http://www.ebi.ac.uk/efo/efo_0004761,GCST003359,26902266,5,Serum uric acid levels
http://www.ebi.ac.uk/efo/efo_0007819,GCST003457,26915486,5,Advanced glycation end-product levels
http://www.ebi.ac.uk/efo/efo_0001360,GCST003457,26915486,5,Advanced glycation end-product levels
http://www.ebi.ac.uk/efo/efo_0000249,GCST003423,26913989,1,Alzheimer's disease or small vessel stroke
http://www.ebi.ac.uk/efo/efo_1001504,GCST003423,26913989,1,Alzheimer's disease or small vessel stroke
http://www.ebi.ac.uk/efo/efo_0000384,GCST003360,26891255,5,Crohn's disease
http://www.orpha.net/ordo/orphanet_388,GCST008016,26887379,2,Hirschsprung disease
http://www.ebi.ac.uk/efo/efo_0004286,GCST003377,26888256,4,Venous thromboembolism
http://www.ebi.ac.uk/efo/efo_0004612,GCST003391,26879886,11,Low high density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0000707,GCST003422,26908436,5,Squamous cell carcinoma
http://purl.obolibrary.org/obo/hp_0012235,GCST003450,26876947,2,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
http://www.ebi.ac.uk/efo/efo_0004609,GCST003450,26876947,2,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
http://purl.obolibrary.org/obo/go_0097338,GCST003450,26876947,2,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
http://purl.obolibrary.org/obo/hp_0002140,GCST003390,26908601,13,Thrombosis
http://www.ebi.ac.uk/efo/efo_0004286,GCST003390,26908601,13,Thrombosis
http://www.ebi.ac.uk/efo/efo_0000712,GCST003390,26908601,13,Thrombosis
http://purl.obolibrary.org/obo/hp_0001977,GCST003390,26908601,13,Thrombosis
http://www.ebi.ac.uk/efo/efo_0003907,GCST003390,26908601,13,Thrombosis
http://www.ebi.ac.uk/efo/efo_0003827,GCST003390,26908601,13,Thrombosis
http://www.ebi.ac.uk/efo/efo_0007802,GCST003434,26859814,13,Obsessive-compulsive symptoms
http://purl.obolibrary.org/obo/go_0097336,GCST003432,26856250,1,Early response to risperidone in schizophrenia
http://www.orpha.net/ordo/orphanet_141136,GCST004412,26853712,13,Craniofacial microsomia
http://www.ebi.ac.uk/efo/efo_0007801,GCST003433,26861389,5,Serum lycopene concentrations
http://www.ebi.ac.uk/efo/efo_0004254,GCST003402,27333618,2,Membranous nephropathy
http://www.ebi.ac.uk/efo/efo_0000249,GCST003427,26830138,203,Alzheimer disease and age of onset
http://www.ebi.ac.uk/efo/efo_0004847,GCST003427,26830138,203,Alzheimer disease and age of onset
http://www.ebi.ac.uk/efo/efo_0004354,GCST003428,26835600,2,Chronotype
http://www.ebi.ac.uk/efo/efo_0004354,GCST003429,26835600,77,Morning vs. evening chronotype
http://www.ebi.ac.uk/efo/efo_0007793,GCST003368,26833098,9,circulating leptin levels adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0000612,GCST003471,26708285,9,Myocardial infarction
http://www.ebi.ac.uk/efo/efo_0000378,GCST003470,26708285,9,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_0007800,GCST003435,26833246,47,Body fat percentage
http://www.ebi.ac.uk/efo/efo_0007813,GCST003466,26833182,0,Cotinine levels in current smokers
http://www.ebi.ac.uk/efo/efo_0005000,GCST003367,26833098,10,circulating leptin levels
http://www.ebi.ac.uk/efo/efo_0004920,GCST003328,26840454,0,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
http://purl.obolibrary.org/obo/go_0097328,GCST003328,26840454,0,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
http://www.ebi.ac.uk/efo/efo_0001075,GCST003328,26840454,0,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
http://purl.obolibrary.org/obo/go_1901555,GCST003328,26840454,0,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
http://www.ebi.ac.uk/efo/efo_0007787,GCST003358,26822151,2,Betaine levels in individuals undergoing cardiac evaluation
http://www.ebi.ac.uk/efo/efo_0006512,GCST003358,26822151,2,Betaine levels in individuals undergoing cardiac evaluation
http://www.ebi.ac.uk/efo/efo_0007818,GCST003459,26824906,0,Endurance athleticism
http://www.ebi.ac.uk/efo/efo_0000707,GCST003327,26829030,12,Squamous cell carcinoma
http://www.ebi.ac.uk/efo/efo_0007818,GCST003458,26824906,3,World class endurance athleticism
http://www.ebi.ac.uk/efo/efo_0001360,GCST003400,26818947,56,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000692,GCST003341,26821981,21,antipsychotic drug dosage in schizophrenia or schizoaffective disorder
http://www.ebi.ac.uk/efo/efo_0007792,GCST003341,26821981,21,antipsychotic drug dosage in schizophrenia or schizoaffective disorder
http://www.ebi.ac.uk/efo/efo_0005411,GCST003341,26821981,21,antipsychotic drug dosage in schizophrenia or schizoaffective disorder
http://www.ebi.ac.uk/efo/efo_0007790,GCST003339,26819262,9,Epstein Barr virus nuclear antigen 1 IgG levels
http://www.ebi.ac.uk/efo/efo_0003885,GCST003340,26819262,4,Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0007790,GCST003340,26819262,4,Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0000685,GCST003330,26815016,1,Rheumatoid factor seropositivity in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0007791,GCST003330,26815016,1,Rheumatoid factor seropositivity in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0005767,GCST003330,26815016,1,Rheumatoid factor seropositivity in rheumatoid arthritis
http://www.orpha.net/ordo/orphanet_46724,GCST003318,26818729,0,Brain arteriovenous malformations (sporadic)
http://www.ebi.ac.uk/efo/efo_1000654,GCST003300,26811534,0,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
http://www.ebi.ac.uk/efo/efo_0005257,GCST003300,26811534,0,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
http://www.ebi.ac.uk/efo/efo_0000318,GCST003300,26811534,0,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
http://www.ebi.ac.uk/efo/efo_1000654,GCST003299,26811534,0,Cardiomyopathy in childhood cancer survivors
http://www.ebi.ac.uk/efo/efo_0000318,GCST003299,26811534,0,Cardiomyopathy in childhood cancer survivors
http://www.ebi.ac.uk/efo/efo_0007654,GCST003278,27179730,1,Ideal cardiovascular health (clinical and behavioural)
http://www.ebi.ac.uk/efo/efo_0007653,GCST003279,27179730,1,Ideal cardiovascular health (clinical)
http://www.ebi.ac.uk/efo/efo_0000289,GCST003378,26806518,10,Response to lithium treatment in bipolar disorder
http://purl.obolibrary.org/obo/go_0010226,GCST003378,26806518,10,Response to lithium treatment in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0005278,GCST003298,26908625,3,NT-proBNP levels in acute coronary syndrome
http://www.ebi.ac.uk/efo/efo_0005208,GCST003371,26831199,0,Glomerular filtration rate (creatinine)
http://www.ebi.ac.uk/efo/efo_0004518,GCST003371,26831199,0,Glomerular filtration rate (creatinine)
http://www.ebi.ac.uk/efo/efo_0005208,GCST003372,26831199,63,Glomerular filtration rate (creatinine)
http://www.ebi.ac.uk/efo/efo_0004518,GCST003372,26831199,63,Glomerular filtration rate (creatinine)
http://www.ebi.ac.uk/efo/efo_0003884,GCST003374,26831199,10,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0005208,GCST003375,26831199,1,Glomerular filtration rate (cystatin C)
http://www.ebi.ac.uk/efo/efo_0004617,GCST003375,26831199,1,Glomerular filtration rate (cystatin C)
http://www.ebi.ac.uk/efo/efo_0005208,GCST003373,26831199,1,Glomerular filtration rate in diabetics (creatinine)
http://www.ebi.ac.uk/efo/efo_0000400,GCST003373,26831199,1,Glomerular filtration rate in diabetics (creatinine)
http://www.ebi.ac.uk/efo/efo_0004518,GCST003373,26831199,1,Glomerular filtration rate in diabetics (creatinine)
http://www.ebi.ac.uk/efo/efo_0004309,GCST003383,26805783,13,Platelet count
http://www.ebi.ac.uk/efo/efo_0005208,GCST003401,26831199,37,Glomerular filtration rate in non diabetics (creatinine)
http://www.ebi.ac.uk/efo/efo_0004518,GCST003401,26831199,37,Glomerular filtration rate in non diabetics (creatinine)
http://www.ebi.ac.uk/efo/efo_0004342,GCST003335,26785701,8,Waist circumference
http://www.ebi.ac.uk/efo/efo_0004343,GCST003337,26785701,0,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0007789,GCST003336,26785701,12,Waist circumference adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0007788,GCST003338,26785701,10,Waist-to-hip ratio adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0004574,GCST003302,26780889,6,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004612,GCST003304,26780889,7,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004530,GCST003301,26780889,5,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004611,GCST003303,26780889,4,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0000685,GCST003329,26776603,12,Response to anti-TNF therapy in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004653,GCST003329,26776603,12,Response to anti-TNF therapy in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0005842,GCST003385,26766742,0,Colorectal cancer (menopausal hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0003961,GCST003385,26766742,0,Colorectal cancer (menopausal hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0004639,GCST003362,26763881,0,Phospholipid levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST003361,26763881,1,LDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST003363,26763881,2,HDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0005842,GCST003387,26766742,0,Colorectal cancer (oestrogen hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0003961,GCST003387,26766742,0,Colorectal cancer (oestrogen hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0005842,GCST003386,26766742,1,Colorectal cancer (oestrogen-progestogen hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0003961,GCST003386,26766742,1,Colorectal cancer (oestrogen-progestogen hormone therapy interaction)
http://www.orpha.net/ordo/orphanet_3389,GCST003451,26767831,1,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0004530,GCST003364,26763881,3,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004820,GCST003331,26763874,1,Sex ratio
http://www.ebi.ac.uk/efo/efo_0006788,GCST003370,26754954,1,Anxiety disorder
http://www.ebi.ac.uk/efo/efo_0007795,GCST003369,26754954,1,Anxiety disorder (factor score)
http://purl.obolibrary.org/obo/hp_0012235,GCST003580,26599303,1,Antithyroid drug-induced agranulocytosis
http://www.ebi.ac.uk/efo/efo_0007633,GCST003580,26599303,1,Antithyroid drug-induced agranulocytosis
http://www.ebi.ac.uk/efo/efo_0006335,GCST003365,26752167,8,Systolic blood pressure (cigarette smoking interaction)
http://www.ebi.ac.uk/efo/efo_0005671,GCST003365,26752167,8,Systolic blood pressure (cigarette smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006336,GCST003366,26752167,0,Diastolic blood pressure (cigarette smoking interaction)
http://www.ebi.ac.uk/efo/efo_0005671,GCST003366,26752167,0,Diastolic blood pressure (cigarette smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004190,GCST003344,26752265,6,Glaucoma (high intraocular pressure)
http://www.ebi.ac.uk/efo/efo_1001022,GCST003343,26752265,3,Glaucoma (low intraocular pressure)
http://www.ebi.ac.uk/efo/efo_0004190,GCST003342,26752265,5,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0007784,GCST003332,26746183,1,Rapid functional decline in sporadic amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0001357,GCST003332,26746183,1,Rapid functional decline in sporadic amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0007784,GCST003333,26746183,0,Moderate functional decline in sporadic amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0001357,GCST003333,26746183,0,Moderate functional decline in sporadic amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0007810,GCST003460,26741287,1,IgG1 response to Plasmodium falciparum antigen (GLURP)
http://www.ebi.ac.uk/efo/efo_0007811,GCST003464,26741287,0,IgG3 response to Plasmodium falciparum antigen (MSP2 FC27)
http://www.ebi.ac.uk/efo/efo_0007811,GCST003463,26741287,0,IgG3 response to Plasmodium falciparum antigen (MSP2 3D7)
http://www.ebi.ac.uk/efo/efo_0007810,GCST003462,26741287,0,IgG1 response to Plasmodium falciparum antigen (MSP1)
http://www.ebi.ac.uk/efo/efo_0007812,GCST003461,26741287,2,"IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7)"
http://www.ebi.ac.uk/efo/efo_0007701,GCST003388,26733130,7,Bone mineral density (spine)
http://www.ebi.ac.uk/efo/efo_0007702,GCST003389,26733130,7,Bone mineral density (hip)
http://purl.obolibrary.org/obo/hp_0002140,GCST003324,26732560,4,Ischemic stroke
http://www.ebi.ac.uk/efo/efo_1001504,GCST003321,26732560,1,Small vessel stroke
http://purl.obolibrary.org/obo/hp_0002140,GCST003323,26732560,0,Ischemic stroke (cardioembolic)
http://www.ebi.ac.uk/efo/efo_1001493,GCST003323,26732560,0,Ischemic stroke (cardioembolic)
http://purl.obolibrary.org/obo/hp_0002140,GCST003320,26732560,0,Ischemic stroke (undetermined subtype)
http://purl.obolibrary.org/obo/hp_0002140,GCST003322,26732560,3,Ischemic stroke (large artery atherosclerosis)
http://www.ebi.ac.uk/efo/efo_0005524,GCST003322,26732560,3,Ischemic stroke (large artery atherosclerosis)
http://www.ebi.ac.uk/efo/efo_0001071,GCST003325,26732429,6,Lung cancer
http://www.ebi.ac.uk/efo/efo_0000571,GCST003326,26732429,5,Adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0007786,GCST003334,26732621,2,Length of menstrual cycle
http://www.ebi.ac.uk/efo/efo_0003761,GCST003319,26845276,2,Major depressive disorder (stressful life events interaction)
http://www.ebi.ac.uk/efo/efo_0004778,GCST003319,26845276,2,Major depressive disorder (stressful life events interaction)
http://www.ebi.ac.uk/efo/efo_0007781,GCST003319,26845276,2,Major depressive disorder (stressful life events interaction)
http://www.ebi.ac.uk/efo/efo_0004252,GCST005113,26545403,8,Nasopharyngeal carcinoma
http://www.ebi.ac.uk/efo/efo_0004533,GCST003540,27897004,8,Clinical laboratory measurements
http://www.ebi.ac.uk/efo/efo_0004838,GCST003540,27897004,8,Clinical laboratory measurements
http://www.ebi.ac.uk/efo/efo_0004509,GCST003540,27897004,8,Clinical laboratory measurements
http://www.ebi.ac.uk/efo/efo_0004297,GCST003540,27897004,8,Clinical laboratory measurements
http://www.ebi.ac.uk/efo/efo_0004527,GCST003540,27897004,8,Clinical laboratory measurements
http://www.ebi.ac.uk/efo/efo_0004468,GCST003540,27897004,8,Clinical laboratory measurements
http://www.ebi.ac.uk/efo/efo_0005047,GCST003540,27897004,8,Clinical laboratory measurements
http://www.ebi.ac.uk/efo/efo_0004570,GCST003540,27897004,8,Clinical laboratory measurements
http://purl.obolibrary.org/obo/hp_0002140,GCST003211,26718567,2,C-reactive protein levels in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0004458,GCST003211,26718567,2,C-reactive protein levels in ischemic stroke
http://purl.obolibrary.org/obo/hp_0002140,GCST003235,26718567,2,Prothrombin fragments F1+2 levels in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0007776,GCST003235,26718567,2,Prothrombin fragments F1+2 levels in ischemic stroke
http://purl.obolibrary.org/obo/hp_0002140,GCST003212,26718567,1,Fibrinogen levels in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0004623,GCST003212,26718567,1,Fibrinogen levels in ischemic stroke
http://purl.obolibrary.org/obo/hp_0002140,GCST003233,26718567,6,Thrombin-antithrombin complex levels in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0007775,GCST003233,26718567,6,Thrombin-antithrombin complex levels in ischemic stroke
http://purl.obolibrary.org/obo/hp_0002140,GCST003213,26718567,6,Creatinine levels in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0004518,GCST003213,26718567,6,Creatinine levels in ischemic stroke
http://purl.obolibrary.org/obo/hp_0002140,GCST003234,26718567,7,Thrombomodulin levels in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0007774,GCST003234,26718567,7,Thrombomodulin levels in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0000178,GCST003218,26701879,6,Non-cardia gastric cancer
http://www.ebi.ac.uk/efo/efo_0004340,GCST003248,26865924,4,Body mass index
http://www.ebi.ac.uk/efo/efo_0007777,GCST003249,26865924,2,Basal metabolic rate
http://www.ebi.ac.uk/efo/efo_1001492,GCST003199,26782385,0,Atrophic age-related macular degeneration
http://purl.obolibrary.org/obo/hp_0000023,GCST003198,26686553,4,Inguinal hernia
http://www.ebi.ac.uk/efo/efo_0004845,GCST003195,26685716,2,Magnesium levels
http://www.ebi.ac.uk/efo/efo_1001492,GCST003219,26691988,52,Advanced age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0001365,GCST003219,26691988,52,Advanced age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0004683,GCST003219,26691988,52,Advanced age-related macular degeneration
http://purl.obolibrary.org/obo/hp_0002140,GCST003258,26708676,3,Ischemic stroke
http://purl.obolibrary.org/obo/hp_0002140,GCST003261,26708676,1,Ischemic stroke (undetermined subtype)
http://purl.obolibrary.org/obo/hp_0002140,GCST003260,26708676,1,Ischemic stroke (small artery occlusion)
http://www.ebi.ac.uk/efo/efo_1001495,GCST003260,26708676,1,Ischemic stroke (small artery occlusion)
http://purl.obolibrary.org/obo/hp_0002140,GCST003259,26708676,2,Ischemic stroke (large artery atherosclerosis)
http://www.ebi.ac.uk/efo/efo_0005524,GCST003259,26708676,2,Ischemic stroke (large artery atherosclerosis)
http://purl.obolibrary.org/obo/hp_0002140,GCST003257,26708676,2,Ischemic stroke (cardioembolic)
http://www.ebi.ac.uk/efo/efo_1001493,GCST003257,26708676,2,Ischemic stroke (cardioembolic)
http://purl.obolibrary.org/obo/hp_0002140,GCST003245,26674333,8,White matter hyperintensities in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0005665,GCST003245,26674333,8,White matter hyperintensities in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0007769,GCST003197,26675016,2,Thoracic-to-hip circumference ratio
http://www.ebi.ac.uk/efo/efo_0004631,GCST003191,26704534,2,Vitamin D levels
http://www.ebi.ac.uk/efo/efo_0007772,GCST003196,26686025,1,Calcaneal bone ultrasound measurement (speed of sound)
http://www.ebi.ac.uk/efo/efo_0000692,GCST003579,26656879,0,Antipsychotic drug-induced weight gain in schizophrenia
http://www.ebi.ac.uk/efo/efo_0004567,GCST003579,26656879,0,Antipsychotic drug-induced weight gain in schizophrenia
http://www.ebi.ac.uk/efo/efo_0003885,GCST003193,26644207,3,Response to interferon beta in multiple sclerosis
http://purl.obolibrary.org/obo/go_0035456,GCST003193,26644207,3,Response to interferon beta in multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0004314,GCST003263,26634245,124,Post bronchodilator FEV1 in COPD
http://purl.obolibrary.org/obo/go_0097366,GCST003263,26634245,124,Post bronchodilator FEV1 in COPD
http://www.ebi.ac.uk/efo/efo_0000341,GCST003263,26634245,124,Post bronchodilator FEV1 in COPD
http://www.ebi.ac.uk/efo/efo_0004713,GCST003267,26634245,12,Pre bronchodilator FEV1/FVC ratio
http://www.ebi.ac.uk/efo/efo_0004314,GCST003266,26634245,12,Pre bronchodilator FEV1
http://purl.obolibrary.org/obo/go_0097366,GCST003265,26634245,473,Post bronchodilator FEV1/FVC ratio in COPD
http://www.ebi.ac.uk/efo/efo_0000341,GCST003265,26634245,473,Post bronchodilator FEV1/FVC ratio in COPD
http://www.ebi.ac.uk/efo/efo_0004713,GCST003265,26634245,473,Post bronchodilator FEV1/FVC ratio in COPD
http://www.ebi.ac.uk/efo/efo_0004314,GCST003262,26634245,1182,Post bronchodilator FEV1
http://purl.obolibrary.org/obo/go_0097366,GCST003262,26634245,1182,Post bronchodilator FEV1
http://purl.obolibrary.org/obo/go_0097366,GCST003264,26634245,1631,Post bronchodilator FEV1/FVC ratio
http://www.ebi.ac.uk/efo/efo_0004713,GCST003264,26634245,1631,Post bronchodilator FEV1/FVC ratio
http://www.ebi.ac.uk/efo/efo_0000400,GCST003250,26631737,2,Urinary albumin-to-creatinine ratio in diabetes
http://www.ebi.ac.uk/efo/efo_0007778,GCST003250,26631737,2,Urinary albumin-to-creatinine ratio in diabetes
http://www.ebi.ac.uk/efo/efo_0007778,GCST003255,26631737,12,Urinary albumin-to-creatinine ratio
http://purl.obolibrary.org/obo/hp_0012594,GCST003253,26631737,15,Microalbuminuria
http://www.ebi.ac.uk/efo/efo_0007778,GCST003254,26631737,10,Urinary albumin-to-creatinine ratio in non-diabetics
http://www.ebi.ac.uk/efo/efo_0005842,GCST003209,26621817,16,Colorectal or endometrial cancer
http://www.ebi.ac.uk/efo/efo_0004230,GCST003209,26621817,16,Colorectal or endometrial cancer
http://www.ebi.ac.uk/efo/efo_0005842,GCST003208,26621817,13,Colorectal or endometrial cancer
http://www.ebi.ac.uk/efo/efo_0004230,GCST003208,26621817,13,Colorectal or endometrial cancer
http://www.ebi.ac.uk/efo/efo_0007773,GCST003269,26626624,10,Cutaneous psoriasis
http://www.ebi.ac.uk/efo/efo_0000676,GCST003269,26626624,10,Cutaneous psoriasis
http://www.ebi.ac.uk/efo/efo_0007773,GCST003271,26626624,0,Psoriatic arthritis vs Cutaneous psoriasis
http://www.ebi.ac.uk/efo/efo_0003778,GCST003271,26626624,0,Psoriatic arthritis vs Cutaneous psoriasis
http://www.ebi.ac.uk/efo/efo_0000676,GCST003271,26626624,0,Psoriatic arthritis vs Cutaneous psoriasis
http://www.ebi.ac.uk/efo/efo_0003778,GCST003270,26626624,14,Psoriatic arthritis
http://www.ebi.ac.uk/efo/efo_1001494,GCST003268,26626624,39,Psoriasis vulgaris
http://www.ebi.ac.uk/efo/efo_0002690,GCST003252,26606652,40,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_1000782,GCST003188,26600424,0,Acute mountain sickness
http://www.ebi.ac.uk/efo/efo_0000270,GCST003176,26620591,2,Asthma
http://www.ebi.ac.uk/efo/efo_0004340,GCST003177,26604143,39,Childhood body mass index
http://www.ebi.ac.uk/efo/efo_0000182,GCST003189,26870257,2,Hepatocellular carcinoma in hepatitis B infection
http://www.ebi.ac.uk/efo/efo_0004197,GCST003189,26870257,2,Hepatocellular carcinoma in hepatitis B infection
http://www.ebi.ac.uk/efo/efo_0009306,GCST006203,29315502,1,Atazanavir levels
http://www.ebi.ac.uk/efo/efo_0004631,GCST005782,29325163,15,Serum 25-Hydroxyvitamin D levels
http://www.ebi.ac.uk/efo/efo_0006917,GCST005313,29317701,0,Spontaneous preterm birth (preterm birth)
http://www.ebi.ac.uk/efo/efo_0000409,GCST006196,29310926,5,Type 1 diabetes in high risk HLA genotype individuals (time to event)
http://www.ebi.ac.uk/efo/efo_0001359,GCST006196,29310926,5,Type 1 diabetes in high risk HLA genotype individuals (time to event)
http://www.ebi.ac.uk/efo/efo_0007658,GCST006196,29310926,5,Type 1 diabetes in high risk HLA genotype individuals (time to event)
http://www.ebi.ac.uk/efo/efo_0000482,GCST006197,29310926,9,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)
http://www.ebi.ac.uk/efo/efo_0001359,GCST006197,29310926,9,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)
http://www.ebi.ac.uk/efo/efo_0007658,GCST006197,29310926,9,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)
http://www.ebi.ac.uk/efo/efo_0004866,GCST006197,29310926,9,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)
http://www.ebi.ac.uk/efo/efo_0000275,GCST005306,29290336,10,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0003923,GCST005349,29304378,20,Total body bone mineral density (age over 60)
http://www.ebi.ac.uk/efo/efo_0003923,GCST005350,29304378,18,Total body bone mineral density (age 45-60)
http://www.ebi.ac.uk/efo/efo_0003923,GCST005346,29304378,8,Total body bone mineral density (age 30-45)
http://www.ebi.ac.uk/efo/efo_0003923,GCST005344,29304378,1,Total body bone mineral density (age 15-30)
http://www.ebi.ac.uk/efo/efo_0003923,GCST005345,29304378,8,Total body bone mineral density (age 0-15)
http://www.ebi.ac.uk/efo/efo_0003923,GCST005348,29304378,242,Total body bone mineral density
http://www.ebi.ac.uk/efo/efo_0004344,GCST005314,29309628,2,Offspring birth weight
http://www.ebi.ac.uk/efo/efo_0005939,GCST005314,29309628,2,Offspring birth weight
http://www.ebi.ac.uk/efo/efo_0008531,GCST005353,29293525,0,GLP-1-stimulated insulin secretion
http://www.ebi.ac.uk/efo/efo_0008537,GCST005551,29293537,4,Systemic sclerosis (anti-topoisomerase-positive)
http://www.ebi.ac.uk/efo/efo_0008536,GCST005552,29293537,3,Systemic sclerosis (anti-centromere-positive)
http://www.ebi.ac.uk/efo/efo_0000404,GCST005553,29293537,3,Diffuse cutaneous systemic sclerosis
http://www.ebi.ac.uk/efo/efo_1001017,GCST005555,29293537,8,Limited cutaneous systemic scleroderma
http://www.ebi.ac.uk/efo/efo_0000717,GCST005554,29293537,10,Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0008537,GCST005332,29293537,2,Systemic sclerosis (anti-topoisomerase-positive)
http://www.ebi.ac.uk/efo/efo_0008536,GCST005333,29293537,2,Systemic sclerosis (anti-centromere-positive)
http://www.ebi.ac.uk/efo/efo_0000404,GCST005335,29293537,3,Diffuse cutaneous systemic sclerosis
http://www.ebi.ac.uk/efo/efo_1001017,GCST005334,29293537,6,Limited cutaneous systemic scleroderma
http://www.ebi.ac.uk/efo/efo_0000717,GCST005336,29293537,6,Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0005410,GCST005389,29364747,4,Tooth agenesis
http://www.ebi.ac.uk/efo/efo_0005410,GCST005392,29364747,1,Tooth agenesis (maxillary second premolars)
http://www.ebi.ac.uk/efo/efo_0005410,GCST005391,29364747,2,Tooth agenesis (maxillary lateral incisors)
http://www.ebi.ac.uk/efo/efo_0005410,GCST005390,29364747,1,Tooth agenesis (mandibular second premolars)
http://www.ebi.ac.uk/efo/efo_0004994,GCST005277,29354237,0,Lumbar spondylosis (Kellgren-Lawrence grade)
http://www.ebi.ac.uk/efo/efo_0004994,GCST005278,29354237,0,Lumbar spondylosis (presence and severity of osteophytes)
http://www.ebi.ac.uk/efo/efo_0007869,GCST005328,29292387,13,Subjective well-being
http://www.ebi.ac.uk/efo/efo_0007006,GCST005324,29292387,32,Depressive symptoms
http://www.ebi.ac.uk/efo/efo_0006792,GCST005276,29263008,4,Dementia with Lewy bodies
http://www.ebi.ac.uk/efo/efo_0004994,GCST005279,29354237,0,Lumbar spondylosis (disc space narrowing)
http://www.ebi.ac.uk/efo/efo_0007660,GCST005327,29292387,12,Neuroticism
http://www.ebi.ac.uk/efo/efo_0007660,GCST005326,29292387,37,Neuroticism (MTAG)
http://www.ebi.ac.uk/efo/efo_0007869,GCST005325,29292387,49,Subjective well-being (MTAG)
http://www.ebi.ac.uk/efo/efo_0007006,GCST005323,29292387,64,Depressive symptoms (MTAG)
http://www.ebi.ac.uk/efo/efo_1001253,GCST005197,29288229,0,Antiepileptic drug-induced maculopapular exanthema
http://purl.obolibrary.org/obo/go_0036277,GCST005197,29288229,0,Antiepileptic drug-induced maculopapular exanthema
http://www.ebi.ac.uk/efo/efo_1001253,GCST005200,29288229,1,Phenytoin-induced maculopapular exanthema
http://www.ebi.ac.uk/efo/efo_0006345,GCST005200,29288229,1,Phenytoin-induced maculopapular exanthema
http://www.ebi.ac.uk/efo/efo_0007661,GCST005199,29288229,0,Lamotrigine-induced maculopapular exanthema
http://www.ebi.ac.uk/efo/efo_1001253,GCST005199,29288229,0,Lamotrigine-induced maculopapular exanthema
http://www.ebi.ac.uk/efo/efo_1001253,GCST005198,29288229,1,Carbamazepine-induced maculopapular exanthema
http://www.ebi.ac.uk/efo/efo_0008484,GCST005198,29288229,1,Carbamazepine-induced maculopapular exanthema
http://www.ebi.ac.uk/efo/efo_0003095,GCST005190,29271184,2,Nonalcoholic fatty liver disease
http://www.ebi.ac.uk/efo/efo_0004235,GCST005347,29278698,1,Pseudoexfoliation syndrome
http://www.orpha.net/ordo/orphanet_2573,GCST005575,29273593,35,Moyamoya disease
http://www.ebi.ac.uk/efo/efo_0004340,GCST008125,29273807,0,Body mass index
http://www.ebi.ac.uk/efo/efo_0004340,GCST008127,29273807,0,Body mass index
http://www.ebi.ac.uk/efo/efo_0004340,GCST008126,29273807,0,Body mass index
http://www.ebi.ac.uk/efo/efo_0004340,GCST008124,29273807,0,Body mass index
http://www.ebi.ac.uk/efo/efo_0004340,GCST008128,29273807,5,Body mass index
http://www.ebi.ac.uk/efo/efo_0004340,GCST008129,29273807,92,Body mass index
http://www.ebi.ac.uk/efo/efo_0000270,GCST006862,29273806,24,Asthma
http://www.ebi.ac.uk/efo/efo_0004591,GCST005213,29273806,5,Asthma (childhood onset)
http://www.ebi.ac.uk/efo/efo_0000270,GCST005212,29273806,40,Asthma
http://www.ebi.ac.uk/efo/efo_0000378,GCST005172,29263402,2,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_0007998,GCST007013,29274321,6,Hippocampal volume in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0005035,GCST007013,29274321,6,Hippocampal volume in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0004670,GCST007012,29274321,6,Cerebrospinal fluid AB1-42 levels
http://www.ebi.ac.uk/efo/efo_0004874,GCST007006,29274321,17,Logical memory (delayed recall) in normal cognition
http://www.ebi.ac.uk/efo/efo_0007998,GCST006996,29274321,4,Cerebrospinal AB1-42 levels in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0004670,GCST006996,29274321,4,Cerebrospinal AB1-42 levels in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0004874,GCST007011,29274321,4,Logical memory (immediate recall)
http://www.ebi.ac.uk/efo/efo_0004874,GCST007010,29274321,4,Logical memory (delayed recall)
http://www.ebi.ac.uk/efo/efo_0005035,GCST007009,29274321,8,Hippocampal volume
http://www.ebi.ac.uk/efo/efo_0004763,GCST007008,29274321,6,Cerebrospinal fluid p-tau levels
http://www.ebi.ac.uk/efo/efo_0004760,GCST007007,29274321,4,Cerebrospinal fluid t-tau levels
http://www.ebi.ac.uk/efo/efo_0004874,GCST007005,29274321,9,Logical memory (immediate recall) in normal cognition
http://www.ebi.ac.uk/efo/efo_0005035,GCST007004,29274321,2,Hippocampal volume in normal cognition
http://www.ebi.ac.uk/efo/efo_0004763,GCST007003,29274321,3,Cerebrospinal fluid p-tau levels in normal cognition
http://www.ebi.ac.uk/efo/efo_0004760,GCST007002,29274321,7,Cerebrospinal fluid t-tau levels in normal cognition
http://www.ebi.ac.uk/efo/efo_0004670,GCST007001,29274321,16,Cerebrospinal AB1-42 levels in normal cognition
http://www.ebi.ac.uk/efo/efo_0007998,GCST007000,29274321,5,Logical memory (delayed recall) in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0004874,GCST007000,29274321,5,Logical memory (delayed recall) in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0007998,GCST006999,29274321,5,Logical memory (immediate recall) in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0004874,GCST006999,29274321,5,Logical memory (immediate recall) in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0007998,GCST006998,29274321,7,Cerebrospinal fluid p-tau levels in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0004760,GCST006998,29274321,7,Cerebrospinal fluid p-tau levels in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0007998,GCST006997,29274321,3,Cerebrospinal fluid t-tau levels in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0004760,GCST006997,29274321,3,Cerebrospinal fluid t-tau levels in mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0000249,GCST006995,29274321,2,Logical memory (delayed recall) in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0004874,GCST006995,29274321,2,Logical memory (delayed recall) in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0000249,GCST006994,29274321,4,Logical memory (immediate recall) in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0004874,GCST006994,29274321,4,Logical memory (immediate recall) in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0000249,GCST006993,29274321,15,Hippocampal volume in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0005035,GCST006993,29274321,15,Hippocampal volume in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0000249,GCST006992,29274321,4,Cerebrospinal fluid p-tau levels in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0004763,GCST006992,29274321,4,Cerebrospinal fluid p-tau levels in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0000249,GCST006991,29274321,3,Cerebrospinal fluid t-tau levels in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0004760,GCST006991,29274321,3,Cerebrospinal fluid t-tau levels in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0000249,GCST006990,29274321,3,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0004670,GCST006990,29274321,3,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0008474,GCST005214,29266176,4,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_0007965,GCST005214,29266176,4,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_0000220,GCST005214,29266176,4,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_1002029,GCST005268,29253858,2,Chronic rhinosinusitis with nasal polyps
http://www.ebi.ac.uk/efo/efo_0007660,GCST005232,29255261,166,Neuroticism
http://www.ebi.ac.uk/efo/efo_0003761,GCST006174,29505938,0,Depressive symptoms
http://www.ebi.ac.uk/efo/efo_0008165,GCST005177,29253144,0,Rubella-specific interferon-gamma secretion
http://www.ebi.ac.uk/efo/efo_0004645,GCST005177,29253144,0,Rubella-specific interferon-gamma secretion
http://www.ebi.ac.uk/efo/efo_0003923,GCST006130,29240982,2,Pediatric areal bone mineral density (concordant skeletal phenotype)
http://www.ebi.ac.uk/efo/efo_0003923,GCST006129,29240982,2,Pediatric areal bone mineral density (spine vs radius & hip discordant skeletal phenotype)
http://www.ebi.ac.uk/efo/efo_0003923,GCST006247,29240982,4,Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype)
http://www.ebi.ac.uk/efo/efo_0004810,GCST005176,29253144,1,Rubella-specific interleukin-6 secretion
http://www.ebi.ac.uk/efo/efo_0004645,GCST005176,29253144,1,Rubella-specific interleukin-6 secretion
http://www.ebi.ac.uk/efo/efo_0004695,GCST005170,29235454,56,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0008476,GCST005248,29230059,1,Delayed reward discounting
http://www.ebi.ac.uk/efo/efo_0004723,GCST005173,29221444,84,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005173,29221444,84,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004723,GCST005175,29221444,68,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005175,29221444,68,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004723,GCST005174,29221444,53,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST005174,29221444,53,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0008486,GCST005247,29217827,2,Male sexual orientation
http://www.ebi.ac.uk/efo/efo_0006336,GCST005169,29208002,6,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0000378,GCST005196,29212778,254,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_0000378,GCST005195,29212778,148,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_0006340,GCST005203,29212900,0,Mean arterial pressure (dietary potassium intake interaction)
http://www.ebi.ac.uk/efo/efo_0008470,GCST005203,29212900,0,Mean arterial pressure (dietary potassium intake interaction)
http://www.ebi.ac.uk/efo/efo_0006336,GCST005202,29212900,0,Diastolic blood pressure (dietary potassium intake interaction)
http://www.ebi.ac.uk/efo/efo_0008470,GCST005202,29212900,0,Diastolic blood pressure (dietary potassium intake interaction)
http://www.ebi.ac.uk/efo/efo_0000637,GCST005158,29210060,9,Overall survival in osteosarcoma
http://www.ebi.ac.uk/efo/efo_0000638,GCST005158,29210060,9,Overall survival in osteosarcoma
http://www.ebi.ac.uk/efo/efo_0007824,GCST005191,29220522,11,Hair shape
http://www.ebi.ac.uk/efo/efo_0000378,GCST005194,29212778,259,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_0006335,GCST005168,29208002,6,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004682,GCST005171,29213071,62,QT interval
http://www.ebi.ac.uk/efo/efo_0008541,GCST005364,29207912,2,Opioid requirements during laparoscopic-assisted colectomy
http://www.ebi.ac.uk/efo/efo_0008544,GCST005364,29207912,2,Opioid requirements during laparoscopic-assisted colectomy
http://www.ebi.ac.uk/efo/efo_0006335,GCST005204,29212900,1,Systolic blood pressure (dietary potassium intake interaction)
http://www.ebi.ac.uk/efo/efo_0008470,GCST005204,29212900,1,Systolic blood pressure (dietary potassium intake interaction)
http://www.ebi.ac.uk/efo/efo_0005763,GCST005201,29212900,0,Pulse pressure (dietary potassium intake interaction)
http://www.ebi.ac.uk/efo/efo_0008470,GCST005201,29212900,0,Pulse pressure (dietary potassium intake interaction)
http://www.ebi.ac.uk/efo/efo_0004860,GCST005182,29206233,13,Common carotid intima-media thickness in HIV negative individuals
http://www.ebi.ac.uk/efo/efo_0004860,GCST005183,29206233,10,Common carotid intima-media thickness
http://www.ebi.ac.uk/efo/efo_0004860,GCST005184,29206233,12,Common carotid intima-media thickness in HIV infection
http://www.ebi.ac.uk/efo/efo_0000764,GCST005184,29206233,12,Common carotid intima-media thickness in HIV infection
http://www.ebi.ac.uk/efo/efo_0003888,GCST005361,29325848,0,Attention deficit hyperactivity disorder (sex interaction)
http://www.ebi.ac.uk/efo/efo_0008343,GCST005361,29325848,0,Attention deficit hyperactivity disorder (sex interaction)
http://www.ebi.ac.uk/efo/efo_0003888,GCST005362,29325848,20,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_1000764,GCST005655,29203360,12,Seborrheic dermatitis
http://www.ebi.ac.uk/efo/efo_0003888,GCST005363,29325848,0,Sex difference in attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0005951,GCST005363,29325848,0,Sex difference in attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0004708,GCST005211,29196614,9,Nodular sclerosis Hodgkin lymphoma
http://www.ebi.ac.uk/efo/efo_0007796,GCST006702,29227965,8,Parental longevity (combined parental age at death)
http://www.ebi.ac.uk/efo/efo_0007796,GCST006701,29227965,17,Parental longevity (father's attained age)
http://www.ebi.ac.uk/efo/efo_0007796,GCST006700,29227965,5,Parental longevity (father's age at death)
http://www.ebi.ac.uk/efo/efo_0007796,GCST006696,29227965,8,Parental longevity (mother's attained age)
http://www.ebi.ac.uk/efo/efo_0007796,GCST006699,29227965,3,Parental longevity (mother's age at death)
http://www.ebi.ac.uk/efo/efo_0007796,GCST006698,29227965,9,Parental longevity (both parents in top 10%)
http://www.ebi.ac.uk/efo/efo_0007796,GCST006697,29227965,38,"Parental longevity (combined parental attained age, Martingale residuals)"
http://www.ebi.ac.uk/efo/efo_0006920,GCST005206,29237677,1,B-type natriuretic peptide levels
http://www.ebi.ac.uk/efo/efo_0008467,GCST005246,29251981,9,Inhibitory control
http://www.ebi.ac.uk/efo/efo_0008466,GCST005187,29212897,2,Matrix metalloproteinase-8 levels
http://www.ebi.ac.uk/efo/efo_0004745,GCST005205,29237677,2,N-terminal pro B-type natriuretic peptide levels
http://www.ebi.ac.uk/efo/efo_0008468,GCST005207,29237677,2,Midregional pro atrial natriuretic peptide levels
http://www.ebi.ac.uk/efo/efo_0008469,GCST005208,29237677,4,B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio
http://www.ebi.ac.uk/efo/efo_0000183,GCST005209,29196614,6,Hodgkin's lymphoma
http://www.ebi.ac.uk/efo/efo_1002031,GCST005210,29196614,3,Mixed cellularity Hodgkin lymphoma
http://www.ebi.ac.uk/efo/efo_0007667,GCST005192,29198719,178,Lobe attachment (rater-scored or self-reported)
http://www.ebi.ac.uk/efo/efo_0007667,GCST005193,29198719,19,Lobe attachment (rater scored)
http://www.ebi.ac.uk/efo/efo_0007009,GCST005188,29195075,3,Skin pigmentation
http://www.ebi.ac.uk/efo/efo_0008483,GCST005245,29187748,0,Thalamus volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0006935,GCST005245,29187748,0,Thalamus volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0008487,GCST005286,29187748,1,Lateral ventricle volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0008483,GCST005286,29187748,1,Lateral ventricle volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0008483,GCST005244,29187748,0,Putamen volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0006932,GCST005244,29187748,0,Putamen volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0008483,GCST005243,29187748,0,Hippocampal volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0005035,GCST005243,29187748,0,Hippocampal volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0008483,GCST005239,29187748,0,Amygdala volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0006934,GCST005239,29187748,0,Amygdala volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0006933,GCST005242,29187748,1,Pallidum volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0008483,GCST005242,29187748,1,Pallidum volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0008483,GCST005241,29187748,4,Nucleus accumbens volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0006931,GCST005241,29187748,4,Nucleus accumbens volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0008475,GCST005237,29187730,4,Mood instability
http://www.ebi.ac.uk/efo/efo_0004279,GCST005189,29195075,5,Tanning
http://www.ebi.ac.uk/efo/efo_0008483,GCST005240,29187748,2,Caudate volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0004830,GCST005240,29187748,2,Caudate volume in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0003761,GCST005108,29187746,3,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0008475,GCST005238,29187730,4,Mood instability
http://www.ebi.ac.uk/efo/efo_0002614,GCST006800,29188820,0,Childhood insulin resistance
http://purl.obolibrary.org/obo/go_0070527,GCST008171,29185836,33,Platelet aggregation
http://www.ebi.ac.uk/efo/efo_0004337,GCST005142,29186694,69,Cognitive ability
http://www.ebi.ac.uk/efo/efo_0000482,GCST005900,29423119,1,Survival in endocrine treated breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_1000649,GCST005900,29423119,1,Survival in endocrine treated breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_0007613,GCST005900,29423119,1,Survival in endocrine treated breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_0000482,GCST005901,29423119,2,Survival in breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_1000649,GCST005901,29423119,2,Survival in breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_0004337,GCST005141,29186694,82,Cognitive ability (MTAG)
http://www.ebi.ac.uk/efo/efo_0004784,GCST005141,29186694,82,Cognitive ability (MTAG)
http://www.ebi.ac.uk/efo/efo_0004765,GCST005086,29178545,0,Visceral adipose tissue (sex interaction)
http://www.ebi.ac.uk/efo/efo_0008343,GCST005086,29178545,0,Visceral adipose tissue (sex interaction)
http://www.ebi.ac.uk/efo/efo_0009273,GCST005943,29868224,1,Epstein-Barr virus immune response (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0004765,GCST005085,29178545,0,Visceral adipose tissue
http://www.ebi.ac.uk/efo/efo_0009272,GCST005944,29868224,4,Viral capsid antigen IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0009274,GCST005942,29868224,0,Viral capsid antigen IgG levels
http://www.ebi.ac.uk/efo/efo_0009271,GCST005941,29868224,1,Epstein Barr virus nuclear antigen 1 IgG seropositivity
http://www.ebi.ac.uk/efo/efo_0007790,GCST005963,29868224,2,Epstein Barr virus nuclear antigen 1 IgG levels
http://www.ebi.ac.uk/efo/efo_0004625,GCST005109,29186428,3,Progranulin levels
http://www.ebi.ac.uk/efo/efo_0004765,GCST005087,29178545,0,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004765,GCST005088,29178545,0,Visceral adipose tissue adjusted for BMI (sex interaction)
http://www.ebi.ac.uk/efo/efo_0008343,GCST005088,29178545,0,Visceral adipose tissue adjusted for BMI (sex interaction)
http://www.ebi.ac.uk/efo/efo_0004767,GCST005089,29178545,0,Visceral adipose tissue/subcutaneous adipose tissue ratio
http://www.ebi.ac.uk/efo/efo_0008343,GCST005090,29178545,0,Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction)
http://www.ebi.ac.uk/efo/efo_0004767,GCST005090,29178545,0,Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction)
http://www.ebi.ac.uk/efo/efo_0004766,GCST005091,29178545,6,Subcutaneous adipose tissue
http://www.ebi.ac.uk/efo/efo_0004766,GCST005092,29178545,1,Subcutaneous adipose tissue (sex interaction)
http://www.ebi.ac.uk/efo/efo_0008343,GCST005092,29178545,1,Subcutaneous adipose tissue (sex interaction)
http://www.ebi.ac.uk/efo/efo_0003888,GCST006216,29413154,0,Attention deficit hyperactivity disorder or educational attainment (years of education) (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004784,GCST006216,29413154,0,Attention deficit hyperactivity disorder or educational attainment (years of education) (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000311,GCST005275,29299148,26,Cancer
http://www.ebi.ac.uk/efo/efo_0004541,GCST005145,29170429,7,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0003902,GCST005097,29170203,3,Fractures (vertebral)
http://www.ebi.ac.uk/efo/efo_0008462,GCST005154,29168253,0,Alloimmunization response to pregnancy (HLA class I and II)
http://www.ebi.ac.uk/efo/efo_0008462,GCST005155,29168253,0,Alloimmunization response to pregnancy
http://www.ebi.ac.uk/efo/efo_0008462,GCST005157,29168253,0,Alloimmunization response to pregnancy (HLA class II)
http://www.ebi.ac.uk/efo/efo_0008462,GCST005156,29168253,2,Alloimmunization response to pregnancy (HLA class I)
http://www.ebi.ac.uk/efo/efo_0000714,GCST005106,29158497,0,Breast cancer (survival)
http://www.ebi.ac.uk/efo/efo_0000305,GCST005106,29158497,0,Breast cancer (survival)
http://purl.obolibrary.org/obo/go_0036276,GCST007061,29160301,11,Response to antidepressants (symptom remission)
http://www.ebi.ac.uk/efo/efo_0005658,GCST007060,29160301,8,Response to SSRI (symptom remission)
http://purl.obolibrary.org/obo/go_0036276,GCST007059,29160301,18,Response to antidepressants (symptom improvement)
http://www.ebi.ac.uk/efo/efo_0005658,GCST007042,29160301,0,Response to SSRI (symptom improvement)
http://www.ebi.ac.uk/efo/efo_0005199,GCST005144,29160300,1,Tacrolimus trough concentration in kidney transplant patients
http://www.ebi.ac.uk/efo/efo_0008458,GCST005144,29160300,1,Tacrolimus trough concentration in kidney transplant patients
http://www.ebi.ac.uk/efo/efo_0008451,GCST005117,29158487,0,Activities of daily living score
http://www.ebi.ac.uk/efo/efo_0006941,GCST005122,29158487,0,Hand grip strength
http://www.ebi.ac.uk/efo/efo_0008453,GCST005119,29158487,0,Calf circumference
http://www.ebi.ac.uk/efo/efo_0003926,GCST005123,29158487,0,Cognitive performance
http://www.ebi.ac.uk/efo/efo_0007680,GCST005120,29158487,0,Four meter walk test score
http://www.ebi.ac.uk/efo/efo_0008452,GCST005118,29158487,0,Mid-arm muscle circumference
http://www.ebi.ac.uk/efo/efo_0008454,GCST005121,29158487,0,Short physical performance battery score
http://www.ebi.ac.uk/efo/efo_0004505,GCST005143,29151059,7,Telomere length
http://www.ebi.ac.uk/efo/efo_0004191,GCST005116,29146897,58,Male-pattern baldness
http://www.ebi.ac.uk/efo/efo_0006932,GCST005083,29147026,10,Putamen volume
http://www.ebi.ac.uk/efo/efo_0001073,GCST005114,29145611,0,Osteoporosis or obesity (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0003882,GCST005114,29145611,0,Osteoporosis or obesity (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0009392,GCST006632,29130521,9,Decline in glucose metabolism in posterior cingulate cortex
http://www.ebi.ac.uk/efo/efo_0007738,GCST006632,29130521,9,Decline in glucose metabolism in posterior cingulate cortex
http://www.ebi.ac.uk/efo/efo_0004462,GCST005080,29127183,9,PR interval
http://purl.obolibrary.org/obo/hp_0000175,GCST005079,29124805,0,Orofacial clefts (cleft lip vs. cleft lip and palate)
http://www.orpha.net/ordo/orphanet_139039,GCST005079,29124805,0,Orofacial clefts (cleft lip vs. cleft lip and palate)
http://www.ebi.ac.uk/efo/efo_0003959,GCST005079,29124805,0,Orofacial clefts (cleft lip vs. cleft lip and palate)
http://www.ebi.ac.uk/efo/efo_1001504,GCST005057,29123153,7,Small vessel stroke
http://www.ebi.ac.uk/efo/efo_0004518,GCST007919,29124443,21,Creatinine levels
http://www.ebi.ac.uk/efo/efo_0005208,GCST007917,29124443,20,Estimated glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0004761,GCST007918,29124443,28,Serum uric acid levels
http://www.ebi.ac.uk/efo/efo_0009104,GCST007916,29124443,23,Hyperuricemia
http://www.ebi.ac.uk/efo/efo_0003884,GCST007920,29124443,16,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0000692,GCST005082,29121268,8,Bipolar disorder lithium response (categorical) or schizophrenia
http://www.ebi.ac.uk/efo/efo_0000289,GCST005082,29121268,8,Bipolar disorder lithium response (categorical) or schizophrenia
http://purl.obolibrary.org/obo/go_0010226,GCST005082,29121268,8,Bipolar disorder lithium response (categorical) or schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST005081,29121268,8,Bipolar disorder lithium response (continuous) or schizophrenia
http://www.ebi.ac.uk/efo/efo_0000289,GCST005081,29121268,8,Bipolar disorder lithium response (continuous) or schizophrenia
http://purl.obolibrary.org/obo/go_0010226,GCST005081,29121268,8,Bipolar disorder lithium response (continuous) or schizophrenia
http://www.ebi.ac.uk/efo/efo_1001930,GCST005048,29118346,2,Idiopathic osteonecrosis of the femoral head
http://www.ebi.ac.uk/efo/efo_0008457,GCST005128,29112194,7,Cannabis dependence symptom count
http://www.ebi.ac.uk/efo/efo_0007191,GCST005133,29112194,1,Cannabis dependence
http://www.ebi.ac.uk/efo/efo_0004270,GCST005107,29209388,0,Restless legs syndrome
http://www.ebi.ac.uk/efo/efo_0007536,GCST005044,29097723,1,Primary vesicoureteric reflux
http://www.ebi.ac.uk/efo/efo_0007536,GCST005045,29097723,0,Primary vesicoureteric reflux
http://www.ebi.ac.uk/efo/efo_0004325,GCST005039,29097388,2,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)
http://www.ebi.ac.uk/efo/efo_0007981,GCST005039,29097388,2,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)
http://www.ebi.ac.uk/efo/efo_0007766,GCST005039,29097388,2,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)
http://www.ebi.ac.uk/efo/efo_0007765,GCST005669,29246731,1,Delta-6 desaturase activity response to n3-polyunsaturated fat supplement
http://www.ebi.ac.uk/efo/efo_0009131,GCST005669,29246731,1,Delta-6 desaturase activity response to n3-polyunsaturated fat supplement
http://www.ebi.ac.uk/efo/efo_0007764,GCST005668,29246731,6,Delta-5 desaturase activity response to n3-polyunsaturated fat supplement
http://www.ebi.ac.uk/efo/efo_0009131,GCST005668,29246731,6,Delta-5 desaturase activity response to n3-polyunsaturated fat supplement
http://www.ebi.ac.uk/efo/efo_0003949,GCST005093,29109912,9,Iris color (a* coordinate)
http://www.ebi.ac.uk/efo/efo_0003949,GCST005094,29109912,14,Iris color (L* coordinate)
http://www.ebi.ac.uk/efo/efo_0006336,GCST005041,29097388,3,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
http://www.ebi.ac.uk/efo/efo_0007981,GCST005041,29097388,3,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
http://www.ebi.ac.uk/efo/efo_0007766,GCST005041,29097388,3,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
http://www.ebi.ac.uk/efo/efo_0006335,GCST005040,29097388,1,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
http://www.ebi.ac.uk/efo/efo_0007981,GCST005040,29097388,1,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
http://www.ebi.ac.uk/efo/efo_0007766,GCST005040,29097388,1,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
http://www.ebi.ac.uk/efo/efo_0007009,GCST005084,29109912,0,Skin pigmentation
http://www.ebi.ac.uk/efo/efo_0008463,GCST005163,29093273,2,Glucagon levels in response to oral glucose tolerance test (120 minutes)
http://www.ebi.ac.uk/efo/efo_0004307,GCST005163,29093273,2,Glucagon levels in response to oral glucose tolerance test (120 minutes)
http://www.ebi.ac.uk/efo/efo_0008464,GCST005166,29093273,12,GIP levels in response to oral glucose tolerance test (120 minutes)
http://www.ebi.ac.uk/efo/efo_0004307,GCST005166,29093273,12,GIP levels in response to oral glucose tolerance test (120 minutes)
http://www.ebi.ac.uk/efo/efo_0008465,GCST005165,29093273,1,GLP-1 levels in response to oral glucose tolerance test (120 minutes)
http://www.ebi.ac.uk/efo/efo_0004307,GCST005165,29093273,1,GLP-1 levels in response to oral glucose tolerance test (120 minutes)
http://www.ebi.ac.uk/efo/efo_0004467,GCST005161,29093273,1,Insulin levels in response to oral glucose tolerance test (120 minutes)
http://www.ebi.ac.uk/efo/efo_0004307,GCST005161,29093273,1,Insulin levels in response to oral glucose tolerance test (120 minutes)
http://www.ebi.ac.uk/efo/efo_0004467,GCST005160,29093273,3,Insulin levels in response to oral glucose tolerance test (30 minutes)
http://www.ebi.ac.uk/efo/efo_0004307,GCST005160,29093273,3,Insulin levels in response to oral glucose tolerance test (30 minutes)
http://www.ebi.ac.uk/efo/efo_0008465,GCST005164,29093273,4,GLP-1 levels in response to oral glucose tolerance test (fasting)
http://www.ebi.ac.uk/efo/efo_0004307,GCST005164,29093273,4,GLP-1 levels in response to oral glucose tolerance test (fasting)
http://www.ebi.ac.uk/efo/efo_0008464,GCST005167,29093273,2,GIP levels in response to oral glucose tolerance test (fasting)
http://www.ebi.ac.uk/efo/efo_0004307,GCST005167,29093273,2,GIP levels in response to oral glucose tolerance test (fasting)
http://www.ebi.ac.uk/efo/efo_0008463,GCST005162,29093273,4,Glucagon levels in response to oral glucose tolerance test (fasting)
http://www.ebi.ac.uk/efo/efo_0004307,GCST005162,29093273,4,Glucagon levels in response to oral glucose tolerance test (fasting)
http://www.ebi.ac.uk/efo/efo_0003949,GCST005095,29109912,6,Iris heterochromicity
http://www.ebi.ac.uk/efo/efo_0003949,GCST005096,29109912,7,Iris color (b* coordinate)
http://www.ebi.ac.uk/efo/efo_0004467,GCST005159,29093273,1,Insulin levels in response to oral glucose tolerance test (fasting)
http://www.ebi.ac.uk/efo/efo_0004307,GCST005159,29093273,1,Insulin levels in response to oral glucose tolerance test (fasting)
http://www.ebi.ac.uk/efo/efo_0000660,GCST005043,29104669,0,Polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0008447,GCST005053,29066854,0,Neutrophil-to-lymphocyte ratio
http://www.ebi.ac.uk/efo/efo_0004309,GCST005054,29066854,5,Platelet count
http://www.ebi.ac.uk/efo/efo_0004587,GCST005055,29066854,0,Lymphocyte counts
http://www.ebi.ac.uk/efo/efo_0004833,GCST005056,29066854,1,Neutrophil count
http://www.ebi.ac.uk/efo/efo_0008446,GCST005052,29066854,0,Platelet-to-lymphocyte ratio
http://www.ebi.ac.uk/efo/efo_0004713,GCST005130,29095316,0,Lung function (FEV1/FVC)
http://www.ebi.ac.uk/efo/efo_0004312,GCST005131,29095316,2,Lung function (forced vital capacity)
http://www.ebi.ac.uk/efo/efo_0004313,GCST005129,29095316,0,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity)
http://www.ebi.ac.uk/efo/efo_0004270,GCST005042,29029846,20,Restless legs syndrome
http://www.ebi.ac.uk/efo/efo_0004845,GCST005125,29093028,1,Serum magnesium levels
http://www.ebi.ac.uk/efo/efo_0008450,GCST005126,29093028,0,Fractional excretion of magnesium
http://www.ebi.ac.uk/efo/efo_0000305,GCST005111,29059430,5,Breast cancer in childhood cancer survivors
http://www.ebi.ac.uk/efo/efo_1000654,GCST005111,29059430,5,Breast cancer in childhood cancer survivors
http://purl.obolibrary.org/obo/go_0009314,GCST005112,29059430,3,Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy
http://www.ebi.ac.uk/efo/efo_0000305,GCST005112,29059430,3,Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy
http://www.ebi.ac.uk/efo/efo_1000654,GCST005112,29059430,3,Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy
http://www.ebi.ac.uk/efo/efo_0000305,GCST005110,29059430,3,Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy
http://www.ebi.ac.uk/efo/efo_1000654,GCST005110,29059430,3,Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy
http://www.ebi.ac.uk/efo/efo_0004314,GCST005132,29095316,2,Lung function (forced expiratory volume in 1 second)
http://www.ebi.ac.uk/efo/efo_0008449,GCST005124,29093028,2,Urinary magnesium-to-creatinine ratio
http://www.ebi.ac.uk/efo/efo_0008431,GCST005127,29095316,3,Lung function (maximal voluntary ventilation)
http://www.ebi.ac.uk/efo/efo_0003892,GCST005127,29095316,3,Lung function (maximal voluntary ventilation)
http://www.ebi.ac.uk/efo/efo_0008483,GCST005236,29082582,5,Problematic alcohol use in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0007835,GCST005236,29082582,5,Problematic alcohol use in trauma-exposed individuals
http://www.ebi.ac.uk/efo/efo_0004614,GCST005513,29084231,12,Apolipoprotein A1 levels
http://www.ebi.ac.uk/efo/efo_0008596,GCST005512,29084231,1,Triglyceride levels in chylomicrons and largest VLDL
http://www.ebi.ac.uk/efo/efo_0004530,GCST005512,29084231,1,Triglyceride levels in chylomicrons and largest VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005512,29084231,1,Triglyceride levels in chylomicrons and largest VLDL
http://www.ebi.ac.uk/efo/efo_0008596,GCST005511,29084231,3,Phospholipid levels in chylomicrons and largest VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005511,29084231,3,Phospholipid levels in chylomicrons and largest VLDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005511,29084231,3,Phospholipid levels in chylomicrons and largest VLDL
http://www.ebi.ac.uk/efo/efo_0008596,GCST005510,29084231,2,Chylomicron and largest VLDL particle concentration
http://www.ebi.ac.uk/efo/efo_0008317,GCST005510,29084231,2,Chylomicron and largest VLDL particle concentration
http://www.ebi.ac.uk/efo/efo_0004530,GCST005509,29084231,3,Triglyceride levels in small HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005509,29084231,3,Triglyceride levels in small HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005508,29084231,2,Small HDL particle concentration
http://www.ebi.ac.uk/efo/efo_0004612,GCST005507,29084231,6,Free cholesterol levels in medium HDL
http://www.ebi.ac.uk/efo/efo_0008589,GCST005506,29084231,5,Cholesterol ester levels in medium HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005506,29084231,5,Cholesterol ester levels in medium HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005505,29084231,5,Total cholesterol levels in medium HDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005504,29084231,17,Phospholipid levels in medium HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005504,29084231,17,Phospholipid levels in medium HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005503,29084231,11,Medium HDL particle concentration
http://www.ebi.ac.uk/efo/efo_0008591,GCST005502,29084231,5,Free cholesterol levels in large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005502,29084231,5,Free cholesterol levels in large HDL
http://www.ebi.ac.uk/efo/efo_0008589,GCST005501,29084231,3,Cholesterol ester levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005501,29084231,3,Cholesterol ester levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005500,29084231,3,Total cholesterol levels in large HDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005499,29084231,19,Phospholipid levels in large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005499,29084231,19,Phospholipid levels in large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005497,29084231,15,Large HDL particle concentration
http://www.ebi.ac.uk/efo/efo_0004530,GCST005498,29084231,19,Triglyceride levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005498,29084231,19,Triglyceride levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0008591,GCST005496,29084231,2,Free cholesterol levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005496,29084231,2,Free cholesterol levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0008589,GCST005495,29084231,0,Cholesterol ester levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005495,29084231,0,Cholesterol ester levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005494,29084231,0,Total cholesterol levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005493,29084231,0,Phospholipid levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005493,29084231,0,Phospholipid levels in very large HDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005492,29084231,2,Very large HDL particle concentration
http://www.ebi.ac.uk/efo/efo_0004611,GCST005491,29084231,22,Total cholesterol levels in small LDL
http://www.ebi.ac.uk/efo/efo_0004611,GCST005490,29084231,26,Small LDL particle concentration
http://www.ebi.ac.uk/efo/efo_0008589,GCST005489,29084231,9,Cholesterol ester levels in medium LDL
http://www.ebi.ac.uk/efo/efo_0004611,GCST005489,29084231,9,Cholesterol ester levels in medium LDL
http://www.ebi.ac.uk/efo/efo_0004611,GCST005488,29084231,8,Total cholesterol levels in medium LDL
http://www.ebi.ac.uk/efo/efo_0004611,GCST005487,29084231,1,Phospholipid levels in medium LDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005487,29084231,1,Phospholipid levels in medium LDL
http://www.ebi.ac.uk/efo/efo_0004611,GCST005486,29084231,8,Medium LDL particle concentration
http://www.ebi.ac.uk/efo/efo_0008591,GCST005485,29084231,12,Free cholesterol levels in large LDL
http://www.ebi.ac.uk/efo/efo_0004611,GCST005485,29084231,12,Free cholesterol levels in large LDL
http://www.ebi.ac.uk/efo/efo_0008589,GCST005484,29084231,6,Cholesterol ester levels in large LDL
http://www.ebi.ac.uk/efo/efo_0004611,GCST005484,29084231,6,Cholesterol ester levels in large LDL
http://www.ebi.ac.uk/efo/efo_0004611,GCST005483,29084231,8,Total cholesterol levels in large LDL
http://www.ebi.ac.uk/efo/efo_0004611,GCST005482,29084231,0,Phospholipid levels in large LDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005482,29084231,0,Phospholipid levels in large LDL
http://www.ebi.ac.uk/efo/efo_0004611,GCST005481,29084231,7,Large LDL particle concentration
http://www.ebi.ac.uk/efo/efo_0004530,GCST005480,29084231,10,Triglyceride levels in IDL
http://www.ebi.ac.uk/efo/efo_0008595,GCST005480,29084231,10,Triglyceride levels in IDL
http://www.ebi.ac.uk/efo/efo_0008591,GCST005479,29084231,9,Free cholesterol levels in IDL
http://www.ebi.ac.uk/efo/efo_0008595,GCST005479,29084231,9,Free cholesterol levels in IDL
http://www.ebi.ac.uk/efo/efo_0008595,GCST005478,29084231,8,IDL particle concentration
http://www.ebi.ac.uk/efo/efo_0004639,GCST005477,29084231,0,Phospholipid levels in IDL
http://www.ebi.ac.uk/efo/efo_0008595,GCST005477,29084231,0,Phospholipid levels in IDL
http://www.ebi.ac.uk/efo/efo_0008595,GCST005476,29084231,1,IDL particle concentration
http://www.ebi.ac.uk/efo/efo_0004530,GCST005475,29084231,11,Triglyceride levels in very small VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005475,29084231,11,Triglyceride levels in very small VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005474,29084231,3,Phospholipid levels in very small VLDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005474,29084231,3,Phospholipid levels in very small VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005473,29084231,4,Very small VLDL particle concentration
http://www.ebi.ac.uk/efo/efo_0004530,GCST005472,29084231,30,Triglyceride levels in small VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005472,29084231,30,Triglyceride levels in small VLDL
http://www.ebi.ac.uk/efo/efo_0008591,GCST005471,29084231,1,Free cholesterol levels in small VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005471,29084231,1,Free cholesterol levels in small VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005470,29084231,1,Total cholesterol levels in small VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005469,29084231,24,Phospholipid levels in small VLDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005469,29084231,24,Phospholipid levels in small VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005468,29084231,25,Small VLDL particle concentration
http://www.ebi.ac.uk/efo/efo_0004530,GCST005467,29084231,26,Triglyceride levels in medium VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005467,29084231,26,Triglyceride levels in medium VLDL
http://www.ebi.ac.uk/efo/efo_0008591,GCST005466,29084231,22,Free cholesterol levels in medium VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005466,29084231,22,Free cholesterol levels in medium VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005465,29084231,2,Cholesterol ester levels in medium VLDL
http://www.ebi.ac.uk/efo/efo_0008589,GCST005465,29084231,2,Cholesterol ester levels in medium VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005464,29084231,19,Total cholesterol levels in medium VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005463,29084231,24,Phospholipid levels in medium VLDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005463,29084231,24,Phospholipid levels in medium VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005462,29084231,24,Medium VLDL particle concentration
http://www.ebi.ac.uk/efo/efo_0008317,GCST005461,29084231,0,Cholesterol ester levels in large VLDL
http://www.ebi.ac.uk/efo/efo_0008589,GCST005461,29084231,0,Cholesterol ester levels in large VLDL
http://www.ebi.ac.uk/efo/efo_0004530,GCST005460,29084231,20,Triglyceride levels in large VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005460,29084231,20,Triglyceride levels in large VLDL
http://www.ebi.ac.uk/efo/efo_0008591,GCST005459,29084231,0,Free cholesterol levels in large VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005459,29084231,0,Free cholesterol levels in large VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005458,29084231,0,Total cholesterol levels in large VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005454,29084231,18,Phospholipid levels in large VLDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005454,29084231,18,Phospholipid levels in large VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005453,29084231,21,Very large VLDL particle concentration
http://www.ebi.ac.uk/efo/efo_0004530,GCST005452,29084231,4,Triglyceride levels in very large VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005452,29084231,4,Triglyceride levels in very large VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005451,29084231,2,Phospholipid levels in very large VLDL
http://www.ebi.ac.uk/efo/efo_0004639,GCST005451,29084231,2,Phospholipid levels in very large VLDL
http://www.ebi.ac.uk/efo/efo_0008317,GCST005450,29084231,4,Very large VLDL particle concentration
http://www.ebi.ac.uk/efo/efo_0008594,GCST005457,29084231,1,Mean diameter of VLDL particles
http://www.ebi.ac.uk/efo/efo_0008593,GCST005456,29084231,12,Mean diameter of LDL particles
http://www.ebi.ac.uk/efo/efo_0008592,GCST005455,29084231,17,Mean diameter of HDL particles
http://www.ebi.ac.uk/efo/efo_0004530,GCST005449,29084231,54,Total triglycerides levels
http://www.ebi.ac.uk/efo/efo_0004574,GCST005448,29084231,58,Serum total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST005447,29084231,53,Total cholesterol levels in LDL
http://www.ebi.ac.uk/efo/efo_0004612,GCST005446,29084231,37,Total cholesterol levels in HDL
http://www.ebi.ac.uk/efo/efo_0008591,GCST005445,29084231,7,Free cholesterol levels
http://www.ebi.ac.uk/efo/efo_0008589,GCST005444,29084231,7,Esterified cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004614,GCST005443,29084231,4,Ratio of apolipoprotein A1 to apolipoprotein B
http://www.ebi.ac.uk/efo/efo_0004615,GCST005443,29084231,4,Ratio of apolipoprotein A1 to apolipoprotein B
http://www.ebi.ac.uk/efo/efo_0004615,GCST005442,29084231,5,Apolipoprotein B levels
http://www.ebi.ac.uk/efo/efo_0003785,GCST005038,29083406,136,"Allergic disease (asthma, hay fever or eczema)"
http://www.ebi.ac.uk/efo/efo_0007817,GCST005051,29077507,31,Obstructive sleep apnea trait (apnea hypopnea index)
http://www.ebi.ac.uk/efo/efo_0008455,GCST005050,29077507,7,Obstructive sleep apnea during REM sleep (apnea hypopnea index)
http://www.ebi.ac.uk/efo/efo_0008456,GCST005049,29077507,0,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
http://www.ebi.ac.uk/efo/efo_0000249,GCST006121,29107063,1,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000249,GCST006120,29107063,1,Alzheimer's disease (age of onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST006120,29107063,1,Alzheimer's disease (age of onset)
http://www.ebi.ac.uk/efo/efo_0008459,GCST005115,29229094,2,Response to mepolizumab in severe asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST005115,29229094,2,Response to mepolizumab in severe asthma
http://www.ebi.ac.uk/efo/efo_0003761,GCST005022,29071344,47,Major depression and alcohol dependence
http://www.ebi.ac.uk/efo/efo_0003829,GCST005022,29071344,47,Major depression and alcohol dependence
http://www.ebi.ac.uk/efo/efo_0000685,GCST004998,29065906,2,Severe progression in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0008336,GCST004998,29065906,2,Severe progression in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000692,GCST005028,29064472,11,Pursuit maintenance gain in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0008433,GCST005028,29064472,11,Pursuit maintenance gain in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0000289,GCST005028,29064472,11,Pursuit maintenance gain in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0005411,GCST005028,29064472,11,Pursuit maintenance gain in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0006874,GCST005027,29064472,3,Anti-saccade error rate in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0000692,GCST005027,29064472,3,Anti-saccade error rate in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0000289,GCST005027,29064472,3,Anti-saccade error rate in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0005411,GCST005027,29064472,3,Anti-saccade error rate in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0000692,GCST005026,29064472,22,Initial pursuit acceleration in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0008434,GCST005026,29064472,22,Initial pursuit acceleration in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0000289,GCST005026,29064472,22,Initial pursuit acceleration in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0005411,GCST005026,29064472,22,Initial pursuit acceleration in psychotic disorders
http://www.ebi.ac.uk/efo/efo_0008438,GCST005035,29065852,0,Fasting growth hormone levels
http://www.ebi.ac.uk/efo/efo_0006874,GCST005025,29064472,41,Anti-saccade response
http://www.ebi.ac.uk/efo/efo_0008433,GCST005024,29064472,111,Pursuit maintenance gain
http://www.ebi.ac.uk/efo/efo_0008434,GCST005023,29064472,56,Initial pursuit acceleration
http://www.ebi.ac.uk/efo/efo_0000305,GCST004988,29059683,803,Breast cancer
http://www.ebi.ac.uk/efo/efo_0000692,GCST004987,29064910,34,Antipsychotic drug-induced QTc interval change in schizophrenia
http://www.ebi.ac.uk/efo/efo_0008003,GCST004987,29064910,34,Antipsychotic drug-induced QTc interval change in schizophrenia
http://purl.obolibrary.org/obo/go_0097332,GCST004987,29064910,34,Antipsychotic drug-induced QTc interval change in schizophrenia
http://www.ebi.ac.uk/efo/efo_0006945,GCST004985,29058489,0,White coat effect (clinic diastolic blood pressure minus home diastolic blood pressure)
http://www.ebi.ac.uk/efo/efo_0007658,GCST005075,29058716,10,Breast Cancer in BRCA1 mutation carriers
http://www.ebi.ac.uk/efo/efo_0000305,GCST005075,29058716,10,Breast Cancer in BRCA1 mutation carriers
http://www.ebi.ac.uk/efo/efo_0000305,GCST005077,29058716,10,Breast cancer
http://www.ebi.ac.uk/efo/efo_0003819,GCST004989,29057527,0,Early childhood caries
http://www.ebi.ac.uk/efo/efo_0007878,GCST004990,29058377,5,Alcohol consumption over the past year
http://www.ebi.ac.uk/efo/efo_0006944,GCST004984,29058489,0,White coat effect (clinic systolic blood pressure minus home systolic blood pressure)
http://www.ebi.ac.uk/efo/efo_1000650,GCST005076,29058716,46,Breast cancer (estrogen-receptor negative)
http://www.ebi.ac.uk/efo/efo_0007019,GCST004978,29051540,0,Cow's milk allergy
http://www.ebi.ac.uk/efo/efo_0004318,GCST005911,29059373,0,Smoking interaction in squamous cell lung cancer (1df test)
http://www.ebi.ac.uk/efo/efo_0000708,GCST005911,29059373,0,Smoking interaction in squamous cell lung cancer (1df test)
http://www.ebi.ac.uk/efo/efo_0004318,GCST005909,29059373,0,Smoking interaction in lung adenocarcinoma (1df test)
http://www.ebi.ac.uk/efo/efo_0000571,GCST005909,29059373,0,Smoking interaction in lung adenocarcinoma (1df test)
http://www.ebi.ac.uk/efo/efo_0007018,GCST004977,29051540,2,Hen's egg allergy
http://www.ebi.ac.uk/efo/efo_0007017,GCST004980,29051540,1,Peanut allergy
http://www.ebi.ac.uk/efo/efo_0007016,GCST004979,29051540,2,Food allergy
http://www.ebi.ac.uk/efo/efo_0000768,GCST004986,29066090,8,Idiopathic pulmonary fibrosis
http://www.ebi.ac.uk/efo/efo_0004318,GCST005910,29059373,0,Smoking interaction in non-small cell lung cancer (1df test)
http://www.ebi.ac.uk/efo/efo_0003060,GCST005910,29059373,0,Smoking interaction in non-small cell lung cancer (1df test)
http://www.ebi.ac.uk/efo/efo_0006943,GCST007577,29045471,0,Blood pressure (parental or offspring effect)
http://www.ebi.ac.uk/efo/efo_0005423,GCST004981,29016859,1,Curve progression in adolescent idiopathic scoliosis
http://www.ebi.ac.uk/efo/efo_0008336,GCST004981,29016859,1,Curve progression in adolescent idiopathic scoliosis
http://www.ebi.ac.uk/efo/efo_0007796,GCST004983,29030599,5,Parental lifespan
http://www.ebi.ac.uk/efo/efo_1001494,GCST006036,29031612,2,Psoriasis vulgaris
http://www.ebi.ac.uk/efo/efo_0007017,GCST006039,29030101,8,Peanut allergy
http://www.ebi.ac.uk/efo/efo_0007016,GCST006038,29030101,6,Food allergy
http://www.ebi.ac.uk/efo/efo_0005112,GCST004951,29018042,0,Post-term birth
http://www.ebi.ac.uk/efo/efo_0005842,GCST005148,29228715,6,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0008435,GCST005033,28990592,0,Gestational weight gain (maternal effect)
http://www.ebi.ac.uk/efo/efo_0008436,GCST005034,28990592,0,Late gestational weight gain (maternal effect)
http://www.ebi.ac.uk/efo/efo_0008437,GCST005029,28990592,0,Early gestation weight gain (maternal effect)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004946,28991256,222,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0003829,GCST004955,28990359,4,Risky sexual behaviors in alcohol dependence
http://www.ebi.ac.uk/efo/efo_0007877,GCST004955,28990359,4,Risky sexual behaviors in alcohol dependence
http://www.ebi.ac.uk/efo/efo_0008460,GCST005147,29228715,131,Colonoscopy-negative controls vs population controls
http://www.ebi.ac.uk/efo/efo_0005406,GCST005153,29228715,9,Colorectal adenoma (advanced)
http://www.ebi.ac.uk/efo/efo_0005842,GCST005152,29228715,13,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0003829,GCST004956,28990359,7,Risky sexual behaviors (alcohol dependence interaction)
http://www.ebi.ac.uk/efo/efo_0007877,GCST004956,28990359,7,Risky sexual behaviors (alcohol dependence interaction)
http://www.ebi.ac.uk/efo/efo_0007959,GCST005030,28990592,0,Late gestational weight gain (fetal effect)
http://www.ebi.ac.uk/efo/efo_0008436,GCST005030,28990592,0,Late gestational weight gain (fetal effect)
http://www.ebi.ac.uk/efo/efo_0007959,GCST005031,28990592,0,Gestational weight gain (fetal effect)
http://www.ebi.ac.uk/efo/efo_0008435,GCST005031,28990592,0,Gestational weight gain (fetal effect)
http://www.ebi.ac.uk/efo/efo_0008437,GCST005032,28990592,0,Early gestational weight gain (fetal effect)
http://www.ebi.ac.uk/efo/efo_0007959,GCST005032,28990592,0,Early gestational weight gain (fetal effect)
http://www.ebi.ac.uk/efo/efo_0005406,GCST005151,29228715,21,Colorectal adenoma (advanced)
http://www.ebi.ac.uk/efo/efo_0005842,GCST005150,29228715,42,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0005842,GCST005149,29228715,42,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0007490,GCST004945,28983962,0,Lumbar spinal stenosis
http://www.ebi.ac.uk/efo/efo_0007052,GCST004954,28979981,0,Antisocial behavior
http://www.ebi.ac.uk/efo/efo_0007052,GCST006489,28979981,0,Antisocial behavior
http://www.ebi.ac.uk/efo/efo_0007052,GCST006490,28979981,0,Antisocial behavior
http://www.ebi.ac.uk/efo/efo_0002506,GCST005225,28934396,0,Osteoarthritis or lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_0007701,GCST005225,28934396,0,Osteoarthritis or lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_0004616,GCST005224,28934396,0,Knee osteoarthritis or femoral neck bone mineral density
http://www.ebi.ac.uk/efo/efo_0007785,GCST005224,28934396,0,Knee osteoarthritis or femoral neck bone mineral density
http://www.ebi.ac.uk/efo/efo_1000786,GCST005229,28934396,0,Hip osteoarthritis or femoral neck bone mineral density
http://www.ebi.ac.uk/efo/efo_0007785,GCST005229,28934396,0,Hip osteoarthritis or femoral neck bone mineral density
http://www.ebi.ac.uk/efo/efo_0002506,GCST005228,28934396,0,Osteoarthritis or femoral neck bone mineral density
http://www.ebi.ac.uk/efo/efo_0007785,GCST005228,28934396,0,Osteoarthritis or femoral neck bone mineral density
http://www.ebi.ac.uk/efo/efo_0004616,GCST005227,28934396,0,Knee osteoarthritis or lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_0007701,GCST005227,28934396,0,Knee osteoarthritis or lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_1000786,GCST005226,28934396,0,Hip osteoarthritis or lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_0007701,GCST005226,28934396,0,Hip osteoarthritis or lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_0005842,GCST004895,28960316,5,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0005192,GCST006804,28957414,195,Red cell distribution width
http://www.ebi.ac.uk/efo/efo_0003821,GCST004944,28957430,0,Migraine or coronary artery disease
http://www.ebi.ac.uk/efo/efo_0000378,GCST004944,28957430,0,Migraine or coronary artery disease
http://www.ebi.ac.uk/efo/efo_1002021,GCST004952,28957384,42,Ankle injury
http://www.orpha.net/ordo/orphanet_3389,GCST004922,29036319,12,Tuberculosis
http://www.orpha.net/ordo/orphanet_3389,GCST004923,29036319,3,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0003939,GCST006173,28941034,0,BMI x dairy intake interaction (1df interaction test)
http://www.ebi.ac.uk/efo/efo_0004340,GCST006173,28941034,0,BMI x dairy intake interaction (1df interaction test)
http://www.ebi.ac.uk/efo/efo_0001357,GCST004901,28931804,4,Amyotrophic lateral sclerosis (sporadic)
http://www.ebi.ac.uk/efo/efo_0000378,GCST004918,28979897,0,Coronary artery disease severity measurement
http://www.ebi.ac.uk/efo/efo_0008387,GCST004969,28927378,0,Caudate activity during disappointment
http://www.ebi.ac.uk/efo/efo_0008397,GCST004969,28927378,0,Caudate activity during disappointment
http://www.ebi.ac.uk/efo/efo_0007849,GCST004969,28927378,0,Caudate activity during disappointment
http://www.ebi.ac.uk/efo/efo_0008410,GCST005009,28928442,67,Pneumonia
http://www.ebi.ac.uk/efo/efo_0008409,GCST005008,28928442,59,Scarlet fever
http://www.ebi.ac.uk/efo/efo_0008408,GCST005007,28928442,53,Strep throat
http://www.ebi.ac.uk/efo/efo_0008405,GCST005004,28928442,39,Hepatitis B
http://www.ebi.ac.uk/efo/efo_0008403,GCST005002,28928442,44,Mononucleosis
http://www.ebi.ac.uk/efo/efo_0008418,GCST005020,28928442,38,Rubella
http://www.ebi.ac.uk/efo/efo_0007904,GCST005013,28928442,102,Childhood ear infection
http://www.ebi.ac.uk/efo/efo_0007924,GCST005014,28928442,204,Tonsillectomy
http://www.ebi.ac.uk/efo/efo_0008413,GCST005012,28928442,61,Urinary tract infection frequency
http://www.ebi.ac.uk/efo/efo_0008419,GCST005021,28928442,45,Chronic sinus infection
http://www.ebi.ac.uk/efo/efo_0008417,GCST005019,28928442,34,Number of common colds
http://www.ebi.ac.uk/efo/efo_0008416,GCST005018,28928442,24,Rheumatic fever
http://www.ebi.ac.uk/efo/efo_0008415,GCST005017,28928442,36,Hepatitis A
http://www.ebi.ac.uk/efo/efo_0008414,GCST005016,28928442,32,Measles
http://www.ebi.ac.uk/efo/efo_0007904,GCST005015,28928442,34,Myringotomy
http://www.ebi.ac.uk/efo/efo_0008412,GCST005011,28928442,51,Yeast infection
http://www.ebi.ac.uk/efo/efo_0008411,GCST005010,28928442,38,Bacterial meningitis
http://www.ebi.ac.uk/efo/efo_0008407,GCST005006,28928442,67,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0008406,GCST005005,28928442,81,Plantar warts
http://www.ebi.ac.uk/efo/efo_0008404,GCST005003,28928442,55,Mumps
http://www.ebi.ac.uk/efo/efo_0008402,GCST005000,28928442,49,Cold sores
http://www.ebi.ac.uk/efo/efo_0008401,GCST005001,28928442,75,Shingles
http://www.ebi.ac.uk/efo/efo_0008397,GCST004972,28927378,0,Putamen actvity during disappointment
http://www.ebi.ac.uk/efo/efo_0007849,GCST004972,28927378,0,Putamen actvity during disappointment
http://www.ebi.ac.uk/efo/efo_0008389,GCST004972,28927378,0,Putamen actvity during disappointment
http://www.ebi.ac.uk/efo/efo_0007849,GCST004971,28927378,0,Putamen activity during reward
http://www.ebi.ac.uk/efo/efo_0008389,GCST004971,28927378,0,Putamen activity during reward
http://www.ebi.ac.uk/efo/efo_0008396,GCST004971,28927378,0,Putamen activity during reward
http://www.ebi.ac.uk/efo/efo_0008400,GCST004999,28928442,36,Chickenpox
http://www.ebi.ac.uk/efo/efo_0008387,GCST004970,28927378,31,Caudate activity during reward
http://www.ebi.ac.uk/efo/efo_0007849,GCST004970,28927378,31,Caudate activity during reward
http://www.ebi.ac.uk/efo/efo_0008396,GCST004970,28927378,31,Caudate activity during reward
http://www.ebi.ac.uk/efo/efo_0000692,GCST004953,28922980,3,Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia
http://www.ebi.ac.uk/efo/efo_0008388,GCST004953,28922980,3,Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia
http://www.ebi.ac.uk/efo/efo_0004920,GCST004897,28935272,4,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
http://www.ebi.ac.uk/efo/efo_0001075,GCST004897,28935272,4,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
http://purl.obolibrary.org/obo/go_0072718,GCST004897,28935272,4,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
http://purl.obolibrary.org/obo/go_1901555,GCST004897,28935272,4,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
http://www.ebi.ac.uk/efo/efo_0000621,GCST004885,28924153,2,Neuroblastoma (MYCN amplification)
http://www.ebi.ac.uk/efo/efo_0000621,GCST004884,28924153,1,Neuroblastoma (1p deletion)
http://www.ebi.ac.uk/efo/efo_0000621,GCST004882,28924153,0,Neuroblastoma (11q deletion vs 11q undeleted and MYCN amplification)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004993,28924203,1,White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0005674,GCST004993,28924203,1,White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0007738,GCST004993,28924203,1,White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0000638,GCST004896,28935272,10,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin
http://www.ebi.ac.uk/efo/efo_0001075,GCST004896,28935272,10,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin
http://purl.obolibrary.org/obo/go_0072718,GCST004896,28935272,10,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin
http://purl.obolibrary.org/obo/go_1901555,GCST004896,28935272,10,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin
http://www.ebi.ac.uk/efo/efo_0000692,GCST004994,28924203,1,White matter microstructure in first episode schizophrenia (left anterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0005674,GCST004994,28924203,1,White matter microstructure in first episode schizophrenia (left anterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0007738,GCST004994,28924203,1,White matter microstructure in first episode schizophrenia (left anterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0000621,GCST004883,28924153,1,Neuroblastoma (11q deletion)
http://www.ebi.ac.uk/efo/efo_0008420,GCST004997,28924203,1,Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004997,28924203,1,Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0005674,GCST004997,28924203,1,Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0007738,GCST004997,28924203,1,Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0008420,GCST004991,28924203,1,White matter microstructure in first episode schizophrenia (left inferior parietal cortex)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004991,28924203,1,White matter microstructure in first episode schizophrenia (left inferior parietal cortex)
http://www.ebi.ac.uk/efo/efo_0005674,GCST004991,28924203,1,White matter microstructure in first episode schizophrenia (left inferior parietal cortex)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004995,28924203,1,White matter microstructure in first episode schizophrenia (left posterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0005674,GCST004995,28924203,1,White matter microstructure in first episode schizophrenia (left posterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0007738,GCST004995,28924203,1,White matter microstructure in first episode schizophrenia (left posterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004996,28924203,1,Total mean fractional anisotropy measurement in first episode schizophrenia
http://www.ebi.ac.uk/efo/efo_0008399,GCST004996,28924203,1,Total mean fractional anisotropy measurement in first episode schizophrenia
http://www.ebi.ac.uk/efo/efo_0005674,GCST004996,28924203,1,Total mean fractional anisotropy measurement in first episode schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST004992,28924203,1,White matter microstructure in first episode schizophrenia (right posterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0005674,GCST004992,28924203,1,White matter microstructure in first episode schizophrenia (right posterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0007738,GCST004992,28924203,1,White matter microstructure in first episode schizophrenia (right posterior cingulate cortex)
http://www.ebi.ac.uk/efo/efo_0000182,GCST006037,28921602,1,Hepatocellular carcinoma in hepatitis C infection
http://www.ebi.ac.uk/efo/efo_0003047,GCST006037,28921602,1,Hepatocellular carcinoma in hepatitis C infection
http://www.ebi.ac.uk/efo/efo_0004465,GCST005877,29212154,1,Fasting blood glucose
http://www.ebi.ac.uk/efo/efo_0006335,GCST005876,29212154,1,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST005875,29212154,1,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004612,GCST005874,29212154,1,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004530,GCST005873,29212154,1,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004342,GCST005872,29212154,1,Waist circumference
http://www.ebi.ac.uk/efo/efo_0000195,GCST005871,29212154,2,Metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0002686,GCST006040,28927820,2,Atopy
http://www.ebi.ac.uk/efo/efo_0004318,GCST004976,28921760,3,nicotine metabolite ratio in current smokers
http://www.ebi.ac.uk/efo/efo_0007794,GCST004976,28921760,3,nicotine metabolite ratio in current smokers
http://www.ebi.ac.uk/efo/efo_0004616,GCST004881,28916551,6,Knee osteoarthritis
http://www.ebi.ac.uk/efo/efo_0008421,GCST004942,28918882,1,Pediatric non-alcoholic fatty liver disease activity score
http://www.ebi.ac.uk/efo/efo_1001249,GCST004943,28918882,2,Pediatric nonalcoholic steatohepatitis
http://www.ebi.ac.uk/efo/efo_0003095,GCST004938,28918882,5,Liver fibrosis in pediatric non-alcoholic fatty acid liver disease
http://purl.obolibrary.org/obo/hp_0001395,GCST004938,28918882,5,Liver fibrosis in pediatric non-alcoholic fatty acid liver disease
http://www.ebi.ac.uk/efo/efo_0004321,GCST004893,28902444,0,Suicide attempts
http://www.ebi.ac.uk/efo/efo_0004541,GCST004903,28898252,0,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004541,GCST007953,28898252,14,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004541,GCST007952,28898252,2,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004541,GCST007954,28898252,52,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004541,GCST007951,28898252,1,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004340,GCST004904,28892062,265,Body mass index
http://www.ebi.ac.uk/efo/efo_0002508,GCST004902,28892059,55,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0007001,GCST004941,28887542,2,Dehydroepiandrosterone sulphate levels
http://www.ebi.ac.uk/efo/efo_0000094,GCST005972,29296818,3,Acute lymphoblastic leukemia (B-cell precursor)
http://www.ebi.ac.uk/efo/efo_0005208,GCST005063,28887542,0,Glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0004611,GCST005068,28887542,0,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004741,GCST005070,28887542,0,Urea levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST005073,28887542,0,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004908,GCST005074,28887542,0,Testosterone levels
http://www.ebi.ac.uk/efo/efo_0004459,GCST005072,28887542,0,Ferritin levels
http://www.ebi.ac.uk/efo/efo_0004628,GCST005071,28887542,0,Insulin-like growth factor 1 levels
http://www.ebi.ac.uk/efo/efo_0004458,GCST005067,28887542,0,C-reactive protein levels
http://www.ebi.ac.uk/efo/efo_0004509,GCST005060,28887542,0,Hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST005058,28887542,0,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0000094,GCST005971,29296818,1,B cell acute lymphoblastic leukaemia in adulthood
http://www.ebi.ac.uk/efo/efo_0000094,GCST005970,29296818,1,B cell acute lymphoblastic leukaemia in young adulthood
http://www.ebi.ac.uk/efo/efo_0000094,GCST005969,29296818,1,Acute lymphoblastic leukemia in childhood (B cell precursor)
http://www.ebi.ac.uk/efo/efo_0000094,GCST005968,29296818,1,B cell acute lymphoblastic leukaemia (abnormal cytogenetics)
http://www.ebi.ac.uk/efo/efo_0000094,GCST005967,29296818,3,B cell acute lymphoblastic leukaemia (Philadelphia chromosome negative)
http://www.ebi.ac.uk/efo/efo_0000094,GCST005966,29296818,3,B cell acute lymphoblastic leukaemia (hyperdiploid negative)
http://www.ebi.ac.uk/efo/efo_0000094,GCST005965,29296818,3,B cell acute lymphoblastic leukaemia (normal cytogenetics)
http://www.ebi.ac.uk/efo/efo_0004532,GCST005069,28887542,0,Gamma glutamyl transferase levels
http://www.ebi.ac.uk/efo/efo_0004518,GCST005066,28887542,0,Creatinine levels
http://www.ebi.ac.uk/efo/efo_0004574,GCST005065,28887542,0,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004736,GCST005064,28887542,0,Aspartate aminotransferase levels
http://www.ebi.ac.uk/efo/efo_0004623,GCST005062,28887542,0,Fibrinogen levels
http://www.ebi.ac.uk/efo/efo_0004533,GCST005061,28887542,0,Serum alkaline phosphatase levels
http://www.ebi.ac.uk/efo/efo_0004535,GCST005059,28887542,0,Serum albumin level
http://www.ebi.ac.uk/efo/efo_0004246,GCST004859,28886140,1,Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0004735,GCST004940,28887542,1,Alanine transaminase levels
http://www.ebi.ac.uk/efo/efo_0004541,GCST004939,28887542,2,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0003917,GCST004898,28877031,5,Preterm birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST004898,28877031,5,Preterm birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005112,GCST004899,28877031,11,Gestational age at birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST004899,28877031,11,Gestational age at birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0004229,GCST004858,28886342,28,Dupuytren's disease
http://www.ebi.ac.uk/efo/efo_0008428,GCST004930,28878392,7,IgG sialylation phenotypes (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0005193,GCST004925,28878392,9,IgG N-glycosylation phenotypes (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0008424,GCST004926,28878392,6,IgG digalactosylation phenotypes (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0008423,GCST004924,28878392,6,IgG monogalactosylation phenotypes (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0008425,GCST004927,28878392,9,IgG galactosylation phenotypes (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0008426,GCST004928,28878392,5,IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0008427,GCST004929,28878392,7,IgG fucosylation phenotypes (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0008430,GCST004932,28878392,3,IgG monosialylation phenotypes (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0008429,GCST004931,28878392,4,IgG disialylation phenotypes (multivariate analysis)
http://www.ebi.ac.uk/efo/efo_0006336,GCST004890,28871152,1,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0000537,GCST004889,28871152,0,Hypertension
http://www.ebi.ac.uk/efo/efo_0005763,GCST004892,28871152,0,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0005842,GCST004840,28869801,0,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0006335,GCST004888,28871152,1,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0009270,GCST006288,28869591,766,Heel bone mineral density
http://www.ebi.ac.uk/efo/efo_0001360,GCST004894,28869590,157,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0005842,GCST004839,28869801,1,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0006340,GCST004891,28871152,1,Mean arterial pressure
http://www.ebi.ac.uk/efo/efo_0001065,GCST004873,28881265,32,Endometriosis
http://www.ebi.ac.uk/efo/efo_0000305,GCST007414,28864454,0,Breast cancer
http://www.ebi.ac.uk/efo/efo_0009780,GCST007418,28864454,0,Breast cancer (HER2 negative)
http://www.ebi.ac.uk/efo/efo_1000294,GCST007419,28864454,0,Breast cancer (HER2 positive)
http://www.ebi.ac.uk/efo/efo_0009781,GCST007417,28864454,0,Breast cancer (progesterone-receptor negative)
http://www.ebi.ac.uk/efo/efo_0009781,GCST007420,28864454,1,Breast cancer (progesterone-receptor positive)
http://www.ebi.ac.uk/efo/efo_1000650,GCST007416,28864454,0,Breast cancer (estrogen-receptor negative)
http://www.ebi.ac.uk/efo/efo_1000649,GCST007415,28864454,2,Breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_0004761,GCST004825,28776340,2,Hyperuricemia
http://www.ebi.ac.uk/efo/efo_1001870,GCST005549,28714976,17,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0001361,GCST004947,29088834,1,Pulmonary arterial hypertension
http://www.ebi.ac.uk/efo/efo_0001360,GCST006145,28838971,1,Type 2 diabetes
http://www.orpha.net/ordo/orphanet_70589,GCST004783,28839172,0,Bronchopulmonary dysplasia in preterm infants
http://www.ebi.ac.uk/efo/efo_0003917,GCST004783,28839172,0,Bronchopulmonary dysplasia in preterm infants
http://www.ebi.ac.uk/efo/efo_0008385,GCST004801,28835685,0,Response to ranibizumab in age-related macular degeneration (visual acuity)
http://www.ebi.ac.uk/efo/efo_0008348,GCST004801,28835685,0,Response to ranibizumab in age-related macular degeneration (visual acuity)
http://www.ebi.ac.uk/efo/efo_0001365,GCST004801,28835685,0,Response to ranibizumab in age-related macular degeneration (visual acuity)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004838,28843344,0,Coronary artery disease and/or body mass index (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000378,GCST004838,28843344,0,Coronary artery disease and/or body mass index (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000731,GCST004779,28836065,4,Uterine fibroids
http://www.ebi.ac.uk/efo/efo_0008348,GCST004802,28835685,0,Response to ranibizumab in age-related macular degeneration (dry maculae)
http://www.ebi.ac.uk/efo/efo_0001365,GCST004802,28835685,0,Response to ranibizumab in age-related macular degeneration (dry maculae)
http://www.ebi.ac.uk/efo/efo_0008375,GCST004802,28835685,0,Response to ranibizumab in age-related macular degeneration (dry maculae)
http://www.ebi.ac.uk/efo/efo_0008348,GCST004803,28835685,0,Response to ranibizumab in age-related macular degeneration (additional treatment requirement)
http://www.ebi.ac.uk/efo/efo_0001365,GCST004803,28835685,0,Response to ranibizumab in age-related macular degeneration (additional treatment requirement)
http://www.ebi.ac.uk/efo/efo_0008383,GCST004803,28835685,0,Response to ranibizumab in age-related macular degeneration (additional treatment requirement)
http://www.ebi.ac.uk/efo/efo_0005110,GCST004814,28820441,2,Interleukin-6 (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0004810,GCST004814,28820441,2,Interleukin-6 (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0005110,GCST004822,28820441,0,P-Selectin (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0008254,GCST004822,28820441,0,P-Selectin (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0005110,GCST004819,28820441,0,Osteoprotegerin (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0005918,GCST004819,28820441,0,Osteoprotegerin (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0005110,GCST004815,28820441,2,C-reactive protein (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0004458,GCST004815,28820441,2,C-reactive protein (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0005110,GCST004817,28820441,1,Tumor necrosis factor receptor II (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0008384,GCST004817,28820441,1,Tumor necrosis factor receptor II (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0005110,GCST004821,28820441,1,Monocyte chemoattractant protein-1 (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0004749,GCST004821,28820441,1,Monocyte chemoattractant protein-1 (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0005110,GCST004820,28820441,1,Cellular adhesion molecule (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0008353,GCST004820,28820441,1,Cellular adhesion molecule (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0005110,GCST004818,28820441,1,Intercellular adhesion molecule 1 (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0004520,GCST004818,28820441,1,Intercellular adhesion molecule 1 (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0005110,GCST004816,28820441,0,Lipoprotein-associated phospholipase A2 (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0004746,GCST004816,28820441,0,Lipoprotein-associated phospholipase A2 (red blood cell fatty acid level interaction)
http://www.ebi.ac.uk/efo/efo_0001360,GCST004782,28828242,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000220,GCST007727,28817678,2,Acute lymphoblastic leukemia (childhood)
http://www.ebi.ac.uk/efo/efo_0003888,GCST004778,28809852,1,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0008354,GCST004823,28808816,12,Cognitive function
http://www.ebi.ac.uk/efo/efo_0001061,GCST004833,28806749,14,Cervical cancer
http://www.ebi.ac.uk/efo/efo_0005843,GCST004780,28843169,10,Cortisol levels (saliva)
http://www.ebi.ac.uk/efo/efo_0004874,GCST004831,28800603,1,Verbal memory performance (delayed recall level)
http://www.ebi.ac.uk/efo/efo_0008325,GCST005137,28800628,0,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching)
http://www.ebi.ac.uk/efo/efo_0008398,GCST005137,28800628,0,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching)
http://www.ebi.ac.uk/efo/efo_0008325,GCST005139,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
http://www.ebi.ac.uk/efo/efo_0008333,GCST005139,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
http://www.ebi.ac.uk/efo/efo_0008334,GCST005139,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
http://www.ebi.ac.uk/efo/efo_0008335,GCST005139,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
http://www.ebi.ac.uk/efo/efo_0008325,GCST005138,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
http://www.ebi.ac.uk/efo/efo_0008333,GCST005138,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
http://www.ebi.ac.uk/efo/efo_0008334,GCST005138,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
http://www.ebi.ac.uk/efo/efo_0008335,GCST005138,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
http://www.ebi.ac.uk/efo/efo_0008325,GCST005136,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
http://www.ebi.ac.uk/efo/efo_0008333,GCST005136,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
http://www.ebi.ac.uk/efo/efo_0008334,GCST005136,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
http://www.ebi.ac.uk/efo/efo_0008335,GCST005136,28800628,0,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
http://www.ebi.ac.uk/efo/efo_0004874,GCST004832,28800603,0,Verbal memory performance (delayed recall change)
http://www.ebi.ac.uk/efo/efo_0004874,GCST004828,28800603,3,Verbal memory performance (immediate recall level)
http://www.ebi.ac.uk/efo/efo_0008325,GCST005140,28800628,0,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change)
http://www.ebi.ac.uk/efo/efo_0008335,GCST005140,28800628,0,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change)
http://www.ebi.ac.uk/efo/efo_0008325,GCST005135,28800628,0,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change)
http://www.ebi.ac.uk/efo/efo_0008333,GCST005135,28800628,0,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change)
http://www.ebi.ac.uk/efo/efo_0008325,GCST005134,28800628,0,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change)
http://www.ebi.ac.uk/efo/efo_0008334,GCST005134,28800628,0,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change)
http://www.ebi.ac.uk/efo/efo_0004874,GCST004829,28800603,7,Verbal memory performance (residualized delayed recall level)
http://www.ebi.ac.uk/efo/efo_0004874,GCST004827,28800603,4,Verbal memory performance (immediate recall change)
http://www.ebi.ac.uk/efo/efo_0004874,GCST004830,28800603,4,Verbal memory performance (residualized delayed recall change)
http://www.ebi.ac.uk/efo/efo_0008349,GCST004786,28783044,0,Thiazide-induced hyponatremia
http://www.ebi.ac.uk/efo/efo_1001345,GCST004784,28776448,0,Alcoholic hepatitis
http://www.ebi.ac.uk/efo/efo_0000182,GCST005858,28779025,0,Hepatocellular carcinoma in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0004268,GCST005858,28779025,0,Hepatocellular carcinoma in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0004606,GCST005857,28779025,0,Gallbladder carcinoma in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0004268,GCST005857,28779025,0,Gallbladder carcinoma in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0005842,GCST005856,28779025,1,Colorectal carcinoma in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0004268,GCST005856,28779025,1,Colorectal carcinoma in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0000482,GCST005860,28779025,3,Cholangiocarcinoma in primary sclerosing cholangitis (time to event)
http://www.ebi.ac.uk/efo/efo_0005221,GCST005860,28779025,3,Cholangiocarcinoma in primary sclerosing cholangitis (time to event)
http://www.ebi.ac.uk/efo/efo_0004268,GCST005860,28779025,3,Cholangiocarcinoma in primary sclerosing cholangitis (time to event)
http://www.ebi.ac.uk/efo/efo_0005221,GCST005855,28779025,1,Cholangiocarcinoma in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0004268,GCST005855,28779025,1,Cholangiocarcinoma in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0004268,GCST005852,28779025,0,Colectomy in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0000482,GCST005859,28779025,3,Liver transplant-free survival in primary sclerosing cholangitis (time to event)
http://www.ebi.ac.uk/efo/efo_0004268,GCST005859,28779025,3,Liver transplant-free survival in primary sclerosing cholangitis (time to event)
http://www.ebi.ac.uk/efo/efo_0004268,GCST005854,28779025,0,Primary sclerosing cholangitis (small duct vs large duct)
http://www.ebi.ac.uk/efo/efo_0005676,GCST005853,28779025,3,Autoimmune hepatitis in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0004268,GCST005853,28779025,3,Autoimmune hepatitis in primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0007785,GCST004835,28840121,0,Femoral neck bone geometry
http://www.ebi.ac.uk/efo/efo_0007701,GCST004834,28840121,0,Lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_0008372,GCST004813,28775256,3,Laterality in neovascular age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0004683,GCST004813,28775256,3,Laterality in neovascular age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0001663,GCST004982,29117387,2,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0001365,GCST004872,28813576,0,Age-related macular degeneration (SNP x mitochondrial C16069T interaction)
http://www.ebi.ac.uk/efo/efo_0008369,GCST004794,28763065,3,Brain volume in infants (intracranial brain volume)
http://purl.obolibrary.org/obo/hp_0012235,GCST004781,28762467,32,Sulfasalazine-induced agranulocytosis
http://www.ebi.ac.uk/efo/efo_0008324,GCST004781,28762467,32,Sulfasalazine-induced agranulocytosis
http://www.ebi.ac.uk/efo/efo_0005094,GCST004826,28794112,20,P wave duration
http://www.ebi.ac.uk/efo/efo_0008368,GCST004797,28763065,12,Brain volume in infants (grey matter)
http://www.ebi.ac.uk/efo/efo_0000249,GCST004880,28870582,0,Alzheimer's disease or type 2 diabetes (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001360,GCST004880,28870582,0,Alzheimer's disease or type 2 diabetes (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0008367,GCST004796,28763065,4,Brain volume in infants (cerebrospinal fluid)
http://www.ebi.ac.uk/efo/efo_0008370,GCST004795,28763065,6,Brain volume in infants (white matter)
http://www.ebi.ac.uk/efo/efo_0008379,GCST004824,28794112,12,P wave terminal force
http://www.ebi.ac.uk/efo/efo_0001365,GCST004871,28813576,1,Age-related macular degeneration (SNP x mitochondrial G12771A interaction)
http://www.ebi.ac.uk/efo/efo_0001365,GCST004870,28813576,1,Age-related macular degeneration (SNP x mitochondrial A4917G interaction)
http://www.ebi.ac.uk/efo/efo_0001365,GCST004869,28813576,0,Age-related macular degeneration (SNP x mitochondrial T5004C interaction)
http://www.ebi.ac.uk/efo/efo_0001365,GCST004868,28813576,2,Advanced age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0008204,GCST004789,28763429,0,Change in LVEF in response to paclitaxel in HER2+ breast cancer
http://purl.obolibrary.org/obo/go_1901555,GCST004789,28763429,0,Change in LVEF in response to paclitaxel in HER2+ breast cancer
http://www.ebi.ac.uk/efo/efo_0008347,GCST004788,28763429,0,Change in LVEF in response to paclitaxel and in response to paclitaxel and trastuzumab in HER+ breast cancer
http://www.ebi.ac.uk/efo/efo_0008204,GCST004788,28763429,0,Change in LVEF in response to paclitaxel and in response to paclitaxel and trastuzumab in HER+ breast cancer
http://purl.obolibrary.org/obo/go_1901555,GCST004788,28763429,0,Change in LVEF in response to paclitaxel and in response to paclitaxel and trastuzumab in HER+ breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST004836,28761973,0,Femoral neck bone mineral density or breast cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0007785,GCST004836,28761973,0,Femoral neck bone mineral density or breast cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000305,GCST004837,28761973,0,Lumbar spine bone mineral density or breast cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0007701,GCST004837,28761973,0,Lumbar spine bone mineral density or breast cancer (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0008347,GCST004790,28763429,6,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer
http://www.ebi.ac.uk/efo/efo_0008204,GCST004790,28763429,6,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer
http://purl.obolibrary.org/obo/go_1901555,GCST004790,28763429,6,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer
http://www.ebi.ac.uk/efo/efo_0008395,GCST004968,28753643,0,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline)
http://www.ebi.ac.uk/efo/efo_0005672,GCST004968,28753643,0,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline)
http://www.ebi.ac.uk/efo/efo_0008432,GCST004968,28753643,0,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline)
http://www.ebi.ac.uk/efo/efo_0001645,GCST004968,28753643,0,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline)
http://www.ebi.ac.uk/efo/efo_0008395,GCST004967,28753643,7,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)
http://purl.obolibrary.org/obo/hp_0002014,GCST004967,28753643,7,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0005672,GCST004967,28753643,7,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0001645,GCST004967,28753643,7,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0007040,GCST004769,28754176,1,Mental development (prenatal lead exposure interaction)
http://www.ebi.ac.uk/efo/efo_0008230,GCST004769,28754176,1,Mental development (prenatal lead exposure interaction)
http://www.ebi.ac.uk/efo/efo_0008395,GCST004959,28753643,1,Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction)
http://www.ebi.ac.uk/efo/efo_0005672,GCST004959,28753643,1,Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction)
http://www.ebi.ac.uk/efo/efo_0001645,GCST004959,28753643,1,Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction)
http://www.ebi.ac.uk/efo/efo_0000612,GCST004959,28753643,1,Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction)
http://www.ebi.ac.uk/efo/efo_0004746,GCST004963,28753643,16,Lipoprotein phospholipase A2 activity in cardiovascular disease
http://www.ebi.ac.uk/efo/efo_0005672,GCST004963,28753643,16,Lipoprotein phospholipase A2 activity in cardiovascular disease
http://www.ebi.ac.uk/efo/efo_0001645,GCST004963,28753643,16,Lipoprotein phospholipase A2 activity in cardiovascular disease
http://www.ebi.ac.uk/efo/efo_0008395,GCST004957,28753643,2,Major coronary event in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0005672,GCST004957,28753643,2,Major coronary event in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0001645,GCST004957,28753643,2,Major coronary event in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0006919,GCST004957,28753643,2,Major coronary event in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0008395,GCST004960,28753643,0,Odor events in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0008386,GCST004960,28753643,0,Odor events in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0005672,GCST004960,28753643,0,Odor events in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0001645,GCST004960,28753643,0,Odor events in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0008395,GCST004958,28753643,5,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)
http://www.ebi.ac.uk/efo/efo_0005672,GCST004958,28753643,5,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)
http://www.ebi.ac.uk/efo/efo_0001645,GCST004958,28753643,5,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)
http://www.ebi.ac.uk/efo/efo_0006919,GCST004958,28753643,5,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)
http://www.ebi.ac.uk/efo/efo_0005672,GCST004965,28753643,0,Myocardial infarction in placebo-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0001645,GCST004965,28753643,0,Myocardial infarction in placebo-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0000612,GCST004965,28753643,0,Myocardial infarction in placebo-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0008344,GCST004965,28753643,0,Myocardial infarction in placebo-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0008395,GCST004964,28753643,2,Myocardial infarction in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0005672,GCST004964,28753643,2,Myocardial infarction in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0001645,GCST004964,28753643,2,Myocardial infarction in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0000612,GCST004964,28753643,2,Myocardial infarction in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0008395,GCST004962,28753643,3,Diarrhoea in darapladib-treated cardiovascular disease (time to event)
http://purl.obolibrary.org/obo/hp_0002014,GCST004962,28753643,3,Diarrhoea in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0005672,GCST004962,28753643,3,Diarrhoea in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0001645,GCST004962,28753643,3,Diarrhoea in darapladib-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0005672,GCST004961,28753643,2,Major coronary event in placebo-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0001645,GCST004961,28753643,2,Major coronary event in placebo-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0006919,GCST004961,28753643,2,Major coronary event in placebo-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_0008344,GCST004961,28753643,2,Major coronary event in placebo-treated cardiovascular disease (time to event)
http://www.ebi.ac.uk/efo/efo_1002013,GCST004860,28754779,156,Alcoholic chronic pancreatitis
http://www.ebi.ac.uk/efo/efo_0008237,GCST004768,28754176,1,Motor development (prenatal lead exposure interaction)
http://www.ebi.ac.uk/efo/efo_0007040,GCST004768,28754176,1,Motor development (prenatal lead exposure interaction)
http://www.ebi.ac.uk/efo/efo_0008395,GCST004966,28753643,3,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease
http://www.ebi.ac.uk/efo/efo_0005672,GCST004966,28753643,3,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease
http://www.ebi.ac.uk/efo/efo_0008432,GCST004966,28753643,3,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease
http://www.ebi.ac.uk/efo/efo_0001645,GCST004966,28753643,3,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease
http://www.ebi.ac.uk/efo/efo_0000692,GCST004975,28746715,0,Schizophrenia or general cognitive function (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0008354,GCST004975,28746715,0,Schizophrenia or general cognitive function (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004973,28746715,0,Schizophrenia or verbal-numerical reasoning (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0008394,GCST004973,28746715,0,Schizophrenia or verbal-numerical reasoning (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004974,28746715,0,Schizophrenia or reaction time (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0008393,GCST004974,28746715,0,Schizophrenia or reaction time (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0007878,GCST004886,28937693,20,Alcohol consumption
http://www.ebi.ac.uk/efo/efo_0007878,GCST004887,28937693,8,Alcohol consumption in current drinkers
http://www.ebi.ac.uk/efo/efo_0003923,GCST004772,28743860,10,"Bone mineral density (paediatric, total body less head)"
http://www.ebi.ac.uk/efo/efo_0004995,GCST004770,28743860,1,Lean body mass
http://www.ebi.ac.uk/efo/efo_0000692,GCST004767,28744025,0,Schizophrenia (age at onset)
http://www.ebi.ac.uk/efo/efo_0003923,GCST004771,28743860,12,TB-LM or TBLH-BMD (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004995,GCST004771,28743860,12,TB-LM or TBLH-BMD (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0006336,GCST004777,28739976,71,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0007681,GCST004766,28736931,26,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes
http://purl.obolibrary.org/obo/go_1903491,GCST004766,28736931,26,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST004766,28736931,26,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes
http://purl.obolibrary.org/obo/go_1901557,GCST004766,28736931,26,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes
http://purl.obolibrary.org/obo/go_1903491,GCST004765,28736931,35,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST004765,28736931,35,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0007806,GCST004765,28736931,35,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://purl.obolibrary.org/obo/go_1901557,GCST004765,28736931,35,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0007804,GCST004764,28736931,7,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://purl.obolibrary.org/obo/go_1903491,GCST004764,28736931,7,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST004764,28736931,7,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://purl.obolibrary.org/obo/go_1901557,GCST004764,28736931,7,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004314,GCST004800,28738859,3,Forced expiratory volume in 1 second (environmental tobacco smoke interaction)
http://www.ebi.ac.uk/efo/efo_0008361,GCST004800,28738859,3,Forced expiratory volume in 1 second (environmental tobacco smoke interaction)
http://www.ebi.ac.uk/efo/efo_0005763,GCST004775,28739976,46,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST004776,28739976,96,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0003885,GCST004752,28739605,1,Relapse in multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0004952,GCST004752,28739605,1,Relapse in multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0007805,GCST004763,28736931,6,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://purl.obolibrary.org/obo/go_1903491,GCST004763,28736931,6,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST004763,28736931,6,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://purl.obolibrary.org/obo/go_1901557,GCST004763,28736931,6,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004631,GCST004726,28757204,16,Vitamin D levels
http://www.ebi.ac.uk/efo/efo_0004980,GCST005037,28724990,5,Appendicular lean mass
http://www.ebi.ac.uk/efo/efo_0004995,GCST005036,28724990,7,Lean body mass
http://www.ebi.ac.uk/efo/efo_0003829,GCST004756,28714907,5,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0002690,GCST005752,28714469,183,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0002690,GCST007400,28714469,71,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0000378,GCST007990,28714974,20,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_1000802,GCST004755,28714907,0,Chronic alcoholic pancreatitis or alcohol-related cirrhosis
http://www.ebi.ac.uk/efo/efo_1002013,GCST004755,28714907,0,Chronic alcoholic pancreatitis or alcohol-related cirrhosis
http://www.ebi.ac.uk/efo/efo_1000802,GCST004757,28714907,3,Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis
http://www.ebi.ac.uk/efo/efo_0003829,GCST004757,28714907,3,Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis
http://www.ebi.ac.uk/efo/efo_1002013,GCST004757,28714907,3,Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis
http://www.ebi.ac.uk/efo/efo_0000378,GCST004787,28714975,72,"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)"
http://www.ebi.ac.uk/efo/efo_0001365,GCST004737,28703135,4,Neovascular age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0004683,GCST004737,28703135,4,Neovascular age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0000685,GCST005826,28706201,2,Sero-negative rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000182,GCST007514,28700999,0,Hepatitis B virus-related hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0000501,GCST004754,28703219,0,Follicular thyroid cancer
http://www.ebi.ac.uk/efo/efo_0000641,GCST004753,28703219,9,Papillary thyroid cancer
http://www.ebi.ac.uk/efo/efo_1002017,GCST004798,28703219,10,Differentiated thyroid cancer
http://www.ebi.ac.uk/efo/efo_0006941,GCST005235,29313844,19,Hand grip strength
http://www.ebi.ac.uk/efo/efo_0004995,GCST005234,29313844,0,Lean mass index
http://www.ebi.ac.uk/efo/efo_0005409,GCST005233,29313844,0,Fat mass index
http://www.ebi.ac.uk/efo/efo_0003761,GCST004740,28696415,0,Duloxetine response in major depressive disorder (remitter/non-remitter status)
http://www.ebi.ac.uk/efo/efo_0008345,GCST004740,28696415,0,Duloxetine response in major depressive disorder (remitter/non-remitter status)
http://www.ebi.ac.uk/efo/efo_0003761,GCST004739,28696415,2,Placebo response in major depressive disorder (% change in symptom score)
http://www.ebi.ac.uk/efo/efo_0008344,GCST004739,28696415,2,Placebo response in major depressive disorder (% change in symptom score)
http://www.ebi.ac.uk/efo/efo_1000965,GCST004745,28698626,7,Immunoglobulin A vasculitis
http://www.ebi.ac.uk/efo/efo_0003761,GCST004738,28696415,2,Duloxetine response in major depressive disorder (% change in symptom score)
http://www.ebi.ac.uk/efo/efo_0008345,GCST004738,28696415,2,Duloxetine response in major depressive disorder (% change in symptom score)
http://www.ebi.ac.uk/efo/efo_0003761,GCST004743,28696415,0,Placebo response in major depressive disorder (responder/non-responder status)
http://www.ebi.ac.uk/efo/efo_0008344,GCST004743,28696415,0,Placebo response in major depressive disorder (responder/non-responder status)
http://www.ebi.ac.uk/efo/efo_0003761,GCST004742,28696415,0,Placebo response in major depressive disorder (remitter/non-remitter status)
http://www.ebi.ac.uk/efo/efo_0008344,GCST004742,28696415,0,Placebo response in major depressive disorder (remitter/non-remitter status)
http://www.ebi.ac.uk/efo/efo_0003761,GCST004741,28696415,0,Duloxetine response in major depressive disorder (responder/non-responder status)
http://www.ebi.ac.uk/efo/efo_0008345,GCST004741,28696415,0,Duloxetine response in major depressive disorder (responder/non-responder status)
http://www.ebi.ac.uk/efo/efo_0005922,GCST004799,28680059,0,Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma
http://www.ebi.ac.uk/efo/efo_0008346,GCST004799,28680059,0,Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma
http://www.orpha.net/ordo/orphanet_85443,GCST004804,28679651,1,Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile)
http://www.ebi.ac.uk/efo/efo_0008366,GCST004804,28679651,1,Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile)
http://www.ebi.ac.uk/efo/efo_0004337,GCST005626,29731509,1,Extremely high intelligence
http://www.orpha.net/ordo/orphanet_85443,GCST004808,28679651,1,Immunoglobulin light chain (AL) amyloidosis (serum IgG profile)
http://www.ebi.ac.uk/efo/efo_0008366,GCST004808,28679651,1,Immunoglobulin light chain (AL) amyloidosis (serum IgG profile)
http://www.orpha.net/ordo/orphanet_85443,GCST004812,28679651,1,Immunoglobulin light chain (AL) amyloidosis (kidney involvement)
http://www.ebi.ac.uk/efo/efo_0008371,GCST004812,28679651,1,Immunoglobulin light chain (AL) amyloidosis (kidney involvement)
http://www.ebi.ac.uk/efo/efo_0008365,GCST004805,28679651,1,Immunoglobulin light chain (AL) amyloidosis (heart involvement)
http://www.orpha.net/ordo/orphanet_85443,GCST004805,28679651,1,Immunoglobulin light chain (AL) amyloidosis (heart involvement)
http://www.orpha.net/ordo/orphanet_85443,GCST004809,28679651,2,Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile)
http://www.ebi.ac.uk/efo/efo_0008366,GCST004809,28679651,2,Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile)
http://www.orpha.net/ordo/orphanet_85443,GCST004811,28679651,1,Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile)
http://www.ebi.ac.uk/efo/efo_0008366,GCST004811,28679651,1,Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile)
http://www.orpha.net/ordo/orphanet_85443,GCST004810,28679651,0,Immunoglobulin light (AL) amyloidosis (serum Ig kappa profile)
http://www.ebi.ac.uk/efo/efo_0008366,GCST004810,28679651,0,Immunoglobulin light (AL) amyloidosis (serum Ig kappa profile)
http://www.ebi.ac.uk/efo/efo_0008365,GCST004806,28679651,1,Immunoglobulin light chain (AL) amyloidosis (heart and kidney involvement)
http://www.orpha.net/ordo/orphanet_85443,GCST004806,28679651,1,Immunoglobulin light chain (AL) amyloidosis (heart and kidney involvement)
http://www.ebi.ac.uk/efo/efo_0008371,GCST004806,28679651,1,Immunoglobulin light chain (AL) amyloidosis (heart and kidney involvement)
http://www.orpha.net/ordo/orphanet_85443,GCST004807,28679651,1,Immunoglobulin light chain (AL) amyloidosis (liver involvement)
http://www.ebi.ac.uk/efo/efo_0008374,GCST004807,28679651,1,Immunoglobulin light chain (AL) amyloidosis (liver involvement)
http://www.ebi.ac.uk/efo/efo_0001359,GCST004724,28672053,2,Foot ulcer in diabetes and neuropathy
http://www.ebi.ac.uk/efo/efo_1001459,GCST004724,28672053,2,Foot ulcer in diabetes and neuropathy
http://www.ebi.ac.uk/efo/efo_0001360,GCST004724,28672053,2,Foot ulcer in diabetes and neuropathy
http://www.ebi.ac.uk/efo/efo_0004149,GCST004724,28672053,2,Foot ulcer in diabetes and neuropathy
http://www.ebi.ac.uk/efo/efo_0001359,GCST004725,28672053,3,Foot ulcer and neuropathy in diabetes
http://www.ebi.ac.uk/efo/efo_1001459,GCST004725,28672053,3,Foot ulcer and neuropathy in diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST004725,28672053,3,Foot ulcer and neuropathy in diabetes
http://www.ebi.ac.uk/efo/efo_0004149,GCST004725,28672053,3,Foot ulcer and neuropathy in diabetes
http://www.ebi.ac.uk/efo/efo_0004242,GCST004703,28641744,13,Obsessive-compulsive disorder or autism spectrum disorder
http://www.ebi.ac.uk/efo/efo_0003756,GCST004703,28641744,13,Obsessive-compulsive disorder or autism spectrum disorder
http://www.ebi.ac.uk/efo/efo_0006945,GCST007828,28234671,2,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006944,GCST007829,28234671,7,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0000182,GCST004736,28662289,4,Familial hepatitis B virus-related hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0004197,GCST004736,28662289,4,Familial hepatitis B virus-related hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0008008,GCST004638,28656603,1,Benign prostatic hyperplasia and/or lower urinary tract symptoms
http://www.ebi.ac.uk/efo/efo_0000284,GCST004638,28656603,1,Benign prostatic hyperplasia and/or lower urinary tract symptoms
http://www.ebi.ac.uk/efo/efo_0000729,GCST005837,28658209,0,Inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0000384,GCST005837,28658209,0,Inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST005837,28658209,0,Inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0000769,GCST004735,28654678,42,Epstein-Barr virus copy number in lymphoblastoid cell lines
http://www.ebi.ac.uk/efo/efo_0008111,GCST004640,28644415,23,Western dietary pattern
http://www.ebi.ac.uk/efo/efo_0008111,GCST004639,28644415,42,Prudent dietary pattern
http://www.ebi.ac.uk/efo/efo_0007701,GCST004717,28651948,0,Lumbar spine bone mineral density or coronary artery disease (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000378,GCST004717,28651948,0,Lumbar spine bone mineral density or coronary artery disease (pleiotropy)
http://purl.obolibrary.org/obo/hp_0012076,GCST004641,28632202,28,Borderline personality disorder
http://www.orpha.net/ordo/orphanet_399,GCST004691,28642124,20,Huntington's disease progression
http://www.ebi.ac.uk/efo/efo_0008336,GCST004691,28642124,20,Huntington's disease progression
http://www.ebi.ac.uk/efo/efo_0007980,GCST004376,28627999,1,Cerebral blood flow
http://www.ebi.ac.uk/efo/efo_0008011,GCST005945,29296746,4,ADAMTS13 levels
http://www.ebi.ac.uk/efo/efo_0008307,GCST004690,28628665,3,Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous)
http://www.ebi.ac.uk/efo/efo_0008322,GCST004690,28628665,3,Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous)
http://www.ebi.ac.uk/efo/efo_0004215,GCST004585,28630421,1,Anorexia nervosa (excluding migration to or from binge-eating disorder or bulimia nervosa)
http://www.ebi.ac.uk/efo/efo_0008307,GCST004689,28628665,4,Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous)
http://www.ebi.ac.uk/efo/efo_0008322,GCST004689,28628665,4,Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous)
http://www.ebi.ac.uk/efo/efo_0008338,GCST004709,28701861,8,Fear of severe pain
http://www.ebi.ac.uk/efo/efo_0008330,GCST004706,28701861,4,Fear of pain
http://www.ebi.ac.uk/efo/efo_0008339,GCST004707,28701861,6,Fear of medical pain (dental)
http://www.ebi.ac.uk/efo/efo_0008340,GCST004708,28701861,19,Fear of minor pain
http://www.ebi.ac.uk/efo/efo_0008003,GCST004734,28613276,23,Heart rate variability traits (SDNN)
http://www.ebi.ac.uk/efo/efo_0008003,GCST004732,28613276,12,Heart rate variability traits (pvRSA/HF)
http://www.ebi.ac.uk/efo/efo_0008003,GCST004733,28613276,22,Heart rate variability traits (RMSSD)
http://www.ebi.ac.uk/efo/efo_0008329,GCST004727,28608620,3,Facial emotion recognition
http://www.ebi.ac.uk/efo/efo_0008329,GCST004731,28608620,2,Facial emotion recognition (fearful faces)
http://www.ebi.ac.uk/efo/efo_0008329,GCST004728,28608620,4,Facial emotion recognition (angry faces)
http://www.ebi.ac.uk/efo/efo_0008329,GCST004730,28608620,4,Facial emotion recognition (sad faces)
http://www.ebi.ac.uk/efo/efo_0008329,GCST004729,28608620,1,Facial emotion recognition (happy faces)
http://www.ebi.ac.uk/efo/efo_1000566,GCST004635,28604728,43,Testicular germ cell tumor
http://www.ebi.ac.uk/efo/efo_0004698,GCST006488,28604731,2,Insomnia complaints
http://www.ebi.ac.uk/efo/efo_0004698,GCST006487,28604731,1,Insomnia complaints
http://www.ebi.ac.uk/efo/efo_0006527,GCST004747,28604730,23,Lung cancer in never smokers
http://www.ebi.ac.uk/efo/efo_0001071,GCST004747,28604730,23,Lung cancer in never smokers
http://www.ebi.ac.uk/efo/efo_0006527,GCST004749,28604730,111,Lung cancer in ever smokers
http://www.ebi.ac.uk/efo/efo_0001071,GCST004749,28604730,111,Lung cancer in ever smokers
http://www.ebi.ac.uk/efo/efo_0000702,GCST004746,28604730,50,Small cell lung carcinoma
http://www.ebi.ac.uk/efo/efo_0000708,GCST004750,28604730,101,Squamous cell lung carcinoma
http://www.ebi.ac.uk/efo/efo_0000571,GCST004744,28604730,79,Lung adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0007875,GCST004699,28604731,6,Daytime sleepiness
http://www.ebi.ac.uk/efo/efo_0008341,GCST004698,28604731,1,Snoring
http://www.ebi.ac.uk/efo/efo_0007828,GCST004693,28604731,4,Daytime nap
http://www.ebi.ac.uk/efo/efo_0008328,GCST004697,28604731,5,Ease of getting up in the morning
http://www.ebi.ac.uk/efo/efo_0004354,GCST004696,28604731,9,Chronotype
http://www.ebi.ac.uk/efo/efo_0004698,GCST004702,28604731,1,Insomnia complaints (dichotomous)
http://www.ebi.ac.uk/efo/efo_0004698,GCST004701,28604731,1,Insomnia complaints (continuous)
http://www.ebi.ac.uk/efo/efo_0004698,GCST004700,28604731,0,Insomnia complaints (sex interaction)
http://www.ebi.ac.uk/efo/efo_0005271,GCST004694,28604731,3,Sleep duration
http://www.ebi.ac.uk/efo/efo_0004698,GCST004695,28604731,2,Insomnia complaints
http://www.ebi.ac.uk/efo/efo_1000566,GCST004713,28604732,37,Testicular germ cell tumor
http://www.ebi.ac.uk/efo/efo_0001071,GCST004748,28604730,135,Lung cancer
http://www.ebi.ac.uk/efo/efo_0004326,GCST004715,28610988,2,Heart rate
http://www.ebi.ac.uk/efo/efo_0008003,GCST004714,28610988,3,Heart rate variability traits (SDNN)
http://www.ebi.ac.uk/efo/efo_0008003,GCST004716,28610988,2,Heart rate variability traits (RMSSD)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004842,28598419,1,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
http://www.ebi.ac.uk/efo/efo_0003917,GCST004842,28598419,1,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
http://www.ebi.ac.uk/efo/efo_0005939,GCST004842,28598419,1,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004843,28598419,0,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
http://www.ebi.ac.uk/efo/efo_0003917,GCST004843,28598419,0,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
http://www.ebi.ac.uk/efo/efo_0005939,GCST004843,28598419,0,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
http://www.ebi.ac.uk/efo/efo_0005112,GCST004844,28598419,3,Gestational age at birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST004844,28598419,3,Gestational age at birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0006917,GCST004845,28598419,2,Spontaneous preterm birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST004845,28598419,2,Spontaneous preterm birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0000681,GCST004710,28598434,26,Renal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0003917,GCST004841,28598419,0,Preterm birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST004841,28598419,0,Preterm birth (maternal effect)
http://www.ebi.ac.uk/efo/efo_0004682,GCST004642,28749367,6,QT interval (ambient particulate matter interaction)
http://www.ebi.ac.uk/efo/efo_0008255,GCST004642,28749367,6,QT interval (ambient particulate matter interaction)
http://www.ebi.ac.uk/efo/efo_0008009,GCST004643,28588231,8,"1,5-anhydroglucitol levels"
http://www.ebi.ac.uk/efo/efo_0009183,GCST005755,28584286,125,Cognitive empathy
http://www.ebi.ac.uk/efo/efo_1001460,GCST008256,28585551,10,Diverticulitis
http://www.ebi.ac.uk/efo/efo_0009959,GCST008257,28585551,4,Diverticular disease
http://www.orpha.net/ordo/orphanet_232,GCST004644,28584135,1,Vaso-occlusive pain in sickle-cell anemia
http://www.ebi.ac.uk/efo/efo_0008316,GCST004644,28584135,1,Vaso-occlusive pain in sickle-cell anemia
http://www.ebi.ac.uk/efo/efo_0004342,GCST008151,28552196,118,Waist circumference
http://www.ebi.ac.uk/efo/efo_0004778,GCST006620,27864402,13,Self-rated health
http://www.ebi.ac.uk/efo/efo_0005093,GCST008162,28552196,114,Hip circumference
http://www.ebi.ac.uk/efo/efo_0005207,GCST004721,28468790,20,Congenital heart disease (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005207,GCST004718,28468790,10,Congenital heart disease (inherited effect)
http://www.ebi.ac.uk/efo/efo_0005938,GCST004722,28468790,9,Left ventricular obstructive tract defect (maternal effect)
http://www.orpha.net/ordo/orphanet_2445,GCST004723,28468790,22,Conotruncal heart defects (maternal effects)
http://www.ebi.ac.uk/efo/efo_0005938,GCST004719,28468790,15,Left ventricular obstructive tract defect (inherited effect)
http://www.ebi.ac.uk/efo/efo_0004342,GCST008160,28552196,118,Waist circumference
http://www.ebi.ac.uk/efo/efo_0007789,GCST008161,28552196,139,Waist circumference adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0007788,GCST008159,28552196,85,Waist-to-hip ratio adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004340,GCST008158,28552196,153,Body mass index
http://www.ebi.ac.uk/efo/efo_0005409,GCST008157,28552196,73,Body fat mass
http://www.ebi.ac.uk/efo/efo_0004339,GCST008163,28552196,630,Height
http://www.orpha.net/ordo/orphanet_2445,GCST004720,28468790,10,Conotruncal heart defects (inherited effects)
http://purl.obolibrary.org/obo/hp_0002140,GCST004598,28495826,3,vWF levels in ischaemic stroke and hyperhomocysteinaemia
http://www.ebi.ac.uk/efo/efo_0004629,GCST004598,28495826,3,vWF levels in ischaemic stroke and hyperhomocysteinaemia
http://www.ebi.ac.uk/efo/efo_0004578,GCST004598,28495826,3,vWF levels in ischaemic stroke and hyperhomocysteinaemia
http://www.ebi.ac.uk/efo/efo_0008039,GCST008156,28552196,148,Hip circumference adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004343,GCST008155,28552196,80,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0005409,GCST008154,28552196,79,Trunk fat mass
http://www.ebi.ac.uk/efo/efo_0004995,GCST008153,28552196,76,Lean body mass
http://www.ebi.ac.uk/efo/efo_0004338,GCST008152,28552196,200,Weight
http://www.ebi.ac.uk/efo/efo_0001360,GCST004773,28566273,24,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST004774,28566273,12,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0007710,GCST004372,28577822,8,Language performance in older adults (adjusted for episodic memory)
http://www.ebi.ac.uk/efo/efo_0004874,GCST004372,28577822,8,Language performance in older adults (adjusted for episodic memory)
http://www.ebi.ac.uk/efo/efo_0007797,GCST004372,28577822,8,Language performance in older adults (adjusted for episodic memory)
http://www.ebi.ac.uk/efo/efo_0004466,GCST004533,28548082,0,Fasting blood insulin
http://www.ebi.ac.uk/efo/efo_0008036,GCST004761,28548082,1,Fasting blood glucose adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0008038,GCST004760,28548082,0,Hip bone size adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004844,GCST004538,28548082,0,Hip bone size
http://www.ebi.ac.uk/efo/efo_0004612,GCST004537,28548082,4,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004340,GCST004529,28548082,0,Body mass index
http://www.ebi.ac.uk/efo/efo_0004308,GCST004553,28548082,2,White blood cell count
http://www.ebi.ac.uk/efo/efo_0004530,GCST004550,28548082,4,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004574,GCST004548,28548082,2,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0006335,GCST004547,28548082,0,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004305,GCST004546,28548082,1,Red blood cell count
http://www.ebi.ac.uk/efo/efo_0004309,GCST004545,28548082,0,Platelet count
http://www.ebi.ac.uk/efo/efo_0004527,GCST004542,28548082,2,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0004611,GCST004541,28548082,2,Low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004501,GCST004540,28548082,0,Homeostasis model assessment of insulin resistance adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004501,GCST004539,28548082,0,Homeostasis model assessment of insulin resistance
http://www.ebi.ac.uk/efo/efo_0004509,GCST004536,28548082,1,Hemoglobin
http://www.ebi.ac.uk/efo/efo_0007788,GCST004556,28548082,0,Waist-to-hip ratio adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0004343,GCST004555,28548082,1,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0004338,GCST004554,28548082,1,Weight
http://www.ebi.ac.uk/efo/efo_0007789,GCST004552,28548082,0,Waist circumference adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0004342,GCST004551,28548082,0,Waist circumference
http://www.ebi.ac.uk/efo/efo_0008317,GCST004759,28548082,3,Very low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004348,GCST004535,28548082,0,Hematocrit
http://www.ebi.ac.uk/efo/efo_0004526,GCST004544,28548082,1,Mean corpuscular volume
http://www.ebi.ac.uk/efo/efo_0004528,GCST004543,28548082,1,Mean corpuscular hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0004339,GCST004534,28548082,0,Height
http://www.ebi.ac.uk/efo/efo_0008037,GCST004762,28548082,0,Fasting blood insulin adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004465,GCST004532,28548082,0,Fasting blood glucose
http://www.ebi.ac.uk/efo/efo_0006336,GCST004531,28548082,1,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004458,GCST004530,28548082,1,C-reactive protein levels
http://www.ebi.ac.uk/efo/efo_0003761,GCST004486,28540843,1,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0000676,GCST004346,28537254,61,Psoriasis
http://www.ebi.ac.uk/efo/efo_0004295,GCST004353,28542097,1,Left ventricular function change in anthracycline treatment
http://www.ebi.ac.uk/efo/efo_0005257,GCST004353,28542097,1,Left ventricular function change in anthracycline treatment
http://www.ebi.ac.uk/efo/efo_0001065,GCST004549,28537267,35,Endometriosis
http://www.ebi.ac.uk/efo/efo_0003756,GCST004377,28533516,1,Restricted and repetitive behaviours in autism spectrum disorder
http://www.ebi.ac.uk/efo/efo_0004782,GCST004377,28533516,1,Restricted and repetitive behaviours in autism spectrum disorder
http://www.ebi.ac.uk/efo/efo_0000692,GCST004521,28540026,301,Autism spectrum disorder or schizophrenia
http://www.ebi.ac.uk/efo/efo_0003756,GCST004521,28540026,301,Autism spectrum disorder or schizophrenia
http://www.ebi.ac.uk/efo/efo_0004337,GCST004364,28530673,36,Intelligence
http://www.ebi.ac.uk/efo/efo_0003756,GCST004520,28540026,3,Autism spectrum disorder
http://www.ebi.ac.uk/efo/efo_0008337,GCST004678,28525603,6,Psychosis proneness (hypomanic personality scale)
http://www.ebi.ac.uk/efo/efo_0008337,GCST004684,28525603,2,Psychosis proneness (revised physical anhedonia scale and revised social anhedonia scale)
http://www.ebi.ac.uk/efo/efo_0008337,GCST004683,28525603,2,Psychosis proneness (perceptual aberration scale and revised social anhedonia scale)
http://www.ebi.ac.uk/efo/efo_0008337,GCST004688,28525603,1,Psychosis proneness (perceptual aberration scale and revised physical anhedonia scale)
http://www.ebi.ac.uk/efo/efo_0008337,GCST004682,28525603,5,Psychosis proneness (hypomanic personality scale and revised social anhedonia scale)
http://www.ebi.ac.uk/efo/efo_0008337,GCST004681,28525603,6,Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale)
http://www.ebi.ac.uk/efo/efo_0008337,GCST004687,28525603,0,Psychosis proneness (schizoidia scale)
http://www.ebi.ac.uk/efo/efo_0008337,GCST004679,28525603,4,Psychosis proneness (hypomanic personality scale and perceptual aberration scale)
http://www.ebi.ac.uk/efo/efo_0008337,GCST004686,28525603,2,Psychosis proneness (revised social anhedonia scale)
http://www.ebi.ac.uk/efo/efo_0008337,GCST004680,28525603,1,Psychosis proneness (revised physical anhedonia scale)
http://www.ebi.ac.uk/efo/efo_0008337,GCST004685,28525603,3,Psychosis proneness (perceptual aberration scale)
http://www.ebi.ac.uk/efo/efo_0007627,GCST004526,28521775,4,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
http://www.ebi.ac.uk/efo/efo_0000621,GCST004510,28545128,9,Sporadic neuroblastoma
http://www.ebi.ac.uk/efo/efo_0007627,GCST004527,28521775,1,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
http://www.ebi.ac.uk/efo/efo_0007627,GCST004525,28521775,9,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)
http://www.ebi.ac.uk/efo/efo_0005671,GCST004511,28520984,0,Smoking status (daily vs non-daily)
http://www.ebi.ac.uk/efo/efo_0006527,GCST004514,28520984,0,Smoking status (ever vs never smokers)
http://www.ebi.ac.uk/efo/efo_0006527,GCST004513,28520984,0,Smoking status (current vs former)
http://www.ebi.ac.uk/efo/efo_0005671,GCST004512,28520984,2,Smoking status (heavy vs light)
http://www.ebi.ac.uk/efo/efo_0006925,GCST004399,28512139,28,Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms
http://www.ebi.ac.uk/efo/efo_0004614,GCST004399,28512139,28,Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms
http://www.ebi.ac.uk/efo/efo_0005413,GCST004400,28512992,2,Bone erosion in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0006925,GCST004398,28512139,44,Lipoprotein (a) levels
http://www.ebi.ac.uk/efo/efo_0004459,GCST004573,28334935,11,Iron status biomarkers (ferritin levels)
http://www.ebi.ac.uk/efo/efo_0007708,GCST004490,28641921,24,Cerebrospinal fluid t-tau:AB1-42 ratio
http://www.ebi.ac.uk/efo/efo_0004670,GCST004492,28641921,4,Cerebrospinal fluid AB1-42 levels
http://www.ebi.ac.uk/efo/efo_0006333,GCST004572,28334935,32,Iron status biomarkers (transferrin saturation)
http://www.ebi.ac.uk/efo/efo_0004760,GCST004491,28641921,7,Cerebrospinal fluid t-tau levels
http://www.ebi.ac.uk/efo/efo_0006334,GCST004571,28334935,34,Iron status biomarkers (total iron binding capacity)
http://www.ebi.ac.uk/efo/efo_0006332,GCST004570,28334935,19,Iron status biomarkers (iron levels)
http://www.orpha.net/ordo/orphanet_232,GCST004378,28552477,0,Mean corpuscular hemoglobin concentration in sickle cell disease
http://www.ebi.ac.uk/efo/efo_0004528,GCST004378,28552477,0,Mean corpuscular hemoglobin concentration in sickle cell disease
http://www.orpha.net/ordo/orphanet_232,GCST004379,28552477,15,Red blood cell density in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0007978,GCST004379,28552477,15,Red blood cell density in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0006335,GCST004385,28498854,9,Systolic blood pressure
http://purl.obolibrary.org/obo/go_0031427,GCST004358,28500057,3,Methotrexate-induced interstitial lung disease in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000685,GCST004358,28500057,3,Methotrexate-induced interstitial lung disease in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004244,GCST004358,28500057,3,Methotrexate-induced interstitial lung disease in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0005763,GCST004388,28498854,32,Blood pressure traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0006336,GCST004388,28498854,32,Blood pressure traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0006335,GCST004388,28498854,32,Blood pressure traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0000537,GCST004388,28498854,32,Blood pressure traits (multi-trait analysis)
http://www.ebi.ac.uk/efo/efo_0000537,GCST004384,28498854,7,Hypertension
http://www.ebi.ac.uk/efo/efo_0005763,GCST004387,28498854,9,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST004386,28498854,15,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004215,GCST004367,28494655,6,Anorexia nervosa
http://www.ebi.ac.uk/efo/efo_1001161,GCST004366,28492228,2,Rheumatic heart disease
http://www.ebi.ac.uk/efo/efo_0008006,GCST004574,28502801,14,Skin aging (microtopography measurement)
http://www.ebi.ac.uk/efo/efo_0008000,GCST004487,28490609,9,Peak insulin response
http://www.ebi.ac.uk/efo/efo_0008001,GCST006679,28490609,0,insulin secretion rate (BMI adjusted)
http://www.ebi.ac.uk/efo/efo_0006831,GCST006677,28490609,1,Acute insulin response (insulin secretion adjusted)
http://www.ebi.ac.uk/efo/efo_0006831,GCST006678,28490609,0,Acute insulin response (insulin secretion and BMI adjusted)
http://www.ebi.ac.uk/efo/efo_0008000,GCST006676,28490609,1,Peak insulin response (insulin secretion adjusted)
http://www.ebi.ac.uk/efo/efo_0008000,GCST006675,28490609,1,Peak insulin response (BMI and insulin secretion adjusted)
http://www.ebi.ac.uk/efo/efo_0006832,GCST006681,28490609,0,Insulin disposition index (BMI adjusted)
http://www.ebi.ac.uk/efo/efo_0006832,GCST004489,28490609,1,Insulin disposition index
http://www.ebi.ac.uk/efo/efo_0008001,GCST004488,28490609,2,Insulin secretion rate
http://www.ebi.ac.uk/efo/efo_0006831,GCST004575,28490609,8,Acute insulin response
http://www.ebi.ac.uk/efo/efo_0007878,GCST004405,28485404,8,Alcohol consumption (drinks per week)
http://www.ebi.ac.uk/efo/efo_0004329,GCST004405,28485404,8,Alcohol consumption (drinks per week)
http://www.ebi.ac.uk/efo/efo_0007878,GCST004404,28485404,7,Alcohol consumption (drinkers vs non-drinkers)
http://www.ebi.ac.uk/efo/efo_0004329,GCST004404,28485404,7,Alcohol consumption (drinkers vs non-drinkers)
http://www.ebi.ac.uk/efo/efo_0008005,GCST004524,28476931,9,Energy expenditure (24h)
http://www.ebi.ac.uk/efo/efo_0008004,GCST004523,28476931,10,Resting metabolic rate
http://www.ebi.ac.uk/efo/efo_0004514,GCST004350,28472463,21,Bone ultrasound measurement (velocity of sound)
http://www.ebi.ac.uk/efo/efo_0004514,GCST004351,28472463,28,Bone ultrasound measurement (broadband ultrasound attenuation)
http://www.ebi.ac.uk/efo/efo_0004624,GCST004345,28471803,2,Elevated serum prostate-specific antigen levels in healthy men
http://www.ebi.ac.uk/efo/efo_0000638,GCST004485,28470677,61,Survival in pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0002618,GCST004485,28470677,61,Survival in pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0000270,GCST004390,28461288,3,Asthma
http://www.ebi.ac.uk/efo/efo_0005208,GCST004293,28452372,3,Glomerular filtration rate (cystatin C)
http://www.ebi.ac.uk/efo/efo_0004617,GCST004293,28452372,3,Glomerular filtration rate (cystatin C)
http://www.ebi.ac.uk/efo/efo_0007979,GCST004374,28453389,0,Resistance to antipsychotic treatment in schizophrenia (childhood trauma interaction)
http://www.ebi.ac.uk/efo/efo_0000692,GCST004374,28453389,0,Resistance to antipsychotic treatment in schizophrenia (childhood trauma interaction)
http://purl.obolibrary.org/obo/go_0097332,GCST004374,28453389,0,Resistance to antipsychotic treatment in schizophrenia (childhood trauma interaction)
http://www.ebi.ac.uk/efo/efo_0004526,GCST004335,28453575,16,Mean corpuscular volume
http://www.ebi.ac.uk/efo/efo_0004527,GCST004334,28453575,14,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0000692,GCST004375,28453389,0,Resistance to antipsychotic treatment in schizophrenia
http://purl.obolibrary.org/obo/go_0097332,GCST004375,28453389,0,Resistance to antipsychotic treatment in schizophrenia
http://www.ebi.ac.uk/efo/efo_0005192,GCST004333,28453575,1,Red cell distribution width
http://www.ebi.ac.uk/efo/efo_0004509,GCST004331,28453575,3,Hemoglobin
http://www.ebi.ac.uk/efo/efo_0004305,GCST004332,28453575,5,Red blood cell count
http://www.ebi.ac.uk/efo/efo_0004528,GCST004329,28453575,9,Mean corpuscular hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0004348,GCST004330,28453575,3,Hematocrit
http://www.ebi.ac.uk/efo/efo_0005208,GCST004292,28452372,57,Glomerular filtration rate (creatinine)
http://www.ebi.ac.uk/efo/efo_0004518,GCST004292,28452372,57,Glomerular filtration rate (creatinine)
http://www.ebi.ac.uk/efo/efo_0007788,GCST004576,28448500,145,Waist-to-hip ratio adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0008002,GCST004576,28448500,145,Waist-to-hip ratio adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0007788,GCST004577,28448500,8,Waist-to-hip ratio adjusted for BMI in inactive individuals
http://www.ebi.ac.uk/efo/efo_0008002,GCST004577,28448500,8,Waist-to-hip ratio adjusted for BMI in inactive individuals
http://www.ebi.ac.uk/efo/efo_0007788,GCST004578,28448500,143,Waist-to-hip ratio adjusted for BMI in active individuals
http://www.ebi.ac.uk/efo/efo_0008002,GCST004578,28448500,143,Waist-to-hip ratio adjusted for BMI in active individuals
http://www.ebi.ac.uk/efo/efo_0007789,GCST004564,28448500,235,Waist circumference adjusted for BMI in active individuals
http://www.ebi.ac.uk/efo/efo_0008002,GCST004564,28448500,235,Waist circumference adjusted for BMI in active individuals
http://www.ebi.ac.uk/efo/efo_0008002,GCST004560,28448500,45,Body mass index in physically inactive individuals
http://www.ebi.ac.uk/efo/efo_0004340,GCST004560,28448500,45,Body mass index in physically inactive individuals
http://www.ebi.ac.uk/efo/efo_0008002,GCST004559,28448500,195,Body mass index in physically active individuals
http://www.ebi.ac.uk/efo/efo_0004340,GCST004559,28448500,195,Body mass index in physically active individuals
http://www.ebi.ac.uk/efo/efo_0007789,GCST004563,28448500,253,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0008002,GCST004563,28448500,253,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0008002,GCST004568,28448500,2,Body mass index (physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004568,28448500,2,Body mass index (physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0007788,GCST004566,28448500,0,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0008002,GCST004566,28448500,0,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0007789,GCST004562,28448500,260,Waist circumference adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0008002,GCST004562,28448500,260,Waist circumference adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0008002,GCST004557,28448500,266,Body mass index
http://www.ebi.ac.uk/efo/efo_0004340,GCST004557,28448500,266,Body mass index
http://www.ebi.ac.uk/efo/efo_0003885,GCST004290,28445677,5,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0000275,GCST004352,28460022,6,Early onset atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0007788,GCST004567,28448500,141,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0008002,GCST004567,28448500,141,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0008002,GCST004558,28448500,242,Body mass index (joint analysis main effects and physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004558,28448500,242,Body mass index (joint analysis main effects and physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0007789,GCST004565,28448500,14,Waist circumference adjusted for BMI in inactive individuals
http://www.ebi.ac.uk/efo/efo_0008002,GCST004565,28448500,14,Waist circumference adjusted for BMI in inactive individuals
http://www.ebi.ac.uk/efo/efo_0007789,GCST004561,28448500,0,Waist circumference adjusted for BMI (physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0008002,GCST004561,28448500,0,Waist circumference adjusted for BMI (physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0004318,GCST004496,28443625,2,BMI (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004496,28443625,2,BMI (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004318,GCST004509,28443625,1,Waist-to-hip ratio adjusted for BMI in smokers
http://www.ebi.ac.uk/efo/efo_0007788,GCST004509,28443625,1,Waist-to-hip ratio adjusted for BMI in smokers
http://www.ebi.ac.uk/efo/efo_0004318,GCST004507,28443625,45,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
http://www.ebi.ac.uk/efo/efo_0007788,GCST004507,28443625,45,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004318,GCST004495,28443625,145,BMI (adjusted for smoking behaviour)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004495,28443625,145,BMI (adjusted for smoking behaviour)
http://www.ebi.ac.uk/efo/efo_0007788,GCST004508,28443625,46,Waist-to-hip ratio adjusted for BMI in non-smokers
http://www.ebi.ac.uk/efo/efo_0004318,GCST004498,28443625,30,BMI in smokers
http://www.ebi.ac.uk/efo/efo_0004340,GCST004498,28443625,30,BMI in smokers
http://www.ebi.ac.uk/efo/efo_0004318,GCST004503,28443625,15,Waist circumference adjusted for BMI in smokers
http://www.ebi.ac.uk/efo/efo_0007789,GCST004503,28443625,15,Waist circumference adjusted for BMI in smokers
http://www.ebi.ac.uk/efo/efo_0004340,GCST004499,28443625,105,BMI in non-smokers
http://www.ebi.ac.uk/efo/efo_0007789,GCST004504,28443625,108,Waist circumference adjusted for BMI in non-smokers
http://www.ebi.ac.uk/efo/efo_0007948,GCST004410,28447399,3,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)
http://www.ebi.ac.uk/efo/efo_0007983,GCST004410,28447399,3,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)
http://www.ebi.ac.uk/efo/efo_0004318,GCST004505,28443625,116,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
http://www.ebi.ac.uk/efo/efo_0007788,GCST004505,28443625,116,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
http://www.ebi.ac.uk/efo/efo_0004318,GCST004502,28443625,2,Waist circumference adjusted for BMI (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0007789,GCST004502,28443625,2,Waist circumference adjusted for BMI (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004318,GCST004497,28443625,140,Body mass index (joint analysis main effects and smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004497,28443625,140,Body mass index (joint analysis main effects and smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004318,GCST004501,28443625,135,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
http://www.ebi.ac.uk/efo/efo_0007789,GCST004501,28443625,135,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004318,GCST004506,28443625,2,Waist-to-hip ratio adjusted for BMI (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0007788,GCST004506,28443625,2,Waist-to-hip ratio adjusted for BMI (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004318,GCST004500,28443625,140,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
http://www.ebi.ac.uk/efo/efo_0007789,GCST004500,28443625,140,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
http://www.ebi.ac.uk/efo/efo_0000180,GCST004407,28447399,9,Neurocognitive impairment in HIV-1 infection (dichotomous)
http://www.ebi.ac.uk/efo/efo_0007998,GCST004407,28447399,9,Neurocognitive impairment in HIV-1 infection (dichotomous)
http://www.ebi.ac.uk/efo/efo_0007948,GCST004409,28447399,2,HIV-associated neurocognitive disorder
http://www.ebi.ac.uk/efo/efo_0007948,GCST004408,28447399,3,HIV-associated neurocognitive disorder (mild neurocognitive disorder)
http://www.ebi.ac.uk/efo/efo_0007982,GCST004408,28447399,3,HIV-associated neurocognitive disorder (mild neurocognitive disorder)
http://www.ebi.ac.uk/efo/efo_0007948,GCST004411,28447399,4,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)
http://www.ebi.ac.uk/efo/efo_0007982,GCST004411,28447399,4,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)
http://www.ebi.ac.uk/efo/efo_0007983,GCST004411,28447399,4,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)
http://www.ebi.ac.uk/efo/efo_0000180,GCST004406,28447399,6,Neurocognitive impairment in HIV-1 infection (continuous)
http://www.ebi.ac.uk/efo/efo_0007998,GCST004406,28447399,6,Neurocognitive impairment in HIV-1 infection (continuous)
http://www.ebi.ac.uk/efo/efo_0003768,GCST004294,28440896,14,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0007841,GCST004327,28441456,16,Facial morphology (factor 23)
http://www.ebi.ac.uk/efo/efo_0007841,GCST004326,28441456,20,Facial morphology (factor 22)
http://www.ebi.ac.uk/efo/efo_0007843,GCST004325,28441456,25,"Facial morphology (factor 21, depth of nasal alae)"
http://www.ebi.ac.uk/efo/efo_0007858,GCST004318,28441456,21,"Facial morphology (factor 14, intercanthal width)"
http://www.ebi.ac.uk/efo/efo_0007843,GCST004317,28441456,16,"Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)"
http://www.ebi.ac.uk/efo/efo_0007955,GCST004317,28441456,16,"Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)"
http://www.ebi.ac.uk/efo/efo_0007955,GCST004316,28441456,18,"Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface)"
http://www.ebi.ac.uk/efo/efo_0007843,GCST004315,28441456,19,"Facial morphology (factor 11, projection of the nose)"
http://www.ebi.ac.uk/efo/efo_0007856,GCST004313,28441456,19,"Facial morphology (factor 9, facial height related to vertical position of nasion)"
http://www.ebi.ac.uk/efo/efo_0007858,GCST004312,28441456,19,"Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion)"
http://www.ebi.ac.uk/efo/efo_0007843,GCST004311,28441456,17,"Facial morphology (factor 7, width of cartilaginous portion of nose)"
http://www.ebi.ac.uk/efo/efo_0007845,GCST004310,28441456,22,"Facial morphology (factor 6, height of vermillion lower lip)"
http://www.ebi.ac.uk/efo/efo_0007955,GCST004309,28441456,17,"Facial morphology (factor 5, width of mouth relative to central midface)"
http://www.ebi.ac.uk/efo/efo_0007856,GCST004308,28441456,20,"Facial morphology (factor 4, facial height related to vertical position of gnathion)"
http://www.ebi.ac.uk/efo/efo_0007858,GCST004306,28441456,16,"Facial morphology (factor 2, vertical position of orbits relative to midface)"
http://www.ebi.ac.uk/efo/efo_0007841,GCST004324,28441456,22,Facial morphology (factor 20)
http://www.ebi.ac.uk/efo/efo_0007841,GCST004323,28441456,32,Facial morphology (factor 19)
http://www.ebi.ac.uk/efo/efo_0007841,GCST004322,28441456,21,Facial morphology (factor 18)
http://www.ebi.ac.uk/efo/efo_0007845,GCST004321,28441456,26,"Facial morphology (factor 17, height of vermillion upper lip)"
http://www.ebi.ac.uk/efo/efo_0007841,GCST004320,28441456,15,Facial morphology (factor 16)
http://www.ebi.ac.uk/efo/efo_0007845,GCST004319,28441456,26,"Facial morphology (factor 15, philtrum width)"
http://www.ebi.ac.uk/efo/efo_0007845,GCST004307,28441456,16,"Facial morphology (factor 3, length of philtrum)"
http://www.ebi.ac.uk/efo/efo_0007843,GCST004314,28441456,14,"Facial morphology (factor 10, width of nasal floor)"
http://www.ebi.ac.uk/efo/efo_0003925,GCST004291,28441426,9,Residual cognition
http://purl.obolibrary.org/obo/go_0007568,GCST004291,28441426,9,Residual cognition
http://www.ebi.ac.uk/efo/efo_0006342,GCST004303,28449029,5,Aggressive periodontitis
http://www.ebi.ac.uk/efo/efo_0007855,GCST004328,28441456,22,"Facial morphology (factor 1, breadth of lateral portion of upper face)"
http://purl.obolibrary.org/obo/hp_0100543,GCST004253,28560309,11,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)
http://www.ebi.ac.uk/efo/efo_0000249,GCST004253,28560309,11,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)
http://www.ebi.ac.uk/efo/efo_0007710,GCST004253,28560309,11,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)
http://www.ebi.ac.uk/efo/efo_0007788,GCST004518,28430825,13,Waist-to-hip ratio adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0004340,GCST004519,28430825,32,Body mass index (adult)
http://www.ebi.ac.uk/efo/efo_0007971,GCST004360,28429243,1,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_1000649,GCST004360,28429243,1,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_0007970,GCST004360,28429243,1,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_0007971,GCST004359,28429243,2,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_1000649,GCST004359,28429243,2,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_1001486,GCST004302,28425483,22,Primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0002689,GCST004227,28424481,15,Obstetric antiphospholipid syndrome
http://www.ebi.ac.uk/efo/efo_0007972,GCST004363,28429243,5,Plasma androstenedione levels in resected early stage-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_1000649,GCST004363,28429243,5,Plasma androstenedione levels in resected early stage-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_1000649,GCST004362,28429243,2,Plasma estrone levels in resected estrogen-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_0007970,GCST004362,28429243,2,Plasma estrone levels in resected estrogen-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_0007972,GCST004361,28429243,14,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_1000649,GCST004361,28429243,14,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_0007970,GCST004361,28429243,14,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer
http://www.ebi.ac.uk/efo/efo_0003888,GCST004336,28416812,1,Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0007969,GCST004336,28416812,1,Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0007968,GCST004344,28421636,0,Tissue factor pathway inhibitor levels
http://www.ebi.ac.uk/efo/efo_0000275,GCST004373,28416822,19,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0000275,GCST004301,28416818,9,Prevalent atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0000275,GCST004300,28416818,5,Incident atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0000275,GCST004295,28416818,10,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0000275,GCST004299,28416818,1,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0000275,GCST004298,28416818,1,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0000275,GCST004297,28416818,20,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0000275,GCST004296,28416818,8,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0006328,GCST004271,28437668,2,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)
http://www.ebi.ac.uk/efo/efo_1001892,GCST004271,28437668,2,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)
http://www.ebi.ac.uk/efo/efo_0006328,GCST004275,28437668,5,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)
http://www.ebi.ac.uk/efo/efo_1001892,GCST004275,28437668,5,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)
http://www.ebi.ac.uk/efo/efo_0006328,GCST004274,28437668,4,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)
http://www.ebi.ac.uk/efo/efo_1001892,GCST004274,28437668,4,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)
http://www.ebi.ac.uk/efo/efo_0006328,GCST004273,28437668,3,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)
http://www.ebi.ac.uk/efo/efo_1001892,GCST004273,28437668,3,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)
http://www.ebi.ac.uk/efo/efo_0006328,GCST004270,28437668,3,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)
http://www.ebi.ac.uk/efo/efo_1001892,GCST004270,28437668,3,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)
http://www.ebi.ac.uk/efo/efo_0006328,GCST004272,28437668,0,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 12 weeks)
http://www.ebi.ac.uk/efo/efo_1001892,GCST004272,28437668,0,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 12 weeks)
http://www.ebi.ac.uk/efo/efo_0001360,GCST004304,28406950,1,Prevalent type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST004305,28406950,2,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0008204,GCST004653,28394258,0,Peak velocity of the mitral E-wave
http://www.ebi.ac.uk/efo/efo_0008206,GCST004648,28394258,6,Left  ventricle systolic dysfunction
http://www.ebi.ac.uk/efo/efo_0008206,GCST004645,28394258,1,Left ventricular fractional shortening
http://www.ebi.ac.uk/efo/efo_0008205,GCST004659,28394258,1,Left ventricular mass
http://www.ebi.ac.uk/efo/efo_0008205,GCST004646,28394258,21,Left ventricle wall thickness
http://www.ebi.ac.uk/efo/efo_0008205,GCST004655,28394258,2,Left ventricle diastolic internal dimension
http://www.ebi.ac.uk/efo/efo_0008205,GCST004647,28394258,16,Left atrial antero-posterior diameter
http://www.ebi.ac.uk/efo/efo_0005037,GCST004651,28394258,8,Aortic root size
http://www.ebi.ac.uk/efo/efo_0008204,GCST004660,28394258,0,Heart failure with preserved ejection fraction
http://www.ebi.ac.uk/efo/efo_0008204,GCST004650,28394258,0,Diastolic dysfunction with preserved ejection pressure
http://www.ebi.ac.uk/efo/efo_0008204,GCST004657,28394258,0,Ratio of the peak velocity of the excursion of the lateral mitral annulus in the early diastolic phase and the peak velocity of the mitral E-wave
http://www.ebi.ac.uk/efo/efo_0008204,GCST004654,28394258,0,Deceleration time of the mitral E-wave
http://www.ebi.ac.uk/efo/efo_0008204,GCST004656,28394258,1,Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.
http://www.ebi.ac.uk/efo/efo_0008204,GCST004652,28394258,2,Peak velocity of the mitral A-wave
http://www.ebi.ac.uk/efo/efo_0008204,GCST004658,28394258,0,Peak velocity of excursion of lateral mitral annulus in early diastolic phase
http://www.ebi.ac.uk/efo/efo_0008204,GCST004649,28394258,5,Isovolumetric relaxation time
http://www.ebi.ac.uk/efo/efo_0000203,GCST004287,28375557,0,Monoclonal gammopathy of undetermined significance
http://www.ebi.ac.uk/efo/efo_0007940,GCST004343,28374850,3,Chronic venous disease
http://purl.obolibrary.org/obo/hp_0002619,GCST004343,28374850,3,Chronic venous disease
http://www.ebi.ac.uk/efo/efo_0007964,GCST004281,28235828,2,Midgestational circulating levels of organochlorine pesticides
http://www.ebi.ac.uk/efo/efo_0007960,GCST004281,28235828,2,Midgestational circulating levels of organochlorine pesticides
http://www.ebi.ac.uk/efo/efo_0009105,GCST006054,28373541,9,High altitude adaptation
http://www.ebi.ac.uk/efo/efo_0007042,GCST004283,28235828,25,Midgestational circulating levels of PCBs
http://www.ebi.ac.uk/efo/efo_0007964,GCST004283,28235828,25,Midgestational circulating levels of PCBs
http://www.ebi.ac.uk/efo/efo_0007964,GCST004282,28235828,0,Midgestational circulating levels of organochlorine pesticides (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007959,GCST004282,28235828,0,Midgestational circulating levels of organochlorine pesticides (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007960,GCST004282,28235828,0,Midgestational circulating levels of organochlorine pesticides (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007961,GCST004286,28235828,11,Midgestational circulating levels of PBDEs (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007964,GCST004286,28235828,11,Midgestational circulating levels of PBDEs (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007959,GCST004286,28235828,11,Midgestational circulating levels of PBDEs (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007962,GCST004286,28235828,11,Midgestational circulating levels of PBDEs (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007961,GCST004285,28235828,9,Midgestational circulating levels of PBDEs
http://www.ebi.ac.uk/efo/efo_0007964,GCST004285,28235828,9,Midgestational circulating levels of PBDEs
http://www.ebi.ac.uk/efo/efo_0007962,GCST004285,28235828,9,Midgestational circulating levels of PBDEs
http://www.ebi.ac.uk/efo/efo_0007042,GCST004284,28235828,11,Midgestational circulating levels of PCBs (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007964,GCST004284,28235828,11,Midgestational circulating levels of PCBs (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007959,GCST004284,28235828,11,Midgestational circulating levels of PCBs (fetal genetic effect)
http://www.ebi.ac.uk/efo/efo_0007966,GCST004264,28207573,27,Clopidogrel active metabolite levels
http://www.ebi.ac.uk/efo/efo_0008377,GCST004865,28199695,96,Itch intensity from mosquito bite adjusted by bite size
http://www.ebi.ac.uk/efo/efo_0008378,GCST004865,28199695,96,Itch intensity from mosquito bite adjusted by bite size
http://www.ebi.ac.uk/efo/efo_0008380,GCST004864,28199695,45,Perceived unattractiveness to mosquitoes
http://www.ebi.ac.uk/efo/efo_0008378,GCST004863,28199695,147,Mosquito bite size
http://www.ebi.ac.uk/efo/efo_0008377,GCST004862,28199695,240,Itch intensity from mosquito bite adjusted by bite size
http://www.ebi.ac.uk/efo/efo_0008378,GCST004862,28199695,240,Itch intensity from mosquito bite adjusted by bite size
http://www.ebi.ac.uk/efo/efo_0007866,GCST004262,28388302,3,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis
http://www.orpha.net/ordo/orphanet_3389,GCST004262,28388302,3,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis
http://www.ebi.ac.uk/efo/efo_0006904,GCST004262,28388302,3,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis
http://www.ebi.ac.uk/efo/efo_0000764,GCST004262,28388302,3,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis
http://www.ebi.ac.uk/efo/efo_0004228,GCST004262,28388302,3,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis
http://www.ebi.ac.uk/efo/efo_0006340,GCST004259,28348047,4,Mean arterial pressure (long-term average)
http://www.ebi.ac.uk/efo/efo_0005763,GCST004260,28348047,0,Pulse pressure (long-term average)
http://www.ebi.ac.uk/efo/efo_0006336,GCST004258,28348047,3,Diastolic blood pressure (long-term average)
http://www.ebi.ac.uk/efo/efo_0001065,GCST004370,28333195,10,Deep ovarian and/or rectovaginal disease with dense adhesions
http://www.ebi.ac.uk/efo/efo_0001065,GCST004369,28333195,4,Ovarian disease with few adhesions
http://www.ebi.ac.uk/efo/efo_0008377,GCST004861,28199695,98,Itch intensity from mosquito bite
http://www.ebi.ac.uk/efo/efo_0004645,GCST004268,28289848,1,Immune response to measles vaccine (measles-induced IFN gamma)
http://www.ebi.ac.uk/efo/efo_0004985,GCST004266,28207573,1,Response to clopidogrel therapy
http://purl.obolibrary.org/obo/go_1903493,GCST004266,28207573,1,Response to clopidogrel therapy
http://www.ebi.ac.uk/efo/efo_0001065,GCST004368,28333195,6,Endometriosis
http://www.ebi.ac.uk/efo/efo_0004286,GCST004256,28373160,9,Venous thromboembolism
http://www.ebi.ac.uk/efo/efo_0006904,GCST004261,28388302,1,Liver injury in anti-retroviral drug treated HIV
http://www.ebi.ac.uk/efo/efo_0000764,GCST004261,28388302,1,Liver injury in anti-retroviral drug treated HIV
http://www.ebi.ac.uk/efo/efo_0004228,GCST004261,28388302,1,Liver injury in anti-retroviral drug treated HIV
http://www.ebi.ac.uk/efo/efo_0006335,GCST004257,28348047,4,Systolic blood pressure (long-term average)
http://www.ebi.ac.uk/efo/efo_0004645,GCST004269,28289848,6,Immune response to measles vaccine (measles-specific neutralising antibody titre)
http://www.ebi.ac.uk/efo/efo_1002012,GCST004265,28358823,3,Anterior cruciate ligament rupture
http://www.ebi.ac.uk/efo/efo_1001434,GCST004263,28358823,4,Achilles tendinopathy
http://www.ebi.ac.uk/efo/efo_0007967,GCST004267,28360221,37,Blood osmolality (transformed sodium)
http://www.ebi.ac.uk/efo/efo_0000253,GCST003175,26580837,6,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0004530,GCST003217,26582766,9,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004612,GCST003215,26582766,6,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004611,GCST003216,26582766,7,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004574,GCST003214,26582766,14,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0007757,GCST003182,26569114,5,Staphylococcus aureus nasal carriage (persistent)
http://www.ebi.ac.uk/efo/efo_0007758,GCST003181,26569114,7,Staphylococcus aureus nasal carriage (intermittent)
http://www.ebi.ac.uk/efo/efo_0000692,GCST003190,26531332,1,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0007770,GCST003200,26566055,1,Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours)
http://www.ebi.ac.uk/efo/efo_0004623,GCST003194,26561523,41,Fibrinogen levels
http://www.ebi.ac.uk/efo/efo_0007771,GCST003224,26573232,0,Response to anthracycline-based chemotherapy in breast cancer (pathologic complete response)
http://www.ebi.ac.uk/efo/efo_0000305,GCST003224,26573232,0,Response to anthracycline-based chemotherapy in breast cancer (pathologic complete response)
http://www.ebi.ac.uk/efo/efo_0005257,GCST003224,26573232,0,Response to anthracycline-based chemotherapy in breast cancer (pathologic complete response)
http://www.ebi.ac.uk/efo/efo_0000180,GCST003183,26553974,18,Setpoint viral load in HIV-1 infection
http://www.ebi.ac.uk/efo/efo_0006319,GCST003183,26553974,18,Setpoint viral load in HIV-1 infection
http://www.ebi.ac.uk/efo/efo_0000311,GCST003232,26546620,1,Response to Pazopanib in cancer (hepatotoxicity)
http://www.ebi.ac.uk/efo/efo_0007779,GCST003232,26546620,1,Response to Pazopanib in cancer (hepatotoxicity)
http://www.ebi.ac.uk/efo/efo_0004735,GCST003232,26546620,1,Response to Pazopanib in cancer (hepatotoxicity)
http://www.ebi.ac.uk/efo/efo_0004710,GCST003225,26545240,33,Pelvic organ prolapse (moderate/severe)
http://www.ebi.ac.uk/efo/efo_0004591,GCST003180,26542096,7,Atopic march
http://www.ebi.ac.uk/efo/efo_0000274,GCST003180,26542096,7,Atopic march
http://www.ebi.ac.uk/efo/efo_0007755,GCST003180,26542096,7,Atopic march
http://www.ebi.ac.uk/efo/efo_0004710,GCST003226,26545240,25,Pelvic organ prolapse
http://www.ebi.ac.uk/efo/efo_1001050,GCST003179,26589003,0,Multiple system atrophy
http://www.ebi.ac.uk/efo/efo_0007753,GCST003221,26528553,35,Gut microbiome composition (summer)
http://www.ebi.ac.uk/efo/efo_0007753,GCST003223,26528553,33,Gut microbiome composition (winter)
http://www.ebi.ac.uk/efo/efo_0007753,GCST003222,26528553,9,Gut microbiome composition (summer and winter)
http://www.ebi.ac.uk/efo/efo_1001293,GCST005879,26525574,1,Collagenous colitis
http://www.ebi.ac.uk/efo/efo_0004246,GCST003192,26434682,2,Coronary artery aneurysm in Kawasaki disease
http://www.ebi.ac.uk/efo/efo_1000881,GCST003192,26434682,2,Coronary artery aneurysm in Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0004704,GCST005560,26414677,2,Menopause (age at onset)
http://www.ebi.ac.uk/efo/efo_0004339,GCST005354,26366551,0,Height
http://www.ebi.ac.uk/efo/efo_0004704,GCST005312,26414677,51,Menopause (age at onset)
http://purl.obolibrary.org/obo/go_0007608,GCST003174,26632684,22,Sense of smell
http://www.ebi.ac.uk/efo/efo_0000537,GCST003186,26516778,1,Cardiovascular disease in hypertension (ACE inhibitor interaction)
http://www.ebi.ac.uk/efo/efo_0000319,GCST003186,26516778,1,Cardiovascular disease in hypertension (ACE inhibitor interaction)
http://www.ebi.ac.uk/efo/efo_0005325,GCST003186,26516778,1,Cardiovascular disease in hypertension (ACE inhibitor interaction)
http://purl.obolibrary.org/obo/go_0036270,GCST003202,26516778,0,Myocardial infarction in hypertension (diuretic interaction)
http://www.ebi.ac.uk/efo/efo_0000537,GCST003202,26516778,0,Myocardial infarction in hypertension (diuretic interaction)
http://www.ebi.ac.uk/efo/efo_0000612,GCST003202,26516778,0,Myocardial infarction in hypertension (diuretic interaction)
http://www.ebi.ac.uk/efo/efo_0000537,GCST003201,26516778,0,Myocardial infarction in hypertension (beta blocker interaction)
http://www.ebi.ac.uk/efo/efo_0007766,GCST003201,26516778,0,Myocardial infarction in hypertension (beta blocker interaction)
http://www.ebi.ac.uk/efo/efo_0000612,GCST003201,26516778,0,Myocardial infarction in hypertension (beta blocker interaction)
http://www.ebi.ac.uk/efo/efo_0000537,GCST003187,26516778,0,Myocardial infarction in hypertension (ACE inhibitor interaction)
http://www.ebi.ac.uk/efo/efo_0005325,GCST003187,26516778,0,Myocardial infarction in hypertension (ACE inhibitor interaction)
http://www.ebi.ac.uk/efo/efo_0000612,GCST003187,26516778,0,Myocardial infarction in hypertension (ACE inhibitor interaction)
http://www.ebi.ac.uk/efo/efo_0000537,GCST003203,26516778,0,Cardiovascular disease in hypertension (beta blocker interaction)
http://www.ebi.ac.uk/efo/efo_0007766,GCST003203,26516778,0,Cardiovascular disease in hypertension (beta blocker interaction)
http://www.ebi.ac.uk/efo/efo_0000319,GCST003203,26516778,0,Cardiovascular disease in hypertension (beta blocker interaction)
http://purl.obolibrary.org/obo/go_0036270,GCST003204,26516778,0,Cardiovascular disease in hypertension (diuretic interaction)
http://www.ebi.ac.uk/efo/efo_0000537,GCST003204,26516778,0,Cardiovascular disease in hypertension (diuretic interaction)
http://www.ebi.ac.uk/efo/efo_0000319,GCST003204,26516778,0,Cardiovascular disease in hypertension (diuretic interaction)
http://www.ebi.ac.uk/efo/efo_0000537,GCST003206,26516778,1,Myocardial infarction in hypertension (calcium channel blocker interaction)
http://www.ebi.ac.uk/efo/efo_0007767,GCST003206,26516778,1,Myocardial infarction in hypertension (calcium channel blocker interaction)
http://www.ebi.ac.uk/efo/efo_0000612,GCST003206,26516778,1,Myocardial infarction in hypertension (calcium channel blocker interaction)
http://www.ebi.ac.uk/efo/efo_0000537,GCST003205,26516778,2,Cardiovascular disease in hypertension (calcium channel blocker interaction)
http://www.ebi.ac.uk/efo/efo_0000319,GCST003205,26516778,2,Cardiovascular disease in hypertension (calcium channel blocker interaction)
http://www.ebi.ac.uk/efo/efo_0007767,GCST003205,26516778,2,Cardiovascular disease in hypertension (calcium channel blocker interaction)
http://www.ebi.ac.uk/efo/efo_0004578,GCST003157,26519441,1,Plasma homocysteine levels
http://www.ebi.ac.uk/efo/efo_1000566,GCST003247,26503584,3,Testicular germ cell tumor
http://www.ebi.ac.uk/efo/efo_1000566,GCST003246,26503584,3,Testicular germ cell tumor
http://www.ebi.ac.uk/efo/efo_0000289,GCST003161,26503763,4,Objective response to lithium treatment in bipolar disorder
http://purl.obolibrary.org/obo/go_0010226,GCST003161,26503763,4,Objective response to lithium treatment in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST003159,26503763,4,Objective response to lithium treatment
http://purl.obolibrary.org/obo/go_0010226,GCST003159,26503763,4,Objective response to lithium treatment
http://www.ebi.ac.uk/efo/efo_0000289,GCST003160,26503763,4,Subjective response to lithium treatment in bipolar disorder
http://purl.obolibrary.org/obo/go_0010226,GCST003160,26503763,4,Subjective response to lithium treatment in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST003158,26503763,4,Subjective response to lithium treatment
http://purl.obolibrary.org/obo/go_0010226,GCST003158,26503763,4,Subjective response to lithium treatment
http://www.ebi.ac.uk/efo/efo_0002690,GCST003156,26502338,47,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0002690,GCST003155,26502338,53,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004265,GCST003154,26488411,4,Peripheral artery disease
http://www.ebi.ac.uk/efo/efo_0007681,GCST003207,26491034,5,Response to exercise (triglyceride level interaction)
http://www.ebi.ac.uk/efo/efo_0007768,GCST003207,26491034,5,Response to exercise (triglyceride level interaction)
http://www.ebi.ac.uk/efo/efo_0004629,GCST003210,26486471,10,Low vWF levels
http://www.ebi.ac.uk/efo/efo_0004767,GCST003162,26480920,0,Visceral adipose tissue/subcutaneous adipose tissue ratio
http://www.ebi.ac.uk/efo/efo_0004766,GCST003164,26480920,0,Subcutaneous adipose tissue
http://www.ebi.ac.uk/efo/efo_0004764,GCST003168,26480920,0,Total adipose tissue
http://www.ebi.ac.uk/efo/efo_0004765,GCST003166,26480920,0,Visceral adipose tissue
http://www.ebi.ac.uk/efo/efo_0004767,GCST003173,26480920,3,Visceral adipose tissue/subcutaneous adipose tissue ratio
http://www.ebi.ac.uk/efo/efo_0004765,GCST003172,26480920,1,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004765,GCST003171,26480920,4,Visceral adipose tissue
http://www.ebi.ac.uk/efo/efo_0004766,GCST003170,26480920,9,Subcutaneous adipose tissue
http://www.ebi.ac.uk/efo/efo_0004767,GCST003163,26480920,0,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004764,GCST003169,26480920,0,Total adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004765,GCST003167,26480920,0,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004766,GCST003165,26480920,0,Subcutaneous adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_1000802,GCST003153,26482880,3,Cirrhosis (alcohol related)
http://www.ebi.ac.uk/efo/efo_0000274,GCST003184,26482879,40,Atopic dermatitis
http://www.ebi.ac.uk/efo/efo_0003767,GCST006960,26490195,0,Inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0000403,GCST003178,26460308,2,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy
http://www.ebi.ac.uk/efo/efo_0000482,GCST003178,26460308,2,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy
http://www.ebi.ac.uk/efo/efo_0007754,GCST003178,26460308,2,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy
http://www.ebi.ac.uk/efo/efo_1001490,GCST003251,26562150,21,Late-onset myasthenia gravis
http://www.ebi.ac.uk/efo/efo_0007746,GCST003151,26451028,7,White matter lesion progression
http://www.ebi.ac.uk/efo/efo_1001489,GCST003149,26450422,1,Skin and soft tissue Staphylococcus aureus infection
http://www.ebi.ac.uk/efo/efo_0007746,GCST003152,26451028,6,White matter lesion progression (adjusted for white matter lesion burden at baseline)
http://www.ebi.ac.uk/efo/efo_0005681,GCST003150,26450422,2,Staphylococcus aureus infection
http://www.ebi.ac.uk/efo/efo_0001663,GCST003148,26443449,14,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0003768,GCST003185,26440539,3,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0007745,GCST003147,26433129,4,Plasma lactate levels
http://www.ebi.ac.uk/efo/efo_0000519,GCST003220,26424050,7,Glioblastoma
http://www.ebi.ac.uk/efo/efo_0007788,GCST005962,26426971,85,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)
http://www.ebi.ac.uk/efo/efo_0008343,GCST005962,26426971,85,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)
http://www.ebi.ac.uk/efo/efo_0008007,GCST005962,26426971,85,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)
http://www.ebi.ac.uk/efo/efo_0007788,GCST005961,26426971,0,Waist-to-hip ratio adjusted for BMI x age interaction
http://www.ebi.ac.uk/efo/efo_0008007,GCST005961,26426971,0,Waist-to-hip ratio adjusted for BMI x age interaction
http://www.ebi.ac.uk/efo/efo_0007788,GCST005960,26426971,0,Waist-to-hip ratio adjusted for BMI x sex x age interaction
http://www.ebi.ac.uk/efo/efo_0008343,GCST005960,26426971,0,Waist-to-hip ratio adjusted for BMI x sex x age interaction
http://www.ebi.ac.uk/efo/efo_0008007,GCST005960,26426971,0,Waist-to-hip ratio adjusted for BMI x sex x age interaction
http://www.ebi.ac.uk/efo/efo_0007788,GCST005959,26426971,33,Waist-to-hip ratio adjusted for BMI x sex interaction
http://www.ebi.ac.uk/efo/efo_0008343,GCST005959,26426971,33,Waist-to-hip ratio adjusted for BMI x sex interaction
http://www.ebi.ac.uk/efo/efo_0007788,GCST005958,26426971,20,Waist-to-hip ratio adjusted for BMI (age >50)
http://www.ebi.ac.uk/efo/efo_0007788,GCST005957,26426971,15,Waist-to-hip ratio adjusted for BMI (age <50)
http://www.ebi.ac.uk/efo/efo_0007788,GCST005956,26426971,85,Waist-to-hip ratio adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0008343,GCST005955,26426971,0,Body mass index x sex x age interaction
http://www.ebi.ac.uk/efo/efo_0004340,GCST005955,26426971,0,Body mass index x sex x age interaction
http://www.ebi.ac.uk/efo/efo_0008007,GCST005955,26426971,0,Body mass index x sex x age interaction
http://www.ebi.ac.uk/efo/efo_0004340,GCST005954,26426971,5,Body mass index x age interaction
http://www.ebi.ac.uk/efo/efo_0008007,GCST005954,26426971,5,Body mass index x age interaction
http://www.ebi.ac.uk/efo/efo_0004340,GCST005953,26426971,11,Body mass index (age <50)
http://www.ebi.ac.uk/efo/efo_0004340,GCST005952,26426971,8,Body mass index (age>50)
http://www.ebi.ac.uk/efo/efo_0004340,GCST005951,26426971,200,Body mass index
http://www.ebi.ac.uk/efo/efo_0007933,GCST005546,26367794,2,Forearm bone mineral density
http://www.ebi.ac.uk/efo/efo_0007701,GCST005545,26367794,4,Lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_0007785,GCST005544,26367794,3,Femoral neck bone mineral density
http://www.ebi.ac.uk/efo/efo_0008343,GCST005950,26426971,15,Body mass index x sex x age interaction (4df test)
http://www.ebi.ac.uk/efo/efo_0004340,GCST005950,26426971,15,Body mass index x sex x age interaction (4df test)
http://www.ebi.ac.uk/efo/efo_0008007,GCST005950,26426971,15,Body mass index x sex x age interaction (4df test)
http://www.ebi.ac.uk/efo/efo_0008343,GCST005949,26426971,0,Body mass index x sex interaction
http://www.ebi.ac.uk/efo/efo_0004340,GCST005949,26426971,0,Body mass index x sex interaction
http://www.ebi.ac.uk/efo/efo_0000326,GCST003228,26424050,11,Glioma
http://www.ebi.ac.uk/efo/efo_0007747,GCST003146,26366535,1,Postburn hypertrophic scarring severity
http://www.ebi.ac.uk/efo/efo_0000326,GCST003227,26424050,11,Non-glioblastoma glioma
http://www.ebi.ac.uk/efo/efo_0001068,GCST003145,26416757,3,Severe malaria
http://www.ebi.ac.uk/efo/efo_0009797,GCST003143,26417704,29,Lung disease severity in cystic fibrosis
http://www.ebi.ac.uk/efo/efo_0000660,GCST003144,26416764,9,Polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0003884,GCST003142,26420894,4,Proteinuria in chronic kidney disease
http://purl.obolibrary.org/obo/hp_0000093,GCST003142,26420894,4,Proteinuria in chronic kidney disease
http://purl.obolibrary.org/obo/hp_0010886,GCST003138,26422391,5,Juvenile osteochondritis dissecans
http://www.ebi.ac.uk/efo/efo_0005208,GCST003139,26420894,22,Glomerular filtration rate in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST003139,26420894,22,Glomerular filtration rate in chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST003141,26420894,9,Proteinuria and chronic kidney disease
http://purl.obolibrary.org/obo/hp_0000093,GCST003141,26420894,9,Proteinuria and chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST003140,26420894,5,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0005203,GCST003132,26433762,5,Eating disorder in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST003132,26433762,5,Eating disorder in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0007659,GCST003131,26545630,1,Cerebrospinal fluid clusterin levels in APOEe4+ carriers
http://www.ebi.ac.uk/efo/efo_0007657,GCST003131,26545630,1,Cerebrospinal fluid clusterin levels in APOEe4+ carriers
http://www.ebi.ac.uk/efo/efo_0000249,GCST003137,26545630,1,Cerebrospinal fluid clusterin levels in APOEe4- carriers
http://www.ebi.ac.uk/efo/efo_0007657,GCST003137,26545630,1,Cerebrospinal fluid clusterin levels in APOEe4- carriers
http://www.ebi.ac.uk/efo/efo_0007656,GCST003133,26545630,15,Plasma clusterin levels
http://www.ebi.ac.uk/efo/efo_0000289,GCST003136,26433762,0,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0005203,GCST003135,26433762,10,Bipolar disorder and eating disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST003135,26433762,10,Bipolar disorder and eating disorder
http://www.ebi.ac.uk/efo/efo_0007657,GCST003134,26545630,24,Cerebrospinal fluid clusterin levels
http://www.ebi.ac.uk/efo/efo_0005664,GCST006879,26401656,25,Blood metabolite levels
http://www.ebi.ac.uk/efo/efo_0003756,GCST003130,26398136,4,Autism spectrum disorder
http://www.ebi.ac.uk/efo/efo_1001486,GCST003129,26394269,30,Primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0005423,GCST003128,26394188,4,Adolescent idiopathic scoliosis
http://www.ebi.ac.uk/efo/efo_0006335,GCST003272,26390057,17,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST003273,26390057,20,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006340,GCST003275,26390057,13,Mean arterial pressure
http://www.ebi.ac.uk/efo/efo_0005763,GCST003274,26390057,11,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0000537,GCST003276,26390057,0,Hypertension
http://www.ebi.ac.uk/efo/efo_0006925,GCST003127,26377243,19,Lipoprotein (a) levels
http://www.ebi.ac.uk/efo/efo_1001488,GCST003123,26379185,34,Severe influenza A (H1N1) infection
http://www.ebi.ac.uk/efo/efo_1001488,GCST003124,26379185,35,Mild influenza (H1N1) infection
http://www.ebi.ac.uk/efo/efo_1001488,GCST003125,26379185,14,Influenza A (H1N1) infection
http://www.ebi.ac.uk/efo/efo_0007743,GCST003126,26379185,7,Influenza A (H1N1) severity
http://www.orpha.net/ordo/orphanet_797,GCST005538,26051272,9,Sarcoidosis
http://www.ebi.ac.uk/efo/efo_0003829,GCST003121,26365420,18,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0004509,GCST003122,26366553,8,Hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004317,GCST003120,26362575,0,Extraversion
http://www.ebi.ac.uk/efo/efo_0000783,GCST006051,26362759,7,Idiopathic inflammatory myopathy
http://www.ebi.ac.uk/efo/efo_0003063,GCST006052,26362759,8,Polymyositis
http://www.ebi.ac.uk/efo/efo_0000398,GCST006053,26362759,4,Dermatomyositis or juvenile dermatomyositis
http://www.ebi.ac.uk/efo/efo_0000557,GCST006053,26362759,4,Dermatomyositis or juvenile dermatomyositis
http://www.ebi.ac.uk/efo/efo_0005116,GCST003119,26352407,20,Urinary metabolites
http://www.ebi.ac.uk/efo/efo_0003761,GCST003118,26348319,2,Response to serotonin reuptake inhibitors in non-psychotic unipolar depression
http://www.ebi.ac.uk/efo/efo_0005658,GCST003118,26348319,2,Response to serotonin reuptake inhibitors in non-psychotic unipolar depression
http://www.ebi.ac.uk/efo/efo_0000378,GCST003116,26343387,45,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_0000612,GCST003117,26343387,38,Myocardial infarction
http://www.ebi.ac.uk/efo/efo_1001250,GCST003115,26350878,2,Rotator cuff tears
http://www.ebi.ac.uk/efo/efo_0007117,GCST003114,26343869,12,Carotid intima media thickness
http://www.ebi.ac.uk/efo/efo_0005271,GCST003112,26333835,0,Sleep duration
http://www.ebi.ac.uk/efo/efo_0005271,GCST003111,26333835,0,Sleep duration
http://www.ebi.ac.uk/efo/efo_0005194,GCST003113,26421299,5,Cingulate cortical amyloid beta load
http://www.ebi.ac.uk/efo/efo_0007738,GCST003113,26421299,5,Cingulate cortical amyloid beta load
http://www.ebi.ac.uk/efo/efo_0003892,GCST003110,26325155,0,Post-bronchodilator lung function in asthma (FEV1)
http://www.ebi.ac.uk/efo/efo_0004314,GCST003110,26325155,0,Post-bronchodilator lung function in asthma (FEV1)
http://purl.obolibrary.org/obo/go_0097366,GCST003110,26325155,0,Post-bronchodilator lung function in asthma (FEV1)
http://www.ebi.ac.uk/efo/efo_0000270,GCST003110,26325155,0,Post-bronchodilator lung function in asthma (FEV1)
http://www.ebi.ac.uk/efo/efo_0000729,GCST006583,26177304,0,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0004570,GCST006074,26148204,20,Bilirubin levels in tenofovir-treated HIV infection
http://www.ebi.ac.uk/efo/efo_0009279,GCST006074,26148204,20,Bilirubin levels in tenofovir-treated HIV infection
http://www.ebi.ac.uk/efo/efo_0000764,GCST006074,26148204,20,Bilirubin levels in tenofovir-treated HIV infection
http://www.ebi.ac.uk/efo/efo_0009279,GCST006073,26148204,81,Tenofovir clearance in HIV infection
http://www.ebi.ac.uk/efo/efo_0000764,GCST006073,26148204,81,Tenofovir clearance in HIV infection
http://www.ebi.ac.uk/efo/efo_0003892,GCST003107,26325155,0,Post-bronchodilator lung function in asthma (FEV1/FVC)
http://purl.obolibrary.org/obo/go_0097366,GCST003107,26325155,0,Post-bronchodilator lung function in asthma (FEV1/FVC)
http://www.ebi.ac.uk/efo/efo_0000270,GCST003107,26325155,0,Post-bronchodilator lung function in asthma (FEV1/FVC)
http://www.ebi.ac.uk/efo/efo_0004713,GCST003107,26325155,0,Post-bronchodilator lung function in asthma (FEV1/FVC)
http://www.ebi.ac.uk/efo/efo_0009279,GCST006072,26148204,106,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)
http://www.ebi.ac.uk/efo/efo_0000764,GCST006072,26148204,106,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)
http://www.ebi.ac.uk/efo/efo_0007934,GCST006072,26148204,106,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)
http://www.ebi.ac.uk/efo/efo_0009279,GCST006069,26148204,98,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)
http://www.ebi.ac.uk/efo/efo_0000764,GCST006069,26148204,98,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)
http://www.ebi.ac.uk/efo/efo_0007934,GCST006069,26148204,98,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)
http://www.ebi.ac.uk/efo/efo_0009279,GCST006071,26148204,0,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction)
http://www.ebi.ac.uk/efo/efo_0000764,GCST006071,26148204,0,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction)
http://www.ebi.ac.uk/efo/efo_0009279,GCST006070,26148204,0,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction)
http://www.ebi.ac.uk/efo/efo_0000764,GCST006070,26148204,0,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction)
http://www.ebi.ac.uk/efo/efo_0007934,GCST006070,26148204,0,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction)
http://www.ebi.ac.uk/efo/efo_0005937,GCST003108,26323598,1,Antipsychotic drug-induced weight gain (time interaction)
http://www.ebi.ac.uk/efo/efo_0004567,GCST003108,26323598,1,Antipsychotic drug-induced weight gain (time interaction)
http://www.ebi.ac.uk/efo/efo_0004567,GCST003109,26323598,1,Antipsychotic drug-induced weight gain
http://www.ebi.ac.uk/efo/efo_0007701,GCST003106,26235824,1,Low bone mineral density (spine)
http://www.ebi.ac.uk/efo/efo_0007702,GCST003105,26235824,1,Low bone mineral density (hip)
http://www.ebi.ac.uk/efo/efo_0003756,GCST003104,26314684,1,Autism spectrum disorder
http://www.ebi.ac.uk/efo/efo_0002690,GCST003103,26316170,7,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004703,GCST003101,26312577,9,Bone mineral density (spine) and age at menarche
http://www.ebi.ac.uk/efo/efo_0007701,GCST003101,26312577,9,Bone mineral density (spine) and age at menarche
http://www.ebi.ac.uk/efo/efo_0007702,GCST003102,26312577,8,Bone mineral density (hip) and age at menarche
http://www.ebi.ac.uk/efo/efo_0004703,GCST003102,26312577,8,Bone mineral density (hip) and age at menarche
http://www.ebi.ac.uk/efo/efo_0000401,GCST003098,26305897,38,Diabetic kidney disease
http://www.ebi.ac.uk/efo/efo_0000401,GCST003099,26305897,20,Diabetic kidney disease
http://www.ebi.ac.uk/efo/efo_0000714,GCST003100,26307654,4,Prostate cancer (survival)
http://www.ebi.ac.uk/efo/efo_0001663,GCST003100,26307654,4,Prostate cancer (survival)
http://www.ebi.ac.uk/efo/efo_0006812,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.ebi.ac.uk/efo/efo_0001359,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.orpha.net/ordo/orphanet_1572,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.ebi.ac.uk/efo/efo_0003898,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.ebi.ac.uk/efo/efo_0000676,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.ebi.ac.uk/efo/efo_0001060,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.ebi.ac.uk/efo/efo_0000729,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.ebi.ac.uk/efo/efo_0000384,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.ebi.ac.uk/efo/efo_0005140,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.ebi.ac.uk/efo/efo_0002609,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.ebi.ac.uk/efo/efo_0002690,GCST003097,26301688,46,Pediatric autoimmune diseases
http://www.ebi.ac.uk/efo/efo_0007737,GCST003095,26299439,4,Adiponectin levels (BMI-adjusted)
http://www.ebi.ac.uk/efo/efo_0004502,GCST003096,26299439,5,Adiponectin levels
http://purl.obolibrary.org/obo/hp_0001634,GCST003094,26301497,8,Mitral valve prolapse
http://www.ebi.ac.uk/efo/efo_0007706,GCST003089,26297903,3,Manic episodes in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST003089,26297903,3,Manic episodes in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0007705,GCST003090,26297903,7,Depressive and manic episodes in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0007704,GCST003090,26297903,7,Depressive and manic episodes in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST003090,26297903,7,Depressive and manic episodes in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0007650,GCST003088,26293465,7,Soluble interleukin-2 receptor subunit alpha
http://www.ebi.ac.uk/efo/efo_0000783,GCST003092,26291516,23,Myositis
http://www.ebi.ac.uk/efo/efo_0003768,GCST003093,26289589,0,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0007704,GCST003091,26297903,7,Depressive episodes in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST003091,26297903,7,Depressive episodes in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0007002,GCST005269,26284813,3,Luteinizing hormone levels in polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0000660,GCST005269,26284813,3,Luteinizing hormone levels in polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0007001,GCST005274,26284813,0,DHEAS levels in polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0000660,GCST005274,26284813,0,DHEAS levels in polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0000660,GCST005273,26284813,7,Polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0000660,GCST005272,26284813,4,Testosterone levels in polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0004908,GCST005272,26284813,4,Testosterone levels in polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0000660,GCST005271,26284813,1,Sex hormone-binding globulin levels in polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0004696,GCST005271,26284813,1,Sex hormone-binding globulin levels in polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0000660,GCST005270,26284813,4,Follicule stimulating hormone levels in polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0004768,GCST005270,26284813,4,Follicule stimulating hormone levels in polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0004340,GCST003087,26278006,1,Body mass index variance
http://www.ebi.ac.uk/efo/efo_0003845,GCST003086,26272126,4,Kidney stones
http://www.ebi.ac.uk/efo/efo_0000685,GCST006807,26272072,0,ACPA-negative rheumatoid arthritis (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006807,26272072,0,ACPA-negative rheumatoid arthritis (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0009460,GCST006807,26272072,0,ACPA-negative rheumatoid arthritis (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0000685,GCST006410,26272072,15,ACPA-positive rheumatoid arthritis (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006527,GCST006410,26272072,15,ACPA-positive rheumatoid arthritis (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0009459,GCST006410,26272072,15,ACPA-positive rheumatoid arthritis (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0002508,GCST005548,26268663,0,Parkinson's disease
http://purl.obolibrary.org/obo/go_0061476,GCST003085,26265036,16,Warfarin maintenance dose
http://purl.obolibrary.org/obo/go_0051384,GCST003083,26265699,3,Glucocorticoid-induced osteonecrosis (time dependent analysis)
http://www.ebi.ac.uk/efo/efo_0004259,GCST003083,26265699,3,Glucocorticoid-induced osteonecrosis (time dependent analysis)
http://purl.obolibrary.org/obo/go_0051384,GCST003084,26265699,10,Glucocorticoid-induced osteonecrosis
http://www.ebi.ac.uk/efo/efo_0004259,GCST003084,26265699,10,Glucocorticoid-induced osteonecrosis
http://www.ebi.ac.uk/efo/efo_0007646,GCST003082,26268530,9,Longitudinal change in brain amyloid plaque burden
http://purl.obolibrary.org/obo/go_0051384,GCST003081,26265699,11,Glucocorticoid-induced osteonecrosis (age 10 years and older)
http://www.ebi.ac.uk/efo/efo_0004259,GCST003081,26265699,11,Glucocorticoid-induced osteonecrosis (age 10 years and older)
http://purl.obolibrary.org/obo/go_0051384,GCST003080,26265699,0,Glucocorticoid-induced osteonecrosis (time independent analysis)
http://www.ebi.ac.uk/efo/efo_0004259,GCST003080,26265699,0,Glucocorticoid-induced osteonecrosis (time independent analysis)
http://www.ebi.ac.uk/efo/efo_0007707,GCST003073,26252872,17,Cerebral amyloid deposition (PET imaging)
http://www.ebi.ac.uk/efo/efo_0007707,GCST003077,26252872,1,Cerebral amyloid deposition positivity (PET imaging)
http://www.ebi.ac.uk/efo/efo_0007659,GCST003076,26252872,0,Cerebral amyloid deposition in APOEe4 carriers (PET imaging)
http://www.ebi.ac.uk/efo/efo_0007707,GCST003076,26252872,0,Cerebral amyloid deposition in APOEe4 carriers (PET imaging)
http://www.ebi.ac.uk/efo/efo_0007708,GCST003079,26252872,6,Cerebrospinal fluid t-tau:AB1-42 ratio
http://www.ebi.ac.uk/efo/efo_0007709,GCST003078,26252872,4,Cerebrospinal fluid p-Tau181p:AB1-42 ratio
http://www.ebi.ac.uk/efo/efo_0004763,GCST003071,26252872,4,Cerebrospinal P-tau181p levels
http://www.ebi.ac.uk/efo/efo_0006794,GCST003071,26252872,4,Cerebrospinal P-tau181p levels
http://www.ebi.ac.uk/efo/efo_0006794,GCST003070,26252872,6,Cerebrospinal T-tau levels
http://www.ebi.ac.uk/efo/efo_0004760,GCST003070,26252872,6,Cerebrospinal T-tau levels
http://www.ebi.ac.uk/efo/efo_0007707,GCST003074,26252872,26,Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)
http://purl.obolibrary.org/obo/hp_0100543,GCST003075,26252872,143,Cognitive decline rate in late mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0007710,GCST003075,26252872,143,Cognitive decline rate in late mild cognitive impairment
http://www.ebi.ac.uk/efo/efo_0000692,GCST003069,26249676,6,Left superior temporal gyrus thickness (schizophrenia interaction)
http://www.ebi.ac.uk/efo/efo_0007739,GCST003069,26249676,6,Left superior temporal gyrus thickness (schizophrenia interaction)
http://www.ebi.ac.uk/efo/efo_0004670,GCST003072,26252872,8,Cerebrospinal fluid AB1-42 levels
http://www.ebi.ac.uk/efo/efo_0006794,GCST003072,26252872,8,Cerebrospinal fluid AB1-42 levels
http://www.ebi.ac.uk/efo/efo_0007700,GCST003065,26242244,21,Exploratory eye movement dysfunction in schizophrenia (responsive search score)
http://www.ebi.ac.uk/efo/efo_0007700,GCST003064,26242244,15,Exploratory eye movement dysfunction in schizophrenia (cognitive search score)
http://www.ebi.ac.uk/efo/efo_0007700,GCST003068,26242244,19,Exploratory eye movement dysfunction in schizophrenia (number of eye fixations)
http://www.ebi.ac.uk/efo/efo_0007700,GCST003067,26242244,2,Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length)
http://www.ebi.ac.uk/efo/efo_0007700,GCST003066,26242244,8,Exploratory eye movement dysfunction in schizophrenia (total eye scanning length)
http://www.ebi.ac.uk/efo/efo_0005762,GCST003063,26629533,3,Neuropathic pain in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST003063,26629533,3,Neuropathic pain in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0005611,GCST003614,26239289,1,Opioid dependence
http://www.ebi.ac.uk/efo/efo_1000654,GCST003062,26237429,2,Anthracycline-induced cardiotoxicity in childhood cancer
http://www.ebi.ac.uk/efo/efo_1001482,GCST003062,26237429,2,Anthracycline-induced cardiotoxicity in childhood cancer
http://www.ebi.ac.uk/efo/efo_0005257,GCST003062,26237429,2,Anthracycline-induced cardiotoxicity in childhood cancer
http://www.ebi.ac.uk/efo/efo_0000389,GCST003061,26237428,16,Cutaneous malignant melanoma
http://www.ebi.ac.uk/efo/efo_0002508,GCST003060,26233692,0,Parkinson's disease in GBA mutation carriers (age at onset)
http://www.ebi.ac.uk/efo/efo_0007698,GCST003060,26233692,0,Parkinson's disease in GBA mutation carriers (age at onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST003060,26233692,0,Parkinson's disease in GBA mutation carriers (age at onset)
http://www.ebi.ac.uk/efo/efo_0002508,GCST003059,26227905,22,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0004920,GCST003058,26222057,3,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)
http://www.ebi.ac.uk/efo/efo_1001480,GCST003058,26222057,3,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)
http://www.ebi.ac.uk/efo/efo_0007682,GCST003058,26222057,3,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)
http://www.ebi.ac.uk/efo/efo_0007683,GCST003058,26222057,3,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)
http://www.ebi.ac.uk/efo/efo_0004920,GCST003057,26222057,1,Progression free survival in metastatic colorectal cancer (chemotherapy interaction)
http://www.ebi.ac.uk/efo/efo_1001480,GCST003057,26222057,1,Progression free survival in metastatic colorectal cancer (chemotherapy interaction)
http://www.ebi.ac.uk/efo/efo_0007682,GCST003057,26222057,1,Progression free survival in metastatic colorectal cancer (chemotherapy interaction)
http://www.ebi.ac.uk/efo/efo_0007683,GCST003057,26222057,1,Progression free survival in metastatic colorectal cancer (chemotherapy interaction)
http://www.ebi.ac.uk/efo/efo_0007680,GCST003054,26219847,5,Gait rhythm
http://www.ebi.ac.uk/efo/efo_0007680,GCST003056,26219847,3,Gait variability
http://www.ebi.ac.uk/efo/efo_0007680,GCST003055,26219847,5,Tandem gait
http://www.ebi.ac.uk/efo/efo_0004562,GCST003053,26209787,0,Cryptorchidism
http://www.ebi.ac.uk/efo/efo_0005423,GCST003052,26211971,4,Adolescent idiopathic scoliosis
http://www.ebi.ac.uk/efo/efo_0000638,GCST003051,26198393,1,Multiple myeloma (survival)
http://www.ebi.ac.uk/efo/efo_0001378,GCST003051,26198393,1,Multiple myeloma (survival)
http://www.ebi.ac.uk/efo/efo_0000692,GCST003050,26198764,29,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST003048,26198764,620,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0001071,GCST003049,26199339,0,Lung cancer (asbestos exposure interaction)
http://www.ebi.ac.uk/efo/efo_0004806,GCST003049,26199339,0,Lung cancer (asbestos exposure interaction)
http://www.ebi.ac.uk/efo/efo_0000729,GCST003045,26192919,134,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0003767,GCST003043,26192919,202,Inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0007685,GCST003046,26190474,3,Trichloroethylene-induced hypersensitivity syndrome
http://purl.obolibrary.org/obo/hp_0006695,GCST003047,26194203,1,Atrioventricular septal defects in Down syndrome
http://www.ebi.ac.uk/efo/efo_0001064,GCST003047,26194203,1,Atrioventricular septal defects in Down syndrome
http://www.ebi.ac.uk/efo/efo_0000384,GCST003044,26192919,165,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0003770,GCST003042,26188370,1,Sight-threatening diabetic retinopathy in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST003042,26188370,1,Sight-threatening diabetic retinopathy in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0007617,GCST003040,26188009,0,Hearing function (high tone)
http://www.ebi.ac.uk/efo/efo_0007616,GCST003040,26188009,0,Hearing function (high tone)
http://www.ebi.ac.uk/efo/efo_0007617,GCST003033,26188009,0,Hearing function (medium tone)
http://www.ebi.ac.uk/efo/efo_0007616,GCST003033,26188009,0,Hearing function (medium tone)
http://www.ebi.ac.uk/efo/efo_0007617,GCST003036,26188009,0,Hearing function (low tone)
http://www.ebi.ac.uk/efo/efo_0007616,GCST003036,26188009,0,Hearing function (low tone)
http://www.ebi.ac.uk/efo/efo_0007618,GCST003034,26188009,0,Hearing function (8 kHz)
http://www.ebi.ac.uk/efo/efo_0007616,GCST003034,26188009,0,Hearing function (8 kHz)
http://www.ebi.ac.uk/efo/efo_0007618,GCST003035,26188009,0,Hearing function (4 kHz)
http://www.ebi.ac.uk/efo/efo_0007616,GCST003035,26188009,0,Hearing function (4 kHz)
http://www.ebi.ac.uk/efo/efo_0007618,GCST003032,26188009,0,Hearing function (2 kHz)
http://www.ebi.ac.uk/efo/efo_0007616,GCST003032,26188009,0,Hearing function (2 kHz)
http://www.ebi.ac.uk/efo/efo_0007618,GCST003041,26188009,0,Hearing function (1 kHz)
http://www.ebi.ac.uk/efo/efo_0007616,GCST003041,26188009,0,Hearing function (1 kHz)
http://www.ebi.ac.uk/efo/efo_0007618,GCST003037,26188009,0,Hearing function (0.5 kHz)
http://www.ebi.ac.uk/efo/efo_0007616,GCST003037,26188009,0,Hearing function (0.5 kHz)
http://www.ebi.ac.uk/efo/efo_0007618,GCST003039,26188009,0,Hearing function (0.25 kHz)
http://www.ebi.ac.uk/efo/efo_0007616,GCST003039,26188009,0,Hearing function (0.25 kHz)
http://www.ebi.ac.uk/efo/efo_0003870,GCST003038,26186006,0,Intracranial aneurysm
http://www.ebi.ac.uk/efo/efo_0003888,GCST003030,26184070,10,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0007679,GCST003030,26184070,10,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0004318,GCST003031,26183928,3,MGMT methylation in smokers
http://www.ebi.ac.uk/efo/efo_0006959,GCST003031,26183928,3,MGMT methylation in smokers
http://www.ebi.ac.uk/efo/efo_0005415,GCST003028,26174136,3,Serum alpha1-antitrypsin levels
http://www.ebi.ac.uk/efo/efo_0003757,GCST003029,26176695,0,Asperger syndrome
http://www.ebi.ac.uk/efo/efo_0007638,GCST003026,26169365,11,Yu-Zhi constitution type in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST003026,26169365,11,Yu-Zhi constitution type in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0007639,GCST003024,26174610,0,Ultraviolet-induced skin pigmentation (minimal erythema dose)
http://www.ebi.ac.uk/efo/efo_0003888,GCST003025,26174813,25,Attention function in attention deficit hyperactive disorder
http://www.ebi.ac.uk/efo/efo_0007636,GCST003025,26174813,25,Attention function in attention deficit hyperactive disorder
http://www.ebi.ac.uk/efo/efo_0005325,GCST003027,26169577,1,Cough in response to angiotensin-converting enzyme inhibitor drugs
http://purl.obolibrary.org/obo/hp_0012735,GCST003027,26169577,1,Cough in response to angiotensin-converting enzyme inhibitor drugs
http://www.ebi.ac.uk/efo/efo_0003924,GCST003023,26184321,6,Blond vs non-blond hair color
http://www.ebi.ac.uk/efo/efo_0003924,GCST003019,26184321,2,Black vs. non-black hair color
http://www.ebi.ac.uk/efo/efo_0003924,GCST003020,26184321,3,Red vs non-red hair color
http://www.ebi.ac.uk/efo/efo_0003924,GCST003022,26184321,8,Light vs. dark hair color
http://www.ebi.ac.uk/efo/efo_0003924,GCST003021,26184321,8,Brown vs. non-brown hair color
http://www.ebi.ac.uk/efo/efo_0005842,GCST003017,26151821,22,Colorectal cancer
http://purl.obolibrary.org/obo/hp_0012235,GCST003018,26151496,9,Thionamide-induced agranulocytosis in Graves' disease
http://www.ebi.ac.uk/efo/efo_0007633,GCST003018,26151496,9,Thionamide-induced agranulocytosis in Graves' disease
http://www.ebi.ac.uk/efo/efo_0004237,GCST003018,26151496,9,Thionamide-induced agranulocytosis in Graves' disease
http://www.ebi.ac.uk/efo/efo_0007634,GCST003016,26207136,1,Hypersomnia during a major depressive episode in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST003016,26207136,1,Hypersomnia during a major depressive episode in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0005246,GCST003016,26207136,1,Hypersomnia during a major depressive episode in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004329,GCST003015,26146898,0,Alcohol consumption
http://www.ebi.ac.uk/efo/efo_0007684,GCST003014,26256467,9,Postprandial triglyceride response to high fat diet meal
http://www.ebi.ac.uk/efo/efo_0007681,GCST003014,26256467,9,Postprandial triglyceride response to high fat diet meal
http://www.ebi.ac.uk/efo/efo_0005665,GCST003013,25663218,36,White matter hyperintensity burden
http://www.ebi.ac.uk/efo/efo_0003100,GCST003627,26138065,0,Neuropathy in taxane-treated breast cancer
http://purl.obolibrary.org/obo/go_1902519,GCST003627,26138065,0,Neuropathy in taxane-treated breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST003627,26138065,0,Neuropathy in taxane-treated breast cancer
http://purl.obolibrary.org/obo/go_1901555,GCST003627,26138065,0,Neuropathy in taxane-treated breast cancer
http://www.ebi.ac.uk/efo/efo_0003918,GCST003012,25325441,2,Obstructive sleep apnea
http://www.ebi.ac.uk/efo/efo_0002609,GCST003011,27186693,0,Arthritis (juvenile idiopathic)
http://www.ebi.ac.uk/efo/efo_0000178,GCST003010,26129866,4,Gastric cancer
http://www.ebi.ac.uk/efo/efo_0000178,GCST003007,26129866,2,Non-cardia gastric cancer
http://www.ebi.ac.uk/efo/efo_1001252,GCST003009,26129866,1,Cardia gastric cancer
http://www.ebi.ac.uk/efo/efo_0007662,GCST003008,26121980,16,Triptolide cytotoxicity
http://www.ebi.ac.uk/efo/efo_0006952,GCST003008,26121980,16,Triptolide cytotoxicity
http://www.ebi.ac.uk/efo/efo_1001254,GCST003006,26121033,1,Noise-induced hearing loss
http://www.ebi.ac.uk/efo/efo_0007665,GCST002994,26105758,3,Ear protrusion
http://www.ebi.ac.uk/efo/efo_0007671,GCST002996,26105758,5,Folding of antihelix
http://www.ebi.ac.uk/efo/efo_0007670,GCST002997,26105758,6,Helix rolling
http://www.ebi.ac.uk/efo/efo_0007667,GCST002998,26105758,4,Lobe attachment
http://www.ebi.ac.uk/efo/efo_0007666,GCST002999,26105758,8,Lobe size
http://www.ebi.ac.uk/efo/efo_0007664,GCST003001,26105758,7,Ear morphology
http://www.ebi.ac.uk/efo/efo_0007674,GCST003000,26105758,0,Darwin's tubercle
http://www.ebi.ac.uk/efo/efo_0007673,GCST003005,26105758,2,Superior crus of antihelix expression
http://www.ebi.ac.uk/efo/efo_0007672,GCST003004,26105758,0,Crus helix expression
http://www.ebi.ac.uk/efo/efo_0007669,GCST003003,26105758,1,Antitragus size
http://www.ebi.ac.uk/efo/efo_0007668,GCST003002,26105758,1,Tragus size
http://purl.obolibrary.org/obo/hp_0002015,GCST002995,26116289,19,Dysphagia
http://www.ebi.ac.uk/efo/efo_0004647,GCST002993,26100964,0,Platinum-induced hepatotoxicity in non-small cell lung cancer
http://www.ebi.ac.uk/efo/efo_0003060,GCST002993,26100964,0,Platinum-induced hepatotoxicity in non-small cell lung cancer
http://www.ebi.ac.uk/efo/efo_0004228,GCST002993,26100964,0,Platinum-induced hepatotoxicity in non-small cell lung cancer
http://www.ebi.ac.uk/efo/efo_0002618,GCST002991,26098869,17,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0000503,GCST002990,26098866,7,Gastric adenocarcinoma (histologically verified)
http://www.ebi.ac.uk/efo/efo_0000178,GCST002992,26098866,8,Gastric cancer
http://www.ebi.ac.uk/efo/efo_0007677,GCST002989,26112879,21,LDL peak particle diameter (total fat intake interaction)
http://www.ebi.ac.uk/efo/efo_0007678,GCST002989,26112879,21,LDL peak particle diameter (total fat intake interaction)
http://www.ebi.ac.uk/efo/efo_0007663,GCST002984,26087016,3,Early childhood aggressive behavior
http://www.ebi.ac.uk/efo/efo_0000712,GCST002987,26089329,27,Stroke
http://purl.obolibrary.org/obo/hp_0002140,GCST002988,26089329,9,Ischemic stroke
http://www.ebi.ac.uk/efo/efo_0007663,GCST002986,26087016,6,Childhood and early adolescence aggressive behavior
http://www.ebi.ac.uk/efo/efo_0000249,GCST002983,26339675,3,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0007663,GCST002985,26087016,7,Middle childhood and early adolescence aggressive behavior
http://www.ebi.ac.uk/efo/efo_0000180,GCST002976,26039976,9,HIV-1 viral setpoint
http://www.ebi.ac.uk/efo/efo_0006319,GCST002976,26039976,9,HIV-1 viral setpoint
http://www.ebi.ac.uk/efo/efo_0007622,GCST002977,26083729,2,Advanced glycation end-product levels
http://www.ebi.ac.uk/efo/efo_0007675,GCST002978,26084801,2,Metastasis at diagnosis in osteosarcoma
http://www.ebi.ac.uk/efo/efo_0004953,GCST002978,26084801,2,Metastasis at diagnosis in osteosarcoma
http://www.ebi.ac.uk/efo/efo_0000637,GCST002978,26084801,2,Metastasis at diagnosis in osteosarcoma
http://www.ebi.ac.uk/efo/efo_0005921,GCST002979,26083242,2,Response to montelukast in asthma (change in FEV1)
http://www.ebi.ac.uk/efo/efo_0007612,GCST002979,26083242,2,Response to montelukast in asthma (change in FEV1)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002979,26083242,2,Response to montelukast in asthma (change in FEV1)
http://www.ebi.ac.uk/efo/efo_0004517,GCST002980,26083723,0,Arterial stiffness (pulse-wave velocity)
http://www.ebi.ac.uk/efo/efo_0007645,GCST002981,26081443,6,Longitudinal alcohol consumption
http://www.ebi.ac.uk/efo/efo_0003776,GCST002982,26083657,3,Acute kidney injury in coronary artery bypass surgery (creatinine rise)
http://purl.obolibrary.org/obo/hp_0001919,GCST002982,26083657,3,Acute kidney injury in coronary artery bypass surgery (creatinine rise)
http://www.ebi.ac.uk/efo/efo_0004518,GCST002982,26083657,3,Acute kidney injury in coronary artery bypass surgery (creatinine rise)
http://www.ebi.ac.uk/efo/efo_0003776,GCST002975,26385043,3,Postoperative atrial fibrillation in coronary artery bypass grafting surgery
http://www.ebi.ac.uk/efo/efo_0000275,GCST002975,26385043,3,Postoperative atrial fibrillation in coronary artery bypass grafting surgery
http://www.orpha.net/ordo/orphanet_278,GCST002971,26077951,4,Corticobasal degeneration
http://www.ebi.ac.uk/efo/efo_0003761,GCST002972,26079190,1,Suicide attempts in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0004321,GCST002972,26079190,1,Suicide attempts in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0007624,GCST002973,26079190,3,Suicide
http://www.ebi.ac.uk/efo/efo_0007619,GCST002974,26079190,3,Suicide ideation score in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST002974,26079190,3,Suicide ideation score in major depressive disorder
http://www.orpha.net/ordo/orphanet_278,GCST002970,26077951,4,Corticobasal degeneration
http://www.ebi.ac.uk/efo/efo_0007623,GCST002969,26079190,5,Suicide behavior
http://www.ebi.ac.uk/efo/efo_0000180,GCST002968,25950743,0,Response to stavudine in HIV (lipoatrophy)
http://www.ebi.ac.uk/efo/efo_0006998,GCST002968,25950743,0,Response to stavudine in HIV (lipoatrophy)
http://purl.obolibrary.org/obo/hp_0100578,GCST002968,25950743,0,Response to stavudine in HIV (lipoatrophy)
http://www.ebi.ac.uk/efo/efo_0006462,GCST002967,26075790,6,Mucinous ovarian carcinoma
http://www.ebi.ac.uk/efo/efo_0009460,GCST003256,26077402,1,Joint damage progression in ACPA-negative rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0005413,GCST003256,26077402,1,Joint damage progression in ACPA-negative rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0005059,GCST002961,26068415,15,Acylcarnitine levels
http://www.ebi.ac.uk/efo/efo_0005664,GCST002961,26068415,15,Acylcarnitine levels
http://www.ebi.ac.uk/efo/efo_0005664,GCST002959,26068415,0,Hexose levels
http://www.ebi.ac.uk/efo/efo_0007631,GCST002959,26068415,0,Hexose levels
http://www.ebi.ac.uk/efo/efo_0004622,GCST002964,26068415,7,Sphingolipid levels
http://www.ebi.ac.uk/efo/efo_0005664,GCST002964,26068415,7,Sphingolipid levels
http://www.ebi.ac.uk/efo/efo_0007630,GCST002965,26068415,38,Glycerophospholipid levels
http://www.ebi.ac.uk/efo/efo_0005664,GCST002965,26068415,38,Glycerophospholipid levels
http://www.ebi.ac.uk/efo/efo_0005664,GCST002966,26068415,9,Amino acid levels
http://www.ebi.ac.uk/efo/efo_0005134,GCST002966,26068415,9,Amino acid levels
http://www.orpha.net/ordo/orphanet_282,GCST002960,26154020,9,Frontotemporal dementia
http://www.ebi.ac.uk/efo/efo_0001358,GCST002963,26114229,9,Post-traumatic stress disorder
http://www.ebi.ac.uk/efo/efo_0007614,GCST002962,26073756,0,Asthma exacerbations
http://www.ebi.ac.uk/efo/efo_0007044,GCST002958,26067905,0,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
http://www.ebi.ac.uk/efo/efo_0004599,GCST002958,26067905,0,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
http://www.ebi.ac.uk/efo/efo_0004318,GCST002956,26053186,246,3-hydroxypropylmercapturic acid levels in smokers
http://www.ebi.ac.uk/efo/efo_0007014,GCST002956,26053186,246,3-hydroxypropylmercapturic acid levels in smokers
http://www.ebi.ac.uk/efo/efo_0004318,GCST002957,26053186,240,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
http://www.ebi.ac.uk/efo/efo_0007015,GCST002957,26053186,240,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
http://www.ebi.ac.uk/efo/efo_0000249,GCST002954,26049409,3,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0006992,GCST002955,25979521,7,Forced expiratory volume in 1 second (occupational environmental exposures interaction)
http://www.ebi.ac.uk/efo/efo_0006994,GCST002955,25979521,7,Forced expiratory volume in 1 second (occupational environmental exposures interaction)
http://www.ebi.ac.uk/efo/efo_0004314,GCST002955,25979521,7,Forced expiratory volume in 1 second (occupational environmental exposures interaction)
http://www.ebi.ac.uk/efo/efo_0006993,GCST002955,25979521,7,Forced expiratory volume in 1 second (occupational environmental exposures interaction)
http://www.ebi.ac.uk/efo/efo_0007933,GCST002953,26041818,2,Pediatric areal bone mineral density (radius)
http://www.ebi.ac.uk/efo/efo_0007621,GCST002952,26041818,3,Pediatric bone mineral content (radius)
http://www.ebi.ac.uk/efo/efo_0005921,GCST002951,26031901,21,Response to zileuton treatment in asthma (FEV1 change interaction)
http://www.ebi.ac.uk/efo/efo_0007676,GCST002951,26031901,21,Response to zileuton treatment in asthma (FEV1 change interaction)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002951,26031901,21,Response to zileuton treatment in asthma (FEV1 change interaction)
http://www.ebi.ac.uk/efo/efo_0000474,GCST002950,26220383,0,Epilepsy
http://www.ebi.ac.uk/efo/efo_0007661,GCST002949,26220383,27,Epilepsy and lamotrigine-induced maculopapular eruptions
http://www.ebi.ac.uk/efo/efo_1001253,GCST002949,26220383,27,Epilepsy and lamotrigine-induced maculopapular eruptions
http://www.ebi.ac.uk/efo/efo_0000474,GCST002949,26220383,27,Epilepsy and lamotrigine-induced maculopapular eruptions
http://www.ebi.ac.uk/efo/efo_0007628,GCST002942,26030696,17,Percentage gas trapping
http://www.ebi.ac.uk/efo/efo_0007649,GCST002947,26030142,0,Renal elimination rate in vancomycin therapy
http://www.ebi.ac.uk/efo/efo_0007647,GCST002947,26030142,0,Renal elimination rate in vancomycin therapy
http://www.ebi.ac.uk/efo/efo_0007648,GCST002946,26030142,0,Vancomycin trough in vancomycin therapy
http://www.ebi.ac.uk/efo/efo_0007647,GCST002946,26030142,0,Vancomycin trough in vancomycin therapy
http://www.ebi.ac.uk/efo/efo_0004194,GCST002943,26028593,23,IgA nephropathy
http://www.ebi.ac.uk/efo/efo_0001663,GCST002944,26034056,57,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0007647,GCST002948,26030142,1,Peak creatinine levels in vancomycin therapy
http://www.ebi.ac.uk/efo/efo_0004518,GCST002948,26030142,1,Peak creatinine levels in vancomycin therapy
http://www.ebi.ac.uk/efo/efo_1000478,GCST002940,26029870,4,Sporadic pituitary adenoma
http://www.ebi.ac.uk/efo/efo_0007626,GCST002945,26030696,52,Emphysema imaging phenotypes
http://www.ebi.ac.uk/efo/efo_0007627,GCST002941,26030696,14,Airway imaging phenotypes
http://purl.obolibrary.org/obo/go_0070527,GCST002939,26024889,0,Platelet aggregation
http://www.ebi.ac.uk/efo/efo_0007583,GCST002928,26025379,28,Nickel levels
http://www.ebi.ac.uk/efo/efo_0007578,GCST002938,26025379,42,Copper levels
http://www.ebi.ac.uk/efo/efo_0004845,GCST002933,26058915,5,Magnesium levels
http://www.ebi.ac.uk/efo/efo_0007576,GCST002936,26025379,30,Cadmium levels
http://www.ebi.ac.uk/efo/efo_0007580,GCST002927,26025379,24,Mercury levels
http://www.ebi.ac.uk/efo/efo_0007584,GCST002934,26025379,24,Zinc levels
http://www.ebi.ac.uk/efo/efo_0007040,GCST002935,26025379,28,Lead levels
http://www.ebi.ac.uk/efo/efo_0007582,GCST002937,26025379,17,Molybdenum levels
http://www.ebi.ac.uk/efo/efo_0007581,GCST002932,26025379,37,Manganese levels
http://www.ebi.ac.uk/efo/efo_0007575,GCST002931,26025379,16,Aluminium levels
http://www.ebi.ac.uk/efo/efo_0007577,GCST002930,26025379,19,Cobalt levels
http://www.ebi.ac.uk/efo/efo_0007579,GCST002929,26025379,19,Chromium levels
http://www.ebi.ac.uk/efo/efo_0004730,GCST002925,26014426,15,Sex hormone levels
http://www.ebi.ac.uk/efo/efo_0007591,GCST002926,26025128,9,Bone mineral accretion in asthma (oral corticosteroid dose interaction)
http://purl.obolibrary.org/obo/go_0031960,GCST002926,26025128,9,Bone mineral accretion in asthma (oral corticosteroid dose interaction)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002926,26025128,9,Bone mineral accretion in asthma (oral corticosteroid dose interaction)
http://www.ebi.ac.uk/efo/efo_0001378,GCST002921,26007630,8,Multiple myeloma
http://www.ebi.ac.uk/efo/efo_0006952,GCST002924,26015512,3,Paclitaxel-induced cytotoxicity
http://purl.obolibrary.org/obo/go_1901555,GCST002924,26015512,3,Paclitaxel-induced cytotoxicity
http://www.ebi.ac.uk/efo/efo_0001378,GCST002922,26007630,9,Multiple myeloma and monoclonal gammopathy
http://www.ebi.ac.uk/efo/efo_0000203,GCST002922,26007630,9,Multiple myeloma and monoclonal gammopathy
http://www.ebi.ac.uk/efo/efo_0003100,GCST002923,26015512,0,Paclitaxel-induced neuropathy
http://purl.obolibrary.org/obo/go_1901555,GCST002923,26015512,0,Paclitaxel-induced neuropathy
http://www.ebi.ac.uk/efo/efo_0005842,GCST002919,25990418,19,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0007660,GCST002920,25993607,12,Neuroticism
http://purl.obolibrary.org/obo/go_0036274,GCST002918,25987243,3,Lapatinib-induced hepatotoxicity
http://www.ebi.ac.uk/efo/efo_0004228,GCST002918,25987243,3,Lapatinib-induced hepatotoxicity
http://www.ebi.ac.uk/efo/efo_0007586,GCST002916,25987507,14,Cannabis use (initiation)
http://www.ebi.ac.uk/efo/efo_0007585,GCST002917,25987507,9,Cannabis use (age at onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST002917,25987507,9,Cannabis use (age at onset)
http://www.ebi.ac.uk/efo/efo_0007124,GCST002913,25985088,2,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis
http://www.ebi.ac.uk/efo/efo_1000780,GCST002913,25985088,2,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis
http://www.ebi.ac.uk/efo/efo_0007125,GCST002913,25985088,2,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis
http://www.ebi.ac.uk/efo/efo_0001358,GCST002914,25988933,0,Post-traumatic stress disorder
http://www.ebi.ac.uk/efo/efo_0004881,GCST002915,25987655,8,Asparaginase hypersensitivity in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_0000220,GCST002915,25987655,8,Asparaginase hypersensitivity in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_0000614,GCST002912,25986216,4,Narcolepsy with cataplexy
http://www.ebi.ac.uk/efo/efo_0003885,GCST002910,25914168,0,Response to interferon beta in multiple sclerosis
http://purl.obolibrary.org/obo/go_0035456,GCST002910,25914168,0,Response to interferon beta in multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0004838,GCST002911,25972035,12,Calcium levels
http://www.ebi.ac.uk/efo/efo_0004274,GCST002909,25967671,5,Gout
http://www.ebi.ac.uk/efo/efo_0004621,GCST006799,25972531,1,Pyridoxal 5'-phosphate levels
http://www.ebi.ac.uk/efo/efo_0004621,GCST006798,25972531,0,4-pyridoxic acid levels
http://www.ebi.ac.uk/efo/efo_0004621,GCST006797,25972531,0,Pyridoxal levels
http://www.ebi.ac.uk/efo/efo_0003784,GCST002906,25963972,7,Skin colour saturation
http://www.ebi.ac.uk/efo/efo_0004795,GCST002908,25963972,4,Skin sensitivity to sun
http://www.ebi.ac.uk/efo/efo_0003784,GCST002907,25963972,3,Perceived skin darkness
http://www.ebi.ac.uk/efo/efo_0006988,GCST002905,25963331,0,Endophenotypes for schizophrenia in healthy individuals
http://www.ebi.ac.uk/efo/efo_0000714,GCST002903,25964295,0,Survival in breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_1000649,GCST002903,25964295,0,Survival in breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_0000305,GCST002903,25964295,0,Survival in breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_0004574,GCST002896,25961943,47,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004611,GCST002898,25961943,43,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004530,GCST002897,25961943,35,Triglycerides
http://www.ebi.ac.uk/efo/efo_1000654,GCST002904,25963547,1,Obesity in adult survivors of childhood cancer not exposed to cranial radiation
http://www.ebi.ac.uk/efo/efo_0001073,GCST002904,25963547,1,Obesity in adult survivors of childhood cancer not exposed to cranial radiation
http://www.ebi.ac.uk/efo/efo_0004612,GCST002899,25961943,42,HDL cholesterol
http://purl.obolibrary.org/obo/go_0009314,GCST002900,25963547,4,Obesity in adult survivors of childhood cancer exposed to cranial radiation
http://www.ebi.ac.uk/efo/efo_1000654,GCST002900,25963547,4,Obesity in adult survivors of childhood cancer exposed to cranial radiation
http://www.ebi.ac.uk/efo/efo_0001073,GCST002900,25963547,4,Obesity in adult survivors of childhood cancer exposed to cranial radiation
http://www.ebi.ac.uk/efo/efo_0000714,GCST002901,25964295,1,Survival in endocrine treated breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_1000649,GCST002901,25964295,1,Survival in endocrine treated breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_0000305,GCST002901,25964295,1,Survival in endocrine treated breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_0007613,GCST002901,25964295,1,Survival in endocrine treated breast cancer (estrogen-receptor positive)
http://www.ebi.ac.uk/efo/efo_1000650,GCST002902,25964295,0,Survival in breast cancer (estrogen-receptor negative)
http://www.ebi.ac.uk/efo/efo_0000714,GCST002902,25964295,0,Survival in breast cancer (estrogen-receptor negative)
http://www.ebi.ac.uk/efo/efo_0000305,GCST002902,25964295,0,Survival in breast cancer (estrogen-receptor negative)
http://www.ebi.ac.uk/efo/efo_0000305,GCST002895,25956309,2,Breast cancer
http://www.ebi.ac.uk/efo/efo_0005937,GCST002893,25953783,2,Body mass index (age interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST002894,25953783,9,Body mass index
http://www.ebi.ac.uk/efo/efo_0003776,GCST002892,25948407,15,Perioperative myocardial infarction in coronary artery bypass surgery
http://www.ebi.ac.uk/efo/efo_0000612,GCST002892,25948407,15,Perioperative myocardial infarction in coronary artery bypass surgery
http://www.ebi.ac.uk/efo/efo_0000676,GCST002889,25939698,6,Psoriasis
http://www.ebi.ac.uk/efo/efo_0003761,GCST002885,25944848,4,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)
http://www.ebi.ac.uk/efo/efo_0000692,GCST002885,25944848,4,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)
http://www.ebi.ac.uk/efo/efo_0000289,GCST002885,25944848,4,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)
http://purl.obolibrary.org/obo/go_0097333,GCST002885,25944848,4,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)
http://www.ebi.ac.uk/efo/efo_0007635,GCST002885,25944848,4,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)
http://www.ebi.ac.uk/efo/efo_0003761,GCST002888,25944848,3,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)
http://www.ebi.ac.uk/efo/efo_0000692,GCST002888,25944848,3,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)
http://www.ebi.ac.uk/efo/efo_0000289,GCST002888,25944848,3,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)
http://www.ebi.ac.uk/efo/efo_0007635,GCST002888,25944848,3,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)
http://purl.obolibrary.org/obo/go_0097332,GCST002888,25944848,3,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)
http://www.ebi.ac.uk/efo/efo_0003761,GCST002887,25944848,4,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)
http://www.ebi.ac.uk/efo/efo_0000692,GCST002887,25944848,4,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)
http://www.ebi.ac.uk/efo/efo_0000289,GCST002887,25944848,4,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)
http://www.ebi.ac.uk/efo/efo_0007635,GCST002887,25944848,4,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)
http://purl.obolibrary.org/obo/go_0036277,GCST002887,25944848,4,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)
http://www.ebi.ac.uk/efo/efo_0006999,GCST002886,25939597,3,Prostate cancer aggressiveness
http://www.ebi.ac.uk/efo/efo_0007000,GCST002886,25939597,3,Prostate cancer aggressiveness
http://www.ebi.ac.uk/efo/efo_0001663,GCST002886,25939597,3,Prostate cancer aggressiveness
http://www.ebi.ac.uk/efo/efo_0003761,GCST002891,25944848,1,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)
http://www.ebi.ac.uk/efo/efo_0000692,GCST002891,25944848,1,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)
http://www.ebi.ac.uk/efo/efo_0000289,GCST002891,25944848,1,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)
http://www.ebi.ac.uk/efo/efo_0007635,GCST002891,25944848,1,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)
http://purl.obolibrary.org/obo/go_0036276,GCST002891,25944848,1,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)
http://www.ebi.ac.uk/efo/efo_0001663,GCST002890,25939597,18,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0003834,GCST002884,25827949,7,Cutaneous lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0007007,GCST002882,25935875,6,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
http://www.ebi.ac.uk/efo/efo_0005672,GCST002882,25935875,6,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
http://www.ebi.ac.uk/efo/efo_0007020,GCST002883,25935875,2,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
http://www.ebi.ac.uk/efo/efo_0005672,GCST002883,25935875,2,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
http://www.ebi.ac.uk/efo/efo_0006955,GCST002881,25934476,4,ADAMTS13 activity
http://www.ebi.ac.uk/efo/efo_0006337,GCST004751,25676789,26,Serum uric acid levels in response to allopurinol in gout
http://www.ebi.ac.uk/efo/efo_0004274,GCST004751,25676789,26,Serum uric acid levels in response to allopurinol in gout
http://www.ebi.ac.uk/efo/efo_0004761,GCST004751,25676789,26,Serum uric acid levels in response to allopurinol in gout
http://www.ebi.ac.uk/efo/efo_1000651,GCST002880,25935106,5,Recalcitrant atopic dermatitis
http://www.ebi.ac.uk/efo/efo_0004239,GCST002879,25802187,12,Chronic hepatitis B infection
http://www.ebi.ac.uk/efo/efo_0007052,GCST002877,25918995,0,Adult antisocial behavior
http://www.ebi.ac.uk/efo/efo_1000656,GCST002878,25918841,2,Creutzfeldt-Jakob disease (sporadic)
http://www.ebi.ac.uk/efo/efo_0006812,GCST002876,25936594,11,Type 1 diabetes and autoimmune thyroid diseases
http://www.ebi.ac.uk/efo/efo_0001359,GCST002876,25936594,11,Type 1 diabetes and autoimmune thyroid diseases
http://www.ebi.ac.uk/efo/efo_0006995,GCST002875,25918132,180,Diisocyanate-induced asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST002875,25918132,180,Diisocyanate-induced asthma
http://www.ebi.ac.uk/efo/efo_0000676,GCST002874,25903422,68,Psoriasis
http://www.ebi.ac.uk/efo/efo_0002892,GCST002873,25855579,3,Thyroid cancer
http://www.ebi.ac.uk/efo/efo_0004531,GCST002872,25898920,4,Blood metabolite levels
http://www.ebi.ac.uk/efo/efo_0006958,GCST002872,25898920,4,Blood metabolite levels
http://www.ebi.ac.uk/efo/efo_0005664,GCST002872,25898920,4,Blood metabolite levels
http://www.ebi.ac.uk/efo/efo_0006957,GCST002872,25898920,4,Blood metabolite levels
http://www.ebi.ac.uk/efo/efo_0003761,GCST002868,25897834,20,Response to serotonin reuptake inhibitors in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0005658,GCST002868,25897834,20,Response to serotonin reuptake inhibitors in major depressive disorder
http://purl.obolibrary.org/obo/go_0036273,GCST002865,25898129,0,Response to statin therapy (LDL cholesterol subfractions)
http://www.ebi.ac.uk/efo/efo_0004611,GCST002865,25898129,0,Response to statin therapy (LDL cholesterol subfractions)
http://purl.obolibrary.org/obo/hp_0000708,GCST002863,25897833,2,Behavioral disturbance or psychiatric symptoms in prion disease
http://www.ebi.ac.uk/efo/efo_0004720,GCST002863,25897833,2,Behavioral disturbance or psychiatric symptoms in prion disease
http://www.ebi.ac.uk/efo/efo_0004720,GCST002864,25897833,3,Mood disorder in prion disease
http://www.ebi.ac.uk/efo/efo_0004247,GCST002864,25897833,3,Mood disorder in prion disease
http://www.ebi.ac.uk/efo/efo_0004720,GCST002867,25897833,3,Psychotic symptoms in prion disease
http://www.ebi.ac.uk/efo/efo_0005940,GCST002867,25897833,3,Psychotic symptoms in prion disease
http://purl.obolibrary.org/obo/hp_0000708,GCST002866,25897833,3,Behavioral disturbance or psychiatric symptoms and prion disease
http://www.ebi.ac.uk/efo/efo_0004720,GCST002866,25897833,3,Behavioral disturbance or psychiatric symptoms and prion disease
http://www.ebi.ac.uk/efo/efo_0004720,GCST002862,25897833,3,Mood disorder and prion disease
http://www.ebi.ac.uk/efo/efo_0004247,GCST002862,25897833,3,Mood disorder and prion disease
http://www.ebi.ac.uk/efo/efo_0004720,GCST002871,25897833,1,Psychotic symptoms and prion disease
http://www.ebi.ac.uk/efo/efo_0005940,GCST002871,25897833,1,Psychotic symptoms and prion disease
http://www.ebi.ac.uk/efo/efo_0004611,GCST002870,25898129,0,LDL cholesterol subfractions
http://www.ebi.ac.uk/efo/efo_0000685,GCST002869,25896534,0,"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis"
http://www.ebi.ac.uk/efo/efo_0004653,GCST002869,25896534,0,"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis"
http://www.ebi.ac.uk/efo/efo_1000650,GCST002861,25890600,3,Breast cancer (survival)
http://www.ebi.ac.uk/efo/efo_0000714,GCST002861,25890600,3,Breast cancer (survival)
http://www.ebi.ac.uk/efo/efo_1000649,GCST002861,25890600,3,Breast cancer (survival)
http://www.ebi.ac.uk/efo/efo_0000305,GCST002861,25890600,3,Breast cancer (survival)
http://www.ebi.ac.uk/efo/efo_0004845,GCST002860,25886283,15,Magnesium levels
http://www.ebi.ac.uk/efo/efo_0004810,GCST002858,25896417,2,Cytokine and corticosteroid-stimulated IL-6 production
http://purl.obolibrary.org/obo/go_0031960,GCST002858,25896417,2,Cytokine and corticosteroid-stimulated IL-6 production
http://purl.obolibrary.org/obo/go_0034097,GCST002858,25896417,2,Cytokine and corticosteroid-stimulated IL-6 production
http://www.ebi.ac.uk/efo/efo_0004838,GCST002857,25886283,6,Calcium levels
http://www.ebi.ac.uk/efo/efo_0004810,GCST002859,25896417,2,Cytokine-stimulated IL-6 production
http://purl.obolibrary.org/obo/go_0034097,GCST002859,25896417,2,Cytokine-stimulated IL-6 production
http://www.ebi.ac.uk/efo/efo_0008343,GCST002856,25898001,4,Carotid artery intima media thickness (sex interaction)
http://www.ebi.ac.uk/efo/efo_0007117,GCST002856,25898001,4,Carotid artery intima media thickness (sex interaction)
http://www.ebi.ac.uk/efo/efo_1000566,GCST002855,25877299,8,Testicular germ cell tumor
http://www.ebi.ac.uk/efo/efo_0007120,GCST002851,25888059,0,Sasang constitutional medicine type (Tae-Yang)
http://www.ebi.ac.uk/efo/efo_0007119,GCST002851,25888059,0,Sasang constitutional medicine type (Tae-Yang)
http://www.ebi.ac.uk/efo/efo_0007121,GCST002852,25888059,0,Sasang constitutional medicine type (So-Yang)
http://www.ebi.ac.uk/efo/efo_0007119,GCST002852,25888059,0,Sasang constitutional medicine type (So-Yang)
http://www.ebi.ac.uk/efo/efo_0007122,GCST002853,25888059,0,Sasang constitutional medicine type (Tae-Eum)
http://www.ebi.ac.uk/efo/efo_0007119,GCST002853,25888059,0,Sasang constitutional medicine type (Tae-Eum)
http://www.ebi.ac.uk/efo/efo_0007123,GCST002854,25888059,1,Sasang constitutional medicine type (So-Eum)
http://www.ebi.ac.uk/efo/efo_0007119,GCST002854,25888059,1,Sasang constitutional medicine type (So-Eum)
http://www.ebi.ac.uk/efo/efo_0004363,GCST002850,25869804,4,Information processing speed
http://www.ebi.ac.uk/efo/efo_0007046,GCST002849,25869804,0,Executive function
http://www.ebi.ac.uk/efo/efo_0000409,GCST002847,25867717,2,Disease-free survival in breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST002847,25867717,2,Disease-free survival in breast cancer
http://www.ebi.ac.uk/efo/efo_0004300,GCST002846,25918517,7,Lifespan
http://www.ebi.ac.uk/efo/efo_0003888,GCST002848,25875332,0,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0000274,GCST002844,25865352,6,Atopic dermatitis
http://www.ebi.ac.uk/efo/efo_0002690,GCST002845,25862617,1,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004193,GCST002842,25855136,13,Basal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0007118,GCST002843,25865494,44,Sitting height ratio
http://www.ebi.ac.uk/efo/efo_1000648,GCST002841,25848760,1,Developmental dysplasia of the hip
http://www.ebi.ac.uk/efo/efo_0004251,GCST002840,25849990,3,Myeloproliferative neoplasms
http://www.ebi.ac.uk/efo/efo_0007042,GCST002839,25839716,57,Polychlorinated biphenyl levels
http://www.ebi.ac.uk/efo/efo_0004991,GCST002838,25643325,3,Myasthenia gravis
http://www.ebi.ac.uk/efo/efo_0000305,GCST007236,25751625,74,Breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST004950,25751625,88,Breast cancer
http://www.ebi.ac.uk/efo/efo_0001359,GCST005536,25751624,51,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0006954,GCST002837,25813999,1,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)
http://www.ebi.ac.uk/efo/efo_0006956,GCST002837,25813999,1,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)
http://www.ebi.ac.uk/efo/efo_0007053,GCST002833,25823687,1,Platinum-induced myelosuppression in non-small cell lung cancer
http://www.ebi.ac.uk/efo/efo_0004647,GCST002833,25823687,1,Platinum-induced myelosuppression in non-small cell lung cancer
http://www.ebi.ac.uk/efo/efo_0003060,GCST002833,25823687,1,Platinum-induced myelosuppression in non-small cell lung cancer
http://www.ebi.ac.uk/efo/efo_0004345,GCST002834,25823570,1,Corneal curvature
http://www.ebi.ac.uk/efo/efo_0005318,GCST002836,25823570,1,Axial length
http://www.ebi.ac.uk/efo/efo_0000681,GCST002835,25826619,3,Renal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0007040,GCST002831,25820613,15,Lead levels in blood
http://www.ebi.ac.uk/efo/efo_0004531,GCST002830,25811787,36,Urate levels in lean individuals
http://www.ebi.ac.uk/efo/efo_0005936,GCST002830,25811787,36,Urate levels in lean individuals
http://www.ebi.ac.uk/efo/efo_1001209,GCST006198,25817017,3,Giant cell arteritis
http://www.ebi.ac.uk/efo/efo_0004531,GCST002827,25811787,6,Urate levels (BMI interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST002827,25811787,6,Urate levels (BMI interaction)
http://www.ebi.ac.uk/efo/efo_0007041,GCST002828,25811787,35,Urate levels in obese individuals
http://www.ebi.ac.uk/efo/efo_0004531,GCST002828,25811787,35,Urate levels in obese individuals
http://www.ebi.ac.uk/efo/efo_0004531,GCST002829,25811787,43,Urate levels in overweight individuals
http://www.ebi.ac.uk/efo/efo_0005935,GCST002829,25811787,43,Urate levels in overweight individuals
http://www.ebi.ac.uk/efo/efo_0004531,GCST002826,25811787,16,Urate levels (BMI interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST002826,25811787,16,Urate levels (BMI interaction)
http://www.ebi.ac.uk/efo/efo_0003780,GCST002823,25799145,0,Behcet's disease
http://www.ebi.ac.uk/efo/efo_0003780,GCST002824,25799145,1,Behcet's disease
http://www.ebi.ac.uk/efo/efo_0002614,GCST002825,25798622,1,Insulin resistance/response
http://www.ebi.ac.uk/efo/efo_0000409,GCST002820,25866641,12,Survival in microsatellite instability low/stable colorectal cancer
http://www.ebi.ac.uk/efo/efo_0005842,GCST002820,25866641,12,Survival in microsatellite instability low/stable colorectal cancer
http://www.ebi.ac.uk/efo/efo_0007054,GCST002820,25866641,12,Survival in microsatellite instability low/stable colorectal cancer
http://www.ebi.ac.uk/efo/efo_0000638,GCST002820,25866641,12,Survival in microsatellite instability low/stable colorectal cancer
http://www.ebi.ac.uk/efo/efo_0000409,GCST002821,25866641,18,Survival in rectal cancer
http://www.ebi.ac.uk/efo/efo_1000657,GCST002821,25866641,18,Survival in rectal cancer
http://www.ebi.ac.uk/efo/efo_0000638,GCST002821,25866641,18,Survival in rectal cancer
http://www.ebi.ac.uk/efo/efo_0000409,GCST002822,25866641,12,Survival in colon cancer
http://www.ebi.ac.uk/efo/efo_0004288,GCST002822,25866641,12,Survival in colon cancer
http://www.ebi.ac.uk/efo/efo_0000638,GCST002822,25866641,12,Survival in colon cancer
http://www.ebi.ac.uk/efo/efo_0005423,GCST002819,25784220,1,Adolescent idiopathic scoliosis
http://www.ebi.ac.uk/efo/efo_0000180,GCST002818,25786224,7,HIV-1 susceptibility
http://www.orpha.net/ordo/orphanet_391311,GCST002818,25786224,7,HIV-1 susceptibility
http://www.ebi.ac.uk/efo/efo_0000249,GCST002814,25778476,4,Alzheimer's disease (APOE e4 interaction)
http://www.ebi.ac.uk/efo/efo_0007659,GCST002814,25778476,4,Alzheimer's disease (APOE e4 interaction)
http://www.ebi.ac.uk/efo/efo_0000249,GCST002817,25778476,29,Alzheimer's disease in APOE e4- carriers
http://www.ebi.ac.uk/efo/efo_0000249,GCST002813,25778476,17,Alzheimer's disease in APOE e4+ carriers
http://www.ebi.ac.uk/efo/efo_0007050,GCST002815,25781172,5,Bipolar disorder (inflammation and infection response interaction)
http://www.ebi.ac.uk/efo/efo_0000289,GCST002815,25781172,5,Bipolar disorder (inflammation and infection response interaction)
http://www.ebi.ac.uk/efo/efo_0007037,GCST002815,25781172,5,Bipolar disorder (inflammation and infection response interaction)
http://www.ebi.ac.uk/efo/efo_0007010,GCST002816,25781442,2,Colorectal cancer (aspirin and/or NSAID use interaction)
http://www.ebi.ac.uk/efo/efo_0007013,GCST002816,25781442,2,Colorectal cancer (aspirin and/or NSAID use interaction)
http://www.ebi.ac.uk/efo/efo_0007012,GCST002816,25781442,2,Colorectal cancer (aspirin and/or NSAID use interaction)
http://www.ebi.ac.uk/efo/efo_0005842,GCST002816,25781442,2,Colorectal cancer (aspirin and/or NSAID use interaction)
http://www.ebi.ac.uk/efo/efo_0000692,GCST002812,25781172,4,Schizophrenia (inflammation and infection response interaction)
http://www.ebi.ac.uk/efo/efo_0007050,GCST002812,25781172,4,Schizophrenia (inflammation and infection response interaction)
http://www.ebi.ac.uk/efo/efo_0007047,GCST002812,25781172,4,Schizophrenia (inflammation and infection response interaction)
http://www.ebi.ac.uk/efo/efo_0007037,GCST002812,25781172,4,Schizophrenia (inflammation and infection response interaction)
http://purl.obolibrary.org/obo/hp_0000175,GCST002811,25775280,6,Nonsyndromic cleft lip with or without cleft palate
http://www.ebi.ac.uk/efo/efo_0003959,GCST002811,25775280,6,Nonsyndromic cleft lip with or without cleft palate
http://www.orpha.net/ordo/orphanet_3389,GCST002810,25774636,2,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0000289,GCST002809,25827505,4,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004286,GCST002808,25772935,10,Venous thromboembolism
http://www.orpha.net/ordo/orphanet_93930,GCST002807,25763902,25,Classic bladder exstrophy
http://www.ebi.ac.uk/efo/efo_0006947,GCST002803,25758996,2,Red wine liking
http://www.ebi.ac.uk/efo/efo_0006948,GCST002802,25758996,2,White wine liking
http://www.ebi.ac.uk/efo/efo_0001360,GCST002806,25760438,17,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0005937,GCST002805,25760438,11,Body mass index
http://www.ebi.ac.uk/efo/efo_0007034,GCST002804,25758998,7,Antibody level in response to infection
http://www.ebi.ac.uk/efo/efo_0004748,GCST008165,25743335,13,Thyroid stimulating hormone levels
http://www.ebi.ac.uk/efo/efo_0005130,GCST008164,25743335,4,Free thyroxine concentration
http://www.ebi.ac.uk/efo/efo_0006918,GCST002800,25742292,11,Number of children (6+ vs. 0 or 1)
http://www.ebi.ac.uk/efo/efo_0006923,GCST002800,25742292,11,Number of children (6+ vs. 0 or 1)
http://www.ebi.ac.uk/efo/efo_0006918,GCST002799,25742292,12,Number of pregnancies
http://www.ebi.ac.uk/efo/efo_0006923,GCST002799,25742292,12,Number of pregnancies
http://www.ebi.ac.uk/efo/efo_0006918,GCST002801,25742292,8,Number of children
http://www.ebi.ac.uk/efo/efo_0006923,GCST002801,25742292,8,Number of children
http://purl.obolibrary.org/obo/go_0097366,GCST002796,25562107,1,Bronchodilator response in asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST002796,25562107,1,Bronchodilator response in asthma
http://www.ebi.ac.uk/efo/efo_0004192,GCST005539,25337690,2,Alopecia areata
http://www.ebi.ac.uk/efo/efo_0000341,GCST002795,25101718,5,Chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006347,GCST002797,25101718,2,Pulmonary artery enlargement in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST002797,25101718,2,Pulmonary artery enlargement in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006347,GCST002798,25101718,1,Pulmonary artery enlargement and chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST002798,25101718,1,Pulmonary artery enlargement and chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006898,GCST002794,25517131,19,Airway wall thickness
http://www.ebi.ac.uk/efo/efo_0003776,GCST002793,25881214,7,Vein graft stenosis in coronary artery bypass grafting
http://www.ebi.ac.uk/efo/efo_0007051,GCST002793,25881214,7,Vein graft stenosis in coronary artery bypass grafting
http://www.ebi.ac.uk/efo/efo_0003100,GCST002792,25710658,5,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_0000220,GCST002792,25710658,5,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_0006950,GCST002792,25710658,5,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_0007016,GCST002790,25710614,5,Food allergy
http://www.ebi.ac.uk/efo/efo_0007018,GCST002789,25710614,5,Egg allergy
http://www.ebi.ac.uk/efo/efo_0007019,GCST002788,25710614,5,Milk allergy
http://www.ebi.ac.uk/efo/efo_0007017,GCST002791,25710614,3,Peanut allergy
http://www.ebi.ac.uk/efo/efo_0006959,GCST002786,25713168,3,Gene methylation in lung tissue
http://www.ebi.ac.uk/efo/efo_0006942,GCST002785,25705849,4,Facial pigmentation
http://www.ebi.ac.uk/efo/efo_0004235,GCST002787,25706626,4,Exfoliation syndrome
http://www.ebi.ac.uk/efo/efo_0005202,GCST002784,25695618,0,Blood pressure response to hydrochlorothiazide in hypertension
http://www.ebi.ac.uk/efo/efo_0006945,GCST002784,25695618,0,Blood pressure response to hydrochlorothiazide in hypertension
http://www.ebi.ac.uk/efo/efo_0000537,GCST002784,25695618,0,Blood pressure response to hydrochlorothiazide in hypertension
http://www.ebi.ac.uk/efo/efo_0006944,GCST002784,25695618,0,Blood pressure response to hydrochlorothiazide in hypertension
http://www.ebi.ac.uk/efo/efo_0007788,GCST002782,25673412,286,Waist-to-hip ratio adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0005093,GCST004066,25673412,142,Hip circumference
http://www.ebi.ac.uk/efo/efo_0007789,GCST004063,25673412,169,Waist circumference adjusted for body mass index
http://www.ebi.ac.uk/efo/efo_0008039,GCST004067,25673412,225,Hip circumference adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004342,GCST004065,25673412,106,Waist circumference
http://www.ebi.ac.uk/efo/efo_0004343,GCST004064,25673412,78,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0004340,GCST002783,25673413,634,Body mass index
http://www.ebi.ac.uk/efo/efo_0000649,GCST002781,25672891,2,Periodontitis
http://www.ebi.ac.uk/efo/efo_0006951,GCST002780,25665007,0,Cisplatin-induced hearing loss in brain tumor patients
http://www.ebi.ac.uk/efo/efo_0004238,GCST002780,25665007,0,Cisplatin-induced hearing loss in brain tumor patients
http://purl.obolibrary.org/obo/go_0072718,GCST002780,25665007,0,Cisplatin-induced hearing loss in brain tumor patients
http://www.ebi.ac.uk/efo/efo_0004276,GCST002779,25672763,1,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
http://www.ebi.ac.uk/efo/efo_0004775,GCST002779,25672763,1,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
http://www.ebi.ac.uk/efo/efo_0006997,GCST002779,25672763,1,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
http://www.ebi.ac.uk/efo/efo_0002508,GCST002778,25663231,10,Parkinson disease and lewy body pathology
http://www.ebi.ac.uk/efo/efo_0007021,GCST002778,25663231,10,Parkinson disease and lewy body pathology
http://www.ebi.ac.uk/efo/efo_0006952,GCST002777,25656473,18,Clozapine-induced cytotoxicity
http://purl.obolibrary.org/obo/go_0097338,GCST002777,25656473,18,Clozapine-induced cytotoxicity
http://www.ebi.ac.uk/efo/efo_0001065,GCST002776,25722978,0,Endometriosis
http://www.ebi.ac.uk/efo/efo_0000249,GCST002775,25649651,7,Alzheimer's disease (survival time)
http://www.ebi.ac.uk/efo/efo_0000714,GCST002775,25649651,7,Alzheimer's disease (survival time)
http://www.ebi.ac.uk/efo/efo_0004337,GCST002774,25644384,34,Cognitive function
http://www.ebi.ac.uk/efo/efo_0004274,GCST002773,25646370,6,Gout
http://www.ebi.ac.uk/efo/efo_0001054,GCST002772,25642632,22,Leprosy
http://www.ebi.ac.uk/efo/efo_0000180,GCST002771,25461247,35,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
http://www.ebi.ac.uk/efo/efo_0006904,GCST002771,25461247,35,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
http://www.ebi.ac.uk/efo/efo_0006906,GCST002771,25461247,35,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
http://www.ebi.ac.uk/efo/efo_0000180,GCST002769,25461247,27,Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
http://www.ebi.ac.uk/efo/efo_0006906,GCST002769,25461247,27,Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
http://www.ebi.ac.uk/efo/efo_0006905,GCST002769,25461247,27,Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
http://www.ebi.ac.uk/efo/efo_0006941,GCST002770,25637336,2,Hand grip strength
http://www.ebi.ac.uk/efo/efo_0006946,GCST002768,25637581,0,Behavioral disinhibition
http://www.ebi.ac.uk/efo/efo_0004695,GCST002767,25637523,48,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0004466,GCST007898,25631608,7,Fasting blood insulin
http://www.ebi.ac.uk/efo/efo_0004465,GCST007899,25631608,22,Fasting blood glucose
http://www.ebi.ac.uk/efo/efo_0004683,GCST002766,25629512,7,Exudative age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0006937,GCST002763,25631615,19,Optic disc area
http://www.ebi.ac.uk/efo/efo_0006940,GCST002762,25631615,30,Optic cup area
http://www.ebi.ac.uk/efo/efo_0006940,GCST002764,25631615,16,Optic cup area
http://www.ebi.ac.uk/efo/efo_0006937,GCST002765,25631615,10,Optic disc area
http://www.ebi.ac.uk/efo/efo_0005039,GCST002760,25625606,3,Hippocampal atrophy
http://www.ebi.ac.uk/efo/efo_0008036,GCST007858,25625282,10,Fasting blood glucose adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0008037,GCST007857,25625282,6,Fasting blood insulin adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0005035,GCST002761,25625606,19,Hippocampal volume
http://www.ebi.ac.uk/efo/efo_0006928,GCST002759,25628336,35,Motion sickness
http://www.ebi.ac.uk/efo/efo_0003885,GCST002758,25616667,3,Oligoclonal band status in multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0005206,GCST002758,25616667,3,Oligoclonal band status in multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0004192,GCST004866,25608926,34,Alopecia areata
http://www.ebi.ac.uk/efo/efo_0003885,GCST002757,25616667,3,Immunoglobulin G index levels in multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0006929,GCST002757,25616667,3,Immunoglobulin G index levels in multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0006930,GCST002756,25607358,12,Subcortical brain region volumes
http://www.ebi.ac.uk/efo/efo_0007010,GCST002755,25649181,10,Depressive symptoms (SSRI exposure interaction)
http://www.ebi.ac.uk/efo/efo_0007006,GCST002755,25649181,10,Depressive symptoms (SSRI exposure interaction)
http://www.ebi.ac.uk/efo/efo_0007011,GCST002755,25649181,10,Depressive symptoms (SSRI exposure interaction)
http://www.ebi.ac.uk/efo/efo_0005921,GCST002754,25601762,2,Response to inhaled glucocorticoid treatment in asthma (change in FEV1)
http://purl.obolibrary.org/obo/go_0051384,GCST002754,25601762,2,Response to inhaled glucocorticoid treatment in asthma (change in FEV1)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002754,25601762,2,Response to inhaled glucocorticoid treatment in asthma (change in FEV1)
http://www.ebi.ac.uk/efo/efo_1001857,GCST006575,25604533,58,Takayasu arteritis
http://www.ebi.ac.uk/efo/efo_0006921,GCST002751,25599974,5,Spontaneous preterm birth (preterm birth)
http://www.ebi.ac.uk/efo/efo_0006917,GCST002751,25599974,5,Spontaneous preterm birth (preterm birth)
http://www.ebi.ac.uk/efo/efo_0006922,GCST002752,25599974,2,Spontaneous preterm birth (preterm delivery)
http://www.ebi.ac.uk/efo/efo_0006917,GCST002752,25599974,2,Spontaneous preterm birth (preterm delivery)
http://www.ebi.ac.uk/efo/efo_0001071,GCST002753,25644374,0,Lung cancer and family history of lung cancer
http://www.ebi.ac.uk/efo/efo_0006953,GCST002753,25644374,0,Lung cancer and family history of lung cancer
http://www.ebi.ac.uk/efo/efo_0000341,GCST002750,25584925,3,Chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006996,GCST002749,25628645,10,Response to Homoharringtonine (cytotoxicity)
http://www.ebi.ac.uk/efo/efo_0006952,GCST002749,25628645,10,Response to Homoharringtonine (cytotoxicity)
http://www.orpha.net/ordo/orphanet_398934,GCST002748,25581431,21,Epithelial ovarian cancer
http://www.ebi.ac.uk/efo/efo_0006916,GCST002747,25583994,1,Response to Dalcetrapib treatment in acute coronary syndrome
http://www.ebi.ac.uk/efo/efo_0005672,GCST002747,25583994,1,Response to Dalcetrapib treatment in acute coronary syndrome
http://www.ebi.ac.uk/efo/efo_0006919,GCST002747,25583994,1,Response to Dalcetrapib treatment in acute coronary syndrome
http://www.ebi.ac.uk/efo/efo_0006925,GCST002746,25575512,15,Lipoprotein (a) - cholesterol levels
http://www.ebi.ac.uk/efo/efo_0000180,GCST002744,25884002,1,HDL Cholesterol in HIV-infection
http://www.ebi.ac.uk/efo/efo_0004612,GCST002744,25884002,1,HDL Cholesterol in HIV-infection
http://www.ebi.ac.uk/efo/efo_0004833,GCST002743,25884002,2,Neutrophil count in HIV-infection
http://www.ebi.ac.uk/efo/efo_0000180,GCST002743,25884002,2,Neutrophil count in HIV-infection
http://www.ebi.ac.uk/efo/efo_0000180,GCST002745,25884002,11,Total bilirubin levels in HIV-1 infection
http://www.ebi.ac.uk/efo/efo_0004570,GCST002745,25884002,11,Total bilirubin levels in HIV-1 infection
http://www.ebi.ac.uk/efo/efo_1000630,GCST002742,25569183,4,Marginal zone lymphoma
http://www.ebi.ac.uk/efo/efo_0000676,GCST002738,25574825,20,Psoriasis
http://www.ebi.ac.uk/efo/efo_0000274,GCST002737,25574825,7,Atopic dermatitis
http://www.ebi.ac.uk/efo/efo_0001071,GCST002739,25566987,0,Lung cancer (household air pollution interaction)
http://www.ebi.ac.uk/efo/efo_0006924,GCST002739,25566987,0,Lung cancer (household air pollution interaction)
http://www.ebi.ac.uk/efo/efo_1000636,GCST002740,25574825,88,Inflammatory skin disease
http://www.ebi.ac.uk/efo/efo_0000660,GCST002741,25574032,3,Polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0006920,GCST002736,25561047,2,B-type natriuretic peptide levels
http://www.ebi.ac.uk/efo/efo_0000305,GCST002735,25824743,2,Breast cancer
http://www.ebi.ac.uk/efo/efo_0006900,GCST002731,25552591,3,Endothelial growth factor levels
http://www.ebi.ac.uk/efo/efo_0006902,GCST002731,25552591,3,Endothelial growth factor levels
http://www.ebi.ac.uk/efo/efo_0006901,GCST002731,25552591,3,Endothelial growth factor levels
http://www.ebi.ac.uk/efo/efo_0006903,GCST002731,25552591,3,Endothelial growth factor levels
http://www.ebi.ac.uk/efo/efo_0004309,GCST002733,25705162,3,Platelet count
http://purl.obolibrary.org/obo/hp_0012115,GCST002730,25705159,9,Hepatitis
http://www.ebi.ac.uk/efo/efo_0000195,GCST002732,25705158,2,Metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0006818,GCST002729,25557950,7,Crohn's disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0005624,GCST002729,25557950,7,Crohn's disease-related phenotypes
http://purl.obolibrary.org/obo/hp_0012219,GCST002729,25557950,7,Crohn's disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0005627,GCST002729,25557950,7,Crohn's disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0000384,GCST002729,25557950,7,Crohn's disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0006819,GCST002729,25557950,7,Crohn's disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0006820,GCST002729,25557950,7,Crohn's disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0006527,GCST002734,25551457,3,"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)"
http://www.ebi.ac.uk/efo/efo_0004329,GCST002734,25551457,3,"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)"
http://www.ebi.ac.uk/efo/efo_0004623,GCST002734,25551457,3,"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)"
http://www.ebi.ac.uk/efo/efo_0004340,GCST002734,25551457,3,"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)"
http://www.ebi.ac.uk/efo/efo_0006817,GCST002728,25533513,1,Yang-deficiency constitution
http://www.ebi.ac.uk/efo/efo_0000714,GCST002727,25526632,3,Breast cancer (survival)
http://www.ebi.ac.uk/efo/efo_0000305,GCST002727,25526632,3,Breast cancer (survival)
http://www.ebi.ac.uk/efo/efo_0006830,GCST002726,25524916,74,Glucose homeostasis traits
http://www.ebi.ac.uk/efo/efo_0006832,GCST002726,25524916,74,Glucose homeostasis traits
http://www.ebi.ac.uk/efo/efo_0004471,GCST002726,25524916,74,Glucose homeostasis traits
http://www.ebi.ac.uk/efo/efo_0006896,GCST002726,25524916,74,Glucose homeostasis traits
http://www.ebi.ac.uk/efo/efo_0006833,GCST002726,25524916,74,Glucose homeostasis traits
http://www.ebi.ac.uk/efo/efo_0006831,GCST002726,25524916,74,Glucose homeostasis traits
http://www.ebi.ac.uk/efo/efo_0004573,GCST004389,25521368,6,Circulating chemerin levels
http://www.ebi.ac.uk/efo/efo_0000714,GCST002725,25533491,2,Sepsis from pneumonia (survival)
http://www.ebi.ac.uk/efo/efo_0003106,GCST002725,25533491,2,Sepsis from pneumonia (survival)
http://www.ebi.ac.uk/efo/efo_0006834,GCST002725,25533491,2,Sepsis from pneumonia (survival)
http://purl.obolibrary.org/obo/hp_0100806,GCST002725,25533491,2,Sepsis from pneumonia (survival)
http://www.ebi.ac.uk/efo/efo_0006897,GCST002724,25514360,26,Airway responsiveness in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST002724,25514360,26,Airway responsiveness in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006865,GCST002723,25524241,6,Urgency urinary incontinence
http://www.ebi.ac.uk/efo/efo_0006816,GCST002722,25503805,0,Heparin-induced thrombocytopenia
http://purl.obolibrary.org/obo/hp_0001873,GCST002722,25503805,0,Heparin-induced thrombocytopenia
http://www.ebi.ac.uk/efo/efo_0003884,GCST002720,25493955,8,Kidney function decline traits
http://www.ebi.ac.uk/efo/efo_0006836,GCST002720,25493955,8,Kidney function decline traits
http://www.ebi.ac.uk/efo/efo_0006829,GCST002720,25493955,8,Kidney function decline traits
http://www.ebi.ac.uk/efo/efo_0006821,GCST002721,25646338,131,Trans fatty acid levels
http://www.ebi.ac.uk/efo/efo_0006876,GCST002719,25562672,8,Seasonality
http://www.ebi.ac.uk/efo/efo_0001360,GCST002718,25483131,6,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001359,GCST002716,25476525,1,Diabetic nephropathy in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0000401,GCST002716,25476525,1,Diabetic nephropathy in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004579,GCST002717,25488688,2,Serum IgE levels
http://www.ebi.ac.uk/efo/efo_0006864,GCST002715,25475840,9,Breastfeeding duration
http://www.ebi.ac.uk/efo/efo_0006828,GCST002714,25477429,3,Plasma renin activity levels
http://www.ebi.ac.uk/efo/efo_0006808,GCST002712,25500335,13,Red blood cell fatty acid levels
http://www.ebi.ac.uk/efo/efo_0005110,GCST002712,25500335,13,Red blood cell fatty acid levels
http://www.ebi.ac.uk/efo/efo_0006811,GCST002712,25500335,13,Red blood cell fatty acid levels
http://www.ebi.ac.uk/efo/efo_0006810,GCST002712,25500335,13,Red blood cell fatty acid levels
http://www.ebi.ac.uk/efo/efo_0006809,GCST002712,25500335,13,Red blood cell fatty acid levels
http://www.ebi.ac.uk/efo/efo_0006807,GCST002712,25500335,13,Red blood cell fatty acid levels
http://www.ebi.ac.uk/efo/efo_0000220,GCST002713,25468567,1,Acute lymphoblastic leukemia (adolescents and young adults)
http://www.ebi.ac.uk/efo/efo_0005271,GCST002711,25469926,13,Sleep duration
http://www.ebi.ac.uk/efo/efo_0006867,GCST002706,25387706,13,Electrodermal activity
http://www.ebi.ac.uk/efo/efo_0006869,GCST002706,25387706,13,Electrodermal activity
http://www.ebi.ac.uk/efo/efo_0006866,GCST002706,25387706,13,Electrodermal activity
http://www.ebi.ac.uk/efo/efo_0006868,GCST002706,25387706,13,Electrodermal activity
http://www.ebi.ac.uk/efo/efo_0006875,GCST002708,25387708,6,Acoustic startle blink response
http://www.ebi.ac.uk/efo/efo_0006874,GCST002710,25387707,5,Anti-saccade response
http://www.ebi.ac.uk/efo/efo_0004748,GCST002707,25436638,18,Serum thyroid-stimulating hormone levels
http://www.ebi.ac.uk/efo/efo_0006873,GCST002709,25387704,27,Electroencephalogram traits
http://www.ebi.ac.uk/efo/efo_0006872,GCST002709,25387704,27,Electroencephalogram traits
http://www.ebi.ac.uk/efo/efo_0006883,GCST002709,25387704,27,Electroencephalogram traits
http://www.ebi.ac.uk/efo/efo_0006870,GCST002709,25387704,27,Electroencephalogram traits
http://www.ebi.ac.uk/efo/efo_0004357,GCST002709,25387704,27,Electroencephalogram traits
http://www.ebi.ac.uk/efo/efo_0006871,GCST002709,25387704,27,Electroencephalogram traits
http://www.ebi.ac.uk/efo/efo_0006812,GCST002705,25429627,3,Hashimoto thyroiditis versus Graves' disease
http://www.ebi.ac.uk/efo/efo_0003779,GCST002705,25429627,3,Hashimoto thyroiditis versus Graves' disease
http://www.ebi.ac.uk/efo/efo_0004237,GCST002705,25429627,3,Hashimoto thyroiditis versus Graves' disease
http://www.ebi.ac.uk/efo/efo_0004624,GCST002703,25434496,5,Prostate-specific antigen levels
http://www.ebi.ac.uk/efo/efo_0005536,GCST002704,25431337,2,Fractional exhaled nitric oxide levels
http://www.ebi.ac.uk/efo/efo_0004339,GCST002702,25429064,125,Height
http://www.ebi.ac.uk/efo/efo_0004874,GCST002701,25648963,43,Verbal declarative memory
http://www.ebi.ac.uk/efo/efo_1000059,GCST002700,25420145,5,Cervical artery dissection
http://www.ebi.ac.uk/efo/efo_0006882,GCST002699,25917933,4,Suicide in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST002699,25917933,4,Suicide in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004321,GCST002699,25917933,4,Suicide in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004232,GCST002697,25407941,6,Eosinophilic esophagitis
http://www.ebi.ac.uk/efo/efo_0006795,GCST002698,25411163,1,Serum VEGFR2 concentration
http://www.ebi.ac.uk/efo/efo_0006788,GCST002696,25390645,15,Anxiety disorder
http://www.ebi.ac.uk/efo/efo_0004333,GCST002695,25385369,1,Episodic memory
http://www.ebi.ac.uk/efo/efo_0006789,GCST002693,25383971,1,Enteric fever
http://www.ebi.ac.uk/efo/efo_0004337,GCST002694,25383866,3,General cognitive ability
http://www.ebi.ac.uk/efo/efo_0005937,GCST002692,25378290,4,Body mass index (change over time)
http://www.orpha.net/ordo/orphanet_232,GCST002691,25670933,1,Alloimmunization response to red blood cell transfusion in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0006804,GCST002691,25670933,1,Alloimmunization response to red blood cell transfusion in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0006802,GCST002691,25670933,1,Alloimmunization response to red blood cell transfusion in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0006796,GCST002690,25378659,21,Very long-chain saturated fatty acid levels (fatty acid 20:0)
http://www.ebi.ac.uk/efo/efo_0006796,GCST002689,25378659,4,Very long-chain saturated fatty acid levels (fatty acid 24:0)
http://www.ebi.ac.uk/efo/efo_0006796,GCST002688,25378659,11,Very long-chain saturated fatty acid levels (fatty acid 22:0)
http://www.ebi.ac.uk/efo/efo_0004633,GCST002686,25376901,4,Protein C levels
http://www.ebi.ac.uk/efo/efo_0004576,GCST002687,25372704,2,Fetal hemoglobin levels in sickle cell anemia
http://www.orpha.net/ordo/orphanet_232,GCST002687,25372704,2,Fetal hemoglobin levels in sickle cell anemia
http://purl.obolibrary.org/obo/hp_0000483,GCST002685,25367360,17,Refractive astigmatism
http://www.ebi.ac.uk/efo/efo_0003770,GCST002684,25364816,1,Diabetic retinopathy in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST002684,25364816,1,Diabetic retinopathy in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003892,GCST002683,25409777,0,Pulmonary function
http://www.ebi.ac.uk/efo/efo_0004242,GCST002682,25158072,15,Tourette's syndrome or obsessive-compulsive disorder
http://www.ebi.ac.uk/efo/efo_0004895,GCST002682,25158072,15,Tourette's syndrome or obsessive-compulsive disorder
http://www.ebi.ac.uk/efo/efo_0001358,GCST002681,25456346,7,Post-traumatic stress disorder
http://www.ebi.ac.uk/efo/efo_0004461,GCST002677,25352340,5,Iron status biomarkers (ferritin levels)
http://www.ebi.ac.uk/efo/efo_0004459,GCST002677,25352340,5,Iron status biomarkers (ferritin levels)
http://www.ebi.ac.uk/efo/efo_0004461,GCST002678,25352340,9,Iron status biomarkers (transferrin levels)
http://www.ebi.ac.uk/efo/efo_0006341,GCST002678,25352340,9,Iron status biomarkers (transferrin levels)
http://www.ebi.ac.uk/efo/efo_0004461,GCST002679,25352340,5,Iron status biomarkers (iron levels)
http://www.ebi.ac.uk/efo/efo_0006332,GCST002679,25352340,5,Iron status biomarkers (iron levels)
http://www.ebi.ac.uk/efo/efo_0004461,GCST002680,25352340,6,Iron status biomarkers (transferrin saturation)
http://www.ebi.ac.uk/efo/efo_0006333,GCST002680,25352340,6,Iron status biomarkers (transferrin saturation)
http://www.ebi.ac.uk/efo/efo_0005941,GCST002676,25353672,5,Mammographic density
http://purl.obolibrary.org/obo/go_0036273,GCST002675,25350695,6,Response to statins (LDL cholesterol change)
http://www.ebi.ac.uk/efo/efo_0004611,GCST002675,25350695,6,Response to statins (LDL cholesterol change)
http://purl.obolibrary.org/obo/hp_0002373,GCST002672,25344690,7,Febrile seizures
http://www.ebi.ac.uk/efo/efo_0006519,GCST002674,25344690,10,Febrile seizures (MMR vaccine-related)
http://purl.obolibrary.org/obo/hp_0002373,GCST002673,25344690,4,Febrile seizures (MMR vaccine-unrelated)
http://www.ebi.ac.uk/efo/efo_0006331,GCST002671,25343990,16,Toenail selenium levels
http://www.ebi.ac.uk/efo/efo_0006331,GCST002670,25343990,12,Blood and toenail selenium levels
http://www.ebi.ac.uk/efo/efo_0006502,GCST002669,25342443,5,Percent mammographic density
http://www.ebi.ac.uk/efo/efo_0005941,GCST002669,25342443,5,Percent mammographic density
http://www.ebi.ac.uk/efo/efo_0006504,GCST002668,25342443,8,Mammographic density (non-dense area)
http://www.ebi.ac.uk/efo/efo_0005941,GCST002668,25342443,8,Mammographic density (non-dense area)
http://www.ebi.ac.uk/efo/efo_0006503,GCST002667,25342443,12,Mammographic density (dense area)
http://www.ebi.ac.uk/efo/efo_0005941,GCST002667,25342443,12,Mammographic density (dense area)
http://www.ebi.ac.uk/efo/efo_0006517,GCST002666,25338677,8,Interferon alpha levels in systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0002690,GCST002666,25338677,8,Interferon alpha levels in systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004744,GCST002665,25340798,5,Cerebrospinal fluid levels of Alzheimer's disease-related proteins
http://www.ebi.ac.uk/efo/efo_0006515,GCST002665,25340798,5,Cerebrospinal fluid levels of Alzheimer's disease-related proteins
http://www.ebi.ac.uk/efo/efo_0000249,GCST002665,25340798,5,Cerebrospinal fluid levels of Alzheimer's disease-related proteins
http://www.ebi.ac.uk/efo/efo_0004751,GCST002665,25340798,5,Cerebrospinal fluid levels of Alzheimer's disease-related proteins
http://www.ebi.ac.uk/efo/efo_0004810,GCST002665,25340798,5,Cerebrospinal fluid levels of Alzheimer's disease-related proteins
http://www.ebi.ac.uk/efo/efo_0006514,GCST002665,25340798,5,Cerebrospinal fluid levels of Alzheimer's disease-related proteins
http://www.ebi.ac.uk/efo/efo_0004749,GCST002665,25340798,5,Cerebrospinal fluid levels of Alzheimer's disease-related proteins
http://www.ebi.ac.uk/efo/efo_0006516,GCST002663,25335168,11,Superior frontal gyrus grey matter volume
http://www.ebi.ac.uk/efo/efo_0004887,GCST002664,25729143,4,Maximal oxygen uptake response
http://www.ebi.ac.uk/efo/efo_0000305,GCST002662,25327703,2,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004612,GCST002661,25329471,0,HDL cholesterol (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0006513,GCST002660,25457201,2,Hereditary hemochromatosis-related traits (HFE mutation homozygotes)
http://www.ebi.ac.uk/efo/efo_0006341,GCST002660,25457201,2,Hereditary hemochromatosis-related traits (HFE mutation homozygotes)
http://www.ebi.ac.uk/efo/efo_0006332,GCST002660,25457201,2,Hereditary hemochromatosis-related traits (HFE mutation homozygotes)
http://www.ebi.ac.uk/efo/efo_0001645,GCST002659,25328121,0,Coronary artery disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0006512,GCST002659,25328121,0,Coronary artery disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0000220,GCST002657,25310577,2,Acute lymphoblastic leukemia (childhood)
http://www.orpha.net/ordo/orphanet_388,GCST002658,25310821,6,Hirschsprung disease
http://www.ebi.ac.uk/efo/efo_0000289,GCST002656,25451450,0,Migraine in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0003821,GCST002656,25451450,0,Migraine in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004194,GCST002655,25305756,32,IgA nephropathy
http://www.ebi.ac.uk/efo/efo_0006510,GCST002654,25297839,2,Shingles
http://www.ebi.ac.uk/efo/efo_0004618,GCST002653,25411281,5,Circulating phylloquinone levels
http://www.ebi.ac.uk/efo/efo_0006508,GCST002652,25293881,14,Cotinine glucuronidation
http://www.ebi.ac.uk/efo/efo_0006507,GCST002649,25293881,2,Nicotine glucouronidation
http://www.ebi.ac.uk/efo/efo_0004330,GCST002651,25288136,4,Coffee consumption
http://www.ebi.ac.uk/efo/efo_0004330,GCST002650,25288136,9,Coffee consumption (cups per day)
http://www.ebi.ac.uk/efo/efo_0006782,GCST002650,25288136,9,Coffee consumption (cups per day)
http://www.ebi.ac.uk/efo/efo_0003888,GCST002648,25284319,0,Persistent attention-deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0004339,GCST002647,25282103,173,Height
http://www.ebi.ac.uk/efo/efo_0000292,GCST002645,25281661,1,Bladder cancer
http://www.ebi.ac.uk/efo/efo_0006785,GCST002646,25281659,15,Infant length
http://www.ebi.ac.uk/efo/efo_0006784,GCST002644,25281659,6,Birth length
http://www.ebi.ac.uk/efo/efo_0000096,GCST002643,25279986,9,Follicular lymphoma
http://www.ebi.ac.uk/efo/efo_0005093,GCST002641,25271088,5,Hip circumference (psychosocial stress interaction)
http://www.ebi.ac.uk/efo/efo_0006783,GCST002641,25271088,5,Hip circumference (psychosocial stress interaction)
http://purl.obolibrary.org/obo/go_1903491,GCST002642,25089948,7,Response to simvastatin treatment (PCSK9 protein level change)
http://www.ebi.ac.uk/efo/efo_0006899,GCST002642,25089948,7,Response to simvastatin treatment (PCSK9 protein level change)
http://www.ebi.ac.uk/efo/efo_0003756,GCST002639,25534755,6,Autism spectrum disorder-related traits
http://www.ebi.ac.uk/efo/efo_0003758,GCST002639,25534755,6,Autism spectrum disorder-related traits
http://www.ebi.ac.uk/efo/efo_0005426,GCST002639,25534755,6,Autism spectrum disorder-related traits
http://www.ebi.ac.uk/efo/efo_0000217,GCST002638,25317112,7,Gastritis
http://www.ebi.ac.uk/efo/efo_0004246,GCST002640,25266886,1,Inflammatory biomarkers in Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0004872,GCST002640,25266886,1,Inflammatory biomarkers in Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0004458,GCST002640,25266886,1,Inflammatory biomarkers in Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0000400,GCST002637,25317111,2,Medication adherence in chronic diseases
http://www.ebi.ac.uk/efo/efo_0000537,GCST002637,25317111,2,Medication adherence in chronic diseases
http://www.ebi.ac.uk/efo/efo_0006344,GCST002637,25317111,2,Medication adherence in chronic diseases
http://www.ebi.ac.uk/efo/efo_0000403,GCST002636,25261932,8,Diffuse large B cell lymphoma
http://www.ebi.ac.uk/efo/efo_0003870,GCST002633,25256182,4,Intracranial aneurysm
http://www.ebi.ac.uk/efo/efo_0008343,GCST002635,25256105,1,Aggressive periodontitis (sex interaction)
http://www.ebi.ac.uk/efo/efo_0006342,GCST002635,25256105,1,Aggressive periodontitis (sex interaction)
http://www.ebi.ac.uk/efo/efo_0006511,GCST002634,25303641,1,Kashin-Beck disease
http://www.ebi.ac.uk/efo/efo_0006335,GCST002630,25249183,15,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0000537,GCST002627,25249183,12,Hypertension
http://www.ebi.ac.uk/efo/efo_0006336,GCST002631,25249183,14,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004570,GCST002628,25246029,1,Bilirubin levels in extreme obesity
http://www.ebi.ac.uk/efo/efo_0001073,GCST002628,25246029,1,Bilirubin levels in extreme obesity
http://www.ebi.ac.uk/efo/efo_0006506,GCST002632,25246029,4,Hepatic lipid content in extreme obesity
http://www.ebi.ac.uk/efo/efo_0001073,GCST002632,25246029,4,Hepatic lipid content in extreme obesity
http://www.ebi.ac.uk/efo/efo_0000555,GCST002629,25248455,2,Irritable bowel syndrome
http://www.ebi.ac.uk/efo/efo_0004832,GCST002626,25241763,18,Vertical cup-disc ratio
http://www.ebi.ac.uk/efo/efo_0006524,GCST002623,25245031,1,L-arginine levels
http://www.ebi.ac.uk/efo/efo_0000341,GCST002621,25241909,1,Chronic bronchitis in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006505,GCST002621,25241909,1,Chronic bronchitis in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST002625,25241909,11,Chronic bronchitis and chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006505,GCST002625,25241909,11,Chronic bronchitis and chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0006523,GCST002622,25245031,1,Symmetrical dimethylarginine levels
http://www.ebi.ac.uk/efo/efo_0006522,GCST002620,25245031,1,Asymmetrical dimethylarginine levels
http://www.ebi.ac.uk/efo/efo_0000341,GCST002624,25241909,3,Chronic obstructive pulmonary disease
http://purl.obolibrary.org/obo/hp_0011141,GCST002619,25352737,3,Age-related cataracts
http://www.ebi.ac.uk/efo/efo_0004847,GCST002618,25352737,3,Age-related cataracts (age at onset)
http://purl.obolibrary.org/obo/hp_0011141,GCST002618,25352737,3,Age-related cataracts (age at onset)
http://www.ebi.ac.uk/efo/efo_0006312,GCST002616,25240745,21,Mitochondrial DNA levels
http://www.ebi.ac.uk/efo/efo_0005673,GCST002613,25234806,4,Chronic mucus hypersecretion
http://www.ebi.ac.uk/efo/efo_0001378,GCST002614,25237182,0,Multiple myeloma
http://purl.obolibrary.org/obo/hp_0000545,GCST002615,25233373,4,Myopia
http://www.ebi.ac.uk/efo/efo_0000341,GCST002612,25234806,0,Chronic mucus hypersecretion in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005673,GCST002612,25234806,0,Chronic mucus hypersecretion in chronic obstructive pulmonary disease
http://purl.obolibrary.org/obo/hp_0000540,GCST002617,25233373,5,Hyperopia
http://www.ebi.ac.uk/efo/efo_0004465,GCST002610,25223902,1,Fasting plasma glucose (childhood)
http://www.ebi.ac.uk/efo/efo_0006316,GCST002611,25226531,8,Expressive vocabulary in infants
http://www.ebi.ac.uk/efo/efo_0004461,GCST002609,25224454,3,Iron status biomarkers
http://www.ebi.ac.uk/efo/efo_0003892,GCST002608,25221879,6,Pulmonary function in asthmatics
http://www.ebi.ac.uk/efo/efo_0000270,GCST002608,25221879,6,Pulmonary function in asthmatics
http://www.ebi.ac.uk/efo/efo_0001663,GCST002606,25217961,41,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0006317,GCST002607,25217962,1,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)
http://www.ebi.ac.uk/efo/efo_0006315,GCST002607,25217962,1,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)
http://www.ebi.ac.uk/efo/efo_0003767,GCST002607,25217962,1,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)
http://www.ebi.ac.uk/efo/efo_0001378,GCST002605,25218607,0,Response to chemotherapy in multiple myeloma (oral mucositis) (high-dose melphalan)
http://www.ebi.ac.uk/efo/efo_0006314,GCST002605,25218607,0,Response to chemotherapy in multiple myeloma (oral mucositis) (high-dose melphalan)
http://www.ebi.ac.uk/efo/efo_0006313,GCST002605,25218607,0,Response to chemotherapy in multiple myeloma (oral mucositis) (high-dose melphalan)
http://www.ebi.ac.uk/efo/efo_0004609,GCST002604,25223841,1,Schizophrenia (treatment resistant)
http://www.ebi.ac.uk/efo/efo_0009694,GCST007161,25224099,0,beta-lactam allergy measurement
http://purl.obolibrary.org/obo/go_0036273,GCST002603,25214527,2,Creatine kinase in statin users
http://www.ebi.ac.uk/efo/efo_0004534,GCST002603,25214527,2,Creatine kinase in statin users
http://www.ebi.ac.uk/efo/efo_0004631,GCST002602,25208829,11,Vitamin D levels
http://www.ebi.ac.uk/efo/efo_0006309,GCST002601,25208887,4,Plasma plasminogen levels
http://www.ebi.ac.uk/efo/efo_0005202,GCST002600,25201287,0,Response to thiazide diuretic treatment (hypokalemia)
http://purl.obolibrary.org/obo/hp_0002900,GCST002600,25201287,0,Response to thiazide diuretic treatment (hypokalemia)
http://www.ebi.ac.uk/efo/efo_0004300,GCST002599,25199915,7,Longevity (90 years and older)
http://www.ebi.ac.uk/efo/efo_1000811,GCST007361,25200001,4,Acute anterior uveitis in ankylosing spondylitis
http://www.ebi.ac.uk/efo/efo_0003898,GCST007361,25200001,4,Acute anterior uveitis in ankylosing spondylitis
http://www.ebi.ac.uk/efo/efo_1000811,GCST007362,25200001,14,Acute anterior uveitis (with or without ankylosing spondylitis)
http://www.ebi.ac.uk/efo/efo_0004784,GCST002598,25201988,68,Educational attainment
http://www.ebi.ac.uk/efo/efo_0006352,GCST002597,25194280,6,Laryngeal squamous cell carcinoma
http://www.ebi.ac.uk/efo/efo_0000253,GCST007144,25442119,0,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0000253,GCST007145,25442119,0,Amyotrophic lateral sclerosis (age of onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST007145,25442119,0,Amyotrophic lateral sclerosis (age of onset)
http://www.ebi.ac.uk/efo/efo_0000253,GCST007146,25442119,1,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0006521,GCST002596,25192705,3,Colorectal cancer (calcium intake interaction)
http://www.ebi.ac.uk/efo/efo_0005842,GCST002596,25192705,3,Colorectal cancer (calcium intake interaction)
http://purl.obolibrary.org/obo/hp_0012235,GCST002595,25187353,28,Clozapine-induced agranulocytosis
http://purl.obolibrary.org/obo/go_0097338,GCST002595,25187353,28,Clozapine-induced agranulocytosis
http://www.ebi.ac.uk/efo/efo_0006790,GCST002588,25188341,7,Cerebral amyloid angiopathy
http://www.ebi.ac.uk/efo/efo_0005678,GCST002589,25188341,29,Hippocampal sclerosis
http://www.ebi.ac.uk/efo/efo_0006800,GCST002590,25188341,21,Vascular brain injury
http://www.ebi.ac.uk/efo/efo_0006791,GCST002590,25188341,21,Vascular brain injury
http://www.ebi.ac.uk/efo/efo_0006792,GCST002591,25188341,40,Lewy body disease
http://www.ebi.ac.uk/efo/efo_0006799,GCST002591,25188341,40,Lewy body disease
http://www.ebi.ac.uk/efo/efo_0006798,GCST002592,25188341,34,Neuritic plaque
http://www.ebi.ac.uk/efo/efo_0006797,GCST002594,25188341,37,Neurofibrillary tangles
http://purl.obolibrary.org/obo/hp_0000726,GCST002593,25188341,51,Dementia and core Alzheimer's disease neuropathologic changes
http://www.ebi.ac.uk/efo/efo_0006801,GCST002593,25188341,51,Dementia and core Alzheimer's disease neuropathologic changes
http://www.ebi.ac.uk/efo/efo_0006526,GCST002587,25189868,37,Blood pressure (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004318,GCST002587,25189868,37,Blood pressure (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006527,GCST002587,25189868,37,Blood pressure (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006336,GCST002587,25189868,37,Blood pressure (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006335,GCST002587,25189868,37,Blood pressure (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004325,GCST002587,25189868,37,Blood pressure (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0005671,GCST002587,25189868,37,Blood pressure (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006525,GCST002587,25189868,37,Blood pressure (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0005949,GCST002585,25186300,1,Antinuclear antibody levels
http://www.ebi.ac.uk/efo/efo_0004465,GCST002586,25187374,14,Fasting plasma glucose
http://www.ebi.ac.uk/efo/efo_0006335,GCST002583,25410890,0,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels)
http://www.ebi.ac.uk/efo/efo_0004325,GCST002583,25410890,0,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels)
http://www.ebi.ac.uk/efo/efo_0006518,GCST002583,25410890,0,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels)
http://www.ebi.ac.uk/efo/efo_0004318,GCST002584,25072098,1,Exhaled carbon monoxide levels
http://www.ebi.ac.uk/efo/efo_0006520,GCST002584,25072098,1,Exhaled carbon monoxide levels
http://www.ebi.ac.uk/efo/efo_0004190,GCST002581,25173107,2,Glaucoma (high intraocular pressure)
http://www.ebi.ac.uk/efo/efo_0004695,GCST002580,25173106,8,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0004190,GCST002582,25173105,9,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0005852,GCST002579,25130324,33,Heschl's gyrus morphology
http://www.ebi.ac.uk/efo/efo_0004459,GCST002578,25162662,1,Ferritin levels
http://www.ebi.ac.uk/efo/efo_0000714,GCST002577,25145502,3,Non-small cell lung cancer (survival)
http://www.ebi.ac.uk/efo/efo_0003060,GCST002577,25145502,3,Non-small cell lung cancer (survival)
http://www.orpha.net/ordo/orphanet_398934,GCST002576,25134534,6,Epithelial ovarian cancer
http://www.ebi.ac.uk/efo/efo_0005938,GCST002574,25138779,1,Congenital left-sided heart lesions (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST002574,25138779,1,Congenital left-sided heart lesions (maternal effect)
http://www.ebi.ac.uk/efo/efo_0005935,GCST002570,25133637,3,Overweight status
http://www.ebi.ac.uk/efo/efo_0005936,GCST002569,25133637,2,Underweight status
http://www.ebi.ac.uk/efo/efo_0004339,GCST002573,25133637,3,Height
http://www.ebi.ac.uk/efo/efo_0005937,GCST002575,25133637,6,Body mass index (change over time)
http://www.ebi.ac.uk/efo/efo_0005938,GCST002572,25138779,3,Congenital left-sided heart lesions
http://www.ebi.ac.uk/efo/efo_0004340,GCST002571,25133637,4,Body mass index
http://www.ebi.ac.uk/efo/efo_0005922,GCST002568,25129146,10,Esophageal squamous cell carcinoma
http://www.ebi.ac.uk/efo/efo_0000685,GCST005562,25014791,3,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0005943,GCST002567,25117820,3,Response to chemotherapy in breast cancer (hypertension) (bevacizumab)
http://www.ebi.ac.uk/efo/efo_0000305,GCST002567,25117820,3,Response to chemotherapy in breast cancer (hypertension) (bevacizumab)
http://www.ebi.ac.uk/efo/efo_0005942,GCST002567,25117820,3,Response to chemotherapy in breast cancer (hypertension) (bevacizumab)
http://www.ebi.ac.uk/efo/efo_0005944,GCST002566,25117820,13,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)
http://www.ebi.ac.uk/efo/efo_0005942,GCST002566,25117820,13,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)
http://www.ebi.ac.uk/efo/efo_0000305,GCST002566,25117820,13,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)
http://www.ebi.ac.uk/efo/efo_0000289,GCST002564,25111785,0,Bipolar disorder (early onset)
http://www.ebi.ac.uk/efo/efo_0005271,GCST002565,25109461,0,Sleep duration
http://www.ebi.ac.uk/efo/efo_0004209,GCST002563,25108383,24,Hypospadias
http://www.ebi.ac.uk/efo/efo_0004233,GCST007229,25108385,1,Thiopurine-induced early leukopenia in Crohn's disease
http://www.ebi.ac.uk/efo/efo_0006317,GCST007229,25108385,1,Thiopurine-induced early leukopenia in Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000384,GCST007229,25108385,1,Thiopurine-induced early leukopenia in Crohn's disease
http://www.orpha.net/ordo/orphanet_3437,GCST002562,25108386,4,Vogt-Koyanagi-Harada syndrome
http://www.ebi.ac.uk/efo/efo_0005842,GCST002561,25105248,1,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0001360,GCST002560,25102180,20,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0006346,GCST002558,25096692,0,Phenytoin-induced severe cutaneous adverse reactions
http://www.ebi.ac.uk/efo/efo_0006345,GCST002558,25096692,0,Phenytoin-induced severe cutaneous adverse reactions
http://www.ebi.ac.uk/efo/efo_0000712,GCST002559,25147783,8,Vitamin B levels in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0004843,GCST002559,25147783,8,Vitamin B levels in ischemic stroke
http://www.ebi.ac.uk/efo/efo_0004308,GCST002556,25096241,16,White blood cell count
http://www.ebi.ac.uk/efo/efo_0005091,GCST002555,25096241,11,Monocyte count
http://www.ebi.ac.uk/efo/efo_0004833,GCST002557,25096241,9,Neutrophil count
http://www.ebi.ac.uk/efo/efo_0006794,GCST002554,25140149,4,Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction)
http://www.ebi.ac.uk/efo/efo_0006793,GCST002554,25140149,4,Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction)
http://www.ebi.ac.uk/efo/efo_0002618,GCST002553,25086665,10,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0005854,GCST002552,25085501,1,Allergic rhinitis in asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST002552,25085501,1,Allergic rhinitis in asthma
http://www.ebi.ac.uk/efo/efo_0005854,GCST002550,25085501,26,Allergic rhinitis
http://www.ebi.ac.uk/efo/efo_0005854,GCST002551,25085501,7,Allergic rhinitis in non-asthmatics
http://www.ebi.ac.uk/efo/efo_0005658,GCST002549,24528284,15,Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)
http://www.ebi.ac.uk/efo/efo_0009360,GCST006522,24869959,22,Upper eyelid sagging severity
http://www.ebi.ac.uk/efo/efo_0000729,GCST002548,25082827,9,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0005918,GCST002546,25080503,4,Osteoprotegerin levels
http://www.ebi.ac.uk/efo/efo_0000474,GCST002547,25087078,9,Epilepsy
http://www.ebi.ac.uk/efo/efo_1001510,GCST004401,25065397,8,Reading disability or specific language impairment (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0005424,GCST004401,25065397,8,Reading disability or specific language impairment (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0004337,GCST004402,25065397,5,Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy)
http://www.ebi.ac.uk/efo/efo_1001510,GCST004402,25065397,5,Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0005424,GCST004402,25065397,5,Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0002508,GCST002544,25064009,26,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0005895,GCST002545,25064007,8,Ossification of the posterior longitudinal ligament of the spine
http://purl.obolibrary.org/obo/go_0007605,GCST002543,25060954,5,Hearing function
http://www.ebi.ac.uk/efo/efo_0005890,GCST002540,25057126,5,Osteoarthritis biomarkers
http://www.ebi.ac.uk/efo/efo_0004703,GCST002541,25231870,122,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0004327,GCST002542,25055868,9,Electrocardiographic traits
http://www.ebi.ac.uk/efo/efo_0000692,GCST002539,25056061,98,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0005851,GCST002538,25044758,2,Height adjusted BMI
http://www.ebi.ac.uk/efo/efo_0000305,GCST002537,25038754,4,Breast cancer
http://www.orpha.net/ordo/orphanet_232,GCST002536,25042611,3,Hemoglobin A2 levels in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0005845,GCST002536,25042611,3,Hemoglobin A2 levels in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0004462,GCST002535,25035420,5,PR interval
http://www.ebi.ac.uk/efo/efo_0005055,GCST002533,25035420,6,QRS duration
http://www.ebi.ac.uk/efo/efo_0005846,GCST002534,25030430,2,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection
http://www.ebi.ac.uk/efo/efo_0004220,GCST002534,25030430,2,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection
http://www.ebi.ac.uk/efo/efo_0000516,GCST002529,25027321,8,Glaucoma
http://www.ebi.ac.uk/efo/efo_0005849,GCST002532,25028398,1,High serum lipase activity
http://www.ebi.ac.uk/efo/efo_0000249,GCST002531,25027320,2,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0004670,GCST002531,25027320,2,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia
http://www.ebi.ac.uk/efo/efo_0005849,GCST002530,25028398,2,Serum lipase activity
http://www.ebi.ac.uk/efo/efo_0005842,GCST002528,25023989,1,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0004232,GCST002527,25017104,17,Eosinophilic esophagitis
http://www.ebi.ac.uk/efo/efo_0005843,GCST002526,25010111,0,Cortisol levels (plasma)
http://www.ebi.ac.uk/efo/efo_0005850,GCST002525,25006744,25,Local histogram emphysema pattern
http://www.ebi.ac.uk/efo/efo_0000649,GCST002524,25008200,2,Chronic periodontitis
http://www.ebi.ac.uk/efo/efo_0005229,GCST002522,25003214,2,Reading or mathematical ability
http://www.ebi.ac.uk/efo/efo_0004875,GCST002522,25003214,2,Reading or mathematical ability
http://www.ebi.ac.uk/efo/efo_0000249,GCST002523,25043464,0,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004314,GCST002521,25044411,2,Lung function (forced expiratory volume in 1 second)
http://www.ebi.ac.uk/efo/efo_0001060,GCST002520,24999842,8,Celiac disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST002519,24993907,3,Asthma or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000270,GCST002519,24993907,3,Asthma or chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005921,GCST002517,24983941,0,Rate of change of FEV1 (time interaction)
http://www.ebi.ac.uk/efo/efo_0004314,GCST002517,24983941,0,Rate of change of FEV1 (time interaction)
http://www.ebi.ac.uk/efo/efo_0004565,GCST002518,24962563,7,Food antigen IgG levels
http://www.ebi.ac.uk/efo/efo_0005844,GCST002518,24962563,7,Food antigen IgG levels
http://www.orpha.net/ordo/orphanet_182098,GCST002515,24986923,3,Pneumoconiosis in silica exposure
http://www.ebi.ac.uk/efo/efo_0005853,GCST002515,24986923,3,Pneumoconiosis in silica exposure
http://www.orpha.net/ordo/orphanet_282,GCST002516,24943344,2,Frontotemporal dementia
http://www.ebi.ac.uk/efo/efo_0000756,GCST002514,24980573,6,Melanoma
http://www.ebi.ac.uk/efo/efo_0005842,GCST002512,24978480,0,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0005842,GCST002513,24978480,0,Colorectal cancer (SNP x SNP interaction)
http://purl.obolibrary.org/obo/go_0009314,GCST002511,24974847,1,Response to radiotherapy in prostate cancer (toxicity)
http://www.ebi.ac.uk/efo/efo_0001663,GCST002511,24974847,1,Response to radiotherapy in prostate cancer (toxicity)
http://www.ebi.ac.uk/efo/efo_0000253,GCST002510,24931836,1,Amyotrophic lateral sclerosis or frontotemporal dementia
http://www.orpha.net/ordo/orphanet_282,GCST002510,24931836,1,Amyotrophic lateral sclerosis or frontotemporal dementia
http://www.ebi.ac.uk/efo/efo_0000253,GCST002509,24931836,6,Amyotrophic lateral sclerosis
http://www.orpha.net/ordo/orphanet_282,GCST002508,24931836,1,Frontotemporal dementia
http://www.ebi.ac.uk/efo/efo_0005762,GCST002507,24974787,2,Neuropathic pain in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST002507,24974787,2,Neuropathic pain in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004325,GCST002506,24975945,0,Blood pressure
http://www.ebi.ac.uk/efo/efo_0003761,GCST002505,24964207,1,Suicidal ideation in depression or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004320,GCST002505,24964207,1,Suicidal ideation in depression or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST002505,24964207,1,Suicidal ideation in depression or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST002503,24964207,3,Suicide attempts in depression or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST002503,24964207,3,Suicide attempts in depression or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004321,GCST002503,24964207,3,Suicide attempts in depression or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004265,GCST002504,25009551,3,Peripheral artery disease
http://www.ebi.ac.uk/efo/efo_0004345,GCST002502,24963161,4,Corneal curvature
http://www.ebi.ac.uk/efo/efo_0004682,GCST002500,24952745,74,QT interval
http://www.orpha.net/ordo/orphanet_179,GCST002501,24957906,3,Birdshot chorioretinopathy
http://purl.obolibrary.org/obo/hp_0011142,GCST002498,24951543,15,Age-related nuclear cataracts
http://www.ebi.ac.uk/efo/efo_0004344,GCST002499,24950379,1,Birth weight
http://www.ebi.ac.uk/efo/efo_0003923,GCST002496,24945404,11,"Bone mineral density (paediatric, upper limb)"
http://www.ebi.ac.uk/efo/efo_0003923,GCST002493,24945404,19,"Bone mineral density (paediatric, skull)"
http://www.ebi.ac.uk/efo/efo_0004325,GCST002495,24954895,3,Blood pressure (age interaction)
http://www.ebi.ac.uk/efo/efo_0008007,GCST002495,24954895,3,Blood pressure (age interaction)
http://www.ebi.ac.uk/efo/efo_0004325,GCST002497,24954895,28,Blood pressure
http://www.ebi.ac.uk/efo/efo_0003923,GCST002492,24945404,11,"Bone mineral density (paediatric, lower limb)"
http://www.ebi.ac.uk/efo/efo_0003923,GCST002494,24945404,15,"Bone mineral density (paediatric, total body less head)"
http://www.ebi.ac.uk/efo/efo_0004239,GCST002490,24940741,5,Chronic hepatitis B infection
http://www.ebi.ac.uk/efo/efo_0004307,GCST007668,25043022,1,Two-hour glucose
http://www.ebi.ac.uk/efo/efo_0004466,GCST007671,25043022,0,Fasting blood insulin
http://www.ebi.ac.uk/efo/efo_0004465,GCST007670,25043022,0,Fasting blood glucose
http://www.ebi.ac.uk/efo/efo_0008473,GCST007669,25043022,0,Two-hour insulin response
http://www.ebi.ac.uk/efo/efo_0004733,GCST002488,24942650,0,Anti-citrullinated peptide antibody
http://www.ebi.ac.uk/efo/efo_0005782,GCST002487,24939585,49,Age-related hearing impairment (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0005760,GCST002485,24941225,13,Elevated serum carcinoembryonic antigen levels
http://www.ebi.ac.uk/efo/efo_0005767,GCST002489,24942650,0,Rheumatoid factor
http://www.ebi.ac.uk/efo/efo_0004235,GCST002486,24938310,2,Exfoliation glaucoma or exfoliation syndrome
http://www.ebi.ac.uk/efo/efo_0005782,GCST002491,24939585,30,Age-related hearing impairment
http://www.ebi.ac.uk/efo/efo_0005766,GCST002484,24934506,0,Skin fluorescence
http://www.ebi.ac.uk/efo/efo_0004312,GCST002483,24929828,7,Lung function (forced vital capacity)
http://www.ebi.ac.uk/efo/efo_0005671,GCST002482,24954085,4,Carotid plaque burden (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0006501,GCST002482,24954085,4,Carotid plaque burden (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0003894,GCST002481,24927181,14,Acne (severe)
http://www.ebi.ac.uk/efo/efo_0002690,GCST002479,24925725,17,Lupus nephritis in systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0005761,GCST002479,24925725,17,Lupus nephritis in systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0000183,GCST002480,24920014,7,Hodgkin's lymphoma
http://www.ebi.ac.uk/efo/efo_0004624,GCST002476,24919509,2,Prostate-specific antigen levels
http://www.ebi.ac.uk/efo/efo_0000612,GCST002475,24916648,4,Myocardial infarction
http://www.ebi.ac.uk/efo/efo_0004847,GCST002477,24962325,28,Alcohol dependence (age at onset)
http://www.ebi.ac.uk/efo/efo_0003829,GCST002477,24962325,28,Alcohol dependence (age at onset)
http://www.ebi.ac.uk/efo/efo_0004911,GCST002478,24916650,0,Coronary heart disease in familial hypercholesterolemia
http://www.ebi.ac.uk/efo/efo_0001645,GCST002478,24916650,0,Coronary heart disease in familial hypercholesterolemia
http://www.ebi.ac.uk/efo/efo_0000326,GCST002474,24908248,3,Glioma (high-grade)
http://www.ebi.ac.uk/efo/efo_0005768,GCST002473,25015694,0,Response to rate control therapy in atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0000275,GCST002473,25015694,0,Response to rate control therapy in atrial fibrillation
http://purl.obolibrary.org/obo/go_0043278,GCST002472,24909733,1,Morphine dose requirement in tonsillectomy and adenoidectomy surgery
http://www.ebi.ac.uk/efo/efo_0006336,GCST004705,24903457,2,Blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST004705,24903457,2,Blood pressure
http://www.ebi.ac.uk/efo/efo_0004302,GCST002471,24903457,2,Blood pressure (anthropometric measures interaction)
http://www.ebi.ac.uk/efo/efo_0006336,GCST002471,24903457,2,Blood pressure (anthropometric measures interaction)
http://www.ebi.ac.uk/efo/efo_0006335,GCST002471,24903457,2,Blood pressure (anthropometric measures interaction)
http://www.ebi.ac.uk/efo/efo_0005763,GCST002470,24892410,1,Pulse pressure in young-onset hypertension
http://www.ebi.ac.uk/efo/efo_0004772,GCST002470,24892410,1,Pulse pressure in young-onset hypertension
http://www.ebi.ac.uk/efo/efo_0004574,GCST002467,24886709,2,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004530,GCST002468,24886709,8,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004612,GCST002469,24886709,2,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0005407,GCST002465,24751813,2,Response to haloperidol in psychosis
http://purl.obolibrary.org/obo/go_1905119,GCST002465,24751813,2,Response to haloperidol in psychosis
http://www.ebi.ac.uk/efo/efo_0001071,GCST002466,24880342,5,Lung cancer
http://www.ebi.ac.uk/efo/efo_0000707,GCST002466,24880342,5,Lung cancer
http://www.ebi.ac.uk/efo/efo_0000571,GCST002466,24880342,5,Lung cancer
http://www.ebi.ac.uk/efo/efo_0001359,GCST002464,24871321,0,End-stage renal disease or diabetic nephropathy in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0003884,GCST002464,24871321,0,End-stage renal disease or diabetic nephropathy in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0000401,GCST002464,24871321,0,End-stage renal disease or diabetic nephropathy in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0002690,GCST002463,24871463,25,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0000249,GCST002462,24958192,0,Alzheimer's disease (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0000292,GCST002460,24861552,2,Urinary bladder cancer
http://www.ebi.ac.uk/efo/efo_0004340,GCST002461,24861553,25,Body mass index
http://www.ebi.ac.uk/efo/efo_0004995,GCST002459,24863034,0,Lean body mass
http://www.ebi.ac.uk/efo/efo_0004748,GCST002458,24852370,4,Serum thyroid-stimulating hormone levels
http://www.ebi.ac.uk/efo/efo_0005094,GCST002457,24850809,3,P wave duration
http://www.ebi.ac.uk/efo/efo_0005095,GCST002456,24850809,8,PR segment
http://www.ebi.ac.uk/efo/efo_0002508,GCST002455,24842889,4,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0007681,GCST006055,24847101,5,Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels)
http://www.ebi.ac.uk/efo/efo_0009308,GCST006055,24847101,5,Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels)
http://www.ebi.ac.uk/efo/efo_0005842,GCST002454,24836286,20,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0003890,GCST002452,24832863,0,Substance dependence phenotypes
http://www.ebi.ac.uk/efo/efo_0000729,GCST002453,24837172,5,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0005680,GCST002450,24823311,10,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)
http://www.ebi.ac.uk/efo/efo_0005680,GCST002444,24823311,8,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)
http://www.ebi.ac.uk/efo/efo_0004242,GCST002451,24821223,2,Obsessive-compulsive disorder
http://www.ebi.ac.uk/efo/efo_0008343,GCST002445,24824216,6,Asthma (sex interaction)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002445,24824216,6,Asthma (sex interaction)
http://www.ebi.ac.uk/efo/efo_0005680,GCST002446,24823311,8,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)
http://www.ebi.ac.uk/efo/efo_0005682,GCST002447,24825563,2,Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry)
http://www.ebi.ac.uk/efo/efo_0005680,GCST002448,24823311,6,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)
http://www.ebi.ac.uk/efo/efo_0005680,GCST002449,24823311,8,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)
http://www.ebi.ac.uk/efo/efo_0005664,GCST002442,24816252,54,Blood metabolite ratios
http://www.ebi.ac.uk/efo/efo_0005664,GCST002443,24816252,245,Blood metabolite levels
http://www.ebi.ac.uk/efo/efo_0005681,GCST002440,24847357,4,Staphylococcus aureus infection
http://www.ebi.ac.uk/efo/efo_0004645,GCST002441,24811271,11,Immune response to measles-mumps-rubella vaccine
http://www.ebi.ac.uk/efo/efo_0004875,GCST002439,24801482,0,Mathematical ability
http://www.orpha.net/ordo/orphanet_2445,GCST002438,24800985,11,Conotruncal heart defects
http://www.ebi.ac.uk/efo/efo_0004505,GCST002437,24795349,2,Telomere length
http://www.ebi.ac.uk/efo/efo_0004340,GCST002435,24827717,2,Body mass index
http://www.ebi.ac.uk/efo/efo_0000685,GCST002434,24782177,4,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000685,GCST002433,24782177,11,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000555,GCST002436,24797007,2,Irritable bowel syndrome
http://www.ebi.ac.uk/efo/efo_0005921,GCST002432,24792382,10,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
http://purl.obolibrary.org/obo/go_0031960,GCST002432,24792382,10,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002432,24792382,10,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
http://www.ebi.ac.uk/efo/efo_0001663,GCST002431,24785509,10,Response to radiotherapy in cancer (late toxicity)
http://www.ebi.ac.uk/efo/efo_0005678,GCST002430,24770881,1,Hippocampal sclerosis of aging
http://www.ebi.ac.uk/efo/efo_0000249,GCST002429,24770881,3,Alzheimer's disease
http://purl.obolibrary.org/obo/go_0036273,GCST002428,24816038,0,Cardiovascular event reduction in the elderly at risk for vascular disease (statin therapy interaction)
http://www.ebi.ac.uk/efo/efo_0005677,GCST002426,24770850,1,Puberty onset (genital enlargement)
http://www.ebi.ac.uk/efo/efo_0005677,GCST002425,24770850,2,Puberty onset
http://www.ebi.ac.uk/efo/efo_0005677,GCST002427,24770850,2,Puberty onset (breast development)
http://www.ebi.ac.uk/efo/efo_0004458,GCST002424,24763700,5,C-reactive protein levels
http://www.ebi.ac.uk/efo/efo_0005676,GCST002423,24768677,3,Autoimmune hepatitis type-1
http://www.ebi.ac.uk/efo/efo_0000249,GCST002422,24755620,5,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0001663,GCST002421,24753544,6,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0005924,GCST002420,24882193,1,Binge eating behaviour in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST002420,24882193,1,Binge eating behaviour in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0005924,GCST002419,24882193,2,Binge eating behaviour and bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST002419,24882193,2,Binge eating behaviour and bipolar disorder
http://www.ebi.ac.uk/efo/efo_0005842,GCST002415,24743840,13,Colorectal cancer (diet interaction)
http://www.ebi.ac.uk/efo/efo_0008111,GCST002415,24743840,13,Colorectal cancer (diet interaction)
http://www.ebi.ac.uk/efo/efo_0004748,GCST002417,24722205,3,Plasma thyroid-stimulating hormone levels
http://www.ebi.ac.uk/efo/efo_0005666,GCST002416,24722205,2,Thyroid peroxidase antibody positivity
http://www.ebi.ac.uk/efo/efo_0005130,GCST002418,24722205,3,Free thyroxine concentration
http://www.ebi.ac.uk/efo/efo_0005675,GCST002414,24740207,3,Serum vitamin D-binding protein levels
http://www.ebi.ac.uk/efo/efo_0001663,GCST002413,24740154,9,Prostate cancer (early onset)
http://www.ebi.ac.uk/efo/efo_0003060,GCST002412,24737549,2,Non-small cell lung cancer (recurrence rate)
http://www.ebi.ac.uk/efo/efo_0005842,GCST002411,24737748,9,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0005674,GCST002409,24736177,5,White matter microstructure (global fractional anisotropy)
http://www.ebi.ac.uk/efo/efo_0002506,GCST002410,24728293,1,"Osteoarthritis (hand, severe)"
http://www.ebi.ac.uk/efo/efo_0005673,GCST002407,24714607,1,Chronic mucus hypersecretion
http://www.ebi.ac.uk/efo/efo_0004363,GCST007693,24629169,2,perceptual and visual search speed (trail making test A)
http://www.ebi.ac.uk/efo/efo_0009332,GCST007698,24629169,0,perceptual and visual search speed and executive function (trail making test BA) (age interaction)
http://www.ebi.ac.uk/efo/efo_0004363,GCST007698,24629169,0,perceptual and visual search speed and executive function (trail making test BA) (age interaction)
http://www.ebi.ac.uk/efo/efo_0009332,GCST007697,24629169,0,executive function (trail making test B) (age interaction)
http://www.ebi.ac.uk/efo/efo_0004363,GCST007696,24629169,1,perceptual and visual search speed (trail making test A) (age interaction)
http://www.ebi.ac.uk/efo/efo_0009332,GCST007695,24629169,0,perceptual and visual search speed and executive function (trail making test BA)
http://www.ebi.ac.uk/efo/efo_0004363,GCST007695,24629169,0,perceptual and visual search speed and executive function (trail making test BA)
http://www.ebi.ac.uk/efo/efo_0009332,GCST007694,24629169,1,executive function (trail making test B)
http://purl.obolibrary.org/obo/go_0031427,GCST002408,24709693,18,Response to methotrexate in juvenile idiopathic arthritis
http://www.ebi.ac.uk/efo/efo_0005672,GCST002406,24952865,2,Plasma cystastin c levels in acute coronary syndrome
http://www.ebi.ac.uk/efo/efo_0001061,GCST002405,24700089,9,Cervical cancer
http://www.ebi.ac.uk/efo/efo_0004471,GCST005216,24699409,6,Corrected insulin response adjusted for insulin sensitivity index
http://www.ebi.ac.uk/efo/efo_0008473,GCST005216,24699409,6,Corrected insulin response adjusted for insulin sensitivity index
http://www.ebi.ac.uk/efo/efo_0006832,GCST005222,24699409,4,Insulin disposition index
http://www.ebi.ac.uk/efo/efo_0008473,GCST005218,24699409,2,Area under the curve of insulin levels
http://www.ebi.ac.uk/efo/efo_0008473,GCST005215,24699409,6,Corrected insulin response
http://www.ebi.ac.uk/efo/efo_0004467,GCST005219,24699409,3,Incremental insulin
http://www.ebi.ac.uk/efo/efo_0008473,GCST005223,24699409,1,Ratio of the area under the curve for insulin and the area under the curve for glucose
http://www.ebi.ac.uk/efo/efo_0008473,GCST005217,24699409,4,Insulin levels adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004467,GCST005220,24699409,2,Insulin levels
http://www.ebi.ac.uk/efo/efo_0004471,GCST005221,24699409,1,Insulin sensitivity index
http://www.ebi.ac.uk/efo/efo_0004300,GCST002404,24688116,3,Longevity (90 years and older)
http://www.ebi.ac.uk/efo/efo_0004300,GCST002403,24688116,4,Longevity (85 years and older)
http://www.ebi.ac.uk/efo/efo_0001358,GCST002401,24677629,7,Post-traumatic stress disorder
http://www.ebi.ac.uk/efo/efo_0004912,GCST002402,24676358,1,Serum IgA levels
http://www.ebi.ac.uk/efo/efo_0005691,GCST002400,24675659,0,Plasma trimethylamine N-oxide levels
http://www.orpha.net/ordo/orphanet_199315,GCST002399,24667120,1,Clubfoot
http://www.ebi.ac.uk/efo/efo_0004351,GCST002398,24680774,2,Resting heart rate
http://www.ebi.ac.uk/efo/efo_0005671,GCST002393,24665060,8,Smoking quantity
http://www.ebi.ac.uk/efo/efo_0000292,GCST002397,24662972,5,Bladder cancer (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004319,GCST002395,24665060,4,Smoking cessation
http://www.ebi.ac.uk/efo/efo_0004847,GCST002394,24665060,8,Age of smoking initiation
http://www.ebi.ac.uk/efo/efo_0005670,GCST002394,24665060,8,Age of smoking initiation
http://www.ebi.ac.uk/efo/efo_0005670,GCST002396,24665060,27,Smoking initiation
http://www.ebi.ac.uk/efo/efo_0006527,GCST002392,24658283,2,Lung cancer (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0001071,GCST002392,24658283,2,Lung cancer (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004578,GCST002391,24651765,5,Plasma homocysteine levels (post-methionine load test)
http://www.ebi.ac.uk/efo/efo_0004541,GCST002390,24647736,12,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0005669,GCST002389,24656865,1,Intracerebral hemorrhage
http://www.ebi.ac.uk/efo/efo_0005653,GCST002388,24625756,19,Serum metabolite levels
http://www.ebi.ac.uk/efo/efo_0005690,GCST002387,24614497,0,Musical aptitude
http://www.ebi.ac.uk/efo/efo_0003925,GCST002386,24684796,25,Cognitive function
http://www.ebi.ac.uk/efo/efo_0000289,GCST002385,24618891,6,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0005689,GCST002384,24604477,0,NHDL cholesterol
http://www.ebi.ac.uk/efo/efo_0005668,GCST002383,24603532,1,Anterior chamber depth
http://www.ebi.ac.uk/efo/efo_0005667,GCST002382,24595857,2,Urinary albumin excretion rate in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004819,GCST002381,24123702,1,Resistin levels
http://www.ebi.ac.uk/efo/efo_0006835,GCST002379,24487271,7,Pyoderma gangrenosum in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST002379,24487271,7,Pyoderma gangrenosum in inflammatory bowel disease
http://purl.obolibrary.org/obo/hp_0012219,GCST002380,24487271,5,Erythema nodosum in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST002380,24487271,5,Erythema nodosum in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0005663,GCST002376,24578125,5,Urinary uromodulin levels
http://www.ebi.ac.uk/efo/efo_0004791,GCST002374,24578379,5,Plasma plasminogen activator levels
http://www.ebi.ac.uk/efo/efo_0005665,GCST002377,24578207,4,White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy
http://purl.obolibrary.org/obo/go_0031427,GCST002375,24583629,2,Response to methotrexate in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0005666,GCST002373,24586183,5,Thyroid peroxidase antibody levels
http://www.ebi.ac.uk/efo/efo_0005666,GCST002378,24586183,9,Thyroid peroxidase antibody positivity
http://www.ebi.ac.uk/efo/efo_0005425,GCST002371,24571439,4,Parent of origin effect on language impairment (paternal)
http://www.ebi.ac.uk/efo/efo_0005687,GCST002370,24582949,0,Fibromyalgia
http://www.ebi.ac.uk/efo/efo_0005425,GCST002369,24571439,0,Parent of origin effect on language impairment (maternal)
http://www.ebi.ac.uk/efo/efo_0004827,GCST002372,24569950,19,Political ideology
http://www.ebi.ac.uk/efo/efo_0003756,GCST002368,24574247,0,Maternal genotype effects in autism spectrum disorder families
http://www.ebi.ac.uk/efo/efo_0004828,GCST002368,24574247,0,Maternal genotype effects in autism spectrum disorder families
http://www.ebi.ac.uk/efo/efo_0005427,GCST002367,24564958,17,Social communication problems
http://purl.obolibrary.org/obo/go_0061479,GCST002366,24554482,11,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)
http://purl.obolibrary.org/obo/go_0061479,GCST002365,24554482,13,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
http://purl.obolibrary.org/obo/go_0061479,GCST002363,24554482,16,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)
http://www.ebi.ac.uk/efo/efo_0005116,GCST002364,24586186,39,Urinary metabolites (H-NMR features)
http://www.ebi.ac.uk/efo/efo_0005661,GCST002362,24839885,13,Preschool internalizing problems
http://www.ebi.ac.uk/efo/efo_0006338,GCST002358,24556642,14,Pit-and-Fissure caries
http://www.ebi.ac.uk/efo/efo_0005660,GCST002359,24535457,8,Plasma amyloid beta peptide concentrations (ABx-42)
http://www.ebi.ac.uk/efo/efo_0006339,GCST002361,24556642,31,Smooth-surface caries
http://www.ebi.ac.uk/efo/efo_0005659,GCST002360,24535457,10,Plasma amyloid beta peptide concentrations (ABx-40)
http://www.ebi.ac.uk/efo/efo_0000685,GCST002357,24532677,6,Rheumatoid arthritis (ACPA-negative)
http://www.ebi.ac.uk/efo/efo_0000685,GCST006048,24532676,52,Rheumatoid arthritis (ACPA-positive)
http://www.ebi.ac.uk/efo/efo_0004761,GCST002355,24513273,4,Serum uric acid levels
http://www.ebi.ac.uk/efo/efo_0004695,GCST002356,24518671,1,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0004215,GCST002354,24514567,2,Anorexia nervosa
http://www.ebi.ac.uk/efo/efo_0002508,GCST002353,24511991,8,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0001360,GCST002352,24509480,62,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000341,GCST002351,24621683,9,Chronic obstructive pulmonary disease (moderate to severe)
http://www.ebi.ac.uk/efo/efo_0000341,GCST002350,24621683,6,Chronic obstructive pulmonary disease (severe)
http://www.ebi.ac.uk/efo/efo_0005657,GCST002347,24503447,3,Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity)
http://www.ebi.ac.uk/efo/efo_0005657,GCST002349,24503447,4,Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)
http://purl.obolibrary.org/obo/hp_0000175,GCST002348,24516586,1,Cleft plate (environmental tobacco smoke interaction)
http://www.ebi.ac.uk/efo/efo_0008361,GCST002348,24516586,1,Cleft plate (environmental tobacco smoke interaction)
http://www.ebi.ac.uk/efo/efo_0000305,GCST002346,24493630,18,Breast cancer (early onset)
http://www.ebi.ac.uk/efo/efo_0005686,GCST002344,24687471,0,Receptive language ability
http://www.ebi.ac.uk/efo/efo_0004530,GCST007849,24507774,8,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004611,GCST007848,24507774,5,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004612,GCST007850,24507774,9,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004337,GCST006523,24342994,7,General cognitive ability
http://www.ebi.ac.uk/efo/efo_0005655,GCST002345,24483146,22,Response to cytadine analogues (cytosine arabinoside)
http://purl.obolibrary.org/obo/go_0036272,GCST002343,24483146,10,Response to cytidine analogues (gemcitabine)
http://purl.obolibrary.org/obo/go_0031960,GCST002342,24486069,2,Asthma (corticosteroid response)
http://www.ebi.ac.uk/efo/efo_0005842,GCST002340,24448986,1,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0004505,GCST002341,24465473,2,Telomere length
http://www.ebi.ac.uk/efo/efo_0001360,GCST002339,24465431,2,Type 2 diabetes (young onset) and obesity
http://www.ebi.ac.uk/efo/efo_0000289,GCST002338,24444492,0,Bipolar I disorder
http://www.ebi.ac.uk/efo/efo_0001357,GCST002337,24529757,175,Amyotrophic lateral sclerosis (sporadic)
http://www.ebi.ac.uk/efo/efo_0004505,GCST002336,24478790,8,Telomere length
http://www.ebi.ac.uk/efo/efo_0004514,GCST002335,24430505,8,Bone properties (heel)
http://www.ebi.ac.uk/efo/efo_0005654,GCST002333,24430505,10,Bone properties (heel)
http://www.ebi.ac.uk/efo/efo_0003923,GCST002334,24430505,2,Bone properties (heel)
http://www.ebi.ac.uk/efo/efo_0004772,GCST002332,24413707,0,Hypertension (young onset)
http://www.ebi.ac.uk/efo/efo_0004193,GCST002331,24403052,11,Basal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0003894,GCST002329,24399259,3,Acne (severe)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002330,24406073,0,Asthma
http://www.ebi.ac.uk/efo/efo_0003892,GCST002328,24387323,0,Lung function
http://www.ebi.ac.uk/efo/efo_0000289,GCST002327,24387768,0,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000464,GCST002326,24383474,3,Pulmonary emphysema
http://www.ebi.ac.uk/efo/efo_1001017,GCST005533,24387989,4,Limited cutaneous systemic scleroderma
http://www.ebi.ac.uk/efo/efo_0000717,GCST005534,24387989,12,Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0000404,GCST005535,24387989,1,Diffuse cutaneous systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0004874,GCST002325,24392092,1,Memory performance
http://www.ebi.ac.uk/efo/efo_0000685,GCST002323,24449572,8,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0003829,GCST004712,24166409,19,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0007835,GCST004711,24166409,49,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0003015,GCST002324,24489884,14,Anger
http://www.ebi.ac.uk/efo/efo_0004574,GCST002321,24386095,18,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004530,GCST002321,24386095,18,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004611,GCST002321,24386095,18,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004612,GCST002321,24386095,18,Lipid traits
http://www.ebi.ac.uk/efo/efo_0003956,GCST002322,24388013,21,Asthma and hay fever
http://www.ebi.ac.uk/efo/efo_0000270,GCST002322,24388013,21,Asthma and hay fever
http://purl.obolibrary.org/obo/hp_0001268,GCST002320,24468470,11,Cognitive decline (age-related)
http://www.orpha.net/ordo/orphanet_93957,GCST002319,24375517,3,Musician's dystonia
http://www.ebi.ac.uk/efo/efo_0000685,GCST002318,24390342,181,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0001360,GCST002317,24390345,4,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004252,GCST006524,24376627,41,Nasopharyngeal carcinoma (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0004220,GCST002316,24376798,1,Chronic hepatitis C infection
http://www.ebi.ac.uk/efo/efo_0005538,GCST002315,24357727,4,Thrombin generation potential phenotypes
http://www.ebi.ac.uk/efo/efo_0003884,GCST002313,24351856,1,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0005208,GCST002314,24351856,4,Glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0000649,GCST002312,24347629,10,Periodontal disease-related phenotypes
http://www.ebi.ac.uk/efo/efo_0004761,GCST002311,24379826,2,Serum uric acid levels
http://www.ebi.ac.uk/efo/efo_0005763,GCST002310,24376456,4,Pulse pressure (alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0004329,GCST002310,24376456,4,Pulse pressure (alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0006336,GCST002308,24376456,9,Mean arterial pressure (alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0004329,GCST002308,24376456,9,Mean arterial pressure (alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0006336,GCST002309,24376456,4,Diastolic blood pressure (alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0004329,GCST002309,24376456,4,Diastolic blood pressure (alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0006335,GCST002307,24376456,11,Systolic blood pressure (alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0004329,GCST002307,24376456,11,Systolic blood pressure (alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0000289,GCST002306,24322204,51,Bipolar disorder (body mass index interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST002306,24322204,51,Bipolar disorder (body mass index interaction)
http://www.ebi.ac.uk/efo/efo_0005537,GCST002305,24325915,5,"Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)"
http://www.ebi.ac.uk/efo/efo_0001071,GCST006866,24325914,1,Lung cancer (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0005536,GCST002304,24315451,25,Fractional exhaled nitric oxide (childhood)
http://www.ebi.ac.uk/efo/efo_0004541,GCST002303,24405752,1,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004579,GCST002302,24324648,1,IgE levels
http://www.ebi.ac.uk/efo/efo_0004340,GCST002301,24348519,8,Body mass index
http://www.ebi.ac.uk/efo/efo_0000685,GCST002300,23918589,2,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0001645,GCST002298,24778558,3,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0000095,GCST002299,24292274,19,Chronic lymphocytic leukemia
http://www.ebi.ac.uk/efo/efo_0004645,GCST002297,24282030,2,Hepatitis B vaccine response
http://www.ebi.ac.uk/efo/efo_0004340,GCST002296,24281739,3,Body mass index (education interaction)
http://www.ebi.ac.uk/efo/efo_0003829,GCST002293,24277619,2,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0000692,GCST002295,24280982,12,Schizophrenia or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST002295,24280982,12,Schizophrenia or bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004329,GCST002294,24277619,3,Alcohol consumption (max-drinks)
http://www.ebi.ac.uk/efo/efo_0005526,GCST002292,24277619,3,Response to alcohol consumption (flushing response)
http://purl.obolibrary.org/obo/go_0097366,GCST002291,24280104,5,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)
http://purl.obolibrary.org/obo/go_0031960,GCST002291,24280104,5,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002291,24280104,5,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)
http://www.ebi.ac.uk/efo/efo_0001645,GCST002289,24262325,23,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_0005524,GCST002290,24262325,17,Coronary artery disease or large artery stroke
http://www.ebi.ac.uk/efo/efo_0001645,GCST002290,24262325,17,Coronary artery disease or large artery stroke
http://www.ebi.ac.uk/efo/efo_0000712,GCST002287,24262325,14,Coronary artery disease or ischemic stroke
http://www.ebi.ac.uk/efo/efo_0001645,GCST002287,24262325,14,Coronary artery disease or ischemic stroke
http://www.ebi.ac.uk/efo/efo_0005524,GCST002288,24262325,9,Large artery stroke
http://www.ebi.ac.uk/efo/efo_0000712,GCST002286,24262325,6,Ischemic stroke
http://www.ebi.ac.uk/efo/efo_0005528,GCST002282,24324551,24,Parasitemia in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0005530,GCST002282,24324551,24,Parasitemia in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0005530,GCST002281,24324551,25,Ejection fraction in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0005527,GCST002281,24324551,25,Ejection fraction in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0004682,GCST002278,24324551,14,QT interval in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0005530,GCST002278,24324551,14,QT interval in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0004462,GCST002279,24324551,102,PR interval in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0005530,GCST002279,24324551,102,PR interval in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0004556,GCST002280,24324551,20,Antibody status in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0005530,GCST002280,24324551,20,Antibody status in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0005529,GCST002285,24324551,18,Chagas cardiomyopathy in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0005530,GCST002285,24324551,18,Chagas cardiomyopathy in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0001357,GCST002283,24256812,4,Amyotrophic lateral sclerosis (sporadic)
http://www.ebi.ac.uk/efo/efo_0005055,GCST002284,24324551,38,QRS duration in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0005530,GCST002284,24324551,38,QRS duration in Tripanosoma cruzi seropositivity
http://www.ebi.ac.uk/efo/efo_0000692,GCST002277,24253340,1,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0003923,GCST002276,24249740,24,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0004591,GCST002275,24241537,6,Asthma (childhood onset)
http://www.ebi.ac.uk/efo/efo_0003885,GCST002274,24234648,1,Multiple sclerosis or amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0000253,GCST002274,24234648,1,Multiple sclerosis or amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0000681,GCST002273,24220699,1,Renal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0000681,GCST002272,24220910,0,Renal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0005534,GCST002271,24265751,0,Delayed encephalopathy in acute carbon monoxide poisoning
http://www.ebi.ac.uk/efo/efo_0004541,GCST002270,24244560,3,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0005307,GCST002269,24223155,1,Drug-induced torsades de pointes
http://purl.obolibrary.org/obo/go_0042493,GCST002269,24223155,1,Drug-induced torsades de pointes
http://www.ebi.ac.uk/efo/efo_0003758,GCST002268,24189344,11,Autism
http://www.orpha.net/ordo/orphanet_398934,GCST002267,24190013,0,Epithelial ovarian cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST002265,24080446,2,Breast cancer (menopausal hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0003961,GCST002265,24080446,2,Breast cancer (menopausal hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0000553,GCST002266,24080446,2,Lobular breast cancer (menopausal hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0003961,GCST002266,24080446,2,Lobular breast cancer (menopausal hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0001663,GCST002264,24185611,0,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0005531,GCST002263,24236485,9,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)
http://www.ebi.ac.uk/efo/efo_0005533,GCST002263,24236485,9,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)
http://www.ebi.ac.uk/efo/efo_0005532,GCST002263,24236485,9,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)
http://www.ebi.ac.uk/efo/efo_0003885,GCST005531,24076602,126,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0000699,GCST005532,24097067,6,Sjgren's syndrome
http://www.ebi.ac.uk/efo/efo_0000699,GCST004879,24097067,3,Sjgren's syndrome
http://www.ebi.ac.uk/efo/efo_0000699,GCST004878,24097067,15,Sjgren's syndrome
http://www.ebi.ac.uk/efo/efo_0004325,GCST002262,24192120,0,Blood pressure (response to antihypertensive medication)
http://www.ebi.ac.uk/efo/efo_0005405,GCST002262,24192120,0,Blood pressure (response to antihypertensive medication)
http://www.ebi.ac.uk/efo/efo_0005410,GCST002257,24172245,0,Tooth agenesis (maxillary third molar)
http://www.ebi.ac.uk/efo/efo_0005410,GCST002256,24172245,1,Tooth agenesis (third molar)
http://www.ebi.ac.uk/efo/efo_0000614,GCST002261,24204295,3,Narcolepsy (age of onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST002261,24204295,3,Narcolepsy (age of onset)
http://www.ebi.ac.uk/efo/efo_0000614,GCST002259,24204295,2,Narcolepsy (onset before 2009 H1N1 influenza pandemic)
http://www.ebi.ac.uk/efo/efo_0000614,GCST002260,24204295,5,Narcolepsy
http://www.ebi.ac.uk/efo/efo_0005410,GCST002258,24172245,2,Tooth agenesis (mandibular third molar)
http://www.ebi.ac.uk/efo/efo_0004812,GCST002255,24182552,3,Inflammatory biomarkers
http://www.ebi.ac.uk/efo/efo_0004754,GCST002255,24182552,3,Inflammatory biomarkers
http://www.ebi.ac.uk/efo/efo_0000692,GCST002254,24166486,5,"Schizophrenia, schizoaffective disorder or bipolar disorder"
http://www.ebi.ac.uk/efo/efo_0000289,GCST002254,24166486,5,"Schizophrenia, schizoaffective disorder or bipolar disorder"
http://www.ebi.ac.uk/efo/efo_0005411,GCST002254,24166486,5,"Schizophrenia, schizoaffective disorder or bipolar disorder"
http://www.ebi.ac.uk/efo/efo_0008111,GCST002251,24204828,12,Homeostasis model assessment of beta-cell function (dietary factor interaction)
http://www.ebi.ac.uk/efo/efo_0004469,GCST002251,24204828,12,Homeostasis model assessment of beta-cell function (dietary factor interaction)
http://www.ebi.ac.uk/efo/efo_0008111,GCST002253,24204828,15,Homeostasis model assessment of insulin resistance (dietary factor interaction)
http://www.ebi.ac.uk/efo/efo_0004501,GCST002253,24204828,15,Homeostasis model assessment of insulin resistance (dietary factor interaction)
http://www.ebi.ac.uk/efo/efo_0008111,GCST002248,24204828,14,Fasting insulin (dietary factor interaction)
http://www.ebi.ac.uk/efo/efo_0004466,GCST002248,24204828,14,Fasting insulin (dietary factor interaction)
http://www.ebi.ac.uk/efo/efo_0004325,GCST002249,24165912,11,Blood pressure measurement (high sodium intervention)
http://www.ebi.ac.uk/efo/efo_0005401,GCST002249,24165912,11,Blood pressure measurement (high sodium intervention)
http://www.ebi.ac.uk/efo/efo_0004325,GCST002250,24165912,10,Blood pressure measurement (low sodium intervention)
http://www.ebi.ac.uk/efo/efo_0005402,GCST002250,24165912,10,Blood pressure measurement (low sodium intervention)
http://www.ebi.ac.uk/efo/efo_0004325,GCST002252,24165912,13,Blood pressure measurement (high sodium and potassium intervention)
http://www.ebi.ac.uk/efo/efo_0005401,GCST002252,24165912,13,Blood pressure measurement (high sodium and potassium intervention)
http://www.ebi.ac.uk/efo/efo_0005403,GCST002252,24165912,13,Blood pressure measurement (high sodium and potassium intervention)
http://www.ebi.ac.uk/efo/efo_0004325,GCST002247,24165912,7,Blood pressure measurement (cold pressor test)
http://www.ebi.ac.uk/efo/efo_0005404,GCST002247,24165912,7,Blood pressure measurement (cold pressor test)
http://www.ebi.ac.uk/efo/efo_0000249,GCST002245,24162737,33,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0004197,GCST002246,24162738,3,Hepatitis B
http://www.ebi.ac.uk/efo/efo_0003902,GCST002244,24513584,0,Fractures (vertebral)
http://www.ebi.ac.uk/efo/efo_0000292,GCST002243,24163127,7,Bladder cancer
http://www.ebi.ac.uk/efo/efo_0000292,GCST002240,24163127,10,Bladder cancer
http://www.ebi.ac.uk/efo/efo_0005418,GCST002242,24159190,24,Serum dimethylarginine levels (asymmetric/symetric ratio)
http://www.ebi.ac.uk/efo/efo_0005418,GCST002239,24159190,30,Symmetrical dimethylarginine levels
http://www.ebi.ac.uk/efo/efo_0006522,GCST002241,24159190,21,Asymmetrical dimethylarginine levels
http://www.ebi.ac.uk/efo/efo_0005418,GCST002241,24159190,21,Asymmetrical dimethylarginine levels
http://www.ebi.ac.uk/efo/efo_0005419,GCST002238,24152035,5,Contrast sensitivity
http://www.ebi.ac.uk/efo/efo_0000183,GCST002237,24149102,6,Hodgkin's lymphoma
http://www.ebi.ac.uk/efo/efo_0000220,GCST002236,24141364,0,Acute lymphoblastic leukemia (childhood)
http://purl.obolibrary.org/obo/go_0014072,GCST002235,24143882,3,Opioid sensitivity
http://www.ebi.ac.uk/efo/efo_0000305,GCST002234,24143190,4,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004502,GCST002233,24105470,10,Adiponectin levels
http://www.ebi.ac.uk/efo/efo_0000478,GCST002232,24121790,8,Esophageal adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0000280,GCST002230,24121790,7,Barrett's esophagus
http://www.ebi.ac.uk/efo/efo_0000478,GCST002231,24121790,10,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
http://www.ebi.ac.uk/efo/efo_0000405,GCST002231,24121790,10,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
http://www.ebi.ac.uk/efo/efo_0000280,GCST002231,24121790,10,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
http://www.ebi.ac.uk/efo/efo_0003894,GCST002229,24114350,0,Acne (severe teenage)
http://www.ebi.ac.uk/efo/efo_0005426,GCST002228,24133439,6,Social autistic-like traits
http://www.ebi.ac.uk/efo/efo_0004340,GCST002227,24064335,3,Body mass index
http://www.ebi.ac.uk/efo/efo_0005409,GCST002226,24064335,2,Fat body mass
http://www.ebi.ac.uk/efo/efo_0004994,GCST002225,24216480,2,Disc degeneration (lumbar)
http://www.ebi.ac.uk/efo/efo_0001360,GCST002224,24101674,2,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000699,GCST002217,24097066,5,Sjgren's syndrome
http://www.ebi.ac.uk/efo/efo_0004530,GCST002216,24097068,40,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004574,GCST002221,24097068,73,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004611,GCST002222,24097068,58,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004612,GCST002223,24097068,71,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004230,GCST002215,24096698,0,Endometrial cancer
http://www.ebi.ac.uk/efo/efo_0004230,GCST002218,24096698,9,Endometrial cancer
http://www.ebi.ac.uk/efo/efo_0004530,GCST002219,24097068,1,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004611,GCST002220,24097068,1,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004533,GCST002214,24094242,4,Serum alkaline phosphatase levels
http://www.ebi.ac.uk/efo/efo_0006527,GCST002213,24098343,0,Coronary artery calcification (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004723,GCST002213,24098343,0,Coronary artery calcification (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0005406,GCST002212,24084763,0,Colorectal adenoma (advanced)
http://www.ebi.ac.uk/efo/efo_0000222,GCST002210,24159609,0,Acute myeloid leukemia
http://www.ebi.ac.uk/efo/efo_0005407,GCST002211,24132900,10,Psychosis (atypical)
http://www.ebi.ac.uk/efo/efo_0004735,GCST002207,24124411,11,Liver enzyme levels (alanine transaminase)
http://www.ebi.ac.uk/efo/efo_0004736,GCST002208,24124411,8,Liver enzyme levels (aspartate transaminase)
http://www.ebi.ac.uk/efo/efo_0005252,GCST002209,24124408,5,Orthostatic hypotension
http://www.ebi.ac.uk/efo/efo_0009902,GCST002205,24065183,1,Handedness
http://www.ebi.ac.uk/efo/efo_0009902,GCST002206,24065183,1,Handedness
http://www.ebi.ac.uk/efo/efo_0001421,GCST002204,24065354,0,Liver disease in chronic hepatitis B virus infection
http://www.ebi.ac.uk/efo/efo_0004239,GCST002204,24065354,0,Liver disease in chronic hepatitis B virus infection
http://www.ebi.ac.uk/efo/efo_0000692,GCST002203,24086445,3,Gray matter volume (schizophrenia interaction)
http://www.ebi.ac.uk/efo/efo_0005420,GCST002203,24086445,3,Gray matter volume (schizophrenia interaction)
http://www.ebi.ac.uk/efo/efo_0004838,GCST002201,24068962,13,Calcium levels
http://www.ebi.ac.uk/efo/efo_0003761,GCST002200,24047446,3,Anxiety and major depressive disorder
http://www.ebi.ac.uk/efo/efo_0005230,GCST002200,24047446,3,Anxiety and major depressive disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST002202,24047446,8,Anxiety in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0005230,GCST002202,24047446,8,Anxiety in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0004768,GCST002199,24049095,6,Follicule stimulating hormone
http://www.ebi.ac.uk/efo/efo_0005421,GCST002196,24047826,1,Homoarginine levels
http://www.ebi.ac.uk/efo/efo_0004697,GCST002195,24049095,7,Hormone measurements
http://www.ebi.ac.uk/efo/efo_0004696,GCST002195,24049095,7,Hormone measurements
http://www.ebi.ac.uk/efo/efo_0004908,GCST002195,24049095,7,Hormone measurements
http://www.orpha.net/ordo/orphanet_3389,GCST002197,24057671,2,Tuberculosis
http://www.orpha.net/ordo/orphanet_3389,GCST002198,24057671,25,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0005427,GCST002194,24047820,4,Social communication problems
http://www.ebi.ac.uk/efo/efo_0004214,GCST002193,24046328,1,Abdominal aortic aneurysm
http://www.ebi.ac.uk/efo/efo_0004704,GCST002192,24045676,2,Menopause (age at onset)
http://www.ebi.ac.uk/efo/efo_0000692,GCST002190,24043878,1,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004703,GCST002191,24045676,0,Menarche (age at onset)
http://www.orpha.net/ordo/orphanet_232,GCST002187,24058526,10,Systolic blood pressure in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0006335,GCST002187,24058526,10,Systolic blood pressure in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0003761,GCST002188,24039173,5,"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia"
http://www.ebi.ac.uk/efo/efo_0000692,GCST002188,24039173,5,"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia"
http://www.ebi.ac.uk/efo/efo_0000289,GCST002188,24039173,5,"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia"
http://www.ebi.ac.uk/efo/efo_0005412,GCST002188,24039173,5,"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia"
http://www.ebi.ac.uk/efo/efo_0005422,GCST002189,24037343,0,Skin youthfulness
http://www.ebi.ac.uk/efo/efo_0009902,GCST002183,24068947,10,Relative hand skill in reading disability
http://www.ebi.ac.uk/efo/efo_0005424,GCST002183,24068947,10,Relative hand skill in reading disability
http://www.ebi.ac.uk/efo/efo_0001359,GCST002182,24029427,1,End-stage renal disease in Type 1 diabetics
http://www.ebi.ac.uk/efo/efo_0003884,GCST002182,24029427,1,End-stage renal disease in Type 1 diabetics
http://www.ebi.ac.uk/efo/efo_0004584,GCST002184,24026423,11,Mean platelet volume
http://www.ebi.ac.uk/efo/efo_0009902,GCST002185,24068947,3,Relative hand skill
http://www.ebi.ac.uk/efo/efo_0004309,GCST002186,24026423,8,Platelet count
http://www.ebi.ac.uk/efo/efo_0005400,GCST002181,24025145,3,Adverse response to chemotherapy in breast cancer (alopecia)
http://www.ebi.ac.uk/efo/efo_0005400,GCST002177,24025145,7,Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
http://www.ebi.ac.uk/efo/efo_0005260,GCST002177,24025145,7,Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
http://www.ebi.ac.uk/efo/efo_0005425,GCST002175,24024963,0,Reading disability and language impairment
http://www.ebi.ac.uk/efo/efo_0005424,GCST002175,24024963,0,Reading disability and language impairment
http://www.ebi.ac.uk/efo/efo_0005400,GCST002180,24025145,4,Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)
http://purl.obolibrary.org/obo/go_1902519,GCST002180,24025145,4,Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)
http://www.ebi.ac.uk/efo/efo_0005400,GCST002179,24025145,5,Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
http://purl.obolibrary.org/obo/go_1901555,GCST002179,24025145,5,Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
http://purl.obolibrary.org/obo/go_1902518,GCST002178,24025145,8,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
http://www.ebi.ac.uk/efo/efo_0005400,GCST002178,24025145,8,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
http://purl.obolibrary.org/obo/go_0036275,GCST002178,24025145,8,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
http://purl.obolibrary.org/obo/go_1902520,GCST002178,24025145,8,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
http://purl.obolibrary.org/obo/go_1902522,GCST002176,24025145,3,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)
http://purl.obolibrary.org/obo/go_1902518,GCST002176,24025145,3,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)
http://www.ebi.ac.uk/efo/efo_0005400,GCST002176,24025145,3,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)
http://purl.obolibrary.org/obo/go_0036275,GCST002176,24025145,3,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)
http://www.ebi.ac.uk/efo/efo_0004574,GCST002174,24023260,6,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004530,GCST002174,24023260,6,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004611,GCST002174,24023260,6,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004612,GCST002174,24023260,6,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004530,GCST002173,24023261,6,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004611,GCST002173,24023261,6,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004612,GCST002173,24023261,6,Lipid traits
http://www.ebi.ac.uk/efo/efo_0003829,GCST002172,24015780,0,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0001358,GCST002171,24080187,0,Post-traumatic stress disorder
http://www.orpha.net/ordo/orphanet_99701,GCST002170,24014518,2,Mesial temporal lobe epilepsy with hippocampal sclerosis
http://www.ebi.ac.uk/efo/efo_0005423,GCST002169,24023777,1,Adolescent idiopathic scoliosis (severe)
http://www.ebi.ac.uk/efo/efo_0004695,GCST002168,24002674,10,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0005416,GCST002166,23999434,14,Serum protein levels (sST2)
http://www.ebi.ac.uk/efo/efo_0004325,GCST002167,24001895,6,Blood pressure
http://www.ebi.ac.uk/efo/efo_0004314,GCST002165,24023788,9,Lung function (FEV1)
http://www.ebi.ac.uk/efo/efo_0004313,GCST002163,24023788,12,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity)
http://www.ebi.ac.uk/efo/efo_0004312,GCST002162,24023788,9,Lung function (FVC)
http://www.ebi.ac.uk/efo/efo_0004713,GCST002164,24023788,5,Lung function (FEV1/FVC)
http://www.ebi.ac.uk/efo/efo_0005297,GCST002160,23740775,5,Wegener's granulomatosis
http://www.ebi.ac.uk/efo/efo_0005297,GCST002159,23740775,1,Wegener's granulomatosis
http://www.ebi.ac.uk/efo/efo_0000249,GCST002161,23836404,0,Alzheimer's disease (neuritic plaque pathology)
http://www.ebi.ac.uk/efo/efo_0005417,GCST002157,24009623,8,Response to mTOR inhibitor (everolimus)
http://www.ebi.ac.uk/efo/efo_0000094,GCST002158,23996088,6,Acute lymphoblastic leukemia (B-cell precursor)
http://www.ebi.ac.uk/efo/efo_0005417,GCST002156,24009623,5,Response to mTOR inhibitor (rapamycin)
http://www.ebi.ac.uk/efo/efo_0002506,GCST002155,23989986,5,Osteoarthritis (hip)
http://purl.obolibrary.org/obo/go_0097366,GCST002154,23992748,0,Asthma (bronchodilator response)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002154,23992748,0,Asthma (bronchodilator response)
http://www.ebi.ac.uk/efo/efo_0000319,GCST002153,23982368,1,Cardiovascular heart disease in diabetics
http://www.ebi.ac.uk/efo/efo_0001360,GCST002153,23982368,1,Cardiovascular heart disease in diabetics
http://www.ebi.ac.uk/efo/efo_0005414,GCST002152,23984888,1,Airway hyperresponsiveness
http://www.ebi.ac.uk/efo/efo_0000398,GCST002151,23983088,1,Dermatomyositis
http://www.ebi.ac.uk/efo/efo_0005429,GCST002150,23979607,1,Borderline personality disorder features
http://www.ebi.ac.uk/efo/efo_0000692,GCST002149,23974872,27,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004992,GCST002148,23974705,1,Otitis media (chronic/recurrent)
http://www.ebi.ac.uk/efo/efo_0004623,GCST002147,23969696,24,Fibrinogen
http://www.ebi.ac.uk/efo/efo_0005415,GCST002146,23990791,0,Serum alpha1-antitrypsin levels
http://www.ebi.ac.uk/efo/efo_0004707,GCST002145,23989729,4,Infantile hypertrophic pyloric stenosis
http://www.ebi.ac.uk/efo/efo_0002610,GCST002142,23958962,15,Cocaine dependence
http://www.ebi.ac.uk/efo/efo_0004325,GCST002143,23972371,11,Blood pressure
http://purl.obolibrary.org/obo/go_0050913,GCST002144,23966204,3,Bitter taste perception
http://purl.obolibrary.org/obo/go_0042493,GCST002141,23962720,7,Epilepsy (remission after treatment)
http://www.ebi.ac.uk/efo/efo_0000474,GCST002141,23962720,7,Epilepsy (remission after treatment)
http://www.ebi.ac.uk/efo/efo_0001378,GCST002140,23955597,6,Multiple myeloma
http://www.ebi.ac.uk/efo/efo_0009459,GCST002139,23956247,0,Joint damage progression in ACPA-positive rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0005413,GCST002139,23956247,0,Joint damage progression in ACPA-positive rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004342,GCST002137,23966867,7,Waist circumference
http://www.ebi.ac.uk/efo/efo_0004343,GCST002138,23966867,6,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0000649,GCST002129,24024966,15,Periodontitis (DPAL)
http://www.ebi.ac.uk/efo/efo_0005430,GCST002131,23942779,20,Behavioural disinhibition (generation interaction)
http://www.ebi.ac.uk/efo/efo_0008364,GCST002131,23942779,20,Behavioural disinhibition (generation interaction)
http://www.ebi.ac.uk/efo/efo_0005431,GCST002131,23942779,20,Behavioural disinhibition (generation interaction)
http://www.ebi.ac.uk/efo/efo_0005432,GCST002131,23942779,20,Behavioural disinhibition (generation interaction)
http://www.ebi.ac.uk/efo/efo_0004329,GCST002131,23942779,20,Behavioural disinhibition (generation interaction)
http://www.ebi.ac.uk/efo/efo_0003829,GCST002131,23942779,20,Behavioural disinhibition (generation interaction)
http://www.ebi.ac.uk/efo/efo_0005432,GCST002132,23942779,4,Non-substance related behavioral disinhibition
http://www.ebi.ac.uk/efo/efo_0005431,GCST002133,23942779,10,Illicit drug use
http://www.ebi.ac.uk/efo/efo_0003829,GCST002134,23942779,4,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0004329,GCST002130,23942779,2,Alcohol consumption
http://www.ebi.ac.uk/efo/efo_0000649,GCST002126,24024966,28,Periodontitis (CDC/AAP)
http://www.ebi.ac.uk/efo/efo_0000649,GCST002127,24024966,37,Periodontitis (Mean PAL)
http://www.ebi.ac.uk/efo/efo_0005430,GCST002135,23942779,6,Nicotine use
http://www.ebi.ac.uk/efo/efo_0000649,GCST002136,24024966,18,Periodontitis (PAL4Q3)
http://www.ebi.ac.uk/efo/efo_0001360,GCST002128,23945395,16,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST002123,23937595,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004329,GCST002121,23953852,0,Alcohol consumption
http://www.ebi.ac.uk/efo/efo_0004579,GCST002125,23967269,2,IgE levels in asthmatics (D.f. specific)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002125,23967269,2,IgE levels in asthmatics (D.f. specific)
http://www.ebi.ac.uk/efo/efo_0004579,GCST002124,23967269,3,IgE levels in asthmatics (D.p. specific)
http://www.ebi.ac.uk/efo/efo_0000270,GCST002124,23967269,3,IgE levels in asthmatics (D.p. specific)
http://www.ebi.ac.uk/efo/efo_0004579,GCST002122,23967269,4,IgE levels in asthmatics
http://www.ebi.ac.uk/efo/efo_0000270,GCST002122,23967269,4,IgE levels in asthmatics
http://www.ebi.ac.uk/efo/efo_0005275,GCST002120,23934736,20,Metabolite levels (Dihydroxy docosatrienoic acid)
http://www.ebi.ac.uk/efo/efo_0005276,GCST002119,23934736,29,Metabolite levels  (X-11787)
http://www.ebi.ac.uk/efo/efo_0005408,GCST002118,23934736,23,Metabolite levels (Pyroglutamine)
http://www.ebi.ac.uk/efo/efo_0004207,GCST002117,23933737,2,Myopia (severe)
http://www.ebi.ac.uk/efo/efo_0005318,GCST002115,24144296,21,Axial length
http://www.ebi.ac.uk/efo/efo_0004325,GCST002116,23929743,0,Blood pressure variability
http://www.ebi.ac.uk/efo/efo_0005321,GCST002114,23918034,5,Molar-incisor hypomineralization
http://www.ebi.ac.uk/efo/efo_0003892,GCST002113,23932459,7,Pulmonary function
http://www.ebi.ac.uk/efo/efo_0004314,GCST002113,23932459,7,Pulmonary function
http://www.ebi.ac.uk/efo/efo_0004713,GCST002113,23932459,7,Pulmonary function
http://www.ebi.ac.uk/efo/efo_0004312,GCST002113,23932459,7,Pulmonary function
http://www.ebi.ac.uk/efo/efo_0001060,GCST002112,23936387,15,Celiac disease
http://www.ebi.ac.uk/efo/efo_0004365,GCST002111,23903073,8,Personality dimensions
http://purl.obolibrary.org/obo/go_0007608,GCST002105,23910658,1,Odorant perception (isobutyraldehyde)
http://www.ebi.ac.uk/efo/efo_0005320,GCST002108,23921680,2,Allergic dermatitis (nickel)
http://purl.obolibrary.org/obo/go_0007608,GCST002107,23910658,1,Odorant perception (&beta;-ionone)
http://purl.obolibrary.org/obo/go_0007608,GCST002106,23910658,1,Odorant perception (&beta;-damascenone)
http://www.ebi.ac.uk/efo/efo_0004526,GCST002109,23935956,4,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004527,GCST002109,23935956,4,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0005187,GCST002110,23903356,10,Glycemic traits (pregnancy)
http://www.ebi.ac.uk/efo/efo_0004465,GCST002110,23903356,10,Glycemic traits (pregnancy)
http://www.ebi.ac.uk/efo/efo_0004307,GCST002110,23903356,10,Glycemic traits (pregnancy)
http://www.ebi.ac.uk/efo/efo_0004505,GCST002103,23900074,1,Telomere length
http://www.orpha.net/ordo/orphanet_70589,GCST002104,23897914,26,Bronchopulmonary dysplasia
http://www.ebi.ac.uk/efo/efo_0002892,GCST002102,23894154,2,Thyroid cancer
http://www.ebi.ac.uk/efo/efo_0000180,GCST002101,23935489,1,HIV-1 susceptibility
http://www.ebi.ac.uk/efo/efo_0000274,GCST002100,23886662,4,Atopic dermatitis
http://www.ebi.ac.uk/efo/efo_0005842,GCST002099,23875689,0,Colorectal cancer
http://www.orpha.net/ordo/orphanet_130,GCST002098,23872634,3,Brugada syndrome
http://www.ebi.ac.uk/efo/efo_0004723,GCST002097,23870195,48,Coronary artery calcification
http://www.ebi.ac.uk/efo/efo_0000677,GCST002096,23871474,0,Psychosis
http://www.ebi.ac.uk/efo/efo_0003761,GCST002095,23857890,2,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0000384,GCST002094,23850713,8,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000407,GCST002093,23853074,0,Idiopathic dilated cardiomyopathy
http://www.ebi.ac.uk/efo/efo_0005322,GCST002092,23874384,3,Callous-unemotional behaviour
http://www.ebi.ac.uk/efo/efo_0005324,GCST002090,23834954,7,Sensory disturbances after bilateral sagittal split ramus osteotomy
http://www.ebi.ac.uk/efo/efo_0005325,GCST002091,23838604,0,Angioedema in response to angiotensin-converting enzyme inhibitor
http://www.ebi.ac.uk/efo/efo_0005532,GCST002091,23838604,0,Angioedema in response to angiotensin-converting enzyme inhibitor
http://www.ebi.ac.uk/efo/efo_0004695,GCST002089,23836780,1,Intraocular pressure
http://www.ebi.ac.uk/efo/efo_0004591,GCST002088,23829686,19,Asthma (childhood onset)
http://www.ebi.ac.uk/efo/efo_0004578,GCST002087,23824729,18,Homocysteine levels
http://www.ebi.ac.uk/efo/efo_1001857,GCST006863,23830517,5,Takayasu arteritis
http://www.ebi.ac.uk/efo/efo_0004458,GCST002086,23844046,4,C-reactive protein
http://www.ebi.ac.uk/efo/efo_0000588,GCST002085,23827383,0,Malignant mesothelioma
http://www.ebi.ac.uk/efo/efo_0003898,GCST005530,23749187,2,Ankylosing spondylitis (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0003898,GCST005529,23749187,70,Ankylosing spondylitis
http://www.ebi.ac.uk/efo/efo_0003785,GCST002083,23817569,35,Self-reported allergy
http://www.ebi.ac.uk/efo/efo_0005298,GCST002084,23817571,12,Allergic sensitization
http://www.ebi.ac.uk/efo/efo_0001061,GCST002082,23817570,4,Cervical cancer
http://www.ebi.ac.uk/efo/efo_0005296,GCST002078,23793025,32,Migraine without aura
http://www.ebi.ac.uk/efo/efo_0003821,GCST002079,23793025,37,Migraine - clinic-based
http://www.ebi.ac.uk/efo/efo_0003821,GCST002081,23793025,59,Migraine
http://www.ebi.ac.uk/efo/efo_0005295,GCST002080,23793025,23,Migraine with aura
http://www.ebi.ac.uk/efo/efo_0000692,GCST002076,23805179,0,Hippocampal volume in schizophrenia
http://www.ebi.ac.uk/efo/efo_0005035,GCST002076,23805179,0,Hippocampal volume in schizophrenia
http://www.ebi.ac.uk/efo/efo_0002508,GCST002077,23793441,3,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0004873,GCST002075,23823136,0,Lipopolysaccharide induced cytokine levels
http://www.ebi.ac.uk/efo/efo_0004569,GCST002074,23776197,10,Paclitaxel-induced neuropathy
http://purl.obolibrary.org/obo/go_1901555,GCST002074,23776197,10,Paclitaxel-induced neuropathy
http://www.ebi.ac.uk/efo/efo_0000095,GCST002073,23770605,21,Chronic lymphocytic leukemia
http://www.ebi.ac.uk/efo/efo_0003885,GCST002072,23785401,1,Multiple sclerosis (OCB status)
http://www.ebi.ac.uk/efo/efo_0004731,GCST002071,23776548,2,Retinal arteriolar caliber
http://www.ebi.ac.uk/efo/efo_0004318,GCST002070,23752247,0,Smoking behavior
http://www.ebi.ac.uk/efo/efo_0004239,GCST002068,23760081,6,Chronic hepatitis B infection
http://www.ebi.ac.uk/efo/efo_0000717,GCST002069,23740937,20,Systemic lupus erythematosus and Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0002690,GCST002069,23740937,20,Systemic lupus erythematosus and Systemic sclerosis
http://purl.obolibrary.org/obo/go_0036270,GCST002067,23753411,1,Response to diuretic therapy in hypertension
http://www.ebi.ac.uk/efo/efo_0000574,GCST002066,23749188,1,B cell non-Hodgkin lymphoma
http://www.ebi.ac.uk/efo/efo_0004329,GCST002065,23743675,16,Alcohol consumption
http://www.ebi.ac.uk/efo/efo_0004302,GCST002063,23754948,10,Sexual dimorphism in anthropometric traits
http://www.ebi.ac.uk/efo/efo_0005951,GCST002063,23754948,10,Sexual dimorphism in anthropometric traits
http://purl.obolibrary.org/obo/hp_0000483,GCST002064,23761726,7,Corneal astigmatism
http://purl.obolibrary.org/obo/go_0061476,GCST002061,23755828,1,Warfarin maintenance dose
http://www.ebi.ac.uk/efo/efo_0005299,GCST002059,23738518,5,Non-word repetition
http://www.ebi.ac.uk/efo/efo_0005301,GCST002062,23738518,10,Reading and spelling
http://www.ebi.ac.uk/efo/efo_0005300,GCST002060,23738518,15,Word reading
http://purl.obolibrary.org/obo/go_0006306,GCST002057,23725790,7,DNA methylation (parent-of-origin)
http://purl.obolibrary.org/obo/go_0006306,GCST002058,23725790,19,DNA methylation (variation)
http://www.ebi.ac.uk/efo/efo_0000637,GCST002056,23727862,6,Osteosarcoma
http://purl.obolibrary.org/obo/hp_0001268,GCST002055,23732972,0,Cognitive decline
http://www.ebi.ac.uk/efo/efo_0000685,GCST005563,23603763,0,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0001359,GCST005563,23603763,0,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0000676,GCST005563,23603763,0,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)"
http://www.orpha.net/ordo/orphanet_797,GCST005563,23603763,0,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0001060,GCST005563,23603763,0,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0000729,GCST005563,23603763,0,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0000384,GCST005563,23603763,0,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0004268,GCST005563,23603763,0,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)"
http://www.ebi.ac.uk/efo/efo_0004268,GCST006670,23603763,19,Primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0003888,GCST002048,23728934,4,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0005280,GCST002051,23728906,0,Sleep latency
http://www.ebi.ac.uk/efo/efo_0007876,GCST002052,23728906,3,Insomnia
http://www.ebi.ac.uk/efo/efo_0005271,GCST002053,23728906,7,Sleep duration
http://www.ebi.ac.uk/efo/efo_0005273,GCST002054,23728906,2,Sleep depth
http://www.ebi.ac.uk/efo/efo_0005272,GCST002049,23728906,7,Sleep quality
http://www.ebi.ac.uk/efo/efo_0005274,GCST002050,23728906,5,Sleep time
http://www.ebi.ac.uk/efo/efo_0004784,GCST002045,23722424,9,Educational attainment
http://www.ebi.ac.uk/efo/efo_0004784,GCST002047,23722424,4,Educational attainment
http://purl.obolibrary.org/obo/go_0036276,GCST002046,23726668,3,Response to antidepressant treatment (citalopram)
http://www.ebi.ac.uk/efo/efo_0005266,GCST002039,23720494,10,Blood trace element (Se levels)
http://www.ebi.ac.uk/efo/efo_0004612,GCST002043,23726366,9,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004530,GCST002044,23726366,7,Triglycerides
http://www.ebi.ac.uk/efo/efo_0005268,GCST002040,23720494,11,Blood trace element (Zn levels)
http://www.ebi.ac.uk/efo/efo_0005267,GCST002041,23720494,7,Blood trace element (Cu levels)
http://www.ebi.ac.uk/efo/efo_0004529,GCST002042,23726366,5,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0001358,GCST002038,23726511,2,Post-traumatic stress disorder
http://www.ebi.ac.uk/efo/efo_0001358,GCST002037,23726511,19,Post-traumatic stress disorder (asjusted for relatedness)
http://www.ebi.ac.uk/efo/efo_0005269,GCST002036,23708190,2,Congenital heart malformation
http://purl.obolibrary.org/obo/go_0009314,GCST002034,23719583,3,Adverse response to radiation therapy
http://www.ebi.ac.uk/efo/efo_0005207,GCST002035,23708191,2,Congenital heart disease
http://purl.obolibrary.org/obo/go_0042476,GCST002031,23704328,11,Primary tooth development (number of teeth)
http://www.ebi.ac.uk/efo/efo_0001068,GCST002033,23717212,6,Malaria
http://www.ebi.ac.uk/efo/efo_0005279,GCST002029,23746317,1,Temporomandibular joint disorder
http://www.ebi.ac.uk/efo/efo_0000714,GCST002032,23704207,0,Non-small cell lung cancer (survival)
http://www.ebi.ac.uk/efo/efo_0003060,GCST002032,23704207,0,Non-small cell lung cancer (survival)
http://purl.obolibrary.org/obo/go_0044691,GCST002030,23704328,13,Primary tooth development (time to first tooth eruption)
http://www.ebi.ac.uk/efo/efo_0005266,GCST002028,23698163,4,Serum selenium levels
http://www.ebi.ac.uk/efo/efo_0004306,GCST002027,23696099,7,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004246,GCST002026,23677057,1,Coronary arterial lesions in patients with Kawasaki disease
http://www.ebi.ac.uk/efo/efo_1000881,GCST002026,23677057,1,Coronary arterial lesions in patients with Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0001663,GCST002024,23668334,0,Prostate cancer
http://www.orpha.net/ordo/orphanet_586,GCST002025,23670970,1,Cystic fibrosis-related diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST002025,23670970,1,Cystic fibrosis-related diabetes
http://www.ebi.ac.uk/efo/efo_0005088,GCST002022,23666240,15,Testicular germ cell tumor
http://www.ebi.ac.uk/efo/efo_0005088,GCST002023,23666239,11,Testicular germ cell tumor
http://www.ebi.ac.uk/efo/efo_0004340,GCST002021,23669352,14,Body mass index
http://www.ebi.ac.uk/efo/efo_0004273,GCST002020,23666238,2,Scoliosis
http://www.ebi.ac.uk/efo/efo_0004579,GCST002019,23661040,0,IgE levels
http://www.ebi.ac.uk/efo/efo_0000384,GCST002018,23665963,1,Crohn's disease (time to surgery)
http://www.ebi.ac.uk/efo/efo_0000384,GCST002017,23665963,2,Crohn's disease (need for surgery)
http://www.ebi.ac.uk/efo/efo_0004365,GCST002015,23658558,0,Personality dimensions
http://www.ebi.ac.uk/efo/efo_0004365,GCST002016,23658558,0,Personality dimensions
http://www.ebi.ac.uk/efo/efo_0005247,GCST002014,23652523,2,Helicobacter pylori serologic status
http://www.ebi.ac.uk/efo/efo_0004703,GCST002013,23667675,8,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0000714,GCST002010,23644492,1,Esophageal squamous cell cancer (length of survival)
http://www.ebi.ac.uk/efo/efo_0000707,GCST002010,23644492,1,Esophageal squamous cell cancer (length of survival)
http://www.ebi.ac.uk/efo/efo_0002916,GCST002010,23644492,1,Esophageal squamous cell cancer (length of survival)
http://www.ebi.ac.uk/efo/efo_0003923,GCST002011,23644456,2,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0004286,GCST002012,23650146,8,Venous thromboembolism
http://purl.obolibrary.org/obo/go_1902518,GCST002002,23648065,3,Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)
http://purl.obolibrary.org/obo/go_0097327,GCST002002,23648065,3,Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)
http://purl.obolibrary.org/obo/go_0036272,GCST002003,23648065,5,Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)
http://purl.obolibrary.org/obo/go_0097327,GCST002003,23648065,5,Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)
http://www.ebi.ac.uk/efo/efo_0004647,GCST001998,23648065,6,Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
http://purl.obolibrary.org/obo/go_0097327,GCST001998,23648065,6,Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
http://purl.obolibrary.org/obo/go_0036275,GCST001997,23648065,4,Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)
http://purl.obolibrary.org/obo/go_0097327,GCST001997,23648065,4,Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)
http://purl.obolibrary.org/obo/go_1902522,GCST001996,23648065,5,Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)
http://purl.obolibrary.org/obo/go_0097327,GCST001996,23648065,5,Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)
http://purl.obolibrary.org/obo/go_0097327,GCST002009,23648065,3,Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)
http://purl.obolibrary.org/obo/go_1902520,GCST002009,23648065,3,Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)
http://purl.obolibrary.org/obo/go_0097327,GCST002008,23648065,6,Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
http://www.ebi.ac.uk/efo/efo_0005257,GCST002008,23648065,6,Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
http://purl.obolibrary.org/obo/go_0072718,GCST002007,23648065,7,Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
http://purl.obolibrary.org/obo/go_0097327,GCST002007,23648065,7,Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
http://purl.obolibrary.org/obo/go_0097328,GCST002006,23648065,7,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
http://purl.obolibrary.org/obo/go_1901555,GCST002006,23648065,7,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
http://purl.obolibrary.org/obo/go_0097327,GCST002006,23648065,7,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
http://purl.obolibrary.org/obo/go_0097327,GCST002005,23648065,6,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
http://purl.obolibrary.org/obo/go_0097329,GCST002005,23648065,6,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
http://purl.obolibrary.org/obo/go_0097328,GCST002004,23648065,9,Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
http://purl.obolibrary.org/obo/go_0097327,GCST002004,23648065,9,Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
http://purl.obolibrary.org/obo/go_1902521,GCST002000,23648065,4,Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)
http://purl.obolibrary.org/obo/go_0097327,GCST002000,23648065,4,Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)
http://purl.obolibrary.org/obo/go_1901563,GCST001993,23648065,3,Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)
http://purl.obolibrary.org/obo/go_0097327,GCST001993,23648065,3,Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)
http://purl.obolibrary.org/obo/go_0072758,GCST001994,23648065,6,Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
http://purl.obolibrary.org/obo/go_0097327,GCST001994,23648065,6,Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
http://purl.obolibrary.org/obo/go_1902519,GCST001995,23648065,7,Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
http://purl.obolibrary.org/obo/go_0097327,GCST001995,23648065,7,Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
http://purl.obolibrary.org/obo/go_1901555,GCST001999,23648065,8,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
http://purl.obolibrary.org/obo/go_0097327,GCST001999,23648065,8,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
http://purl.obolibrary.org/obo/go_0097327,GCST002001,23648065,12,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
http://www.ebi.ac.uk/efo/efo_0005260,GCST002001,23648065,12,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
http://www.ebi.ac.uk/efo/efo_0004208,GCST001992,23678272,1,Vitiligo (non-segmental)
http://www.ebi.ac.uk/efo/efo_0005244,GCST001991,23643386,5,Weight loss (gastric bypass surgery)
http://www.ebi.ac.uk/efo/efo_0005245,GCST001991,23643386,5,Weight loss (gastric bypass surgery)
http://www.ebi.ac.uk/efo/efo_0001365,GCST001986,23577725,5,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0001365,GCST001987,23577725,3,Age-related macular degeneration (extreme sampling)
http://www.ebi.ac.uk/efo/efo_0006527,GCST001990,23577725,3,Age-related macular degeneration (smoking status interaction)
http://www.ebi.ac.uk/efo/efo_0001365,GCST001990,23577725,3,Age-related macular degeneration (smoking status interaction)
http://www.ebi.ac.uk/efo/efo_0003939,GCST001989,23636237,1,Dietary macronutrient intake
http://www.ebi.ac.uk/efo/efo_0003939,GCST001988,23636237,6,Dietary macronutrient intake
http://www.ebi.ac.uk/efo/efo_0005244,GCST001985,23633212,2,Weight loss (gastric bypass surgery)
http://www.ebi.ac.uk/efo/efo_0005245,GCST001985,23633212,2,Weight loss (gastric bypass surgery)
http://www.ebi.ac.uk/efo/efo_0004237,GCST001984,23612905,5,Graves' disease
http://www.ebi.ac.uk/efo/efo_0005250,GCST001983,23620144,1,Job-related exhaustion
http://www.ebi.ac.uk/efo/efo_0004237,GCST001982,23612905,1,Graves' disease
http://www.ebi.ac.uk/efo/efo_0000253,GCST001981,23624525,2,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0005243,GCST001979,23620142,5,Circulating myeloperoxidase levels (serum)
http://www.ebi.ac.uk/efo/efo_0005243,GCST001980,23620142,3,Circulating myeloperoxidase levels (plasma)
http://www.ebi.ac.uk/efo/efo_0000770,GCST001978,23626673,0,Malignant pleural mesothelioma
http://www.ebi.ac.uk/efo/efo_1001999,GCST005528,23603761,31,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)
http://www.ebi.ac.uk/efo/efo_1002020,GCST005528,23603761,31,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)
http://www.ebi.ac.uk/efo/efo_1002019,GCST005528,23603761,31,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)
http://www.ebi.ac.uk/efo/efo_0004570,GCST001976,23642732,1,Bilirubin levels
http://www.ebi.ac.uk/efo/efo_0003770,GCST001977,23562823,1,Diabetic retinopathy
http://www.ebi.ac.uk/efo/efo_0005242,GCST001975,23594818,1,Psychosis (methamphetamine induced)
http://www.ebi.ac.uk/efo/efo_0000768,GCST001974,24429156,5,Idiopathic pulmonary fibrosis
http://www.ebi.ac.uk/efo/efo_0000692,GCST001972,23594818,1,Methamphetamine dependence
http://www.ebi.ac.uk/efo/efo_0004703,GCST001973,23599027,15,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0005246,GCST001971,23646285,5,Hypersomnia (HLA-DQB1*06:02 negative)
http://www.ebi.ac.uk/efo/efo_0004704,GCST001970,23592221,0,Menopause (age at onset)
http://www.ebi.ac.uk/efo/efo_0004326,GCST001969,23583979,32,Heart rate
http://www.ebi.ac.uk/efo/efo_0004340,GCST001967,23583978,7,Body mass index
http://www.ebi.ac.uk/efo/efo_0004244,GCST001968,23583980,16,Interstitial lung disease
http://www.ebi.ac.uk/efo/efo_0005240,GCST001966,23585552,4,Rhegmatogenous retinal detachment
http://www.ebi.ac.uk/efo/efo_0001360,GCST001965,23575436,11,Glycemic traits
http://www.ebi.ac.uk/efo/efo_0000249,GCST001963,23571587,2,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0004302,GCST001964,23575227,5,Anthropometric traits in newborns
http://www.ebi.ac.uk/efo/efo_0001372,GCST001964,23575227,5,Anthropometric traits in newborns
http://www.ebi.ac.uk/efo/efo_0003923,GCST001962,23572186,1,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0005203,GCST001960,23568457,8,Eating disorders
http://www.ebi.ac.uk/efo/efo_0005203,GCST001959,23568457,11,Eating disorders (purging via substances)
http://www.ebi.ac.uk/efo/efo_0005204,GCST001958,23568457,23,Bulimia nervosa
http://www.ebi.ac.uk/efo/efo_0005203,GCST001961,23568457,15,Anorexia nervosa
http://www.ebi.ac.uk/efo/efo_0001073,GCST001957,23563609,18,Obesity (early onset extreme)
http://www.ebi.ac.uk/efo/efo_0004302,GCST001956,23563607,86,Height
http://www.ebi.ac.uk/efo/efo_0004340,GCST001955,23563607,10,Body mass index
http://www.ebi.ac.uk/efo/efo_0004302,GCST001954,23563607,4,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0004302,GCST001953,23563607,66,Obesity
http://www.ebi.ac.uk/efo/efo_0000249,GCST001951,23562540,6,Alzheimer's disease biomarkers
http://www.ebi.ac.uk/efo/efo_0004704,GCST001950,23593202,6,Femoral neck bone geometry and menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0005241,GCST001952,23593239,2,Self-employment
http://www.ebi.ac.uk/efo/efo_0000249,GCST001947,23565137,2,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0000668,GCST001949,23551011,18,Preeclampsia
http://www.ebi.ac.uk/efo/efo_0005230,GCST001948,23565138,0,Anxiety
http://www.ebi.ac.uk/efo/efo_0004340,GCST001935,23517042,9,Body mass index in non-asthmatics
http://www.ebi.ac.uk/efo/efo_0000729,GCST001938,23511034,7,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0005127,GCST001946,23555189,4,PCA3 expression level
http://www.ebi.ac.uk/efo/efo_0003888,GCST001943,23527680,22,Attention deficit hyperactivity disorder (inattention symptoms)
http://www.ebi.ac.uk/efo/efo_0003888,GCST001944,23527680,25,Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
http://www.ebi.ac.uk/efo/efo_0004340,GCST001945,23517042,6,Body mass index in asthmatics
http://www.ebi.ac.uk/efo/efo_0000270,GCST001945,23517042,6,Body mass index in asthmatics
http://www.ebi.ac.uk/efo/efo_0004279,GCST001939,23548203,5,Tanning
http://www.ebi.ac.uk/efo/efo_0003784,GCST001940,23548203,4,Non-melanoma skin cancer
http://www.ebi.ac.uk/efo/efo_0001075,GCST001941,23535730,17,Ovarian cancer
http://www.ebi.ac.uk/efo/efo_0001663,GCST001942,23535732,23,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0004505,GCST001936,23535734,3,Telomere length
http://www.ebi.ac.uk/efo/efo_0000305,GCST001937,23535729,63,Breast cancer
http://www.ebi.ac.uk/efo/efo_0003924,GCST001932,23548203,6,Hair color
http://www.ebi.ac.uk/efo/efo_0003949,GCST001929,23548203,8,Eye color
http://www.ebi.ac.uk/efo/efo_0000305,GCST001930,23535733,17,Breast cancer
http://www.ebi.ac.uk/efo/efo_0003888,GCST001931,23527680,21,Attention deficit hyperactivity disorder (combined symptoms)
http://www.ebi.ac.uk/efo/efo_0003958,GCST001933,23548203,4,Sunburns
http://www.ebi.ac.uk/efo/efo_0000729,GCST001934,23511034,1,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0003884,GCST001924,23539754,0,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0005208,GCST001923,23535967,6,Glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0005055,GCST001920,23534349,9,QRS duration
http://www.ebi.ac.uk/efo/efo_0000685,GCST001927,23555300,4,Response to anti-TNF therapy in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004653,GCST001927,23555300,4,Response to anti-TNF therapy in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0003095,GCST001928,23535911,4,Pediatric non-alcoholic fatty liver disease activity score
http://www.ebi.ac.uk/efo/efo_0001422,GCST001928,23535911,4,Pediatric non-alcoholic fatty liver disease activity score
http://www.ebi.ac.uk/efo/efo_0004653,GCST001926,23555300,1,Response to anti-TNF therapy in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004462,GCST001925,23534349,9,PR interval
http://www.ebi.ac.uk/efo/efo_0004326,GCST001921,23534349,5,Heart rate
http://www.ebi.ac.uk/efo/efo_0004682,GCST001922,23534349,8,QT interval
http://www.ebi.ac.uk/efo/efo_0003892,GCST001918,23541324,4,Pulmonary function in asthmatics
http://www.ebi.ac.uk/efo/efo_0000305,GCST007302,23544012,5,Breast cancer in BRCA2 mutation carriers
http://www.ebi.ac.uk/efo/efo_0001360,GCST001919,23532257,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000305,GCST001916,23544013,6,Breast Cancer in BRCA1 mutation carriers
http://www.ebi.ac.uk/efo/efo_0001075,GCST001917,23544013,7,Ovarian cancer in BRCA1 mutation carriers
http://www.ebi.ac.uk/efo/efo_0000249,GCST001915,23535033,44,Alzheimer's disease (cognitive decline)
http://www.ebi.ac.uk/efo/efo_0004697,GCST001914,23518928,18,Estradiol plasma levels (breast cancer)
http://www.ebi.ac.uk/efo/efo_0004286,GCST001913,23509962,37,Venous thromboembolism (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0000220,GCST001912,23512250,3,Acute lymphoblastic leukemia (childhood)
http://purl.obolibrary.org/obo/go_0097366,GCST001911,23508266,2,Asthma (bronchodilator response)
http://www.ebi.ac.uk/efo/efo_0000270,GCST001911,23508266,2,Asthma (bronchodilator response)
http://www.ebi.ac.uk/efo/efo_0000614,GCST001909,23496005,4,Narcolepsy with cataplexy
http://www.ebi.ac.uk/efo/efo_0005211,GCST001910,23508960,1,Aspirin hydrolysis (plasma)
http://www.ebi.ac.uk/efo/efo_0001361,GCST001908,23502781,1,Pulmonary arterial hypertension (without BMPR2 mutations)
http://www.ebi.ac.uk/efo/efo_0001378,GCST001906,23502783,25,Multiple myeloma (IgH translocation)
http://www.ebi.ac.uk/efo/efo_0001378,GCST001907,23502783,14,Multiple myeloma (hyperdiploidy)
http://www.ebi.ac.uk/efo/efo_0004530,GCST001905,23505323,9,Hypertriglyceridemia
http://www.ebi.ac.uk/efo/efo_0004612,GCST001904,23505323,5,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004731,GCST001903,23493294,2,Central corneal thickness
http://www.ebi.ac.uk/efo/efo_0004723,GCST001902,23561647,2,Coronary artery calcification
http://www.ebi.ac.uk/efo/efo_0001061,GCST001900,23482656,6,Cervical cancer
http://www.ebi.ac.uk/efo/efo_0004829,GCST001901,23478653,7,Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
http://www.ebi.ac.uk/efo/efo_0003060,GCST001901,23478653,7,Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
http://www.ebi.ac.uk/efo/efo_0000516,GCST001899,23536807,2,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0001365,GCST001899,23536807,2,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0006338,GCST001897,23470693,8,Pit-and-Fissure caries
http://www.ebi.ac.uk/efo/efo_0006339,GCST001896,23470693,11,Smooth-surface caries
http://purl.obolibrary.org/obo/hp_0000539,GCST001898,23474815,1,Refractive error
http://www.ebi.ac.uk/efo/efo_0005205,GCST001895,23467860,2,Response to dabigatran etexilate treatment
http://www.ebi.ac.uk/efo/efo_0001065,GCST001894,23472165,15,Endometriosis
http://www.ebi.ac.uk/efo/efo_0003885,GCST001891,23472185,3,Multiple sclerosis (OCB status)
http://www.ebi.ac.uk/efo/efo_0003885,GCST001892,23472185,8,Multiple sclerosis (OCB status)
http://www.ebi.ac.uk/efo/efo_0005206,GCST001892,23472185,8,Multiple sclerosis (OCB status)
http://www.ebi.ac.uk/efo/efo_0005055,GCST001893,23463857,5,Electrocardiographic conduction measures
http://www.ebi.ac.uk/efo/efo_0004682,GCST001890,23459443,17,QT interval (drug interaction)
http://www.ebi.ac.uk/efo/efo_0005210,GCST001889,23471985,12,Brain connectivity
http://www.ebi.ac.uk/efo/efo_0000649,GCST001888,23459936,3,Periodontitis
http://www.ebi.ac.uk/efo/efo_0001365,GCST001884,23455636,19,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0004339,GCST001885,23456168,11,Height
http://www.ebi.ac.uk/efo/efo_0005091,GCST001887,23314186,6,Monocyte count
http://www.ebi.ac.uk/efo/efo_0000756,GCST001886,23455637,1,Melanoma
http://www.ebi.ac.uk/efo/efo_0003829,GCST001883,23456092,1,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0004725,GCST001882,23281178,9,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0000305,GCST001879,23468962,13,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004207,GCST001881,23406873,5,Myopia (pathological)
http://www.ebi.ac.uk/efo/efo_0003890,GCST001880,23533358,3,Addiction
http://www.ebi.ac.uk/efo/efo_0001382,GCST001876,23449627,14,Pubertal anthropometrics
http://www.ebi.ac.uk/efo/efo_0005201,GCST001876,23449627,14,Pubertal anthropometrics
http://www.ebi.ac.uk/efo/efo_0003888,GCST001877,23453885,74,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)"
http://www.ebi.ac.uk/efo/efo_0003761,GCST001877,23453885,74,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)"
http://www.ebi.ac.uk/efo/efo_0000692,GCST001877,23453885,74,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)"
http://www.ebi.ac.uk/efo/efo_0003756,GCST001877,23453885,74,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)"
http://www.ebi.ac.uk/efo/efo_0000289,GCST001877,23453885,74,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)"
http://www.ebi.ac.uk/efo/efo_0004246,GCST001878,23454411,0,Coronary arterial lesions in patients with Kawasaki disease
http://www.ebi.ac.uk/efo/efo_1000881,GCST001878,23454411,0,Coronary arterial lesions in patients with Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0003829,GCST001874,23455491,1,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0004339,GCST001875,23449627,11,Pubertal anthropometrics
http://www.ebi.ac.uk/efo/efo_0004509,GCST001873,23446634,15,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004305,GCST001873,23446634,15,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004528,GCST001873,23446634,15,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004526,GCST001873,23446634,15,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004348,GCST001873,23446634,15,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004527,GCST001873,23446634,15,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0005192,GCST001873,23446634,15,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0005200,GCST001872,23509613,13,Presence of antiphospholipid antibodies
http://www.ebi.ac.uk/efo/efo_0003923,GCST001870,23437003,7,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0005199,GCST001871,23432519,4,Renal transplant outcome
http://www.ebi.ac.uk/efo/efo_0000305,GCST001869,23423446,0,Breast cancer (menopausal hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0003961,GCST001869,23423446,0,Breast cancer (menopausal hormone therapy interaction)
http://www.ebi.ac.uk/efo/efo_0004220,GCST001867,23420232,2,Chronic hepatitis C infection
http://www.ebi.ac.uk/efo/efo_0004875,GCST001866,23423138,1,Mathematical ability in children with dyslexia
http://www.ebi.ac.uk/efo/efo_0000249,GCST001868,23419831,13,Alzheimer's disease biomarkers
http://www.ebi.ac.uk/efo/efo_0005262,GCST001864,23388002,0,Mitral annular calcification
http://www.ebi.ac.uk/efo/efo_0005239,GCST001865,23388002,1,Aortic-valve calcification
http://www.ebi.ac.uk/efo/efo_0005197,GCST001863,23417110,16,Beta-2 microglubulin plasma levels
http://www.ebi.ac.uk/efo/efo_0003939,GCST001861,23408455,0,Confectionary intake
http://www.orpha.net/ordo/orphanet_232,GCST001862,23406172,4,Sickle cell anemia (haemolysis)
http://www.ebi.ac.uk/efo/efo_0003885,GCST001860,23412934,16,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0005202,GCST001859,23400010,59,Thiazide-induced adverse metabolic effects in hypertensive patients
http://www.ebi.ac.uk/efo/efo_0004530,GCST001859,23400010,59,Thiazide-induced adverse metabolic effects in hypertensive patients
http://www.ebi.ac.uk/efo/efo_0004465,GCST001859,23400010,59,Thiazide-induced adverse metabolic effects in hypertensive patients
http://www.ebi.ac.uk/efo/efo_0000180,GCST001857,23372042,0,HIV-1 susceptibility
http://purl.obolibrary.org/obo/hp_0000539,GCST001858,23396134,26,Refractive error
http://www.ebi.ac.uk/efo/efo_0004730,GCST001856,23408906,60,Thyroid hormone levels
http://purl.obolibrary.org/obo/go_0042493,GCST001855,23392654,0,Response to antiplatelet therapy
http://www.ebi.ac.uk/efo/efo_0003839,GCST001854,23393555,11,Retinopathy in non-diabetics
http://www.ebi.ac.uk/efo/efo_0005196,GCST001853,23381795,7,Circulating vasoactive peptide levels
http://www.ebi.ac.uk/efo/efo_0000692,GCST001851,23894747,14,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004725,GCST001852,23378610,6,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0003761,GCST001850,23377640,49,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0005193,GCST001848,23382691,693,IgG glycosylation
http://www.ebi.ac.uk/efo/efo_0004570,GCST001846,23371916,10,Bilirubin levels
http://www.ebi.ac.uk/efo/efo_0001645,GCST001845,23364394,5,Coronary heart disease
http://purl.obolibrary.org/obo/go_0009314,GCST001847,23376709,1,Urinary symptoms in response to radiotherapy in prostate cancer
http://www.ebi.ac.uk/efo/efo_0008008,GCST001847,23376709,1,Urinary symptoms in response to radiotherapy in prostate cancer
http://www.ebi.ac.uk/efo/efo_0001663,GCST001847,23376709,1,Urinary symptoms in response to radiotherapy in prostate cancer
http://www.ebi.ac.uk/efo/efo_0005193,GCST001849,23382691,6,IgG glycosylation
http://www.ebi.ac.uk/efo/efo_0004315,GCST001842,23364009,1,Drinking behavior
http://www.ebi.ac.uk/efo/efo_0003939,GCST001844,23372041,3,Dietary macronutrient intake
http://www.ebi.ac.uk/efo/efo_0001360,GCST001843,23386860,4,Type 2 diabetes (dietary heme iron intake interaction)
http://www.ebi.ac.uk/efo/efo_0008355,GCST001843,23386860,4,Type 2 diabetes (dietary heme iron intake interaction)
http://www.ebi.ac.uk/efo/efo_0004337,GCST001837,23358156,6,Intelligence (childhood)
http://www.ebi.ac.uk/efo/efo_0005110,GCST001834,23362303,9,Oleic acid (18:1n-9) levels
http://www.ebi.ac.uk/efo/efo_0005110,GCST001840,23362303,11,Stearic acid (18:0) levels
http://www.ebi.ac.uk/efo/efo_0005110,GCST001841,23362303,15,Palmitoleic acid (16:1n-7) levels
http://www.ebi.ac.uk/efo/efo_0000692,GCST001839,23358160,3,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST001833,23358160,1,Schizophrenia (cytomegalovirus infection interaction)
http://www.ebi.ac.uk/efo/efo_0001062,GCST001833,23358160,1,Schizophrenia (cytomegalovirus infection interaction)
http://www.ebi.ac.uk/efo/efo_0005195,GCST001835,23374588,3,Response to cholinesterase inhibitors in Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000249,GCST001835,23374588,3,Response to cholinesterase inhibitors in Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0005110,GCST001838,23362303,12,Palmitic acid (16:0) levels
http://www.ebi.ac.uk/efo/efo_0000692,GCST001836,23382809,3,Schizophrenia (negative symptoms)
http://www.ebi.ac.uk/efo/efo_0005842,GCST001832,23350875,3,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST001831,23354978,3,Breast cancer
http://www.ebi.ac.uk/efo/efo_0003882,GCST001830,23349225,1,Osteoporosis
http://www.ebi.ac.uk/efo/efo_0003939,GCST001829,23337944,0,Fat intake
http://www.ebi.ac.uk/efo/efo_0000319,GCST001828,23337848,0,Vascular constriction
http://www.ebi.ac.uk/efo/efo_0000574,GCST001826,23349640,13,Lymphoma
http://www.ebi.ac.uk/efo/efo_0003060,GCST001827,23341777,1,Squamous cell carcinoma
http://www.ebi.ac.uk/efo/efo_0004742,GCST001825,23328707,1,Beta-trace protein levels
http://www.ebi.ac.uk/efo/efo_0005131,GCST001818,23319000,9,Metabolite levels (HVA/5-HIAA ratio)
http://www.ebi.ac.uk/efo/efo_0005132,GCST001818,23319000,9,Metabolite levels (HVA/5-HIAA ratio)
http://www.ebi.ac.uk/efo/efo_0005131,GCST001823,23319000,25,Metabolite levels (HVA/MHPG ratio)
http://www.ebi.ac.uk/efo/efo_0005133,GCST001823,23319000,25,Metabolite levels (HVA/MHPG ratio)
http://purl.obolibrary.org/obo/hp_0000483,GCST001819,23322567,17,Corneal astigmatism
http://www.ebi.ac.uk/efo/efo_0005133,GCST001821,23319000,11,Metabolite levels (5-HIAA/ MHPG Ratio)
http://www.ebi.ac.uk/efo/efo_0005132,GCST001821,23319000,11,Metabolite levels (5-HIAA/ MHPG Ratio)
http://www.ebi.ac.uk/efo/efo_0005133,GCST001822,23319000,20,Metabolite levels (MHPG)
http://www.ebi.ac.uk/efo/efo_0005132,GCST001820,23319000,13,Metabolite levels (5-HIAA)
http://www.ebi.ac.uk/efo/efo_0005131,GCST001824,23319000,13,Metabolite levels (HVA)
http://www.ebi.ac.uk/efo/efo_0005131,GCST001817,23319000,12,Metabolite levels (HVA-5-HIAA Factor score)
http://www.ebi.ac.uk/efo/efo_0005132,GCST001817,23319000,12,Metabolite levels (HVA-5-HIAA Factor score)
http://www.ebi.ac.uk/efo/efo_0000305,GCST001816,23319801,5,Breast cancer (prognosis)
http://www.ebi.ac.uk/efo/efo_0005129,GCST001815,23321320,5,Hepatitis C induced liver cirrhosis
http://www.ebi.ac.uk/efo/efo_0001365,GCST001814,23326517,31,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0005128,GCST001813,23303382,5,Hematology traits
http://www.ebi.ac.uk/efo/efo_0000289,GCST001811,23326512,1,Bipolar disorder (mania)
http://www.ebi.ac.uk/efo/efo_0004556,GCST001812,23326239,2,Epstein-Barr virus immune response (EBNA-1)
http://www.ebi.ac.uk/efo/efo_0000769,GCST001812,23326239,2,Epstein-Barr virus immune response (EBNA-1)
http://www.ebi.ac.uk/efo/efo_0004704,GCST001810,23307926,8,Menopause (age at onset)
http://www.ebi.ac.uk/efo/efo_0001360,GCST001809,23300278,17,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0005127,GCST001808,23300138,11,Tumor biomarkers
http://purl.obolibrary.org/obo/hp_0001636,GCST001807,23297363,6,Tetralogy of Fallot
http://www.ebi.ac.uk/efo/efo_0004345,GCST001806,23291589,26,Corneal structure
http://www.ebi.ac.uk/efo/efo_0005045,GCST001805,23291585,1,Leishmaniasis (visceral)
http://www.ebi.ac.uk/efo/efo_0003780,GCST001804,23291587,6,Behcet's disease
http://www.ebi.ac.uk/efo/efo_0004345,GCST001803,23401653,1,Corneal curvature
http://www.ebi.ac.uk/efo/efo_0004761,GCST001801,23703922,6,Uric acid levels
http://www.ebi.ac.uk/efo/efo_0003761,GCST001802,23290196,2,Depression (quantitative trait)
http://www.ebi.ac.uk/efo/efo_0004555,GCST001800,23279374,9,&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
http://www.ebi.ac.uk/efo/efo_0004624,GCST001799,23359319,2,Prostate-specific antigen levels
http://www.ebi.ac.uk/efo/efo_0000614,GCST005522,23459209,8,Narcolepsy
http://www.ebi.ac.uk/efo/efo_0004630,GCST001798,23381943,23,End-stage coagulation
http://www.ebi.ac.uk/efo/efo_0004629,GCST001798,23381943,23,End-stage coagulation
http://www.ebi.ac.uk/efo/efo_0004634,GCST001798,23381943,23,End-stage coagulation
http://www.ebi.ac.uk/efo/efo_0004298,GCST001797,23275298,0,Cardiac structure and function
http://www.ebi.ac.uk/efo/efo_0004624,GCST001796,23269536,3,Prostate-specific antigen levels
http://www.ebi.ac.uk/efo/efo_0002690,GCST001795,23273568,34,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0005842,GCST001794,23300701,7,Colorectal cancer (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0004634,GCST001793,23267103,7,Coagulation factor levels
http://www.ebi.ac.uk/efo/efo_0004531,GCST001791,23263486,47,Urate levels
http://www.ebi.ac.uk/efo/efo_0004467,GCST008112,23263489,1,Proinsulin levels (early-phase conversion)
http://www.ebi.ac.uk/efo/efo_0004467,GCST008113,23263489,1,Proinsulin levels (late-phase conversion)
http://www.ebi.ac.uk/efo/efo_0006832,GCST008111,23263489,1,Insulin disposition index
http://www.ebi.ac.uk/efo/efo_0009961,GCST008110,23263489,4,Insulinogenic index
http://www.ebi.ac.uk/efo/efo_0004467,GCST008109,23263489,8,Fasting blood proinsulin levels
http://www.ebi.ac.uk/efo/efo_0005842,GCST001792,23263487,7,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0004274,GCST001790,23263486,6,Gout
http://www.orpha.net/ordo/orphanet_70589,GCST001789,23263444,0,Lipoprotein diameter
http://www.ebi.ac.uk/efo/efo_0004841,GCST001788,23263445,1,Digit length ratio
http://www.ebi.ac.uk/efo/efo_0000384,GCST001785,23266558,11,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0005842,GCST001787,23266556,15,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0003819,GCST001786,23259602,34,Dental caries
http://www.ebi.ac.uk/efo/efo_0003892,GCST001784,23284291,53,Pulmonary function (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0005671,GCST001784,23284291,53,Pulmonary function (smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004309,GCST001783,23263863,8,Platelet count
http://www.ebi.ac.uk/efo/efo_0004526,GCST001781,23263863,10,Mean corpuscular volume
http://www.ebi.ac.uk/efo/efo_0004528,GCST001782,23263863,6,Mean corpuscular hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0004509,GCST001779,23263863,12,Hematology traits
http://www.ebi.ac.uk/efo/efo_0004308,GCST001779,23263863,12,Hematology traits
http://www.ebi.ac.uk/efo/efo_0004305,GCST001779,23263863,12,Hematology traits
http://www.ebi.ac.uk/efo/efo_0004348,GCST001779,23263863,12,Hematology traits
http://www.ebi.ac.uk/efo/efo_0004527,GCST001780,23263863,10,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0000538,GCST001778,23255317,0,Hypertrophic cardiomyopathy
http://www.ebi.ac.uk/efo/efo_0004611,GCST001777,23247145,1,LDL (oxidized)
http://www.ebi.ac.uk/efo/efo_0000182,GCST001775,23242368,2,Hepatocellular carcinoma in hepatitis B infection
http://www.ebi.ac.uk/efo/efo_0005043,GCST001776,23247143,18,Cardiac Troponin-T levels
http://www.ebi.ac.uk/efo/efo_0004778,GCST001774,23237013,0,Reporting of stressful life event
http://www.ebi.ac.uk/efo/efo_0007781,GCST001774,23237013,0,Reporting of stressful life event
http://purl.obolibrary.org/obo/go_0097332,GCST001773,23241943,8,Response to antipsychotic treatment
http://purl.obolibrary.org/obo/go_0031427,GCST001770,23233662,1,Methotrexate clearance (acute lymphoblastic leukemia)
http://www.ebi.ac.uk/efo/efo_0004257,GCST001771,23229837,1,Neuroticism
http://www.ebi.ac.uk/efo/efo_0000685,GCST001772,23233654,0,Response to TNF-alpha inhibitors in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004653,GCST001772,23233654,0,Response to TNF-alpha inhibitors in rheumatoid arthritis
http://purl.obolibrary.org/obo/go_0007568,GCST001767,23223146,4,Aging (facial)
http://www.ebi.ac.uk/efo/efo_0004776,GCST001769,23216389,2,Alcohol and nicotine co-dependence
http://www.ebi.ac.uk/efo/efo_0003780,GCST001768,23001997,6,Behcet's disease
http://www.ebi.ac.uk/efo/efo_0003095,GCST001766,23213074,4,Non-alcoholic fatty liver disease histology (other)
http://www.ebi.ac.uk/efo/efo_0005047,GCST001765,23222517,45,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004642,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004730,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005119,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004749,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004340,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004626,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005110,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004684,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005112,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005109,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004870,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005115,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005116,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004741,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004620,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0003939,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004520,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004339,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005093,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005108,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0003940,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004326,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004747,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004697,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004748,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004342,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004574,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004810,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005106,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004344,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005134,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004458,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004501,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005114,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004502,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004612,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004736,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005000,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004818,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0006335,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005118,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0003923,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004338,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004465,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004578,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005111,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004735,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0005117,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004627,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004908,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004471,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0006336,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004887,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004530,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004611,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004995,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004466,GCST001762,23251661,949,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004641,GCST001764,23218918,6,White matter integrity (bipolar disorder risk interaction)
http://www.ebi.ac.uk/efo/efo_0000289,GCST001764,23218918,6,White matter integrity (bipolar disorder risk interaction)
http://purl.obolibrary.org/obo/hp_0001268,GCST001761,23207651,1,Cognitive decline
http://www.ebi.ac.uk/efo/efo_0004641,GCST001760,23218918,7,White matter integrity
http://www.ebi.ac.uk/efo/efo_0000270,GCST001763,23181788,1,Asthma
http://www.ebi.ac.uk/efo/efo_0001360,GCST001759,23209189,6,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004344,GCST001758,23202124,10,Birth weight
http://www.ebi.ac.uk/efo/efo_0000692,GCST001757,23212062,16,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0000685,GCST005568,23143596,56,Rheumatoid arthritis (ACPA-positive)
http://www.ebi.ac.uk/efo/efo_0000685,GCST005567,23143596,2,Rheumatoid arthritis (ACPA-negative)
http://www.ebi.ac.uk/efo/efo_0000685,GCST005569,23143596,50,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0006812,GCST005524,22922229,11,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)
http://www.ebi.ac.uk/efo/efo_0003779,GCST005524,22922229,11,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)
http://www.ebi.ac.uk/efo/efo_0004237,GCST005524,22922229,11,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)
http://www.ebi.ac.uk/efo/efo_0000676,GCST005527,23143594,41,Psoriasis
http://www.ebi.ac.uk/efo/efo_0003779,GCST005525,22922229,1,Hashimoto thyroiditis
http://www.ebi.ac.uk/efo/efo_0004237,GCST005526,22922229,12,Graves' disease
http://www.ebi.ac.uk/efo/efo_0004508,GCST001756,23207799,1,Spine bone size
http://purl.obolibrary.org/obo/go_1901555,GCST001755,23204130,0,Paclitaxel-induced neuropathy
http://www.ebi.ac.uk/efo/efo_0004149,GCST001755,23204130,0,Paclitaxel-induced neuropathy
http://www.ebi.ac.uk/efo/efo_0005671,GCST001754,23192594,3,Waist-to-hip circumference ratio (ever vs never smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004343,GCST001754,23192594,3,Waist-to-hip circumference ratio (ever vs never smoking interaction)
http://www.ebi.ac.uk/efo/efo_0007878,GCST004579,23192594,3,Waist-to-hip circumference ratio (alcohol intake interaction)
http://www.ebi.ac.uk/efo/efo_0004343,GCST004579,23192594,3,Waist-to-hip circumference ratio (alcohol intake interaction)
http://www.ebi.ac.uk/efo/efo_0008002,GCST004583,23192594,2,Waist-to-hip circumference ratio (recreational physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0004343,GCST004583,23192594,2,Waist-to-hip circumference ratio (recreational physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0005671,GCST004584,23192594,3,Waist-to-hip circumference ratio (smoking years interaction)
http://www.ebi.ac.uk/efo/efo_0004343,GCST004584,23192594,3,Waist-to-hip circumference ratio (smoking years interaction)
http://www.ebi.ac.uk/efo/efo_0008111,GCST004582,23192594,3,Waist-to-hip circumference ratio (dietary energy interaction)
http://www.ebi.ac.uk/efo/efo_0004343,GCST004582,23192594,3,Waist-to-hip circumference ratio (dietary energy interaction)
http://www.ebi.ac.uk/efo/efo_0005671,GCST004581,23192594,3,Body mass index  (smoking years interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004581,23192594,3,Body mass index  (smoking years interaction)
http://www.ebi.ac.uk/efo/efo_0005671,GCST004586,23192594,3,Body mass index (ever vs never smoking interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004586,23192594,3,Body mass index (ever vs never smoking interaction)
http://www.ebi.ac.uk/efo/efo_0008002,GCST004580,23192594,3,Body mass index (recreational physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004580,23192594,3,Body mass index (recreational physical activity interaction)
http://www.ebi.ac.uk/efo/efo_0008111,GCST004587,23192594,3,Body mass index (dietary energy interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST004587,23192594,3,Body mass index (dietary energy interaction)
http://www.ebi.ac.uk/efo/efo_0007878,GCST001753,23192594,3,Body mass index (alcohol intake interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST001753,23192594,3,Body mass index (alcohol intake interaction)
http://www.ebi.ac.uk/efo/efo_0004252,GCST001752,23209447,6,Nasopharyngeal carcinoma
http://purl.obolibrary.org/obo/go_0014072,GCST001751,23183491,1,Opioid sensitivity
http://www.ebi.ac.uk/efo/efo_0000681,GCST001750,23184150,2,Renal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0002618,GCST001749,23180869,7,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0004351,GCST001748,23183192,2,Resting heart rate
http://purl.obolibrary.org/obo/hp_0012042,GCST001747,23180272,1,Aspirin exacerbated respiratory disease in asthmatics
http://www.ebi.ac.uk/efo/efo_0004682,GCST001746,23166209,29,QT interval
http://www.orpha.net/ordo/orphanet_35093,GCST001745,23160099,2,Sagittal craniosynostosis
http://purl.obolibrary.org/obo/go_1901905,GCST001744,23151678,4,Serum tamsulosin hydrochloride concentration
http://www.ebi.ac.uk/efo/efo_0000249,GCST001743,23150908,1,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004262,GCST001742,23149450,0,Panic disorder
http://www.ebi.ac.uk/efo/efo_0000278,GCST001741,23143602,5,Pancreatitis
http://www.ebi.ac.uk/efo/efo_0001071,GCST001740,23143601,7,Lung cancer
http://purl.obolibrary.org/obo/go_1901557,GCST001738,23149075,12,Response to fenofibrate (adiponectin levels)
http://www.ebi.ac.uk/efo/efo_0004579,GCST001739,23146381,4,IgE levels
http://www.ebi.ac.uk/efo/efo_0001059,GCST001736,23137000,2,Cataracts in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST001736,23137000,2,Cataracts in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004684,GCST001737,23144326,34,Chronic obstructive pulmonary disease-related biomarkers
http://www.ebi.ac.uk/efo/efo_0004810,GCST001737,23144326,34,Chronic obstructive pulmonary disease-related biomarkers
http://www.ebi.ac.uk/efo/efo_0000341,GCST001737,23144326,34,Chronic obstructive pulmonary disease-related biomarkers
http://www.ebi.ac.uk/efo/efo_0004811,GCST001737,23144326,34,Chronic obstructive pulmonary disease-related biomarkers
http://www.ebi.ac.uk/efo/efo_0004623,GCST001737,23144326,34,Chronic obstructive pulmonary disease-related biomarkers
http://www.ebi.ac.uk/efo/efo_0004458,GCST001737,23144326,34,Chronic obstructive pulmonary disease-related biomarkers
http://www.ebi.ac.uk/efo/efo_0005080,GCST001737,23144326,34,Chronic obstructive pulmonary disease-related biomarkers
http://www.ebi.ac.uk/efo/efo_0005081,GCST001737,23144326,34,Chronic obstructive pulmonary disease-related biomarkers
http://www.ebi.ac.uk/efo/efo_0003060,GCST001734,23144319,13,Non-small cell lung cancer
http://www.ebi.ac.uk/efo/efo_0004462,GCST001735,23139255,8,PR interval
http://www.ebi.ac.uk/efo/efo_0000692,GCST001733,23142968,1,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0001073,GCST001732,23818313,3,Obesity
http://www.ebi.ac.uk/efo/efo_0006527,GCST001731,23114982,0,Colorectal cancer (environment interaction)
http://www.ebi.ac.uk/efo/efo_0005842,GCST001731,23114982,0,Colorectal cancer (environment interaction)
http://www.ebi.ac.uk/efo/efo_0007878,GCST001731,23114982,0,Colorectal cancer (environment interaction)
http://www.ebi.ac.uk/efo/efo_0005935,GCST001731,23114982,0,Colorectal cancer (environment interaction)
http://www.ebi.ac.uk/efo/efo_0004746,GCST001726,23118302,7,Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
http://www.ebi.ac.uk/efo/efo_0003767,GCST001725,23128233,110,Inflammatory bowel disease
http://purl.obolibrary.org/obo/go_1990054,GCST001730,23047291,1,Response to temozolomide
http://www.ebi.ac.uk/efo/efo_0000729,GCST001728,23128233,23,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0000384,GCST001729,23128233,30,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0004746,GCST001727,23118302,9,Lipoprotein-associated phospholipase A2 activity and mass
http://www.ebi.ac.uk/efo/efo_0003949,GCST001723,23118974,3,Eye color
http://www.ebi.ac.uk/efo/efo_0004993,GCST001724,23118916,3,IgM levels
http://www.ebi.ac.uk/efo/efo_0004995,GCST001722,23108985,1,Body mass (lean)
http://www.ebi.ac.uk/efo/efo_0001071,GCST001721,23108145,2,Lung Cancer (DNA repair capacity)
http://www.ebi.ac.uk/efo/efo_0001663,GCST001719,23104005,1,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0001065,GCST001720,23104006,7,Endometriosis
http://www.ebi.ac.uk/efo/efo_0004992,GCST001717,23133572,0,Otitis media (chronic/recurrent)
http://www.ebi.ac.uk/efo/efo_0001071,GCST001718,23103227,7,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)"
http://www.ebi.ac.uk/efo/efo_0000707,GCST001718,23103227,7,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)"
http://www.ebi.ac.uk/efo/efo_0000178,GCST001718,23103227,7,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)"
http://purl.obolibrary.org/obo/go_0036273,GCST001716,23100282,0,Response to statin therapy
http://www.ebi.ac.uk/efo/efo_0000289,GCST001715,23092984,16,Bipolar disorder with mood-incongruent psychosis
http://www.ebi.ac.uk/efo/efo_0005653,GCST006249,23093944,110,Serum metabolite levels
http://www.ebi.ac.uk/efo/efo_0001663,GCST001714,23065704,4,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0003819,GCST001713,23064961,32,Dental caries
http://www.ebi.ac.uk/efo/efo_0005845,GCST001710,23043469,2,HbA2 levels
http://www.ebi.ac.uk/efo/efo_0004747,GCST001711,23056639,2,Protein biomarker
http://www.ebi.ac.uk/efo/efo_0004207,GCST001712,23049088,64,Myopia (pathological)
http://www.ebi.ac.uk/efo/efo_0000274,GCST001709,23042114,17,Atopic dermatitis
http://www.ebi.ac.uk/efo/efo_0002690,GCST001708,23053960,5,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0003780,GCST001707,23041938,0,Behcet's disease
http://www.ebi.ac.uk/efo/efo_0000712,GCST001706,23041239,8,Stroke (ischemic)
http://www.ebi.ac.uk/efo/efo_0004985,GCST001705,23054467,0,Platelet reactivity
http://www.ebi.ac.uk/efo/efo_0004732,GCST001703,23031429,3,Apolipoprotein Levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST001704,23031429,1,Cholesterol and Triglycerides
http://www.ebi.ac.uk/efo/efo_0004612,GCST001704,23031429,1,Cholesterol and Triglycerides
http://www.ebi.ac.uk/efo/efo_1001486,GCST005581,22961000,47,Primary biliary cirrhosis
http://www.ebi.ac.uk/efo/efo_0001663,GCST001702,23023329,3,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0000270,GCST001701,23028483,2,Asthma
http://purl.obolibrary.org/obo/go_0009314,GCST001700,23021708,0,Erectile dysfunction and prostate cancer treatment
http://www.ebi.ac.uk/efo/efo_0001663,GCST001700,23021708,0,Erectile dysfunction and prostate cancer treatment
http://www.ebi.ac.uk/efo/efo_0004234,GCST001700,23021708,0,Erectile dysfunction and prostate cancer treatment
http://www.ebi.ac.uk/efo/efo_0004535,GCST001699,23022100,16,Serum albumin level
http://www.ebi.ac.uk/efo/efo_0004536,GCST001698,23022100,12,Serum total protein level
http://www.ebi.ac.uk/efo/efo_0000289,GCST001695,23010768,0,Bipolar disorder (Negative mood delusions)
http://www.ebi.ac.uk/efo/efo_0004318,GCST001696,23049750,3,Smoking behavior
http://www.ebi.ac.uk/efo/efo_0004505,GCST001697,23001564,4,Telomere length
http://www.ebi.ac.uk/efo/efo_0004749,GCST001691,23017229,5,Monocyte chemoattractant protein-1 levels
http://purl.obolibrary.org/obo/go_0097327,GCST001692,23006423,16,Response to taxane treatment (docetaxel)
http://purl.obolibrary.org/obo/go_1901555,GCST001694,23006423,13,Response to taxane treatment (placlitaxel)
http://www.ebi.ac.uk/efo/efo_0000220,GCST001693,23007406,10,Acute lymphoblastic leukemia (childhood)
http://www.ebi.ac.uk/efo/efo_0000305,GCST001690,23001122,3,Breast cancer (male)
http://www.ebi.ac.uk/efo/efo_0000712,GCST001689,22990015,4,Stroke (pediatric)
http://www.ebi.ac.uk/efo/efo_0009181,GCST006519,22997280,2,Growth differentiation factor-15 levels
http://www.ebi.ac.uk/efo/efo_0004996,GCST001688,23028342,11,Type 1 diabetes nephropathy
http://www.ebi.ac.uk/efo/efo_0004994,GCST001687,22993228,35,Disc degeneration (lumbar)
http://www.ebi.ac.uk/efo/efo_0004267,GCST001685,23000144,7,Primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0004792,GCST001684,22990020,4,Plasminogen activator inhibitor type 1 levels (PAI-1)
http://www.ebi.ac.uk/efo/efo_0000341,GCST001686,22986903,0,Chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005126,GCST001677,22982463,2,Paraoxonase activity
http://www.ebi.ac.uk/efo/efo_0000677,GCST001682,22981920,0,Personality disorders
http://www.ebi.ac.uk/efo/efo_0004984,GCST001679,23028341,10,Complement C3 and C4 levels
http://www.ebi.ac.uk/efo/efo_0004983,GCST001679,23028341,10,Complement C3 and C4 levels
http://www.ebi.ac.uk/efo/efo_0000305,GCST001683,22976474,4,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004345,GCST001680,22969067,10,Corneal curvature
http://www.ebi.ac.uk/efo/efo_0000685,GCST001681,23028356,2,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004743,GCST001678,23028347,0,Facial morphology
http://www.ebi.ac.uk/efo/efo_0004340,GCST001676,22982992,1,Body mass index
http://www.ebi.ac.uk/efo/efo_0000707,GCST001674,22960999,7,Esophageal cancer (squamous cell)
http://www.ebi.ac.uk/efo/efo_0002916,GCST001674,22960999,7,Esophageal cancer (squamous cell)
http://www.ebi.ac.uk/efo/efo_0000280,GCST001675,22961001,5,Barrett's esophagus
http://www.ebi.ac.uk/efo/efo_0002916,GCST001672,22960999,4,Esophageal cancer  (alcohol interaction)
http://www.ebi.ac.uk/efo/efo_0004228,GCST001673,22968431,1,Drug-induced liver injury
http://www.ebi.ac.uk/efo/efo_0004565,GCST001671,23225573,1,IgG levels
http://www.ebi.ac.uk/efo/efo_0000305,GCST001667,22951594,2,Breast cancer
http://www.ebi.ac.uk/efo/efo_0001360,GCST001666,22961080,10,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003843,GCST001668,22956598,1,Pain
http://www.ebi.ac.uk/efo/efo_0003870,GCST001665,22961961,1,Intracranial aneurysm
http://www.ebi.ac.uk/efo/efo_0004208,GCST001670,22951725,4,Vitiligo
http://www.ebi.ac.uk/efo/efo_0000660,GCST001669,22951595,0,Polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0000253,GCST001663,22959728,13,Amyotrophic lateral sclerosis (age of onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST001663,22959728,13,Amyotrophic lateral sclerosis (age of onset)
http://www.ebi.ac.uk/efo/efo_0000253,GCST004792,22959728,6,Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals
http://www.ebi.ac.uk/efo/efo_0000253,GCST004793,22959728,4,Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals
http://www.ebi.ac.uk/efo/efo_0000253,GCST004791,22959728,3,Amyotrophic lateral sclerosis (C9orf72 mutation interaction)
http://www.ebi.ac.uk/efo/efo_0000253,GCST001664,22959728,15,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0000474,GCST001662,22949513,10,Generalized epilepsy
http://www.ebi.ac.uk/efo/efo_0004910,GCST001661,22945461,0,CYP3A4 enzyme activity
http://www.ebi.ac.uk/efo/efo_0000621,GCST001660,22941191,6,Neuroblastoma
http://www.ebi.ac.uk/efo/efo_0000712,GCST001659,22941190,1,Stroke (ischemic)
http://www.ebi.ac.uk/efo/efo_0000692,GCST001657,22885689,11,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0001360,GCST005047,22885922,110,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000249,GCST001658,22881374,13,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0004979,GCST001656,22960237,2,Comprehensive strength and appendicular lean mass
http://www.ebi.ac.uk/efo/efo_0004515,GCST001656,22960237,2,Comprehensive strength and appendicular lean mass
http://www.ebi.ac.uk/efo/efo_0003758,GCST001655,22935194,0,Autism
http://www.orpha.net/ordo/orphanet_797,GCST001654,22936702,2,Sarcoidosis
http://www.ebi.ac.uk/efo/efo_0004909,GCST001653,22936694,6,Androgen levels
http://www.ebi.ac.uk/efo/efo_0004908,GCST001653,22936694,6,Androgen levels
http://www.ebi.ac.uk/efo/efo_0000384,GCST001652,22936669,10,Crohn's disease
http://purl.obolibrary.org/obo/go_0042493,GCST001651,22952603,89,Response to amphetamines
http://www.ebi.ac.uk/efo/efo_0004458,GCST001650,22939635,11,C-reactive protein
http://www.ebi.ac.uk/efo/efo_0000516,GCST001649,22922875,5,Glaucoma (primary angle closure)
http://www.ebi.ac.uk/efo/efo_0000305,GCST001648,22923054,1,Breast cancer
http://www.ebi.ac.uk/efo/efo_0000289,GCST001647,22925353,15,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0001663,GCST001646,22923026,8,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0004611,GCST001645,23067351,1,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0000677,GCST001644,22911880,7,Eating disorders
http://www.ebi.ac.uk/efo/efo_0000677,GCST001643,22915352,0,Depression (age of onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST001643,22915352,0,Depression (age of onset)
http://purl.obolibrary.org/obo/go_0036276,GCST001641,22907730,0,Response to antidepressants
http://www.ebi.ac.uk/efo/efo_0004915,GCST001642,22907691,1,Vaspin levels
http://www.ebi.ac.uk/efo/efo_0004913,GCST001640,22903471,14,Lentiform nucleus volume
http://www.ebi.ac.uk/efo/efo_0001071,GCST001638,22899653,1,Lung cancer
http://www.ebi.ac.uk/efo/efo_0004723,GCST001639,22916037,34,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0001068,GCST001637,22895189,4,Malaria
http://www.ebi.ac.uk/efo/efo_0004895,GCST001635,22889924,7,Tourette syndrome
http://www.ebi.ac.uk/efo/efo_0004242,GCST001636,22889921,3,Obsessive-compulsive disorder
http://www.ebi.ac.uk/efo/efo_0000660,GCST001634,22885925,11,Polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0000326,GCST001633,22886559,3,Glioma
http://purl.obolibrary.org/obo/go_1901557,GCST001632,22890011,10,Response to fenofibrate
http://www.ebi.ac.uk/efo/efo_0000692,GCST001631,22883433,2,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004647,GCST001629,22872573,5,Response to platinum-based chemotherapy in non-small-cell lung cancer
http://www.ebi.ac.uk/efo/efo_0003060,GCST001629,22872573,5,Response to platinum-based chemotherapy in non-small-cell lung cancer
http://www.ebi.ac.uk/efo/efo_0001358,GCST001630,22869035,0,Post-traumatic stress disorder
http://www.ebi.ac.uk/efo/efo_0003959,GCST001628,22863734,31,Orofacial clefts
http://www.orpha.net/ordo/orphanet_79102,GCST001627,22863731,1,Thyrotoxic hypokalemic periodic paralysis
http://www.ebi.ac.uk/efo/efo_0004912,GCST001626,22864923,1,IgA levels
http://purl.obolibrary.org/obo/go_1901555,GCST001624,22843789,0,Paclitaxel-induced neuropathy
http://www.ebi.ac.uk/efo/efo_0004149,GCST001624,22843789,0,Paclitaxel-induced neuropathy
http://www.ebi.ac.uk/efo/efo_0004820,GCST001625,22843499,0,Sex ratio at birth
http://www.ebi.ac.uk/efo/efo_0003892,GCST001621,22837378,30,Airflow obstruction
http://www.orpha.net/ordo/orphanet_797,GCST001622,22837380,1,Sarcoidosis
http://www.ebi.ac.uk/efo/efo_0003047,GCST001623,22841784,6,Hepatitis C induced liver fibrosis
http://www.ebi.ac.uk/efo/efo_0001422,GCST001623,22841784,6,Hepatitis C induced liver fibrosis
http://www.ebi.ac.uk/efo/efo_0003758,GCST001619,22843504,4,Autism
http://www.ebi.ac.uk/efo/efo_0004819,GCST001620,22843503,4,Resistin levels
http://www.ebi.ac.uk/efo/efo_0003890,GCST001616,22823124,6,Cannabis use (initiation)
http://www.ebi.ac.uk/efo/efo_0004914,GCST001618,22828495,0,Neural processing (facial expression)
http://www.ebi.ac.uk/efo/efo_0002508,GCST001617,22911860,0,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0000729,GCST001615,22821403,2,Sclerosing cholangitis and ulcerative colitis (combined)
http://www.ebi.ac.uk/efo/efo_0004268,GCST001615,22821403,2,Sclerosing cholangitis and ulcerative colitis (combined)
http://www.ebi.ac.uk/efo/efo_0004731,GCST001614,22814818,2,Central corneal thickness
http://www.ebi.ac.uk/efo/efo_0004826,GCST001613,22808956,18,Antineutrophil cytoplasmic antibody-associated vasculitis
http://www.ebi.ac.uk/efo/efo_0004696,GCST001612,22829776,30,Sex hormone-binding globulin levels
http://www.ebi.ac.uk/efo/efo_0000540,GCST001611,23055271,6,Myasthenia gravis
http://www.ebi.ac.uk/efo/efo_0004742,GCST001610,22797727,15,Renal function-related traits (BUN)
http://www.ebi.ac.uk/efo/efo_0004741,GCST001610,22797727,15,Renal function-related traits (BUN)
http://www.ebi.ac.uk/efo/efo_0000571,GCST001609,22797724,4,Lung adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0004742,GCST001608,22797727,4,Renal function-related traits (urea)
http://www.ebi.ac.uk/efo/efo_0004761,GCST001608,22797727,4,Renal function-related traits (urea)
http://www.ebi.ac.uk/efo/efo_0004742,GCST001607,22797727,10,Renal function-related traits (eGRFcrea)
http://www.ebi.ac.uk/efo/efo_0004742,GCST001606,22797727,9,Renal function-related traits (sCR)
http://www.ebi.ac.uk/efo/efo_0004308,GCST001605,22788528,9,C-reactive protein and white blood cell count
http://www.ebi.ac.uk/efo/efo_0004458,GCST001605,22788528,9,C-reactive protein and white blood cell count
http://www.ebi.ac.uk/efo/efo_0000182,GCST001603,22807686,3,Hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0004467,GCST001604,22791750,6,Insulin-related traits
http://www.ebi.ac.uk/efo/efo_0004699,GCST001601,22780124,5,Gambling
http://www.ebi.ac.uk/efo/efo_0000249,GCST001602,22785395,0,Alzheimer's disease
http://purl.obolibrary.org/obo/go_0007568,GCST001599,22773346,8,Aging
http://www.ebi.ac.uk/efo/efo_0004565,GCST001600,22673310,1,IgG levels
http://www.ebi.ac.uk/efo/efo_0004325,GCST001598,22763476,4,Blood pressure
http://www.ebi.ac.uk/efo/efo_0004840,GCST001593,22792071,2,Cortical thickness
http://purl.obolibrary.org/obo/go_0097366,GCST001597,22792082,1,Asthma (bronchodilator response)
http://www.ebi.ac.uk/efo/efo_0000270,GCST001597,22792082,1,Asthma (bronchodilator response)
http://www.ebi.ac.uk/efo/efo_0003923,GCST001594,22792070,2,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0003923,GCST001595,22792071,1,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0000516,GCST001596,22792221,1,Glaucoma
http://purl.obolibrary.org/obo/go_0036276,GCST001591,22760553,17,Response to citalopram treatment
http://www.ebi.ac.uk/efo/efo_0002506,GCST001592,22763110,4,Osteoarthritis
http://www.ebi.ac.uk/efo/efo_0003108,GCST001590,22764253,1,Essential tremor
http://www.ebi.ac.uk/efo/efo_0000649,GCST001588,22699663,16,Periodontal microbiota
http://www.ebi.ac.uk/efo/efo_0007876,GCST001586,22754043,9,Insomnia (caffeine-induced)
http://www.ebi.ac.uk/efo/efo_0001645,GCST001587,22751097,8,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0001075,GCST001589,22794196,0,Ovarian cancer
http://www.ebi.ac.uk/efo/efo_0004884,GCST001585,22747683,38,Breast size
http://www.ebi.ac.uk/efo/efo_0004341,GCST001584,22744181,1,Lean body mass and age at menarche (combined)
http://www.ebi.ac.uk/efo/efo_0004703,GCST001584,22744181,1,Lean body mass and age at menarche (combined)
http://www.ebi.ac.uk/efo/efo_0001073,GCST001583,23505185,1,Adiposity
http://www.ebi.ac.uk/efo/efo_0004197,GCST001582,22737229,4,Hepatitis B (viral clearance)
http://www.ebi.ac.uk/efo/efo_0004682,GCST001580,22726844,3,QT interval
http://www.ebi.ac.uk/efo/efo_0001645,GCST001581,22745674,3,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0004683,GCST001579,22705344,6,Age-related macular degeneration (choroidal neovascularisation)
http://www.ebi.ac.uk/efo/efo_1001492,GCST001577,22705344,1,Age-related macular degeneration (CNV vs. GA)
http://www.ebi.ac.uk/efo/efo_0004683,GCST001577,22705344,1,Age-related macular degeneration (CNV vs. GA)
http://www.ebi.ac.uk/efo/efo_1001492,GCST001578,22705344,9,Age-related macular degeneration (geographic atrophy)
http://www.ebi.ac.uk/efo/efo_0004694,GCST001575,22701019,0,Factor XI
http://www.ebi.ac.uk/efo/efo_0003095,GCST001576,22719876,5,Nonalcoholic fatty liver disease
http://www.ebi.ac.uk/efo/efo_0008390,GCST001573,22703881,2,Prothrombin time
http://www.ebi.ac.uk/efo/efo_0004310,GCST001574,22703881,9,Activated partial thromboplastin time
http://www.ebi.ac.uk/efo/efo_0001365,GCST001571,22694956,6,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0001359,GCST001572,22704111,6,Erectile dysfunction in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004234,GCST001572,22704111,6,Erectile dysfunction in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0000095,GCST001570,22700719,8,Chronic lymphocytic leukemia
http://www.ebi.ac.uk/efo/efo_0000692,GCST001565,22688191,15,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0000289,GCST001569,22688191,4,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0008343,GCST001566,22692763,0,Bone mineral density (sex interaction)
http://www.ebi.ac.uk/efo/efo_0003923,GCST001566,22692763,0,Bone mineral density (sex interaction)
http://www.ebi.ac.uk/efo/efo_0000692,GCST001567,22688191,13,Bipolar disorder and schizophrenia
http://www.ebi.ac.uk/efo/efo_0000289,GCST001567,22688191,13,Bipolar disorder and schizophrenia
http://www.ebi.ac.uk/efo/efo_0001669,GCST001568,22693232,0,Influenza (severity)
http://www.ebi.ac.uk/efo/efo_0000270,GCST001564,22694930,0,Asthma
http://www.ebi.ac.uk/efo/efo_0003821,GCST001563,22683712,10,Migraine
http://www.ebi.ac.uk/efo/efo_0003821,GCST001562,22678113,0,Migraine
http://www.ebi.ac.uk/efo/efo_0004207,GCST001561,22685421,4,Myopia (pathological)
http://www.ebi.ac.uk/efo/efo_0004631,GCST001560,22673963,1,Vitamin D levels
http://www.ebi.ac.uk/efo/efo_0004885,GCST001559,22683750,3,Cardiac repolarization
http://www.ebi.ac.uk/efo/efo_0004286,GCST001557,22672568,5,Venous thromboembolism
http://www.ebi.ac.uk/efo/efo_0004829,GCST001558,22664479,2,Response to irinotecan in non-small-cell lung cancer
http://www.ebi.ac.uk/efo/efo_0003060,GCST001558,22664479,2,Response to irinotecan in non-small-cell lung cancer
http://www.ebi.ac.uk/efo/efo_0004696,GCST001554,22675492,8,Sex hormone-binding globulin levels
http://www.ebi.ac.uk/efo/efo_0004908,GCST001555,22675492,5,Testosterone levels
http://www.ebi.ac.uk/efo/efo_0004697,GCST001553,22675492,8,Estradiol levels
http://www.ebi.ac.uk/efo/efo_0002618,GCST001556,22665904,0,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0004550,GCST001551,22856363,0,Amygdala reactivity
http://www.ebi.ac.uk/efo/efo_0004731,GCST001552,22661486,0,Central corneal thickness
http://www.ebi.ac.uk/efo/efo_0004805,GCST001549,22648509,5,Formal thought disorder in schizophrenia
http://www.ebi.ac.uk/efo/efo_0001360,GCST001550,22693455,12,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004191,GCST001548,22693459,8,Male-pattern baldness
http://www.ebi.ac.uk/efo/efo_0004645,GCST001547,22658931,8,Immune response to anthrax vaccine
http://purl.obolibrary.org/obo/go_0036273,GCST001545,22666496,1,Coronary heart disease event reduction (statin therapy interaction)
http://www.ebi.ac.uk/efo/efo_0001645,GCST001545,22666496,1,Coronary heart disease event reduction (statin therapy interaction)
http://www.ebi.ac.uk/efo/efo_0002508,GCST001546,22658654,5,Parkinson's disease (motor and cognition)
http://www.ebi.ac.uk/efo/efo_0001071,GCST001543,22637743,2,Lung cancer (asbestos exposure interaction)
http://www.ebi.ac.uk/efo/efo_0004806,GCST001543,22637743,2,Lung cancer (asbestos exposure interaction)
http://www.ebi.ac.uk/efo/efo_0005842,GCST001544,22634755,3,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0004365,GCST001541,22628180,0,Personality dimensions
http://www.ebi.ac.uk/efo/efo_0002608,GCST001542,22628157,4,HIV-associated dementia
http://www.ebi.ac.uk/efo/efo_0004804,GCST001540,22633400,6,Male fertility
http://www.ebi.ac.uk/efo/efo_0004803,GCST001540,22633400,6,Male fertility
http://www.ebi.ac.uk/efo/efo_0004802,GCST001540,22633400,6,Male fertility
http://www.ebi.ac.uk/efo/efo_0004318,GCST001539,22832964,5,Smoking behavior
http://www.ebi.ac.uk/efo/efo_0004645,GCST001537,22610502,10,Immune reponse to smallpox (secreted IL-12p40)
http://www.ebi.ac.uk/efo/efo_0004873,GCST001537,22610502,10,Immune reponse to smallpox (secreted IL-12p40)
http://www.ebi.ac.uk/efo/efo_0004645,GCST001538,22610502,32,Immune reponse to smallpox (secreted IFN-alpha)
http://www.ebi.ac.uk/efo/efo_0004873,GCST001538,22610502,32,Immune reponse to smallpox (secreted IFN-alpha)
http://www.ebi.ac.uk/efo/efo_0004645,GCST001536,22610502,6,Immune reponse to smallpox (secreted TNF-alpha)
http://www.ebi.ac.uk/efo/efo_0004873,GCST001536,22610502,6,Immune reponse to smallpox (secreted TNF-alpha)
http://www.ebi.ac.uk/efo/efo_0004645,GCST001532,22610502,9,Immune response to smallpox vaccine (IL-6)
http://www.ebi.ac.uk/efo/efo_0004873,GCST001532,22610502,9,Immune response to smallpox vaccine (IL-6)
http://www.ebi.ac.uk/efo/efo_0004645,GCST001533,22610502,13,Immune reponse to smallpox (secreted IL-1beta)
http://www.ebi.ac.uk/efo/efo_0004873,GCST001533,22610502,13,Immune reponse to smallpox (secreted IL-1beta)
http://www.ebi.ac.uk/efo/efo_0004645,GCST001534,22610502,6,Immune reponse to smallpox (secreted IL-10)
http://www.ebi.ac.uk/efo/efo_0004873,GCST001534,22610502,6,Immune reponse to smallpox (secreted IL-10)
http://www.ebi.ac.uk/efo/efo_0004645,GCST001535,22610502,17,Immune reponse to smallpox (secreted IL-2)
http://www.ebi.ac.uk/efo/efo_0004873,GCST001535,22610502,17,Immune reponse to smallpox (secreted IL-2)
http://www.ebi.ac.uk/efo/efo_0005039,GCST001530,22745009,12,Hippocampal atrophy
http://www.ebi.ac.uk/efo/efo_0004825,GCST001531,22832960,16,Temperament
http://purl.obolibrary.org/obo/go_0036276,GCST001528,22584459,1,Response to antidepressants
http://www.ebi.ac.uk/efo/efo_0000249,GCST001529,22832961,8,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004340,GCST001526,22581228,20,Fasting blood insulin (BMI interaction)
http://www.ebi.ac.uk/efo/efo_0004466,GCST001526,22581228,20,Fasting blood insulin (BMI interaction)
http://www.ebi.ac.uk/efo/efo_0004465,GCST005186,22581228,33,Fasting blood glucose
http://www.ebi.ac.uk/efo/efo_0004466,GCST005185,22581228,10,Fasting blood insulin
http://www.ebi.ac.uk/efo/efo_0004340,GCST001527,22581228,33,Fasting blood glucose (BMI interaction)
http://www.ebi.ac.uk/efo/efo_0004465,GCST001527,22581228,33,Fasting blood glucose (BMI interaction)
http://www.ebi.ac.uk/efo/efo_0004766,GCST001521,22589738,39,Subcutaneous adipose tissue
http://www.ebi.ac.uk/efo/efo_0004765,GCST001523,22589738,45,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004340,GCST001523,22589738,45,Visceral adipose tissue adjusted for BMI
http://www.ebi.ac.uk/efo/efo_0004765,GCST001524,22589738,42,Visceral adipose tissue/subcutaneous adipose tissue ratio
http://www.ebi.ac.uk/efo/efo_0004765,GCST001525,22589738,40,Visceral fat
http://www.ebi.ac.uk/efo/efo_0007890,GCST001522,22589742,1,Pericardial fat
http://purl.obolibrary.org/obo/go_1901556,GCST001520,22566498,20,Response to angiotensin II receptor blocker therapy
http://www.ebi.ac.uk/efo/efo_0000537,GCST001520,22566498,20,Response to angiotensin II receptor blocker therapy
http://www.ebi.ac.uk/efo/efo_0004827,GCST001511,22566634,10,Economic and political preferences (time)
http://www.ebi.ac.uk/efo/efo_0004827,GCST001515,22566634,15,Economic and political preferences (immigration/crime)
http://www.ebi.ac.uk/efo/efo_0004827,GCST001514,22566634,12,Economic and political preferences (feminism/equality)
http://www.ebi.ac.uk/efo/efo_0004827,GCST001513,22566634,7,Economic and political preferences (fairness)
http://www.ebi.ac.uk/efo/efo_0004827,GCST001512,22566634,17,Economic and political preferences (environmentalism)
http://purl.obolibrary.org/obo/go_1901556,GCST001518,22566498,5,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
http://www.ebi.ac.uk/efo/efo_0000537,GCST001518,22566498,5,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
http://www.ebi.ac.uk/efo/efo_0004567,GCST001517,22566560,1,Antipsychotic drug-induced weight gain
http://www.ebi.ac.uk/efo/efo_0002506,GCST001516,22566624,1,Osteoarthritis
http://www.ebi.ac.uk/efo/efo_0004827,GCST001519,22566634,17,Economic and political preferences
http://www.ebi.ac.uk/efo/efo_0004208,GCST001509,22561518,14,Vitiligo
http://www.ebi.ac.uk/efo/efo_0000685,GCST001510,22569225,8,Response to TNF-alpha inhibitors in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004653,GCST001510,22569225,8,Response to TNF-alpha inhibitors in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000270,GCST001508,22561531,7,Asthma
http://www.ebi.ac.uk/efo/efo_0003924,GCST001507,22556244,1,Hair color
http://www.ebi.ac.uk/efo/efo_0004800,GCST001503,22554406,8,Electroencephalographic traits in alcoholism
http://www.ebi.ac.uk/efo/efo_0003829,GCST001503,22554406,8,Electroencephalographic traits in alcoholism
http://www.ebi.ac.uk/efo/efo_0004695,GCST001506,22570627,2,Intraocular pressure
http://www.orpha.net/ordo/orphanet_3389,GCST001504,22551897,0,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0003885,GCST001505,22570697,1,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0004591,GCST001502,22560479,5,Asthma (childhood onset)
http://www.ebi.ac.uk/efo/efo_0004985,GCST001501,22550155,6,Platelet thrombus formation
http://www.ebi.ac.uk/efo/efo_0007615,GCST001501,22550155,6,Platelet thrombus formation
http://www.orpha.net/ordo/orphanet_654,GCST001500,22544364,7,Wilms tumor
http://www.ebi.ac.uk/efo/efo_0000275,GCST001499,22544366,10,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0004190,GCST001498,22605921,0,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0004568,GCST001496,22558069,5,Non-albumin protein levels
http://www.orpha.net/ordo/orphanet_232,GCST001497,22558097,1,Cholelithiasis-related traits in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0004799,GCST001497,22558097,1,Cholelithiasis-related traits in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0004570,GCST001497,22558097,1,Cholelithiasis-related traits in sickle cell anemia
http://www.ebi.ac.uk/efo/efo_0000270,GCST001495,22538805,1,Asthma
http://www.ebi.ac.uk/efo/efo_0004190,GCST001493,22570617,4,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0000279,GCST001494,22541561,1,Non-obstructive azoospermia
http://www.ebi.ac.uk/efo/efo_0004645,GCST001491,22542470,37,Immune response to smallpox vaccine (IL-6)
http://www.ebi.ac.uk/efo/efo_0004300,GCST001492,22533364,0,Longevity
http://www.ebi.ac.uk/efo/efo_0003768,GCST001490,22524403,1,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0000305,GCST001489,22532574,1,Percent mammographic density
http://www.ebi.ac.uk/efo/efo_0004274,GCST001488,22513714,0,Gout
http://www.ebi.ac.uk/efo/efo_0004465,GCST001486,22508271,3,Fasting plasma glucose
http://www.ebi.ac.uk/efo/efo_0004296,GCST001487,22494929,4,Thyroid function
http://www.ebi.ac.uk/efo/efo_0004577,GCST001484,22504419,3,Head circumference (infant)
http://www.ebi.ac.uk/efo/efo_0007785,GCST007691,22504420,35,Femoral neck bone mineral density
http://www.ebi.ac.uk/efo/efo_0004464,GCST001481,22504417,2,Brain structure
http://www.ebi.ac.uk/efo/efo_0004886,GCST001483,22504418,2,Intracranial volume
http://www.ebi.ac.uk/efo/efo_0003923,GCST001482,22504420,34,Lumbar spine bone mineral density
http://www.ebi.ac.uk/efo/efo_0005035,GCST001485,22504421,5,Hippocampal volume
http://www.ebi.ac.uk/efo/efo_0001359,GCST001479,22526605,0,Type 1 diabetes autoantibodies
http://www.ebi.ac.uk/efo/efo_0004866,GCST001479,22526605,0,Type 1 diabetes autoantibodies
http://www.ebi.ac.uk/efo/efo_0004744,GCST001480,22503698,0,Oral cancers (chewing tobacco related)
http://www.ebi.ac.uk/efo/efo_0003868,GCST001480,22503698,0,Oral cancers (chewing tobacco related)
http://www.ebi.ac.uk/efo/efo_0004739,GCST001478,22511988,1,Circulating cell-free DNA
http://www.ebi.ac.uk/efo/efo_0004714,GCST001477,22509378,3,Sexual dysfunction (female)
http://www.ebi.ac.uk/efo/efo_0000685,GCST001476,22491018,31,Response to tocilizumab in rheumatoid arthritis
http://purl.obolibrary.org/obo/go_0042493,GCST001476,22491018,31,Response to tocilizumab in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0001073,GCST001475,22484627,5,Obesity
http://www.ebi.ac.uk/efo/efo_0004705,GCST001474,22493691,19,Hypothyroidism
http://www.ebi.ac.uk/efo/efo_0000676,GCST001473,22482804,4,Crohn's disease and psoriasis
http://www.ebi.ac.uk/efo/efo_0000384,GCST001473,22482804,4,Crohn's disease and psoriasis
http://www.ebi.ac.uk/efo/efo_0004458,GCST001472,22492993,1,C-reactive protein
http://www.ebi.ac.uk/efo/efo_0004776,GCST001471,22488850,8,Alcohol and nicotine co-dependence
http://www.ebi.ac.uk/efo/efo_0000519,GCST001470,22472174,1,Glioblastoma
http://www.ebi.ac.uk/efo/efo_0003761,GCST001469,22472876,5,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0004608,GCST001468,22466613,0,Cystic fibrosis (meconium ileus)
http://www.ebi.ac.uk/efo/efo_0004589,GCST001462,22479309,1,Brachial circumference
http://www.ebi.ac.uk/efo/efo_0000537,GCST001467,22479346,0,Hypertension
http://www.ebi.ac.uk/efo/efo_0004712,GCST001464,22455414,0,Podoconiosis
http://www.ebi.ac.uk/efo/efo_0004502,GCST001465,22479202,21,Adiponectin levels
http://www.ebi.ac.uk/efo/efo_0004502,GCST001463,22479202,10,Adiponectin levels
http://www.ebi.ac.uk/efo/efo_0003884,GCST001466,22479191,2,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0001360,GCST001461,22456796,4,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000253,GCST001460,22470424,2,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0003885,GCST001459,22457343,1,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0000305,GCST001457,22452962,1,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004609,GCST001458,22479419,2,Schizophrenia (treatment resistant)
http://www.ebi.ac.uk/efo/efo_0000685,GCST001454,22446963,15,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004246,GCST001456,22446961,6,Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0004246,GCST001455,22446962,5,Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0004714,GCST001453,22445761,5,Sexual dysfunction (SSRI/SNRI-related)
http://www.ebi.ac.uk/efo/efo_0004190,GCST001451,22419738,3,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0004719,GCST001452,22437316,0,Pemphigus vulgaris
http://purl.obolibrary.org/obo/go_0033273,GCST001450,22437554,8,Response to Vitamin E supplementation
http://www.ebi.ac.uk/efo/efo_0000249,GCST001449,22430674,1,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004230,GCST001447,22426144,0,Endometrial cancer
http://www.ebi.ac.uk/efo/efo_0004340,GCST001448,22446040,3,Body mass index
http://www.ebi.ac.uk/efo/efo_0004314,GCST001444,22424883,39,Pulmonary function decline
http://www.ebi.ac.uk/efo/efo_0004713,GCST001444,22424883,39,Pulmonary function decline
http://www.ebi.ac.uk/efo/efo_0002508,GCST001445,22438815,6,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0004641,GCST001446,22425255,2,White matter integrity
http://www.orpha.net/ordo/orphanet_139039,GCST001442,22419666,17,Orofacial clefts
http://www.ebi.ac.uk/efo/efo_0000668,GCST001443,22432041,0,Preeclampsia
http://www.ebi.ac.uk/efo/efo_0004190,GCST001441,22428042,1,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0004574,GCST001440,22417934,2,Body mass index and cholesterol (psychopharmacological treatment)
http://purl.obolibrary.org/obo/go_0042493,GCST001440,22417934,2,Body mass index and cholesterol (psychopharmacological treatment)
http://www.ebi.ac.uk/efo/efo_0004340,GCST001440,22417934,2,Body mass index and cholesterol (psychopharmacological treatment)
http://www.ebi.ac.uk/efo/efo_0004584,GCST001439,22423221,3,Mean platelet volume
http://www.ebi.ac.uk/efo/efo_0004309,GCST008047,22423221,10,Platelet count
http://www.orpha.net/ordo/orphanet_79102,GCST001437,22399142,1,Thyrotoxic hypokalemic periodic paralysis
http://www.ebi.ac.uk/efo/efo_0000384,GCST001438,22412388,17,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000195,GCST001436,22399527,22,Metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0004640,GCST001435,22403646,1,Haptoglobin levels
http://www.ebi.ac.uk/efo/efo_0004585,GCST001434,22391508,0,Naphthyl-keratin adduct levels
http://www.ebi.ac.uk/efo/efo_0004607,GCST001433,22387998,2,Duodenal ulcer
http://www.ebi.ac.uk/efo/efo_0002508,GCST001430,22451204,17,Parkinson's disease
http://purl.obolibrary.org/obo/go_0036277,GCST001431,22379998,12,Adverse response to lamotrigine and phenytoin
http://www.ebi.ac.uk/efo/efo_0004253,GCST001432,22396660,3,Nephrolithiasis
http://www.ebi.ac.uk/efo/efo_0004315,GCST001429,22613542,0,Drinking behavior
http://www.ebi.ac.uk/efo/efo_0004337,GCST001428,22449649,21,Intelligence
http://www.ebi.ac.uk/efo/efo_0003768,GCST001427,22377092,0,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0001663,GCST001426,22367438,0,Prostate cancer (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0004620,GCST001424,22367966,6,Vitamin B12 levels
http://www.ebi.ac.uk/efo/efo_0000537,GCST001423,22384028,3,Hypertension
http://purl.obolibrary.org/obo/go_0036273,GCST001425,22368281,1,Response to statin therapy
http://www.ebi.ac.uk/efo/efo_0000305,GCST001420,22383897,3,Breast cancer
http://purl.obolibrary.org/obo/go_0007608,GCST001422,22362865,0,Odorant perception
http://www.ebi.ac.uk/efo/efo_0004880,GCST001421,22383894,2,Arsenic metabolism
http://www.ebi.ac.uk/efo/efo_0004782,GCST001419,22365631,13,Temperament (bipolar disorder)
http://www.ebi.ac.uk/efo/efo_0004365,GCST001419,22365631,13,Temperament (bipolar disorder)
http://www.ebi.ac.uk/efo/efo_0000289,GCST001419,22365631,13,Temperament (bipolar disorder)
http://www.ebi.ac.uk/efo/efo_0004220,GCST001418,22497812,1,Lipid levels in hepatitis C treatment
http://www.ebi.ac.uk/efo/efo_0004611,GCST001418,22497812,1,Lipid levels in hepatitis C treatment
http://www.ebi.ac.uk/efo/efo_0002609,GCST001417,22354554,4,Arthritis (juvenile idiopathic)
http://www.ebi.ac.uk/efo/efo_0004340,GCST001415,22344219,7,Body mass index
http://www.ebi.ac.uk/efo/efo_0004340,GCST001416,22344221,10,Body mass index (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0004639,GCST001414,22359512,25,Phospholipid levels (plasma)
http://www.ebi.ac.uk/efo/efo_0004743,GCST001412,22341974,1,Facial morphology
http://www.ebi.ac.uk/efo/efo_0008381,GCST001411,22343285,1,Occipital cortical area (total cortical area interaction)
http://www.ebi.ac.uk/efo/efo_0004771,GCST001411,22343285,1,Occipital cortical area (total cortical area interaction)
http://www.ebi.ac.uk/efo/efo_0004622,GCST001413,22359512,10,Sphingolipid levels
http://www.ebi.ac.uk/efo/efo_0004340,GCST001409,22333899,0,Body mass index (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0004644,GCST001410,22342860,1,Cardiac repolarization
http://purl.obolibrary.org/obo/go_0036273,GCST001408,22331829,8,Response to statins (LDL cholesterol change)
http://www.ebi.ac.uk/efo/efo_0007804,GCST001408,22331829,8,Response to statins (LDL cholesterol change)
http://www.ebi.ac.uk/efo/efo_0000174,GCST001407,22327514,3,Ewing sarcoma
http://www.ebi.ac.uk/efo/efo_0004266,GCST001406,22321639,0,Premature ovarian failure
http://www.ebi.ac.uk/efo/efo_0004606,GCST001404,22318345,5,Gallbladder cancer
http://www.ebi.ac.uk/efo/efo_0000537,GCST001405,22322875,3,Hypertension risk in short sleep duration
http://www.ebi.ac.uk/efo/efo_0004807,GCST001405,22322875,3,Hypertension risk in short sleep duration
http://purl.obolibrary.org/obo/go_0042493,GCST001402,22310353,8,Treatment response for severe sepsis
http://www.ebi.ac.uk/efo/efo_0001645,GCST001401,22319020,5,Coronary heart disease
http://purl.obolibrary.org/obo/go_0036275,GCST001403,22310351,0,Fluorouracil treatment response in colorectal cancer
http://www.ebi.ac.uk/efo/efo_0004707,GCST001399,22306654,5,Infantile hypertrophic pyloric stenosis
http://www.orpha.net/ordo/orphanet_3389,GCST001398,22306650,1,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0000712,GCST001400,22306652,1,Stroke
http://www.ebi.ac.uk/efo/efo_0001359,GCST001394,22293688,2,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0000384,GCST001396,22293688,1,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0001360,GCST001397,22293688,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003888,GCST001395,22420046,0,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0004541,GCST001393,22290723,1,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004725,GCST001391,22286219,13,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004529,GCST001392,22286219,18,Lipid metabolism phenotypes
http://purl.obolibrary.org/obo/go_0036272,GCST001390,22293537,2,Response to gemcitabine in pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0002618,GCST001390,22293537,2,Response to gemcitabine in pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0004587,GCST001389,22286170,2,Lymphocyte counts
http://www.ebi.ac.uk/efo/efo_0003870,GCST001388,22286173,4,Intracranial aneurysm
http://www.ebi.ac.uk/efo/efo_0000183,GCST001387,22286212,4,Hodgkin's lymphoma
http://www.ebi.ac.uk/efo/efo_0002690,GCST001384,22291604,2,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004304,GCST001385,22291609,7,Inflammatory biomarkers
http://www.ebi.ac.uk/efo/efo_0004810,GCST001385,22291609,7,Inflammatory biomarkers
http://www.ebi.ac.uk/efo/efo_0004458,GCST001385,22291609,7,Inflammatory biomarkers
http://www.ebi.ac.uk/efo/efo_0004749,GCST001385,22291609,7,Inflammatory biomarkers
http://www.ebi.ac.uk/efo/efo_0004599,GCST001386,22282500,0,Acute graft versus host disease
http://www.ebi.ac.uk/efo/efo_0004610,GCST001383,22295056,0,Acute lung injury
http://www.ebi.ac.uk/efo/efo_0002892,GCST001382,22267200,3,Thyroid cancer
http://www.ebi.ac.uk/efo/efo_0004704,GCST001381,22267201,19,Menopause (age at onset)
http://www.orpha.net/ordo/orphanet_355,GCST001380,22388998,3,Gaucher disease severity
http://www.ebi.ac.uk/efo/efo_0004300,GCST001379,22279548,0,Longevity
http://www.ebi.ac.uk/efo/efo_0004503,GCST001378,22443383,9,Hemostatic factors and hematological phenotypes
http://www.orpha.net/ordo/orphanet_3389,GCST001377,22239941,0,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0004269,GCST001376,22247754,2,Life threatening arrhythmia
http://www.ebi.ac.uk/efo/efo_0004593,GCST001375,22233651,3,Diabetes (gestational)
http://www.ebi.ac.uk/efo/efo_0004761,GCST001374,22229870,6,Uric acid levels
http://www.ebi.ac.uk/efo/efo_0000482,GCST001373,22232737,3,Breast cancer (survival)
http://www.ebi.ac.uk/efo/efo_0000714,GCST001373,22232737,3,Breast cancer (survival)
http://www.ebi.ac.uk/efo/efo_0000305,GCST001373,22232737,3,Breast cancer (survival)
http://www.ebi.ac.uk/efo/efo_0000249,GCST001372,22245343,2,Alzheimer's disease
http://purl.obolibrary.org/obo/go_1901557,GCST001371,22228203,19,Inflammatory biomarkers
http://www.ebi.ac.uk/efo/efo_0004828,GCST001370,22219177,51,Prostate cancer (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0001663,GCST001370,22219177,51,Prostate cancer (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0001360,GCST001369,22238593,4,Type 2 diabetes
http://purl.obolibrary.org/obo/go_0097327,GCST001368,22864933,22,Capecitabine sensitivity
http://www.ebi.ac.uk/efo/efo_0004720,GCST001366,22210626,11,Prion diseases
http://www.ebi.ac.uk/efo/efo_0004530,GCST001367,22171074,3,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004750,GCST006102,22205395,15,Interleukin-10 levels
http://www.ebi.ac.uk/efo/efo_0004754,GCST006104,22205395,7,Interleukin-1-receptor antagonist levels
http://www.ebi.ac.uk/efo/efo_0004810,GCST006103,22205395,20,Interleukin-6 levels
http://www.ebi.ac.uk/efo/efo_0004634,GCST001365,22216198,8,Anticoagulant levels
http://www.ebi.ac.uk/efo/efo_0000279,GCST001362,22197933,4,Non-obstructive azoospermia
http://www.ebi.ac.uk/efo/efo_0004194,GCST001364,22197929,9,IgA nephropathy
http://www.ebi.ac.uk/efo/efo_0000274,GCST001363,22197932,6,Atopic dermatitis
http://www.ebi.ac.uk/efo/efo_0003912,GCST001361,22199011,2,Ankle-brachial index
http://www.ebi.ac.uk/efo/efo_0000289,GCST001359,22205951,3,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000270,GCST001360,22188591,0,Asthma
http://www.ebi.ac.uk/efo/efo_0000289,GCST001358,22182935,5,Bipolar disorder
http://purl.obolibrary.org/obo/go_0097327,GCST001357,22180457,1,Response to tamoxifen in breast cancer
http://www.ebi.ac.uk/efo/efo_0004274,GCST001356,22179738,36,Gout
http://www.ebi.ac.uk/efo/efo_0004326,GCST001354,22174390,2,Heart rate variability traits
http://www.ebi.ac.uk/efo/efo_0004999,GCST005046,21908519,41,N-glycan levels
http://www.ebi.ac.uk/efo/efo_0003778,GCST001355,22170493,2,Psoriatic arthritis
http://www.ebi.ac.uk/efo/efo_0006319,GCST001352,22174851,14,HIV-1 viral setpoint
http://www.ebi.ac.uk/efo/efo_0000180,GCST001353,22174851,9,HIV-1 susceptibility
http://www.orpha.net/ordo/orphanet_391311,GCST001353,22174851,9,HIV-1 susceptibility
http://www.ebi.ac.uk/efo/efo_0002618,GCST001350,22158540,11,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0001360,GCST001351,22158537,10,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004577,GCST001349,22156575,0,Brain development
http://www.ebi.ac.uk/efo/efo_0000182,GCST001348,22174901,0,Hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0004723,GCST001347,22144573,3,Coronary artery calcification
http://purl.obolibrary.org/obo/go_0036272,GCST001346,22142827,3,Response to gemcitabine in pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0002618,GCST001346,22142827,3,Response to gemcitabine in pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0003898,GCST001345,22138694,5,Ankylosing spondylitis
http://www.ebi.ac.uk/efo/efo_0004893,GCST001344,22140272,0,Testicular dysgenesis syndrome
http://www.ebi.ac.uk/efo/efo_0001663,GCST001338,22130093,2,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0000180,GCST001343,21897333,17,Fat distribution (HIV)
http://www.ebi.ac.uk/efo/efo_0004341,GCST001343,21897333,17,Fat distribution (HIV)
http://www.ebi.ac.uk/efo/efo_0000249,GCST001342,22159054,11,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0003885,GCST001341,22190364,19,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0004710,GCST001340,22105264,0,Pelvic organ prolapse
http://purl.obolibrary.org/obo/hp_0000483,GCST001339,22144915,6,Corneal astigmatism
http://www.ebi.ac.uk/efo/efo_0004226,GCST001334,22137330,6,Creutzfeldt-Jakob disease (variant)
http://www.ebi.ac.uk/efo/efo_0004309,GCST001337,22139419,56,Platelet count
http://www.ebi.ac.uk/efo/efo_0004584,GCST001335,22139419,29,Mean platelet volume
http://www.ebi.ac.uk/efo/efo_0004703,GCST001336,22131368,0,Menarche and menopause (age at onset)
http://www.ebi.ac.uk/efo/efo_0004704,GCST001336,22131368,0,Menarche and menopause (age at onset)
http://www.ebi.ac.uk/efo/efo_0004570,GCST001333,22118420,0,Bilirubin levels
http://www.ebi.ac.uk/efo/efo_0004323,GCST001332,22126837,2,Cognitive function
http://www.ebi.ac.uk/efo/efo_0001378,GCST001331,22120009,3,Multiple myeloma
http://www.ebi.ac.uk/efo/efo_0000474,GCST001329,22116939,1,Epilepsy
http://www.ebi.ac.uk/efo/efo_0004770,GCST001330,22116950,7,Ovarian reserve
http://www.ebi.ac.uk/efo/efo_0004718,GCST001328,22116812,0,Vascular dementia
http://www.ebi.ac.uk/efo/efo_0004874,GCST001327,22105620,0,Memory performance
http://www.ebi.ac.uk/efo/efo_0001360,GCST001326,22101970,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004220,GCST001325,22095909,9,Response to hepatitis C treatment
http://www.ebi.ac.uk/efo/efo_0004570,GCST001324,22085899,9,Bilirubin levels
http://www.ebi.ac.uk/efo/efo_0004708,GCST001323,22086417,2,Nodular sclerosis Hodgkin lymphoma
http://purl.obolibrary.org/obo/hp_0100543,GCST004371,22833209,3,Rate of cognitive decline in mild cognitive impairment (time interaction)
http://www.ebi.ac.uk/efo/efo_0007710,GCST004371,22833209,3,Rate of cognitive decline in mild cognitive impairment (time interaction)
http://www.ebi.ac.uk/efo/efo_0008336,GCST004371,22833209,3,Rate of cognitive decline in mild cognitive impairment (time interaction)
http://www.ebi.ac.uk/efo/efo_0004246,GCST001322,22081228,2,Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0004777,GCST001319,22072270,0,Alcohol withdrawal symptoms
http://www.ebi.ac.uk/efo/efo_0000220,GCST001320,22076464,31,Acute lymphoblastic leukemia (childhood)
http://www.ebi.ac.uk/efo/efo_0000341,GCST001321,22080838,4,Chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005139,GCST001318,22075249,1,Serum ceruloplasmin levels
http://www.ebi.ac.uk/efo/efo_0004579,GCST001316,22075330,11,IgE levels
http://www.ebi.ac.uk/efo/efo_0004724,GCST001317,22068335,1,Aortic stiffness
http://www.ebi.ac.uk/efo/efo_0004511,GCST001315,22087292,2,Femoral neck bone geometry
http://www.ebi.ac.uk/efo/efo_0004502,GCST001314,22065538,1,Adiponectin levels
http://www.ebi.ac.uk/efo/efo_0001060,GCST005523,22057235,43,Celiac disease
http://www.ebi.ac.uk/efo/efo_0003829,GCST001313,22064162,8,Depression and alcohol dependence
http://www.ebi.ac.uk/efo/efo_0004214,GCST001312,22055160,1,Abdominal aortic aneurysm
http://www.ebi.ac.uk/efo/efo_0004362,GCST001311,22054870,1,Cognitive decline
http://www.ebi.ac.uk/efo/efo_0003956,GCST001303,22036096,9,IgE grass sensitization
http://www.ebi.ac.uk/efo/efo_0003956,GCST001310,22036096,9,Allergic rhinitis
http://www.ebi.ac.uk/efo/efo_0000270,GCST001306,22295569,0,Asthma
http://www.ebi.ac.uk/efo/efo_0004532,GCST001307,22010049,4,Gamma glutamyl transferase levels
http://purl.obolibrary.org/obo/go_0036276,GCST001308,22041458,22,Response to anti-depressant treatment in major depressive disorder
http://www.ebi.ac.uk/efo/efo_0000270,GCST001309,22051697,0,Asthma
http://www.ebi.ac.uk/efo/efo_0004864,GCST001304,22044751,8,Renal sinus fat
http://www.ebi.ac.uk/efo/efo_0000178,GCST001300,22037551,2,Gastric cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST001298,22037553,1,Breast cancer
http://www.ebi.ac.uk/efo/efo_0000692,GCST001299,22037552,2,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004308,GCST001302,22037903,4,White blood cell count
http://www.ebi.ac.uk/efo/efo_0000692,GCST001301,22037555,2,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004191,GCST001297,22032556,2,Male-pattern baldness
http://www.ebi.ac.uk/efo/efo_0004192,GCST001295,22027810,0,Alopecia areata
http://www.ebi.ac.uk/efo/efo_0004913,GCST001296,22030708,0,Suicidal ideation
http://www.ebi.ac.uk/efo/efo_0004298,GCST001294,22029572,0,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0001054,GCST001292,22019778,4,Leprosy
http://www.ebi.ac.uk/efo/efo_0004273,GCST001293,22019779,1,Scoliosis
http://www.ebi.ac.uk/efo/efo_0004339,GCST001290,22021425,8,Height
http://www.ebi.ac.uk/efo/efo_0004647,GCST001291,22020760,3,Response to platinum-based agents
http://www.ebi.ac.uk/efo/efo_0004574,GCST001289,22028671,1,Lipid traits
http://www.ebi.ac.uk/efo/efo_0005409,GCST001288,22013104,5,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004340,GCST001288,22013104,5,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0001073,GCST001288,22013104,5,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0003888,GCST001287,22012869,2,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0000681,GCST001283,22010048,3,Renal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0007911,GCST006796,22833195,0,Excitement-seeking behaviour
http://www.ebi.ac.uk/efo/efo_0000249,GCST001280,22005931,13,Alzheimer's disease (age of onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST001280,22005931,13,Alzheimer's disease (age of onset)
http://www.ebi.ac.uk/efo/efo_0004266,GCST001284,21989058,1,Premature ovarian failure
http://www.ebi.ac.uk/efo/efo_0003829,GCST001281,22004471,6,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0000249,GCST001282,22005930,8,Psychosis in Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0005940,GCST001282,22005930,8,Psychosis in Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000249,GCST001285,22005930,11,Psychosis and Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0005940,GCST001285,22005930,11,Psychosis and Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004318,GCST001286,22006218,6,Smoking behavior
http://www.ebi.ac.uk/efo/efo_0002690,GCST001279,22004975,0,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004735,GCST001275,22001757,4,Liver enzyme levels (alanine transaminase)
http://www.ebi.ac.uk/efo/efo_0004532,GCST001277,22001757,26,Liver enzyme levels (gamma-glutamyl transferase)
http://www.ebi.ac.uk/efo/efo_0004533,GCST001276,22001757,14,Liver enzyme levels (alkaline phosphatase)
http://www.ebi.ac.uk/efo/efo_0004227,GCST001278,22001756,4,Dengue shock syndrome
http://www.ebi.ac.uk/efo/efo_0004746,GCST001273,22003152,7,Lipoprotein-associated phospholipase A2 activity and mass
http://www.orpha.net/ordo/orphanet_156071,GCST001274,22003120,0,Corneal structure
http://purl.obolibrary.org/obo/go_0009615,GCST001272,21993531,9,Cytomegalovirus antibody response
http://www.ebi.ac.uk/efo/efo_0004325,GCST001270,21996601,0,Blood pressure
http://purl.obolibrary.org/obo/go_0097332,GCST001271,21990027,1,Response to antipsychotic therapy (extrapyramidal side effects)
http://www.ebi.ac.uk/efo/efo_0000756,GCST001266,21983785,2,Melanoma
http://www.ebi.ac.uk/efo/efo_0004761,GCST001269,21983786,5,Serum uric acid levels
http://www.ebi.ac.uk/efo/efo_0004274,GCST001268,21983786,3,Gout
http://www.ebi.ac.uk/efo/efo_0000756,GCST001267,21983787,10,Melanoma
http://www.ebi.ac.uk/efo/efo_0004705,GCST001265,21981779,1,Hypothyroidism
http://www.ebi.ac.uk/efo/efo_0004611,GCST001262,21977987,0,LDL cholesterol
http://www.orpha.net/ordo/orphanet_156071,GCST001261,21979947,5,Corneal structure
http://www.ebi.ac.uk/efo/efo_0004730,GCST001264,21998597,2,Testosterone levels
http://www.ebi.ac.uk/efo/efo_0004339,GCST001263,21998595,33,Height
http://www.ebi.ac.uk/efo/efo_0001645,GCST001260,21971053,3,Coronary heart disease
http://purl.obolibrary.org/obo/go_0010226,GCST001259,21961650,0,Response to lithium treatment in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0001075,GCST001258,21964575,1,Ovarian cancer
http://www.ebi.ac.uk/efo/efo_0004197,GCST001257,22004137,1,Hepatitis B
http://www.ebi.ac.uk/efo/efo_0004889,GCST001256,21980348,0,Postoperative ventricular dysfunction
http://www.ebi.ac.uk/efo/efo_0001359,GCST001255,21980299,9,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0003829,GCST001254,21956439,3,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0004286,GCST001253,21980494,4,Venous thromboembolism
http://purl.obolibrary.org/obo/go_0051384,GCST001252,21991891,0,Asthma treatment response
http://www.ebi.ac.uk/efo/efo_0003892,GCST001248,21946350,18,Pulmonary function
http://www.ebi.ac.uk/efo/efo_0004193,GCST001250,21946351,1,Basal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0003892,GCST001251,21946350,16,Pulmonary function
http://www.ebi.ac.uk/efo/efo_0004508,GCST001249,21947420,0,Spine bone size
http://www.ebi.ac.uk/efo/efo_0004736,GCST001247,21943158,19,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0004571,GCST001247,21943158,19,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0004530,GCST001247,21943158,19,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0004459,GCST001247,21943158,19,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0004532,GCST001247,21943158,19,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0004611,GCST001247,21943158,19,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0004458,GCST001247,21943158,19,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0004761,GCST001247,21943158,19,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0004612,GCST001247,21943158,19,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0000712,GCST001246,21940970,0,Stroke
http://www.ebi.ac.uk/efo/efo_0000756,GCST001245,21926416,1,Melanoma
http://www.ebi.ac.uk/efo/efo_0000712,GCST001243,21957438,0,Stroke
http://www.ebi.ac.uk/efo/efo_0003819,GCST001244,21940522,3,Dental caries
http://www.ebi.ac.uk/efo/efo_0000289,GCST001241,21926972,18,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000692,GCST001242,21926974,25,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0001073,GCST001240,21935397,4,Obesity (extreme)
http://www.ebi.ac.uk/efo/efo_0004276,GCST001239,21912425,1,Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
http://www.ebi.ac.uk/efo/efo_0004775,GCST001239,21912425,1,Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
http://www.ebi.ac.uk/efo/efo_0004532,GCST001234,21909109,7,Gamma glutamyl transpeptidase
http://www.ebi.ac.uk/efo/efo_0006336,GCST001228,21909115,19,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004282,GCST001229,21909107,1,Thoracic aortic aneurysms and dissections
http://www.ebi.ac.uk/efo/efo_0004530,GCST001230,21909109,5,Triglycerides
http://www.ebi.ac.uk/efo/efo_0003914,GCST001231,21909108,11,Carotid intima media thickness
http://www.ebi.ac.uk/efo/efo_0001365,GCST001232,21909106,2,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0004535,GCST001233,21909109,18,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004725,GCST001233,21909109,18,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004735,GCST001233,21909109,18,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST001233,21909109,18,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004465,GCST001233,21909109,18,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004761,GCST001233,21909109,18,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0000537,GCST001238,21909115,11,Hypertension
http://www.ebi.ac.uk/efo/efo_0006335,GCST001227,21909115,20,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0004325,GCST001235,21909110,14,Blood pressure
http://www.ebi.ac.uk/efo/efo_0004612,GCST001237,21909109,9,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004325,GCST001236,21909110,27,Blood pressure
http://www.ebi.ac.uk/efo/efo_0004510,GCST001225,21896673,1,HPV seropositivity
http://www.ebi.ac.uk/efo/efo_0000270,GCST001226,21907864,4,Asthma
http://www.ebi.ac.uk/efo/efo_0004540,GCST001223,21912186,0,Chronic fatigue syndrome
http://www.ebi.ac.uk/efo/efo_0000305,GCST001224,21908515,2,Breast cancer
http://purl.obolibrary.org/obo/go_0044691,GCST001221,21931568,4,Permanent tooth development
http://www.ebi.ac.uk/efo/efo_0004736,GCST001222,21900944,1,Aspartate aminotransferase levels
http://www.ebi.ac.uk/efo/efo_0004237,GCST001219,21900946,7,Graves' disease
http://www.ebi.ac.uk/efo/efo_0004725,GCST001220,21931564,3,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004614,GCST001218,21900290,4,Lp (a) levels
http://www.ebi.ac.uk/efo/efo_0004725,GCST001217,21886157,37,Metabolic traits
http://www.ebi.ac.uk/efo/efo_0004330,GCST001215,21876539,4,Coffee consumption
http://www.ebi.ac.uk/efo/efo_0004857,GCST001216,21878437,2,Retinol levels
http://www.ebi.ac.uk/efo/efo_0004224,GCST001214,21878436,1,Coronary restenosis
http://www.ebi.ac.uk/efo/efo_0001360,GCST001213,21874001,6,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003829,GCST001211,21876473,1,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0004467,GCST001212,21873549,10,Proinsulin levels
http://www.ebi.ac.uk/efo/efo_0003060,GCST001210,21866343,1,Non-small cell lung cancer
http://www.ebi.ac.uk/efo/efo_0002506,GCST001209,21871595,1,Osteoarthritis
http://www.ebi.ac.uk/efo/efo_0002614,GCST001208,21901158,14,Insulin resistance/response
http://www.ebi.ac.uk/efo/efo_0004571,GCST001207,21862451,3,Butyrylcholinesterase levels
http://www.ebi.ac.uk/efo/efo_0004761,GCST001206,21886828,0,Uric acid levels (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0002508,GCST001205,21876681,0,Parkinson's disease (coffee consumption interaction)
http://www.ebi.ac.uk/efo/efo_0004330,GCST001205,21876681,0,Parkinson's disease (coffee consumption interaction)
http://www.ebi.ac.uk/efo/efo_0000685,GCST001203,21844665,1,Rheumatoid arthritis
http://purl.obolibrary.org/obo/go_0072718,GCST001201,21844884,21,Response to platinum-based chemotherapy (cisplatin)
http://purl.obolibrary.org/obo/go_0097328,GCST001204,21844884,18,Response to platinum-based chemotherapy (carboplatin)
http://www.ebi.ac.uk/efo/efo_0004237,GCST001200,21841780,11,Graves' disease
http://www.ebi.ac.uk/efo/efo_0004731,GCST001199,21835309,7,Iris characteristics
http://www.ebi.ac.uk/efo/efo_0003885,GCST001198,21833088,87,Multiple sclerosis
http://www.orpha.net/ordo/orphanet_70589,GCST001197,21836138,0,Bronchopulmonary dysplasia
http://www.ebi.ac.uk/efo/efo_0004337,GCST001195,21826061,0,Intelligence
http://www.ebi.ac.uk/efo/efo_0004280,GCST001196,21826085,1,Tardive dyskinesia
http://www.ebi.ac.uk/efo/efo_0000326,GCST001194,21827660,1,Glioma
http://www.ebi.ac.uk/efo/efo_0000292,GCST001193,21824976,1,Bladder cancer
http://purl.obolibrary.org/obo/go_0036273,GCST001192,21826682,0,Response to statin therapy
http://www.ebi.ac.uk/efo/efo_0001645,GCST001190,21829389,0,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0001359,GCST004383,21829393,1,Thyroid peroxidase autoantibody levels in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0005666,GCST004383,21829393,1,Thyroid peroxidase autoantibody levels in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0001359,GCST004382,21829393,1,Gastric parietal cell autoantibody levels in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004866,GCST004382,21829393,1,Gastric parietal cell autoantibody levels in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0001359,GCST004381,21829393,1,Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004866,GCST004381,21829393,1,Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0001359,GCST004380,21829393,0,Glutamate decarboxylase autoantibody levels in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004866,GCST004380,21829393,0,Glutamate decarboxylase autoantibody levels in type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0001359,GCST001191,21829393,22,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0002508,GCST001189,21812969,3,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0004634,GCST001188,21810271,11,vWF and FVIII levels
http://purl.obolibrary.org/obo/go_0061479,GCST001186,21810746,3,Nevirapine-induced rash
http://www.ebi.ac.uk/efo/efo_0001645,GCST001185,21846871,2,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0004840,GCST001187,21810643,1,Cortical thickness
http://www.ebi.ac.uk/efo/efo_0000270,GCST001183,21804548,14,Asthma
http://www.ebi.ac.uk/efo/efo_0000270,GCST001182,21804549,7,Asthma
http://www.orpha.net/ordo/orphanet_2495,GCST001184,21804547,1,Meningioma
http://www.ebi.ac.uk/efo/efo_0004276,GCST001181,21801394,6,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
http://www.ebi.ac.uk/efo/efo_0004775,GCST001181,21801394,6,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
http://www.ebi.ac.uk/efo/efo_0007759,GCST001180,21829377,10,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)
http://www.ebi.ac.uk/efo/efo_0006809,GCST001179,21829377,20,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)
http://www.ebi.ac.uk/efo/efo_0007761,GCST001177,21829377,3,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)
http://www.ebi.ac.uk/efo/efo_0007760,GCST001178,21829377,17,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)
http://www.ebi.ac.uk/efo/efo_0004233,GCST001175,21799462,2,Epirubicin-induced leukopenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST001176,21795503,0,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004504,GCST001174,21785125,8,Hepcidin levels
http://www.ebi.ac.uk/efo/efo_0001360,GCST001173,21799836,2,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000180,GCST001171,21811574,0,HIV-1 progression
http://www.ebi.ac.uk/efo/efo_0004529,GCST001170,21777205,0,Lipid traits
http://www.ebi.ac.uk/efo/efo_0000270,GCST001172,21814517,2,Asthma
http://www.ebi.ac.uk/efo/efo_0004647,GCST001169,21775533,0,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers
http://purl.obolibrary.org/obo/go_0007568,GCST001166,21782286,8,Aging (time to event)
http://www.ebi.ac.uk/efo/efo_0005919,GCST001168,21775986,5,Recombination measurement
http://www.ebi.ac.uk/efo/efo_0004300,GCST001167,21782286,3,Aging (time to death)
http://purl.obolibrary.org/obo/go_0007568,GCST001167,21782286,3,Aging (time to death)
http://www.ebi.ac.uk/efo/efo_0000289,GCST001164,21771265,3,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004502,GCST001165,21771975,1,Adiponectin levels
http://www.ebi.ac.uk/efo/efo_0004531,GCST001163,21768215,5,Urate levels
http://www.ebi.ac.uk/efo/efo_0004645,GCST001162,21764829,3,Hepatitis B vaccine response
http://www.ebi.ac.uk/efo/efo_0005842,GCST001161,21761138,5,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0004623,GCST001158,21757653,5,Fibrinogen
http://www.ebi.ac.uk/efo/efo_0000717,GCST001156,21779181,12,Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0004762,GCST001155,21757650,4,Vascular endothelial growth factor levels
http://www.ebi.ac.uk/efo/efo_0000717,GCST001160,21779181,6,Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0000319,GCST001157,21779381,5,Cardiovascular disease risk factors
http://www.ebi.ac.uk/efo/efo_0004270,GCST001159,21779176,6,Restless legs syndrome
http://www.ebi.ac.uk/efo/efo_0003888,GCST001154,21784300,7,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0000692,GCST001152,21747397,0,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST001151,21752600,0,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004197,GCST001150,21750111,4,Hepatitis B
http://www.ebi.ac.uk/efo/efo_0000292,GCST001153,21750109,1,Bladder cancer
http://www.ebi.ac.uk/efo/efo_0003898,GCST001149,21743469,13,Ankylosing spondylitis
http://www.ebi.ac.uk/efo/efo_0001663,GCST001148,21743467,9,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0001663,GCST001147,21743057,14,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0000717,GCST001146,21750679,7,Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0004229,GCST001144,21732829,12,Dupuytren's disease
http://purl.obolibrary.org/obo/go_0097327,GCST001145,21755009,0,Chemotherapeutic susceptibility
http://www.ebi.ac.uk/efo/efo_0004867,GCST001142,21729881,3,Vitamin E levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST001143,22303337,0,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004913,GCST001141,21750702,0,Suicidal ideation
http://www.ebi.ac.uk/efo/efo_0001071,GCST001140,21725308,4,Lung cancer
http://www.ebi.ac.uk/efo/efo_0004220,GCST001139,21725309,1,Chronic hepatitis C infection
http://www.ebi.ac.uk/efo/efo_0004244,GCST001136,21787189,2,Interstitial lung disease
http://www.ebi.ac.uk/efo/efo_0004308,GCST001137,21738480,10,White blood cell count
http://www.ebi.ac.uk/efo/efo_0004888,GCST001138,21694509,0,Postoperative nausea and vomiting
http://www.ebi.ac.uk/efo/efo_0000289,GCST001135,21738484,6,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004278,GCST001132,21738491,1,Sudden cardiac arrest
http://www.ebi.ac.uk/efo/efo_0004308,GCST001133,21738479,2,White blood cell count
http://www.ebi.ac.uk/efo/efo_0004308,GCST001134,21738478,20,White blood cell types
http://www.ebi.ac.uk/efo/efo_0004300,GCST001131,21740922,1,Longevity
http://www.ebi.ac.uk/efo/efo_0001073,GCST001130,21708048,2,Obesity
http://www.ebi.ac.uk/efo/efo_0001073,GCST001128,21706003,3,Adiposity
http://www.ebi.ac.uk/efo/efo_0000756,GCST001129,21706340,1,Melanoma
http://www.ebi.ac.uk/efo/efo_0004647,GCST001127,21705454,0,Response to platinum-based agents
http://www.ebi.ac.uk/efo/efo_0004193,GCST001124,21700618,3,Basal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0004340,GCST001123,21701565,0,Body mass index
http://www.ebi.ac.uk/efo/efo_0004340,GCST001125,21701570,2,Body mass index
http://www.ebi.ac.uk/efo/efo_0002508,GCST001126,21738487,11,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0004502,GCST001122,21700879,5,Adiponectin levels
http://www.ebi.ac.uk/efo/efo_0004304,GCST001120,21700265,5,Erythrocyte sedimentation rate
http://www.ebi.ac.uk/efo/efo_0003829,GCST001121,21703634,2,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0000729,GCST001118,21699788,2,Ulcerative colitis or Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000384,GCST001118,21699788,2,Ulcerative colitis or Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000692,GCST001119,21682944,2,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004591,GCST001117,21696813,0,Asthma (childhood onset)
http://www.orpha.net/ordo/orphanet_683,GCST001116,21685912,11,Progressive supranuclear palsy
http://www.ebi.ac.uk/efo/efo_0000692,GCST001115,21688384,2,Schizophrenia (age at onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST001115,21688384,2,Schizophrenia (age at onset)
http://www.ebi.ac.uk/efo/efo_0000692,GCST001114,21688384,0,Schizophrenia (age at onset) (sex interaction)
http://www.ebi.ac.uk/efo/efo_0004847,GCST001114,21688384,0,Schizophrenia (age at onset) (sex interaction)
http://www.ebi.ac.uk/efo/efo_0003884,GCST001107,21698141,0,End-stage renal disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST001112,21685187,11,Lifetime average cigarettes per day in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005671,GCST001112,21685187,11,Lifetime average cigarettes per day in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST001111,21685187,7,Current cigarettes per day in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005671,GCST001111,21685187,7,Current cigarettes per day in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000341,GCST001108,21685187,8,Smoking cessation in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0004319,GCST001108,21685187,8,Smoking cessation in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0004464,GCST001109,21681796,2,White matter hyperintensity burden
http://www.ebi.ac.uk/efo/efo_0000692,GCST001110,21679298,1,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0000341,GCST001113,21685187,21,Age at smoking initiation in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0005670,GCST001113,21685187,21,Age at smoking initiation in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000274,GCST001106,21666691,1,Atopic dermatitis
http://www.ebi.ac.uk/efo/efo_0003821,GCST001105,21666692,3,Migraine
http://www.ebi.ac.uk/efo/efo_0004278,GCST001102,21658281,6,Sudden cardiac arrest
http://www.ebi.ac.uk/efo/efo_0004278,GCST001099,21658281,36,Sudden cardiac arrest
http://www.ebi.ac.uk/efo/efo_0004345,GCST001101,21665993,2,Corneal curvature
http://www.ebi.ac.uk/efo/efo_0004278,GCST001104,21658281,7,Sudden cardiac arrest
http://www.ebi.ac.uk/efo/efo_0001365,GCST001100,21665990,11,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0002628,GCST001098,21665988,0,Peripartum cardiomyopathy
http://www.ebi.ac.uk/efo/efo_0004329,GCST001103,21665994,6,Alcohol consumption (transferrin glycosylation)
http://www.ebi.ac.uk/efo/efo_0003885,GCST001096,21654844,6,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0004784,GCST001097,21694764,0,Educational attainment
http://purl.obolibrary.org/obo/go_0097327,GCST001095,21659360,9,Response to antineoplastic agents
http://www.ebi.ac.uk/efo/efo_0004220,GCST001094,21659334,4,Response to hepatitis C treatment
http://www.ebi.ac.uk/efo/efo_0004458,GCST001093,21647738,3,C-reactive protein
http://www.ebi.ac.uk/efo/efo_0001360,GCST001092,21647700,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000692,GCST001090,21674006,0,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004570,GCST001091,21646302,5,Bilirubin levels
http://www.ebi.ac.uk/efo/efo_0002916,GCST001089,21642993,11,Esophageal cancer
http://www.ebi.ac.uk/efo/efo_0004207,GCST001088,21640322,1,Myopia (pathological)
http://www.ebi.ac.uk/efo/efo_0000249,GCST001087,21627779,5,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004261,GCST001086,21623375,9,Paget's disease
http://www.ebi.ac.uk/efo/efo_0000537,GCST001085,21626137,9,Hypertension (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0001645,GCST001084,21626137,5,Coronary heart disease (SNP X SNP interaction)
http://www.ebi.ac.uk/efo/efo_0007878,GCST001082,21618603,2,Orofacial clefts (maternal alcohol consumption interaction)
http://www.orpha.net/ordo/orphanet_139039,GCST001082,21618603,2,Orofacial clefts (maternal alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0003959,GCST001082,21618603,2,Orofacial clefts (maternal alcohol consumption interaction)
http://www.ebi.ac.uk/efo/efo_0003761,GCST001083,21621269,5,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0004300,GCST001081,21612516,1,Longevity
http://www.ebi.ac.uk/efo/efo_0004516,GCST001080,21611967,0,Fracture-related traits
http://www.ebi.ac.uk/efo/efo_0001645,GCST001079,21606135,5,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0001663,GCST001078,21602798,1,Prostate cancer
http://www.orpha.net/ordo/orphanet_586,GCST001077,21602797,6,Cystic fibrosis severity
http://www.ebi.ac.uk/efo/efo_0002686,GCST001075,21625490,0,Atopy
http://www.ebi.ac.uk/efo/efo_0004220,GCST001076,21703177,1,IFN-related cytopenia
http://www.ebi.ac.uk/efo/efo_0004325,GCST001072,21572416,9,Blood pressure
http://www.ebi.ac.uk/efo/efo_0001360,GCST001070,21573907,5,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003882,GCST001071,21573128,1,Osteoporosis
http://www.ebi.ac.uk/efo/efo_0004725,GCST001073,21572414,5,Urinary metabolites
http://www.ebi.ac.uk/efo/efo_0004325,GCST001074,21572416,8,Blood pressure
http://www.ebi.ac.uk/efo/efo_0004865,GCST001069,21565293,8,Thyroid volume
http://www.ebi.ac.uk/efo/efo_0004505,GCST001068,21573004,1,Telomere length
http://www.ebi.ac.uk/efo/efo_0005088,GCST001067,21551455,2,Testicular cancer
http://www.ebi.ac.uk/efo/efo_0003884,GCST001066,21546767,26,Dialysis-related mortality
http://www.orpha.net/ordo/orphanet_797,GCST001064,21540310,0,Sarcoidosis
http://www.ebi.ac.uk/efo/efo_0000339,GCST001063,21540461,2,Chronic myeloid leukemia
http://www.ebi.ac.uk/efo/efo_0005036,GCST001065,21546496,1,Platelet function and related traits
http://www.ebi.ac.uk/efo/efo_0004309,GCST001061,21507922,10,Platelet count
http://www.ebi.ac.uk/efo/efo_0004833,GCST001059,21507922,20,Neutrophil count
http://www.ebi.ac.uk/efo/efo_0000516,GCST001062,21532571,2,Glaucoma
http://www.ebi.ac.uk/efo/efo_0000765,GCST001060,21502085,7,AIDS progression
http://www.ebi.ac.uk/efo/efo_0000326,GCST001058,21531791,7,Glioma
http://www.ebi.ac.uk/efo/efo_0001073,GCST001057,21552555,14,Obesity
http://www.ebi.ac.uk/efo/efo_0003761,GCST001056,21521612,1,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0003829,GCST001052,21529783,8,Alcoholism (heaviness of drinking)
http://www.ebi.ac.uk/efo/efo_0003829,GCST001054,21529783,6,Alcoholism (alcohol dependence factor score)
http://www.ebi.ac.uk/efo/efo_0003829,GCST001053,21529783,6,Alcoholism (alcohol use disorder factor score)
http://www.ebi.ac.uk/efo/efo_0003829,GCST001055,21529783,2,Alcoholism (12-month weekly alcohol consumption)
http://www.ebi.ac.uk/efo/efo_0004506,GCST001048,21493818,3,Monocyte early outgrowth colony forming units
http://www.ebi.ac.uk/efo/efo_0003923,GCST001050,21533022,9,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0004507,GCST001049,21502573,15,D-dimer levels
http://www.ebi.ac.uk/efo/efo_0000096,GCST001051,21533074,1,Follicular lymphoma
http://www.ebi.ac.uk/efo/efo_0004520,GCST001047,21533024,3,Soluble ICAM-1
http://www.ebi.ac.uk/efo/efo_0000685,GCST001042,21505073,3,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004207,GCST001044,21505071,2,Myopia (pathological)
http://www.ebi.ac.uk/efo/efo_0004464,GCST001045,21502949,2,Caudate nucleus volume
http://www.ebi.ac.uk/efo/efo_0001073,GCST001046,21544081,1,Obesity
http://purl.obolibrary.org/obo/go_0035456,GCST001043,21502966,2,Response to interferon beta therapy
http://www.ebi.ac.uk/efo/efo_0000182,GCST001041,21499248,2,Hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0004230,GCST001040,21499250,2,Endometrial cancer
http://www.orpha.net/ordo/orphanet_1572,GCST001039,21497890,0,Common variable immunodeficiency
http://www.ebi.ac.uk/efo/efo_0004730,GCST001038,21533175,8,Dehydroepiandrosterone sulphate levels
http://www.ebi.ac.uk/efo/efo_0004346,GCST001037,21483430,1,Neuranatomic and neurocognitive phenotypes
http://www.ebi.ac.uk/efo/efo_0004785,GCST001037,21483430,1,Neuranatomic and neurocognitive phenotypes
http://www.ebi.ac.uk/efo/efo_0004228,GCST001036,21570397,2,Drug-induced liver injury (amoxicillin-clavulanate)
http://www.ebi.ac.uk/efo/efo_0004647,GCST001035,21483023,1,Response to platinum-based chemotherapy in non-small-cell lung cancer
http://www.ebi.ac.uk/efo/efo_0003060,GCST001035,21483023,1,Response to platinum-based chemotherapy in non-small-cell lung cancer
http://www.ebi.ac.uk/efo/efo_0000625,GCST001034,21478494,3,Cutaneous nevi
http://www.ebi.ac.uk/efo/efo_0003888,GCST001030,21473668,1,Attention deficit hyperactivity disorder motor coordination
http://www.ebi.ac.uk/efo/efo_0004330,GCST001032,21490707,10,Caffeine consumption
http://www.ebi.ac.uk/efo/efo_0001360,GCST001033,21490949,17,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000403,GCST001031,21471979,2,Large B-cell lymphoma
http://www.ebi.ac.uk/efo/efo_0004329,GCST001029,21471458,1,Alcohol consumption
http://www.ebi.ac.uk/efo/efo_0001663,GCST001028,21467234,0,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0000249,GCST001025,21460840,4,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000249,GCST001026,21460841,9,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0000731,GCST001027,21460842,5,Uterine fibroids
http://www.ebi.ac.uk/efo/efo_0004505,GCST001024,21460395,4,Telomere length
http://www.ebi.ac.uk/efo/efo_0000685,GCST001022,21452313,5,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000407,GCST001023,21459883,2,Idiopathic dilated cardiomyopathy
http://www.ebi.ac.uk/efo/efo_0004461,GCST001021,21483845,9,Iron status biomarkers
http://www.ebi.ac.uk/efo/efo_0004272,GCST001020,21483845,1,Iron deficiency
http://www.ebi.ac.uk/efo/efo_0003821,GCST001019,21448238,2,Migraine
http://www.ebi.ac.uk/efo/efo_0004255,GCST001018,21441931,2,Nephrotic syndrome (acquired)
http://www.ebi.ac.uk/efo/efo_0003770,GCST001017,21441570,19,Diabetic retinopathy
http://www.ebi.ac.uk/efo/efo_0004645,GCST001016,21396408,2,Vaccine-related adverse events
http://www.ebi.ac.uk/efo/efo_0000289,GCST001015,21423239,3,Suicide attempts in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004321,GCST001015,21423239,3,Suicide attempts in bipolar disorder
http://purl.obolibrary.org/obo/go_0036277,GCST001014,21428769,1,Adverse response to carbamazepine
http://www.ebi.ac.uk/efo/efo_0004300,GCST001013,21418511,1,Longevity
http://www.ebi.ac.uk/efo/efo_0000305,GCST001012,21424380,2,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004284,GCST001011,21437268,5,Oral cavity and pharyngeal cancer
http://www.ebi.ac.uk/efo/efo_0004267,GCST001010,21399635,21,Primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0003086,GCST001009,21399633,5,Nephropathy
http://www.ebi.ac.uk/efo/efo_0003095,GCST001008,21423719,1,Nonalcoholic fatty liver disease
http://www.ebi.ac.uk/efo/efo_0000195,GCST001007,21386085,16,Metabolic syndrome (bivariate traits)
http://www.ebi.ac.uk/efo/efo_0004530,GCST001004,21386085,6,Triglycerides-Blood Pressure (TG-BP)
http://www.ebi.ac.uk/efo/efo_0004325,GCST001004,21386085,6,Triglycerides-Blood Pressure (TG-BP)
http://www.ebi.ac.uk/efo/efo_0004530,GCST001005,21386085,8,HDL Cholesterol - Triglycerides (HDLC-TG)
http://www.ebi.ac.uk/efo/efo_0004612,GCST001005,21386085,8,HDL Cholesterol - Triglycerides (HDLC-TG)
http://www.ebi.ac.uk/efo/efo_0004530,GCST001006,21386085,7,Waist Circumference - Triglycerides (WC-TG)
http://www.ebi.ac.uk/efo/efo_0000195,GCST001006,21386085,7,Waist Circumference - Triglycerides (WC-TG)
http://www.ebi.ac.uk/efo/efo_0000195,GCST001003,21386085,5,Metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0001645,GCST000999,21378988,19,Coronary heart disease
http://www.orpha.net/ordo/orphanet_166282,GCST001001,21378987,0,Sick sinus syndrome
http://www.ebi.ac.uk/efo/efo_0001645,GCST001000,21378986,0,Coronary heart disease
http://purl.obolibrary.org/obo/go_0036273,GCST001002,21386754,1,Cerivastatin-induced rhabdomyolysis
http://www.ebi.ac.uk/efo/efo_0003867,GCST001002,21386754,1,Cerivastatin-induced rhabdomyolysis
http://www.ebi.ac.uk/efo/efo_0001645,GCST000998,21378990,30,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0004325,GCST000997,21378095,0,Blood pressure
http://www.ebi.ac.uk/efo/efo_0002690,GCST000996,21408207,24,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004365,GCST000995,21368711,7,Personality traits in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST000995,21368711,7,Personality traits in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004315,GCST000994,21372407,2,Drinking behavior
http://www.ebi.ac.uk/efo/efo_0004330,GCST000992,21357676,2,Coffee consumption
http://www.ebi.ac.uk/efo/efo_0004718,GCST000993,23480133,1,Vascular dementia
http://www.ebi.ac.uk/efo/efo_0004285,GCST000988,21355061,1,Urinary albumin excretion
http://www.ebi.ac.uk/efo/efo_0005842,GCST000989,21357381,0,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0000180,GCST000990,21364930,1,HIV-1 replication
http://www.ebi.ac.uk/efo/efo_0003756,GCST000991,21519539,0,Autism spectrum disorders (language delay)
http://www.ebi.ac.uk/efo/efo_0000249,GCST000986,21390209,2,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0000540,GCST000987,21383967,15,Celiac disease or Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000289,GCST000985,21353194,1,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004569,GCST000983,21339755,1,5-HTT brain serotonin transporter levels
http://www.ebi.ac.uk/efo/efo_0004254,GCST000984,21323541,21,Idiopathic membranous nephropathy
http://www.ebi.ac.uk/efo/efo_0004208,GCST000981,21326295,1,Vitiligo
http://www.ebi.ac.uk/efo/efo_0000249,GCST000980,21379329,1,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0004576,GCST000982,21326311,11,F-cell distribution in sickle cell anaemia
http://www.orpha.net/ordo/orphanet_232,GCST000982,21326311,11,F-cell distribution in sickle cell anaemia
http://www.ebi.ac.uk/efo/efo_0004591,GCST000979,21359210,0,Asthma (childhood onset)
http://www.ebi.ac.uk/efo/efo_0003829,GCST000977,21314694,3,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0004642,GCST000978,21316860,0,Cortisol secretion
http://www.ebi.ac.uk/efo/efo_0001645,GCST000972,21347282,3,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0000537,GCST000973,21347282,8,Hypertension
http://www.ebi.ac.uk/efo/efo_0004612,GCST000974,21347282,18,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004611,GCST000975,21347282,17,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0001360,GCST000976,21347282,2,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004462,GCST000971,21347284,5,PR interval
http://www.ebi.ac.uk/efo/efo_0004832,GCST000970,21307088,4,Optic disc area
http://www.ebi.ac.uk/efo/efo_0004847,GCST000969,21305692,2,Bipolar disorder (age of onset and psychotic symptoms)
http://www.ebi.ac.uk/efo/efo_0005940,GCST000969,21305692,2,Bipolar disorder (age of onset and psychotic symptoms)
http://www.ebi.ac.uk/efo/efo_0000289,GCST000969,21305692,2,Bipolar disorder (age of onset and psychotic symptoms)
http://www.ebi.ac.uk/efo/efo_0004647,GCST000967,21497773,0,Response to platinum-based chemotherapy in head and neck cancers
http://www.ebi.ac.uk/efo/efo_0003770,GCST000966,21310492,8,Diabetic retinopathy
http://www.ebi.ac.uk/efo/efo_0004647,GCST000968,21497773,0,Response to platinum-based chemotherapy in head and neck cancers
http://www.ebi.ac.uk/efo/efo_0004458,GCST000965,21300955,20,C-reactive protein levels
http://www.ebi.ac.uk/efo/efo_0000729,GCST000964,21297633,47,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0004246,GCST000962,21326860,2,Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0004761,GCST000963,21294900,12,Uric acid levels
http://www.ebi.ac.uk/efo/efo_0000289,GCST000961,21254220,24,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0002508,GCST000959,21292315,11,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0002503,GCST000960,21348951,19,Cardiac hypertrophy
http://www.ebi.ac.uk/efo/efo_0005941,GCST000958,21278746,1,Percent mammographic density
http://www.ebi.ac.uk/efo/efo_0004745,GCST000957,21273288,3,Natriuretic peptide levels
http://www.ebi.ac.uk/efo/efo_0003890,GCST000956,21298047,1,Substance dependence
http://www.ebi.ac.uk/efo/efo_0001060,GCST000955,21298027,2,Crohn's disease and celiac disease
http://www.ebi.ac.uk/efo/efo_0000384,GCST000955,21298027,2,Crohn's disease and celiac disease
http://www.ebi.ac.uk/efo/efo_0004329,GCST000954,21270382,4,Alcohol consumption
http://purl.obolibrary.org/obo/go_0036274,GCST000953,21245432,0,Lapatinib-induced hepatotoxicity in breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST000952,21263130,9,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004253,GCST000951,21283782,0,Nephrolithiasis
http://www.ebi.ac.uk/efo/efo_0002508,GCST000950,21248740,0,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0003885,GCST000949,21244703,3,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0000571,GCST000947,21242121,0,Lung adenocarcinoma (clinical stage)
http://www.ebi.ac.uk/efo/efo_0005842,GCST000948,21242260,2,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0001645,GCST000945,21239051,3,Coronary artery disease
http://www.ebi.ac.uk/efo/efo_0001645,GCST000946,21239051,1,Myocardial infarction in coronary artery disease
http://www.ebi.ac.uk/efo/efo_0000612,GCST000946,21239051,1,Myocardial infarction in coronary artery disease
http://www.ebi.ac.uk/efo/efo_0004220,GCST000944,21228123,1,Response to hepatitis C treatment
http://www.ebi.ac.uk/efo/efo_0005037,GCST000943,21223598,7,Aortic root size
http://www.ebi.ac.uk/efo/efo_0000712,GCST000940,22384361,0,Stroke
http://www.ebi.ac.uk/efo/efo_0000712,GCST000941,21155030,0,Stroke (ischemic)
http://www.ebi.ac.uk/efo/efo_0004276,GCST000942,21221126,4,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
http://www.ebi.ac.uk/efo/efo_0004775,GCST000942,21221126,4,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
http://www.ebi.ac.uk/efo/efo_0004246,GCST000939,21221998,2,Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0004626,GCST000937,21216879,8,Insulin-like growth factors
http://www.ebi.ac.uk/efo/efo_0004273,GCST000938,21216876,1,Adolescent idiopathic scoliosis
http://www.ebi.ac.uk/efo/efo_0004298,GCST000936,21212386,3,Cardiac muscle measurement
http://www.ebi.ac.uk/efo/efo_0003896,GCST000936,21212386,3,Cardiac muscle measurement
http://www.ebi.ac.uk/efo/efo_0004461,GCST000935,21208937,5,Iron status biomarkers
http://www.ebi.ac.uk/efo/efo_0008362,GCST000934,21211648,0,Asthma or atopy (farm exposure interaction)
http://www.ebi.ac.uk/efo/efo_0000270,GCST000934,21211648,0,Asthma or atopy (farm exposure interaction)
http://www.ebi.ac.uk/efo/efo_0004458,GCST000933,21196492,4,C-reactive protein
http://www.ebi.ac.uk/efo/efo_0004242,GCST000932,21302353,3,Hoarding
http://purl.obolibrary.org/obo/go_1901558,GCST000927,21186350,1,Response to metformin in type 2 diabetes (glycemic)
http://www.ebi.ac.uk/efo/efo_0008343,GCST000928,21253498,0,Waist-to-hip ratio (sex interaction)
http://www.ebi.ac.uk/efo/efo_0004343,GCST000928,21253498,0,Waist-to-hip ratio (sex interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST000929,21253498,0,Body mass index
http://www.ebi.ac.uk/efo/efo_0004342,GCST000931,21253498,0,Waist circumference (sex interaction)
http://www.ebi.ac.uk/efo/efo_0008343,GCST000931,21253498,0,Waist circumference (sex interaction)
http://www.ebi.ac.uk/efo/efo_0008343,GCST000930,21253498,0,Body mass index (sex interaction)
http://www.ebi.ac.uk/efo/efo_0004340,GCST000930,21253498,0,Body mass index (sex interaction)
http://www.ebi.ac.uk/efo/efo_0004999,GCST000925,21203500,8,N-glycan levels
http://www.ebi.ac.uk/efo/efo_0004887,GCST000926,21183627,0,Maximal oxygen uptake response
http://purl.obolibrary.org/obo/go_1901554,GCST000924,21177773,5,Response to acetaminophen (hepatotoxicity)
http://www.ebi.ac.uk/efo/efo_0002506,GCST000923,21177295,0,Osteoarthritis
http://www.ebi.ac.uk/efo/efo_0007915,GCST006329,21173776,0,Agreeableness
http://www.ebi.ac.uk/efo/efo_0007913,GCST006328,21173776,0,Extraversion
http://www.ebi.ac.uk/efo/efo_0007660,GCST006327,21173776,0,Neuroticism
http://www.ebi.ac.uk/efo/efo_0007912,GCST006326,21173776,1,Conscientiousness
http://www.ebi.ac.uk/efo/efo_0007914,GCST000922,21173776,1,Openness
http://www.ebi.ac.uk/efo/efo_0001365,GCST000921,21197116,0,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0004624,GCST000919,21160077,7,Serum prostate-specific antigen levels
http://www.ebi.ac.uk/efo/efo_0000612,GCST000920,21211798,0,Myocardial infarction
http://www.ebi.ac.uk/efo/efo_0000180,GCST000918,21160409,6,HIV-1 susceptibility
http://www.ebi.ac.uk/efo/efo_0000685,GCST000917,21156761,16,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000660,GCST000914,21151128,5,Polycystic ovary syndrome
http://www.ebi.ac.uk/efo/efo_0004268,GCST000915,21151127,2,Primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0001065,GCST000916,21151130,3,Endometriosis
http://www.ebi.ac.uk/efo/efo_0004461,GCST000913,21149283,5,Iron status biomarkers
http://purl.obolibrary.org/obo/go_0036277,GCST000912,21149285,1,Adverse response to carbamazepine
http://www.ebi.ac.uk/efo/efo_0004625,GCST000911,21087763,1,Progranulin levels
http://www.ebi.ac.uk/efo/efo_0000401,GCST000909,21150874,5,Type 2 diabetes nephropathy
http://www.ebi.ac.uk/efo/efo_0000270,GCST000910,21150878,1,Asthma
http://www.ebi.ac.uk/efo/efo_0004243,GCST000908,21139019,4,Ileal carcinoids
http://www.ebi.ac.uk/efo/efo_0000681,GCST000907,21131975,4,Renal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0004363,GCST000905,21130836,25,Information processing speed
http://www.ebi.ac.uk/efo/efo_0000095,GCST000906,21131588,4,Chronic lymphocytic leukemia
http://www.ebi.ac.uk/efo/efo_0003757,GCST000904,21182207,5,Asperger disorder
http://www.ebi.ac.uk/efo/efo_0000621,GCST000901,21124317,3,Neuroblastoma
http://www.ebi.ac.uk/efo/efo_0000182,GCST000902,21105107,3,Hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0000249,GCST000900,21123754,7,Alzheimer's disease biomarkers
http://purl.obolibrary.org/obo/go_0036271,GCST000903,21130132,7,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
http://www.ebi.ac.uk/efo/efo_0000702,GCST000896,21118971,1,Small-cell lung cancer (survival)
http://www.ebi.ac.uk/efo/efo_0000249,GCST000897,21116278,0,Hippocampal volume (Alzheimer's disease interaction)
http://www.ebi.ac.uk/efo/efo_0005035,GCST000897,21116278,0,Hippocampal volume (Alzheimer's disease interaction)
http://www.ebi.ac.uk/efo/efo_0000249,GCST000895,21116278,4,Whole-brain volume (Alzheimer's disease interaction)
http://www.ebi.ac.uk/efo/efo_0005089,GCST000895,21116278,4,Whole-brain volume (Alzheimer's disease interaction)
http://www.ebi.ac.uk/efo/efo_0000249,GCST000892,21116278,11,Total ventricular volume (Alzheimer's disease interaction)
http://www.ebi.ac.uk/efo/efo_0006930,GCST000892,21116278,11,Total ventricular volume (Alzheimer's disease interaction)
http://www.ebi.ac.uk/efo/efo_0000249,GCST000893,21116278,1,Entorhinal cortical volume (Alzheimer's disease interaction)
http://www.ebi.ac.uk/efo/efo_0005092,GCST000893,21116278,1,Entorhinal cortical volume (Alzheimer's disease interaction)
http://www.ebi.ac.uk/efo/efo_0006930,GCST000898,21116278,8,Total ventricular volume
http://www.ebi.ac.uk/efo/efo_0000249,GCST000889,21116278,1,Entorhinal cortical thickness (Alzheimer's disease interaction)
http://www.ebi.ac.uk/efo/efo_0004840,GCST000889,21116278,1,Entorhinal cortical thickness (Alzheimer's disease interaction)
http://www.ebi.ac.uk/efo/efo_0005035,GCST000890,21116278,3,Hippocampal volume
http://www.ebi.ac.uk/efo/efo_0005089,GCST000891,21116278,4,Whole-brain volume
http://www.ebi.ac.uk/efo/efo_0005092,GCST000899,21116278,1,Entorhinal cortical volume
http://www.ebi.ac.uk/efo/efo_0004840,GCST000894,21116278,5,Entorhinal cortical thickness
http://www.orpha.net/ordo/orphanet_440,GCST000888,21113153,1,Hypospadias
http://www.ebi.ac.uk/efo/efo_0000612,GCST000887,21107343,1,Myocardial infarction
http://www.ebi.ac.uk/efo/efo_0000249,GCST000886,21098978,0,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004335,GCST000883,21107309,11,Response to antipsychotic treatment in schizophrenia (working memory)
http://www.ebi.ac.uk/efo/efo_0004350,GCST000885,21107309,10,Response to antipsychotic treatment in schizophrenia (reasoning)
http://purl.obolibrary.org/obo/go_0097332,GCST000884,21107309,2,Response to antipsychotic treatment
http://www.ebi.ac.uk/efo/efo_0007592,GCST000882,21106707,3,Response to bleomycin (chromatid breaks)
http://www.ebi.ac.uk/efo/efo_0007593,GCST000882,21106707,3,Response to bleomycin (chromatid breaks)
http://purl.obolibrary.org/obo/go_0046677,GCST000882,21106707,3,Response to bleomycin (chromatid breaks)
http://www.ebi.ac.uk/efo/efo_0004512,GCST000881,21104366,1,Bone mineral density (wrist)
http://www.ebi.ac.uk/efo/efo_0000384,GCST000879,21102463,71,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0004703,GCST000880,21102462,42,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0004207,GCST000878,21095009,1,Myopia (pathological)
http://www.ebi.ac.uk/efo/efo_0003923,GCST000877,21124946,1,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0004728,GCST000876,21124955,4,Amyloid A serum levels
http://www.ebi.ac.uk/efo/efo_0001645,GCST000875,21088011,1,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0002508,GCST000874,21084426,3,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0004215,GCST000873,21079607,9,Anorexia nervosa
http://www.ebi.ac.uk/efo/efo_0004311,GCST000872,21076409,12,QRS duration
http://www.ebi.ac.uk/efo/efo_0000714,GCST000871,21079520,3,Non-small cell lung cancer (survival)
http://www.ebi.ac.uk/efo/efo_0003060,GCST000871,21079520,3,Non-small cell lung cancer (survival)
http://www.ebi.ac.uk/efo/efo_0002686,GCST000870,21094521,0,Atopy
http://www.ebi.ac.uk/efo/efo_0002506,GCST000869,21068099,1,Osteoarthritis
http://www.ebi.ac.uk/efo/efo_0000305,GCST000867,21062454,0,Breast cancer (estrogen-receptor negative)
http://www.ebi.ac.uk/efo/efo_0009902,GCST000868,21051773,1,Handedness in dyslexia
http://www.ebi.ac.uk/efo/efo_0005424,GCST000868,21051773,1,Handedness in dyslexia
http://www.ebi.ac.uk/efo/efo_0004653,GCST000865,21061259,0,Response to anti-TNF therapy in rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000249,GCST000864,21059989,0,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004611,GCST000866,21059979,2,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0000677,GCST000862,21057379,6,Bipolar disorder and schizophrenia
http://www.ebi.ac.uk/efo/efo_0007191,GCST000861,21668797,10,Cannabis dependence
http://www.orpha.net/ordo/orphanet_2573,GCST000860,21048783,1,Moyamoya disease
http://www.ebi.ac.uk/efo/efo_0000180,GCST000863,21051598,8,HIV-1 control
http://purl.obolibrary.org/obo/hp_0012042,GCST000859,21072201,0,Aspirin intolerance in asthmatics
http://www.ebi.ac.uk/efo/efo_0002690,GCST000858,21044949,1,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0002508,GCST000855,21044948,3,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0003761,GCST000856,21042317,4,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0004358,GCST000857,21184583,3,Event-related brain oscillations
http://www.ebi.ac.uk/efo/efo_0000677,GCST000854,21041247,4,Suicide risk
http://www.ebi.ac.uk/efo/efo_0004321,GCST000854,21041247,4,Suicide risk
http://www.ebi.ac.uk/efo/efo_0000729,GCST000853,20848476,10,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0004311,GCST000852,21041692,5,Atrioventricular conduction
http://www.ebi.ac.uk/efo/efo_0000183,GCST000851,21037568,5,Hodgkin's lymphoma
http://www.ebi.ac.uk/efo/efo_0000341,GCST000850,21037115,1,Body mass in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0004340,GCST000850,21037115,1,Body mass in chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0004731,GCST000847,21060863,5,Retinal vascular caliber
http://www.ebi.ac.uk/efo/efo_0004863,GCST000845,20981099,1,Recombination measurement (males)
http://www.ebi.ac.uk/efo/efo_0004863,GCST000848,20981099,1,Recombination measurement (females)
http://www.ebi.ac.uk/efo/efo_0000305,GCST000846,21060860,1,Breast cancer in BRCA2 mutation carriers
http://www.ebi.ac.uk/efo/efo_0000537,GCST000849,21082022,1,Hypertension
http://www.ebi.ac.uk/efo/efo_0000714,GCST000844,20978177,0,Prostate cancer mortality
http://www.ebi.ac.uk/efo/efo_0000196,GCST000844,20978177,0,Prostate cancer mortality
http://www.ebi.ac.uk/efo/efo_0005842,GCST000843,20972440,5,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0000292,GCST000842,20972438,10,Bladder cancer
http://www.ebi.ac.uk/efo/efo_0004229,GCST000841,20971583,1,Dupuytren's disease
http://www.ebi.ac.uk/efo/efo_0004338,GCST000837,20966902,7,Weight
http://www.ebi.ac.uk/efo/efo_0004339,GCST000839,20966902,7,Height
http://www.ebi.ac.uk/efo/efo_0004340,GCST000840,20966902,6,Body mass index
http://www.ebi.ac.uk/efo/efo_0004342,GCST000838,20966902,8,Waist circumference
http://www.ebi.ac.uk/efo/efo_0000676,GCST000834,20953189,8,Psoriasis
http://www.ebi.ac.uk/efo/efo_0003778,GCST000835,20953186,3,Psoriatic arthritis
http://www.ebi.ac.uk/efo/efo_0000676,GCST000836,20953188,3,Psoriasis
http://www.ebi.ac.uk/efo/efo_0000676,GCST000833,20953190,17,Psoriasis
http://www.ebi.ac.uk/efo/efo_0004276,GCST000832,20947153,0,Stevens-Johnson syndrome
http://www.ebi.ac.uk/efo/efo_0004280,GCST000831,20939080,0,Tardive dyskinesia in schizophrenia
http://www.ebi.ac.uk/efo/efo_0004343,GCST000829,20935629,16,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0004340,GCST000830,20935630,38,Body mass index
http://www.ebi.ac.uk/efo/efo_0004760,GCST000826,20932310,5,Cerebrospinal T-tau levels
http://www.ebi.ac.uk/efo/efo_0004670,GCST000827,20932310,7,Cerebrospinal fluid AB1-42 levels
http://www.ebi.ac.uk/efo/efo_0004502,GCST000828,20887962,1,Adiponectin levels
http://www.ebi.ac.uk/efo/efo_0004763,GCST000825,20932310,5,Cerebrospinal P-tau181p levels
http://purl.obolibrary.org/obo/go_0009314,GCST000824,20932654,23,Erectile dysfunction and prostate cancer treatment
http://www.ebi.ac.uk/efo/efo_0001663,GCST000824,20932654,23,Erectile dysfunction and prostate cancer treatment
http://www.ebi.ac.uk/efo/efo_0004234,GCST000824,20932654,23,Erectile dysfunction and prostate cancer treatment
http://purl.obolibrary.org/obo/go_0097332,GCST000822,20921969,3,Antipsychotic drug-induced QTc interval prolongation
http://purl.obolibrary.org/obo/go_0009314,GCST000823,20923822,12,Radiation response
http://www.ebi.ac.uk/efo/efo_0000253,GCST000820,20801717,4,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0000270,GCST000819,20920776,0,Asthma
http://www.ebi.ac.uk/efo/efo_0000677,GCST000821,20889312,103,Bipolar disorder and schizophrenia
http://www.ebi.ac.uk/efo/efo_0004531,GCST000818,20884846,11,Urate levels
http://www.ebi.ac.uk/efo/efo_0004339,GCST000817,20881960,199,Height
http://www.ebi.ac.uk/efo/efo_0004320,GCST000816,20877300,4,Suicidal ideation
http://www.ebi.ac.uk/efo/efo_0004305,GCST000814,20927387,13,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004528,GCST000814,20927387,13,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004526,GCST000814,20927387,13,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0004527,GCST000814,20927387,13,Red blood cell traits
http://www.ebi.ac.uk/efo/efo_0003060,GCST000815,20876614,3,Non-small cell lung cancer
http://www.ebi.ac.uk/efo/efo_0004502,GCST000812,20876611,3,Adiponectin levels
http://purl.obolibrary.org/obo/go_0061477,GCST000813,20876420,1,Adverse response to aromatase inhibitors
http://www.ebi.ac.uk/efo/efo_0000571,GCST000810,20871597,2,Lung adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0000305,GCST000811,20872241,4,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004530,GCST000809,20864672,11,Triglycerides
http://www.ebi.ac.uk/efo/efo_0001365,GCST000806,20861866,4,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0000249,GCST000808,20885792,4,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0000270,GCST000804,20860503,10,Asthma
http://www.ebi.ac.uk/efo/efo_0004612,GCST000805,20864672,12,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004611,GCST000807,20864672,11,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004541,GCST000803,20858683,11,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0001075,GCST000800,20852633,2,Ovarian cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST000801,20852631,1,Breast cancer
http://www.ebi.ac.uk/efo/efo_0001075,GCST000802,20852632,7,Ovarian cancer
http://www.ebi.ac.uk/efo/efo_0000537,GCST000799,20877124,0,Hypertension
http://www.ebi.ac.uk/efo/efo_0001360,GCST000796,20862305,4,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004541,GCST000798,20849430,1,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0001065,GCST000797,20844546,2,Endometriosis
http://purl.obolibrary.org/obo/hp_0000539,GCST000795,20835239,1,Refractive error
http://purl.obolibrary.org/obo/hp_0000539,GCST000794,20835236,1,Refractive error
http://www.ebi.ac.uk/efo/efo_0004190,GCST000793,20835238,1,Glaucoma (primary open-angle)
http://purl.obolibrary.org/obo/go_0061476,GCST000792,20833655,5,Warfarin maintenance dose
http://www.ebi.ac.uk/efo/efo_0004296,GCST000791,20826269,0,Thyroid function
http://www.orpha.net/ordo/orphanet_98974,GCST000790,20825314,2,Fuchs's corneal dystrophy
http://www.ebi.ac.uk/efo/efo_0004342,GCST004704,20838585,2,Cardiovascular risk factors
http://www.ebi.ac.uk/efo/efo_0004530,GCST004704,20838585,2,Cardiovascular risk factors
http://www.ebi.ac.uk/efo/efo_0004611,GCST004704,20838585,2,Cardiovascular risk factors
http://www.ebi.ac.uk/efo/efo_0000319,GCST004704,20838585,2,Cardiovascular risk factors
http://www.ebi.ac.uk/efo/efo_0004612,GCST004704,20838585,2,Cardiovascular risk factors
http://www.ebi.ac.uk/efo/efo_0004342,GCST000789,20838585,4,Cardiovascular risk factors (age interaction)
http://www.ebi.ac.uk/efo/efo_0004530,GCST000789,20838585,4,Cardiovascular risk factors (age interaction)
http://www.ebi.ac.uk/efo/efo_0004611,GCST000789,20838585,4,Cardiovascular risk factors (age interaction)
http://www.ebi.ac.uk/efo/efo_0000319,GCST000789,20838585,4,Cardiovascular risk factors (age interaction)
http://www.ebi.ac.uk/efo/efo_0004612,GCST000789,20838585,4,Cardiovascular risk factors (age interaction)
http://www.ebi.ac.uk/efo/efo_0008007,GCST000789,20838585,4,Cardiovascular risk factors (age interaction)
http://www.ebi.ac.uk/efo/efo_0000692,GCST000788,20832056,0,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0001360,GCST000787,20818381,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003770,GCST000786,20871662,0,Diabetic retinopathy
http://www.ebi.ac.uk/efo/efo_0003885,GCST000783,20802204,5,Multiple sclerosis--Brain Glutamate Levels
http://www.ebi.ac.uk/efo/efo_0004300,GCST000785,20834067,39,Longevity
http://www.ebi.ac.uk/efo/efo_0004235,GCST000784,20808326,0,Pseudoexfoliation syndrome
http://www.ebi.ac.uk/efo/efo_0003821,GCST000782,20802479,1,Migraine
http://www.ebi.ac.uk/efo/efo_0004633,GCST000780,20802025,4,Protein C levels
http://www.ebi.ac.uk/efo/efo_0000253,GCST000781,20801718,2,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0003761,GCST000779,20800221,11,Depression (quantitative trait)
http://www.ebi.ac.uk/efo/efo_0004319,GCST000778,20811658,1,Smoking cessation
http://www.ebi.ac.uk/efo/efo_0002916,GCST000776,20729853,0,Esophageal cancer
http://www.ebi.ac.uk/efo/efo_0002916,GCST000777,20729852,4,Esophageal cancer and gastric cancer
http://www.ebi.ac.uk/efo/efo_0000178,GCST000777,20729852,4,Esophageal cancer and gastric cancer
http://www.ebi.ac.uk/efo/efo_0004731,GCST000775,20719862,5,Central corneal thickness
http://www.ebi.ac.uk/efo/efo_0003761,GCST000774,20713499,5,"Schizophrenia, bipolar disorder and depression (combined)"
http://www.ebi.ac.uk/efo/efo_0000677,GCST000774,20713499,5,"Schizophrenia, bipolar disorder and depression (combined)"
http://www.ebi.ac.uk/efo/efo_0000289,GCST000774,20713499,5,"Schizophrenia, bipolar disorder and depression (combined)"
http://www.ebi.ac.uk/efo/efo_0002508,GCST000772,20711177,4,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0000614,GCST000771,20711174,2,Narcolepsy
http://www.ebi.ac.uk/efo/efo_0004212,GCST000773,20711176,4,Keloid
http://www.ebi.ac.uk/efo/efo_0000464,GCST000770,20709820,7,Emphysema-related traits
http://www.ebi.ac.uk/efo/efo_0004838,GCST000769,20705733,10,Calcium levels
http://www.ebi.ac.uk/efo/efo_0003095,GCST000766,20708005,13,Non-alcoholic fatty liver disease histology (lobular)
http://www.ebi.ac.uk/efo/efo_0001422,GCST000766,20708005,13,Non-alcoholic fatty liver disease histology (lobular)
http://www.ebi.ac.uk/efo/efo_0003095,GCST000767,20708005,6,Non-alcoholic fatty liver disease histology (AST)
http://www.ebi.ac.uk/efo/efo_0001422,GCST000767,20708005,6,Non-alcoholic fatty liver disease histology (AST)
http://www.ebi.ac.uk/efo/efo_0004735,GCST000765,20708005,16,Non-alcoholic fatty liver disease histology (other)
http://www.ebi.ac.uk/efo/efo_0003095,GCST000765,20708005,16,Non-alcoholic fatty liver disease histology (other)
http://www.ebi.ac.uk/efo/efo_0001422,GCST000765,20708005,16,Non-alcoholic fatty liver disease histology (other)
http://www.ebi.ac.uk/efo/efo_0000270,GCST000768,20698975,0,Asthma
http://www.orpha.net/ordo/orphanet_3389,GCST000764,20694014,14,Tuberculosis
http://www.ebi.ac.uk/efo/efo_0004249,GCST000762,20694013,1,Meningococcal disease
http://www.ebi.ac.uk/efo/efo_0004747,GCST000763,20694011,12,Immunoglobulin A
http://www.ebi.ac.uk/efo/efo_0004530,GCST000758,20686565,32,Triglycerides
http://www.ebi.ac.uk/efo/efo_0003888,GCST000757,20732627,0,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0004612,GCST000755,20686565,47,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0000571,GCST000761,20700438,1,Lung adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0004611,GCST000759,20686565,37,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004574,GCST000760,20686565,52,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004845,GCST000756,20700443,9,Magnesium levels
http://www.ebi.ac.uk/efo/efo_0000195,GCST000753,20694148,18,Metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0004365,GCST000754,20691247,7,Personality dimensions
http://www.ebi.ac.uk/efo/efo_0000220,GCST000749,20670164,0,Acute lymphoblastic leukemia (childhood)
http://www.ebi.ac.uk/efo/efo_0003888,GCST000751,20732625,5,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0000182,GCST000752,20676096,1,Hepatocellular carcinoma
http://www.ebi.ac.uk/efo/efo_0004778,GCST000747,20707712,10,Self-rated health
http://www.ebi.ac.uk/efo/efo_0004653,GCST000748,20014019,4,Response to anti-TNF alpha therapy in inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0001663,GCST000750,20676098,11,Prostate cancer
http://purl.obolibrary.org/obo/go_0050913,GCST000746,20675712,1,Bitter taste response
http://www.ebi.ac.uk/efo/efo_0003761,GCST000743,20673876,3,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0003884,GCST000742,20686651,4,Chronic kidney disease and serum creatinine levels
http://www.ebi.ac.uk/efo/efo_0004518,GCST000742,20686651,4,Chronic kidney disease and serum creatinine levels
http://www.ebi.ac.uk/efo/efo_0002618,GCST000745,20686608,17,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0004339,GCST000744,20668459,1,Height
http://www.ebi.ac.uk/efo/efo_0004236,GCST000741,20668430,1,Glomerulosclerosis
http://www.ebi.ac.uk/efo/efo_0003758,GCST000740,20663923,2,Autism
http://www.ebi.ac.uk/efo/efo_0004537,GCST000738,20662065,5,Neonatal lupus
http://www.ebi.ac.uk/efo/efo_0002690,GCST000739,20659327,0,Serologic markers in systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004211,GCST000737,20657596,5,Hypertriglyceridemia
http://www.ebi.ac.uk/efo/efo_0004838,GCST000736,20661308,1,Calcium levels
http://www.ebi.ac.uk/efo/efo_0000096,GCST000734,20639881,3,Follicular lymphoma
http://www.ebi.ac.uk/efo/efo_0004228,GCST000735,20639878,1,Lumiracoxib-related liver injury
http://www.ebi.ac.uk/efo/efo_0004267,GCST000733,20639880,6,Primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0004632,GCST000732,20602913,0,Nevus count
http://www.ebi.ac.uk/efo/efo_0004351,GCST000731,20639392,10,Resting heart rate
http://www.ebi.ac.uk/efo/efo_0004570,GCST000730,20639394,14,Bilirubin levels
http://www.ebi.ac.uk/efo/efo_0004272,GCST000729,20637204,1,Ribavirin-induced anemia
http://purl.obolibrary.org/obo/go_1901559,GCST000729,20637204,1,Ribavirin-induced anemia
http://www.ebi.ac.uk/efo/efo_0003780,GCST000726,20622878,2,Behcet's disease
http://www.ebi.ac.uk/efo/efo_0004287,GCST000725,20622880,0,Ventricular fibrillation
http://www.ebi.ac.uk/efo/efo_0003780,GCST000728,20622879,2,Behcet's disease
http://www.ebi.ac.uk/efo/efo_0004214,GCST000727,20622881,2,Abdominal aortic aneurysm
http://www.ebi.ac.uk/efo/efo_0004257,GCST000724,20634892,1,Neuroticism (age interaction)
http://www.ebi.ac.uk/efo/efo_0008007,GCST000724,20634892,1,Neuroticism (age interaction)
http://www.ebi.ac.uk/efo/efo_0004257,GCST004569,20634892,2,Neuroticism
http://www.ebi.ac.uk/efo/efo_0003870,GCST000723,20613766,0,Intracranial aneurysm
http://www.ebi.ac.uk/efo/efo_0005842,GCST000722,20610541,0,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0001065,GCST000721,20601957,2,Endometriosis
http://www.ebi.ac.uk/efo/efo_0004265,GCST000720,20610895,2,Peripheral artery disease
http://www.ebi.ac.uk/efo/efo_0004596,GCST000717,20664687,0,Cataracts in type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003086,GCST000718,20595679,1,Nephropathy
http://www.ebi.ac.uk/efo/efo_0004192,GCST000719,20596022,8,Alopecia areata
http://www.ebi.ac.uk/efo/efo_0004881,GCST000715,20592726,1,Asparaginase hypersensitivity in acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_0003885,GCST000716,20598377,4,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0001360,GCST000712,20581827,26,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004216,GCST000714,20585324,12,Conduct disorder
http://www.ebi.ac.uk/efo/efo_0004216,GCST000713,20585324,17,Conduct disorder (symptom count)
http://www.ebi.ac.uk/efo/efo_0004631,GCST000711,20600896,0,Vitamin D levels
http://www.ebi.ac.uk/efo/efo_0003924,GCST000707,20585627,12,Hair color
http://www.ebi.ac.uk/efo/efo_0003949,GCST000710,20585627,8,Eye color
http://purl.obolibrary.org/obo/go_0050909,GCST000706,20585627,16,Common traits (Other)
http://www.ebi.ac.uk/efo/efo_0003889,GCST000706,20585627,16,Common traits (Other)
http://www.ebi.ac.uk/efo/efo_0005038,GCST000706,20585627,16,Common traits (Other)
http://www.ebi.ac.uk/efo/efo_0004354,GCST000706,20585627,16,Common traits (Other)
http://www.ebi.ac.uk/efo/efo_0003947,GCST000706,20585627,16,Common traits (Other)
http://www.ebi.ac.uk/efo/efo_0004291,GCST000706,20585627,16,Common traits (Other)
http://purl.obolibrary.org/obo/go_0007608,GCST000706,20585627,16,Common traits (Other)
http://purl.obolibrary.org/obo/hp_0009907,GCST000706,20585627,16,Common traits (Other)
http://purl.obolibrary.org/obo/hp_0000483,GCST000706,20585627,16,Common traits (Other)
http://purl.obolibrary.org/obo/hp_0025095,GCST000706,20585627,16,Common traits (Other)
http://www.ebi.ac.uk/efo/efo_0003963,GCST000708,20585627,4,Freckling
http://www.ebi.ac.uk/efo/efo_0000305,GCST000709,20585626,1,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004509,GCST000704,20534544,0,Hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0000384,GCST000705,20570966,7,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000692,GCST000702,20558996,0,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004861,GCST000703,20558539,5,Phosphorus levels
http://www.ebi.ac.uk/efo/efo_0005088,GCST000701,20543847,6,Testicular germ cell cancer
http://www.ebi.ac.uk/efo/efo_0004832,GCST000700,20548946,9,Vertical cup-disc ratio
http://www.ebi.ac.uk/efo/efo_0003882,GCST000698,20548944,7,Osteoporosis-related phenotypes
http://www.ebi.ac.uk/efo/efo_0004832,GCST000699,20548946,3,Optic disc parameters
http://www.ebi.ac.uk/efo/efo_0003762,GCST000697,20541252,3,Vitamin D insufficiency
http://www.ebi.ac.uk/efo/efo_0003884,GCST000696,20532800,1,End-stage renal disease (non-diabetic)
http://www.ebi.ac.uk/efo/efo_0000289,GCST000695,20528957,0,Migraine in psychiatric disorder
http://www.ebi.ac.uk/efo/efo_0003821,GCST000695,20528957,0,Migraine in psychiatric disorder
http://www.ebi.ac.uk/efo/efo_0004862,GCST000694,20529992,3,Phytosterol levels
http://www.ebi.ac.uk/efo/efo_0004208,GCST000692,20526339,4,Vitiligo
http://purl.obolibrary.org/obo/go_0070527,GCST000693,20526338,15,Platelet aggregation
http://www.ebi.ac.uk/efo/efo_0004263,GCST000691,20522523,6,Partial epilepsies
http://www.ebi.ac.uk/efo/efo_0004647,GCST000688,20463552,0,Response to platinum-based chemotherapy in small-cell lung cancer
http://www.ebi.ac.uk/efo/efo_0003761,GCST000689,20516156,4,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0004240,GCST000690,20520587,0,Heroin addiction
http://www.ebi.ac.uk/efo/efo_0004252,GCST000687,20512145,7,Nasopharyngeal carcinoma
http://www.ebi.ac.uk/efo/efo_0002618,GCST000686,20484958,0,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0003949,GCST000685,20463881,3,Eye color traits
http://www.ebi.ac.uk/efo/efo_0003888,GCST000684,20732626,10,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0004731,GCST000683,20485516,2,Central corneal thickness
http://www.ebi.ac.uk/efo/efo_0000249,GCST000682,20460622,1,Alzheimer's disease
http://www.orpha.net/ordo/orphanet_30391,GCST000681,20460270,3,Biliary atresia
http://www.ebi.ac.uk/efo/efo_0000305,GCST000678,20453838,13,Breast cancer
http://www.ebi.ac.uk/efo/efo_0000685,GCST000679,20453842,29,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000685,GCST000677,20453841,4,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0003885,GCST000680,20453840,2,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0000249,GCST000676,20452100,2,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000289,GCST000674,20451256,0,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0003144,GCST000675,20445134,16,Heart failure
http://www.ebi.ac.uk/efo/efo_0003959,GCST000673,20436469,2,Cleft lip
http://www.ebi.ac.uk/efo/efo_0004261,GCST000672,20436471,4,Paget's disease
http://www.ebi.ac.uk/efo/efo_0004746,GCST000671,20442857,5,Lipoprotein-associated phospholipase A2 activity and mass
http://www.ebi.ac.uk/efo/efo_0004357,GCST000670,20421487,0,Electroencephalogram traits
http://www.ebi.ac.uk/efo/efo_0004505,GCST000669,20421499,4,Telomere length
http://www.ebi.ac.uk/efo/efo_0004318,GCST000667,20418888,5,Smoking behavior
http://www.ebi.ac.uk/efo/efo_0004318,GCST000668,20418889,1,Smoking behavior
http://www.ebi.ac.uk/efo/efo_0004318,GCST000666,20418890,5,Smoking behavior
http://www.ebi.ac.uk/efo/efo_0004631,GCST000664,20418485,3,Vitamin D levels
http://www.ebi.ac.uk/efo/efo_0001360,GCST000665,20418489,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001073,GCST000663,20421936,5,Obesity (early onset extreme)
http://www.ebi.ac.uk/efo/efo_0004208,GCST000662,20410501,10,Vitiligo
http://www.ebi.ac.uk/efo/efo_0003144,GCST000661,20400778,11,Mortality in heart failure
http://www.ebi.ac.uk/efo/efo_0004352,GCST000661,20400778,11,Mortality in heart failure
http://www.ebi.ac.uk/efo/efo_0004302,GCST000660,20400458,0,Anthropometric traits
http://www.ebi.ac.uk/efo/efo_0004832,GCST000659,20395239,9,Optic nerve measurement (cup area)
http://www.ebi.ac.uk/efo/efo_0004832,GCST000655,20395239,4,Optic nerve measurement (cup-to-disc ratio)
http://www.ebi.ac.uk/efo/efo_0004832,GCST000657,20395239,7,Optic nerve measurement (disc area)
http://www.ebi.ac.uk/efo/efo_0000180,GCST000656,20205591,10,HIV-1 viral setpoint
http://www.ebi.ac.uk/efo/efo_0004832,GCST000658,20395239,6,Optic nerve measurement (rim area)
http://www.ebi.ac.uk/efo/efo_0000289,GCST000654,20386566,2,Bipolar I disorder
http://www.ebi.ac.uk/efo/efo_0001365,GCST000653,20385826,11,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0001365,GCST000652,20385819,8,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0000717,GCST000650,20383147,4,Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0004518,GCST000651,20383145,5,Creatinine levels
http://www.ebi.ac.uk/efo/efo_0004617,GCST000649,20383146,28,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST000649,20383146,28,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0004518,GCST000649,20383146,28,Chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0004344,GCST000648,20372150,2,Birth weight
http://www.ebi.ac.uk/efo/efo_0004574,GCST000647,20370913,0,Cholesterol
http://www.ebi.ac.uk/efo/efo_0003870,GCST000646,20364137,6,Intracranial aneurysm
http://www.ebi.ac.uk/efo/efo_0000516,GCST000645,20363506,2,Glaucoma
http://www.ebi.ac.uk/efo/efo_0004340,GCST000642,20397748,2,Body mass index
http://purl.obolibrary.org/obo/go_0036276,GCST000643,20360315,8,Response to antidepressants
http://www.ebi.ac.uk/efo/efo_0004339,GCST000644,20397748,8,Height
http://www.ebi.ac.uk/efo/efo_0003761,GCST000641,20351715,9,Bipolar disorder or major depressive disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST000641,20351715,9,Bipolar disorder or major depressive disorder
http://www.ebi.ac.uk/efo/efo_0003761,GCST006582,20351715,3,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0000289,GCST006865,20351715,21,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0002892,GCST000640,20350937,1,"Thyroid cancer (Papillary, radiation-related)"
http://www.ebi.ac.uk/efo/efo_0000292,GCST000639,20348956,3,Urinary bladder cancer
http://www.ebi.ac.uk/efo/efo_0004278,GCST000638,20360844,0,Sudden cardiac arrest
http://www.ebi.ac.uk/efo/efo_0006913,GCST000636,20308991,2,Brain cytoarchitecture
http://www.ebi.ac.uk/efo/efo_0000305,GCST000637,20332263,0,Breast cancer (prognosis)
http://purl.obolibrary.org/obo/go_0036273,GCST000635,20339536,36,Response to statin therapy
http://www.ebi.ac.uk/efo/efo_0004337,GCST000634,20306291,0,Cognitive ability
http://www.ebi.ac.uk/efo/efo_0001071,GCST000633,20304703,1,Lung cancer
http://www.ebi.ac.uk/efo/efo_0004310,GCST000631,20303064,3,Activated partial thromboplastin time
http://www.ebi.ac.uk/efo/efo_0004616,GCST000629,20305777,1,Knee osteoarthritis
http://www.ebi.ac.uk/efo/efo_0004841,GCST000630,20303062,1,Digit length ratio
http://www.ebi.ac.uk/efo/efo_0004300,GCST000632,20304771,1,Longevity
http://www.ebi.ac.uk/efo/efo_0004573,GCST000628,20237162,7,Chemerin levels
http://www.ebi.ac.uk/efo/efo_0004630,GCST000626,20231535,2,Factor VIII levels
http://www.ebi.ac.uk/efo/efo_0004629,GCST000627,20231535,4,vWF levels
http://www.ebi.ac.uk/efo/efo_0004619,GCST000625,20231535,2,Factor VII levels
http://www.ebi.ac.uk/efo/efo_0000729,GCST000623,20228798,6,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0000729,GCST000624,20228799,21,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0004518,GCST000622,20222955,0,Creatinine levels
http://www.ebi.ac.uk/efo/efo_0004572,GCST000621,20212171,1,C4b binding protein levels
http://www.ebi.ac.uk/efo/efo_0004232,GCST000620,20208534,14,Eosinophilic esophagitis (pediatric)
http://www.ebi.ac.uk/efo/efo_0003829,GCST000619,20202923,0,Alcohol dependence
http://purl.obolibrary.org/obo/go_0097332,GCST000618,20195266,37,Response to antipsychotic treatment
http://www.ebi.ac.uk/efo/efo_0004464,GCST000615,20197096,4,Brain structure (hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0005035,GCST000615,20197096,4,Brain structure (hippocampal volume)
http://www.ebi.ac.uk/efo/efo_0004319,GCST000616,20235792,0,Smoking cessation
http://www.ebi.ac.uk/efo/efo_0000249,GCST000614,20197096,5,Brain structure (temporal lobe volume)
http://www.ebi.ac.uk/efo/efo_0003829,GCST000617,20201924,0,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0004595,GCST000613,20487506,0,HIV (mother-to-child transmission)
http://www.ebi.ac.uk/efo/efo_0001060,GCST000612,20190752,40,Celiac disease
http://www.ebi.ac.uk/efo/efo_0004339,GCST000611,20189936,25,Height
http://purl.obolibrary.org/obo/go_0042476,GCST000609,20195514,6,Primary tooth development (time to first tooth eruption)
http://purl.obolibrary.org/obo/go_0042476,GCST000610,20195514,9,Primary tooth development (number of teeth)
http://www.ebi.ac.uk/efo/efo_0000220,GCST000608,20189245,0,Acute lymphoblastic leukemia (childhood)
http://www.ebi.ac.uk/efo/efo_0000692,GCST000607,20185149,3,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004575,GCST000606,20147318,1,E-selectin levels
http://www.ebi.ac.uk/efo/efo_0004635,GCST000605,20167575,1,Soluble leptin receptor levels
http://www.ebi.ac.uk/efo/efo_0000341,GCST000603,20173748,3,Chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0004220,GCST000604,20173735,2,Chronic hepatitis C infection
http://www.ebi.ac.uk/efo/efo_0000275,GCST000602,20173747,3,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0001360,GCST000601,20174558,3,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004833,GCST000600,20172861,2,Neutrophil count
http://www.ebi.ac.uk/efo/efo_0004522,GCST000599,20167578,5,Soluble levels of adhesion molecules
http://www.ebi.ac.uk/efo/efo_0004464,GCST000597,20171287,19,Brain structure
http://www.ebi.ac.uk/efo/efo_0003923,GCST000598,20164292,0,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0000180,GCST000596,20064070,1,HIV-1 progression
http://www.ebi.ac.uk/efo/efo_0003096,GCST000595,20154673,0,Frontotemporal lobar degeneration
http://www.ebi.ac.uk/efo/efo_0004578,GCST000594,20154341,1,Homocysteine levels
http://www.ebi.ac.uk/efo/efo_0003885,GCST000593,20159113,2,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0002690,GCST000592,20169177,2,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004581,GCST000590,20150558,2,Interleukin-18 levels
http://www.ebi.ac.uk/efo/efo_0004465,GCST000591,20152958,1,Fasting plasma glucose
http://www.ebi.ac.uk/efo/efo_0004505,GCST000586,20139977,1,Telomere length
http://www.ebi.ac.uk/efo/efo_0004526,GCST000585,20139978,17,Mean corpuscular volume
http://www.ebi.ac.uk/efo/efo_0004535,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004736,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004533,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004509,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004735,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004532,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004348,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004534,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004747,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004761,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004612,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004518,GCST000583,20139978,29,Hematological and biochemical traits
http://www.ebi.ac.uk/efo/efo_0004531,GCST000581,20139978,5,Urate levels
http://www.ebi.ac.uk/efo/efo_0004509,GCST000587,20139978,15,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0004527,GCST000587,20139978,15,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0004309,GCST000580,20139978,7,Platelet count
http://www.ebi.ac.uk/efo/efo_0004530,GCST000584,20139978,6,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004509,GCST000582,20139978,7,Mean corpuscular hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0004528,GCST000582,20139978,7,Mean corpuscular hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0004308,GCST000589,20139978,5,White blood cell count
http://www.ebi.ac.uk/efo/efo_0004305,GCST000588,20139978,8,Red blood cell count
http://www.ebi.ac.uk/efo/efo_0003926,GCST000579,20125193,62,Cognitive performance
http://www.ebi.ac.uk/efo/efo_0003761,GCST000578,20125088,9,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0000270,GCST000576,20159242,3,Asthma
http://www.ebi.ac.uk/efo/efo_0003885,GCST000577,20117844,1,Multiple sclerosis (severity)
http://www.ebi.ac.uk/efo/efo_0003882,GCST000575,20200953,1,Osteoporosis-related phenotypes
http://www.ebi.ac.uk/efo/efo_0002618,GCST000574,20101243,3,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0004346,GCST000573,20100581,12,Brain imaging
http://www.ebi.ac.uk/efo/efo_0003923,GCST000572,20096396,1,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0004466,GCST000571,20081858,2,Fasting blood insulin
http://www.ebi.ac.uk/efo/efo_0004469,GCST005180,20081858,10,Homeostasis model assessment of beta-cell function
http://www.ebi.ac.uk/efo/efo_0004501,GCST005179,20081858,2,Homeostasis model assessment of insulin resistance
http://www.ebi.ac.uk/efo/efo_0004465,GCST000568,20081858,16,Fasting blood glucose
http://www.ebi.ac.uk/efo/efo_0004307,GCST000569,20081857,5,Two-hour glucose challenge
http://www.ebi.ac.uk/efo/efo_0004247,GCST000570,20081856,1,Major mood disorders
http://www.ebi.ac.uk/efo/efo_0002508,GCST000567,20070850,6,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0004238,GCST000566,20068591,2,Hearing impairment
http://www.ebi.ac.uk/efo/efo_0004463,GCST000565,20066004,2,Angiotensin-converting enzyme activity
http://www.ebi.ac.uk/efo/efo_0003898,GCST000563,20062062,9,Ankylosing spondylitis
http://www.ebi.ac.uk/efo/efo_0004462,GCST000562,20062060,9,PR interval
http://www.ebi.ac.uk/efo/efo_0005054,GCST000561,20062063,18,Electrocardiographic traits
http://www.ebi.ac.uk/efo/efo_0005055,GCST000561,20062063,18,Electrocardiographic traits
http://www.ebi.ac.uk/efo/efo_0004327,GCST000561,20062063,18,Electrocardiographic traits
http://www.ebi.ac.uk/efo/efo_0004462,GCST000561,20062063,18,Electrocardiographic traits
http://www.ebi.ac.uk/efo/efo_0004326,GCST000561,20062063,18,Electrocardiographic traits
http://www.ebi.ac.uk/efo/efo_0004682,GCST000561,20062063,18,Electrocardiographic traits
http://www.ebi.ac.uk/efo/efo_0004327,GCST000564,20062061,3,Electrocardiographic traits
http://www.ebi.ac.uk/efo/efo_0003882,GCST000560,20072603,1,Osteoporosis
http://www.ebi.ac.uk/efo/efo_0004574,GCST000559,20066028,1,Cholesterol
http://www.ebi.ac.uk/efo/efo_0002506,GCST000558,20112360,1,Osteoarthritis
http://www.ebi.ac.uk/efo/efo_0004220,GCST000557,20060832,1,Chronic hepatitis C infection
http://www.ebi.ac.uk/efo/efo_0004550,GCST000556,20215924,2,Functional MRI
http://www.ebi.ac.uk/efo/efo_0000180,GCST000555,20009918,7,Carotid atherosclerosis in HIV infection
http://www.ebi.ac.uk/efo/efo_0004860,GCST000555,20009918,7,Carotid atherosclerosis in HIV infection
http://www.ebi.ac.uk/efo/efo_0005053,GCST000555,20009918,7,Carotid atherosclerosis in HIV infection
http://www.ebi.ac.uk/efo/efo_0003781,GCST000555,20009918,7,Carotid atherosclerosis in HIV infection
http://www.ebi.ac.uk/efo/efo_0004715,GCST000554,20044523,0,Subclinical brain infarct
http://www.ebi.ac.uk/efo/efo_0004839,GCST000553,20045101,2,CD4:CD8 lymphocyte ratio
http://www.ebi.ac.uk/efo/efo_0004335,GCST000552,20038948,0,Memory (short-term)
http://www.ebi.ac.uk/efo/efo_0003761,GCST000551,20038947,9,Major depressive disorder (broad)
http://www.ebi.ac.uk/efo/efo_0004725,GCST000550,20037589,5,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0000180,GCST000549,20041166,42,HIV-1 control
http://www.ebi.ac.uk/efo/efo_0000270,GCST000548,20032318,2,Asthma
http://www.ebi.ac.uk/efo/efo_0003959,GCST000547,20023658,6,Orofacial clefts
http://www.ebi.ac.uk/efo/efo_0001054,GCST000546,20018961,6,Leprosy
http://www.ebi.ac.uk/efo/efo_0004576,GCST000545,20018918,3,Fetal hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0003892,GCST000544,20010834,7,Pulmonary function
http://www.ebi.ac.uk/efo/efo_0003892,GCST000542,20010835,8,Pulmonary function
http://www.ebi.ac.uk/efo/efo_0004782,GCST000543,20012890,0,Social and non-social autistic-like traits
http://www.ebi.ac.uk/efo/efo_0004511,GCST000541,20175129,0,Femoral neck bone geometry
http://www.ebi.ac.uk/efo/efo_0002686,GCST000540,19961619,1,Atopy
http://www.ebi.ac.uk/efo/efo_0001359,GCST000539,19966805,2,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0004502,GCST000538,20011104,3,Adiponectin levels
http://www.ebi.ac.uk/efo/efo_0004502,GCST000537,20018283,1,Adiponectin levels
http://www.ebi.ac.uk/efo/efo_0004892,GCST000536,19954339,0,Sasang constitutional medicine type
http://www.ebi.ac.uk/efo/efo_0000717,GCST000535,19950302,0,Systemic sclerosis
http://www.ebi.ac.uk/efo/efo_0004268,GCST000534,19944697,0,Primary sclerosing cholangitis
http://www.ebi.ac.uk/efo/efo_0004529,GCST000533,19936222,73,Lipid metabolism phenotypes
http://www.orpha.net/ordo/orphanet_2133,GCST000532,20183929,3,Beta thalassemia/hemoglobin E disease
http://www.ebi.ac.uk/efo/efo_0002508,GCST000528,19915575,10,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0003767,GCST000531,19915574,4,Inflammatory bowel disease (early onset)
http://www.ebi.ac.uk/efo/efo_0000729,GCST000527,19915572,13,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0000729,GCST000529,19915573,7,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0002508,GCST000530,19915576,4,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0004875,GCST000524,20039944,0,Mathematical ability
http://www.ebi.ac.uk/efo/efo_0000270,GCST000525,19910028,0,Asthma
http://www.ebi.ac.uk/efo/efo_0004467,GCST000526,19902172,0,Insulin-related traits
http://purl.obolibrary.org/obo/go_0097327,GCST000523,19901119,21,Methotrexate phramacokinetics (acute lymphoblastic leukemia)
http://www.ebi.ac.uk/efo/efo_0004339,GCST000522,19893584,15,Height
http://www.ebi.ac.uk/efo/efo_0000649,GCST000521,19897590,1,Periodontitis
http://www.ebi.ac.uk/efo/efo_0004208,GCST000520,19890347,4,Vitiligo
http://www.ebi.ac.uk/efo/efo_0005038,GCST000519,19896111,15,Hair morphology
http://www.ebi.ac.uk/efo/efo_0003884,GCST000518,19929986,0,End-stage renal disease
http://www.ebi.ac.uk/efo/efo_0002690,GCST004867,19838195,41,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0004461,GCST000517,19880490,1,Iron levels
http://www.ebi.ac.uk/efo/efo_0003923,GCST000515,19874204,2,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0004541,GCST000516,19875614,0,Glycemic control in type 1 diabetes (HbA1c)
http://purl.obolibrary.org/obo/go_0097332,GCST000514,19875103,17,Response to antipsychotic therapy (extrapyramidal side effects)
http://www.orpha.net/ordo/orphanet_232,GCST000513,20029952,0,Sickle cell anemia (severity)
http://www.ebi.ac.uk/efo/efo_0004338,GCST000511,19851299,9,Weight
http://www.ebi.ac.uk/efo/efo_0004340,GCST000512,19851299,10,Body mass index
http://www.ebi.ac.uk/efo/efo_0004526,GCST000510,19853236,6,Hematology traits
http://www.ebi.ac.uk/efo/efo_0004527,GCST000510,19853236,6,Hematology traits
http://www.ebi.ac.uk/efo/efo_0004309,GCST000510,19853236,6,Hematology traits
http://www.ebi.ac.uk/efo/efo_0004256,GCST000508,19850125,0,Neuromyelitis optica
http://purl.obolibrary.org/obo/go_0036276,GCST000509,19846067,7,Response to citalopram treatment
http://www.ebi.ac.uk/efo/efo_0002690,GCST000507,19838193,18,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0000571,GCST000506,19836008,5,Lung adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0004527,GCST000504,19862010,9,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0004308,GCST000498,19820697,12,Hematological parameters
http://www.ebi.ac.uk/efo/efo_0004305,GCST000498,19820697,12,Hematological parameters
http://www.ebi.ac.uk/efo/efo_0004526,GCST000498,19820697,12,Hematological parameters
http://www.ebi.ac.uk/efo/efo_0004527,GCST000498,19820697,12,Hematological parameters
http://www.ebi.ac.uk/efo/efo_0004309,GCST000498,19820697,12,Hematological parameters
http://www.ebi.ac.uk/efo/efo_0004584,GCST000497,19820697,15,Mean platelet volume
http://www.ebi.ac.uk/efo/efo_0004305,GCST000500,19862010,4,Other erythrocyte phenotypes
http://www.ebi.ac.uk/efo/efo_0004528,GCST000500,19862010,4,Other erythrocyte phenotypes
http://www.ebi.ac.uk/efo/efo_0004509,GCST000499,19862010,7,Hemoglobin
http://www.ebi.ac.uk/efo/efo_0004526,GCST000503,19862010,17,Mean corpuscular volume
http://www.ebi.ac.uk/efo/efo_0004348,GCST000502,19862010,8,Hematocrit
http://www.ebi.ac.uk/efo/efo_0004509,GCST000501,19820698,2,Hemoglobin
http://www.ebi.ac.uk/efo/efo_0004461,GCST000505,19820699,4,Iron status biomarkers
http://www.ebi.ac.uk/efo/efo_0003758,GCST000496,19812673,2,Autism
http://www.ebi.ac.uk/efo/efo_0003923,GCST000495,19801982,13,Bone mineral density (hip)
http://www.ebi.ac.uk/efo/efo_0003923,GCST000494,19801982,16,Bone mineral density (spine)
http://www.ebi.ac.uk/efo/efo_0004622,GCST000493,19798445,5,Sphingolipid levels
http://www.ebi.ac.uk/efo/efo_0004336,GCST000492,19786962,2,Speech perception in dyslexia
http://www.ebi.ac.uk/efo/efo_0004207,GCST000491,19779542,1,Myopia (pathological)
http://www.ebi.ac.uk/efo/efo_0002508,GCST000490,19772629,5,Parkinson's disease (age of onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST000490,19772629,5,Parkinson's disease (age of onset)
http://www.ebi.ac.uk/efo/efo_0001663,GCST000488,19767753,19,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0001663,GCST000489,19767754,8,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0000765,GCST000487,19754311,7,AIDS
http://www.ebi.ac.uk/efo/efo_0004220,GCST000486,19749757,1,Response to hepatitis C treatment
http://www.ebi.ac.uk/efo/efo_0004220,GCST000485,19749758,1,Response to hepatitis C treatment
http://www.ebi.ac.uk/efo/efo_0000249,GCST000484,20061627,5,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004729,GCST000483,19744961,9,Folate pathway vitamin levels
http://www.ebi.ac.uk/efo/efo_0001357,GCST000482,19740415,0,Amyotrophic lateral sclerosis (SNP x SNP interaction)
http://www.ebi.ac.uk/efo/efo_0000253,GCST000481,19734901,8,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0000249,GCST000480,19734903,3,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0001360,GCST000478,19734900,6,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000249,GCST000479,19734902,3,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0003926,GCST000477,19734545,59,Cognitive performance
http://www.ebi.ac.uk/efo/efo_0004575,GCST000476,19729612,1,Soluble E-selectin levels
http://www.ebi.ac.uk/efo/efo_0004339,GCST000475,19729412,1,Height
http://www.ebi.ac.uk/efo/efo_0000483,GCST000474,19727025,3,Leisure-time exercise behaviour
http://purl.obolibrary.org/obo/go_0036276,GCST000471,19736353,0,Response to antidepressant treatment
http://www.ebi.ac.uk/efo/efo_0005842,GCST000472,19723657,0,Colorectal cancer
http://purl.obolibrary.org/obo/go_0097332,GCST000473,19721433,9,Response to antipsychotic treatment
http://purl.obolibrary.org/obo/go_0036276,GCST000470,19724244,0,Response to antidepressant treatment
http://www.ebi.ac.uk/efo/efo_0004591,GCST000468,19714205,1,Asthma (childhood onset)
http://www.ebi.ac.uk/efo/efo_0001073,GCST000469,19714249,2,Obesity and osteoporosis
http://www.ebi.ac.uk/efo/efo_0003882,GCST000469,19714249,2,Obesity and osteoporosis
http://purl.obolibrary.org/obo/go_0061478,GCST000467,19706858,1,Response to clopidogrel therapy
http://www.ebi.ac.uk/efo/efo_0002916,GCST000466,19698717,2,Esophageal cancer
http://www.ebi.ac.uk/efo/efo_0004220,GCST000465,19684573,3,Response to hepatitis C treatment
http://www.ebi.ac.uk/efo/efo_0000220,GCST000464,19684603,14,Acute lymphoblastic leukemia (childhood)
http://www.ebi.ac.uk/efo/efo_0000220,GCST000463,19684604,3,Acute lymphoblastic leukemia (childhood)
http://purl.obolibrary.org/obo/go_0097332,GCST000462,19680635,1,Response to antipsychotic treatment
http://www.ebi.ac.uk/efo/efo_0005039,GCST000461,19668339,21,Hippocampal atrophy
http://www.ebi.ac.uk/efo/efo_0004252,GCST000460,19664746,3,Nasopharyngeal carcinoma
http://www.ebi.ac.uk/efo/efo_0001071,GCST000459,19654303,7,Lung cancer
http://www.ebi.ac.uk/efo/efo_0003959,GCST000458,19656524,2,Orofacial clefts
http://www.ebi.ac.uk/efo/efo_0004465,GCST000457,19651812,1,Fasting plasma glucose
http://www.ebi.ac.uk/efo/efo_0001075,GCST000455,19648919,1,Ovarian cancer
http://www.ebi.ac.uk/efo/efo_0002618,GCST000456,19648918,1,Pancreatic cancer
http://www.ebi.ac.uk/efo/efo_0000292,GCST000454,19648920,1,Bladder cancer
http://www.ebi.ac.uk/efo/efo_0004682,GCST000452,20031603,14,QT interval
http://purl.obolibrary.org/obo/go_0035456,GCST000453,19667218,0,Response to interferon beta therapy
http://www.ebi.ac.uk/efo/efo_0004744,GCST000450,20031604,4,Matrix metalloproteinase levels
http://www.ebi.ac.uk/efo/efo_0004831,GCST000451,20031603,20,RR interval (heart rate)
http://www.ebi.ac.uk/efo/efo_0004190,GCST000449,19625618,0,Glaucoma (primary open-angle)
http://www.ebi.ac.uk/efo/efo_0000096,GCST000448,19620980,1,Follicular lymphoma
http://www.ebi.ac.uk/efo/efo_0000537,GCST000447,19609347,2,Hypertension
http://www.ebi.ac.uk/efo/efo_0000275,GCST000445,19597492,3,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0000275,GCST000446,19597491,2,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0004682,GCST000444,19587794,2,QT interval
http://www.ebi.ac.uk/efo/efo_0005037,GCST000442,19584346,6,Aortic root size
http://www.ebi.ac.uk/efo/efo_0004764,GCST000443,19584900,0,Body mass index and fat mass
http://www.ebi.ac.uk/efo/efo_0004340,GCST000443,19584900,0,Body mass index and fat mass
http://www.ebi.ac.uk/efo/efo_0004298,GCST000441,19584346,4,Cardiac structure and function
http://www.ebi.ac.uk/efo/efo_0000326,GCST000440,19578366,3,Glioma (high-grade)
http://www.ebi.ac.uk/efo/efo_0000756,GCST000437,19578364,5,Melanoma
http://www.ebi.ac.uk/efo/efo_0000625,GCST000438,19578365,2,Cutaneous nevi
http://www.ebi.ac.uk/efo/efo_0000326,GCST000439,19578367,7,Glioma
http://purl.obolibrary.org/obo/go_0061476,GCST000436,19578179,4,Acenocoumarol maintenance dosage
http://www.ebi.ac.uk/efo/efo_0000692,GCST000434,19571811,4,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004458,GCST000430,19567438,5,C-reactive protein
http://www.ebi.ac.uk/efo/efo_0003829,GCST000432,19581569,6,Alcohol dependence
http://www.ebi.ac.uk/efo/efo_0000692,GCST000433,19571809,2,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004339,GCST000431,19570815,5,Height
http://www.ebi.ac.uk/efo/efo_0000692,GCST000435,19571808,7,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0003845,GCST000429,19561606,1,Kidney stones
http://www.ebi.ac.uk/efo/efo_0001073,GCST000428,19557161,4,Adiposity
http://www.ebi.ac.uk/efo/efo_0004342,GCST000427,19557197,7,Waist circumference
http://www.ebi.ac.uk/efo/efo_0001073,GCST000426,19553259,13,Obesity (extreme)
http://www.ebi.ac.uk/efo/efo_0003885,GCST000424,19525953,15,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0003885,GCST000425,19525955,8,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0004578,GCST000423,19525478,0,Homocysteine levels
http://www.ebi.ac.uk/efo/efo_0004266,GCST000422,19508998,0,Premature ovarian failure
http://www.ebi.ac.uk/efo/efo_0002506,GCST000421,19508968,0,Osteoarthritis
http://www.ebi.ac.uk/efo/efo_0000685,GCST000420,19503088,5,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004214,GCST000419,19497516,0,Abdominal aortic aneurysm
http://www.ebi.ac.uk/efo/efo_0004761,GCST000418,19503597,11,Uric acid levels
http://www.ebi.ac.uk/efo/efo_0000289,GCST000417,19488044,1,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0005088,GCST000414,19483681,6,Testicular germ cell tumor
http://www.ebi.ac.uk/efo/efo_0005088,GCST000416,19483682,1,Testicular cancer
http://www.ebi.ac.uk/efo/efo_0004228,GCST000415,19483685,6,Drug-induced liver injury (flucloxacillin)
http://www.ebi.ac.uk/efo/efo_0004252,GCST000413,19478819,1,Nasopharyngeal carcinoma
http://www.ebi.ac.uk/efo/efo_0004248,GCST000412,19478329,5,Male infertility
http://www.ebi.ac.uk/efo/efo_0003758,GCST000411,19456320,1,Autism
http://www.ebi.ac.uk/efo/efo_0001068,GCST000410,19465909,3,Malaria
http://www.ebi.ac.uk/efo/efo_0004764,GCST000409,19461586,0,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004267,GCST000408,19458352,7,Primary biliary cholangitis
http://www.ebi.ac.uk/efo/efo_0008205,GCST000407,19454037,2,Left ventricular mass
http://www.ebi.ac.uk/efo/efo_0000253,GCST000406,19451621,16,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0004703,GCST000405,19448623,1,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0004703,GCST000403,19448621,6,Menarche and menopause (age at onset)
http://www.ebi.ac.uk/efo/efo_0004704,GCST000403,19448621,6,Menarche and menopause (age at onset)
http://www.ebi.ac.uk/efo/efo_0004703,GCST000404,19448620,2,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0004703,GCST000400,19448622,1,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0004704,GCST000401,19448619,13,Menopause (age at onset)
http://purl.obolibrary.org/obo/go_0010226,GCST000402,19448189,0,Response to lithium treatment in bipolar disorder
http://www.ebi.ac.uk/efo/efo_0003780,GCST000399,19442274,0,Behcet's disease
http://www.ebi.ac.uk/efo/efo_0000537,GCST000398,19430479,4,Hypertension
http://www.ebi.ac.uk/efo/efo_0004742,GCST000397,19430482,4,Renal function and chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0003884,GCST000397,19430482,4,Renal function and chronic kidney disease
http://www.ebi.ac.uk/efo/efo_0001359,GCST000392,19430480,38,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0006336,GCST000394,19430483,6,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST000395,19430483,3,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST000396,19430479,7,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST000393,19430479,7,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0002614,GCST000391,19430760,0,Insulin resistance/response
http://www.ebi.ac.uk/efo/efo_0000270,GCST000389,19426955,1,Asthma
http://www.ebi.ac.uk/efo/efo_0004772,GCST000390,19421330,1,Hypertension (young onset)
http://www.ebi.ac.uk/efo/efo_0004570,GCST000388,19419973,3,Bilirubin levels
http://www.ebi.ac.uk/efo/efo_0000289,GCST000387,19416921,13,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0004570,GCST000386,19414484,8,Bilirubin levels
http://www.ebi.ac.uk/efo/efo_0000621,GCST000384,19412175,1,Neuroblastoma (high-risk)
http://www.ebi.ac.uk/efo/efo_0000614,GCST000385,19412176,1,Narcolepsy
http://www.ebi.ac.uk/efo/efo_0000305,GCST004948,19330027,2,Breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST004949,19330027,1,Breast cancer
http://www.ebi.ac.uk/efo/efo_0001360,GCST000383,19401414,7,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0003758,GCST000382,19404256,1,Autism
http://www.ebi.ac.uk/efo/efo_0004339,GCST000380,19396169,5,Height
http://www.ebi.ac.uk/efo/efo_0006336,GCST000381,19396169,8,Biomedical quantitative traits
http://www.ebi.ac.uk/efo/efo_0006335,GCST000381,19396169,8,Biomedical quantitative traits
http://www.ebi.ac.uk/efo/efo_0003923,GCST000381,19396169,8,Biomedical quantitative traits
http://www.ebi.ac.uk/efo/efo_0004326,GCST000381,19396169,8,Biomedical quantitative traits
http://www.ebi.ac.uk/efo/efo_0004343,GCST000381,19396169,8,Biomedical quantitative traits
http://www.ebi.ac.uk/efo/efo_0004340,GCST000381,19396169,8,Biomedical quantitative traits
http://www.ebi.ac.uk/efo/efo_0000712,GCST000379,19369658,4,Stroke
http://purl.obolibrary.org/obo/go_0007568,GCST000378,19367585,1,Aging
http://www.ebi.ac.uk/efo/efo_0004612,GCST000377,19359809,1,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004505,GCST000376,19359265,1,Telomere length
http://www.ebi.ac.uk/efo/efo_0004197,GCST000375,19349983,1,Hepatitis B
http://www.ebi.ac.uk/efo/efo_0000274,GCST000374,19349984,1,Atopic dermatitis
http://www.ebi.ac.uk/efo/efo_0000712,GCST000373,19403135,0,Stroke (ischemic)
http://www.ebi.ac.uk/efo/efo_0004339,GCST000372,19343178,20,Height
http://www.ebi.ac.uk/efo/efo_0004279,GCST000371,19340012,10,Tanning
http://www.ebi.ac.uk/efo/efo_0004623,GCST000366,20031576,4,Fibrinogen
http://www.ebi.ac.uk/efo/efo_0004578,GCST000367,20031578,2,Homocysteine levels
http://www.ebi.ac.uk/efo/efo_0004623,GCST000368,20031577,6,Fibrinogen
http://www.ebi.ac.uk/efo/efo_0004517,GCST000370,20031579,1,Arterial stiffness
http://purl.obolibrary.org/obo/go_0036273,GCST000369,20031582,0,Response to statin therapy
http://www.ebi.ac.uk/efo/efo_0000305,GCST000365,19330030,6,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004682,GCST000364,19305409,12,QT interval
http://www.ebi.ac.uk/efo/efo_0004682,GCST000363,19305408,13,QT interval
http://www.ebi.ac.uk/efo/efo_0003892,GCST000362,19300500,1,Pulmonary function
http://purl.obolibrary.org/obo/go_0061476,GCST000360,19300499,4,Warfarin maintenance dose
http://www.ebi.ac.uk/efo/efo_0000341,GCST000359,19300482,2,Chronic obstructive pulmonary disease
http://www.ebi.ac.uk/efo/efo_0000537,GCST000361,19304780,1,Hypertension
http://www.ebi.ac.uk/efo/efo_0004843,GCST000358,19303062,5,Folate pathway vitamin levels
http://www.ebi.ac.uk/efo/efo_0004620,GCST000358,19303062,5,Folate pathway vitamin levels
http://www.ebi.ac.uk/efo/efo_0004621,GCST000358,19303062,5,Folate pathway vitamin levels
http://www.ebi.ac.uk/efo/efo_0004251,GCST000357,19287384,1,Myeloproliferative neoplasms
http://www.ebi.ac.uk/efo/efo_0004733,GCST000356,19287509,1,Anti-cyclic Citrullinated Peptide Antibody
http://www.ebi.ac.uk/efo/efo_0004703,GCST000355,19282985,0,Menarche (age at onset)
http://www.ebi.ac.uk/efo/efo_0004286,GCST000354,19278955,1,Venous thromboembolism
http://www.ebi.ac.uk/efo/efo_0003959,GCST000353,19270707,2,Orofacial clefts
http://www.ebi.ac.uk/efo/efo_0004995,GCST000352,19268274,1,Body mass (lean)
http://www.ebi.ac.uk/efo/efo_0004318,GCST000351,19268276,0,Smoking behavior
http://www.ebi.ac.uk/efo/efo_0000289,GCST000350,19259986,0,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000401,GCST000348,19252134,0,Type 2 diabetes nephropathy
http://www.ebi.ac.uk/efo/efo_0004318,GCST000349,19247474,21,Smoking behavior
http://www.ebi.ac.uk/efo/efo_0003923,GCST000347,19249006,2,Bone mineral density
http://www.orpha.net/ordo/orphanet_586,GCST000346,19242412,0,Cystic fibrosis severity
http://www.ebi.ac.uk/efo/efo_0004213,GCST000345,19230858,1,Otosclerosis
http://www.ebi.ac.uk/efo/efo_0000305,GCST000343,19219042,1,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004327,GCST000344,19389651,7,Electrocardiographic conduction measures
http://www.ebi.ac.uk/efo/efo_0004584,GCST000342,19221038,1,Mean platelet volume
http://www.ebi.ac.uk/efo/efo_0001645,GCST000341,19198611,2,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0001645,GCST000338,19198612,2,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0000612,GCST000340,19198609,9,Myocardial infarction (early onset)
http://www.ebi.ac.uk/efo/efo_0004842,GCST000339,19198610,7,Eosinophil counts
http://www.ebi.ac.uk/efo/efo_0004342,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0004574,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0004341,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0004458,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0004340,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0004612,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0004339,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0006336,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0004530,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0006335,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0004611,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0004338,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0004748,GCST000337,19197348,33,Quantitative traits
http://www.ebi.ac.uk/efo/efo_0002892,GCST000335,19198613,2,Thyroid cancer
http://www.ebi.ac.uk/efo/efo_0000692,GCST000336,19197363,0,Schizophrenia
http://www.orpha.net/ordo/orphanet_388,GCST000334,19196962,2,Hirschsprung disease
http://www.ebi.ac.uk/efo/efo_0000253,GCST000333,19193627,0,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0004318,GCST000332,19188921,0,Smoking behavior
http://www.ebi.ac.uk/efo/efo_0004302,GCST000327,19260139,13,Anthropometric traits
http://www.ebi.ac.uk/efo/efo_0004612,GCST000331,20031564,1,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0000270,GCST000330,19187332,3,Asthma (toluene diisocyanate-induced)
http://www.ebi.ac.uk/efo/efo_0004535,GCST000328,19260141,17,Biochemical measures
http://www.ebi.ac.uk/efo/efo_0004574,GCST000328,19260141,17,Biochemical measures
http://www.ebi.ac.uk/efo/efo_0004530,GCST000328,19260141,17,Biochemical measures
http://www.ebi.ac.uk/efo/efo_0004611,GCST000328,19260141,17,Biochemical measures
http://www.ebi.ac.uk/efo/efo_0004623,GCST000328,19260141,17,Biochemical measures
http://www.ebi.ac.uk/efo/efo_0004761,GCST000328,19260141,17,Biochemical measures
http://www.ebi.ac.uk/efo/efo_0004612,GCST000328,19260141,17,Biochemical measures
http://www.ebi.ac.uk/efo/efo_0003843,GCST000326,19207018,3,Pain
http://www.ebi.ac.uk/efo/efo_0003108,GCST000329,19182806,1,Essential tremor
http://www.ebi.ac.uk/efo/efo_0003923,GCST000325,19181680,0,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0004737,GCST000324,19185284,2,Carotenoid and tocopherol levels
http://www.ebi.ac.uk/efo/efo_0004738,GCST000324,19185284,2,Carotenoid and tocopherol levels
http://www.ebi.ac.uk/efo/efo_0000220,GCST000323,19176441,12,Response to treatment for acute lymphoblastic leukemia
http://purl.obolibrary.org/obo/go_0097327,GCST000323,19176441,12,Response to treatment for acute lymphoblastic leukemia
http://www.ebi.ac.uk/efo/efo_0000676,GCST000322,19169254,8,Psoriasis
http://www.ebi.ac.uk/efo/efo_0000676,GCST000321,19169255,3,Psoriasis
http://www.ebi.ac.uk/efo/efo_0004262,GCST000320,19165232,17,Panic disorder
http://www.ebi.ac.uk/efo/efo_0004502,GCST000319,19165155,2,Adiponectin levels
http://www.ebi.ac.uk/efo/efo_0001073,GCST000317,19151714,13,Obesity
http://www.ebi.ac.uk/efo/efo_0004193,GCST000318,19151717,1,Basal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0004529,GCST000316,19148276,0,Polyunsaturated fatty acid levels
http://www.ebi.ac.uk/efo/efo_0000249,GCST000315,19136949,1,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004246,GCST000314,19132087,2,Kawasaki disease
http://www.ebi.ac.uk/efo/efo_0004614,GCST000312,19124843,1,Lp (a) levels
http://www.ebi.ac.uk/efo/efo_0000249,GCST000313,19125160,1,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000729,GCST000311,19122664,12,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0000249,GCST000310,19118814,3,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0002609,GCST000309,19116933,1,Arthritis (juvenile idiopathic)
http://www.ebi.ac.uk/efo/efo_0001663,GCST000307,19117981,1,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0000765,GCST000308,19115949,3,AIDS progression
http://www.ebi.ac.uk/efo/efo_0004325,GCST000306,19114657,1,Blood pressure
http://www.ebi.ac.uk/efo/efo_0004584,GCST000305,19110211,3,Mean platelet volume
http://www.ebi.ac.uk/efo/efo_0003761,GCST000304,19107115,1,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0004541,GCST000303,19096518,4,Glycated hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004461,GCST000302,19084217,3,Iron status biomarkers
http://www.ebi.ac.uk/efo/efo_0004461,GCST000301,19084217,24,Iron status biomarkers
http://www.ebi.ac.uk/efo/efo_0004530,GCST000300,19074352,1,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004338,GCST000299,19079260,17,Weight
http://www.ebi.ac.uk/efo/efo_0003923,GCST000295,19079262,7,Bone mineral density (spine)
http://www.ebi.ac.uk/efo/efo_0003923,GCST000297,19079262,8,Bone mineral density (hip)
http://www.ebi.ac.uk/efo/efo_0004340,GCST000296,19079260,14,Body mass index
http://www.ebi.ac.uk/efo/efo_0004340,GCST000298,19079261,11,Body mass index
http://www.ebi.ac.uk/efo/efo_0004226,GCST000294,19081515,2,Creutzfeldt-Jakob disease
http://www.ebi.ac.uk/efo/efo_0003761,GCST000293,19065144,0,Major depressive disorder
http://www.ebi.ac.uk/efo/efo_0004612,GCST000290,19060906,14,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004465,GCST000291,19060909,1,Fasting plasma glucose
http://purl.obolibrary.org/obo/go_0006954,GCST000292,19060910,11,Metabolic traits
http://www.ebi.ac.uk/efo/efo_0004530,GCST000292,19060910,11,Metabolic traits
http://www.ebi.ac.uk/efo/efo_0004467,GCST000292,19060910,11,Metabolic traits
http://www.ebi.ac.uk/efo/efo_0004468,GCST000292,19060910,11,Metabolic traits
http://www.ebi.ac.uk/efo/efo_0004611,GCST000283,19060910,7,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004612,GCST000288,19060911,10,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004612,GCST000284,19060910,5,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004530,GCST000289,19060911,8,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004611,GCST000282,19060911,12,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004574,GCST000285,19060911,15,"Cholesterol, total"
http://www.ebi.ac.uk/efo/efo_0004530,GCST000286,19060906,11,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004611,GCST000287,19060906,11,LDL cholesterol
http://purl.obolibrary.org/obo/go_0007610,GCST000279,18821565,15,Inattentive symptoms
http://www.ebi.ac.uk/efo/efo_0003888,GCST000281,18821565,19,Attention deficit hyperactivity disorder
http://purl.obolibrary.org/obo/go_0007610,GCST000278,18821565,14,Hyperactive-impulsive symptoms
http://www.ebi.ac.uk/efo/efo_0003888,GCST000280,18937294,11,Attention deficit hyperactivity disorder (time to onset)
http://www.ebi.ac.uk/efo/efo_0001360,GCST000277,19056611,8,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004238,GCST000275,19047183,0,Hearing impairment
http://www.ebi.ac.uk/efo/efo_0004465,GCST000276,19060907,3,Fasting plasma glucose
http://www.ebi.ac.uk/efo/efo_0005001,GCST000274,19043545,16,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0005059,GCST000274,19043545,16,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004998,GCST000274,19043545,16,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0005058,GCST000274,19043545,16,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004622,GCST000274,19043545,16,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0005002,GCST000274,19043545,16,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004529,GCST000274,19043545,16,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004639,GCST000274,19043545,16,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004846,GCST000274,19043545,16,Metabolite levels
http://www.ebi.ac.uk/efo/efo_0004365,GCST000273,18957941,5,Personality dimensions
http://www.ebi.ac.uk/efo/efo_0004339,GCST000272,19030899,1,Height
http://www.ebi.ac.uk/efo/efo_0000692,GCST000271,19023125,6,Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction)
http://www.ebi.ac.uk/efo/efo_0008358,GCST000271,19023125,6,Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction)
http://www.ebi.ac.uk/efo/efo_0005842,GCST000270,19011631,4,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0003885,GCST000269,19010793,10,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0003885,GCST000266,19010793,11,Multiple sclerosis (severity)
http://www.ebi.ac.uk/efo/efo_0003885,GCST000265,19010793,4,Brain lesion load
http://www.ebi.ac.uk/efo/efo_0003885,GCST000268,19010793,5,Normalized brain volume
http://www.ebi.ac.uk/efo/efo_0003885,GCST000267,19010793,8,Multiple sclerosis (age of onset)
http://www.ebi.ac.uk/efo/efo_0004847,GCST000267,19010793,8,Multiple sclerosis (age of onset)
http://www.ebi.ac.uk/efo/efo_0003870,GCST000262,18997786,4,Intracranial aneurysm
http://www.ebi.ac.uk/efo/efo_0003768,GCST000264,19009022,0,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0003885,GCST000263,18997785,1,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0002508,GCST000261,18985386,1,Parkinson's disease (familial)
http://www.ebi.ac.uk/efo/efo_0000253,GCST000260,18987618,1,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0003888,GCST000259,18980221,0,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0001359,GCST000258,18978792,14,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0001071,GCST000257,18978787,3,Lung cancer
http://www.ebi.ac.uk/efo/efo_0001071,GCST000256,18978790,2,Lung cancer
http://www.ebi.ac.uk/efo/efo_0000249,GCST000255,18976728,2,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004339,GCST000254,18952825,1,Height
http://www.ebi.ac.uk/efo/efo_0003888,GCST000253,18951430,26,Attention deficit hyperactivity disorder and conduct disorder
http://www.ebi.ac.uk/efo/efo_0004216,GCST000253,18951430,26,Attention deficit hyperactivity disorder and conduct disorder
http://www.ebi.ac.uk/efo/efo_0003885,GCST000252,18941528,1,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0004193,GCST000249,18849993,2,Basal cell carcinoma
http://www.ebi.ac.uk/efo/efo_0004191,GCST000251,18849994,1,Male-pattern baldness
http://www.ebi.ac.uk/efo/efo_0004191,GCST000250,18849991,2,Male-pattern baldness
http://www.ebi.ac.uk/efo/efo_0004582,GCST000248,18940312,11,Liver enzyme levels
http://www.ebi.ac.uk/efo/efo_0003888,GCST000246,18839057,26,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0008342,GCST000245,18846501,15,Conduct disorder (maternal expressed emotions interaction)
http://www.ebi.ac.uk/efo/efo_0004216,GCST000245,18846501,15,Conduct disorder (maternal expressed emotions interaction)
http://www.ebi.ac.uk/efo/efo_0003888,GCST000247,18846501,7,Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction)
http://www.ebi.ac.uk/efo/efo_0008342,GCST000247,18846501,7,Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction)
http://www.ebi.ac.uk/efo/efo_0001359,GCST000244,18840781,5,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0000729,GCST000243,18836448,2,Ulcerative colitis
http://www.ebi.ac.uk/efo/efo_0004531,GCST000242,18834626,3,Urate levels
http://www.ebi.ac.uk/efo/efo_0000712,GCST000239,18991354,1,Stroke (ischemic)
http://www.ebi.ac.uk/efo/efo_0004529,GCST000241,19802338,0,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004612,GCST000240,20031538,3,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0000768,GCST000238,18835860,1,Idiopathic pulmonary fibrosis
http://www.ebi.ac.uk/efo/efo_0000249,GCST000237,18823527,2,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0000614,GCST000236,18820697,1,Narcolepsy
http://www.ebi.ac.uk/efo/efo_0003888,GCST000235,18821564,2,Attention deficit hyperactivity disorder
http://www.ebi.ac.uk/efo/efo_0004611,GCST000234,18802019,2,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0001071,GCST000233,18780872,1,Lung cancer
http://www.ebi.ac.uk/efo/efo_0000292,GCST000231,18794855,2,Urinary bladder cancer
http://www.ebi.ac.uk/efo/efo_0000685,GCST000232,18794853,9,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0004238,GCST000230,18760390,0,Hearing impairment
http://www.ebi.ac.uk/efo/efo_0004844,GCST000229,18776929,1,Hip bone size
http://www.ebi.ac.uk/efo/efo_0004620,GCST000228,18776911,1,Vitamin B12 levels
http://www.ebi.ac.uk/efo/efo_0004761,GCST000227,18759275,7,Uric acid levels
http://www.ebi.ac.uk/efo/efo_0004257,GCST000226,18762592,3,Neuroticism
http://www.ebi.ac.uk/efo/efo_0000095,GCST000224,18758461,6,Chronic lymphocytic leukemia
http://www.ebi.ac.uk/efo/efo_0003767,GCST000225,18758464,6,Inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0000571,GCST000223,18729187,0,Lung adenocarcinoma
http://www.ebi.ac.uk/efo/efo_0004579,GCST000222,18846228,2,IgE levels
http://www.ebi.ac.uk/efo/efo_0001360,GCST000219,18711367,1,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000289,GCST000220,18711365,21,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0001360,GCST000221,18711366,3,Type 2 diabetes
http://www.orpha.net/ordo/orphanet_797,GCST000218,19165924,0,Sarcoidosis
http://www.ebi.ac.uk/efo/efo_0000685,GCST000217,18668548,2,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0002690,GCST000216,19165918,8,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0000692,GCST000215,18677311,3,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0004270,GCST000214,18660810,2,Restless legs syndrome
http://purl.obolibrary.org/obo/go_0036273,GCST000213,18650507,1,Response to statin therapy
http://www.orpha.net/ordo/orphanet_797,GCST000212,18723019,1,Crohn's disease and sarcoidosis (combined)
http://www.ebi.ac.uk/efo/efo_0000384,GCST000212,18723019,1,Crohn's disease and sarcoidosis (combined)
http://www.ebi.ac.uk/efo/efo_0004653,GCST000211,18615156,8,Response to TNF antagonist treatment
http://www.ebi.ac.uk/efo/efo_0004520,GCST000210,18604267,4,Soluble ICAM-1
http://www.ebi.ac.uk/efo/efo_0004259,GCST000209,18594024,1,Osteonecrosis of the jaw
http://purl.obolibrary.org/obo/go_0036270,GCST000208,18591461,1,Response to diuretic therapy
http://www.ebi.ac.uk/efo/efo_0000384,GCST000207,18587394,30,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0002609,GCST000206,18576341,1,Arthritis (juvenile idiopathic)
http://www.ebi.ac.uk/efo/efo_0004465,GCST000205,18451265,1,Fasting plasma glucose
http://purl.obolibrary.org/obo/go_0061476,GCST000204,18535201,3,Warfarin maintenance dose
http://www.ebi.ac.uk/efo/efo_0004465,GCST000202,18521185,1,Fasting plasma glucose
http://www.ebi.ac.uk/efo/efo_0004319,GCST000203,18519826,0,Smoking cessation
http://purl.obolibrary.org/obo/go_0036287,GCST000200,18521090,0,Response to iloperidone treatment (PANSS-T score)
http://purl.obolibrary.org/obo/go_0036287,GCST000201,18521091,6,Response to iloperidone treatment (QT prolongation)
http://www.ebi.ac.uk/efo/efo_0004296,GCST000199,18514160,1,Thyroid stimulating hormone levels
http://www.ebi.ac.uk/efo/efo_0003949,GCST000192,18488028,1,Blue vs. green eyes
http://www.ebi.ac.uk/efo/efo_0003924,GCST000193,18488028,1,Red vs. non-red hair color
http://www.ebi.ac.uk/efo/efo_0003924,GCST000194,18488028,1,Blond vs. brown hair color
http://www.ebi.ac.uk/efo/efo_0004795,GCST000195,18488028,1,Skin sensitivity to sun
http://www.ebi.ac.uk/efo/efo_0003963,GCST000197,18488028,1,Freckles
http://www.ebi.ac.uk/efo/efo_0003963,GCST000196,18488028,1,Burning and freckling
http://www.ebi.ac.uk/efo/efo_0003958,GCST000196,18488028,1,Burning and freckling
http://www.ebi.ac.uk/efo/efo_0000756,GCST000198,18488026,1,Melanoma
http://www.ebi.ac.uk/efo/efo_0003924,GCST000190,18483556,7,Black vs. blond hair color
http://www.ebi.ac.uk/efo/efo_0003924,GCST000191,18483556,7,Black vs. red hair color
http://www.ebi.ac.uk/efo/efo_0007937,GCST000189,18464913,49,Protein quantitative trait loci
http://www.ebi.ac.uk/efo/efo_0000621,GCST000188,18463370,1,Neuroblastoma
http://www.ebi.ac.uk/efo/efo_0000305,GCST000187,18463975,1,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004616,GCST000186,18471798,2,Knee osteoarthritis
http://www.ebi.ac.uk/efo/efo_0004342,GCST000184,18454146,4,Waist circumference and related phenotypes
http://www.ebi.ac.uk/efo/efo_0004530,GCST000184,18454146,4,Waist circumference and related phenotypes
http://www.ebi.ac.uk/efo/efo_0004612,GCST000184,18454146,4,Waist circumference and related phenotypes
http://www.ebi.ac.uk/efo/efo_0004340,GCST000185,18454148,2,Body mass index
http://www.ebi.ac.uk/efo/efo_0000249,GCST000183,18449908,0,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0003923,GCST000182,18455228,2,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0003923,GCST000180,18445777,8,Bone mineral density (spine)
http://www.ebi.ac.uk/efo/efo_0003923,GCST000181,18445777,6,Bone mineral density (hip)
http://www.ebi.ac.uk/efo/efo_0004458,GCST000179,18439552,3,C-reactive protein
http://www.ebi.ac.uk/efo/efo_0004458,GCST000178,18439548,7,C-reactive protein
http://www.ebi.ac.uk/efo/efo_0004869,GCST000177,18403759,1,YKL-40 levels
http://www.ebi.ac.uk/efo/efo_0004339,GCST000176,18391950,18,Height
http://www.ebi.ac.uk/efo/efo_0004339,GCST000174,18391952,20,Height
http://www.ebi.ac.uk/efo/efo_0004339,GCST000175,18391951,52,Height
http://www.ebi.ac.uk/efo/efo_0000676,GCST000173,18369459,3,Psoriasis
http://www.ebi.ac.uk/efo/efo_0003768,GCST000171,18385739,1,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0001071,GCST000172,18385676,3,Lung cancer
http://www.ebi.ac.uk/efo/efo_0001071,GCST000170,18385738,1,Lung cancer
http://www.ebi.ac.uk/efo/efo_0001360,GCST000167,18372903,16,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0005842,GCST000168,18372901,3,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0005842,GCST000169,18372905,5,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0004779,GCST000166,18360741,0,Environmental confusion in the home
http://www.ebi.ac.uk/efo/efo_0000676,GCST000165,18364390,2,Psoriasis
http://www.ebi.ac.uk/efo/efo_0000692,GCST000164,18347602,6,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0000692,GCST000163,18332876,1,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0000305,GCST000162,18326623,1,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004531,GCST000161,18327256,1,Urate levels
http://www.ebi.ac.uk/efo/efo_0004531,GCST000160,18327257,1,Urate levels
http://www.ebi.ac.uk/efo/efo_0001073,GCST000159,18325910,0,Obesity
http://www.ebi.ac.uk/efo/efo_0000289,GCST000158,18317468,0,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0001060,GCST000157,18311140,8,Celiac disease
http://www.ebi.ac.uk/efo/efo_0004701,GCST000156,18316681,0,Methamphetamine dependence
http://www.ebi.ac.uk/efo/efo_0000692,GCST000155,18282107,1,Schizophrenia
http://www.ebi.ac.uk/efo/efo_0001663,GCST000153,18264098,2,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0001663,GCST000152,18264097,12,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0001663,GCST000154,18264096,7,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0004611,GCST000151,18262040,3,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004576,GCST000150,18245381,2,Fetal hemoglobin levels
http://www.ebi.ac.uk/efo/efo_0004863,GCST000148,18239089,1,Recombination rate (males)
http://www.ebi.ac.uk/efo/efo_0004863,GCST000149,18239089,1,Recombination rate (females)
http://www.ebi.ac.uk/efo/efo_0003768,GCST000147,18227835,0,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0003949,GCST000146,18252221,1,Iris color
http://www.ebi.ac.uk/efo/efo_0004337,GCST000145,18067574,0,General cognitive ability
http://www.ebi.ac.uk/efo/efo_0002690,GCST000142,18204446,6,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0002690,GCST000143,18204447,1,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0002690,GCST000144,18204098,9,Systemic lupus erythematosus
http://www.ebi.ac.uk/efo/efo_0001359,GCST000141,18198356,1,Type 1 diabetes
http://purl.obolibrary.org/obo/go_0035456,GCST000140,18195134,0,Response to interferon beta therapy
http://www.ebi.ac.uk/efo/efo_0004530,GCST000138,18193044,9,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004530,GCST000139,18193043,9,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004611,GCST000132,18193043,7,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004612,GCST000133,18193044,6,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004611,GCST000134,18193044,7,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004612,GCST000135,18193043,10,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004339,GCST000136,18193045,5,Height
http://www.ebi.ac.uk/efo/efo_0004530,GCST000137,18193046,4,Triglycerides
http://www.ebi.ac.uk/efo/efo_0004611,GCST000131,18179892,3,LDL cholesterol
http://www.ebi.ac.uk/efo/efo_0004531,GCST000130,18179892,1,Urate levels
http://www.ebi.ac.uk/efo/efo_0001073,GCST000129,18159244,1,Obesity (early onset extreme)
http://www.ebi.ac.uk/efo/efo_0001663,GCST000128,18073375,0,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0000253,GCST000127,18084291,3,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0000253,GCST000126,18057069,1,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0004225,GCST000125,18075462,1,Coronary spasm
http://www.ebi.ac.uk/efo/efo_0000249,GCST000124,17998437,1,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004531,GCST000123,17997608,1,Urate levels
http://www.ebi.ac.uk/efo/efo_0000685,GCST000122,17982456,2,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000249,GCST000121,17975299,1,Alzheimer's disease
http://www.ebi.ac.uk/efo/efo_0004795,GCST000116,17952075,2,Skin sensitivity to sun
http://www.ebi.ac.uk/efo/efo_0003949,GCST000120,17952075,1,Blue vs. brown eyes
http://www.ebi.ac.uk/efo/efo_0003949,GCST000117,17952075,3,Blue vs. green eyes
http://www.ebi.ac.uk/efo/efo_0003924,GCST000118,17952075,4,Blond vs. brown hair color
http://www.ebi.ac.uk/efo/efo_0003963,GCST000119,17952075,3,Freckles
http://www.ebi.ac.uk/efo/efo_0003924,GCST000115,17952075,1,Red vs non-red hair color
http://www.ebi.ac.uk/efo/efo_0003784,GCST000114,17999355,3,Skin pigmentation
http://www.ebi.ac.uk/efo/efo_0005842,GCST000113,17934461,1,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0002690,GCST000112,17911428,0,Lupus
http://www.ebi.ac.uk/efo/efo_0004619,GCST000082,17903294,4,Factor VII
http://www.ebi.ac.uk/efo/efo_0004870,GCST000081,17903308,5,Sleep-related phenotypes
http://purl.obolibrary.org/obo/go_0070527,GCST000080,17903294,18,Hemostatic factors and hematological phenotypes
http://www.ebi.ac.uk/efo/efo_0004509,GCST000080,17903294,18,Hemostatic factors and hematological phenotypes
http://www.ebi.ac.uk/efo/efo_0004305,GCST000080,17903294,18,Hemostatic factors and hematological phenotypes
http://www.ebi.ac.uk/efo/efo_0004527,GCST000080,17903294,18,Hemostatic factors and hematological phenotypes
http://www.ebi.ac.uk/efo/efo_0004301,GCST000080,17903294,18,Hemostatic factors and hematological phenotypes
http://www.ebi.ac.uk/efo/efo_0004791,GCST000080,17903294,18,Hemostatic factors and hematological phenotypes
http://www.ebi.ac.uk/efo/efo_0004792,GCST000080,17903294,18,Hemostatic factors and hematological phenotypes
http://www.ebi.ac.uk/efo/efo_0000305,GCST000079,17903305,9,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004529,GCST000078,17903299,0,Lipid traits
http://www.ebi.ac.uk/efo/efo_0004471,GCST000077,17903298,4,Diabetes related insulin traits
http://www.ebi.ac.uk/efo/efo_0004541,GCST000077,17903298,4,Diabetes related insulin traits
http://www.ebi.ac.uk/efo/efo_0002614,GCST000077,17903298,4,Diabetes related insulin traits
http://www.ebi.ac.uk/efo/efo_0004466,GCST000077,17903298,4,Diabetes related insulin traits
http://www.ebi.ac.uk/efo/efo_0004298,GCST000102,17903301,1,Endothelial function traits
http://www.ebi.ac.uk/efo/efo_0000409,GCST000103,17903295,5,Morbidity-free survival
http://www.ebi.ac.uk/efo/efo_0003144,GCST000104,17903304,1,Heart failure
http://www.ebi.ac.uk/efo/efo_0004285,GCST000105,17903292,2,Urinary albumin excretion
http://www.ebi.ac.uk/efo/efo_0003892,GCST000106,17903307,10,Pulmonary function
http://www.ebi.ac.uk/efo/efo_0004325,GCST000107,17903302,13,Tonometry
http://www.ebi.ac.uk/efo/efo_0000400,GCST000108,17903298,1,Diabetes (incident)
http://www.ebi.ac.uk/efo/efo_0004327,GCST000111,17903306,2,Electrocardiographic traits
http://www.ebi.ac.uk/efo/efo_0004298,GCST000110,17903301,8,Echocardiographic traits
http://www.ebi.ac.uk/efo/efo_0004295,GCST000110,17903301,8,Echocardiographic traits
http://www.ebi.ac.uk/efo/efo_0004294,GCST000110,17903301,8,Echocardiographic traits
http://www.ebi.ac.uk/efo/efo_0000275,GCST000109,17903304,3,Atrial fibrillation
http://www.ebi.ac.uk/efo/efo_0004685,GCST000101,17903296,16,Hip geometry
http://www.ebi.ac.uk/efo/efo_0004748,GCST000100,17903292,3,Thyroid stimulating hormone levels
http://www.ebi.ac.uk/efo/efo_0004312,GCST000099,17903307,2,Mean forced vital capacity from 2 exams
http://www.ebi.ac.uk/efo/efo_0003926,GCST000098,17903297,14,Cognitive test performance
http://www.ebi.ac.uk/efo/efo_0004723,GCST000097,17903303,3,Coronary artery calcification
http://www.ebi.ac.uk/efo/efo_0004704,GCST000096,17903295,10,Aging traits
http://purl.obolibrary.org/obo/go_0007568,GCST000096,17903295,10,Aging traits
http://www.ebi.ac.uk/efo/efo_0004328,GCST000096,17903295,10,Aging traits
http://www.ebi.ac.uk/efo/efo_0005056,GCST000096,17903295,10,Aging traits
http://www.ebi.ac.uk/efo/efo_0001663,GCST000095,17903305,5,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0004325,GCST000094,17903302,9,Blood pressure
http://www.ebi.ac.uk/efo/efo_0000319,GCST000093,17903304,1,Major CVD
http://www.ebi.ac.uk/efo/efo_0003923,GCST000092,17903296,8,Bone mineral density
http://www.ebi.ac.uk/efo/efo_0004617,GCST000091,17903292,1,Cystatin C
http://www.ebi.ac.uk/efo/efo_0004340,GCST000090,17903300,3,Body mass index
http://www.ebi.ac.uk/efo/efo_0004328,GCST000089,17903301,4,Exercise treadmill test traits
http://www.ebi.ac.uk/efo/efo_0004868,GCST000088,17903297,5,Volumetric brain MRI
http://www.ebi.ac.uk/efo/efo_0005278,GCST000087,17903303,8,Subclinical atherosclerosis traits (other)
http://www.ebi.ac.uk/efo/efo_0004326,GCST000086,17903306,2,Heart rate variability traits
http://www.ebi.ac.uk/efo/efo_0004465,GCST000085,17903298,6,Fasting plasma glucose
http://www.ebi.ac.uk/efo/efo_0004342,GCST000084,17903300,2,Waist circumference
http://www.ebi.ac.uk/efo/efo_0004618,GCST000083,17903293,21,Select biomarker traits
http://www.ebi.ac.uk/efo/efo_0004533,GCST000083,17903293,21,Select biomarker traits
http://www.ebi.ac.uk/efo/efo_0004790,GCST000083,17903293,21,Select biomarker traits
http://www.ebi.ac.uk/efo/efo_0004684,GCST000083,17903293,21,Select biomarker traits
http://www.ebi.ac.uk/efo/efo_0004735,GCST000083,17903293,21,Select biomarker traits
http://www.ebi.ac.uk/efo/efo_0004789,GCST000083,17903293,21,Select biomarker traits
http://www.ebi.ac.uk/efo/efo_0004458,GCST000083,17903293,21,Select biomarker traits
http://www.ebi.ac.uk/efo/efo_0004749,GCST000083,17903293,21,Select biomarker traits
http://www.ebi.ac.uk/efo/efo_0004570,GCST000083,17903293,21,Select biomarker traits
http://www.ebi.ac.uk/efo/efo_0004631,GCST000083,17903293,21,Select biomarker traits
http://www.ebi.ac.uk/efo/efo_0004467,GCST000073,17848626,0,Type 2 diabetes and 6 quantitative traits
http://www.ebi.ac.uk/efo/efo_0004468,GCST000073,17848626,0,Type 2 diabetes and 6 quantitative traits
http://www.ebi.ac.uk/efo/efo_0001360,GCST000073,17848626,0,Type 2 diabetes and 6 quantitative traits
http://www.ebi.ac.uk/efo/efo_0001360,GCST000076,17846126,0,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST000075,17846124,0,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST000074,17846125,0,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000253,GCST000072,17827064,1,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0000685,GCST000070,17804836,3,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000384,GCST000071,17804789,3,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0004576,GCST000069,17767159,3,F-cell distribution
http://www.ebi.ac.uk/efo/efo_0004339,GCST000068,17767157,1,Height
http://www.ebi.ac.uk/efo/efo_0004235,GCST000067,17690259,1,Glaucoma (exfoliation)
http://www.ebi.ac.uk/efo/efo_0000384,GCST000066,17684544,3,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000253,GCST000065,17671248,0,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0004997,GCST000064,17653210,1,Type 2 diabetes nephropathy
http://www.ebi.ac.uk/efo/efo_0004257,GCST000063,17667963,1,Neuroticism
http://www.ebi.ac.uk/efo/efo_0003885,GCST000062,17660530,6,Multiple sclerosis
http://www.ebi.ac.uk/efo/efo_0000270,GCST000061,17611496,1,Asthma
http://www.ebi.ac.uk/efo/efo_0004338,GCST000060,17658951,3,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004343,GCST000060,17658951,3,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004340,GCST000060,17658951,3,Obesity-related traits
http://www.ebi.ac.uk/efo/efo_0004270,GCST000058,17634447,1,Restless legs syndrome
http://purl.obolibrary.org/obo/go_0009615,GCST000059,17641165,0,HIV-1 viral setpoint
http://www.ebi.ac.uk/efo/efo_0001645,GCST000057,17634449,7,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0004270,GCST000056,17637780,3,Restless legs syndrome
http://www.ebi.ac.uk/efo/efo_0004210,GCST000055,17632509,1,Gallstone disease
http://www.ebi.ac.uk/efo/efo_0001359,GCST000054,17632545,4,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0005842,GCST000053,17618284,1,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0005842,GCST000052,17618283,1,Colorectal cancer
http://www.ebi.ac.uk/efo/efo_0000275,GCST000051,17603472,2,Atrial fibrillation/atrial flutter
http://www.ebi.ac.uk/efo/efo_0001663,GCST000050,17603485,2,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0001360,GCST000049,17668382,2,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001060,GCST000048,17558408,2,Celiac disease
http://www.ebi.ac.uk/efo/efo_0000384,GCST000042,17554300,13,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0001359,GCST000043,17554300,10,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0000289,GCST000044,17554300,7,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0001645,GCST000045,17554300,4,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0000685,GCST000040,17554300,7,Rheumatoid arthritis
http://www.ebi.ac.uk/efo/efo_0000249,GCST000046,17553421,1,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0001360,GCST000047,17554300,7,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000537,GCST000041,17554300,2,Hypertension
http://www.ebi.ac.uk/efo/efo_0000384,GCST000039,17554261,9,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0001359,GCST000038,17554260,12,Type 1 diabetes
http://www.ebi.ac.uk/efo/efo_0000305,GCST000036,17529973,1,Breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST000035,17529967,6,Breast cancer
http://www.ebi.ac.uk/efo/efo_0000305,GCST000037,17529974,2,Breast cancer
http://www.ebi.ac.uk/efo/efo_0004735,GCST000034,17505501,0,Response to ximelagatran treatment (increased serum alanine aminotransferase levels)
http://purl.obolibrary.org/obo/go_0036288,GCST000034,17505501,0,Response to ximelagatran treatment (increased serum alanine aminotransferase levels)
http://www.ebi.ac.uk/efo/efo_0000289,GCST000033,17486107,1,Bipolar disorder
http://www.ebi.ac.uk/efo/efo_0000712,GCST000032,17434096,4,Stroke
http://www.ebi.ac.uk/efo/efo_0001645,GCST000031,17478681,0,Coronary heart disease
http://www.ebi.ac.uk/efo/efo_0000612,GCST000030,17478679,1,Myocardial infarction
http://www.ebi.ac.uk/efo/efo_0004333,GCST000029,17470457,0,Episodic memory
http://www.ebi.ac.uk/efo/efo_0001360,GCST000025,17463249,10,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0004614,GCST004921,17463246,1,Apolipoprotein A1 levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST004920,17463246,2,LDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST004919,17463246,1,HDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST000026,17463246,2,Triglycerides
http://www.ebi.ac.uk/efo/efo_0001360,GCST000027,17460697,3,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST000024,17463248,10,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001360,GCST000028,17463246,8,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0000384,GCST000023,17435756,4,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0004340,GCST000022,17434869,1,Body mass index
http://www.ebi.ac.uk/efo/efo_0003768,GCST000021,17407593,0,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0001663,GCST000019,17401366,3,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0003884,GCST000020,17395743,1,End-stage renal disease
http://www.ebi.ac.uk/efo/efo_0001663,GCST000017,17401363,2,Prostate cancer
http://www.ebi.ac.uk/efo/efo_0000249,GCST000018,17474819,1,Alzheimer's disease (late onset)
http://www.ebi.ac.uk/efo/efo_0000692,GCST000016,17522711,1,Schizophrenia
http://www.orpha.net/ordo/orphanet_683,GCST000015,17357082,0,Progressive supranuclear palsy
http://www.ebi.ac.uk/efo/efo_0000384,GCST000014,17447842,3,Crohn's disease
http://www.ebi.ac.uk/efo/efo_0000253,GCST000013,17362836,6,Amyotrophic lateral sclerosis
http://www.ebi.ac.uk/efo/efo_0001360,GCST000012,17293876,3,Type 2 diabetes
http://www.ebi.ac.uk/efo/efo_0001071,GCST000011,17223258,0,Lung cancer
http://www.ebi.ac.uk/efo/efo_0003768,GCST000010,17158188,2,Nicotine dependence
http://www.ebi.ac.uk/efo/efo_0003890,GCST000009,17099884,0,Addiction
http://www.ebi.ac.uk/efo/efo_0003767,GCST000008,17068223,1,Inflammatory bowel disease
http://www.ebi.ac.uk/efo/efo_0004874,GCST000007,17053149,0,Memory performance
http://www.ebi.ac.uk/efo/efo_0001365,GCST000006,17053108,1,Age-related macular degeneration (wet)
http://www.ebi.ac.uk/efo/efo_0002508,GCST000005,17052657,3,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0004682,GCST000004,16648850,1,QT interval
http://www.ebi.ac.uk/efo/efo_0001073,GCST000003,16614226,0,Obesity
http://www.ebi.ac.uk/efo/efo_0002508,GCST000002,16252231,1,Parkinson's disease
http://www.ebi.ac.uk/efo/efo_0001365,GCST000001,15761122,1,Age-related macular degeneration
http://www.ebi.ac.uk/efo/efo_0007760,GCST003241,26584805,13,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)
http://www.ebi.ac.uk/efo/efo_0007761,GCST003240,26584805,18,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)
http://www.ebi.ac.uk/efo/efo_0006807,GCST003239,26584805,20,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)
http://www.ebi.ac.uk/efo/efo_0007762,GCST003238,26584805,15,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)
http://www.ebi.ac.uk/efo/efo_0007763,GCST003237,26584805,13,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)
http://www.ebi.ac.uk/efo/efo_0006808,GCST003236,26584805,20,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)
http://www.ebi.ac.uk/efo/efo_0007764,GCST003243,26584805,10,Delta-5 desaturase activity
http://www.ebi.ac.uk/efo/efo_0007765,GCST003244,26584805,10,Delta-6 desaturase activity
http://www.ebi.ac.uk/efo/efo_0007759,GCST003242,26584805,11,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)
http://www.ebi.ac.uk/efo/efo_0005842,GCST003229,26586795,1,Survival in colorectal cancer
http://www.ebi.ac.uk/efo/efo_0000714,GCST003229,26586795,1,Survival in colorectal cancer
http://www.ebi.ac.uk/efo/efo_0007675,GCST003231,26586795,1,Survival in colorectal cancer (non-distant metastatic)
http://www.ebi.ac.uk/efo/efo_0005842,GCST003231,26586795,1,Survival in colorectal cancer (non-distant metastatic)
http://www.ebi.ac.uk/efo/efo_0000714,GCST003231,26586795,1,Survival in colorectal cancer (non-distant metastatic)
http://www.ebi.ac.uk/efo/efo_0007675,GCST003230,26586795,4,Survival in colorectal cancer (distant metastatic)
http://www.ebi.ac.uk/efo/efo_0005842,GCST003230,26586795,4,Survival in colorectal cancer (distant metastatic)
http://www.ebi.ac.uk/efo/efo_0000714,GCST003230,26586795,4,Survival in colorectal cancer (distant metastatic)
http://www.ebi.ac.uk/efo/efo_0004574,GCST006034,29403010,45,Total cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004308,GCST005973,29403010,42,White blood cell count
http://www.ebi.ac.uk/efo/efo_0004833,GCST005974,29403010,22,Neutrophil count
http://www.ebi.ac.uk/efo/efo_0004842,GCST005975,29403010,20,Eosinophil counts
http://www.ebi.ac.uk/efo/efo_0005090,GCST005976,29403010,28,White blood cell count (basophil)
http://www.ebi.ac.uk/efo/efo_0005091,GCST005977,29403010,34,Monocyte count
http://www.ebi.ac.uk/efo/efo_0004587,GCST005997,29403010,14,Lymphocyte counts
http://www.ebi.ac.uk/efo/efo_0004305,GCST005996,29403010,60,Red blood cell count
http://www.ebi.ac.uk/efo/efo_0004509,GCST005995,29403010,20,Hemoglobin
http://www.ebi.ac.uk/efo/efo_0004348,GCST005994,29403010,23,Hematocrit
http://www.ebi.ac.uk/efo/efo_0004527,GCST005993,29403010,96,Mean corpuscular hemoglobin
http://www.ebi.ac.uk/efo/efo_0004528,GCST005992,29403010,44,Mean corpuscular hemoglobin concentration
http://www.ebi.ac.uk/efo/efo_0004309,GCST005991,29403010,96,Platelet count
http://www.ebi.ac.uk/efo/efo_0004568,GCST005990,29403010,58,Non-albumin protein levels
http://www.ebi.ac.uk/efo/efo_0007937,GCST005989,29403010,39,Serum total protein level
http://www.ebi.ac.uk/efo/efo_0004535,GCST005988,29403010,17,Serum albumin level
http://www.ebi.ac.uk/efo/efo_0005128,GCST005987,29403010,50,Albumin-globulin ratio
http://www.ebi.ac.uk/efo/efo_0004741,GCST005986,29403010,44,Blood urea nitrogen levels
http://www.ebi.ac.uk/efo/efo_0004518,GCST005985,29403010,68,Creatinine levels
http://www.ebi.ac.uk/efo/efo_0005208,GCST005984,29403010,72,Glomerular filtration rate
http://www.ebi.ac.uk/efo/efo_0004761,GCST005983,29403010,48,Serum uric acid levels
http://www.ebi.ac.uk/efo/efo_0009282,GCST006032,29403010,14,Sodium levels
http://www.ebi.ac.uk/efo/efo_0009283,GCST006031,29403010,15,Potassium levels
http://www.ebi.ac.uk/efo/efo_0009284,GCST006030,29403010,19,Chloride levels
http://www.ebi.ac.uk/efo/efo_0004838,GCST005982,29403010,17,Calcium levels
http://www.ebi.ac.uk/efo/efo_0004861,GCST005981,29403010,10,Phosphorus levels
http://www.ebi.ac.uk/efo/efo_0004570,GCST005980,29403010,20,Total bilirubin levels
http://www.ebi.ac.uk/efo/efo_0006335,GCST005979,29403010,23,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST005978,29403010,18,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006340,GCST006010,29403010,32,Mean arterial pressure
http://www.ebi.ac.uk/efo/efo_0005763,GCST006009,29403010,17,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0008204,GCST006008,29403010,3,Left ventricular internal dimension in diastole
http://www.ebi.ac.uk/efo/efo_0008206,GCST006007,29403010,4,Left ventricular internal dimension in systole
http://www.ebi.ac.uk/efo/efo_0009286,GCST006033,29403010,1,Relative wall thickness
http://www.ebi.ac.uk/efo/efo_0009285,GCST006029,29403010,4,Fractional shortening
http://www.ebi.ac.uk/efo/efo_0005527,GCST006006,29403010,3,Ejection fraction
http://www.ebi.ac.uk/efo/efo_0009287,GCST006028,29403010,0,Interventricular septum thickness
http://www.ebi.ac.uk/efo/efo_0009288,GCST006027,29403010,0,Posterior wall thickness
http://www.ebi.ac.uk/efo/efo_0009289,GCST006026,29403010,0,Left ventricular mass
http://www.ebi.ac.uk/efo/efo_0009290,GCST006025,29403010,0,Left ventricular mass index
http://www.ebi.ac.uk/efo/efo_0009291,GCST006024,29403010,0,E/A ratio
http://www.ebi.ac.uk/efo/efo_0004612,GCST006005,29403010,53,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004611,GCST006004,29403010,29,Low density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST006003,29403010,36,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004468,GCST006002,29403010,21,Blood sugar levels
http://www.ebi.ac.uk/efo/efo_0004541,GCST006001,29403010,28,Hemoglobin A1c levels
http://www.ebi.ac.uk/efo/efo_0004565,GCST006000,29403010,4,Immunoglobulin measurement (zinc sulfate turbidity test)
http://www.ebi.ac.uk/efo/efo_0004736,GCST005999,29403010,30,Aspartate aminotransferase levels
http://www.ebi.ac.uk/efo/efo_0004735,GCST005998,29403010,27,Alanine transaminase levels
http://www.ebi.ac.uk/efo/efo_0004533,GCST006016,29403010,48,Serum alkaline phosphatase levels
http://www.ebi.ac.uk/efo/efo_0004532,GCST006019,29403010,50,Gamma glutamyl transferase levels
http://www.ebi.ac.uk/efo/efo_0004310,GCST006018,29403010,13,Activated partial thromboplastin time
http://www.ebi.ac.uk/efo/efo_0008390,GCST006017,29403010,14,Prothrombin time
http://www.ebi.ac.uk/efo/efo_0004623,GCST006015,29403010,1,Fibrinogen levels
http://www.ebi.ac.uk/efo/efo_0004534,GCST006014,29403010,46,Creatine kinase levels
http://www.ebi.ac.uk/efo/efo_0004808,GCST006013,29403010,14,Lactate dehydrogenase levels
http://www.ebi.ac.uk/efo/efo_0004458,GCST006012,29403010,8,C-reactive protein levels
http://www.ebi.ac.uk/efo/efo_0006335,GCST006624,30224653,130,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST006630,30224653,91,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0005763,GCST006629,30224653,104,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0006335,GCST006628,30224653,60,Systolic blood pressure
http://www.ebi.ac.uk/efo/efo_0006336,GCST006627,30224653,103,Diastolic blood pressure
http://www.ebi.ac.uk/efo/efo_0005763,GCST006626,30224653,47,Pulse pressure
http://www.ebi.ac.uk/efo/efo_0000685,GCST005319,29315334,0,Frontotemporal dementia and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000676,GCST005319,29315334,0,Frontotemporal dementia and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001060,GCST005319,29315334,0,Frontotemporal dementia and immune-mediated diseases (pleiotropy)
http://www.orpha.net/ordo/orphanet_282,GCST005319,29315334,0,Frontotemporal dementia and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000729,GCST005319,29315334,0,Frontotemporal dementia and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000384,GCST005319,29315334,0,Frontotemporal dementia and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000685,GCST005320,29315334,0,Progressive supranuclear palsy and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001359,GCST005320,29315334,0,Progressive supranuclear palsy and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000676,GCST005320,29315334,0,Progressive supranuclear palsy and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001060,GCST005320,29315334,0,Progressive supranuclear palsy and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000729,GCST005320,29315334,0,Progressive supranuclear palsy and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000384,GCST005320,29315334,0,Progressive supranuclear palsy and immune-mediated diseases (pleiotropy)
http://www.orpha.net/ordo/orphanet_683,GCST005320,29315334,0,Progressive supranuclear palsy and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000685,GCST005321,29315334,0,Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001359,GCST005321,29315334,0,Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000676,GCST005321,29315334,0,Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000253,GCST005321,29315334,0,Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001060,GCST005321,29315334,0,Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000729,GCST005321,29315334,0,Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000384,GCST005321,29315334,0,Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy)
http://www.orpha.net/ordo/orphanet_278,GCST005322,29315334,0,Corticobasal degeneration and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000685,GCST005322,29315334,0,Corticobasal degeneration and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001359,GCST005322,29315334,0,Corticobasal degeneration and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000676,GCST005322,29315334,0,Corticobasal degeneration and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0001060,GCST005322,29315334,0,Corticobasal degeneration and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000729,GCST005322,29315334,0,Corticobasal degeneration and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000384,GCST005322,29315334,0,Corticobasal degeneration and immune-mediated diseases (pleiotropy)
http://www.ebi.ac.uk/efo/efo_0000195,GCST004239,28371326,2,Metabolic syndrome
http://www.ebi.ac.uk/efo/efo_0004465,GCST004240,28371326,1,Fasting blood glucose
http://www.ebi.ac.uk/efo/efo_0004530,GCST004241,28371326,3,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST004242,28371326,1,HDL cholesterol
http://www.ebi.ac.uk/efo/efo_0007804,GCST004243,28371326,2,LDL cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004343,GCST004244,28371326,0,Waist-hip ratio
http://www.ebi.ac.uk/efo/efo_0004340,GCST004245,28371326,1,Body mass index
http://www.ebi.ac.uk/efo/efo_0004530,GCST007658,30255771,7,Triglyceride levels (parental genotype effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST007658,30255771,7,Triglyceride levels (parental genotype effect)
http://www.ebi.ac.uk/efo/efo_0004530,GCST007660,30255771,3,Triglyceride levels in response to fenofibrate treatment (parental genotype effect)
http://purl.obolibrary.org/obo/go_1901557,GCST007660,30255771,3,Triglyceride levels in response to fenofibrate treatment (parental genotype effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST007660,30255771,3,Triglyceride levels in response to fenofibrate treatment (parental genotype effect)
http://www.ebi.ac.uk/efo/efo_0007681,GCST007659,30255771,0,Triglyceride change in response to fenofibrate (parental genotype effect)
http://purl.obolibrary.org/obo/go_1901557,GCST007659,30255771,0,Triglyceride change in response to fenofibrate (parental genotype effect)
http://www.ebi.ac.uk/efo/efo_0005939,GCST007659,30255771,0,Triglyceride change in response to fenofibrate (parental genotype effect)
http://www.ebi.ac.uk/efo/efo_0004530,GCST007661,30255771,1,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST007662,30255771,0,Triglyceride levels in response to fenofibrate
http://purl.obolibrary.org/obo/go_1901557,GCST007662,30255771,0,Triglyceride levels in response to fenofibrate
http://www.ebi.ac.uk/efo/efo_0007681,GCST007663,30255771,0,Triglyceride change in response to fenofibrate treatment
http://purl.obolibrary.org/obo/go_1901557,GCST007663,30255771,0,Triglyceride change in response to fenofibrate treatment
http://www.ebi.ac.uk/efo/efo_0004697,GCST005828,29325096,1,Estradiol levels
http://www.ebi.ac.uk/efo/efo_0007970,GCST005827,29325096,4,Estrone levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST007301,30263045,1,High density lipoprotein cholesterol levels
http://www.ebi.ac.uk/efo/efo_0004612,GCST007300,30263045,1,Response to fenofibrate (HDL cholesterol levels)
http://purl.obolibrary.org/obo/go_1901557,GCST007300,30263045,1,Response to fenofibrate (HDL cholesterol levels)
http://www.ebi.ac.uk/efo/efo_0004530,GCST007299,30263045,0,Triglyceride levels
http://www.ebi.ac.uk/efo/efo_0004530,GCST007298,30263045,0,Response to fenofibrate (triglyceride levels)
http://purl.obolibrary.org/obo/go_1901557,GCST007298,30263045,0,Response to fenofibrate (triglyceride levels)
